<SEC-DOCUMENT>0001104659-25-119726.txt : 20251209
<SEC-HEADER>0001104659-25-119726.hdr.sgml : 20251209
<ACCEPTANCE-DATETIME>20251209172601
ACCESSION NUMBER:		0001104659-25-119726
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		10
FILED AS OF DATE:		20251209
DATE AS OF CHANGE:		20251209

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-290954
		FILM NUMBER:		251560054

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		804, 322 - 11 AVENUE SW
		CITY:			CALGARY
		PROVINCE COUNTRY:   	A0
		BUSINESS PHONE:		4036707377

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		804, 322 - 11 AVENUE SW
		CITY:			CALGARY
		PROVINCE COUNTRY:   	A0
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>tm2533062d1_424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0pt"><B>Filed Pursuant to Rule 424(b)(3)</B></P>

<P STYLE="margin: 0pt; text-align: right"><B>Registration No. 333-290954</B></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm2533062d1_424b3img08.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Management Information Circular</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Oncolytics Biotech Inc.</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>with respect to its Special Meeting of Shareholders</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>and</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Prospectus</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Oncolytics Biotech Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AUTHORIZING THE CONTINUANCE, AUTHORIZING THE
DOMESTICATION, AND APPROVAL OF 2026 INCENTIVE AWARD PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This circular/prospectus (this &ldquo;<B>Circular/Prospectus</B>&rdquo;)
is being furnished to you as a shareholder of Oncolytics Biotech Inc., an Alberta corporation (&ldquo;<B>Oncolytics,</B>&rdquo; the &ldquo;<B>Company</B>,&rdquo;
 &ldquo;<B>we</B>,&rdquo; &ldquo;<B>us</B>&rdquo; and &ldquo;<B>our</B>&rdquo;), in connection with (i)&nbsp;subject to and conditional
upon the approval of the Domestication (as described below), the proposed change in the jurisdiction of incorporation of Oncolytics from
the Province of Alberta in Canada to the Province of British Columbia in Canada pursuant to a &ldquo;continuance&rdquo; effected in accordance
with Section&nbsp;189 of the <I>Business Corporations Act</I> (Alberta) (&ldquo;<B>ABCA</B>&rdquo;) and a &ldquo;continuation&rdquo; in
accordance with section 303 of the <I>Business Corporations Act</I> (British Columbia) (the &ldquo;<B>BCBCA</B>&rdquo;) (the &ldquo;<B>Continuance</B>&rdquo;),
(ii)&nbsp;subject to and conditional upon the approval and implementation of the Continuance, the proposed change in the jurisdiction
of Oncolytics from the Province of British Columbia to the State of Nevada in the United States pursuant to a &ldquo;continuation out&rdquo;
effected in accordance with Section&nbsp;308 of the BCBCA and a &ldquo;domestication&rdquo; under Section&nbsp;92A.270 of the <I>Nevada
Revised Statutes </I>(the &ldquo;<B>NRS</B>&rdquo;) (the &ldquo;<B>Domestication</B>&rdquo;), and (iii)&nbsp;subject to and conditional
upon the approval and implementation of the Domestication, the proposed approval and adoption of the Oncolytics Biotech Inc. 2026 Incentive
Award Plan (the &ldquo;<B>2026 Plan</B>&rdquo;). This Circular/Prospectus is being supplied to you in connection with the solicitation
of proxies by management of Oncolytics for use at the special meeting of shareholders of Oncolytics to be held on January 15,
2026 at 10:00 a.m. (Eastern Time).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are pursuing the Continuance and Domestication for a number of reasons.
The Domestication is intended to reduce the regulatory burden and cost of being subject to the laws and regulations of both the United
States and Canada and to facilitate stockholder value creation over the long term by, among other things, reducing our operating costs
and enabling us to compete effectively in raising the capital necessary to continue to implement our strategic plan. In addition, our
operations are located in the United States and a large percentage of our Shareholders (as defined below) are located in the United States.
We chose the State of Nevada to be our proposed domicile in part because the NRS accommodates a continuance authorized under applicable
British Columbia corporate statutes. We also chose the State of Nevada because of the more favourable corporate environment afforded by
the State of Nevada. References to &ldquo;<B>Oncolytics Nevada</B>&rdquo; contained in this Circular/Prospectus refer solely to Oncolytics
Biotech Inc., a Nevada corporation, as of the effective time of the Domestication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">If the Continuance and Domestication are approved by our Shareholders
and we complete the Continuance and Domestication, we will continue our legal existence in Nevada and from the date of the filing of
the Oncolytics Nevada Charter (as defined below), the law of Nevada will apply to us to the same extent as if the Company was organized
as a Nevada corporation on that date. In addition, under the Continuance, each issued and outstanding common share of Oncolytics as an
Alberta corporation will then represent one common share of Oncolytics as a British Columbia company, and under the Domestication, each
outstanding common share of Oncolytics as a British Columbia company will then represent one share of common stock of Oncolytics Nevada
(the common shares of Oncolytics as an Alberta corporation, the common shares of Oncolytics as a British Columbia company and the shares
of common stock of Oncolytics Nevada are, as applicable, referenced herein as our &ldquo;<B>Common Shares</B>&rdquo;). Our Common Shares
are currently traded on The Nasdaq Stock Market, LLC (&ldquo;<B>Nasdaq</B>&rdquo;) under the ticker symbol &ldquo;ONCY.&rdquo; Following
the completion of the Continuance and Domestication, our Common Shares will continue to be listed on Nasdaq under the symbol &ldquo;ONCY.&rdquo;
Our board of directors has reserved the right to terminate or abandon the Continuance and Domestication at any time prior to its effectiveness,
notwithstanding shareholder approval, if it determines for any reason that the consummation of the Continuance or the Domestication would
be inadvisable or not in our best interests.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the special meeting of our Shareholders, in addition to proposals
relating to the Continuance and Domestication as described above, we are also seeking shareholder approval of the 2026 Plan, which approval
is subject to and conditional upon the completion of the Continuance and Domestication, as more fully described in this Circular/Prospectus
and the accompanying Notice of Special Meeting of Shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>This Circular/Prospectus constitutes a prospectus
of Oncolytics under Section&nbsp;5 of the <I>U.S. Securities Act of 1933</I>, as amended (the &ldquo;Securities Act&rdquo;), with respect
to the Common Shares issuable in connection with the Domestication.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Continuance and Domestication are consummated, our Shareholders
will not be required to surrender or exchange their Common Shares, which will represent shares of common stock, par value $0.001 per share,
of Oncolytics Nevada upon the Domestication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>These securities involve a high degree of risk.
See the section entitled </B>&ldquo;<B><U>Risk Factors</U></B>&rdquo; <B>beginning on page&nbsp;10 of the Circular/Prospectus for a discussion
of specified matters that should be considered.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NEITHER THE U.S. SECURITIES AND EXCHANGE COMMISSION
NOR ANY STATE SECURITIES COMMISSION, OR SIMILAR AUTHORITY IN ANY PROVINCE OF CANADA, HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR
DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>This Circular/Prospectus is not an offer to
sell, or a solicitation of an offer to buy, any securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>This Circular/Prospectus is dated December
9, 2025. Except as otherwise stated, the information contained in this Circular/Prospectus is given as of&#9;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>December 9,
2025.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2533062d1_424b3img08.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF SPECIAL MEETING OF SHAREHOLDERS TO
BE HELD ON JANUARY </B> <B>15, 2026</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the Shareholders of Oncolytics Biotech Inc.:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTICE IS HEREBY GIVEN THAT</B> the
special meeting of the holders of common shares (&ldquo;<B>Shareholders</B>&rdquo;) of Oncolytics Biotech Inc.
(&ldquo;<B>Oncolytics,</B>&rdquo; the &ldquo;<B>Company,</B>&rdquo; &ldquo;<B>we,</B>&rdquo; &ldquo;<B>us</B>&rdquo; and
 &ldquo;<B>our</B>&rdquo;) will be held in a virtual-only format via live audio webcast at <I>https://virtual-meetings.tsxtrust.com/1847</I>
(password: onc2026 (case sensitive)) on Thursday, January 15, 2026
at 10:00 a.m.&nbsp;(Eastern Time) (the &ldquo;<B>Meeting</B>&rdquo;), for the following purposes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">to consider and, if thought advisable, pass, with or without variation, a special resolution (the &ldquo;<B>Continuance
Resolution</B>&rdquo;), attached to this Circular/Prospectus (as defined below) as Annex <B>A</B>, authorizing the continuance of Oncolytics
from the Province of Alberta under the <I>Business Corporations Act</I> (Alberta) to the Province of British Columbia under the <I>Business
Corporations Act</I> (British Columbia) (the &ldquo;<B>Continuance</B>&rdquo;) through the adoption of the continuation application (the
 &ldquo;<B>Continuation Application</B>&rdquo;) containing the notice of articles (the &ldquo;<B>Notice of Articles</B>&rdquo;) and the
articles (the &ldquo;<B>Articles</B>&rdquo;), attached to this Circular/Prospectus as Annex <B>B</B> and Annex <B>E</B>, respectively,
subject to and conditional upon the approval of the Domestication Resolution (as described below), all as more fully described in the
Circular/Prospectus;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">to consider and, if thought advisable, pass, with or without variation, a special resolution (the &ldquo;<B>Domestication
Resolution</B>&rdquo;), attached to this Circular/Prospectus as Annex <B>C</B>, authorizing the continuation of Oncolytics out of the
Province of British Columbia and domestication to the State of Nevada and the adoption of the articles of domestication and new articles
of incorporation, copies of which are attached to this Circular/Prospectus as Annexes <B>D</B> and <B>E</B>, respectively, subject to
and conditional upon the approval of the Continuance Resolution (the &ldquo;<B>Domestication</B>&rdquo;), all as more fully described
in the Circular/Prospectus;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">3.</TD>
    <TD STYLE="text-align: justify">to consider, and if thought advisable, approve, subject to and conditional upon the completion of the Continuance and Domestication, the Oncolytics Biotech Inc. 2026 Incentive Award Plan (the &ldquo;<B>2026 Plan</B>&rdquo;), a copy of which is attached to the Circular/Prospectus as Annex <B>F</B>; and</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">to transact such other business as may properly be brought before the Meeting or any adjournment thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying management information
circular and prospectus dated December 9, 2025 (the &ldquo;<B>Circular/Prospectus</B>&rdquo;) more fully describes the details of the
business to be conducted at the Meeting. The Meeting is being conducted in a virtual-only format. After careful consideration, our
Board of Directors (the &ldquo;<B>Board</B>&rdquo;) has unanimously approved each of the proposals and recommends that you vote FOR
each proposal described in the Circular/Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Registered Shareholders (as defined below) and duly appointed proxyholders
will be able to virtually attend the Meeting, submit questions and vote in real time, provided they are connected to the internet and
follow the instructions in the attached Circular/Prospectus. Non-Registered Shareholders (or Beneficial Shareholders) (each, as defined
below) who have not duly appointed themselves as proxyholder will be able to virtually attend the Meeting as guests, but will not be able
to vote at the Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shareholders who wish to appoint a person other
than the management nominees identified in the form of proxy or voting instruction form (including a beneficial Shareholder who wishes
to appoint themselves to attend the Meeting) must carefully follow the instructions in the Circular/Prospectus and on their form of proxy
or voting instruction form. These instructions include the additional step of registering such proxyholder with our transfer agent, TSX
Trust Company (&ldquo;<B>TSX Trust</B>&rdquo;), after submitting the form of proxy or voting instruction form. If you wish that a person
other than the management nominees identified on the form of proxy or voting instruction form attend and participate at the Meeting as
your proxy and vote your Common Shares, you MUST register such proxyholder after having submitted your form of proxy or voting instruction
form identifying such proxyholder. Failure to register the proxyholder with TSX Trust will result in the proxyholder not receiving a control
number to participate in Meeting and only being able to attend as a guest. Guests will be able to listen to the Meeting but will not be
able to vote.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the <I>Business Corporations Act</I> (Alberta) and the
<I>Business Corporations Act</I> (British Columbia), Shareholders have the right to dissent in respect of the Continuance and the Domestication,
respectively, and be paid the fair value of their Common Shares, subject to certain conditions. These dissent rights, and the procedures
for their exercise, are described in the Circular/Prospectus under the headings &ldquo;<I>Dissent Rights of Shareholders &mdash; Alberta</I>&rdquo;
and &ldquo;<I>Dissent Rights of Shareholders &mdash; BC</I>.&rdquo; Only Registered Shareholders are entitled to exercise rights of dissent.
Failure to comply strictly with the dissent procedures described in the Circular/Prospectus will result in the loss or unavailability
of any right of dissent. Shareholders whose Common Shares are registered in the name of a broker, custodian, nominee or other intermediary
(&ldquo;<B>Non-Registered Shareholders</B>&rdquo;) who wish to dissent should be aware that ONLY REGISTERED SHAREHOLDERS ARE ENTITLED
TO DISSENT IN RESPECT OF THE CONTINUANCE OR THE DOMESTICATION. Non-Registered Shareholders (or Beneficial Shareholders) should contact
their broker, investment dealer, bank or other nominee in order to exercise dissent rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Circular/Prospectus constitutes part of a
registration statement on Form&nbsp;F-4 that was filed with the U.S. Securities and Exchange Commission (the &ldquo;<B>SEC</B>&rdquo;).
This Circular/Prospectus incorporates important business and financial information about the Company that is not included in or delivered
with this Circular/Prospectus. This information is available for you to review through the SEC&rsquo;s website at <I>www.sec.gov</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will furnish without charge to each person,
including any beneficial owner, to whom a Circular/Prospectus is delivered, upon written or oral request, a copy of any or all of the
documents incorporated by reference into this Circular/Prospectus but not delivered with the Circular/Prospectus, including exhibits that
are specifically incorporated by reference into such documents. You should direct any requests for documents to Oncolytics Biotech Inc.,
Attention: Kirk Look, Chief Financial Officer, Suite&nbsp;804, 322 &mdash; 11<SUP>th </SUP>Avenue SW, Calgary, Alberta T2R 0C5. Our phone
number is (403) 670-7377. You may also view the documents that we file with the SEC and incorporate by reference in this Circular/Prospectus
on our corporate website at <I>www.oncolyticsbiotech.com</I>. The information on our website is not incorporated by reference and is not
a part of this Circular/Prospectus. <B>In order for you to receive timely delivery of the documents in advance of the Meeting, you must
request the information no later than five business days prior to the date of the Meeting, by January 8,
2026.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SIGNED IN SAN DIEGO, CALIFORNIA,
AS OF DECEMBER 9, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BY ORDER OF THE BOARD</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 50%; font-size: 10pt">/s/ Jared Kelly</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Jared Kelly</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Chief Executive Officer and Director</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS<SUP></SUP></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><A HREF="#pros_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros_001">v</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><A HREF="#pros_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INFORMATION ABOUT THE MEETING AND VOTING YOUR SHARES</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros_002">viii</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 87%"><A HREF="#pros_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solicitation of Proxies</FONT></A></TD>
    <TD STYLE="text-align: right; width: 10%"><A HREF="#pros_003">viii</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registered Shareholders</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros_004">ix</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial Shareholders</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros_005">x</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Voting of Common Shares &mdash; General</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros_006">xii</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quorum for the Meeting</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros_007">xiii</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Holders of Common Shares</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros_008">xiii</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><A HREF="#pros_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SUMMARY</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros_009">1</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><A HREF="#pros_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros_010">10</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks Relating to the Continuance and Domestication of Oncolytics</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros_011">10</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks Relating to our Business</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros_012">13</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><A HREF="#pros_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INFORMATION ABOUT THE SPECIAL MEETING OF ONCOLYTICS SHAREHOLDERS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros_013">14</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proposal No.&nbsp;1: The Continuance</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros_014">14</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proposal No.&nbsp;2: The Domestication</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros_015">14</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proposal No.&nbsp;3: The 2026 Plan</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros_016">15</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros_017"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Business</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros_017">15</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros_018"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Information</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros_018">15</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><A HREF="#pros_019"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROPOSAL NO. 1 &mdash; THE CONTINUANCE</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros_019">16</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros_020"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros_020">16</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros_021"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continuance into BCBCA</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros_021">16</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros_022"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory Approvals for the Continuance; Canadian Securities
Laws and Stock Exchange Implications</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros_022">16</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros_023"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effects of the Continuance</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros_023">16</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros02_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Reasons for the Continuance</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros02_001">17</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros02_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summary Comparison of Shareholder Rights</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros02_002">17</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros02_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dissent Rights of Shareholders &mdash; Alberta</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros02_003">17</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros02_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information Concerning Oncolytics</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros02_004">19</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#propos1_1"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information Concerning Oncolytics following the Continuance
and prior to the Domestication</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#propos1_1">22</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#propos1_2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vote Required and Recommendation of the Board</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#propos1_2">22</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><A HREF="#pros02_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROPOSAL NO. 2 &mdash; THE DOMESTICATION</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros02_007">23</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros02_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros02_008">23</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros02_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Reasons for the Domestication</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros02_009">23</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros02_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effects of Change of Jurisdiction</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros02_010">24</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros02_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder Approval</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros02_011">24</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros02_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory Approvals for the Domestication; Canadian and U.S.
Securities Laws and Stock Exchange Implications</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros02_012">25</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros02_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Officers and Directors</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros02_013">25</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros02_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treatment of the Outstanding Capital Stock and Options</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros02_014">25</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros02_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business, Location, Fiscal Year and Employee Plans</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros02_015">25</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros02_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dissent Rights of Shareholders &mdash; BC</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros02_016">25</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros02_017"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting Treatment of the Domestication</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros02_017">28</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros02_018"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax Consequences of the Domestication</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros02_018">28</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros02_019"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comparison of Rights</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros02_019">44</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros02_020"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information Concerning Oncolytics Nevada</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros02_020">44</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros3_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate Governance</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros3_001">49</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros3_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director and Executive Compensation</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros3_002">50</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros3_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial Ownership of Securities of Oncolytics Nevada</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros3_003">51</A></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 87%"><A HREF="#pros3_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Auditor, Registrar and Transfer Agent</FONT></A></TD>
    <TD STYLE="text-align: right; width: 10%"><A HREF="#pros3_004">51</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros3_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vote Required and Recommendation of the Board</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros3_005">51</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><A HREF="#pros3_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROPOSAL NO. 3 &mdash; APPROVAL OF THE ONCOLYTICS BIOTECH INC. 2026 Plan</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros3_006">51</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros3_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Overview</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros3_007">51</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros3_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026 Plan</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros3_008">52</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros3_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summary of the 2026 Plan</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros3_009">52</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><A HREF="#pros3_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VOTING COMMON SHARES AND THE PRINCIPAL HOLDERS OF COMMON SHARES</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros3_010">58</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros3_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Voting of Common Shares &mdash; General</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros3_011">58</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros3_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Holders of Common Shares</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros3_012">58</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros3_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnification of Directors and Officers</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros3_013">58</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><A HREF="#pros3_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MATERIAL DIFFERENCES BETWEEN ALBERTA CORPORATE LAW AND BRITISH COLUMBIA CORPORATE LAW</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros3_014">59</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><A HREF="#pros3_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MATERIAL DIFFERENCES BETWEEN BRITISH COLUMBIA CORPORATE LAW AND NEVADA CORPORATE LAW</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros3_015">59</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><A HREF="#pros3_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MATERIAL DIFFERENCES BETWEEN ALBERTA CORPORATE LAW AND NEVADA CORPORATE LAW</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros3_016">60</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><A HREF="#pros4_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INTEREST OF CERTAIN PERSONS OR COMPANIES IN MATTERS TO BE ACTED UPON</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros4_001">73</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><A HREF="#pros4_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INTEREST OF INFORMED PERSONS IN MATERIAL TRANSACTIONS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros4_002">73</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><A HREF="#pros4_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HOUSEHOLDING &mdash; SHAREHOLDERS SHARING THE SAME ADDRESS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros4_003">73</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><A HREF="#pros4_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MANAGEMENT CONTRACTS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros4_004">73</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><A HREF="#pros4_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RESTRICTED SECURITIES</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros4_005">73</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><A HREF="#pros4_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADDITIONAL INFORMATION</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros4_006">73</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><A HREF="#pros4_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros4_007">73</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><A HREF="#pros4_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros4_008">73</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><A HREF="#pros4_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros4_009">73</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros4_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Availability of Reports and Other Information</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros4_011">73</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="#pros4_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporation by Reference</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros4_012">74</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><A HREF="#pros4_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APPROVAL</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros4_010">74</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><A HREF="#pros4_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANNEX A &mdash; SPECIAL SHAREHOLDERS RESOLUTION APPROVING THE CONTINUANCE</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros4_013">A-1</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><A HREF="#pros4_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANNEX B &mdash; FORM&nbsp;OF CONTINUATION APPLICATION</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros4_014">B-1</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><A HREF="#pros4_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANNEX C &mdash; SPECIAL SHAREHOLDERS RESOLUTION APPROVING THE DOMESTICATION</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros4_015">C-1</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><A HREF="#pros4_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANNEX D &mdash; FORM&nbsp;OF ARTICLES OF DOMESTICATION</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros4_016">D-1</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><A HREF="#pros4_017"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANNEX E &mdash; FORM&nbsp;OF NEVADA ARTICLES OF INCORPORATION</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros4_017">E-1</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><A HREF="#pros4_018"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANNEX F &mdash; ONCOLYTICS BIOTECH INC. 2026 PLAN</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros4_018">F-1</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><A HREF="#pros4_019"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANNEX G &mdash; SECTION&nbsp;189 AND SECTION&nbsp;191 OF THE ABCA</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros4_019">G-1</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><A HREF="#pros4_020"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANNEX H &mdash; FORM&nbsp;OF NEVADA BYLAWS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros4_020">H-1</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><A HREF="#pros4_021"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANNEX I &mdash; DIVISION 2 OF PART&nbsp;8 OF THE BCBCA</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros4_021">I-1</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><A HREF="#pros4_022"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANNEX J &mdash; MATERIAL DIFFERENCES BETWEEN ALBERTA CORPORATE LAW AND BRITISH COLUMBIA CORPORATE LAW</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros4_022">J-1</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><A HREF="#pros4_023"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANNEX K &mdash; MATERIAL DIFFERENCES BETWEEN BRITISH COLUMBIA CORPORATE LAW AND NEVADA CORPORATE LAW</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#pros4_023">K-1</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><A HREF="#annexl">ANNEX L &ndash; HISTORICAL STATEMENT OF EXECUTIVE COMPENSATION FOR THE YEAR ENDED DECEMBER 31, 2024</A></TD>
    <TD STYLE="text-align: right"><A HREF="#annexl">L-1</A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="pros_001"></A>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Circular/Prospectus (including information incorporated by reference)
contains forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act, Section&nbsp;21E of the <I>U.S. Securities
Exchange Act of 1934</I>, as amended (the &ldquo;<B>Exchange Act</B>&rdquo;), and applicable Canadian securities laws. Such forward-looking
statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, our performance or achievements
or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking
statements. Forward-looking statements are statements that are not historical facts, and include, but are not limited to, the timing,
implementation and adoption of the Continuance, the Domestication, and the 2026 Plan, as applicable, the anticipated benefits of the Continuance,
the Domestication, and the 2026 Plan, as applicable, estimates and their underlying assumptions; statements regarding plans, objectives
and expectations with respect to the efficacy of our technologies; the timing and results of clinical studies related to our technologies;
future operations, products and services; the impact of regulatory initiatives on our operations; the size of and opportunities related
to the markets for our technologies; general industry and macroeconomic growth rates; expectations related to possible joint and/or strategic
ventures and statements regarding future performance. Forward-looking statements generally, but not always, are identified by the words
 &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;intends,&rdquo; &ldquo;estimates,&rdquo; &ldquo;projects,&rdquo;
 &ldquo;potential,&rdquo; &ldquo;possible&rdquo; and similar expressions, or that events or conditions &ldquo;will,&rdquo; &ldquo;may,&rdquo;
 &ldquo;could&rdquo; or &ldquo;should&rdquo; occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The forward-looking statements in this Circular/Prospectus
are subject to various risks and uncertainties, most of which are difficult to predict and generally beyond our control, including, without
limitation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the risk that there is substantial doubt that
we can remain a going concern over the next 12 months;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to all of our potential products,
including pelareorep, being in the research and development stage and requiring further development and testing before they can be marketed
commercially;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to any failure or delay in clinical
trials for our products, including pelareorep, which may cause us to incur additional costs or delay or prevent the commercialization
of our products and could severely harm our business;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks arising due to our candidate product, pelareorep,
being used in combination with other therapies, which exposes us to additional risks;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to external factors outside of
our control;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to the impact of any undesirable
side effects or other properties that our product candidate, pelareorep, may have, which could delay or prevent their regulatory approval;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the risk that we may expend our limited resources
to pursue a particular indication and fail to capitalize on indications that may be more profitable or for which there is a greater likelihood
of success;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the risk that we may not be able to secure a
partnership for pelareorep, which may halt future development;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the risk that we may need additional financing
in the future to fund the research and development of our products and to meet our ongoing capital requirements;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to the intense regulatory approval
processes under which pharmaceutical products are subject;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the risk that our operations and products may
be subject to other government manufacturing and testing regulations;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to our conduct of clinical trials
for pelareorep in sites outside the United States;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to our reliance on patents and
proprietary rights to protect our technology;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the risk that third parties may choose to file
patent infringement claims against us;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the risk related to our ability to protect the
confidentiality of our proprietary information and know-how, which could adversely affect the value of our technology and products;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to the sharing of our trade secrets
with third parties, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated
or disclosed;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to developments in patent law;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to the requirement to obtain protection
under the Hatch-Waxman amendments and similar foreign legislation for extending the term of patents covering our product candidate;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the risk that intellectual property rights do
not necessarily address all potential threats to our business;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the risk that our products may fail or cause
harm, subjecting us to product liability claims;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the risk that new products may not be accepted
by the medical community or consumers;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the risk that interim &ldquo;top-line&rdquo;
and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available
and are subject to audit and verification procedures;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the risk that our technologies may become obsolete;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to our reliance on third-party
manufacturers to produce our clinical products and on other third parties to store, monitor and transport bulk drug substance, and drug
product;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to our reliance on third parties
to produce and provide suitable raw materials for pelareorep production, packaging and testing as well as clinical trial-related testing;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to our reliance on third parties
to monitor, support, conduct, and oversee clinical trials of the products that we are developing and, in some cases, to maintain regulatory
files for those product candidates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to our dependence on Adlai Nortye
Biopharma Co. and our doing business in foreign jurisdictions in connection with our license, development, supply and distribution agreement
with Adlai Nortye Biopharma Co.;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the risk that our employees, independent contractors,
principal investigators, contract research organizations, consultants and vendors may engage in misconduct or other improper activities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to the cost of director and officer
liability insurance;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to our dependence on our key employees
and collaborators;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to our likely status as a &ldquo;passive
foreign investment company&rdquo; which may have adverse U.S. federal income tax consequences for U.S. shareholders;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the risk that we fail to meet all applicable
Nasdaq requirements and the possibility of our shares being delisted from Nasdaq;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the potential dilution of present and prospective
shareholdings;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to disruptions to our information
technology (&ldquo;IT&rdquo;) systems or those of any of our contractors, including disruptions from cybersecurity breaches of our IT
infrastructure;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to ownership of our securities.;
and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to the impact of any prolonged shutdown
of the U.S. government.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This list is not exhaustive of the factors that
may affect any of our forward-looking statements. In evaluating our forward-looking statements, you should specifically consider the risks
and uncertainties described in the section entitled &ldquo;<B>Risk Factors</B>&rdquo; in this circular/prospectus and in the documents
incorporated by reference into this circular/prospectus. In particular, see Part&nbsp;I,&nbsp;Item 3 of our most recent Annual Report
on Form&nbsp;20-F under the heading &ldquo;<B>Risk Factors</B>.&rdquo; If one or more of these risks or uncertainties materialize, or
if underlying assumptions prove incorrect, our actual results may vary materially from those expected, estimated or projected. Forward-looking
statements in this document are not a prediction of future events or circumstances, and those future events or circumstances may not occur.
Given these uncertainties, users of the information included herein, including investors and prospective investors, are cautioned not
to place undue reliance on such forward-looking statements. You should consult our quarterly and annual filings with the securities commissions
or similar regulatory authorities in Canada and the SEC for additional information on risks and uncertainties relating to forward-looking
statements. We do not assume responsibility for the accuracy and completeness of these statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->vi<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>FORWARD-LOOKING STATEMENTS ARE BASED ON OUR
BELIEFS, OPINIONS AND EXPECTATIONS AT THE TIME THEY ARE MADE, AND WE DO NOT ASSUME ANY OBLIGATION TO UPDATE OUR FORWARD-LOOKING STATEMENTS
IF THOSE BELIEFS, OPINIONS, OR EXPECTATIONS, OR OTHER CIRCUMSTANCES, SHOULD CHANGE, EXCEPT AS REQUIRED BY APPLICABLE LAW.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->vii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="pros_002"></A>INFORMATION
ABOUT THE MEETING AND VOTING YOUR SHARES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The following section briefly addresses
some commonly asked questions about the Meeting. This section may not include all the information that is important to you. You
should read carefully this entire Circular/Prospectus and the other documents referred to herein. References are included in certain
parts of this section to direct you to a more detailed discussion of the applicable topic. In this Circular/Prospectus, unless the
context otherwise requires, &ldquo;Oncolytics,&rdquo; the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo; and
 &ldquo;our&rdquo; refers to Oncolytics Biotech Inc. and its consolidated subsidiaries. Unless otherwise stated, all references to
 &ldquo;dollars&rdquo; or the use of the symbol &ldquo;$&rdquo; are to Canadian dollars. Unless otherwise stated, the following
information is provided as of November 28, 2025.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="pros_003"></A><B>Solicitation of Proxies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This management information circular and
circular/prospectus (the &ldquo;<B>Circular/Prospectus</B>&rdquo;) is supplied in connection with the solicitation of proxies by
management of Oncolytics for use at the special meeting (the &ldquo;<B>Meeting</B>&rdquo;) of holders
(&ldquo;<B>Shareholders</B>&rdquo;) of common shares (&ldquo;<B>Common Shares</B>&rdquo;) of the Company to be held on
Thursday, January 15, 2026 at 10:00 a.m.&nbsp;(Eastern
Time), for the purposes as described in the &ldquo;Notice of Special Meeting of Shareholders&rdquo; accompanying this
Circular/Prospectus. The Meeting will be held as a virtual-only meeting. A virtual-only meeting format enfranchises and gives all of
our Shareholders an equal opportunity to participate at the Meeting regardless of their geographic location or the particular
constraints or circumstances. See &ldquo;<I>How to Participate in The Meeting</I>&rdquo; for further information on how you can
virtually attend the Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is expected that the solicitation will primarily
be by mail. Proxies may also be solicited personally or by telephone by regular employees of and by agents engaged by the Company at nominal
cost. The cost of solicitation will be borne by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has retained the services of
Laurel Hill Advisory Group (&ldquo;<B>Laurel Hill</B>&rdquo;) to act as the Company&rsquo;s proxy solicitation agent and assist the
Company in communication with its Shareholders. In connection with such services, the Company will pay Laurel Hill a fee of
approximately $35,000 plus reasonable out-of-pocket expenses. If you
have any questions or require assistance in voting your proxy, please contact Laurel Hill at: 1-877-452-7184 toll free in North
America, or 416-304-0211 (outside North America); or by e-mail at: assistance@laurelhill.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>HOW TO VOTE YOUR COMMON SHARES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD ROWSPAN="2" STYLE="border-left: Black 1pt solid; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 5pt; width: 15%; text-align: center; padding-bottom: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>VOTING
    <BR>
METHOD</B></FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 5pt; width: 43%; text-align: center; padding-bottom: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BENEFICIAL
    SHAREHOLDERS</B></FONT></TD>
    <TD STYLE="border: Black 1pt solid; padding-top: 5pt; width: 42%; text-align: center; padding-bottom: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGISTERED
    SHAREHOLDERS</B></FONT></TD></TR>
  <TR>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 5pt; padding-top: 5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Shares held with a broker,
    bank, or other <BR>
intermediary.</I></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 5pt; padding-top: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Shares held in own name and<BR>
represented
by a physical certificate or DRS.</I></P></TD></TR>
  <TR>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 5pt; text-align: center; padding-bottom: 5pt">&nbsp;</TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 5pt; text-align: center; padding-bottom: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">www.proxyvote.com</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 5pt; padding-bottom: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ONLINE: </B>www.meeting-vote.com</P>
                                                      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EMAIL: </B>proxyvote@tmx.com</P></TD></TR>
  <TR>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 5pt; vertical-align: top; text-align: center; padding-bottom: 5pt">&nbsp;</TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 5pt; text-align: center; padding-bottom: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Call
    the toll-free number listed on your Voting Instruction Form&nbsp;(VIF) and vote using the control number provided therein.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 5pt; text-align: center; padding-bottom: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FAX:
    </B>416-607-7964</FONT></TD></TR>
  <TR>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 5pt; vertical-align: top; text-align: center; padding-bottom: 5pt">&nbsp;</TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 5pt; text-align: center; padding-bottom: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Complete,
    date and sign the voting instruction form and return it in the enclosed postage paid envelope.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 5pt; text-align: center; padding-bottom: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Complete,
    date and sign Management&rsquo;s form of proxy and return it in the enclosed postage paid envelope to <I>TSX Trust Company, Proxy
    Department P.O.&nbsp;Box 721, Agincourt, ON M1S 0A1</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->viii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="pros_004"></A><B>Registered Shareholders</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You are a registered Shareholder (a &ldquo;<B>Registered
Shareholder</B>&rdquo;) if your name is recorded in the Company&rsquo;s register of holders of Common Shares and you hold one or more
share certificates or a DRS Statement which indicate your name and the number of Common Shares which you own.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Voting by Proxy</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a Registered Shareholder, you will receive
a form of proxy from TSX Trust Company (&ldquo;<B>TSX Trust</B>&rdquo;) representing the Common Shares you hold. You may authorize the
management representatives named on the enclosed form of proxy to vote your Common Shares. If you choose this option, you can give your
voting instructions in any of the following ways:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Internet:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Go to <U>www.meeting-vote.com</U> and follow the instructions. You
will need to refer the Control Number printed on your proxy form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Mail:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Complete and return your proxy form in the envelope provided in your
mailing package and mail to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TSX Trust Company Proxy Department</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">P.O.&nbsp;Box 721</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Agincourt, Ontario M1S 0A1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Email:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Scan both sides of your completed proxy form and send to email address:
<U>proxyvote@tmx.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>A Shareholder submitting a proxy has the right
to appoint a person or company to represent him or her at the Meeting as proxyholder on their behalf and to vote their Common Shares
other than the persons designated in the form of proxy furnished by the Company. If you choose this option, you must strike out the preprinted
names and print that person&rsquo;s name in the blank space provided on the back of the enclosed form of proxy, you may indicate how
you want your Common Shares voted, and YOU MUST contact TSX Trust by going to TSX Trust&rsquo;s website to complete and submit the electronic
form at <U>https://www.tsxtrust.com/control-number-request</U> no later than Tuesday, January 13, 2026 at 10:00 a.m.&nbsp;(Eastern
Time) and provide TSX Trust with the required information for your appointee so that TSX Trust may provide the appointee with a control
number. This control number will allow your appointee to log in to, and vote at the Meeting. Without a control number your proxyholder
will only be able to log in to the Meeting as a guest and will not be able to vote. </B>You may also appoint a second person to be your
alternate proxyholder. Neither your proxyholder nor alternate proxyholder need be a Shareholder. The person you appoint must participate
in the Meeting and vote on your behalf in order for your votes to be counted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Unless you intend to participate in the
Meeting and vote at the Meeting (see &ldquo;<I>How to Participate in The Meeting</I>&rdquo; below), please remember that your form
of proxy or voting instruction form must be received no later than Tuesday, January 13, 2026 at 10:00 a.m.&nbsp;(Eastern Time). The
time limit for the deposit of proxies may be waived or extended by the chair of the Meeting at his or her discretion without
notice.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Registered Shareholders who have questions
regarding the Meeting or require assistance with voting, may contact our proxy solicitation agent, Laurel Hill Advisory Group at 1-877-452-7184
(North American Toll Free), 416-304-0211 (Calls Outside North America) or by email at <U>assistance@laurelhill.com</U>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ix<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="pros_005"></A><B>Beneficial Shareholders</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You are a beneficial Shareholder (a &ldquo;<B>Beneficial
Shareholder</B>&rdquo;) if a nominee (i.e. your securities broker, clearing agency, financial institution, trustee or custodian or other
intermediary) holds your Common Shares for you, or for someone else on your behalf.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Voting by Proxy</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Your nominee may have sent to you the Notice of
Special Meeting of Shareholders, including a voting instruction form or a blank proxy form signed by the nominee. You may provide your
voting instructions by filling in the appropriate boxes. Please follow your nominee&rsquo;s instructions for signing and returning the
applicable materials. Sometimes you may be allowed to give your instructions by internet or telephone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If you are a Beneficial Shareholder and you did not receive a form
of proxy or voting instruction form with a control number, please contact your nominee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Unless you intend to participate in the Meeting
and vote at the Meeting (see &ldquo;<I>How to Participate in The Meeting</I>&rdquo; below), please remember that your proxy or voting
instructions must be received no later than Tuesday, January 13,
2026 at 10:00 a.m.&nbsp;(Eastern Time). The time limit for the deposit of proxies may be waived or extended
by the chair of the Meeting at his or her discretion without notice.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Voting at the Meeting</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Your nominee may have sent to you the Notice of
Special Meeting of Shareholders, including a voting instruction form or a blank proxy form signed by the nominee. You may provide your
voting instructions by filling in the appropriate boxes. Please follow your nominee&rsquo;s instructions for signing and returning the
applicable materials. Sometimes you may be allowed to give your instructions by internet or telephone. You can give your voting instructions
in any of the following ways:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Internet:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Go to <U>www.proxyvote.com</U> and follow the instructions. You will
need to refer the control number printed on your voting instruction form to vote your Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Mail:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Enter your voting instructions, sign and date the voting instruction
form, and return the completed voting instruction form in the enclosed postage paid envelope.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Telephone:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Call the telephone number printed on your voting
instruction form. Enter the 16-digit control number printed on the voting instruction form and follow the interactive voice recording
instructions to vote your Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If you are a Beneficial Shareholder and you did not receive a form
of proxy or voting instruction form with a control number please contact your nominee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Unless you intend to participate in the Meeting
and vote at the Meeting (see &ldquo;<I>How to Participate in The Meeting</I>&rdquo; below), please remember that your proxy or voting
instructions must be received no later than Tuesday, January 13,
2026 at 10:00 a.m.&nbsp;(Eastern Time). The time limit for the deposit of proxies may be waived or extended
by the chair of the Meeting at his or her discretion without notice.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are two kinds of Beneficial Shareholders:
those who object to their name being made known to the issuers of securities which they own (called Objecting Beneficial Owners) and
those who do not object (called &ldquo;<B>NOBOs</B>&rdquo; for Non-Objecting Beneficial Owners). Oncolytics may be utilizing the Broadridge
QuickVote&trade; service to assist eligible Shareholders with voting their Common Shares. NOBOs may be contacted by Laurel Hill to obtain
a vote directly over the telephone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Oncolytics will not be sending proxy-related materials
directly to NOBOs, and does not intend to pay for intermediaries to forward to Objecting Beneficial Owners the proxy-related materials.
Objecting Beneficial Owners will not receive the proxy-related materials unless the Objecting Beneficial Owner&rsquo;s intermediary assumes
the cost of delivery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->x<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Beneficial Shareholders who have questions regarding
the Meeting or require assistance with voting, may contact our proxy solicitation agent, Laurel Hill Advisory Group at 1-877-452-7184
(North American Toll Free), 416-304-0211 (Calls Outside North America) or by email at <U>assistance@laurelhill.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>HOW TO PARTICIPATE IN THE MEETING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is holding the Meeting in a virtual-only
format, which will be conducted via live webcast. Shareholders will not be able to physically attend the Meeting in person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Participating in the Meeting online enables Registered
Shareholders and duly appointed proxyholders, including Beneficial Shareholders who have duly appointed themselves as proxyholder, to
listen to the Meeting and to submit questions. Registered Shareholders and duly appointed proxyholders can also vote at the appropriate
times during the Meeting. Beneficial Shareholders who have not properly appointed themselves as proxyholder will be able to attend the
Meeting as guests, but will not be able to vote or ask questions at the Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Questions relating to the business of the Meeting
may be raised when the particular item of business is being considered at the Meeting and will be addressed at that time, prior to voting
on such item of business. Following completion of the business of the Meeting, the Chief Executive Officer will open the floor to questions,
during which time Registered Shareholders and duly appointed proxyholders will have an opportunity to ask questions relating to the Company,
its performance and its operations. Registered Shareholders and duly appointed proxyholders attending virtually may submit questions through
the online platform during the Meeting by selecting the &ldquo;Messaging&rdquo; tab at the top of the screen, and entering their comment
or question in the &ldquo;Ask a Question&rdquo; box at the top of the messaging screen. Instructions will be available on the virtual
Meeting site and technical assistance will be available. Questions can be submitted at any time during the Meeting. Questions will be
read aloud so that all persons in attendance, in person and virtually, may hear.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Questions will be answered in the order received. If you have more
than one question, we request that out of courtesy to your fellow Shareholders, you ask one question at a time and then return to the
queue with any follow-up question you may have. Similar questions may be aggregated by the moderator, and questions and answers will be
posted on our website following the Meeting. In the event we run out of time to answer all questions, we encourage registered Shareholders
and duly appointed proxyholders to submit their questions in writing to our Investor Relations team at the contact information listed
elsewhere in this Circular/Prospectus so they, along with management&rsquo;s answers, can also be posted to our website. The responses
to questions submitted by Registered Shareholders and duly appointed proxyholders attending virtually that are not answered at the Meeting,
will also be posted to our website.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Step 1: Log in online at <U>https://virtual-meetings.tsxtrust.com/1847</U>.
We recommend that you log in at least 15 minutes before the Meeting starts.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Step 2: </B>Follow these instructions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Registered Shareholders: </B>Click
 &ldquo;<B>I have a control number</B>&rdquo; and then enter your control number and password:
onc2026 (case sensitive). The control number located on the form of
proxy or in the email notification you received from TSX Trust is your control number. If you use your control number to log in to
the Meeting, any vote you cast at the Meeting will revoke any proxy you previously submitted. If you do not wish revoke a previously
submitted proxy, you should not vote during the Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Duly appointed proxyholders: </B>Click &ldquo;<B>I
have a control number</B>&rdquo; and then enter your control number and password: onc2026 (case
sensitive). Proxyholders who have been duly appointed and registered with TSX Trust as described in this Circular/Prospectus will receive
a control number by email from TSX Trust after the proxy voting deadline has passed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Guests (including Beneficial Shareholders
who have not duly appointed themselves as proxyholder): </B>Click &ldquo;<B>Guest</B>&rdquo; and then complete the online form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If you attend the Meeting online, it is important
that you are connected to the internet at all times during the Meeting in order to vote when balloting commences. It is your responsibility
to ensure connectivity for the duration of the Meeting. You should allow ample time to check into the Meeting online and complete the
related procedure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTICE TO SHAREHOLDERS IN THE UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our solicitation of proxies is not subject to
the requirements of Section&nbsp;14(a)&nbsp;of the Exchange Act, by virtue an exemption applicable to proxy solicitations by &ldquo;foreign
private issuers&rdquo; as defined in Rule&nbsp;3b-4 under the U.S. Exchange Act. Accordingly, this Circular/Prospectus has been prepared
in accordance with the applicable disclosure requirements in Canada. Residents of the United States should be aware that requirements
are different than those of the United States applicable to proxy statements under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->xi<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It may be difficult for you to enforce your rights
and any claim you may have arising under U.S. federal securities laws, since we are located outside the United States, and certain of
the Company&rsquo;s officers and directors are residents of a country other than the United States. You may not be able to sue or effect
service of process upon a non-U.S. entity or its officers or directors in a non-U.S. court for violations of U.S. securities laws. It
may be difficult to compel a non-U.S. entity and its affiliates to subject themselves to a U.S. court&rsquo;s judgment or to enforce
a judgment obtained from a U.S. court against the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PERSONS MAKING THE SOLICITATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The solicitation is made on behalf of management
of Oncolytics. The costs incurred in the preparation and mailing of this Circular/Prospectus and related materials will be borne by Oncolytics.
In addition to solicitation by mail, proxies may be solicited by personal meetings, telephone or other means of communication and by
directors, officers and employees of Oncolytics, who will not be specifically compensated for any such activity. Oncolytics has also
retained Laurel Hill Advisory Group as its strategic shareholder communications advisor and proxy solicitation agent. In connection with
these services, Laurel Hill will receive approximately $35,000 plus reasonable out-of-pocket expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shareholders who have questions regarding the
Meeting or require assistance with voting may contact Laurel Hill at 1-877-452-7184 (North American Toll Free), 416-304-0211 (Calls Outside
North America) or by email at <U>assistance@laurelhill.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>EXERCISE OF DISCRETION BY PROXY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The persons named in the form of proxy will
vote the Common Shares in respect of which they are appointed in accordance with the direction of the Shareholders appointing them. In
the absence of such direction, such Common Shares will be voted:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>FOR</B>
                                            the Continuance Resolution approving the Continuance, as disclosed in this Circular/Prospectus.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>FOR</B>
                                            the Domestication Resolution approving the Domestication and the articles of incorporation
                                            governing Oncolytics post-Domestication, as disclosed in this Circular/Prospectus.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>FOR</B>
                                            the approval of the 2026 Plan, as disclosed in this Circular/Prospectus.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The form of proxy confers discretionary authority
upon the persons named therein with respect to amendments or variations to matters identified in the Notice and with respect to other
matters which may properly come before the Meeting. </B>At the time of printing of this Circular/Prospectus, management knows of no such
amendments, variations or other matters to come before the Meeting. However, if any other matters that are not currently known to the
Board or management should properly come before the Meeting, the proxy will be voted on such matters in accordance with the best judgment
of the named proxyholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>REVOCABILITY OF PROXY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Submitted proxies may be revoked at any time
prior to their exercise. If you have given a proxy and attend the Meeting at which the proxy is to be used in person, you may revoke
the proxy and vote in person instead. In addition to revocation in any other manner permitted by law, a proxy may be revoked by an instrument
in writing executed by yourself (or your attorney authorized in writing) or, in the case of a Shareholder being a corporation, under
the corporate seal or by a duly authorized officer or attorney. The proxy can be deposited either with TSX Trust as described above under
the heading &ldquo;<I>How to Vote Your Common Shares</I>&rdquo; or at the registered office of Oncolytics, being <B>4000, 421 &mdash;
7<SUP>th</SUP> Avenue S.W., Calgary, Alberta, T2P 4K9, Attention: Kirk Look, </B>at any time up to and including the last business day
preceding the day of the Meeting at which the proxy is to be used, or with the chair of the Meeting on the day of the Meeting, at which
point the proxy is revoked.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>VOTING COMMON SHARES AND THE PRINCIPAL HOLDERS
OF COMMON SHARES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="pros_006"></A><B>Voting of Common Shares &mdash; General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The record date for the purpose of determining holders of Common Shares
is December 9, 2025 (the &ldquo;<B>Record Date</B>&rdquo;). Shareholders of record
on the Record Date are entitled to receive notice of and attend the Meeting and vote at the Meeting on the basis of one vote for each
Common Share held, except to the extent that: (i)&nbsp;a Registered Shareholder has transferred the ownership of any Common Shares subsequent
to the Record Date; and (ii)&nbsp;the transferee of those Common Shares produces properly endorsed share certificates, or otherwise establishes
that he or she owns the Common Shares and demands, not later than the day that is ten (10)&nbsp;calendar days before the Meeting or any
adjournment thereof, that his or her name be included on the Shareholder list before the Meeting, in which case the transferee shall be
entitled to vote his or her Common Shares at the Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->xii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is authorized to issue an unlimited
number of Common Shares. As at the Record Date, there are 107,606,376
Common Shares issued and outstanding. At the Meeting, every Shareholder present in person or represented by proxy and entitled to vote
shall have one vote. On a poll or ballot, every Shareholder present in person or by proxy has one vote for each Common Share of which
such Shareholder is the registered holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When any Common Share is held jointly by several
persons, any one of them may vote at the Meeting in person or by proxy in respect of such Common Share, but if more than one of them
are present at the Meeting in person or by proxy and such joint owners of the proxy so present disagree as to any vote to be cast, the
joint owner present or represented whose name appears first in the register of Shareholders maintained by TSX Trust is entitled to cast
such vote.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="pros_007"></A><B>Quorum for the Meeting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the Meeting, a quorum shall consist of two
persons present in person holding or representing by proxy not less than 5% of the votes attached to all outstanding Common Shares. If
a quorum is not present at the Meeting within one half hour after the time fixed for the holding of the Meeting, it shall stand adjourned
to such day being not less than 21 days later and to such place and time as may be determined by the Chairman of the Meeting. At the
Meeting, the Shareholders present either in person or by proxy shall form a quorum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="pros_008"></A><B>Principal Holders of Common Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the knowledge of the directors and executive
officers of the Company, as at the date hereof, no persons or companies beneficially own, directly or indirectly, or exercise control
or direction over, Common Shares that carry more than 10% of the voting rights attached to the issued Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->xiii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="padding: 5pt; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><A NAME="pros_009"></A><B>SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This summary highlights selected information appearing elsewhere in
this Circular/Prospectus, and does not contain all the information that you should consider in making a decision with respect to the proposals
described in this Circular/Prospectus. You should read this summary together with the more detailed information incorporated by reference
into this Circular/Prospectus, <B>including our financial statements and the related notes incorporated by reference into this Circular/Prospectus
from our </B><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1129928/000112992825000019/oncyf-20241231.htm"><B>Form&nbsp;20-F
for the fiscal year ended December&nbsp;31, 2024</B></A> <B>and the Condensed Interim Consolidated Financial Statements and Management&rsquo;s
Discussion and Analysis for the three and nine months ended September 30, 2025, as well as the exhibits attached thereto. You should carefully
consider, among other things, the matters discussed in the sections of the Form&nbsp;20-F entitled &ldquo;Risk Factors&rdquo; and &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations&rdquo; which are included or incorporated by reference into this
Circular/Prospectus. </B>You should read this Circular/Prospectus and the documents incorporated by reference into this Circular/Prospectus
in their entirety.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All of the dollar amounts in this Circular/Prospectus
are expressed in Canadian dollars, except where otherwise indicated. References to &ldquo;dollars&rdquo; or &ldquo;$&rdquo; are to Canadian
dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When we refer to Oncolytics Biotech Inc., and
its subsidiaries, we use the terms &ldquo;<B>Oncolytics,</B>&rdquo; the &ldquo;<B>Company,</B>&rdquo; &ldquo;<B>us,</B>&rdquo; &ldquo;<B>we</B>&rdquo;
and &ldquo;<B>our</B>.&rdquo; All references to &ldquo;<B>Oncolytics Nevada</B>&rdquo; contained in this Circular/Prospectus refer solely
to Oncolytics Biotech Inc., a Nevada corporation, as of the effective time of the Domestication. In addition, the common shares of Oncolytics
as an Alberta corporation, the common shares of Oncolytics as a British Columbia company and the shares of common stock of Oncolytics
Nevada are, as applicable, referenced herein as our &ldquo;<B>Common Shares</B>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a clinical-stage biopharmaceutical company
developing pelareorep, a well-tolerated intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune
systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer and makes tumors more susceptible
to a broad range of oncology treatments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pelareorep is a proprietary isolate of reovirus,
a naturally occurring, non-pathogenic double-stranded RNA (&ldquo;<B>dsRNA</B>&rdquo;) virus commonly found in environmental waters.
Pelareorep changes the tumor microenvironment (&ldquo;<B>TME</B>&rdquo;) to make it more immunologically favourable, which in turn makes
the tumor more susceptible to various treatment combinations. These treatments include chemotherapies, checkpoint inhibitors, and other
immuno-oncology approaches such as CAR T therapies, bispecific antibodies, and CDK4/6 inhibitors. Pelareorep also induces a new army
of tumor-reactive T cells, helps these cells to infiltrate the tumor through an inflammatory process, and promotes the overexpression
of PD-L1. By priming the immune system with pelareorep, we believe we can increase the proportion of patients who respond to various
cancer treatments, including immunotherapies, especially in cancers where existing treatment regimens have failed or provided limited
benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not been profitable since our inception
and expect to continue to incur substantial losses as we continue research and development efforts. We do not expect to generate significant
revenues until and unless pelareorep becomes commercially viable. As a clinical-stage drug development company, we consistently discuss
and pursue potential partnerships, licensing agreements and other strategic transactions with third parties. Due to the capital-intensive
nature of early-stage drug development, we continuously analyze our available cash and projected operating costs to determine whether
to seek additional funds via the capital markets. To date, we have funded our operations mainly through the issuance of additional capital
via public offerings, equity distribution arrangements, and through the exercise of warrants and options. There can be no assurance that
we will be able to raise additional funds through the sale of our Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Business Strategy</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business strategy is to develop and seek
regulatory approval to market pelareorep in an effective and timely manner. We intend to achieve our business strategy by focusing on
these key areas:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">position
                                            pelareorep as a platform-in-a-product immunotherapy in gastrointestinal tumors, specifically
                                            pancreatic, colorectal, and anal cancer, with a clear registration pathway for each indication;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">leverage
                                            the existing safety and efficacy data of pelareorep in human subjects to either establish
                                            a formal partnership for its development in a given indication or advance pelareorep toward
                                            registration through a relatively small registration-enabling study that would be eligible
                                            for accelerated approval or through an investigator-sponsored trial;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="padding: 5pt; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">maintain
                                            existing and establish new collaborations with key opinion leaders to assist us with scientific
                                            and clinical developments of this new potential pharmaceutical product;</FONT></TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">implement
                                            strategic alliances with select biopharmaceutical companies and laboratories, at a time and
                                            in a manner whereby such alliances may complement and expand our own research and development
                                            efforts. Such alliances may also result in an eventual expansion to include providing additive
                                            sales and marketing capabilities; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">extend
                                            the patent life of pelareorep by highlighting the unique manufacturing process required to
                                            harvest and extract the virus.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of pelareorep&rsquo;s compelling
data in multiple gastrointestinal tumors, our clinical development program intends to move quickly to pursuing registration. Pelareorep
has shown a unique ability to enhance innate and adaptive anti-tumor immune responses leading to clinical outcomes that exceed historical
benchmarks when combined with multiple standard-of-care cancer treatments. This greatly increases opportunities for expanding our clinical
program, business development, and partnering opportunities to address a broad range of gastrointestinal cancers in which immunotherapies
have historically provided limited clinical benefit. We believe this approach has the most promise for expeditious paths to regulatory
approvals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our primary focus is to advance our programs
in gastrointestinal cancers, specifically first-line metastatic pancreatic ductal adenocarcinoma (&ldquo;<B>PDAC</B>&rdquo;), second-line
KRAS-mutated metastatic colorectal cancer (&ldquo;<B>mCRC</B>&rdquo;), and second-line or later squamous cell carcinoma of the anal canal
(&ldquo;<B>SCAC</B>&rdquo;) to registration-enabled clinical studies. In addition, we are exploring other gastrointestinal cancer registrational
opportunities using different treatment regimens in our GOBLET platform study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business strategy is based on attaining a
number of commercial objectives, which, in turn, are supported by a number of product development goals. In the context of this annual
report, statements of our &ldquo;belief&rdquo; are based primarily upon our results derived to date from our research and development
program in animals, early-stage human trials, and our most recent data from mid-stage clinical trials, upon which we believe that we
have a reasonable scientific basis to expect the particular results to occur. It is not possible to predict, based upon studies in animals,
or early to mid-stage human trials, whether a new therapeutic will ultimately prove to be safe and effective in humans. There are no
assurances that the particular result we expect will occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are pursuing a strategy of establishing relationships
with larger companies as strategic partners. It is anticipated that future clinical development into large international or pivotal trials
would generally occur in conjunction with a strategic partner or partners, who would contribute expertise and financial assistance. In
exchange for certain product rights and commitments to market our products, the strategic partners would be expected to share in proceeds
from the sale of our product or products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further information regarding our business is
contained in Item 4 of our Annual Report on Form&nbsp;20-F under the heading &ldquo;<I>Information on the Company</I>,&rdquo; which document
is incorporated by reference in this circular/prospectus. See &ldquo;<I>Incorporation by Reference</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Information About the Special Meeting of Oncolytics
Shareholders (see page&nbsp;14)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Meeting will be held on Thursday,
January 15, 2026, at 10:00 a.m.&nbsp;(Eastern Time) virtually via live webcast at
https:<B>//virtual-meetings.tsxtrust.com/1847</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You are being asked to vote on the following
matters:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">to consider and, if thought advisable, pass,
                                            with or without variation, the Continuance Resolution, attached to this Circular/Prospectus
                                            as Annex <B>A</B>, authorizing the Continuance through the adoption of the Continuation Application
                                            containing the Notice of Articles and the Articles, attached to this Circular/Prospectus
                                            as Annex <B>B</B> and Annex <B>E</B>, respectively, subject to and conditional upon the approval
                                            of the Domestication Resolution;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">to consider and, if thought advisable, pass,
                                            with or without variation, the Domestication Resolution, attached to this Circular/Prospectus
                                            as Annex <B>C</B>, authorizing the Domestication and the adoption of the articles of domestication
                                            and new articles of incorporation, copies of which are attached to this Circular/Prospectus
                                            as Annexes <B>D</B> and <B>E</B>, respectively, subject to and conditional upon the approval
                                            of the Continuance Resolution;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">to consider, and if thought advisable, approve,
                                            subject to and conditional upon the completion of the Continuance and Domestication, the
                                            2026 Plan, a copy of which is attached to the Circular/Prospectus as Annex <B>F</B>; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="padding: 5pt; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">to transact such other business as may properly
                                            be brought before the Meeting or any adjournment thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is authorized to issue an unlimited
number of Common Shares. As at the Record Date, there were 107,606,376
Common Shares issued and outstanding and entitled to vote at the Meeting. Each Common Share entitles its holder to one vote. The Common
Shares are listed on Nasdaq under the symbol &ldquo;ONCY.&rdquo; Our Common Shares will continue to be listed on Nasdaq under their existing
trading symbol, including following the effectiveness of the Domestication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Only Shareholders of record at the close of business
on the Record Date are entitled to notice of the Meeting and to vote at the Meeting or any adjournment or postponement thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A quorum is required in order for the Meeting
to be properly constituted. At the Meeting, a quorum shall consist of two persons present in person holding or representing by proxy
not less than 5% of the votes attached to all outstanding Common Shares. If a quorum is not present at the Meeting within one half hour
after the time fixed for the holding of the Meeting, it shall stand adjourned to such day being not less than 21 days later and to such
place and time as may be determined by the Chairman of the Meeting. At the Meeting, the Shareholders present either in person or by proxy
shall form a quorum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The approval of the 2026 Plan will be determined
by a majority of votes cast at the Meeting by proxy or in person. The Continuance and the Domestication will each require approval by
the affirmative vote of not less than two thirds of the votes cast at the Meeting by proxy or in person. Our Board has reserved the right,
in its sole discretion, to terminate or abandon the Continuance or the Domestication at any time prior to their effectiveness, notwithstanding
Shareholder approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If your Common Shares are registered in your
name and you abstain from voting on any of the proposals set forth in this Circular/Prospectus, your abstention will not have any effect
on the outcome of the vote for such proposal. Abstentions will each be counted for the quorum requirement. If you hold your Common Shares
through a bank, broker or other agent and you do not instruct the bank, broker or other agent on how to vote on any of the proposals
set forth in this Circular/Prospectus, your bank, broker or other agent will not have authority to vote your Common Shares. Broker non-votes
will not have an impact on the outcome of the proposals in this Circular/Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Board has unanimously approved the forms
of the Continuance Resolution and the Domestication Resolution and the other proposals described in this Circular/Prospectus and has
unanimously resolved to submit such proposals to the Company&rsquo;s Shareholders. Our Board recommends that you vote &ldquo;FOR&rdquo;
the approval of the Continuance Resolution, &ldquo;FOR&rdquo; the approval of the Domestication Resolution, and &ldquo;FOR&rdquo; the
approval of the 2026 Plan.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risk Factors (see page&nbsp;10)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In evaluating the Continuance Resolution, the
Domestication Resolution and the other matters set forth in this Circular/Prospectus, you should carefully read this Circular/Prospectus
and especially consider the factors discussed in the section titled &ldquo;<B>Risk Factors</B>&rdquo; beginning on page&nbsp;<B>10</B>
of this Circular/Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SUMMARY OF THE CONTINUANCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This summary of certain information contained
in this Circular/Prospectus relating to the Continuance may not include all the information that is important to you. To understand fully
and for a more complete description of the terms and conditions of the Continuance, you should read this Circular/Prospectus in its entirety
and the documents to which you are referred. See &ldquo;<B>Where You Can Find More Information.</B>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Continuance (see page&nbsp;16)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are currently governed by the ABCA. At the
Meeting, the Shareholders will be asked to consider and, if thought advisable, pass the Continuance Resolution authorizing the Board,
in its sole discretion, to implement the Continuance. Upon completion of the Continuance, the ABCA will cease to apply to us and we will
thereupon become subject to the <I>Business Corporations Act</I> (British Columbia) (the &ldquo;<B>BCBCA</B>&rdquo;), as if we had been
originally incorporated as a company in the Province of British Columbia. The Continuance will not create a new legal entity, affect
the continuity of Oncolytics or result in a change in our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board believes it to be in the best interests
of Oncolytics to have discretion to change our jurisdiction from the Province of Alberta to the Province of British Columbia pursuant
to a &ldquo;continuance&rdquo; effected in accordance with Section&nbsp;189 of the ABCA and section 303 of the BCBCA. The Shareholders
are being asked to consider and, if thought fit, to pass the Continuance Resolution, attached to this Circular/Prospectus as Annex <B>A</B>,
at the Meeting, authorizing the Board, in its sole discretion, to determine whether to implement the Continuance, and if the Board so
determines to proceed with the Continuance, to implement the Continuance and apply under the BCBCA for a certificate of continuation
which shall be issued by the Registrar (the &ldquo;<B>Registrar</B>&rdquo;) appointed under the BCBCA (the &ldquo;<B>Certificate of Continuation</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="padding: 5pt; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Continuance is approved by the Shareholders
at the Meeting, the Continuance would only be implemented upon a determination by the Board that it is in the best interest of Oncolytics
at that time and will be subject to and conditional upon the approval of the Domestication. In connection with any determination to implement
the Continuance, the Board will set the timing for such Continuance. Although it is the current intention of the Board to proceed with
the Continuance prior to the Domestication, it has no obligation to do so and will have no liability associated with any decision as
to whether or not to proceed with the Continuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Continuance is approved by the Shareholders
at the Meeting and the Board so determines to proceed with the Continuance, and further provided that we obtain the authorization of
the Alberta Registrar of Corporations under the ABCA, the Continuance will be effective on the date set forth in the Certificate of Continuation
and the Alberta Registrar of Corporations will issue a certificate of discontinuation in Alberta. On the date shown on the Certificate
of Continuation, we will cease to be governed by the ABCA and will become a company in the Province of British Columbia as if we had
been incorporated under the BCBCA. The certified Notice of Articles (included in the Continuation Application), a form of which is attached
to this Circular/Prospectus as Annex <B>B</B>, will function as our articles of incorporation and contain essentially the same terms
as our current articles of incorporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Regulatory Approvals for the Continuance;
Canadian Securities Laws and Stock Exchange Implications (see page&nbsp;16)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Should the Shareholders approve the Continuance
Resolution at the Meeting and the Board determine to proceed with the Continuance, we anticipate that we will file the Continuation Application
containing the Notice of Articles of Oncolytics which comply with the provisions of the BCBCA and any other necessary documentation with
the Registrar appointed under the BCBCA as required in connection with the Continuance. We will be continued under the jurisdiction of
the Province of British Columbia on the effective date of the Certificate of Continuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Continuance will not otherwise interrupt
our corporate existence, our operations or the trading market of our Common Shares. Each outstanding Common Share at the time of the
Continuance will remain issued and outstanding as a Common Share of Oncolytics after our corporate existence is continued from the Province
of Alberta under the ABCA to the Province of British Columbia under the BCBCA. Following the completion of the Continuance, the Common
Shares will continue to be listed on Nasdaq under the symbol &ldquo;ONCY.&rdquo; We will continue to be subject to the rules&nbsp;and
regulations of Nasdaq and the obligations imposed by the securities regulatory authorities in the United States and in Canada. We will
continue to file periodic reports with applicable securities regulatory bodies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Effects of The Continuance (see page&nbsp;16)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Continuance will not interrupt our corporate
existence or operations. If the Continuance is approved by the Shareholders and the Board determines to proceed with the Continuance,
the Continuance will change our home jurisdiction from the Province of Alberta to the Province of British Columbia. Each outstanding
Common Share at the time of the Continuance will remain issued and outstanding as a Common Share of Oncolytics after our corporate existence
is continued from the Province of Alberta under the ABCA to the Province of British Columbia under the BCBCA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While the rights and privileges of shareholders
of a British Columbia company are, in many instances, comparable to those of shareholders of an Alberta corporation, there are certain
differences. In addition, in connection with the Continuance, we will be governed by newly adopted Articles, the form of such Articles
is attached to this Circular/Prospectus as Annex <B>E</B>, which are different from our current organizational documents. For a more
detailed description of how the new organizational documents and British Columbia corporate law under the BCBCA may differ from our current
organizational documents and Alberta corporate law under the ABCA, see &ldquo;<I>Material Differences between Alberta Corporate Law and
British Columbia Corporate Law</I>&rdquo; attached hereto as Annex <B>J</B>. This description is not intended to be complete and is qualified
in its entirety by reference to the ABCA, the BCBCA and our governing documents. Shareholders should consult their legal advisors regarding
all of the implications of the transactions contemplated in the Continuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="padding: 5pt; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Principal Reasons for the Continuance (see
page&nbsp;17)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Domestication is the key reason for our proposal
of the Continuance. Since the Domestication contemplates a change in our jurisdiction from the Province of British Columbia to the State
of Nevada in the United States, the Board first intends to continue us from the Province of Alberta to the Province of British Columbia
in order to be able to effect the Domestication if it so determines to proceed with the Domestication. For further background on the
reasons for the Domestication, see &ldquo;<I>Summary of the Domestication&mdash;Principal Reasons for the Domestication</I>.&rdquo; The
Board intends to effect the Continuance if the Domestication Resolution is approved by Shareholders at the Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Shareholder Approval of Continuance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Shareholders will be asked at the Meeting
to pass the Continuance Resolution authorizing the Board, in its sole discretion, to effect the Continuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain Shareholders are entitled to dissenters&rsquo;
rights in connection with the Continuance pursuant to Section&nbsp;189(2)&nbsp;and Sections 191(1)(d)&nbsp;and 191(3)&nbsp;of the ABCA.
See &ldquo;<I>Dissenters&rsquo; Rights</I>&rdquo; immediately below for additional information. To be adopted, the Continuance Resolution
must be approved by the affirmative vote of at least two-thirds of the votes cast by the Shareholders present or represented by proxy
at the Meeting. 1.39<SUP></SUP>% of outstanding shares entitled to vote are held by our directors, executive officers and their affiliates
as of the Record Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Continuance is approved by the Shareholders,
the Continuance would only be implemented upon a determination by the Board that it is in the best interest of Oncolytics at that time,
and is subject to and conditioned upon the approval of the Domestication Resolution. In connection with any determination to implement
the Continuance, the Board will set the timing for such Continuance. Although it is the current intention of the Board to proceed with
the Continuance prior to the Domestication, it has no obligation to do so and will have no liability associated with any decision as
to whether or not to proceed with the Continuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise instructed, the persons named
in the enclosed form of proxy intend to vote at the Meeting in favour of the Continuance Resolution. The complete text of the Continuance
Resolution authorizing the Board, in its sole discretion, to effect the Continuance is set forth in &ldquo;<I>Proposal No.&nbsp;1&mdash;The
Continuance&mdash;Vote Required and Recommendation of the Board.</I>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dissenters&rsquo; Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain Shareholders are entitled to, subject
to compliance with certain conditions, dissent from the Continuance and, conditional on the Continuance becoming effective, be entitled
to be paid the fair value for their Common Shares in accordance with Section&nbsp;189(2)&nbsp;and Sections 191(1)(d)&nbsp;and 191(3)&nbsp;of
the ABCA, a copy of which is attached to the Circular/Prospectus as Annex <B>G</B>. Such Shareholders who wish to dissent should seek
the advice of legal advisors and carefully read this Circular/Prospectus and the provisions of Section&nbsp;189 and Section&nbsp;191
of the ABCA. The following description of the rights of a dissenting Shareholder in connection with the Continuance is not a comprehensive
statement of the procedures to be followed by a dissenting Shareholder who seeks payment of the fair value of his, her or its Common
Shares and is qualified in its entirety by the full texts of Section&nbsp;189 and Section&nbsp;191 of the ABCA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A Shareholder who intends to exercise his, her or its dissent rights
under the ABCA in connection with the Continuance should carefully consider and comply with the provisions of Section&nbsp;189 and Section&nbsp;191
of the ABCA. Failure to comply with the provisions of those sections and to adhere to the procedures established therein may result in
the loss of all rights thereunder. Beneficial Shareholders who wish to dissent should be aware that only the registered owner of the Common
Shares is entitled to dissent on behalf of the Beneficial Shareholder. Accordingly, a Beneficial Shareholder desiring to exercise his,
her or its dissent rights under the ABCA in connection with the Continuance must make arrangements for the Common Shares beneficially
owned by him, her or it to be registered in his, her or its name prior to the time the written objection to the Continuance is required
to be received by us or, alternatively, make arrangements for the registered holder of his, her or its Common Shares to dissent on his,
her or its behalf. Beneficial Shareholders who wish to dissent should contact their broker or other intermediary for assistance with exercising
their dissent rights under the ABCA in connection with the Continuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="padding: 5pt; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SUMMARY OF THE DOMESTICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This summary of certain information contained
in this Circular/Prospectus relating to the Domestication may not include all the information that is important to you. To understand
fully and for a more complete description of the terms and conditions of the Domestication, you should read this Circular/Prospectus
in its entirety and the documents to which you are referred. See &ldquo;<B>Where You Can Find More Information.</B>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Domestication (see page&nbsp;23)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to and conditional upon the approval
by the Shareholders of the Continuance Resolution, and subject to the discretion of the Board, the Board is proposing to change our
jurisdiction from the jurisdiction of the Province of British Columbia in Canada to the jurisdiction of the State of Nevada in the
United States by way of a &ldquo;continuation&rdquo; out of British Columbia effected in accordance with Section&nbsp;308 of the
BCBCA and the Domestication under NRS 92A.270, and approve the adoption of the articles of domestication, a form of which is
attached to this Circular/Prospectus as Annex <B>D</B> (the &ldquo;<B>Articles of Domestication</B>&rdquo;), and new articles of
incorporation, a form of which is attached to this Circular/Prospectus as Annex <B>E</B> (the &ldquo;<B>Oncolytics Nevada
Charter</B>&rdquo;), to be effective on the date of the Domestication. We will become subject to the NRS on the effective date of
the Domestication, but we will be deemed for the purposes of the NRS to begin our existence in Nevada on the date we began our
existence in Alberta. Under the NRS, a corporation becomes domesticated in Nevada by filing with the Nevada Secretary of State
articles of domestication and the appropriate charter document for the Company being domesticated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board believes it to be in the best interests
of Oncolytics to have discretion to change our jurisdiction from the jurisdiction of the Province of British Columbia to the State of
Nevada pursuant to a &ldquo;continuation out&rdquo; effected in accordance with Section&nbsp;308 of the BCBCA and a &ldquo;domestication&rdquo;
under NRS 92A.270. Shareholders are being asked to consider and, if thought fit, to pass the Domestication Resolution at the Meeting
(which includes, without limitation, approval of the Oncolytics Nevada Charter), authorizing the Board, in its sole discretion, to determine
whether to implement the Domestication, and if the Board so determines to proceed with the Domestication, to implement the Domestication
and file the Articles of Domestication and the Oncolytics Nevada Charter so that we continue our existence as a corporation incorporated
under the NRS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Domestication and the Oncolytics Nevada
Charter are approved by the Shareholders at the Meeting, the Domestication would only be implemented upon a determination by the Board
that it is in the best interest of Oncolytics at that time and provided that we have previously effected the Continuance or will effect
the Continuance prior to implementing the Domestication. In connection with any determination to implement the Domestication, the Board
will set the timing for such Domestication. Although it is the current intention of the Board to proceed with the Domestication following
the Continuance, it has no obligation to do so and will have no liability associated with any decision as to whether or not to proceed
with the Domestication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Domestication and the Oncolytics Nevada
Charter are approved by the Shareholders at the Meeting and the Board so determines to proceed with the Domestication, subject to and
conditional upon the approval of the Continuance Resolution and the prior implementation of the Continuance, the Domestication will be
effective on the date set forth in the Articles of Domestication and the Oncolytics Nevada Charter as filed with the office of the Nevada
Secretary of State. Thereafter, we will be subject to the Oncolytics Nevada Charter filed in Nevada. Proposed forms of the Articles of
Domestication, the Oncolytics Nevada Charter and bylaws that will be adopted by us and will be in effect upon the effectiveness of the
Domestication (the &ldquo;<B>Oncolytics Nevada Bylaws</B>&rdquo;) are set out in Annexes <B>D, E and H</B>, respectively, to this Circular/Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Principal Reasons for the Domestication (see
page&nbsp;23)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Domestication is intended to reduce the regulatory
burden and cost of being subject to the laws and regulations of both the United States and Canada and to reduce our operating costs and
enable us to compete effectively in raising the capital necessary for us to continue to implement our strategic plan. In addition, our
operations are located in the United States and a large percentage of our Shareholders are located in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We chose the State of Nevada to be our domicile
in part because the NRS accommodates a continuance authorized by the BCBCA. We also chose the State of Nevada because of the more
favourable corporate environment afforded by Nevada. For many years, Nevada has followed a policy of encouraging incorporation in that
state and, in furtherance of that policy, has adopted, construed and implemented comprehensive, flexible corporate laws and corporate
governance responsive to the legal and business needs of corporations organized under its laws. We considered Nevada&rsquo;s statute-focused
approach to corporate law and other merits of Nevada law and determined that Nevada&rsquo;s approach to corporate law is likely to foster
more predictability than Delaware&rsquo;s approach. Among other things, the Nevada statutes codify the fiduciary duties of directors
and officers, which decreases reliance on judicial interpretation and promotes stability and certainty for corporate decision-making.
We also considered the increasingly litigious environment in Delaware, which has engendered less meritorious and costly litigation and
has the potential to cause unnecessary distraction to the Company&rsquo;s directors and management team and potential delay in the Company&rsquo;s
response to the evolving business environment. We believe that a more predictable legal environment will better permit the Company to
respond to emerging business trends and conditions as needed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="padding: 5pt; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Regulatory Approvals for the Domestication;
Canadian and U.S. Securities Laws and Stock Exchange Implications (see page&nbsp;25)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Should the Shareholders approve the Domestication
at the Meeting and the Board so determines to proceed with the Domestication, we anticipate that we will file with the Nevada Secretary of State the Articles of Domestication and the Oncolytics Nevada Charter pursuant to NRS 92A.270, and that we will be domesticated
in Nevada on the effective date of such filings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Domestication will not otherwise interrupt
our corporate existence, our operations or the trading market of our Common Shares. Each outstanding Common Share at the time of the
Domestication will remain issued and outstanding as a share of Oncolytics Nevada common stock after our corporate existence is continued
from the jurisdiction of the Province of British Columbia under the BCBCA and domesticated in Nevada under the NRS. Following the completion
of the Domestication, our Common Shares will continue to be listed on Nasdaq under the symbol &ldquo;ONCY.&rdquo; We will continue to
be subject to the rules&nbsp;and regulations of Nasdaq and the obligations imposed by the securities regulatory authorities in the United
States and in Canada. We will continue to file periodic reports with applicable securities regulatory bodies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Effects of Change of Jurisdiction (see page&nbsp;24)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Domestication will not interrupt our corporate
existence or operations. If the Domestication and the Oncolytics Nevada Charter are approved by the Shareholders and the Board determines
to proceed with the Domestication, the Domestication will change our jurisdiction from the jurisdiction of the Province of British Columbia
to the State of Nevada. Each outstanding Common Share at the time of the Domestication will remain issued and outstanding as a share
of Oncolytics Nevada common stock after our corporate existence is continued from the jurisdiction of the Province of British Columbia
under the BCBCA and domesticated in Nevada under the NRS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While the rights and privileges of stockholders
of a Nevada corporation are, in many instances, comparable to those of shareholders of a BCBCA corporation, there are certain differences.
In addition, in connection with the Domestication, we will be governed by the proposed Oncolytics Nevada Charter and Oncolytics Nevada
Bylaws, which are different from our current organizational documents. For a more detailed description of how the new organizational
documents and Nevada law may differ from the organizational documents to be adopted upon the Continuance and British Columbia corporate
law, see &ldquo;<I>Material Differences between British Columbia Corporate Law and Nevada Corporate Law</I>&rdquo; attached hereto as
Annex <B>K</B>. This description is not intended to be complete and is qualified in its entirety by reference to the NRS, the proposed
Oncolytics Nevada Charter and Oncolytics Nevada Bylaws, the BCBCA and the governing documents to be adopted upon the Continuance. For
a more detailed description of how the new organizational documents and Nevada law may differ from our current organizational documents
and Alberta corporate law, see &ldquo;<I>Material Differences between Alberta Corporate Law and Nevada Corporate Law</I>.&rdquo; This
description is not intended to be complete and is qualified in its entirety by reference to the NRS, the ABCA and our governing documents.
Shareholders should consult their legal advisors regarding all of the implications of the transactions contemplated in the Domestication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Accounting Treatment of the Domestication
(see page&nbsp;28)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the Domestication, pursuant to
NRS 92A.270, we will continue our existence under the NRS as a corporation incorporated in the State of Nevada. Our business, assets
and liabilities and our subsidiaries, on a consolidated basis, as well as our principal location and fiscal year, will be the same immediately
after the Domestication as they were immediately prior to the Domestication. Accordingly, we do not believe there will be any accounting
effects as a result of the Domestication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Tax Consequences of the Domestication (see
page&nbsp;28)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See &ldquo;<I>Proposal No.&nbsp;2 &mdash; The
Domestication&mdash;Tax Consequences of the Domestication</I>&rdquo; for important information regarding tax consequences relating to
the Domestication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5pt; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shareholders should consult their own tax advisors
for advice with respect to the tax consequences to them of the Domestication in their particular circumstances, including the application
and effect of the income and other tax laws of any country, province, state or local tax authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Shareholder Approval of Domestication</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shareholders will be asked at the Meeting to
pass the Domestication Resolution (which includes, without limitation, approval of the Oncolytics Nevada Charter) authorizing the Board,
in its sole discretion, to effect the Domestication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain Shareholders are entitled to dissenters&rsquo;
rights in connection with the Domestication pursuant to Division 2 of Part&nbsp;8 of the BCBCA. See &ldquo;<I>Dissenters&rsquo; Rights</I>&rdquo;
immediately below for additional information. To be adopted, the Domestication Resolution must be approved by the affirmative vote of
at least two-thirds of the votes cast by the Shareholders present or represented by proxy at the Meeting. 1.39%
of outstanding shares entitled to vote are held by our directors, executive officers and their affiliates as of the Record Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Domestication and the Oncolytics Nevada
Charter are approved by the Shareholders, the Domestication would only be implemented upon a determination by the Board that it is in
the best interest of Oncolytics at that time. In connection with any determination to implement the Domestication, the Board will set
the timing for such Domestication. Although it is the current intention of the Board to proceed with the Domestication following the
Continuance, it has no obligation to do so and will have no liability associated with any decision as to whether or not to proceed with
the Domestication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise instructed, the persons named
in the enclosed form of proxy intend to vote at the Meeting in favour of the Domestication Resolution. The complete text of the Domestication
Resolution authorizing the Board, in its sole discretion, to effect the Domestication is set forth in &ldquo;<I>Proposal No.&nbsp;2&mdash;The
Domestication&mdash;Vote Required and Recommendation of the Board</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dissenters&rsquo; Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain Shareholders are entitled to dissenters
rights in connection with the Domestication pursuant to Division 2 of Part&nbsp;8 of the BCBCA, the text of which is attached to the
Circular/Prospectus as Annex <B>I</B>. If such Shareholders wish to dissent and do so pursuant to Division 2 of Part&nbsp;8 of the BCBCA,
and the Board proceeds with the Domestication, such Shareholders will be entitled to be paid the fair value of the Common Shares held
by them. Fair value is determined as of the close of business on the day before the Domestication is approved by the Shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Such Shareholders who wish to dissent should
seek the advice of legal advisors and carefully read this Circular/Prospectus and the provisions of Division 2 of Part&nbsp;8 of the
BCBCA. The following description of the rights of a dissenting Shareholder in connection with the Domestication is not a comprehensive
statement of the procedures to be followed by a dissenting Shareholder who seeks payment of the fair value of his, her or its Common
Shares and is qualified in its entirety by the full text of Division 2 of Part&nbsp;8 of the BCBCA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a Shareholder entitled to dissent wishes to
dissent, such Shareholder must send written notice of dissent (a &ldquo;<B>Notice of Dissent</B>&rdquo;) to us two (2)&nbsp;days before
the Meeting. The giving of a Notice of Dissent does not deprive a Shareholder of his or her right to vote at the Meeting on the Domestication
Resolution. However, if a Shareholder votes (or instructs or is deemed, by submission of any incomplete proxy, to have instructed his
or her proxy holder to vote) in favour of the Domestication Resolution, the Shareholder is not entitled to exercise a dissent right with
respect to the Common Shares voted, and any Dissent Notice delivered with respect to such Common Shares will be rendered invalid. For
greater certainty, a vote in favour of the Domestication Resolution will effectively cancel a Notice of Dissent and eliminate the right
to dissent over the Common Shares specified in the Notice of Dissent. A Shareholder may, however, vote as a proxy for another Shareholder
whose proxy required an affirmative vote without affecting his or her own right to exercise the Dissent Right. A vote against the motion
to approve the Domestication Resolution or the execution or exercise of a proxy does not constitute a Notice of Dissent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A Shareholder who intends to exercise his, her or its dissent rights
under the BCBCA in connection with the Domestication should carefully consider and comply with the provisions of Division 2 of Part&nbsp;8
of the BCBCA. Failure to comply with the provisions of those sections and to adhere to the procedures established therein may result in
the loss of all rights thereunder. Beneficial Shareholders who wish to dissent should be aware that only the registered owner of the Common
Shares is entitled to dissent. Accordingly, a Beneficial Shareholder desiring to exercise his, her or its dissent rights under the BCBCA
in connection with the Domestication must make arrangements for the Common Shares beneficially owned by him, her or it to be registered
in his, her or its name prior to the time the written objection to the Continuance is required to be received by us or, alternatively,
make arrangements for the registered holder of his, her or its Common Shares to dissent on his, her or its behalf. Beneficial Shareholders
who wish to dissent should contact their broker or other intermediary for assistance with exercising their dissent rights under the BCBCA
in connection with the Domestication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="padding: 5pt; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No right of dissent or appraisal is available
to a Shareholder with respect to any other matter to be considered at the Special Meeting other than the Domestication and the Continuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Oncolytics Biotech Inc. was formed under the
<I>Business Corporations Act </I>(Alberta) on April&nbsp;2, 1998 as 779738 Alberta Ltd. On April&nbsp;8, 1998, we changed our name to
Oncolytics Biotech Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our principal place of business is located at 804, 322 11<SUP>th</SUP>
Avenue SW, Calgary, Alberta, Canada T2R 0C5, telephone (403) 670-7377. Our agent for service in the U.S. is Jared Kelly, 4350 Executive
Drive, Suite 325, San Diego, California 92121.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further information regarding the Company is
contained in Item 4 of our Annual Report on Form&nbsp;20-F under the heading &ldquo;<I>Information on the Company</I>,&rdquo; which document
is incorporated by reference in this Circular/Prospectus. See &ldquo;<I>Incorporation by Reference</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="pros_010"></A><FONT STYLE="text-transform: uppercase"><B>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>You should carefully consider all of the information
in this Circular/Prospectus and each of the risks described below, which we believe are the principal risks that we face. Some of the
risks relate to our business, others to the Continuance and the Domestication. Some risks relate principally to the securities markets
and ownership of our Common Shares. The risks and uncertainties described below are not the only ones faced by us. You should carefully
consider the following factors as well as the other information contained in and incorporated by reference into this Circular/Prospectus,
and specifically, the factors described in the section entitled &ldquo;Item 3.D. Risk Factors&rdquo; in our Form&nbsp;20-F. Additional
risks and uncertainties not presently known or that are currently deemed immaterial also may impair our business operations. If any of
the following risks occur, our business, financial condition, operating results and cash flows and the trading price of our Common Shares
could be materially adversely affected.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="pros_011"></A><B>Risks Relating to the Continuance and Domestication of Oncolytics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The rights of Shareholders as they currently
exist under the ABCA, and as they will exist under the BCBCA following completion of the Continuance, will be different from their rights
under Nevada law, which will, in some cases, provide less protection to Stockholders of Oncolytics Nevada following the Domestication.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon consummation of the Continuance, Shareholders
will become Shareholders of a BCBCA corporation, and, upon consummation of the Domestication, which is subject to and conditional upon
the approval by the Shareholders of the Continuance Resolution, and subject to the discretion of the Board, Shareholders will subsequently
become stockholders of a Nevada corporation. There are material differences between the ABCA, the BCBCA and the NRS and our current articles
of incorporation and by-laws as an ABCA corporation, proposed Notice of Articles and Articles as a BCBCA corporation and proposed Oncolytics
Nevada Charter and Oncolytics Nevada Bylaws as a Nevada corporation, as discussed hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The BCBCA provides Shareholders substantially
similar rights as are available to Shareholders under the ABCA, including rights of dissent (see under the heading &ldquo;<I>Dissent
Rights of Shareholders&mdash;BC</I>&rdquo;) and appraisal, and rights to bring derivative actions and oppression actions. However,
there are certain differences between the two statutes and the regulations thereunder. A summary of certain differences between the ABCA
and the BCBCA which we consider to be of significance to Shareholders, is discussed under the heading &ldquo;<I>Material Differences
between Alberta Corporate Law and British Columbia Corporate Law</I>&rdquo; attached hereto as Annex <B>J</B>. This summary is not an
exhaustive review of the two statutes. Reference should be made to the full text of both statutes and the regulations thereunder for
particulars of any differences between them, and Shareholders should consult their legal or other professional advisors with regard to
the implications of the Continuance which may be of importance to them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the BCBCA, certain extraordinary corporate actions, such as continuances,
certain amalgamations, sales, leases or other dispositions of all or substantially all of the undertaking of a company (other than in
the ordinary course of business), liquidations, dissolutions and certain arrangements, are required to be approved by a special majority
of the company&rsquo;s shareholders, and specifies that a company&rsquo;s articles set the requirement for a special majority as two-thirds
of the votes cast by Shareholders; whereas under Nevada law, a majority of shares outstanding is typically required for approval. Furthermore,
Shareholders under the BCBCA are entitled to dissent with respect to a number of extraordinary corporate actions, including an amalgamation,
certain amendments to a corporation&rsquo;s articles of incorporation or the sale of all or substantially all of a corporation&rsquo;s
assets, whereas under Nevada law, stockholders are only entitled to dissenter&rsquo;s rights for certain mergers or consolidations. As
shown by the examples above, if the Domestication and the Oncolytics Nevada Charter are approved and the Continuance is consummated, stockholders
of Oncolytics Nevada (&ldquo;<B>Stockholders</B>&rdquo;), in certain circumstances, may be afforded less protection under the NRS than
they had as Shareholders under the BCBCA. For a more detailed description of how the new organizational documents and Nevada law may differ
from our proposed organizational documents that would be in effect following consummation of the Continuance and British Columbia corporate
law, see &ldquo;<I>Material Differences between British Columbia Corporate Law and Nevada Corporate Law</I>&rdquo; attached hereto as
Annex <B>K</B>. For a more detailed description of how the new organizational documents and Nevada law may differ from our current organizational
documents and Alberta corporate law, see &ldquo;<I>Material Differences between Alberta Corporate Law and Nevada Corporate Law</I>.&rdquo;
This description is not intended to be complete and is qualified in its entirety by reference to the NRS, the ABCA and our governing documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our proposed form of Oncolytics Nevada
Bylaws designates certain courts as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by
our Stockholders, which could limit our Stockholders&rsquo; ability to obtain a favourable judicial forum for disputes with us or our
directors, officers, employees or agents.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our proposed form of Oncolytics Nevada Bylaws, which would be effective
upon the consummation of the Domestication, provides that the Eighth Judicial District Court of the State of Nevada, in Clark County,
Nevada shall, to the fullest extent permitted by law, be the sole and exclusive forum for (1)&nbsp;any derivative action or proceeding
brought on behalf of the Company, (2)&nbsp;any action or proceeding asserting a claim of breach of a fiduciary duty owed by any current
or former director, officer, stockholder, employee or agent of the Company to the Company or the Stockholders, (3)&nbsp;any
action or proceeding asserting a claim arising pursuant to the NRS, the Oncolytics Nevada Charter or Oncolytics Nevada Bylaws, (4)&nbsp;any
proceeding to interpret, apply, enforce or determine the validity of the Nevada Charter or Nevada Bylaws, (5)&nbsp;any internal action
(as defined in NRS Section&nbsp;78.046) and any action or proceeding as to which NRS Title 7 confers jurisdiction to the District Courts
of the State of Nevada, or (6)&nbsp;any action asserting a claim governed by the internal affairs doctrine. The Oncolytics Nevada Bylaws
further provide that the federal district courts of the United States of America are the sole and exclusive forum for the resolution of
any claim asserting a cause of action under the Securities Act. Notwithstanding the foregoing, this exclusive forum provision shall not
apply to suits brought to enforce any liability or duty created by the U.S. Exchange Act, or any other claim for which the federal courts
of the United States have exclusive jurisdiction. To the fullest extent permitted by law, any person or entity purchasing or otherwise
acquiring or holding any interest in shares of our capital stock following the Domestication will be deemed to have notice of, and consented
to, the provisions of our proposed Oncolytics Nevada Bylaws described in this paragraph. This choice-of-forum provision may limit a Stockholder&rsquo;s
ability to bring a claim in a judicial forum that it finds favourable for disputes with Oncolytics Nevada or its directors, officers,
employees or agents, which may discourage such lawsuits against Oncolytics Nevada and such persons. Alternatively, if a court were to
find these provisions of our proposed Oncolytics Nevada Bylaws inapplicable to, or unenforceable in respect of, one or more of the specified
types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could
adversely affect our business and operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The proposed Continuance and Domestication
will result in additional direct and indirect costs whether or not completed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Continuance and the Domestication will each
result in additional direct costs to us. We will incur legal fees, accountants&rsquo; fees, filing fees, mailing expenses, taxes and
financial printing expenses in connection with the Continuance and the Domestication. The Continuance and the Domestication may also
result in certain indirect costs by diverting the attention of our management and employees from the day-to-day management of the business,
which may result in increased administrative costs and expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The Continuance and the Domestication
may result in adverse tax consequences for U.S. holders of Oncolytics Common Shares.<SUP></SUP></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As discussed more fully under &ldquo;<I>U.S.
Federal Income Tax Considerations</I>,&rdquo; it is intended that the Continuance and the Domestication (together, the &ldquo;<B>Redomiciliation
Transaction</B>&rdquo;) qualify as one or more reorganizations within the meaning of Section&nbsp;368(a)(l)(F)&nbsp;of the Code (collectively,
an &ldquo;<B>F Reorganization</B>&rdquo;). However, Oncolytics has not sought, and does not intend to seek, any ruling from the Internal
Revenue Service (&ldquo;<B>IRS</B>&rdquo;) with respect to the qualification of the Redomiciliation Transaction as an F Reorganization.
No assurance can be given that the IRS will agree with the views expressed herein, or that a court will not sustain any challenge by
the IRS in the event of litigation. If the Redomiciliation Transaction fails to qualify as an F Reorganization, a U.S.&nbsp;Holder (as
defined in&nbsp;&ldquo;<I>U.S. Federal Income Tax Considerations&mdash;U.S.&nbsp;Holders&rdquo;</I>) of Oncolytics Common Shares generally
would recognize gain or loss with respect to its Oncolytics Common Shares in an amount equal to the difference, if any, between the fair
market value of the corresponding Common Shares of Oncolytics Nevada (the &ldquo;<B>Oncolytics Nevada Common Shares</B>&rdquo;) received
in the Redomiciliation Transaction and the U.S.&nbsp;Holder&rsquo;s adjusted tax basis in its Oncolytics Common Shares surrendered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assuming that the Redomiciliation
Transaction qualifies as an F Reorganization, subject to the PFIC rules&nbsp;discussed under &ldquo;<I>U.S.&nbsp;Federal Income Tax
Considerations&mdash;U.S.&nbsp;Holders&mdash;Tax Effects of the Redomiciliation Transaction to U.S.&nbsp;Holders&mdash;PFIC
Considerations</I>,&rdquo; U.S.&nbsp;Holders generally will be subject to Section&nbsp;367(b)&nbsp;of the Code. A U.S.&nbsp;Holder
whose Oncolytics Common Shares, on the date of the Redomiciliation Transaction, have a fair market value of less than $50,000 and
who, on the date of the Redomiciliation Transaction, beneficially owns (actually or constructively) less than 10% of the total
combined voting power of all classes of Oncolytics stock entitled to vote and less than 10% of the total value of all classes of
Oncolytics stock generally will not recognize any gain or loss and will not be required to include any part of Oncolytics&rsquo;s
earnings and profits in income as a result of the Redomiciliation Transaction. A U.S.&nbsp;Holder whose public shares, on the date
of the Redomiciliation Transaction, have a fair market value of $50,000 or more and, who on the date of the Redomiciliation
Transaction, beneficially owns (actually or constructively) less than 10% of the total combined voting power of all classes of
Oncolytics stock entitled to vote and less than 10% of the total value of all classes of Oncolytics stock generally will recognize
gain (but not loss) in respect of the Redomiciliation Transaction as if such U.S.&nbsp;Holder exchanged its Oncolytics Common Shares
for Oncolytics Nevada Common Shares in a taxable transaction, unless such U.S.&nbsp;Holder elects in accordance with applicable
Treasury Regulations to include in income as a deemed dividend deemed paid by Oncolytics the &ldquo;all earnings and profits
amount&rdquo; (as defined in the Treasury Regulations under Section&nbsp;367 of the Code) attributable to the public shares held
directly by such U.S.&nbsp;Holder. A U.S.&nbsp;Holder who, on the&nbsp;day of the Redomiciliation Transaction, beneficially owns
(actually or constructively) 10% or more of the total combined voting power of all classes of Oncolytics stock entitled to vote or
10% or more of the total value of all classes of Oncolytics stock, generally will be required to include in income as a deemed
dividend deemed paid by Oncolytics the &ldquo;all earnings and profits amount&rdquo; (as defined in the Treasury Regulations under
Section&nbsp;367 of the Code) attributable to the Oncolytics Common Shares held directly by such U.S.&nbsp;Holder as a result of the
Redomiciliation Transaction. Oncolytics expects to have a deficit in earnings and profits on the date of the Redomiciliation
Transaction. However, it is possible that, notwithstanding Oncolytics&rsquo;s expectations, the amount of Oncolytics&rsquo;s
cumulative net earnings and profits could be positive through the date of the Redomiciliation Transaction. Therefore, there can be
no assurance that Oncolytics indeed will have a deficit in earnings and profits on the date of the Redomiciliation Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">U.S. Holders should consult their tax advisors
for the tax consequences of the Redomiciliation Transaction to their particular situations. For a more detailed description of the U.S.&nbsp;federal
income tax consequences associated with the Redomiciliation Transaction, see &ldquo;<I>U.S. Federal Income Tax Considerations&nbsp;&mdash;&nbsp;U.S.&nbsp;Holders&nbsp;&mdash;&nbsp;Tax
Effects of the Redomiciliation Transaction to U.S.&nbsp;Holders</I>&rdquo; And &ldquo;<I>U.S. Federal Income Tax Considerations&nbsp;&mdash;&nbsp;Non-U.S.&nbsp;Holders&nbsp;&mdash;&nbsp;Tax
Effects of the Redomiciliation Transaction to Non-U.S.&nbsp;Holders</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Following the Redomiciliation Transaction,
non-U.S. holders of Oncolytics Common Shares will generally be subject to U.S. withholding tax up to 30% on distributions or deemed distributions
treated as dividends for U.S. federal income tax purposes.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Non-U.S.&nbsp;Holders (as defined in &ldquo;<I>U.S.&nbsp;Federal
Income Tax Considerations&nbsp;&mdash;&nbsp;Non-U.S.&nbsp;Holders&rdquo;</I>) will generally become subject to withholding tax at 30%
(unless reduced under any applicable United States income tax treaty) on any distributions or deemed distributions treated as dividends
for U.S. federal income tax purposes paid on Oncolytics Nevada Common Shares after the Redomiciliation Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The amount of corporate tax payable by
Oncolytics will be affected by the value of our property on the date of the Domestication.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For Canadian tax purposes, we will be deemed to have a year end immediately
prior to the Domestication and will also be deemed to have sold all of our property and received the fair market value for those properties.
We do not expect that we will be subject to any Canadian taxation on this deemed disposition. However, we will be subject to an additional
corporate emigration tax equal to 5% of the amount by which the fair market value of our property, net of liabilities, exceeds the paid-up
capital of our issued and outstanding shares. We have completed certain calculations of our tax accounts with the assistance of professional
advisors, and assuming the fair market value of our property reflects the market price of our Common Shares, a price of $1.393 per Common
Share as at November 28, 2025 and that the exchange rate of the Canadian dollar to the U.S. dollar is CAD$1.3974 equals US$1.00 as at
November 28, 2025, the Domestication would not result in the imposition of any corporate emigration tax. That said, we may be subject
to the corporate emigration tax if the price of our Common Shares increases or the exchange rate were to change significantly. Further,
it is possible that the Canadian federal tax authorities may not accept our valuations or calculations of our tax accounts, which may
result in additional taxes payable as a result of the Domestication. As is customary, when a Canadian federal tax liability depends largely
on factual matters, we have not applied to the Canadian federal tax authorities for a ruling on such matters and do not intend to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="pros_012"></A><B>Risks Relating to our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should read and consider the risk factors
specific to our business that will continue to affect us after the effectiveness of the Continuance and the Domestication. These risks
are described in the sections entitled &ldquo;<B>Item 3.D. Risk Factors</B>&rdquo; in our Form&nbsp;20-F, which is incorporated by reference
into this Circular/Prospectus, and in other documents that are incorporated by reference into this Circular/Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><A NAME="pros_013"></A><B>INFORMATION
ABOUT THE SPECIAL MEETING OF ONCOLYTICS SHAREHOLDERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the knowledge of the Board and management
of Oncolytics, the only matters to be brought before the Meeting are those set out in the Notice of Special Meeting of Shareholders and
more particularly detailed below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="pros_014"></A><B>Proposal No.&nbsp;1: The Continuance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board believes it to be in Oncolytics&rsquo;
best interests to have discretion to implement the Continuance, in order to change the jurisdiction of incorporation of Oncolytics from
the Province of Alberta to the Province of British Columbia pursuant to Section&nbsp;189 of the ABCA and Section&nbsp;303 of the BCBCA.
Shareholders are being asked to consider and, if thought fit, to pass the Continuance Resolution, with or without variation, approving
the Continuance, subject to and conditional upon the approval of the Domestication Resolution, and authorizing the Board, in its sole
discretion, to determine whether to implement the Continuance, and if the Board so determines to proceed therewith, to implement the
Continuance, which process includes applying for authorization for continuation with the Alberta Registrar of Corporations and filing
the Continuation Application, to which the Notice of Articles are attached, and any other necessary documentation with the Registrar
appointed under the BCBCA. Approval of the Continuance Resolution includes the approval of the Continuance and adoption of the Continuation
Application containing the Notice of Articles and Articles, attached to this Circular/Prospectus as Annex <B>B</B> and Annex <B>E</B>,
respectively. The full text of the Continuance Resolution is attached to this Circular/Prospectus as Annex <B>A</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Continuance Resolution is approved by
the Shareholders, the Continuance would only be implemented upon a determination by the Board that it is in the best interests of Oncolytics
at that time and will be subject to and conditional upon the approval of the Domestication Resolution. In connection with any determination
to implement the Continuance, the Board will set the timing for such Continuance. Although it is the current intention of the Board to
proceed with the Continuance prior to the Domestication, it has no obligation to do so and will have no liability associated with any
decision as to whether or not to proceed with the Continuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Continuance Resolution is approved by
the Shareholders, and the Board so determines to proceed with the Continuance, the Continuance will be effective on the date set forth
in the Certificate of Continuation issued by the Registrar appointed under the BCBCA. Thereafter, we will be subject to the BCBCA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Where you submit a properly executed form of
proxy, but do not specify how you want your Common Shares voted, the individuals named as proxyholders in the enclosed form of proxy
intend to cast the votes represented by proxy at the Meeting FOR Proposal No.&nbsp;1, the Continuance Resolution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="pros_015"></A><B>Proposal No.&nbsp;2: The Domestication</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board believes it to be in Oncolytics&rsquo;
best interests to have discretion to implement the Domestication (including, without limitation, approving the Oncolytics Nevada Charter),
subject to and conditional upon the approval by the Shareholders of the Continuance Resolution, in order to change the jurisdiction of
incorporation of Oncolytics from the Province of British Columbia to the State of Nevada pursuant to a &ldquo;continuation out&rdquo;
effected in accordance with Section&nbsp;308 of the BCBCA and a &ldquo;domestication&rdquo; under NRS 92A.270. Shareholders are being
asked to consider and, if thought fit, to pass the Domestication Resolution, with or without variation, approving the Domestication and
authorizing the Board, in its sole discretion, to determine whether to implement the Domestication (including, without limitation, the
Oncolytics Nevada Charter), and if the Board so determines to proceed therewith, to implement the Domestication, which process includes
filing the Articles of Domestication and the Oncolytics Nevada Charter with the Nevada Secretary of State as the continuing entity incorporated
under the NRS. Approval of the Domestication Resolution includes the approval of the Domestication and approval of the Oncolytics Nevada
Charter. The full text of the Domestication Resolution is attached to this Circular/Prospectus as Annex <B>C</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Domestication Resolution is approved by
the Shareholders, the Domestication would only be implemented upon a determination by the Board that it is in the best interests of Oncolytics
at that time, subject to and conditional upon the approval of the Continuance Resolution and the prior completion of the Continuance
as contemplated by the Continuance Resolution and receipt by Oncolytics of the Certificate of Continuation. In connection with any determination
to implement the Domestication, the Board will set the timing for such Domestication. Although it is the current intention of the Board
to proceed with the Domestication, it has no obligation to do so and will have no liability associated with any decision as to whether
or not to proceed with the Domestication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Domestication Resolution is approved by
the Shareholders and the Board so determines to proceed with the Domestication following completion of the Continuance, the Domestication
will be effective on the date the Articles of Domestication and the Oncolytics Nevada Charter are filed with the office of the Nevada
Secretary of State or such later date (within 90 days of the date of filing) as provided in the Articles of Domestication and the Oncolytics
Nevada Charter. Thereafter, we will be subject to the Oncolytics Nevada Charter filed in Nevada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Where you submit a properly executed form of
proxy, but do not specify how you want your Common Shares voted, the individuals named as proxyholders in the enclosed form of proxy
intend to cast the votes represented by proxy at the Meeting FOR Proposal No.&nbsp;2, the Domestication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="pros_016"></A><B>Proposal No.&nbsp;3: The 2026 Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Domestication, the Board
believes it to be in Oncolytics&rsquo; best interests to approve the Oncolytics Biotech Inc. 2026 Incentive Award Plan (the &ldquo;<B>2026
Plan</B>&rdquo;), which is intended to align our equity compensation plan with rules&nbsp;and market practices applicable to U.S. public
companies in our industry. If the 2026 Plan is approved, we will cease granting awards under the Amended and Restated Stock Option Plan
(the &ldquo;<B>Option Plan</B>&rdquo;) and the Amended and Restated Incentive Share Award Plan (the &ldquo;<B>2023 Plan</B>&rdquo; and
together with the Option Plan, the &ldquo;<B>Prior Plans</B>&rdquo;), but any awards granted under the Prior Plans will remain subject
to the terms of the applicable Prior Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our success is highly dependent on our ability
to attract, retain and motivate persons who make (or are expected to make) important contributions to our company. The purpose of the
2026 Plan is to attract, retain and motivate these individuals with equity-based compensatory opportunities that will align their interests
with those of our Shareholders by giving them the perspective of an owner with an equity stake in the Company. The use of equity awards
as compensation also allows us to conserve cash resources for other important purposes. The full text of the 2026 Plan is attached to
this Circular/Prospectus as Annex <B>F</B>, and the material features of the 2026 Plan are summarized below in the section entitled &ldquo;<I>Proposal
No.&nbsp;3&mdash;The 2026 Plan.</I>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the 2026 Plan is approved by the Shareholders,
it will become effective upon effectiveness of the Domestication. In connection with any determination to implement the Domestication,
the Board will set the timing for such Domestication. Although it is the current intention of the Board to proceed with the Domestication,
it has no obligation to do so and will have no liability associated with any decision as to whether or not to proceed with the Domestication.
If the Board determines, in its sole discretion, not to proceed with the Domestication, the 2026 Plan will not become effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Where you submit a properly executed form of proxy,
but do not specify how you want your Common Shares voted, the individuals named as proxyholders in the enclosed form of proxy intend to
cast the votes represented by proxy at the Meeting FOR Proposal No.&nbsp;3, the 2026 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="pros_017"></A><B>Other Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will consider any other business that may
properly come before the Meeting. As of the date of this Circular/Prospectus, we are not aware of any changes to the items above or any
other business to be considered at the Meeting. If there are changes or new items, your proxyholder can vote your Common Shares on these
items as he or she sees fit. If any other matters properly come before the Meeting, it is the intention of the persons named in the form
of proxy to vote in respect of those matters in accordance with their best judgment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="pros_018"></A><B>Other Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is authorized to issue an unlimited
number of Common Shares. As at the Record Date, there were 107,606,376
Common Shares issued and outstanding. At the Meeting, every Shareholder present in person or represented by proxy and entitled to vote
shall have one vote. On a poll or ballot, every Shareholder present in person or by proxy has one vote for each Common Share of which
such Shareholder is the registered holder. The Common Shares are listed on Nasdaq under the symbol &ldquo;ONCY.&rdquo; Our Common Shares
will continue to be listed on Nasdaq under their existing trading symbol, including following the effectiveness of the Domestication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Only Shareholders of record at the close of business
on the Record Date are entitled to notice of the Meeting and to vote at the Meeting or any adjournment or postponement thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the Meeting, a quorum shall consist of two
persons present in person holding or representing by proxy not less than 5% of the votes attached to all outstanding Common Shares. If
a quorum is not present at the Meeting within one half hour after the time fixed for the holding of the Meeting, it shall stand adjourned
to such day being not less than 21 days later and to such place and time as may be determined by the Chairman of the Meeting. At the
Meeting, the Shareholders present either in person or by proxy shall form a quorum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The approval of the 2026 Plan will be determined
by a majority of votes cast at the Meeting by proxy or in person. The Continuance and the Domestication will each require approval by
the affirmative vote of not less than two-thirds of the votes cast at the Meeting by proxy or in person. Our Board has reserved the right,
in its sole discretion, to terminate or abandon the Continuance or the Domestication at any time prior to their effectiveness, notwithstanding
Shareholder approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If your Common Shares are registered in your
name and you abstain from voting on any of the proposals set forth in this Circular/Prospectus, your abstention will not have any effect
on the outcome of the vote for such proposal. Abstentions will each be counted for the quorum requirement. If you hold your Common Shares
through a bank, broker or other agent and you do not instruct the bank, broker or other agent on how to vote on any of the proposals
set forth in this Circular/Prospectus, your bank, broker or other agent will not have authority to vote your Common Shares. Broker non-votes
will not have an impact on the outcome of the proposals set forth in this Circular/Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="pros_019"></A><FONT STYLE="text-transform: uppercase"><B>PROPOSAL
NO. 1 &mdash; THE CONTINUANCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="pros_020"></A><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are currently governed by the ABCA. At the
Meeting, the Shareholders will be asked to consider and, if thought advisable, pass the Continuance Resolution in the form set out below
and attached to this Circular/Prospectus as Annex <B>A</B>, authorizing the Board, in its sole discretion, to file the Continuation Application
containing the Notice of Articles of Oncolytics which comply with the provisions of the BCBCA and any other necessary documentation with
the Registrar appointed under the BCBCA as required in connection with the Continuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="pros_021"></A><B>Continuance into BCBCA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to apply to the Alberta Registrar of
Corporations under the ABCA for permission to continue from the Province of Alberta under the ABCA to the Province of British Columbia
pursuant to Section&nbsp;189 of the ABCA and Section&nbsp;303 of the BCBCA. A corporation subject to the ABCA may, if authorized by a
special resolution of shareholders of the Company and the Alberta Registrar of Corporations under the ABCA, apply under the BCBCA for
a Certificate of Continuation under the BCBCA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On the date shown on the Certificate of Continuation,
we will cease to be governed by the ABCA and become a company in the Province of British Columbia as if we had been incorporated under
the BCBCA. The certified Notice of Articles will function as our articles of incorporation and contain essentially the same terms as
our current articles of incorporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Continuance will not create a new legal entity,
nor will it prejudice or affect the continuity of Oncolytics. Once continued, we will remain a legal person, retain our rights and obligations
as such, and remain a party to any judicial or administrative proceeding to which we are a party. Our authorized capital will remain
unchanged. The Continuance and the adoption of the certified Notice of Articles and Articles will not result in any substantive changes
to our constitution, powers or management, except as otherwise described herein. The Continuance is not expected to have any material
business or tax consequences on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="pros_022"></A><B>Regulatory Approvals for the Continuance; Canadian Securities Laws
and Stock Exchange Implications</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Should the Shareholders approve the Continuance
Resolution at the Meeting and the Board determines to proceed with the Continuance, we anticipate that we will file the Continuation
Application containing the Notice of Articles of Oncolytics which comply with the provisions of the BCBCA and any other necessary documentation
with the Registrar appointed under the BCBCA as required in connection with the Continuance. We will be continued under the jurisdiction
of the Province of British Columbia on the effective date of the Certificate of Continuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Continuance will not otherwise interrupt
our corporate existence, our operations or the trading market of our Common Shares. Each outstanding Common Share at the time of the
Continuance will remain issued and outstanding as a Common Share of Oncolytics after our corporate existence is continued from the Province
of Alberta under the ABCA to the Province of British Columbia under the BCBCA. Following the completion of the Continuance, the Common
Shares will continue to be listed on Nasdaq under the symbol &ldquo;ONCY.&rdquo; We will continue to be subject to the rules&nbsp;and
regulations of Nasdaq and the obligations imposed by the securities regulatory authority in the United States and, to the extent applicable,
in Canada. We will continue to file periodic reports with applicable securities regulatory bodies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="pros_023"></A><B>Effects of the Continuance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the Continuance, the ABCA will cease to
apply to us and we will thereupon become subject to the BCBCA, as if we had been originally incorporated as a company in the Province
of British Columbia. The Continuance will not create a new legal entity, affect our continuity or result in a change in our business.
The persons named as directors in the Continuation Application (who are also our current directors) will continue to constitute the Board
upon the Continuance becoming effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Continuance will not interrupt our corporate
existence or operations or the trading markets of our Common Shares. Each outstanding Common Share at the time of the Continuance will
remain issued and outstanding as a Common Share after our corporate existence is continued from the Province of Alberta under the ABCA
to the Province of British Columbia under the BCBCA. Our Common Shares will continue to be listed on Nasdaq under the trading symbol
 &ldquo;ONCY.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will continue to be subject to the rules&nbsp;and
regulations of Nasdaq and the obligations imposed by each securities regulatory authority in Canada and the United States, including the
SEC. In addition, we will continue to file periodic reports with the SEC pursuant to the U.S. Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the effective date of the Continuance, our
current constating documents, articles of incorporation and by-laws under the ABCA will be replaced with the Notice of Articles and Articles
in accordance with the BCBCA. The Articles have been approved by the Board and are attached hereto as Annex <B>E</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="pros02_001"></A>Principal Reasons for the Continuance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Domestication is the key reason for our proposal
of the Continuance. Since the Domestication contemplates a change in our jurisdiction from the Province of British Columbia to the State
of Nevada in the United States, the Board first intends to continue us from the Province of Alberta to the Province of British Columbia
in order to be able to effect the Domestication if it so determines to proceed with the Domestication. For further background on the reasons
for the Domestication, see &ldquo;<I>Summary of the Domestication&mdash;Principal Reasons for the Domestication</I>.&rdquo; The Board
intends to effect the Continuance if the Domestication Resolution is approved by Shareholders at the Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="pros02_002"></A>Summary Comparison of Shareholder Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The BCBCA provides shareholders substantially
similar rights as are available to shareholders under the ABCA, including rights of dissent (see under the heading &ldquo;<I>Dissent
Rights of Shareholders &mdash; BC</I>&rdquo;) and appraisal, and rights to bring derivative actions and oppression actions. However,
there are certain differences between the two statutes and the regulations thereunder. A summary of certain differences between the ABCA
and the BCBCA which our management considers to be of significance to Shareholders, is discussed under the heading &ldquo;<I>Material
Differences between Alberta Corporate Law and British Columbia Corporate Law</I>&rdquo; attached hereto as Annex <B>J</B>. This summary
is not an exhaustive review of the two statutes. Reference should be made to the full text of both statutes and the regulations thereunder
for particulars of any differences between them, and Shareholders should consult their legal or other professional advisors with regard
to the implications of the Continuance which may be of importance to them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="pros02_003"></A><B>Dissent Rights of Shareholders &mdash; Alberta</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Registered Shareholders may, subject to compliance
with certain conditions, dissent from the Continuance Resolution and, subject to the Continuance becoming effective, be entitled to be
paid the fair value for their Common Shares in accordance with Section&nbsp;191(3)&nbsp;of the ABCA (the &ldquo;<B>ABCA Dissent Rights</B>&rdquo;).
Registered Shareholders who wish to dissent (the &ldquo;<B>Dissenting Shareholders</B>&rdquo;) should seek the advice of legal advisors
and carefully read this Circular/Prospectus and the provisions of Section&nbsp;191 of the ABCA. The following description of the rights
of a Dissenting Shareholder in connection with the Continuance is not a comprehensive statement of the procedures to be followed by a
Dissenting Shareholder who seeks payment of the fair value of his, her or its Common Shares, and is qualified in its entirety by the
full texts of Section&nbsp;191 of the ABCA. The full text of Section&nbsp;191 of the ABCA addressing dissenters&rsquo; rights in connection
with the Continuance is attached to this Circular/Prospectus as Annex <B>G</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A Shareholder who intends to exercise his, her or its ABCA Dissent
Rights should carefully consider and comply with the provisions of Section&nbsp;191 of the ABCA. Failure to comply with the provisions
of those sections and to adhere to the procedures established therein may result in the loss of all rights thereunder. Non-Registered
Shareholders (or Beneficial Shareholders) who wish to dissent should be aware that only Registered Shareholders are entitled to dissent.
Accordingly, a Non-Registered Shareholder (or Beneficial Shareholder) desiring to exercise his, her or its ABCA Dissent Rights must make
arrangements for the Common Shares beneficially owned by him, her or it to be registered in his, her or its name prior to the time the
written objection to the Continuance Resolution or the Domestication Resolution is required to be received by us or, alternatively, make
arrangements for the Registered Shareholder of his, her or its Common Shares to dissent on his, her or its behalf. Non-Registered Shareholders
(or Beneficial Shareholders) who wish to dissent should contact their broker or other intermediary for assistance with exercising their
ABCA Dissent Rights under the ABCA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A Registered Shareholder who wishes to dissent
shall send a written objection notice (a &ldquo;<B>Dissent Notice</B>&rdquo;) to the Continuance Resolution in compliance with Section&nbsp;191(5)(a)&nbsp;of
the ABCA by mail to the address or by email to the email address below, no later than Thursday, January 15, 2026 at 10:00 a.m.&nbsp;(Eastern
Time) or in the case of any adjournment or postponement, the time of the Meeting so adjourned or postponed, or shall inform the Chair
of the Meeting of such dissent prior to the closing of the Meeting. The Dissent Notice must set out the number of Common Shares in respect
of which the dissent rights are being exercised (the &ldquo;<B>Notice Shares</B>&rdquo;) and: (a)&nbsp;if such Common Shares constitute
all of the Common Shares of which the Dissenting Shareholder is the registered and beneficial owner and the Dissenting Shareholder owns
no other Common Shares beneficially, a statement to that effect; (b)&nbsp;if such Common Shares constitute all of the Common Shares of
which the Registered Shareholder is both the registered and beneficial owner, but the Registered Shareholder beneficially owns additional
Common Shares, a statement to that effect and the names of the Registered Shareholders of those other Common Shares, the number of Common
Shares held by each such Registered Shareholder and a statement that written notices of dissent are being or have been sent with respect
to such other Common Shares; or (c)&nbsp;if the dissent rights are being exercised by a Registered Shareholder who is not the Beneficial
Shareholder, a statement to that effect and the name and address of the Beneficial Shareholder and a statement that the Registered Shareholder
is dissenting with respect to all Common Shares of the beneficial owner of the Common Shares registered in such Registered Shareholder&rsquo;s
name.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>ONCOLYTICS BIOTECH INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>322 11th Avenue SW, Suite&nbsp;804</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Calgary, Alberta T2R 0C5<BR>
Attention: Chief Financial Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Email: info@oncolyticsbiotech.com<BR> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>with a copy (which shall not constitute notice)
to:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>STIKEMAN ELLIOTT LLP</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>199 Bay Street</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Suite&nbsp;5300, Commerce Court West</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Toronto, Ontario, M5L 1B9<BR>
Attention: Jeff Hershenfield</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Email: jhershenfield@stikeman.com</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The execution or exercise of a proxy vote against
the Continuance Resolution does not constitute a written objection for the purposes of section 191(5)&nbsp;of the ABCA. The ABCA does
not provide for partial dissent and, accordingly, a registered Shareholder may only dissent with respect to all of the Common Shares held
by it or on behalf of any one beneficial owner whose shares are registered in its name.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Oncolytics and the Dissenting Shareholder may
agree on the payout value of the Notice Shares; otherwise, either party may apply to the Court of King&rsquo;s Bench of Alberta (the &ldquo;<B>Alberta
Court</B>&rdquo;) to determine the fair value of the Notice Shares. There is no obligation on Oncolytics to make an application to the
Alberta Court. If such Dissenting Shareholder does not reach an agreement with Oncolytics, such Dissenting Shareholder, or Oncolytics,
may apply to the Alberta Court, and the Alberta Court may:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">determine the fair value of the Notice Shares;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">join as party the application of each Dissenting Shareholder who has not agreed with us on the amount
of the fair value of the Notice Shares; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">make consequential orders and give directions as the Alberta Court considers appropriate.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After a determination of the payout value of the
Notice Shares, the Dissenting Shareholder must then promptly be paid that amount. Dissenting Shareholders will not have any right other
than those granted under the ABCA to have their Common Shares appraised or to receive the fair value thereof in connection with the Domestication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The right of a Dissenting Shareholder to dissent
with respect to Notice Shares terminates if, before payment is made to the Dissenting Shareholder of the full amount of money to which
the dissenter is entitled for the Notice Shares, any of the following events occur: (i)&nbsp;the corporate action or arrangement approved
or authorized, or to be approved or authorized, by the resolution or court order in respect of which the dissent notice was sent is abandoned;
(ii)&nbsp;the resolution in respect of which the dissent notice was sent does not pass, or is revoked before the corporate action approved
or authorized by that resolution is taken; (iii)&nbsp;a court permanently enjoins or sets aside the corporate action approved or authorized
by the resolution or court order in respect of which the dissent notice was sent; (iv)&nbsp;the dissent notice is withdrawn with the written
consent of the company; or (v)&nbsp;the Alberta Court determines that the Dissenting Shareholder is not entitled to dissent under the
ABCA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A Dissenting Shareholder is not required to vote
against the Domestication Resolution in order to dissent. However, the right of a Dissenting Shareholder to dissent with respect to Notice
Shares will also terminate if that Dissenting Shareholder votes in favour of the Continuance Resolution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="pros02_004"></A>Information Concerning Oncolytics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>General</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Corporate Overview</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Oncolytics Biotech Inc. was incorporated pursuant
to the ABCA on April&nbsp;2, 1998 as 779738 Alberta Ltd. On April&nbsp;8, 1998, we amended our articles of incorporation and changed our
name to Oncolytics Biotech Inc. On July&nbsp;29, 1999, we amended our articles by removing the private company restrictions included therein
and subdivided the 2,222,222 common shares issued and outstanding into 6,750,000 common shares. On May&nbsp;22, 2018, we amended our articles
to effect a consolidation of the common shares on the basis of 9.5 preconsolidation common shares for each one post-consolidation common
share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Oncolytics is a public company trading on Nasdaq
under the ticker symbol &ldquo;ONCY.&rdquo; The head office and principal place of business of Oncolytics is located at Suite&nbsp;804,
322 &mdash; 11th Avenue S.W., Calgary, Alberta T2R 0C5, our registered office is located at 4000, 421 &mdash; 7th Avenue S.W., Calgary,
Alberta, T2P 4K9 and our telephone number is (403) 670-7377. Our website address is www.oncolyticsbiotech.com. Information contained on
our website or connected thereto does not constitute part of, and is not incorporated by reference into, this Circular/Prospectus or the
registration statement of which it forms a part. We have included our website address in this circular/prospectus solely for informational
purposes. Our agent for service of process in the United States is Jared Kelly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Business of Oncolytics</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a clinical-stage biopharmaceutical company
developing pelareorep, a well-tolerated intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune
systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible
to a broad range of oncology treatments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pelareorep is a proprietary isolate of reovirus,
a naturally occurring, non-pathogenic dsRNA virus commonly found in environmental waters. Pelareorep has shown promising results in creating
a more immunologically favorable TME, which in turn makes the tumor more susceptible to various treatment combinations. These treatments
include chemotherapies, checkpoint inhibitors, and other immuno-oncology approaches such as CAR T therapies, bispecific antibodies, and
CDK4/6 inhibitors. Pelareorep induces a new army of tumor-reactive T cells, helps these cells to infiltrate the tumor through an inflammatory
process, and promotes the overexpression of PD-1/PD-L1. By priming the immune system with pelareorep, we believe we can improve clinical
outcomes for gastrointestinal cancer patients, where immunotherapies have failed or provided limited benefit. Our current focus within
gastrointestinal cancers is first-line metastatic PDAC, second-line KRAS-mutant mCRC, and second-line SCAC. Pelareorep has generated clinical
data that exceeds historical benchmarks when combined with multiple standard-of-care treatments. We plan to align with regulators on the
optimal path to registration for pelareorep in each indication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not been profitable since our inception
and expect to continue to incur substantial losses as we continue research and development efforts. We do not expect to generate significant
revenues until and unless pelareorep becomes commercially viable. As a clinical-stage drug development company, we consistently discuss
and pursue potential partnerships, licensing agreements and other strategic transactions with third parties. Due to the capital intensive
nature of early stage drug development, we continuously analyze our available cash and projected operating costs to determine whether
to seek additional funds via the capital markets. To date, we have funded our operations mainly through the issuance of additional capital
via public offerings, equity distribution arrangements, and through the exercise of warrants and options. There can be no assurance
that we will be able to raise additional funds through the sale of our Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Auditor, Registrar And Transfer Agent</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ernst&nbsp;&amp; Young LLP is the auditor of Oncolytics.
TSX Trust Company is the registrar and transfer agent for the Common Shares at its principal offices located in Toronto, Ontario.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Dividends</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Oncolytics has not declared or paid dividends
since incorporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Prior Sales</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Common Shares</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the 12-month period prior to November 28,
2025, the Company has issued:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">an aggregate of 14,936,852 Common Shares pursuant to an equity distribution agreement and a
                                                                 prospectus supplement dated August&nbsp;2, 2024 to a base shelf prospectus dated July&nbsp;19, 2024 (the &ldquo;<B>2024
                                                                 Prospectus</B>&rdquo;), at prices ranging from US$0.42 to US$1.22 per Common Share, with the weighted average price being US$0.78
                                                                 per Common Share;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">an aggregate of 6,650,000 Common Shares pursuant to a purchase agreement between the Company and Alumni
Capital LP and a prospectus supplement dated April&nbsp;10, 2025 to the 2024 Prospectus, at prices ranging from US$0.30 to US$0.46 per
Common Share, with the weighted average price being US$0.35 per Common Share (and the Company also issued 912,152 commitment shares);</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                               <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>(c)</TD><TD STYLE="text-align: justify">an aggregate of 1,787,018 Common Shares pursuant to an at-the-market
sales agreement and a prospectus supplement dated October 17, 2025 to a base shelf prospectus dated August 29, 2025, at prices ranging
from US$1.02 to US$1.27 per Common Share, with the weighted average price being US$1.13 per Common Share;</TD></TR>
                                                                                                                                               </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">an aggregate of 3,241,405 Common Shares issued to consultants for services rendered; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(e)</TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">an aggregate of 1,604,912 Common Shares on the vesting of restricted
share units (&ldquo;<B>RSUs</B>&rdquo;) granted pursuant to the Company&rsquo;s 2023 Plan.</P></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Options</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the 12-month period preceding November
28, 2025, the Company granted options exercisable for an aggregate of 6,540,696 Common Shares. The particulars of such grants are set
forth in the following table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 25%; border: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>Date of Grant</U></B></FONT></TD>
    <TD STYLE="width: 25%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>Number of <BR>
Options Granted</U></B></FONT></TD>
    <TD STYLE="width: 25%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>Exercise Price</U></B></FONT></TD>
    <TD STYLE="width: 25%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>Expiry Date</U></B></FONT></TD></TR>
  <TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">December&nbsp;18, 2024</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1,581,800</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">C$1.13</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">December&nbsp;18, 2029</FONT></TD></TR>
  <TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">August&nbsp;15, 2025</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">4,958,896</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">US$1.08</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">August&nbsp;15, 2030</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Restricted Share Units</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the 12-month period preceding November
28, 2025, the Company granted awards of RSUs that entitle the holders thereof to receive, upon vesting, an aggregate of 402,108 Common
Shares. The particulars of such grants are set forth in the following table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 34%; border: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>Date of Grant</U></B></FONT></TD>
    <TD STYLE="width: 33%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>Number of RSUs <BR>
Granted</U></B></FONT></TD>
    <TD STYLE="width: 33%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>Vesting Date</U></B></FONT></TD></TR>
  <TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">December&nbsp;1, 2024</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">64,004</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">December&nbsp;1, 2026</FONT></TD></TR>
  <TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">December&nbsp;18, 2024</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">198,000</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">December&nbsp;18, 2025, 2026, 2027<SUP>(1)</SUP></FONT></TD></TR>
  <TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">January&nbsp;1, 2025</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">10,666</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">January&nbsp;1, 2027</FONT></TD></TR>
  <TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">February&nbsp;1, 2025</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">10,666</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">February&nbsp;1, 2027</FONT></TD></TR>
  <TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">March&nbsp;31, 2025</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">86,774</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">March&nbsp;31, 2027</FONT></TD></TR>
  <TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">April&nbsp;1, 2025</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">10,666</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">April&nbsp;1, 2027</FONT></TD></TR>
  <TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">May&nbsp;1, 2025</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">10,666</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">May&nbsp;1, 2027</FONT></TD></TR>
  <TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">June&nbsp;1, 2025</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">10,666</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">June&nbsp;1, 2027</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Note:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">(1)&nbsp;The RSUs
vest as to 1/3 on each of the first, second, and third anniversaries of the grant date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Inducement Grants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the awards included in the above
tables, during the 12-month period preceding November 28, 2025, as a material inducement to his commencing employment as Chief Executive
Officer, and in accordance with Nasdaq Listing Rule 5635(c)(4), the Company granted Jared Kelly an option to purchase 4,750,000 Common
Shares with an exercise price of $0.57. The option has a term of five years from June 11, 2025 and becomes exercisable as to 2,850,000
Common Shares in three annual installments based on Mr. Jared Kelly&rsquo;s continued service and as to 1,900,000 Common Shares based
on the achievement of performance-based vesting conditions. Mr. Kelly was also granted an award of RSUs that entitles him to receive a
number of Common Shares equal to 2% of the Company&rsquo;s then outstanding Common Shares upon the Company entering into a definitive
agreement for certain transactions providing for the acquisition of the Company or the exclusive license of pelareorep.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Further, in addition to the awards included in the above tables, during
the 12-month period preceding November 28, 2025, as a material inducement to his commencing employment as Chief Business Officer, and
in accordance with Nasdaq Listing Rule 5635(c)(4), the Company granted Andrew Aromando an option to purchase 750,000 Common Shares with
an exercise price of $0.93. The option has a term of five years from June 25, 2025 and becomes exercisable as to 250,000 Common Shares
in three annual installments based on Mr. Aromando&rsquo;s continued service. Mr. Aromando was also granted an award of 500,000 RSUs that
vest upon the Company entering into a definitive agreement for certain transactions providing for the acquisition of the Company or the
exclusive license of pelareorep.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Market Price and Trading Volume of Common Shares</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Common Shares are listed on the NASDAQ under
the symbol &ldquo;ONCY.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets out the market price
ranges and trading volumes on the NASDAQ on a monthly basis for a period from November 2024 to December 4, 2025:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: bottom; width: 33%; border: black 1pt solid; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Month</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 15%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>High Price<BR>
(US$)</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 15%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Low Price<BR>
(US$)</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 21%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Closing Price<BR>
(US$)</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 16%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Volume</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">November&nbsp;2024</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.19</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;0.91</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;0.9302</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;6.39M</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">December&nbsp;2024</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.06</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;0.7101</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;0.9138</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;13.75M</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">January&nbsp;2025</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">0.9749</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;0.7102</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;0.729</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;51.59M</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">February&nbsp;2025</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">0.840</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;0.6507</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;0.6608</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;8.36M</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">March&nbsp;2025</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">0.7631</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;0.55</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;0.55</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;4.96M</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">April&nbsp;2025</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">0.65</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;0.4679</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;0.5708</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;7.96M</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">May&nbsp;2025</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">0.581</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;0.339</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;0.34</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;16.67M</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">June&nbsp;2025</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">0.80</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;0.3258</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;0.773</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;23.71M</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">July&nbsp;2025</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.35</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;0.71</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;1.02</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;31.88M</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">August&nbsp;2025</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.15</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;0.80</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;1.04</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;14.29M</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">September&nbsp;2025 </FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.51</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;1.02</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;1.4</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;30.97M</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">October&nbsp;2025</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.47</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;1.095</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;1.19</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;20.28M</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">November 2025</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.19</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">0.8614</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">0.9968</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">15.51M</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">December&nbsp;2025 (through December&nbsp;4)</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.0014</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">0.875</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center">0.9807</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center">3.91M</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The following table sets out the market
price ranges and trading volumes on the TSX on a monthly basis for a period from November 2024 to August&nbsp;22, 2025, when the Common
Shares were delisted from the TSX:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: bottom; width: 33%; border: black 1pt solid; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Month</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 15%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>High Price<BR>
($)</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 15%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Low Price<BR>
($)</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 21%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Closing Price<BR>
($)</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 16%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Volume</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">November&nbsp;2024</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;1.67</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;1.30</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;1.32</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;1.56M</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">December&nbsp;2024</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;1.47</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;1.02</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;1.33</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;3.82M</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">January&nbsp;2025</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;1.40</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;1.03</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;1.07</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;3.03M</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">February&nbsp;2025</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;1.19</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;0.95</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;0.95</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;2.12M</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">March&nbsp;2025</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;1.10</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;0.79</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;0.79</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;1.67M</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">April&nbsp;2025</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;0.90</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;0.67</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;0.77</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;1.27M</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">May&nbsp;2025</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;0.82</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;0.46</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;0.46</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;2.81M</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">June&nbsp;2025</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;1.10</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;0.445</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.04&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;4.41M</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">July&nbsp;2025</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;1.85</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;0.98</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;1.40</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;7.33M</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">August&nbsp;2025 (through August&nbsp;22, 2025)</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;1.50</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;1.13</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;1.42</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;4.83M</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="propos1_1"></A>Information Concerning Oncolytics following the Continuance and
prior to the Domestication</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following the Continuance and prior to the Domestication,
Oncolytics will be subject to the BCBCA as if it had been originally incorporated as a company in the Province of British Columbia. The
Continuance will not create a new legal entity, affect the continuity of Oncolytics or result in a change in the business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="propos1_2"></A>Vote Required and Recommendation of the Board</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the Meeting, Shareholders will be asked to
consider and, if thought advisable, approve, with or without variation, the Continuance Resolution, subject to such amendments, variations
or additions as may be approved at the Meeting, as a special resolution to approve the Continuance. Please refer to Annex <B>A</B> for
the text of the Continuance Resolution to be voted on at the Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to and conditional upon the approval of
the Domestication Resolution, to be adopted, the Continuance Resolution must be approved by the affirmative vote of at least two-thirds
of the votes cast by the Shareholders present or represented by proxy at the Meeting. If your Common Shares are registered in your name
and you abstain from voting on this matter, your abstention will not have any effect on the outcome of the vote. Abstentions will each
be counted for the quorum requirement. If you hold your Common Shares through a bank, broker or other agent and you do not instruct the
bank, broker or other agent on how to vote on this proposal, your bank, broker or other agent will not have authority to vote your Common
Shares. Broker non-votes will not have an impact on the outcome of this proposal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE BOARD BELIEVES THAT THE APPROVAL OF THE
CONTINUANCE RESOLUTION IS IN THE BEST INTERESTS OF ONCOLYTICS AND RECOMMENDS THAT SHAREHOLDERS VOTE IN FAVOUR OF THE APPROVAL OF THE CONTINUANCE
RESOLUTION.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The voting rights pertaining to Common Shares
represented by duly executed proxies in favour of the persons named in the accompanying form of proxy will be exercised, in the absence
of specifications to the contrary, FOR the Continuance Resolution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Please take notice that even if the Continuance
Resolution is approved, it provides that the Board may revoke such Continuance Resolution before the issuance of the certificate of continuation
without the approval of the Shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Please take further notice that even if the Continuance
Resolution is approved, the Continuance Resolution shall be revoked and the Continuance shall not be effected in the event that the requisite
majority of Shareholders does not approve the Domestication Resolution or the Board revokes or abandons the Domestication Resolution or
the Domestication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="pros02_007"></A>PROPOSAL
NO. 2 &mdash; THE DOMESTICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="pros02_008"></A><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to and conditional upon the approval by
the Shareholders of the Continuance Resolution, the Board believes it to be in our best interests to have discretion to change our jurisdiction
from the Province of British Columbia to the State of Nevada in the United States pursuant to a &ldquo;continuation out&rdquo; effected
in accordance with Section&nbsp;308 of the BCBCA and a &ldquo;domestication&rdquo; under NRS 92A.270. The Shareholders are being asked
to consider and, if thought fit, to pass the Domestication Resolution in the form set out below and attached to this Circular/Prospectus
as Annex <B>C</B>, authorizing the Board, in its sole discretion, to determine whether to implement the Domestication, and if the Board
so determines to proceed with the Domestication, to implement the Domestication and file the Articles of Domestication and the Oncolytics
Nevada Charter, subject to and conditional upon the approval by the Shareholders of the Continuance Resolution and our receipt of the
Certificate of Continuation from the Registrar appointed under the BCBCA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Domestication and the Oncolytics Nevada
Charter are approved by the Shareholders at the Meeting, the Domestication would only be implemented upon a determination by the Board
that it is in our best interests at that time. In connection with any determination to implement the Domestication, the Board will set
the timing for such Domestication. Although it is the current intention of the Board to proceed with the Domestication, it has no obligation
to do so and will have no liability associated with any decision as to whether or not to proceed with the Domestication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Domestication and the Oncolytics Nevada
Charter are approved by the Shareholders at the Meeting and the Board so determines to proceed with the Domestication following completion
of the Continuance, the Domestication will be effective on the date the Articles of Domestication and the Oncolytics Nevada Charter are
filed with the office of the Nevada Secretary of State or such later date (within 90 days of the date of filing) as provided in the Articles
of Domestication and the Oncolytics Nevada Charter. Thereafter, we will be subject to the Oncolytics Nevada Charter filed in Nevada.
Proposed forms of the Articles of Domestication, the Oncolytics Nevada Charter, and Oncolytics Nevada Bylaws are set out in Annexes <B>D,
E </B>and <B>H</B>, respectively, to this Circular/Prospectus. We will cease to be a company governed by the BCBCA as of the date Oncolytics
continues into the State of Nevada, which is expected to be on the date set forth in the Articles of Domestication and the Oncolytics
Nevada Charter, as filed with the office of the Nevada Secretary of State.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="pros02_009"></A>Principal Reasons for the Domestication</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Domestication is intended to reduce the regulatory
burden and cost of being subject to the laws and regulations of both the United States and Canada and to facilitate stockholder value
creation over the long term by, among other things, reducing our operating costs and enabling us to compete effectively in raising the
capital necessary for us to continue to implement our strategic plan. In addition, our operations are located in the United States and
a large percentage of our Shareholders are located in the United States. We chose the State of Nevada to be our domicile in part because
the NRS expressly accommodates a continuance authorized by the BCBCA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also chose the State of Nevada because of the
substantial body of case law that has evolved over the years interpreting various provisions of the NRS and the more favourable corporate
environment afforded by Nevada. For many years, Nevada has followed a policy of encouraging incorporation in that state and, in furtherance
of that policy, has adopted, construed and implemented comprehensive, flexible corporate laws and corporate governance responsive to the
legal and business needs of corporations organized under its laws. We considered Nevada&rsquo;s statute-focused approach to corporate
law and other merits of Nevada law and determined that Nevada&rsquo;s approach to corporate law is likely to foster more predictability
than Delaware&rsquo;s approach. Among other things, the Nevada statutes codify the fiduciary duties of directors and officers, which decreases
reliance on judicial interpretation and promotes stability and certainty for corporate decision-making. We also considered the increasingly
litigious environment in Delaware, which has engendered less meritorious and costly litigation and has the potential to cause unnecessary
distraction to the Company&rsquo;s directors and management team and potential delay in the Company&rsquo;s response to the evolving business
environment. We believe that a more predictable legal environment will better permit the Company to respond to emerging business trends
and conditions as needed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In considering its recommendation in favour of
the domestication, the Board weighed the potential Canadian income tax liability to us arising from this transaction. See the sections
entitled &ldquo;<I>U.S. Federal Income Tax Considerations</I>&rdquo; <I>and &ldquo;Canadian Federal Income Tax Consequences.</I>&rdquo;
For the reasons set forth above, the Board believes that the estimated benefits of Domestication currently outweigh any potential detriments,
which we do not consider to be material, resulting from the Domestication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="pros02_010"></A>Effects of Change of Jurisdiction</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Domestication will not interrupt our corporate
existence or operations or the trading market of our Common Shares. If the Domestication and the Oncolytics Nevada Charter are approved
by the Shareholders and the Board determines to proceed with the Domestication following completion of the Continuance, the Domestication
will change our jurisdiction from the Province of British Columbia to the State of Nevada in the U.S. Each outstanding Common Share at
the time of the Domestication will remain issued and outstanding as a share of Oncolytics Nevada common stock after our corporate existence
is continued from British Columbia under the BCBCA and domesticated in Nevada under the NRS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While the rights and privileges of stockholders
of a Nevada corporation are, in many instances, comparable to those of shareholders of a BCBCA corporation, there are certain differences.
In addition, in connection with the Domestication, we will be governed by a newly adopted Oncolytics Nevada Charter and Oncolytics Nevada
Bylaws, which are different from our current organizational documents. For a more detailed description of how the new organizational documents
and Nevada law may differ from our BCBCA-governed organizational documents and British Columbia corporate law under the BCBCA, see &ldquo;<I>Material
Differences between British Columbia Corporate Law and Nevada Corporate Law</I>&rdquo; attached hereto as Annex <B>K</B>. For a more detailed
description of how the new organizational documents and Nevada law may differ from our current organizational documents and Alberta corporate
law, see &ldquo;<I>Material Differences between Alberta Corporate Law and Nevada Corporate Law</I>.&rdquo; This description is not intended
to be complete and is qualified in its entirety by reference to the NRS, the BCBCA, the ABCA and our current and proposed governing documents.
Shareholders should consult their legal advisors regarding all of the implications of the transactions contemplated in the Domestication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="pros02_011"></A>Shareholder Approval</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Domestication is subject to various conditions,
including approval of the Domestication Resolution authorizing the Domestication, in the form set out below under the heading &ldquo;<I>Vote
Required and Recommendation of the Board</I>.&rdquo; Under the BCBCA and the Articles to be adopted on the Continuance, the change of
jurisdiction requires affirmative votes, whether in person or by proxy, of at least two-thirds of the votes cast by the holders of the
Common Shares at the Meeting present in person or by proxy. Assuming we receive the requisite Shareholder approval for the Domestication
and the Oncolytics Nevada Charter, the Board will retain the right to terminate or abandon the Domestication if it determines that consummating
the Domestication would be inadvisable or not in our best interests, or if all of the respective conditions to consummation of the Domestication
have not occurred. There are no time limits on the duration of the authorization resulting from a favourable Shareholder vote.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="pros02_012"></A>Regulatory Approvals for the Domestication; Canadian and U.S. Securities
Laws and Stock Exchange Implications</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Should the Shareholders approve the Domestication
Resolution at the Meeting and the Board so determines to proceed with the Domestication, we anticipate that we will file with the Nevada
Secretary of State the Articles of Domestication and the Oncolytics Nevada Charter pursuant to NRS&nbsp;92A.270, and that we will be domesticated
in Nevada on the effective date of such filings. The change of jurisdiction is further subject to the authorization of the Registrar appointed
under the BCBCA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Domestication will not otherwise interrupt
our corporate existence, our operations or the trading market of our Common Shares. Each outstanding Common Share at the time of the Domestication
will remain issued and outstanding as a share of Oncolytics Nevada common stock after our corporate existence is continued out of British
Columbia under the BCBCA and domesticated in Nevada under the NRS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following the completion of the Domestication,
the Oncolytics Nevada Common Shares will continue to be listed on Nasdaq under the symbol &ldquo;ONCY.&rdquo;
We will continue to be subject to the rules&nbsp;and regulations of Nasdaq and the obligations imposed by the securities regulatory authority
in the United States and, to the extent applicable, in Canada. We will continue to file periodic reports with applicable securities regulatory
bodies.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="pros02_013"></A>Executive Officers and Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board currently consists of eight members,
Patricia Andrews, Deborah Brown, Angela Holtham, Jared Kelly, James Parsons, Wayne Pisano, Jonathan Rigby, and Bernd Seizinger. The Board
will consist of the same eight individuals immediately following the Domestication. Immediately following the Domestication, our executive
officers will also be unchanged. Our executive officers currently include Jared Kelly &ndash; Chief Executive Officer, Kirk Look &ndash;
Chief Financial Officer, Dr.&nbsp;Thomas Heineman &ndash; Chief Medical Officer, Allison Hagerman &ndash; Vice President of Product Development,
and Andrew Aromando &ndash; Chief Business Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="pros02_014"></A>Treatment of the Outstanding Capital Stock and Options</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each outstanding Common Share at the time of the
Domestication will remain issued and outstanding as a share of Oncolytics Nevada common stock after the Domestication. Holders of outstanding
options to purchase Common Shares, and restricted share units that settle into Common Shares, will continue to hold the same securities,
which will remain exercisable for or able to be settled into an equivalent number of Oncolytics Nevada Common Shares after the Domestication,
for the equivalent exercise price per share, without any action by the holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="pros02_015"></A>Business, Location, Fiscal Year and Employee Plans</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Domestication will effect a change in our
jurisdiction and the location of our registered office, and other changes of a legal nature, including changes in our organizational documents,
which are described in this Circular/Prospectus. Our business, assets and liabilities, as well as our fiscal year, will be the same upon
the effectiveness of the Domestication as they are prior to the Domestication. Upon effectiveness of the Domestication, all our obligations
will continue as outstanding and enforceable obligations. Our employee benefit plans and agreements will be continued upon the effectiveness
of the Domestication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="pros02_016"></A>Dissent Rights of Shareholders &mdash; BC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following description of the right to dissent
and appraisal to which Shareholders are entitled in connection with the Domestication (the &ldquo;<B>BCBCA Dissent Rights</B>&rdquo;)
is not a comprehensive statement of the procedures to be followed by a Shareholder and is qualified in its entirety by reference to the
provisions of Division 2 of Part&nbsp;8 of the BCBCA (the &ldquo;<B>BCBCA Dissent Provisions</B>&rdquo;), which are attached to this Circular
as Annex <B>I.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A Shareholder that fully complies with the BCBCA
Dissent Provisions (a &ldquo;<B>Dissenter</B>&rdquo;) has the right to be paid the fair value of the Dissenter&rsquo;s Notice Shares (as
defined below). A Shareholder who intends to exercise its BCBCA Dissent Rights should carefully consider and comply with the provisions
of the BCBCA. Failure to strictly comply with these provisions, and to adhere to the procedures established therein, may result in the
loss of all rights thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Persons who are Non-Registered Shareholders who
wish to dissent should be aware that only Registered Shareholders are entitled to dissent. A Registered Shareholder, such as an intermediary,
who holds Common Shares as a nominee for Non-Registered Shareholders, some of whom wish to dissent, must exercise Dissent Rights on behalf
of any Non-Registered Shareholders who wish to dissent with respect to the Common Shares held for such Non-Registered Shareholders. In
such case, the Notice of Dissent (as defined below) should set forth the number of Common Shares it covers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<!-- Field: Split-Segment; Name: 25 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A Registered Shareholder must give written notice
of his or her dissent (a &ldquo;<B>Notice of Dissent</B>&rdquo;) to the Company by depositing such Notice of Dissent with the Company,
or mailing it to the Company or sending it by email to the Company at the following address:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>ONCOLYTICS BIOTECH INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>322 11th Avenue SW, Suite&nbsp;804</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Calgary, Alberta T2R 0C5<BR>
Attention:Chief Financial Officer <BR>
Email: info@oncolyticsbiotech.com</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>with a copy (which shall not constitute notice)
to:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>STIKEMAN ELLIOTT LLP</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>199 Bay Street</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Suite&nbsp;5300, Commerce Court West</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Toronto, Ontario, M5L 1B9<BR>
Attention: Jeff Hershenfield</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Email: jhershenfield@stikeman.com</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">which Notice of Dissent must be received no later
than Tuesday, January 13, 2026 at 10:00 a.m. (Eastern
Time) at least two days before the date of the Meeting or any adjournment thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A Shareholder who wishes to dissent must prepare
a separate Notice of Dissent for (i)&nbsp;the Shareholder, if the Shareholder is dissenting on its own behalf, and (ii)&nbsp;each person
who beneficially owns Common Shares registered in the Shareholder&rsquo;s name and on whose behalf the Shareholder is dissenting. To be
valid, a Notice of Dissent must:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">identify in each Notice of Dissent the person on whose behalf dissent is being exercised;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">set out the number of Common Shares in respect of which the Shareholder is exercising the Dissent Right
(the &ldquo;<B>Notice Shares</B>&rdquo;), which number cannot be less than all of the Common Shares held by the beneficial holder on whose
behalf the Dissent Right is being exercised;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">if the Notice Shares constitute all of the Common Shares of which the Shareholder is both the registered
owner and beneficial owner and the Shareholder owns no other Common Shares as beneficial owner, a statement to that effect;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">if the Notice Shares constitute all of the Common Shares of which the Shareholder is both the registered
and beneficial owner, but the Shareholder owns other Common Shares as beneficial owner, include a statement to that effect, and set out:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify">the names of the registered owners of those other Common Shares;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD STYLE="text-align: justify">the number of those other Common Shares that are held by each of those registered owners; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(iii)</TD><TD STYLE="text-align: justify">a statement that Notices of Dissent are being or have been sent in respect of all those other Common Shares;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(e)</TD><TD STYLE="text-align: justify">if dissent is being exercised by the Shareholder on behalf of a Beneficial Shareholder who is not
                                                                the Registered Shareholder, include a statement to that effect, and set out:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify">the name and address of the Beneficial Shareholder; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD STYLE="text-align: justify">a statement that the Registered Shareholder is dissenting in relation to all of the Common Shares beneficially
owned by the beneficial owner that are registered in the Registered Shareholder&rsquo;s name.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The giving of a Notice of Dissent does not deprive
a Shareholder of his or her right to vote at the Meeting on the Domestication Resolution. However, if a Shareholder votes (or instructs
or is deemed, by submission of any incomplete proxy, to have instructed his or her proxy holder to vote) in favour of the Domestication
Resolution, the Shareholder is not entitled to exercise BCBCA Dissent Rights with respect to the Common Shares voted, and any Dissent
Notice delivered with respect to such Common Shares will be rendered invalid. For greater certainty, a vote in favour of the Domestication
Resolution will effectively cancel a Notice of Dissent and eliminate the right to dissent over the Common Shares specified in the Notice
of Dissent. A Shareholder may, however, vote as a proxy for another Shareholder whose proxy required an affirmative vote without affecting
his or her own right to exercise the BCBCA Dissent Rights. A vote against the motion to approve the Domestication Resolution or the execution
or exercise of a proxy does not constitute a Notice of Dissent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Company intends to act on the authority
of the Domestication Resolution, it must send a notice (the &ldquo;<B>Notice to Proceed</B>&rdquo;) to each Shareholder that delivered
a Notice of Dissent promptly after the later of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">the date on which the Company forms the intention to proceed, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">the date on which the Notice of Dissent was received.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Notice to Proceed must be dated not earlier
than the date on which it is sent and state that the Company intends to act on the authority of the Domestication Resolution and advise
the Shareholder of the manner in which dissent is to be completed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On receiving a Notice to Proceed, if the Shareholder
wishes to proceed with the dissent, the Shareholder must, within one month of the Notice to Proceed, send to the Company or its transfer
agent for the Notice Shares the following items:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">a written statement that the Shareholder requires the Company to purchase all of the Notice Shares;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">the certificates, if any, representing the Notice Shares, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">in the case of a dissent being exercised by a Shareholder on behalf of a beneficial owner, a written statement
signed by the beneficial owner on whose behalf the dissent is being exercised and setting out whether or not the beneficial owner is the
beneficial owner of other Common Shares, and, if so, setting out the names of the registered owners of those other Common Shares, the
number of other Common Shares held by each registered owner, and a statement that a dissent is being exercised in respect of all those
other Common Shares,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(together, the &ldquo;<B>Notice of Completion</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Shareholder does not send the Notice of
Completion, the right of the Shareholder to dissent with respect to the Notice Shares ceases and the Notice of Dissent is no longer valid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon receipt by the Company of a valid Notice
of Completion, the Shareholder (now a Dissenter) has satisfied its obligations under the BCBCA Dissent Provisions and the Notice Shares
held by the Dissenter will be deemed to have been transferred to the Company (free of any claims) and cancelled and the Dissenter will
cease to have any rights as a Shareholder other than the right to be paid by the Company the fair value of the Dissenter&rsquo;s Notice
Shares in accordance with the BCBCA Dissent Provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company and the Dissenter may agree on the
amount of the payout value of Notice Shares and, in that event, the Company must either promptly pay that amount to the Dissenter or send
a notice to the Dissenter stating that the Company is unable to lawfully pay the Dissenter for the Dissenter&rsquo;s Notice Shares as
the Company is insolvent or the payment would render the Company insolvent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Company and the Dissenter do not agree
on the amount of the payout value of the Notice Shares, the Dissenter or the Company may apply to the Supreme Court of British Columbia
(the &ldquo;<B>BC Court</B>&rdquo;) and the BC Court may:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">determine the payout value of the Notice Shares or order that the payout value of the Notice Shares be
established by arbitration or by reference to the registrar or a referee of the BC Court;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">join in the application each Dissenter who has not agreed with the Company on the amount of the payout
value of Notice Shares; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">make consequential orders and give directions it considers appropriate.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Promptly after a determination of the payout value
of Notice Shares has been made, the Company must either pay that amount to the Dissenter or send a notice to the Dissenter that the Company
is unable lawfully to pay the Dissenter for the Dissenter&rsquo;s Notice Shares as the Company is insolvent or the payment would render
the Company insolvent. If the Dissenter receives a notice that the Company is unable to lawfully pay the Dissenter for the Dissenter&rsquo;s
Notice Shares, whether the payout value was determined by agreement between the Company and the Dissenter or pursuant to a court order,
the Dissenter may, within thirty (30) days after receipt, withdraw the Dissenter&rsquo;s Notice of Dissent. If the Notice of Dissent is
not withdrawn, the Dissenter remains a claimant against the Company to be paid as soon as the Company is lawfully able to do so or, in
a liquidation, to be ranked subordinate to the rights of creditors of the Company but in priority to Shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any notice required to be given by the Company
or a Shareholder to the other in connection with the exercise of the BCBCA Dissent Rights that is mailed will be deemed to have been received,
on the day, Saturdays, Sundays and holidays excepted, following the date of mailing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="pros02_017"></A>Accounting Treatment of the Domestication</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the Domestication, pursuant to NRS&nbsp;92A.270, we will continue our existence under the NRS as a corporation incorporated in the State of Nevada. Our
business, assets and liabilities and our subsidiaries, on a consolidated basis, as well as our principal location and fiscal year, will
be the same immediately after the Domestication as they were immediately prior to the Domestication. Accordingly, we do not believe there
will be any accounting effects as a result of the Domestication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="pros02_018"></A>Tax Consequences of the Domestication</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Domestication may have income tax consequences
in both the United States and Canada. The principal tax consequences of the Domestication to us and our current Shareholders are summarized
below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>U.S. Federal Income Tax Considerations<SUP></SUP></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following discussion is a summary of certain
material U.S. federal income tax considerations (i)&nbsp;for U.S. Holders and Non-U.S. Holders (each as defined below, and together, &ldquo;<B>Holders</B>&rdquo;)
of Oncolytics Common Shares of the Redomiciliation Transaction, including the receipt of cash payment as a result of exercising the dissenting
rights with respect to Oncolytics Common Shares, and (ii)&nbsp;for Non-U.S. Holders of the ownership and disposition of shares of Oncolytics
Nevada Common Shares received in the Redomiciliation Transaction. This section applies only to Holders that hold their Oncolytics Common
Shares and Oncolytics Nevada Common Shares as &ldquo;capital assets&rdquo; for U.S.&nbsp;federal income tax purposes (generally, property
held for investment).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This discussion is limited to U.S.&nbsp;federal
income tax considerations and does not address estate or any gift tax considerations or considerations arising under the tax laws of any
state, local or non-U.S.&nbsp;jurisdiction. This discussion does not describe all of the U.S.&nbsp;federal income tax consequences that
may be relevant to you in light of your particular circumstances, including the alternative minimum tax, the Medicare tax on certain investment
income and the different consequences that may apply if you are subject to special rules&nbsp;under U.S.&nbsp;federal income tax law that
apply to certain types of investors, such as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">financial institutions or financial services
entities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">broker-dealers;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">taxpayers that are subject to the mark-to-market
accounting rules&nbsp;with respect to the Oncolytics Common Shares;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">tax-exempt entities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">governments or agencies or instrumentalities
thereof;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">insurance companies;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">regulated investment companies or real estate
investment trusts;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">partnerships (including entities or arrangements
treated as partnerships for U.S.&nbsp;federal income tax purposes);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">U.S.&nbsp;expatriates or former long-term residents
of the United&nbsp;States;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">persons that actually or constructively own five
percent or more (by vote or value) of Oncolytics stock (except as specifically provided below);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">persons that acquired their Oncolytics Common
Shares pursuant to an exercise of employee share options, in connection with employee share incentive plans or otherwise as compensation;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">persons that hold their Oncolytics Common Shares
as part of a straddle, constructive sale, hedging, wash sale, conversion or other integrated or similar transaction;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">U.S.&nbsp;Holders (as defined below) whose functional
currency is not the U.S.&nbsp;dollar; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;controlled foreign corporations,&rdquo;
 &ldquo;passive foreign investment companies&rdquo; or corporations that accumulate earnings to avoid U.S.&nbsp;federal income tax.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a partnership (or any entity or
arrangement treated as a partnership for U.S.&nbsp;federal income tax purposes) holds Oncolytics Common Shares, the tax treatment of
such partnership and a person treated as a partner of such partnership will generally depend on the status of the partner, the
activities of the partnership, and certain determinations made at the partnership level. Partnerships holding any Oncolytics Common Shares and persons that are treated as partners of such
partnerships should consult their tax advisors as to the particular U.S.&nbsp;federal income tax consequences to them of the
Redomiciliation Transaction and the ownership and disposition of Oncolytics Nevada Common Shares received in the Redomiciliation
Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This discussion is based on the Internal
Revenue Code of 1986, as amended (the &ldquo;<B>Code</B>&rdquo;), temporary and final (and, where noted below, proposed) Treasury
Regulations promulgated thereunder, and judicial and administrative interpretations thereof, all as of the date hereof. All of the
foregoing is subject to change, which change could apply retroactively and could affect the tax considerations described herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following discussion discusses solely the
consequences of the Redomiciliation Transaction and does not discuss any other steps that may be taken by Oncolytics or Oncolytics Nevada
in connection with the Redomiciliation Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not sought, and do not intend to, seek
any rulings from the IRS as to any U.S.&nbsp;federal income tax considerations described herein. There can be no assurance that the IRS
will not take positions inconsistent with the considerations discussed below or that any such positions would not be sustained by a court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THIS DISCUSSION IS ONLY A SUMMARY OF CERTAIN
U.S.&nbsp;FEDERAL INCOME TAX CONSIDERATIONS ASSOCIATED WITH THE REDOMICILIATION TRANSACTION AND, FOR NON-U.S. HOLDERS, THE OWNERSHIP AND DISPOSITION OF ONCOLYTICS
NEVADA COMMON SHARES RECEIVED IN THE REDOMICILIATION TRANSACTION.&nbsp;EACH HOLDER SHOULD CONSULT ITS OWN TAX ADVISOR WITH RESPECT TO
THE PARTICULAR TAX CONSEQUENCES TO SUCH HOLDER OF THE REDOMICILIATION TRANSACTION AND THE OWNERSHIP AND DISPOSITION OF ONCOLYTICS NEVADA
COMMON SHARES RECEIVED IN THE REDOMICILIATION TRANSACTION,&nbsp;INCLUDING THE APPLICABILITY AND EFFECTS OF U.S.&nbsp;FEDERAL NON-INCOME,
STATE AND LOCAL AND NON-U.S.&nbsp;TAX LAWS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>U.S.&nbsp;HOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As used herein, a &ldquo;U.S.&nbsp;Holder&rdquo;
is a beneficial owner of a Oncolytics Common Share who or that is, for U.S.&nbsp;federal income tax purposes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">an individual who is a citizen or resident of
the United States;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">a corporation (or other entity that is treated
as a corporation for U.S.&nbsp;federal income tax purposes) that is created or organized (or treated as created or organized) in or under
the laws of the United&nbsp;States or any state thereof or the District of Columbia;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">an estate whose income is subject to U.S.&nbsp;federal
income tax regardless of its source; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">a trust if (1)&nbsp;a U.S.&nbsp;court can exercise
primary supervision over the administration of such trust and one or more United&nbsp;States persons have the authority to control all
substantial decisions of the trust or (2)&nbsp;it has a valid election in place to be treated as a United&nbsp;States person.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Tax Effects of the Redomiciliation Transaction
to U.S.&nbsp;Holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Generally</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The U.S.&nbsp;federal income tax consequences
of the Redomiciliation Transaction will depend primarily upon whether the Redomiciliation Transaction qualifies as a &ldquo;reorganization&rdquo;
within the meaning of Section&nbsp;368 of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A reorganization under Section 368(a)(1)(F) of
the Code is a &ldquo;mere change in identity, form, or place of organization of one corporation, however effected.&rdquo; Pursuant to the Redomiciliation
Transaction, Oncolytics will change its jurisdiction of incorporation from the Province of Alberta in Canada first to the Province of
British Columbia in Canada and then to the State of Nevada in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is intended that the Redomiciliation Transaction
qualifies as one or more reorganizations under Section 368(a)(1)(F) of the Code (collectively, an &ldquo;<B>F Reorganization</B>&rdquo;).
However, Oncolytics has not sought, and does not intend to seek, any ruling from the IRS with respect to the qualification of the Redomiciliation
Transaction as an F Reorganization, and the closing of the Redomiciliation Transaction is not conditioned on the receipt of any ruling
from the IRS or any opinion of counsel with respect to the qualification of the Redomiciliation Transaction as an F Reorganization. Consequently,
no assurance can be given that the IRS will not assert, or that a court would not sustain, a position contrary to any of those set forth
below. Accordingly, each U.S.&nbsp;Holder of Oncolytics Common Shares is urged to consult its tax advisor with respect to the particular
tax consequence of the Redomiciliation Transaction to such U.S.&nbsp;Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The remainder of this discussion assumes that the Redomiciliation Transaction as a whole will qualify as an F Reorganization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assuming the Redomiciliation Transaction qualifies
as an F Reorganization, U.S.&nbsp;Holders of Oncolytics Common Shares generally should not recognize gain or loss for U.S.&nbsp;federal
income tax purposes on the Redomiciliation Transaction, except as provided below under the sections entitled &ldquo;<I>&mdash;Effects
of Section&nbsp;367 to U.S.&nbsp;Holders of Oncolytics Common Shares</I>&rdquo; and &ldquo;<I>&mdash;PFIC Considerations,</I>&rdquo; and
the Redomiciliation Transaction should be treated for U.S.&nbsp;federal income tax purposes as if Oncolytics (i)&nbsp;transferred all
of its assets and liabilities to Oncolytics Nevada in exchange for all of the outstanding Oncolytics Nevada Common Shares; and (ii)&nbsp;then
distributed the Oncolytics Nevada Common Shares to the holders of Oncolytics Common Shares in liquidation of Oncolytics.&nbsp;The taxable
year of Oncolytics will be deemed to end on the date of the Redomiciliation Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the discussion below under the section
entitled &ldquo;<I>&mdash;PFIC Considerations,</I>&rdquo; if the Redomiciliation Transaction fails to qualify as an F Reorganization,
a U.S.&nbsp;Holder of Oncolytics Common Shares generally would recognize gain or loss with respect to its Oncolytics Common Shares in
an amount equal to the difference, if any, between the fair market value of the corresponding Oncolytics Nevada Common Shares received
in the Redomiciliation Transaction and the U.S.&nbsp;Holder&rsquo;s adjusted tax basis in its Oncolytics Common Shares surrendered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Basis and Holding Period Considerations</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assuming the Redomiciliation Transaction qualifies
as an F Reorganization, subject to the discussion below under the section entitled &ldquo;&mdash;<I>PFIC Considerations</I>&rdquo;:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
tax basis of a Oncolytics Nevada Common Share received by a U.S.&nbsp;Holder in the Redomiciliation Transaction will equal the U.S.&nbsp;Holder&rsquo;s
tax basis in the Oncolytics Common Share surrendered in exchange therefor, increased by any amount included in the income of such U.S.&nbsp;Holder
as a result of Section&nbsp;367 of the Code (as discussed below); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;the
holding period for a Oncolytics Nevada Common Shares received by a U.S.&nbsp;Holder will include such U.S.&nbsp;Holder&rsquo;s holding
period for the Oncolytics Common Shares surrendered in exchange therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Redomiciliation Transaction fails to
qualify as an F Reorganization, the U.S.&nbsp;Holder&rsquo;s basis in the U.S. Holder's Oncolytics Nevada Common Shares would be
equal to the fair market value of such Oncolytics Nevada Common Shares on the date of the Redomiciliation Transaction, and such
U.S.&nbsp;Holder&rsquo;s holding period for the such Oncolytics Nevada Common Shares would begin on the&nbsp;day following the date
of the Redomiciliation Transaction. U.S. Holders who hold different blocks of Oncolytics Common Shares (generally, Oncolytics Common
Shares purchased or acquired on different dates or at different prices) should consult their tax advisors to determine how the above
rules&nbsp;apply to them, and the discussion above does not specifically address all of the consequences to U.S.&nbsp;Holders who
hold different blocks of Oncolytics Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Effects of Section&nbsp;367 to U.S.&nbsp;Holders
of Oncolytics Common Shares</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;367 of the Code applies to certain
transactions involving foreign corporations, including a redomiciliation of a foreign corporation in a transaction that qualifies as an
F Reorganization. Subject to the discussion below under the section entitled &ldquo;&mdash;<I>PFIC Considerations</I>,&rdquo; Section&nbsp;367
of the Code imposes U.S.&nbsp;federal income tax on certain U.S.&nbsp;persons in connection with transactions that would otherwise be
tax-deferred. Section&nbsp;367(b)&nbsp;of the Code will generally apply to U.S.&nbsp;Holders on the date of the Redomiciliation Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>U.S.&nbsp;Holders Who Own 10 Percent or More
(By Vote or Value) of Oncolytics Stock</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the discussion below under the section
entitled &ldquo;&mdash;<I>PFIC Considerations,</I>&rdquo; a U.S.&nbsp;Holder who beneficially owns (actually or constructively) 10% or
more of the total combined voting power of all classes of Oncolytics stock entitled to vote or 10% or more of the total value of all classes
of Oncolytics stock (a &ldquo;<B>10% U.S.&nbsp;Shareholder</B>&rdquo;) on the date of the Redomiciliation Transaction generally must include
in income as a deemed dividend paid by Oncolytics the &ldquo;all earnings and profits amount&rdquo; attributable to the Oncolytics Common
Shares it owns within the meaning of Treasury Regulations under Section&nbsp;367 of the Code. A U.S.&nbsp;Holder&rsquo;s ownership of
any warrants or options with respect to Oncolytics Common Shares will be taken into account in determining whether such U.S.&nbsp;Holder
is a 10% U.S.&nbsp;Shareholder. Complex attribution rules&nbsp;apply in determining whether a U.S.&nbsp;Holder is a 10% U.S.&nbsp;Shareholder,
and all U.S.&nbsp;Holders are urged to consult their tax advisors with respect to these attribution rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A 10% U.S.&nbsp;Shareholder&rsquo;s &ldquo;all
earnings and profits amount&rdquo; with respect to its Oncolytics Common Shares is the net positive earnings and profits of Oncolytics
(as determined under Treasury Regulations under Section&nbsp;367 of the Code) attributable to such Oncolytics Common Shares (as determined
under Treasury Regulations under Section&nbsp;367 of the Code). Treasury Regulations under Section&nbsp;367 of the Code provide that the
 &ldquo;all earnings and profits amount&rdquo; attributable to a shareholder&rsquo;s stock is determined according to the principles of
Section&nbsp;1248 of the Code. In general, Section&nbsp;1248 of the Code and the Treasury Regulations thereunder provide that the amount
of earnings and profits attributable to a block of stock (as defined in Treasury Regulations under Section&nbsp;1248 of the Code) in a
foreign corporation is the ratably allocated portion of the foreign corporation&rsquo;s earnings and profits generated during the period
the shareholder held the block of stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Oncolytics expects to have a deficit in earnings
and profits on the date of the Redomiciliation Transaction. If Oncolytics&rsquo;s cumulative net earnings and profits through the date
of the Redomiciliation Transaction is less than or equal to zero, then a 10% U.S.&nbsp;Shareholder should not be required to include
in gross income an &ldquo;all earnings and profits amount&rdquo; with respect to its Oncolytics Common Shares. However, it is possible
that, notwithstanding Oncolytics&rsquo;s expectations, the amount of Oncolytics&rsquo;s cumulative net earnings and profits could be
positive through the date of the Redomiciliation Transaction, in which case a 10% U.S.&nbsp;Shareholder would be required to include
its &ldquo;all earnings and profits amount&rdquo; in income as a deemed dividend paid by Oncolytics under Treasury Regulations under
Section&nbsp;367 as a result of the Redomiciliation Transaction. Therefore, there can be no assurance that Oncolytics indeed will have
a deficit in earnings and profits on the date of the Redomiciliation Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">U.S.&nbsp;Holders Who Own Less Than 10
Percent (By Vote or Value) of Oncolytics Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the discussion below under the section
entitled &ldquo;&mdash;<I>PFIC Considerations</I>,&rdquo; a U.S.&nbsp;Holder whose Oncolytics Common Shares, on the date of the Redomiciliation
Transaction, have a fair market value of $50,000 or more and who, on the date of the Redomiciliation Transaction, is not a 10% U.S.&nbsp;Shareholder
generally will recognize gain (but not loss) with respect to its Oncolytics Common Shares in the Redomiciliation Transaction or, in the
alternative, may elect to recognize the &ldquo;all earnings and profits&rdquo; amount attributable to such U.S.&nbsp;Holder&rsquo;s Oncolytics
Common Shares as described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the discussion below under the section
entitled &ldquo;&mdash;<I>PFIC Considerations,</I>&rdquo; unless a U.S.&nbsp;Holder makes the &ldquo;all earnings and profits election&rdquo;
as described below, such U.S.&nbsp;Holder generally must recognize gain (but not loss) with respect to Oncolytics Nevada Common Shares
received in the Redomiciliation Transaction in an amount equal to the excess of the fair market value of such Oncolytics Nevada Common
Shares over the U.S.&nbsp;Holder&rsquo;s adjusted tax basis in the Oncolytics Common Shares deemed surrendered in exchange therefor.
U.S.&nbsp;Holders who hold different blocks of Oncolytics Common Shares (generally, Oncolytics Common Shares purchased or acquired on
different dates or at different prices) should consult their tax advisors to determine how the above rules&nbsp;apply to them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In lieu of recognizing any gain as described in
the preceding paragraph, a U.S.&nbsp;Holder may elect to include in income as a deemed dividend paid by Oncolytics the &ldquo;all earnings
and profits amount&rdquo; attributable to its Oncolytics Common Shares under Section&nbsp;367(b)&nbsp;of the Code. There are, however,
strict conditions for making this election. This election must comply with applicable Treasury Regulations and generally must include,
among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(i)</TD><TD STYLE="text-align: justify">a statement that the Redomiciliation Transaction is a Section&nbsp;367(b)&nbsp;exchange
(within the meaning of the applicable Treasury Regulations);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">a complete description of the Redomiciliation Transaction;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">a description of any stock, securities or other consideration
transferred or received in the Redomiciliation Transaction;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(iv)</TD><TD STYLE="text-align: justify">a statement describing the amounts required to be taken into account
for U.S. federal income tax purposes;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(v)</TD><TD STYLE="text-align: justify">a statement that the U.S.&nbsp;Holder is making the election that
includes (A)&nbsp;a copy of the information that the U.S.&nbsp;Holder received from Oncolytics establishing and substantiating the U.S.&nbsp;Holder&rsquo;s
 &ldquo;all earnings and profits amount&rdquo; with respect to the U.S.&nbsp;Holder&rsquo;s Oncolytics Common Shares and (B)&nbsp;a representation
that the U.S.&nbsp;Holder has notified Oncolytics (or Oncolytics Nevada) that the U.S.&nbsp;Holder is making the election; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(vi)</TD><TD STYLE="text-align: justify">certain other information required to be furnished with the U.S.&nbsp;Holder&rsquo;s
tax return or otherwise furnished pursuant to the Code or the Treasury Regulations.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the election must be attached by
an electing U.S. Holder to such U.S. Holder&rsquo;s timely filed U.S.&nbsp;federal income tax return for the year of the Redomiciliation
Transaction, and the U.S.&nbsp;Holder must send notice of making the election to Oncolytics or Oncolytics Nevada no later than the date
such tax return is filed. In connection with this election, Oncolytics may in its discretion provide each U.S.&nbsp;Holder eligible to
make such an election with information regarding Oncolytics&rsquo;s earnings and profits upon written request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Oncolytics expects to have a deficit in earnings
and profits through the date of the Redomiciliation Transaction and if that proves to be the case, U.S.&nbsp;Holders who make this election
are not expected to have any income inclusion under Section&nbsp;367(b)&nbsp;of the Code, provided that the U.S.&nbsp;Holder properly
executes the election and complies with the applicable notice requirements. However, as noted above, if it were ultimately determined
that Oncolytics had positive earnings and profits through the date of the Redomiciliation Transaction, a U.S.&nbsp;Holder that makes
the election described herein could have an &ldquo;all earnings and profits amount&rdquo; with respect to its Oncolytics Common Shares,
and thus could be required to include that amount in income as a deemed dividend paid by Oncolytics under applicable Treasury Regulations
as a result of the Redomiciliation Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A U.S.&nbsp;Holder who is not a 10% U.S.&nbsp;Shareholder
on the date of the Redomiciliation Transaction and whose Oncolytics Common Shares have a fair market value of less than $50,000 on the
date of the Redomiciliation Transaction generally should not be required to recognize any gain or loss or include any part of the &ldquo;all
earnings and profits amount&rdquo; in income under Section&nbsp;367 of the Code in connection with the Redomiciliation Transaction. However,
such U.S.&nbsp;Holder may be subject to taxation under the PFIC rules&nbsp;as discussed below under the section entitled &ldquo;&mdash;<I>PFIC
Considerations</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>EACH U.S.&nbsp;HOLDER IS URGED TO CONSULT ITS
TAX ADVISOR REGARDING THE CONSEQUENCES TO IT OF THE REDOMICILIATION TRANSACTION INCLUDING THE MAKING AN ELECTION TO INCLUDE IN INCOME
THE &ldquo;ALL EARNINGS AND PROFITS AMOUNT&rdquo; ATTRIBUTABLE TO ITS ONCOLYTICS COMMON SHARES UNDER SECTION&nbsp;367(b)&nbsp;OF THE CODE
AND THE APPROPRIATE FILING REQUIREMENTS WITH RESPECT TO SUCH AN ELECTION.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>ALL U.S.&nbsp;HOLDERS ARE URGED TO CONSULT
THEIR TAX ADVISORS WITH RESPECT TO THE EFFECT OF SECTION&nbsp;367 OF THE CODE TO THEIR PARTICULAR CIRCUMSTANCES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>PFIC Considerations</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Regardless of whether the Redomiciliation Transaction
qualifies as an F Reorganization (and, if the Redomiciliation Transaction qualifies as an F Reorganization, in addition to the discussion
under the section entitled &ldquo;&mdash;<I>Effects of Section&nbsp;367 to U.S.&nbsp;Holders of Oncolytics Common Shares</I>&rdquo; above),
the Redomiciliation Transaction could be a taxable event to U.S.&nbsp;Holders under the PFIC provisions of the Code if Oncolytics is considered
a PFIC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Definition of a PFIC</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A foreign (<I>i.e</I>., non-U.S.) corporation
will be classified as a PFIC for U.S.&nbsp;federal income tax purposes if either (i)&nbsp;at least 75% of its gross income in a taxable
year, including its pro rata share of the gross income of any corporation in which it is considered to own at least 25% of the shares
by value, is passive income or (ii)&nbsp;at least 50% of its assets in a taxable year (generally determined based on fair market value
and averaged quarterly over the year), including its pro rata share of the assets of any corporation in which it is considered to own
at least 25% of the shares by value, are held for the production of, or produce, passive income. Passive income generally includes dividends,
interest, rents and royalties (other than rents or royalties derived from the active conduct of a trade or business received from unrelated
persons) and gains from the disposition of passive assets. The determination of whether a foreign corporation is a PFIC is made annually.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>PFIC Status of Oncolytics</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Based on our historic and anticipated
operations and composition of assets and income, Oncolytics believes it was classified as a PFIC during the most recently completed
tax year, and based on current business plans and financial expectations, Oncolytics expects to be a PFIC for the taxable year which
ends as a result of the Redomiciliation Transaction. Due to the factual nature of the determination, no assurance can be given as to
whether Oncolytics would be or would not be a PFIC for any taxable year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Effects of PFIC Rules&nbsp;on the Redomiciliation
Transaction</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if the Redomiciliation Transaction qualifies
as an F Reorganization, Section&nbsp;1291(f)&nbsp;of the Code requires that, to the extent provided in Treasury Regulations, a U.S.&nbsp;person
who disposes of stock of a PFIC (which, under proposed Treasury Regulations may include a U.S.&nbsp;person exchanging warrants of a PFIC
for newly issued warrants in connection with a redomiciliation transaction) recognizes gain notwithstanding any other provision of the
Code. No final Treasury Regulations are currently in effect under Section&nbsp;1291(f)&nbsp;of the Code. However, proposed Treasury Regulations
under Section&nbsp;1291(f)&nbsp;of the Code have been promulgated with a retroactive effective date. If finalized in their current form,
those proposed Treasury Regulations would require gain recognition to U.S.&nbsp;Holders of Oncolytics Common Shares as a result of the
Redomiciliation Transaction if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Oncolytics
(or its predecessor) were classified as a PFIC at any time during such U.S.&nbsp;Holder&rsquo;s holding period in such Oncolytics Common
Shares; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;the
U.S.&nbsp;Holder had not timely made (a)&nbsp;a QEF Election (as defined below) for the first taxable year in which the U.S.&nbsp;Holder
owned such Oncolytics Common Shares or in which Oncolytics was a PFIC, whichever is later (or a QEF Election along with a purging election),
or (b)&nbsp;a MTM Election (as defined below) with respect to such Oncolytics Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The tax on any such recognized gain would be imposed
based on a complex set of computational rules&nbsp;designed to offset the tax deferral with respect to the undistributed earnings of Oncolytics.&nbsp;Under
these rules:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the U.S.&nbsp;Holder&rsquo;s gain will be allocated
ratably over the U.S.&nbsp;Holder&rsquo;s holding period for such U.S.&nbsp;Holder&rsquo;s Oncolytics Common Shares;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the amount of gain allocated to the U.S.&nbsp;Holder&rsquo;s
taxable year in which the U.S.&nbsp;Holder recognized the gain, or to the period in the U.S.&nbsp;Holder&rsquo;s holding period before
the first&nbsp;day of the first taxable year in which Oncolytics was a PFIC, will be taxed as ordinary income;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the amount of gain allocated to other taxable&nbsp;years
(or portions thereof) of the U.S.&nbsp;Holder and included in such U.S.&nbsp;Holder&rsquo;s holding period would be taxed at the highest
tax rate in effect for that year and applicable to the U.S.&nbsp;Holder; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">an additional tax equal to the interest charge
generally applicable to underpayments of tax will be imposed on the U.S.&nbsp;Holder in respect of the tax attributable to each such other
taxable year (described in the third bullet above) of such U.S.&nbsp;Holder.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the proposed Treasury Regulations
provide coordinating rules&nbsp;with Section&nbsp;367(b)&nbsp;of the Code, whereby, if the gain recognition rule&nbsp;of the proposed
Treasury Regulations discussed in the preceding paragraph applies to a disposition of PFIC stock that results from a transfer with respect
to which Section&nbsp;367(b)&nbsp;of the Code requires the U.S.&nbsp;Holder to recognize gain or include an amount in income as a deemed
dividend deemed paid by Oncolytics, the gain realized on the transfer is taxable under the rules&nbsp;described in the preceding paragraph,
and the excess, if any, of the amount to be included in income under Section&nbsp;367(b)&nbsp;of the Code over the gain realized is taxable
as provided under Section&nbsp;367(b)&nbsp;of the Code. See the discussion above under the section entitled &ldquo;&mdash;<I>Effects of
Section&nbsp;367 to U.S.&nbsp;Holders of Oncolytics Common Shares.</I>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is difficult to predict whether, in what form
and with what effective date, final Treasury Regulations under Section&nbsp;1291(f)&nbsp;of the Code may be adopted or how any such final
Treasury Regulations would apply. If the proposed regulations under Section&nbsp;1291(f)&nbsp;were finalized in the current form, U.S.&nbsp;Holders
of Oncolytics Common Shares that have not made a timely and effective QEF Election (or a QEF Election along with a purging election) or
a MTM Election (each as defined below) (a &ldquo;<B>Non-Electing Shareholder</B>&rdquo;) may be subject to taxation under the PFIC rules&nbsp;on
the Redomiciliation Transaction with respect to their Oncolytics Common Shares in the manner set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any gain recognized by a Non-Electing Shareholder
of Oncolytics Common Shares as a result of the Redomiciliation Transaction pursuant to PFIC rules&nbsp;would be taxable income to such
U.S.&nbsp;Holder, taxed under the PFIC rules&nbsp;in the manner set forth above, with no corresponding receipt of cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As noted above, absent a QEF Election (or a QEF
Election along with a purging election) or a MTM Election, the Redomiciliation Transaction could be a taxable event under the PFIC rules&nbsp;regardless
of whether the Redomiciliation Transaction qualifies as an F Reorganization if Oncolytics is considered a PFIC.&nbsp;If the Redomiciliation
Transaction fails to qualify as an F Reorganization, absent a QEF Election (or a QEF Election along with a purging election) or a MTM
Election, a U.S.&nbsp;Holder&rsquo;s gain, if any, would be taxed under the PFIC rules&nbsp;in the manner set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>ALL U.S.&nbsp;HOLDERS ARE URGED TO CONSULT
THEIR TAX ADVISORS REGARDING THE EFFECTS OF THE PFIC RULES ON THE REDOMICILIATION TRANSACTION,&nbsp;INCLUDING THE IMPACT OF ANY PROPOSED
OR FINAL TREASURY REGULATIONS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">QEF Election and Mark-to-Market Election</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The impact of the PFIC rules&nbsp;on a U.S.&nbsp;Holder
of Oncolytics Common Shares will depend on whether the U.S.&nbsp;Holder has made a timely and effective election to treat Oncolytics as
a &ldquo;qualified electing fund&rdquo; under Section&nbsp;1295 of the Code for the taxable year that is the first year in the U.S.&nbsp;Holder&rsquo;s
holding period of Oncolytics Common Shares during which Oncolytics qualified as a PFIC (a &ldquo;<B>QEF Election</B>&rdquo;) or, if in
a later taxable year, the U.S.&nbsp;Holder made a QEF Election along with a purging election. A purging election creates a deemed sale
of the U.S.&nbsp;Holder&rsquo;s Oncolytics Common Shares at their then fair market value and requires the U.S.&nbsp;Holder to recognize
gain pursuant to the purging election subject to the special PFIC tax and interest charge rules&nbsp;described above. As a result of any
such purging election, the U.S.&nbsp;Holder would increase the adjusted tax basis in its Oncolytics Common Shares by the amount of the
gain recognized and, solely for purposes of the PFIC rules, would have a new holding period in its Oncolytics Common Shares. U.S.&nbsp;Holders
are urged to consult their tax advisors as to the application of the rules&nbsp;governing purging elections to their particular circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A U.S.&nbsp;Holder that made a timely and effective
QEF Election (or a QEF Election along with a purging election) or a MTM Election (an &ldquo;<B>Electing Shareholder</B>&rdquo;) generally
would not be subject to the adverse PFIC rules&nbsp;discussed above with respect to its Oncolytics Common Shares. As a result, such an
Electing Shareholder generally should not recognize gain or loss as a result of the Redomiciliation Transaction except to the extent described
under &ldquo;&mdash;<I>Effects of Section&nbsp;367 to U.S.&nbsp;Holders of Oncolytics Common Shares</I>&rdquo; and subject to the discussion
above under &ldquo;&mdash;<I>Tax Effects of the Redomiciliation Transaction to U.S.&nbsp;Holders.</I>&rdquo; If an Electing Shareholder
has made a QEF Election, it would instead include annually in gross income its pro rata share of the ordinary earnings and net capital
gain of Oncolytics, whether or not such amounts are actually distributed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The impact of the PFIC rules&nbsp;on a U.S. Holder
of Oncolytics Common Shares may also depend on whether the U.S.&nbsp;Holder has made a mark-to-market election under Section&nbsp;1296
of the Code. U.S.&nbsp;Holders who hold (actually or constructively) stock of a foreign corporation that is classified as a PFIC may annually
elect to mark such stock to its market value if such stock is &ldquo;marketable stock,&rdquo; generally, stock that is regularly traded
on a national securities exchange that is registered with the SEC, including Nasdaq (a &ldquo;<B>MTM Election</B>&rdquo;). No assurance
can be given that the Oncolytics Common Shares are considered to be marketable stock for purposes of the MTM Election or whether the other
requirements of this election are satisfied. If such an election is available and has been made, such U.S.&nbsp;Holders generally will
not be subject to the special taxation rules&nbsp;of Section&nbsp;1291 of the Code discussed herein with respect to their Oncolytics Common
Shares in connection with the Redomiciliation Transaction or otherwise. Instead, in general, the U.S.&nbsp;Holder will include as ordinary
income each year the excess, if any, of the fair market value of its Oncolytics Common Shares at the end of its taxable year over its
adjusted basis in its Oncolytics Common Shares. The U.S.&nbsp;Holder also will recognize an ordinary loss in respect of the excess, if
any, of its adjusted basis in its Oncolytics Common Shares over the fair market value of its Oncolytics Common Shares at the end of its
taxable year (but only to the extent of the net amount of previously included income as a result of the MTM Election). The U.S.&nbsp;Holder&rsquo;s
basis in its Oncolytics Common Shares will be adjusted to reflect any such income or loss amounts, and any further gain recognized on
a sale or other taxable disposition of its Oncolytics Common Shares will be treated as ordinary income. However, if the MTM Election is
not made by a U.S.&nbsp;Holder with respect to the first taxable year of its holding period for the PFIC stock, then the Section&nbsp;1291
rules&nbsp;discussed above will apply to certain dispositions of, distributions on and other amounts taxable with respect to Oncolytics
Common Shares, including in connection with the Redomiciliation Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE RULES DEALING WITH PFICS ARE VERY COMPLEX
AND ARE IMPACTED BY VARIOUS FACTORS IN ADDITION TO THOSE DESCRIBED ABOVE,&nbsp;INCLUDING THE APPLICATION OF THE RULES ADDRESSING OVERLAPS
IN THE PFIC RULES AND THE SECTION&nbsp;367(b)&nbsp;RULES AND THE RULES RELATING TO CONTROLLED FOREIGN CORPORATIONS.&nbsp;ALL U.S. HOLDERS
ARE URGED TO CONSULT THEIR TAX ADVISORS REGARDING THE CONSEQUENCES TO THEM OF THE PFIC RULES,&nbsp;INCLUDING, WITHOUT LIMITATION, WHETHER
A QEF ELECTION (OR A QEF ELECTION ALONG WITH A PURGING ELECTION), A MTM ELECTION OR ANY OTHER ELECTION IS AVAILABLE AND WHETHER AND HOW
ANY OVERLAP RULES APPLY, AND THE CONSEQUENCES TO THEM OF ANY SUCH ELECTION OR OVERLAP RULE AND THE IMPACT OF ANY PROPOSED OR FINAL PFIC
TREASURY REGULATIONS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Considerations for U.S. Holders Exercising
Dissent Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Generally</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the PFIC rules&nbsp;discussed below,
the U.S.&nbsp;federal income tax consequences to a U.S.&nbsp;Holder of Oncolytics Common Shares that exercises such U.S. Holder&rsquo;s
dissent rights to receive a cash payment for all or a portion of its Oncolytics Common Shares will depend on whether the receipt of such
cash payment in exchange for such U.S. Holder&rsquo;s Oncolytics Common Shares (a &ldquo;redemption&rdquo;) qualifies as a sale of Oncolytics
Common Shares under Section&nbsp;302 of the Code. If the redemption qualifies as a sale, the tax consequences to such U.S.&nbsp;Holder
are as described below under the section entitled &ldquo;&mdash;<I>Taxation of Redemption Treated as a Sale.</I>&rdquo; If the redemption
does not qualify as a sale, a U.S.&nbsp;Holder will be treated as receiving a corporate distribution with the tax consequences to such
U.S.&nbsp;Holder as described below under the section entitled &ldquo;<I>&mdash;Taxation of Redemption Treated as a Distribution.</I>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Whether a redemption of Oncolytics Common Shares
qualifies for sale treatment will depend largely on the total number of Oncolytics Common Shares treated as held by the redeemed U.S.&nbsp;Holder
before and after the redemption relative to all of the Oncolytics stock outstanding both before and after the redemption. The redemption
of Oncolytics Common Shares generally will be treated as a sale of Oncolytics Common Shares rather than as a corporate distribution if
the redemption (1)&nbsp;is &ldquo;substantially disproportionate&rdquo; with respect to the U.S.&nbsp;Holder, (2)&nbsp;results in a &ldquo;complete
termination&rdquo; of the U.S.&nbsp;Holder&rsquo;s interest in Oncolytics or (3)&nbsp;is &ldquo;not essentially equivalent to a dividend&rdquo;
with respect to the U.S.&nbsp;Holder. These tests are explained more fully below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In determining whether any of the foregoing tests
result in a redemption qualifying for sale treatment, a U.S.&nbsp;Holder takes into account not only Oncolytics Common Shares actually
owned by the U.S.&nbsp;Holder, but also Oncolytics Common Shares that are constructively owned by it under certain attribution rules&nbsp;set
forth in the Code. A U.S.&nbsp;Holder may constructively own, in addition to stock owned directly, stock owned by certain related individuals
and entities in which the U.S.&nbsp;Holder has an interest or that have an interest in such U.S.&nbsp;Holder, as well as any stock that
the holder has a right to acquire by exercise of an option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to meet the substantially disproportionate
test, the percentage of Oncolytics&rsquo;s outstanding voting stock actually and constructively owned by the U.S.&nbsp;Holder immediately
following the redemption of Oncolytics Common Shares must, among other requirements, be less than eighty percent (80%) of the percentage
of Oncolytics&rsquo;s outstanding voting stock actually and constructively owned by the U.S.&nbsp;Holder immediately before the redemption
taking into account redemptions by other holders of Oncolytics Common Shares. There will be a complete termination of a U.S.&nbsp;Holder&rsquo;s
interest if either (1)&nbsp;all of the shares of Oncolytics stock actually and constructively owned by the U.S.&nbsp;Holder are redeemed
or (2)&nbsp;all of the Oncolytics Common Shares actually owned by the U.S.&nbsp;Holder are redeemed and the U.S.&nbsp;Holder is eligible
to waive, and effectively waives in accordance with specific rules, the attribution of stock owned by certain family members and the U.S.&nbsp;Holder
does not constructively own any other Oncolytics Common Shares (including any stock constructively owned by the U.S.&nbsp;Holder as a
result of owning options). The redemption of Oncolytics Common Shares will not be essentially equivalent to a dividend if the redemption
results in a &ldquo;meaningful reduction&rdquo; of the U.S.&nbsp;Holder&rsquo;s proportionate interest in Oncolytics. Whether the redemption
will result in a meaningful reduction in a U.S.&nbsp;Holder&rsquo;s proportionate interest in Oncolytics will depend on the particular
facts and circumstances. However, the IRS has indicated in a published ruling that even a small reduction in the proportionate interest
of a small minority stockholder in a publicly held corporation where such stockholder exercises no control over corporate affairs may
constitute such a &ldquo;meaningful reduction.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If none of the foregoing tests is satisfied, then
the redemption of Oncolytics Common Shares will be treated as a corporate distribution to the redeemed U.S.&nbsp;Holder and the tax effects
to such a U.S.&nbsp;Holder will be as described below under the section entitled &ldquo;&mdash;<I>Taxation of Redemption Treated as a
Distribution.</I>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Taxation of Redemption Treated as a Distribution</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the PFIC rules&nbsp;described below,
if the redemption of a U.S.&nbsp;Holder&rsquo;s Oncolytics Common Shares is treated as a corporate distribution, as discussed above under
the section entitled &ldquo;&mdash;<I>Generally</I>,&rdquo; the amount of cash received in the redemption generally will constitute a
dividend for U.S.&nbsp;federal income tax purposes to the extent paid from Oncolytics&rsquo;s current or accumulated earnings and profits,
as determined under U.S.&nbsp;federal income tax principles. Distributions in excess of Oncolytics&rsquo;s current and accumulated earnings
and profits will constitute a return of capital that will be applied against and reduce (but not below zero) the U.S.&nbsp;Holder&rsquo;s
adjusted tax basis in its Oncolytics Common Shares on a per-share basis. Any remaining excess will be treated as gain realized on the
sale of Oncolytics Common Shares and will be treated as described below under the section entitled &ldquo;&mdash;<I>Taxation of Redemption
Treated as a Sale</I>.&rdquo; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Taxation of Redemption Treated as a Sale</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the PFIC rules&nbsp;described below,
if the redemption of a U.S.&nbsp;Holder&rsquo;s Oncolytics Common Shares is treated as a sale, as discussed above under the section entitled
 &ldquo;&mdash;<I>Generally</I>,&rdquo; a U.S.&nbsp;Holder generally will recognize capital gain or loss in an amount equal to the difference
between the amount of cash received in the redemption and the U.S.&nbsp;Holder&rsquo;s adjusted tax basis in the Oncolytics Common Shares
redeemed. Any such capital gain or loss generally will be long-term capital gain or loss if the U.S.&nbsp;holder&rsquo;s holding period
for the Oncolytics Common Shares so disposed of exceeds one year. Long-term capital gains recognized by non-corporate U.S.&nbsp;holders
generally will be eligible to be taxed at reduced rates. The deductibility of capital losses is subject to limitations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">U.S.&nbsp;Holders who hold different blocks of
Oncolytics Common Shares (including as a result of holding different blocks purchased or acquired on different dates or at different prices)
should consult their tax advisors to determine how the above rules&nbsp;apply to them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>PFIC Considerations in Connection with Exercising
Dissent Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If (i)&nbsp;Oncolytics is determined to be a PFIC
for any taxable year (or portion thereof) that is included in the holding period of a U.S. Holder and (ii)&nbsp;the U.S. Holder did not
make a timely and effective QEF Election for Oncolytics&rsquo;s first taxable year as a PFIC in which the U.S. Holder held (or was deemed
to hold) Oncolytics Common Shares (such taxable year as it relates to each U.S. Holder, the &ldquo;<B>First PFIC Holding Year</B>&rdquo;)
or an MTM Election, then such holder will generally be subject to special rules&nbsp;(the &ldquo;<B>Default PFIC Regime</B>&rdquo;) with
respect to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any gain recognized by the U.S. Holder on the
sale of its Oncolytics Common Shares; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any &ldquo;excess distribution&rdquo; made to
the U.S. Holder (generally, any distributions to such U.S. Holder during a taxable year of the U.S. Holder that are greater than 125%
of the average annual distributions received by such U.S. Holder in respect of Oncolytics Common Shares during the three preceding taxable
years of such U.S. Holder or, if shorter, such U.S. Holder&rsquo;s holding period for its Oncolytics Common Shares).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Default PFIC Regime:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the U.S. Holder&rsquo;s gain or excess distribution
will be allocated ratably over the U.S. Holder&rsquo;s holding period for its Oncolytics Common Shares;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the amount of gain allocated to the U.S. Holder&rsquo;s
taxable year in which the U.S. Holder recognized the gain or received the excess distribution, or to the period in the U.S. Holder&rsquo;s
holding period before the first day of the first taxable year in which Oncolytics is a PFIC, will be taxed as ordinary income;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the amount of gain allocated to other taxable
years (or portions thereof) of the U.S. Holder and included in such U.S. Holder&rsquo;s holding period will be taxed at the highest marginal
tax rate in effect for that year and applicable to the U.S. Holder; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">an additional amount equal to the interest charge
generally applicable to underpayments of tax will be imposed on the U.S. Holder in respect of the tax attributable to each such other
taxable year of such U.S. Holder&rsquo;s holding period.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>ALL U.S.&nbsp;HOLDERS ARE URGED TO CONSULT
THEIR TAX ADVISORS AS TO THE TAX CONSEQUENCES TO THEM OF EXERCISING DISSENT RIGHTS,&nbsp;INCLUDING THE POTENTIAL EFFECTS OF THE PFIC RULES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Information Reporting and Backup Withholding</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Payments of cash to a U.S.&nbsp;Holder as a result
of the redemption of Oncolytics Common Shares may be subject to information reporting to the IRS and possible U.S.&nbsp;backup withholding.
Backup withholding will not apply, however, to a U.S.&nbsp;Holder who furnishes a correct taxpayer identification number and makes other
required certifications, or who is otherwise exempt from backup withholding and establishes such exempt status.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Backup withholding is not an additional tax. Amounts
withheld as backup withholding may be credited against a U.S.&nbsp;Holder&rsquo;s U.S.&nbsp;federal income tax liability, and the U.S.&nbsp;Holder
generally may obtain a refund of any excess amounts withheld under the backup withholding rules&nbsp;by timely filing the appropriate
claim for refund with the IRS and furnishing any required information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NON-U.S.&nbsp;HOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As used herein, a &ldquo;Non-U.S.&nbsp;Holder&rdquo;
is a beneficial owner of an Oncolytics Common Share who or that is, for U.S.&nbsp;federal income tax purposes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">a non-resident alien individual, other than certain
former citizens and residents of the United&nbsp;States subject to U.S.&nbsp;tax as expatriates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">a foreign corporation; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">an estate or trust that is not a U.S.&nbsp;Holder.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Effects of the Redomiciliation Transaction
to Non-U.S.&nbsp;Holders</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Redomiciliation Transaction is not expected
to result in any U.S.&nbsp;federal income tax consequences to Non-U.S.&nbsp;Holders of Oncolytics Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following describes U.S.&nbsp;federal income
tax considerations relating to the ownership and disposition of Oncolytics Nevada Common Shares by a Non-U.S.&nbsp;Holder after the Redomiciliation
Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Distributions on Oncolytics Nevada Common Shares</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In general, any distributions made to a Non-U.S.&nbsp;Holder
of Oncolytics Nevada Common Shares, to the extent paid out of Oncolytics Nevada&rsquo;s current or accumulated earnings and profits (as
determined under U.S.&nbsp;federal income tax principles), will constitute U.S.&nbsp;source dividends for U.S.&nbsp;federal income tax
purposes and, provided such dividends are not effectively connected with the Non-U.S.&nbsp;Holder&rsquo;s conduct of a trade or business
within the United&nbsp;States, Oncolytics Nevada or other applicable withholding agent will be required to withhold tax from the gross
amount of the dividend at a rate of 30%, unless such Non-U.S.&nbsp;Holder is eligible for a reduced rate of withholding tax under an applicable
income tax treaty and provides proper certification of its eligibility for such reduced rate (usually on IRS Form&nbsp;W-8BEN or W-8BEN-E).
Any distribution not constituting a dividend will be treated first as reducing (but not below zero) the Non-U.S.&nbsp;Holder&rsquo;s adjusted
tax basis in its Oncolytics Nevada Common Shares and, to the extent such distribution exceeds the Non-U.S.&nbsp;Holder&rsquo;s adjusted
tax basis, as gain realized from the sale or other disposition of the Oncolytics Nevada Common Shares, which will be treated as described
under &ldquo;&mdash;<I>Sale, Taxable Exchange or Other Taxable Disposition of Oncolytics Nevada Common Shares</I>&rdquo; below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The withholding tax described above generally
does not apply to dividends paid to a Non-U.S.&nbsp;Holder who provides a completed IRS Form&nbsp;W-8ECI, certifying that the dividends
are effectively connected with the Non-U.S.&nbsp;Holder&rsquo;s conduct of a trade or business within the United&nbsp;States. Instead,
such effectively connected dividends will be subject to regular U.S.&nbsp;federal income tax as if the Non-U.S.&nbsp;Holder were a U.S.&nbsp;resident,
subject to an applicable income tax treaty providing otherwise. A corporate Non-U.S.&nbsp;Holder receiving effectively connected dividends
may also be subject to an additional &ldquo;branch profits tax&rdquo; imposed at a rate of 30% (or a lower applicable treaty rate).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Sale, Taxable Exchange or Other Taxable Disposition
of Oncolytics Nevada Common Shares</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the discussion below under &ldquo;<I>&mdash;Considerations
for Non-U.S. Holders Exercising Dissent Rights</I>,&rdquo; a Non-U.S.&nbsp;Holder generally will not be subject to U.S.&nbsp;federal income
tax (including withholding of U.S.&nbsp;federal income tax) in respect of gain recognized on a sale, taxable exchange or other taxable
disposition of its Oncolytics Nevada Common Shares, unless:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
gain is effectively connected with the conduct by the Non-U.S.&nbsp;Holder of a trade or business within the United&nbsp;States (and,
under certain income tax treaties, is attributable to a United&nbsp;States permanent establishment or fixed base maintained by the Non-U.S.&nbsp;Holder);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;such
Non-U.S.&nbsp;Holder is an individual who was present in the United&nbsp;States for 183&nbsp;days or more in the taxable year of such
disposition and certain other requirements are met; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">(iii)&nbsp;&nbsp;&nbsp;Oncolytics
Nevada is or has been a &ldquo;United&nbsp;States real property holding corporation&rdquo; for U.S.&nbsp;federal income tax purposes at
any time during the shorter of the five-year period ending on the date of sale or other exchange or the period that the Non-U.S.&nbsp;Holder
held Oncolytics Nevada Common Shares and, in the case where the class Oncolytics Nevada Common Shares are considered to be regularly traded
on an established securities market, the Non-U.S.&nbsp;Holder has owned, directly or constructively, more than five percent (5%) of that
class of Oncolytics Nevada Common Shares at any time within the shorter of the five-year period ending on the date of the sale or other
disposition or such Non-U.S.&nbsp;Holder&rsquo;s holding period for the Oncolytics Nevada Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless an applicable treaty provides otherwise,
gain described in the first bullet point above will be subject to tax at generally applicable U.S.&nbsp;federal income tax rates as if
the Non-U.S.&nbsp;Holder were a U.S.&nbsp;resident. Any gains described in the first bullet point above of a corporate Non-U.S.&nbsp;Holder
may also be subject to an additional &ldquo;branch profits tax&rdquo; at a thirty percent (30%) rate (or a lower applicable income tax
treaty rate). If the second bullet point applies to a Non-U.S.&nbsp;Holder, such Non-U.S.&nbsp;Holder will be subject to U.S.&nbsp;tax
on such Non-U.S.&nbsp;Holder&rsquo;s net capital gain for such year (including any gain realized in connection with the redemption) at
a tax rate of thirty percent (30%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the third bullet point above applies to a Non-U.S.&nbsp;Holder,
gain recognized by such holder will be subject to tax at generally applicable U.S.&nbsp;federal income tax rates. In addition, U.S.&nbsp;federal
withholding at a rate of fifteen percent (15%) of the amount realized upon such sale or other exchange may apply, unless Oncolytics Nevada
Common Shares are considered regularly traded on an established securities market. Whether Oncolytics Nevada is a &ldquo;United&nbsp;States
real property holding corporation&rdquo; is fact specific and depends on the composition of its assets. Oncolytics Nevada does not expect
that it would be a &ldquo;United&nbsp;States real property holding corporation&rdquo; immediately after Redomiciliation Transaction is
completed and/or for the foreseeable future. Due to the factual nature of the determination, no assurance can be provided as to whether
Oncolytics Nevada would be or would not be treated as a &ldquo;United&nbsp;States real property holding corporation&rdquo; in any future
year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NON-U.S.&nbsp;HOLDERS ARE URGED TO CONSULT
THEIR TAX ADVISORS AS TO THE TAX CONSEQUENCES TO THEM OF THE POSSIBILITY OF ONCOLTYICS NEVADA&rsquo;S STATUS AS UNITED STATES REAL PROPERTY
HOLDING CORPORATION.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Considerations for Non-U.S. Holders Exercising
Dissent Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the discussion below under &ldquo;&mdash;<I>Information
Reporting Requirements and Backup Withholding</I>,&rdquo; a Non-U.S. Holder generally will not be subject to U.S. federal income tax (including
withholding of U.S. federal income tax) in respect of its receipt of a cash payment, unless:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify">the receipt of such cash payment is effectively connected with the conduct by the Non-U.S. Holder of a
trade or business within the United States (and, under certain income tax treaties, is attributable to a United States permanent establishment
or fixed base maintained by the Non-U.S. Holder); or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD STYLE="text-align: justify">such Non-U.S. Holder is an individual who was present in the United States for 183 days or more in the
taxable year of such disposition and certain other requirements are met.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless an applicable treaty provides otherwise,
gain described in the first bullet point above will be subject to tax at generally applicable U.S. federal income tax rates as if the
Non-U.S. Holder were a U.S. resident. Any gains described in the first bullet point above of a corporate Non-U.S. Holder may also be subject
to an additional &ldquo;branch profits tax&rdquo; at a thirty percent (30%) rate (or a lower applicable income tax treaty rate).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Non-U.S.&nbsp;Holders should consult their own
tax advisors regarding the application of the foregoing rules&nbsp;in light of their particular facts and circumstances and any applicable
procedures or certification requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Information Reporting Requirements and Backup
Withholding</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Information returns will be filed with the IRS
in connection with payments of dividends on and the proceeds from a sale or other disposition of Oncolytics Nevada Common Shares. A Non-U.S.&nbsp;Holder
may have to comply with certification procedures to avoid such information reporting and backup withholding requirements. The certification
procedures required to claim a reduced rate of withholding under a treaty generally will satisfy the certification requirements necessary
to avoid backup withholding as well. Backup withholding is not an additional tax. The amount of any backup withholding from a payment
to a Non-U.S.&nbsp;Holder may be allowed as a credit against such Non-U.S.&nbsp;Holder&rsquo;s U.S.&nbsp;federal income tax liability
and may entitle such Non-U.S.&nbsp;Holder to a refund, provided that the required information is timely furnished to the IRS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Foreign Account Tax Compliance Act</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sections 1471 through 1474 of the Code and the
Treasury Regulations and administrative guidance promulgated thereunder (commonly referred to as &ldquo;<B>FATCA</B>&rdquo;) impose withholding
of thirty percent (30%) on payments of dividends (including constructive dividends) on Oncolytics Nevada Common Shares to &ldquo;foreign
financial institutions&rdquo; (which is broadly defined for this purpose and in general includes investment vehicles) and certain other
non-U.S.&nbsp;entities unless various U.S.&nbsp;information reporting and due diligence requirements (generally relating to ownership
by U.S.&nbsp;persons of interests in or accounts with those entities) have been satisfied by, or an exemption applies to, the payee (typically
certified as to by the delivery of a properly completed IRS Form&nbsp;W-8BEN or W-8BEN-E). Foreign financial institutions located in jurisdictions
that have an intergovernmental agreement with the United&nbsp;States governing FATCA may be subject to different rules. Under certain
circumstances, a Non-U.S.&nbsp;Holder might be eligible for refunds or credits of such withholding taxes, and a Non-U.S.&nbsp;Holder might
be required to file a U.S.&nbsp;federal income tax return to claim such refunds or credits. Withholding under FATCA was scheduled to apply
to payments of gross proceeds from the sale or other disposition of property that produces U.S.-source interest or dividends beginning
on January&nbsp;1, 2019, but on December&nbsp;13, 2018, the IRS released proposed regulations that, if finalized in their proposed form,
would eliminate the obligation to withhold on gross proceeds. Such proposed regulations also delayed withholding on certain other payments
received from other foreign financial institutions that are allocable, as provided for under final Treasury Regulations, to payments of
U.S.-source dividends, and other fixed or determinable annual or periodic income. Although these proposed Treasury Regulations are not
final, taxpayers generally may rely on them until final Treasury Regulations are issued. Non-U.S.&nbsp;Holders should consult their tax
advisors regarding the effects of FATCA on their ownership and disposition of Oncolytics Nevada Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Canadian Federal Income Tax Consequences</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following summary describes the principal
Canadian federal income tax considerations related to the proposed Domestication that are generally applicable to Shareholders who, at
all relevant times, for purposes of the Income Tax Act (Canada) (the &ldquo;<B>Tax Act</B>&rdquo;): (a)&nbsp;deal at arm&rsquo;s length
with Oncolytics; (b)&nbsp;are not affiliated with Oncolytics; and (c)&nbsp;hold their Oncolytics Common Shares as capital property (each
such Shareholder referred to sometimes in this summary as a &ldquo;<B>Holder</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Generally, a Holder&rsquo;s Oncolytics Common
Shares will be considered to be capital property to the Holder unless the Holder holds such shares in the course of carrying on a business
of trading or dealing in securities or acquired the shares in a transaction considered to be an adventure or concern in the nature of
trade.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This summary is based on the current provisions
of the Tax Act, the regulations (the &ldquo;<B>Regulations</B>&rdquo;) thereunder, and the current published administrative policies and
assessing practices of the Canada Revenue Agency (the &ldquo;<B>CRA</B>&rdquo;) publicly available prior to the date hereof. This summary
also takes into account all specific proposals to amend the Tax Act and the regulations announced by or on behalf of the Minister of Finance
(Canada) prior to the date hereof (the &ldquo;<B>Proposed Amendments</B>&rdquo;), and assumes that all Proposed Amendments will be enacted
in the form proposed, although no assurances can be given in this regard. Except for the Proposed Amendments, this summary does not take
into account or anticipate any changes in law, whether by legislative, governmental, regulatory, or judicial action or decision, or changes
in the administrative practices of the CRA, nor does it take into account other federal or any provincial, territorial or foreign income
tax considerations, which may differ from the Canadian federal income tax considerations discussed below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This summary is based on Oncolytics ceasing to
be resident in Canada for purposes of the Tax Act at the time of the Domestication, and assumes that, from the time of the Domestication
and at all relevant times thereafter, Oncolytics will not be resident in Canada for purposes of the Act, will be resident in the United
States for purposes of the Canada-U.S. Tax Convention (the &ldquo;<B>Treaty</B>&rdquo;) and will be entitled to all of the benefits of
the Treaty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This summary is not applicable to a Holder (i)&nbsp;that
is a &ldquo;financial institution&rdquo; for purposes of certain rules&nbsp;in the Tax Act (referred to as the mark-to-market rules),
(ii)&nbsp;that is a &ldquo;specified financial institution,&rdquo; (iii)&nbsp;an interest in which is or would constitute a &ldquo;tax
shelter investment,&rdquo; (iv)&nbsp;that reports its Canadian tax results in a currency other than the Canadian currency, (v)&nbsp;that
is a corporation that, or is a corporation that does not deal at arm&rsquo;s length for purposes of the Tax Act with a corporation resident
in Canada that, is or becomes, as part of a transaction or event or series of transaction or events that includes the acquisition of Oncolytics
Common Shares (after the Domestication), controlled by a non-resident person or group of non-resident persons that do not deal with each
other at arm&rsquo;s length for purposes of the foreign affiliate dumping rules&nbsp;in section 212.3 of the Tax Act, (vi)&nbsp;that is
a partnership for Canadian federal income tax purposes or is exempt from tax under Part&nbsp;I of the Tax Act, (vii)&nbsp;that acquired
Oncolytics Common Shares under or in connection with an incentive plan or any other equity based compensation arrangement, (viii)&nbsp;that
has entered or will enter into a &ldquo;derivative forward agreement,&rdquo; a &ldquo;synthetic disposition arrangement,&rdquo; a &ldquo;securities
lending arrangement&rdquo; or a &ldquo;dividend rental arrangement,&rdquo; all as defined in the Tax Act, with respect to the Oncolytics
Common Shares, or (ix)&nbsp;in respect of which Oncolytics would at any time be a &ldquo;foreign affiliate&rdquo; for the purpose of the
Tax Act after the Domestication. Such Holders should consult their own tax advisors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This summary does not discuss the Canadian federal
income tax consequences of the Domestication to holders of warrants, options, stock appreciation rights, performance share units,
restricted share units, deferred share units, restricted stock or other share-based awards granted by Oncolytics. Any such holders should
consult with and rely on their own tax advisors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This summary is of a general nature only and is
not exhaustive of all possible Canadian federal income tax considerations. This summary is not, and should not be construed as, legal,
business or tax advice to any particular Holder and no representations with respect to the tax consequences to any particular Holder are
made. Accordingly, all Holders, and all other Shareholders of Oncolytics, should consult their own tax advisors regarding the Canadian
federal income tax consequences of the Domestication applicable to their particular circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Domestication of Oncolytics</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the Domestication, Oncolytics will
cease to be a resident of Canada and a &ldquo;public corporation&rdquo; for purposes of the Tax Act. On ceasing to be a resident of Canada,
Oncolytics will no longer be subject to Canadian income tax on its worldwide income. Subsequent to the Domestication, Oncolytics will
not be subject to Canadian income tax except on any income from business operations that are attributable to a permanent establishment
in Canada, withholding tax on distributions from any Canadian resident subsidiaries, as well as on gains from the disposition of &ldquo;<B>taxable
Canadian property</B>&rdquo; that is not &ldquo;<B>treaty-protected property</B>&rdquo; (each as defined in the Tax Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For Canadian federal income tax purposes, the
Domestication will cause Oncolytics&rsquo; taxation year to be deemed to have ended immediately prior to the Domestication. Immediately
prior to this deemed taxation year end, Oncolytics will be deemed to have disposed of each of its properties for proceeds of disposition
equal to the fair market value of such properties at that time and will be deemed to have reacquired such properties at a cost amount
equal to that fair market value. Oncolytics will be subject to income tax under Part&nbsp;I of the Tax Act on any income and net taxable
capital gains which arise as a result of this deemed disposition (after the utilization of any available capital losses or non-capital
losses).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Oncolytics will also be subject to an additional
 &ldquo;emigration tax&rdquo; under Part&nbsp;XIV of the Tax Act on the amount, if any, by which the fair market value (immediately before
Oncolytics&rsquo; deemed taxation year end resulting from the Domestication), of all of its properties, exceeds the total of the amount
of certain of its liabilities and the paid-up capital (determined for purposes of the emigration tax) of all the issued and outstanding
shares of Oncolytics immediately before the deemed taxation year end. This additional tax is generally payable at the rate of 25% but
is expected to be reduced to 5% by virtue of the Treaty unless it can reasonably be concluded that one of the main reasons for Oncolytics
becoming resident in the United States was to reduce the amount of emigration tax or Canadian withholding tax payable under Part&nbsp;XIII
of the Tax Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Canadian tax consequences to Oncolytics associated
with the Domestication are principally dependent upon the fair market value of Oncolytics&rsquo; assets, the amount of its liabilities,
the Canada-U.S. dollar exchange rate, as well as certain Canadian tax attributes, and accounts and balances of Oncolytics, each as of
the time of the Domestication. Additionally, it is possible that valuations and implied valuations of Oncolytics&rsquo; property are made
available which may be relevant in assessing the potential Canadian tax costs of the Domestication. Further, the fair market value of
Oncolytics&rsquo; properties may change between the date hereof and the time of the Domestication. Oncolytics has not applied to the Canadian federal tax authorities for an advance tax ruling relating to the Domestication and does not
intend to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Currency Conversion</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Generally, for purposes of the Tax Act, all amounts
relating to the acquisition, holding or disposition of Oncolytics Common Shares following the Domestication must be converted into Canadian
dollars based on exchange rates as determined in accordance with the Tax Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Holders Resident in Canada</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following portion of this summary applies
to a Holder who, for purposes of the Tax Act and at all relevant times, is resident, or is deemed to be resident, in Canada (each, a &ldquo;<B>Resident
Holder</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A Resident Holder should not be considered to
have disposed of their Oncolytics Common Shares as a result of the Domestication. A Resident Holder should therefore not be considered
to have a realized a taxable capital gain or loss by reason only of the Domestication. The Domestication should also not have an effect
on the adjusted cost base of a Resident Holder&rsquo;s Oncolytics Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following the Domestication, dividends on
Oncolytics Nevada Common Shares will be required to be included in the Resident Holder&rsquo;s income for the purposes of the Tax
Act. Such dividends received by a Resident Holder who is an individual will not be subject to the gross-up and dividend tax credit
rules&nbsp;in the Tax Act. A Resident Holder that is a corporation is required to include such dividends in computing its income and
generally will not be entitled to deduct the amount of such dividends in computing its taxable income. Any U.S. non-resident
withholding tax imposed on such dividends should generally be eligible, subject to the detailed rules&nbsp;and limitations under the
Tax Act, to be credited against the Resident Holder&rsquo;s income tax or deducted from income. Resident Holders are advised to
consult with and rely on their own advisors with respect to the availability of a Canadian foreign tax credit or deduction having
regard to their particular circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The tax treatment under the Tax Act of a disposition
or deemed disposition of Oncolytics Common Shares by a Resident Holder will not be affected by the Domestication and such a disposition
arising after the Domestication will generally result in a capital gain (or capital loss) to the extent that the proceeds of disposition,
net of any reasonable costs of disposition, exceed (or are less than) the adjusted cost base to the Holder of the Oncolytics Common Shares
immediately before the disposition. One-half of any capital gain (a &ldquo;<B>taxable capital gain</B>&rdquo;) realized by a Resident
Holder on an Oncolytics Common Share will be included in the Resident Holder&rsquo;s income for the year of disposition. One-half of any
capital loss (an &ldquo;<B>allowable capital loss</B>&rdquo;) realized is required to be deducted by the Resident Holder against taxable
capital gains realized in the year of disposition. Any excess of allowable capital losses over taxable capital gains of the Resident Holder
for the year of disposition may be carried back up to three taxation years or forward indefinitely and deducted against net taxable capital
gains in those other years to the extent and in the circumstances prescribed in the Tax Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A Resident Holder that is, throughout the relevant
taxation year, a &ldquo;<I>Canadian-controlled private corporation&rdquo; </I>or at any time in the taxation year, a <I>&ldquo;substantive
CCPC</I>&rdquo; (each as defined in the Tax Act) may be liable to pay an additional refundable tax on its &ldquo;aggregate investment
income&rdquo; for the year, which is defined in the Tax Act to include taxable capital gains realized, and interest and dividends received
or deemed to be received (but not dividends or deemed dividends that are deductible in computing taxable income).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Capital gains realized, or taxable dividends received
or deemed to be received, on the Oncolytics Common Shares by a Resident Holder who is an individual (other than certain trusts) may result
in such Resident Holder being liable, or having an increased liability, for alternative minimum tax under the Tax Act. Resident Holders
who are individuals should consult their own tax advisors in this regard.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A Resident Holder that is a &ldquo;specified
Canadian entity&rdquo; (as defined in the Tax Act) for a taxation year or a fiscal period and whose total &ldquo;cost amount&rdquo;
(as defined in the Tax Act) of &ldquo;specified foreign property&rdquo; (as defined in the Tax Act), including Oncolytics Nevada
Common Shares (following the Domestication), at any time in the year or fiscal period exceeds CAD$100,000 will be required to file
an information return for the taxation year or fiscal period disclosing certain prescribed information in respect of such property.
Penalties may apply where a Resident Holder fails to file the required information return in respect of such Resident Holder&rsquo;s
 &ldquo;specified foreign property&rdquo; on a timely basis in accordance with the Tax Act. Such Resident Holders should consult with
and rely on their own tax advisors regarding such filing obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A Dissenting Shareholder that is a Resident Holder
who holds Oncolytics Common Shares (a &ldquo;<B>Dissenting Resident Holder</B>&rdquo;) and is entitled to be paid fair value for its Dissenting
Common Shares will be deemed to transfer such Dissenting Common Shares to Oncolytics in consideration for a cash payment equal to fair
value from Oncolytics. Although the matter is not free from doubt, the Dissenting Resident Holder will generally be deemed to have received
a dividend on the Oncolytics Common Shares equal to the amount, if any, by which the payment by Oncolytics in the amount of the fair value
of the Oncolytics Common Shares exceeds the paid-up capital of such shares for purposes of the Tax Act immediately before the time of
the Domestication. In the case of a Dissenting Resident Holder that is an individual, the amount of any such deemed dividend will be subject
to the normal dividend gross-up and tax credit rules&nbsp;generally applicable to dividends received from a corporation resident in Canada.
Taxable dividends received by a Resident Holder that is an individual or a trust may increase such Resident Holder&rsquo;s liability for
alternative minimum tax. In the case of a Dissenting Resident Holder that is a corporation, the amount of any such deemed dividend will
generally be included in the Resident Holder&rsquo;s income for the taxation year in which such dividend is deemed to be received and
will generally be deductible in computing the Dissenting Resident Holder&rsquo;s taxable income. The amount of this deemed dividend could,
in some circumstances, be treated as proceeds of disposition in the case of Dissenting Resident Holders that are corporations. The difference
between the amount of such payment and the amount of any deemed dividend would be treated as proceeds of disposition of the Oncolytics
Common Shares for the purposes of computing any capital gain or capital loss realized on the disposition of the Oncolytics Common Shares.
The amount of any capital loss realized by a Dissenting Resident Holder that is a corporation on the disposition of an Oncolytics Common
Share may be reduced by the amount of any dividends received (or deemed to be received) by the Dissenting Resident Holder on such Oncolytics
Common Share to the extent and under the circumstances prescribed by the Tax Act. Similar rules&nbsp;may apply where an Oncolytics Common
Share is owned by a partnership or trust of which a corporation, trust or partnership is a member or beneficiary. Dissenting Resident
Holders to whom these rules&nbsp;may be relevant should consult with and rely on their own tax advisors. Any interest awarded to a Dissenting
Resident Holder by a court will be included in the Dissenting Resident Holder&rsquo;s income for Canadian income tax purposes. Resident
Holders who are considering exercising Dissent Rights in connection with the Domestication are urged to consult with their tax advisors
with respect to the tax consequences to them of dissenting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Holders Not Resident in Canada</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following portion of this summary applies
to a Holder who, at all relevant times, for purposes of the Tax Act and any applicable income tax treaty or convention, is not resident,
and is not deemed to be resident, in Canada and does not use or hold, and is not deemed to use or hold, Oncolytics Common Shares in connection
with carrying on a business in Canada (a &ldquo;<B>Non-Resident Holder</B>&rdquo;). This part of the summary is not applicable to Non-Resident
Holders that are insurers carrying on an insurance business in Canada and elsewhere.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A Non-Resident Holder should not be considered
to have disposed of their Oncolytics Common Shares as a result of the Domestication. A Non-Resident Holder should therefore not be considered
to have realized a taxable capital gain or loss by reason only of the Domestication. The Domestication should also not have an effect
on the adjusted cost base of a Non-Resident Holder&rsquo;s Oncolytics Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following the Domestication, dividends paid on
Oncolytics Common Shares to a Non-Resident Holder will generally not be subject to Canadian withholding tax or other income tax under
the Tax Act, provided that Oncolytics is not at the time of the dividend a corporation resident in Canada for the purposes of the Tax
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A disposition or deemed disposition of Oncolytics
Common Shares by a Non-Resident Holder will generally not result in tax under the Tax Act unless such Oncolytics Common Shares are &ldquo;taxable
Canadian Property&rdquo; and are not &ldquo;treaty-protected property&rdquo; of the Non-Resident Holder (each as defined in the Tax Act)
at the time of disposition. An Oncolytics common share generally will not be taxable Canadian property of a Non-Resident Holder at a particular
time unless, at any time during the 60-month period immediately preceding the time of disposition, (a)&nbsp;more than 50% of the fair
market value of Oncolytics was derived directly or indirectly from one or any combination of real or immovable property situated in Canada,
 &ldquo;Canadian resource property&rdquo; (as defined in the Tax Act), &ldquo;timber resource property&rdquo; (as defined in the Tax Act),
and options in respect of, or interests in, or for civil law rights in, any such property (whether or not such property exists), and (b)&nbsp;if
the Oncolytics Common Share is listed on a designated stock exchange (which currently includes the NASDAQ) at the time of disposition,
25% or more of the issued shares of any class or series of Oncolytics&rsquo; shares were owned by or belonged to one or any combination
of (i)&nbsp;the Non-Resident Holder, (ii)&nbsp;persons with whom the Non-Resident Holder did not deal at arm&rsquo;s length, and (iii)&nbsp;partnerships
in which the Non-Resident Holder or a person described in (ii)&nbsp;holds a membership interest directly or indirectly through one or
more partnerships. Notwithstanding the foregoing, in certain circumstances set out in the Tax Act, Oncolytics Common Shares could be deemed
to be taxable Canadian property to a Non-Resident Holder. Oncolytics Common Shares owned by a Non-Resident Holder will generally be treaty-protected
property if the gain from the disposition of such Oncolytics Common Shares would, because of an applicable income tax treaty or convention
to which Canada is a signatory, be exempt from tax under Part&nbsp;I of the Tax Act. If Oncolytics Common Shares are considered to be
taxable Canadian property but not treaty-protected property to a particular Non-Resident Holder, upon the disposition of such Oncolytics
Common Shares, such Non-Resident Holder will realize a capital gain (or capital loss) generally in the circumstances and computed in the
manner described above as if the Non-Resident Holder were a Resident Holder thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A Dissenting Shareholder that is a Non-Resident
Holder (a &ldquo;<B>Dissenting Non-Resident Holder</B>&rdquo;) and is entitled to be paid fair value for its Dissenting Common Shares
will be deemed to transfer such Dissenting Common Shares to Oncolytics in consideration for a cash payment from Oncolytics equal to the
fair value of such Dissenting Common Shares. Although the matter is not free from doubt, a Dissenting Non-Resident Holder will generally
be deemed to have received a dividend on the Oncolytics Common Shares equal to the amount, if any, by which the payment by Oncolytics
in the amount of the fair value of the Oncolytics Common Shares exceeds the paid-up capital of such shares for purposes of the Tax Act.
Any such deemed dividend will be subject to Canadian withholding tax at a rate of 25% of the gross amount of the dividend but may be reduced
under an applicable tax convention. A Dissenting Non-Resident Holder will also be considered to have disposed of the Oncolytics Common
Shares for proceeds of disposition equal to the amount paid to such Dissenting Non-Resident Holder, less any amount that is deemed to
be a dividend received by the Dissenting Non-Resident Holder, as described above. A Dissenting Shareholder that is a Non-Resident Holder
will not be subject to tax under the Tax Act on any capital gain realized on the disposition of Oncolytics Common Shares unless the Oncolytics
Common Shares are &ldquo;taxable Canadian property&rdquo; for purposes of the Tax Act and are not &ldquo;treaty-protected property&rdquo;
of the Dissenting Non-Resident Holder (each as defined in the Tax Act) at the time of disposition, as described in the immediately preceding
paragraph. Dissenting Non-Resident Holders whose Oncolytics Common Shares may constitute taxable Canadian property that are not &ldquo;treaty
protected property&rdquo; are urged to consult their own tax advisors for advice having regard to their particular circumstances. If the
Oncolytics Common Shares are considered to be taxable Canadian property but not treaty-protected property to a particular Dissenting Non-Resident
Holder, upon the disposition of such Oncolytics Common Shares pursuant to the Domestication, such Dissenting Non-Resident Holder will
realize a capital gain (or capital loss) generally in the circumstances and computed in the manner described above as if the Dissenting
Non-Resident Holder were a Resident Holder thereunder. Any interest paid or credited to a Dissenting Non-Resident Holder in respect of
the exercise of Dissent Rights will generally not be subject to Canadian withholding tax. Non-Resident Holders who are considering exercising
Dissent Rights in connection with the Domestication are urged to consult with their tax advisors with respect to the tax consequences
to them of dissenting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Eligibility for Investment</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on the law on the date hereof, provided
the Oncolytics Common Shares are listed on a designated stock exchange (which currently includes the NASDAQ), the Oncolytics Common Shares
would, on the date of the completion of the Domestication, be qualified investments on such date under the Tax Act for trusts governed
by a registered retirement savings plan (&ldquo;<B>RRSP</B>&rdquo;), registered retirement income fund (&ldquo;<B>RRIF</B>&rdquo;), registered
education savings plan (&ldquo;<B>RESP</B>&rdquo;), deferred profit sharing plan, registered disability savings plan (&ldquo;<B>RDSP</B>&rdquo;),
first home savings account (&ldquo;<B>FHSA</B>&rdquo;) or tax-free savings account (&ldquo;<B>TFSA</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding the foregoing, if the Oncolytics
Common Shares are a &ldquo;prohibited investment&rdquo; for a TFSA, RRSP, RRIF, RESP, FHSA or RDSP, the holder of the TFSA, FHSA or RDSP,
the annuitant of the RRSP or RRIF, or the subscriber of the RESP, as the case may be, will be subject to a penalty tax as set out in the
Tax Act. Provided that, for purposes of the Tax Act, the holder, annuitant, or subscriber, as the case may be, deals at arm&rsquo;s length
with Oncolytics and does not have a &ldquo;<B>significant interest</B>&rdquo; (as defined in the Tax Act for purposes of the prohibited
investment rules) in Oncolytics, the Oncolytics Common Shares will not be a &ldquo;<B>prohibited investment</B>&rdquo; for such RRSPs,
RRIFs, RESPs, RDSPs, FHSAs and TFSAs, as the case may be, under the Tax Act. In addition, the Oncolytics Common Shares will generally
not be a prohibited investment if such shares are &ldquo;excluded property&rdquo; (as defined in the Tax Act for purposes of the prohibited
investment rules) for the RRSP, RRIF, RESP, RDSP, FHSA and TFSA. Holders of Oncolytics Common Shares who intend to hold their shares in
trusts governed by RRSPs, RRIFs, RESPs, RDSPs, FHSAs or TFSAs should consult with their own tax advisors with respect to whether the Oncolytics
Common Shares would be a &ldquo;prohibited investment&rdquo; in their particular circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="pros02_019"></A>Comparison of Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to and conditional upon the prior implementation
of the Continuance, our corporate affairs will be governed by our Notice of Articles, Articles and the provisions of the BCBCA. The BCBCA
differs from the various state laws applicable to U.S. corporations and their stockholders, including Nevada law. A general summary of
the material differences between our proposed Notice of Articles, Articles and the BCBCA under which we will be governed following the
Continuance, and our proposed Oncolytics Nevada Charter and Oncolytics Nevada Bylaws and the NRS, under which we will be governed following
the Domestication, is described under the heading &ldquo;<I>Material Differences between British Columbia Corporate Law and Nevada Corporate
Law</I>&rdquo; attached hereto as Annex <B>K</B>. References to &ldquo;Oncolytics Nevada&rdquo; refer solely to Oncolytics Biotech Inc.,
a Nevada corporation, as of the effective time of the Domestication. This summary is qualified in its entirety by reference to the NRS,
the BCBCA and the then-applicable governing documents of Oncolytics. For a more detailed description of how the new organizational documents
and Nevada law may differ from our current organizational documents and Alberta corporate law, see &ldquo;<I>Material Differences between
Alberta Corporate Law and Nevada Corporate Law</I>.&rdquo; This description is not intended to be complete and is qualified in its entirety
by reference to the NRS, the ABCA and our governing documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="pros02_020"></A>Information Concerning Oncolytics Nevada</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>General and Corporate Structure</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Immediately following the Domestication, Oncolytics
Nevada will continue its legal existence in Nevada and from the date of filing the Oncolytics Nevada Charter Nevada law will apply to
Oncolytics Nevada to the same extent as if it was organized as a Nevada corporation on that date. Its registered office will be located at 701 South Carson Street, Suite 200, Carson City, NV 89701, and its principal business office
will be located at 4350 Executive Drive, Suite 325, San Diego, CA 92121.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Intercorporate Relationships</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following the effective time of the Domestication,
Oncolytics Nevada will have the general structure shown below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Business</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following completion of the Domestication, Oncolytics
Nevada and its subsidiaries will carry on the business currently carried on by Oncolytics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Description of Oncolytics Nevada Capital Stock</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following summary description of the Oncolytics
Nevada capital stock is based on the intended provisions of each of the Oncolytics Nevada Charter and Oncolytics Nevada Bylaws and the
applicable provisions of the NRS. This information may not be complete in all respects and is qualified entirely by reference to the provisions
of the Oncolytics Nevada Charter, Oncolytics Nevada Bylaws and the NRS. For information on how to obtain copies of the Oncolytics Nevada
Charter, Oncolytics Nevada Bylaws, see &ldquo;<I>Where You Can Find More Information</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>General</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Oncolytics Nevada&rsquo;s authorized capital stock
will consist of 1,000,000,000 shares of common stock, par value US$0.001 per share and 100,000,000 shares of preferred stock, par value US$0.001 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Common Stock</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Voting Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each holder of Common Shares will be
entitled to one vote for each share on all matters submitted to a vote of the Stockholders, including the election of directors.
Stockholders will not have cumulative voting rights in the election of directors. Accordingly, in an uncontested election, holders
of a majority of the voting shares will be able to elect all of the directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Dividends</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following completion of the Domestication, Oncolytics
Nevada and its subsidiaries are not expected to pay any dividends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Liquidation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of Oncolytics Nevada&rsquo;s liquidation,
dissolution or winding up, holders of Common Shares will be entitled to share ratably in the net assets legally available for distribution
to Stockholders after the payment of all of Oncolytics Nevada&rsquo;s debts and other liabilities and the satisfaction of any liquidation
preference granted to the holders of any then outstanding shares of preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Rights and Preferences</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Holders of Common Shares will have no pre-emptive,
conversion, subscription or other rights, and there are no redemption or sinking fund provisions applicable to Common Shares. The rights,
preferences and privileges of the holders of Common Shares will be subject to and may be adversely affected by the rights of the holders
of shares of any series of Oncolytics Nevada preferred stock that we may designate in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Fully Paid and Non-assessable</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All outstanding Common Shares are, and the Common
Shares to be issued in connection with the Domestication will be, validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Preferred Stock</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Oncolytics Nevada Charter will authorize the
board of directors of Oncolytics Nevada (the &ldquo;<B>Oncolytics Nevada Board</B>&rdquo;) to issue preferred stock in one or more series
and to determine the preferences, limitations and relative rights of any shares of preferred stock that it shall choose to issue, without
vote or action by the Stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Annual Stockholder Meetings</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Oncolytics Nevada
Bylaws will provide that annual stockholder meetings will be held at a date, place (if any) and time, as exclusively selected by the Oncolytics
Nevada Board. The Oncolytics Nevada Board may, in its sole discretion, determine that any meeting of the Stockholders (including annual
stockholder meetings) shall be held exclusively, or simultaneously with the conduct of the meeting at a physical location, by means of
remote communication (including by webcast), or other available technology permitted under the NRS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Anti-Takeover Effects of Provisions of the
Oncolytics Nevada Charter, the Oncolytics Nevada Bylaws, and Nevada Law.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Some provisions of the NRS, the Oncolytics Nevada
Charter and Oncolytics Nevada Bylaws could make the following transactions difficult: acquisition of Oncolytics Nevada by means of a tender
offer; acquisition of Oncolytics Nevada by means of a proxy contest or otherwise; and removal of incumbent officers and directors of Oncolytics
Nevada. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that Stockholders
may otherwise consider to be in their best interest or in the best interests of Oncolytics Nevada, including transactions that might result
in a premium over the market price for Common Shares. These provisions will replace and substitute applicable provisions of the BCBCA
and we cannot predict whether they will make an acquisition more or less likely compared to those provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These provisions, summarized below, are expected
to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking
to acquire control of Oncolytics Nevada to first negotiate with the Oncolytics Nevada Board. We believe that the benefits of protection
to Oncolytics Nevada&rsquo;s potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or
restructure Oncolytics Nevada outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could
result in an improvement of their terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Nevada Anti-Takeover Statutes</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Combinations with Interested Stockholders</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Oncolytics Nevada will be subject to Nevada&rsquo;s
Combination with Interested Stockholders Statutes (NRS 78.411 to 78.444, inclusive), which prohibit persons deemed &ldquo;interested stockholders&rdquo;
from engaging in a &ldquo;combination&rdquo; with a publicly-held Nevada corporation for two years following the date these persons become
interested stockholders (extended to up to four years if certain conditions are not met), unless the business combination is, or the transaction
by which the person first became an interested stockholder was, approved in advance by the corporation&rsquo;s board of directors. Generally,
an &ldquo;interested stockholder&rdquo; is a person who, together with affiliates and associates, beneficially owns, or within two years
prior to the determination of interested stockholder status, did beneficially own, 10% or more of voting power of the outstanding voting
shares of a corporation and a &ldquo;combination&rdquo; includes a merger and certain asset or stock sales or other transactions resulting
in a financial benefit to the interested stockholder. After the person becomes an interested stockholder, the combination must be approved
by the board of directors and 60% of the corporation&rsquo;s voting power not beneficially owned by the interested stockholder, its affiliates
and associates, at a meeting of the stockholders. Finally, after the two-year period, up to four years from the date the person first
became an interested stockholder, a combination remains prohibited unless: (i)&nbsp;the combination or the transaction by which the person
became an interested stockholder is approved by the board of directors before the person became an interested stockholder&#894; (ii)&nbsp;the
combination is approved by a majority of the outstanding voting power not beneficially owned by the interested stockholder and its affiliates
and associates&#894; or (iii)&nbsp;the consideration to be received by the disinterested stockholders satisfies certain requirements.
But note that these statutes do not apply to any combination of a corporation and an interested stockholder after the expiration of four
years after the person first became an interest stockholder. The combinations statutes in Nevada apply only to Nevada corporations with
200 or more stockholders of record. The existence of this provision may have an anti-takeover effect with respect to transactions not
approved in advance by the Oncolytics Nevada Board, such as discouraging takeover attempts that might result in a premium over the market
price of the Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Companies are entitled to opt out of the business
combination provisions. Any opt-out of the business combination provisions of the NRS must be contained in the original articles of incorporation,
or an amendment to the articles of incorporation approved by a majority of the outstanding voting power not then beneficially owned by
interested stockholders or their affiliates and associates, but the amendment would not be effective until 18 months after the vote of
the stockholders to approve the amendment, and would not apply to any combination with a person who first became an interested stockholder
on or before the effective date of the amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Oncolytics Nevada Charter expressly provides
that Oncolytics Nevada has elected not to be governed by the business combination provisions of the NRS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Acquisition of Controlling Interests</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the restrictions on business combinations
with interested stockholders, Nevada law also protects a corporation and its stockholders from persons acquiring a &ldquo;controlling
interest&rdquo; in a corporation. The provisions can be found in NRS 78.378 to 78.3793, inclusive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to NRS Section&nbsp;78.379, any person
who acquires a controlling interest in a corporation may not exercise voting rights with respect to any control shares unless such voting
rights are conferred by a majority vote of the disinterested stockholders of the issuing corporation at a special meeting of such stockholders
held upon the request and at the expense of the acquiring person. NRS 78.3785 provides that a &ldquo;controlling interest&rdquo; means
the ownership of outstanding voting shares of an issuing corporation sufficient to enable the acquiring person, individually or in association
with others, directly or indirectly, to exercise (i)&nbsp;one-fifth or more but less than one-third, (ii)&nbsp;one-third or more but less
than a majority or (iii)&nbsp;a majority or more of the voting power of the issuing corporation in the election of directors, and once
an acquirer crosses one of these thresholds, shares that it acquired in the transaction taking it over the threshold and within the 90
days immediately preceding the date when the acquiring person acquired or offered to acquire a controlling interest become &ldquo;control
shares&rdquo; to which the voting restrictions described above apply. In the event that the control shares are accorded full voting rights
and the acquiring person acquires control shares with a majority or more of all the voting power, any stockholder, other than the acquiring
person, who does not vote in favor of authorizing voting rights for the control shares is entitled to demand payment for the fair value
of such person&rsquo;s shares, and the corporation must comply with the demand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NRS 78.378(1)&nbsp;provides that these statutes
do not apply to any acquisition of a controlling interest in an issuing corporation if the articles of incorporation or bylaws of the
corporation in effect on the 10th day following the acquisition of a controlling interest by the acquiring person provide that the provisions
of those sections do not apply to the corporation or to an acquisition of a controlling interest specifically by types of existing or
future stockholders, whether or not identified. In addition, NRS 78.3788 provides that the controlling interest statutes apply as of a
particular date only to a corporation that has 200 or more stockholders of record, at least 100 of whom have addresses in Nevada appearing
on the corporation&rsquo;s stock ledger at all times during the 90 days immediately preceding that date, and which does business directly
or indirectly in Nevada. NRS 78.378(2)&nbsp;provides that the corporation may impose stricter requirements if it so desires.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Corporations are entitled to opt out of the above
controlling interest provisions of the NRS. In the Oncolytics Nevada Bylaws, Oncolytics Nevada opts out of these provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Undesignated Preferred Stock</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The ability to authorize undesignated preferred
stock will make it possible for the Oncolytics Nevada Board to issue preferred stock with voting or other rights or preferences that
could impede the success of any attempt to change control of Oncolytics Nevada. These and other provisions may have the effect of deterring
hostile takeovers or delaying changes in control or management of Oncolytics Nevada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Special Stockholder Meetings</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Oncolytics Nevada Charter will provide that,
subject to the rights of the holders of any series of preferred stock, a special meeting of Stockholders may be called only by the Oncolytics
Nevada Board, the Chairperson of the Board or the Chief Executive Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Requirements for Advance Notification of Stockholder
Nominations and Proposals</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Oncolytics Nevada Bylaws will establish advance
notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations
made by or at the direction of the Oncolytics Nevada Board or a committee of the Oncolytics Nevada Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>No Stockholder Action by Written Consent</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Oncolytics
Nevada Bylaws will prohibit Stockholders from acting by written consent without a meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Composition of the Board of Directors; Election
and Removal of Directors; Filling Vacancies</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Oncolytics Nevada Board will consist of
not less than three nor more than 20 directors. In any uncontested elections of directors, a director nominee for the Oncolytics
Nevada Board will be elected by the affirmative vote of a plurality of the votes cast with respect to such director by the shares
represented and entitled to vote at a meeting of the Stockholders for the election of directors at which a quorum is present, voting
together as a single class. An incumbent director who is nominated for an uncontested election and fails to receive a majority of
the votes present and voting for such director&rsquo;s re-election would be required to tender his or her resignation to the
Oncolytics Nevada Board. The Governance Committee of the Oncolytics Nevada Board (or any future committee the equivalent thereof)
will make a recommendation to the Oncolytics Nevada Board on whether to accept or reject the resignation, or whether other action
should be taken. The Oncolytics Nevada Board will act on the recommendation of such committee and will publicly disclose its
decision within 90 days from the date of the certification of the election results. In a contested election, a plurality voting
standard will apply to director elections. The directors of Oncolytics Nevada will be elected at each annual meeting of
Stockholders, and will serve in such capacity until the expiration of the term for which they are elected and until their respective
successors are duly elected or appointed and qualified, and until their earlier death, resignation, retirement, disqualification or removal. As a result, the directors of Oncolytics Nevada will generally serve a term
of approximately one year, contrasted with the current 12-year terms for the Company&rsquo;s directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The directors of Oncolytics Nevada may be removed
only by the affirmative vote of the holders of two-thirds (66 2/3%) of the voting power of the then-outstanding
capital stock of the Company entitled to vote generally in the election of directors, voting together as a single class, which reflects
the requirements of the NRS. Furthermore, any vacancy on the Oncolytics Nevada Board, however occurring, including a vacancy resulting
from an increase in the size of the board, may be filled only by a majority vote of the directors then in office, even if less than a
quorum, or by the sole remaining director. This system of electing and removing directors and filling vacancies may tend to discourage
a third party from making a tender offer or otherwise attempting to obtain control of Oncolytics Nevada, because it generally makes it
more difficult for Stockholders to replace a majority of the directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Choice of Forum</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Oncolytics Nevada Bylaws will provide that
the Eighth Judicial District Court of the State of Nevada, in Clark County, Nevada shall be the sole and exclusive forum for (1)&nbsp;any
derivative action or proceeding brought on behalf of the Company, (2)&nbsp;any action or proceeding asserting a claim of breach of a fiduciary
duty owed by any current or former director, officer, stockholder, employee or agent of the Company to the Company or the Stockholders, (3)&nbsp;any action or proceeding asserting a claim arising pursuant to the NRS, the Oncolytics Nevada Charter or Oncolytics
Nevada Bylaws, (4)&nbsp;any proceeding to interpret, apply, enforce or determine the validity of the Nevada Charter or Nevada Bylaws,
(5)&nbsp;any internal action (as defined in NRS Section&nbsp;78.046) and any action or proceeding as to which NRS Title 7 confers jurisdiction
to the District Courts of the State of Nevada, or (6)&nbsp;any action asserting a claim governed by the internal affairs doctrine. The
Oncolytics Nevada Bylaws further provide that the federal district courts of the United States of America are the sole and exclusive forum
for the resolution of any claim asserting a cause of action under the Securities Act. Although the Oncolytics Nevada Bylaws will contain
the choice of forum provision described above, it is possible that a court could find that such a provision is inapplicable for a particular
claim or action or that such provision is unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Amendment of the Oncolytics Nevada Charter
and Oncolytics Nevada Bylaws</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the approval of the
Oncolytics Nevada Board, except as otherwise provided by Nevada law, the amendment of any of the provisions in the Oncolytics Nevada
Charter will require the approval of the holders of at least a majority of the voting power of the outstanding voting stock,
voting as a single class, provided, that an amendment to increase or decrease the number of authorized shares of any class or series of stock may be approved
by the default voting standard set forth in the Oncolytics Nevada Bylaws, which is more votes cast in favor than against. The Oncolytics Nevada Bylaws may be amended by the Oncolytics Nevada Board or by the holders of at least
two-thirds of the voting power of the then outstanding voting stock voting as a single class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The provisions of the NRS, the Oncolytics Nevada
Charter and Oncolytics Nevada Bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence,
they may also inhibit temporary fluctuations in the market price of Common Shares that often result from actual or rumored hostile takeover
attempts. These provisions may also have the effect of preventing changes in the management of Oncolytics Nevada. It is possible that
these provisions could make it more difficult to accomplish transactions that Stockholders may otherwise deem to be in their best interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Limitations of Liability and Indemnification
Matters</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Oncolytics Nevada Charter will contain provisions
that limit the liability of the directors and officers of Oncolytics Nevada for monetary damages to the fullest extent permitted by Nevada
law. Consequently, Oncolytics Nevada directors and officers will not be individually liable to Oncolytics Nevada, its Stockholders or
its creditors for damages as a result of any act or failure to act, unless the presumption of the business judgment rule&nbsp;is rebutted
and it is proven that the director or officer breached his or her fiduciary duty and such breach involved intentional misconduct, fraud
or knowing violation of law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Oncolytics Nevada Bylaws will provide that
we are required to indemnify the directors and officers of Oncolytics Nevada, in each case to the fullest extent permitted by the NRS.
The Oncolytics Nevada Bylaws will also obligate us to advance expenses incurred by a director or officer in advance of the final disposition
of any action or proceeding, and permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability
arising out of his or her actions in that capacity regardless of whether we would otherwise be permitted to indemnify him or her under
the NRS. We have entered into agreements with the Oncolytics directors, officers and other employees and expect to enter into agreements
to indemnify the Oncolytics Nevada directors, executive officers and other employees as determined by the Oncolytics Nevada Board. With
specified exceptions, these agreements provide for indemnification for related expenses including, among other things, attorneys&rsquo;
fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding to the fullest extent permitted
by applicable law. We believe that these bylaw provisions and indemnification agreements are necessary to attract and retain qualified
persons as directors and officers. Oncolytics Nevada will also maintain directors&rsquo; and officers&rsquo; liability insurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The limitation of liability and indemnification
provisions in the Oncolytics Nevada Charter and Oncolytics Nevada Bylaws may discourage Stockholders from bringing a lawsuit against Oncolytics
Nevada directors and officers for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against
Oncolytics Nevada directors and officers, even though an action, if successful, might benefit Oncolytics Nevada and its Stockholders.
Furthermore, a Stockholder&rsquo;s investment may be adversely affected to the extent that we pay the costs of settlement and damage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Uncertificated Shares</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Oncolytics Nevada will only issue
uncertificated shares of its common and preferred stock, provided that the Oncolytics Nevada Board may provide by resolution that
some or all of the shares of any class or series of stock of Oncolytics Nevada shall be represented by certificates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>No Sinking Fund</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Common Shares have no sinking fund provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="pros3_001"></A><B>Corporate Governance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Oncolytics Nevada Board will be committed
to the highest standards of corporate governance. To this end, the Oncolytics Nevada Board will adopt Corporate Governance Guidelines
(&ldquo;<B>Governance Guidelines</B>&rdquo;) that provide specific provisions for the governance of the Oncolytics Nevada Board and Oncolytics
Nevada. The Oncolytics Nevada Board will also adopt a Code of Business Conduct and Ethics (&ldquo;<B>Code of Conduct</B>&rdquo;) applicable
to all directors, officers and employees that represents Oncolytics Nevada&rsquo;s commitment to the highest standards of ethics and
integrity in the conduct of its business. The Oncolytics Nevada Bylaws, together with the Governance Guidelines, the Oncolytics Nevada
Board committee charters and the Code of Conduct will serve as the governance and compliance framework of Oncolytics Nevada upon the
effective time of the Domestication, the Oncolytics Nevada Board intends to comply with the NRS, the rules&nbsp;of the Nasdaq and SEC
and applicable Canadian securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Nasdaq rules&nbsp;require that listed company
boards have at least a majority of independent directors. The six independent directors will be Deborah Brown, Angela Holtham, Bernd
R. Seizinger, James T. Parsons, Jonathan Rigby and Patricia Andrews. As a result, six of Oncolytics Nevada&rsquo;s eight future directors
will be independent directors under the Nasdaq rules. Mr.&nbsp;Kelly, who will be Oncolytics Nevada&rsquo;s CEO, and Mr.&nbsp;Pisano,
the former Interim CEO, are the only members of the Oncolytics Nevada Board who will not be independent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Committees of the Oncolytics Nevada Board</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Oncolytics Nevada Board will be responsible
for providing oversight of Oncolytics Nevada&rsquo;s business and affairs, including the Company&rsquo;s strategic direction, as well
as the management and financial and operational execution that can best perpetuate the success of the business and support the long-term
interest of Oncolytics Nevada Stockholders. To effectively support its responsibilities, the Oncolytics Nevada Board will have four committees:
an Audit Committee, a Compensation Committee, a Governance Committee and a Science&nbsp;&amp; Development Committee. These Oncolytics
Nevada Board committees will carry out responsibilities in specific committee charters approved by the Oncolytics Nevada Board and consistent
with applicable requirements of the Nasdaq and the SEC. Each of the Oncolytics Nevada Board committees shall be empowered to retain independent
advisors as necessary to fulfill their duties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Audit Committee</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Audit Committee will be established to assist
the Board in carrying out their oversight responsibility for the Company&rsquo;s internal controls, financial reporting and financial
risk management processes. The Audit Committee will be responsible for overseeing Oncolytics Nevada&rsquo;s internal accounting function,
the work of the independent auditor, the integrity of Oncolytics Nevada&rsquo;s financial statements and compliance with legal and regulatory
requirements. The Audit Committee will be established in accordance with Section&nbsp;3(a)(58)(A)&nbsp;of the Exchange Act and each director
on the Audit Committee will be independent within the meaning of Nasdaq listing standards and applicable rules&nbsp;and regulations of
the SEC. Ms.&nbsp;Holtham will be the Chair of the Audit Committee and Mr.&nbsp;Parsons and Ms.&nbsp;Brown will be members of the Audit
Committee following the Domestication. Ms.&nbsp;Holtham, Ms.&nbsp;Brown and Mr.&nbsp;Parsons will also each be designated as an &ldquo;audit
committee financial expert&rdquo; as defined under the applicable SEC rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Audit Committee will oversee Oncolytics Nevada&rsquo;s
corporate accounting and financial reporting process. Among other matters, the Audit Committee will evaluate the independent registered
public accounting firm&rsquo;s qualifications, independence and performance; determine the engagement of the independent registered public
accounting firm; review and approve the scope of the annual audit and the audit fee; discuss with management and the independent registered
public accounting firm the results of the annual audit and the review of Oncolytics Nevada&rsquo;s quarterly consolidated financial statements;
approve the retention of the independent registered public accounting firm to perform any proposed permissible non-audit services; monitor
the rotation of partners of the independent registered public accounting firm on Oncolytics Nevada&rsquo;s engagement team as required
by law; review Oncolytics Nevada&rsquo;s critical accounting policies and estimates; oversee the internal audit function and annually
review the Audit Committee charter and the committee&rsquo;s performance. The Audit Committee will operate under a written charter pursuant
to applicable standards and rules&nbsp;of the SEC and Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Compensation Committee</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Compensation Committee will be established
to assist the Board in carrying out its responsibility for the Company&rsquo;s human resources and compensation policies and processes.
The Compensation Committee will be responsible for overseeing the management of risks related to Oncolytics Nevada&rsquo;s executive
compensation plans and arrangements. Each director serving on the Compensation Committee will be independent within the meaning of the
Nasdaq listing standards and applicable rules&nbsp;and regulations of the SEC. The Compensation Committee will operate under a written
charter pursuant to applicable standards and rules&nbsp;of the SEC and the Nasdaq. Ms.&nbsp;Brown will be the Chair of the Compensation
Committee and Dr.&nbsp;Seizinger, and Ms.&nbsp;Holtham will be members of the Compensation Committee following the Domestication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Compensation Committee will review and recommend
policies relating to compensation and benefits of Oncolytics Nevada executive officers and employees. The Compensation Committee will
review and approve corporate goals and objectives relevant to compensation of the chief executive officer and other executive officers,
evaluate the performance of these executives in light of those goals and objectives and set the compensation of these executives based
on such evaluations. The Compensation Committee will also administer Oncolytics Nevada&rsquo;s incentive and stock plans, including approving
grants and other awards and making other decisions regarding the operation of such plans. The Compensation Committee will review and
evaluate, at least annually, the performance of the Compensation Committee and its members, including compliance of the Compensation
Committee with its charter. In fulfilling its responsibilities, the Compensation Committee will be permitted to delegate any or all of
its responsibilities to a subcommittee of the Compensation Committee, but only to the extent consistent with the Oncolytics Nevada Charter
and Oncolytics Nevada Bylaws, Nasdaq rules&nbsp;and other applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Governance Committee</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Governance Committee will be tasked with
ensuring that the Board structures, procedures and operations align with the Company&rsquo;s governance ambitions, corporate values and
external compliance demands. The Governance Committee governs the Board, providing rigorous oversight to make sure that the Board is
fit for purpose now and in the future and is suitably resourced to carry out its duties and performs those duties effectively. The Governance
Committee will be responsible for overseeing management of Oncolytics Nevada&rsquo;s risks associated with the independence of the Oncolytics
Nevada Board and potential conflicts of interest. Each director serving on the Governance Committee will be independent within the meaning
of the Nasdaq listing standards. Mr.&nbsp;Rigby will be the Chair of the Governance Committee and Ms.&nbsp;Andrews and Mr.&nbsp;Parsons
will be members of the Governance Committee following the Domestication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Governance Committee will be responsible
for making recommendations regarding candidates for directorships and the size and compensation of the Oncolytics Nevada Board. In addition,
the Governance Committee will be responsible for overseeing the Governance Guidelines and reporting and making recommendations concerning
governance matters. The Governance Committee will operate under a written charter that satisfies the applicable standards of the SEC
and the Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Science&nbsp;&amp; Development Committee</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Science&nbsp;&amp; Development Committee
will be responsible for assisting the Oncolytics Nevada Board with the interpretation of scientific data and assisting the Company&rsquo;s
management with the communication of scientific data to stakeholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr.&nbsp;Seizinger will be the Chair of the Science&nbsp;&amp;
Development Committee and Ms.&nbsp;Andrews will be a member of the Science&nbsp;&amp; Development Committee following the Domestication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="pros3_002"></A><B>Director and Executive Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The director and executive compensation programs
currently offered by Oncolytics are described in Oncolytics&rsquo; management information circular filed on SEDAR+ and EDGAR on July&nbsp;7,
2025, available under its profile on SEDAR+ at www.sedarplus.ca, its profile at EDGAR at www.sec.gov or its website at <I>www.oncolyticsbiotech.com</I>.
<B>The director and executive compensation program for Oncolytics Nevada will be the same as that of Oncolytics.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For more details on director and executive compensation, please refer to Annex L.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="pros3_003"></A><B>Beneficial Ownership of Securities of Oncolytics Nevada</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the knowledge of the directors and executive
officers of the Company, no person or company will beneficially own, or control or direct, directly or indirectly, voting securities
of the company carrying 10% or more of the votes attached to any class of voting securities of the Company immediately following the
Domestication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="pros3_004"></A>Auditor, Registrar and Transfer Agent</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The auditor of Oncolytics Nevada will be
Ernst&nbsp;&amp; Young LLP. The transfer agent and registrar for Common Shares will be TSX Trust Company. The transfer agent and
registrar&rsquo;s address is&#8239;301 - 100 Adelaide Street West Toronto, Ontario, M5H 4H1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="pros3_005"></A><B>Vote Required and Recommendation of the Board</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the Meeting, Shareholders will be asked to
consider and, if thought advisable, approve, with or without variation, the Domestication Resolution, subject to such amendments, variations
or additions as may be approved at the Meeting, as a special resolution to approve the Domestication. Please refer to Annex <B>C</B>
for the text of the Domestication Resolution to be voted on at the Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To be adopted, the Domestication Resolution must
be approved by the affirmative vote of at least two-thirds of the votes cast by the Shareholders present or represented by proxy at the
Meeting. If your Common Shares are registered in your name and you abstain from voting on this matter, your abstention will not have
any effect on the outcome of the vote. Abstentions will each be counted for the quorum requirement. If you hold your Common Shares through
a bank, broker or other agent and you do not instruct the bank, broker or other agent on how to vote on this proposal, your bank, broker
or other agent will not have authority to vote your Common Shares. Broker non-votes will not have an impact on the outcome of this proposal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE BOARD BELIEVES THAT THE APPROVAL OF THE
DOMESTICATION RESOLUTION IS IN THE BEST INTERESTS OF ONCOLYTICS AND RECOMMENDS THAT SHAREHOLDERS VOTE IN FAVOUR OF THE APPROVAL OF THE
DOMESTICATION RESOLUTION.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The voting rights pertaining to Common Shares
represented by duly executed proxies in favour of the persons named in the accompanying form of proxy will be exercised, in the absence
of specifications to the contrary, FOR the Domestication Resolution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Please take notice that even if the Domestication
Resolution is approved, it provides that the Board may revoke such Domestication Resolution before the issuance of the Articles of Domestication
without the approval of the Shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Please take further notice that even if the Domestication
Resolution is approved, the Domestication Resolution shall be revoked and the Domestication shall not be effected in the event that the
requisite majority of Shareholders does not approve the Continuance Resolution or the Board revokes or abandons the Continuance Resolution
or the Continuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="pros3_006"></A><FONT STYLE="text-transform: uppercase"><B>PROPOSAL
NO. 3 &mdash; APPROVAL OF THE ONCOLYTICS BIOTECH INC. 2026 Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="pros3_007"></A><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are requesting Shareholders approve the 2026
Plan. The Board has approved the 2026 Plan, subject to shareholder approval and effective upon the effectiveness of the Domestication.
The 2026 Plan is intended to align our equity compensation plan with rules&nbsp;and market practices applicable to U.S. public companies
in our industry. References to &ldquo;shares&rdquo; issuable pursuant to 2026 Plan in this section refer to the shares of common stock
of Oncolytics Nevada after the effectiveness of the Domestication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the 2026 Plan is approved, the number of shares
reserved for issuance under the 2026 Plan will equal the sum of (i)&nbsp;6,500,000 shares; (ii)&nbsp;any shares that remain available
for issuance under the Prior Plans as of the effective date of the 2026 Plan; (iii)&nbsp;any shares that are subject to awards under the
Prior Plans which are forfeited or lapse unexercised and which are not issued under the Prior Plans; and (iv)&nbsp;an annual increase
on the first day of each calendar year beginning January&nbsp;1, 2027 and ending on and including January&nbsp;1, 2036, equal to the lesser
of (A)&nbsp;6% of the aggregate number of shares outstanding on the final day of the immediately preceding calendar year and (B)&nbsp;such
smaller number of shares as is determined by the Board or the compensation committee. Upon the effective date of the 2026 Plan, we will
cease granting awards under the Prior Plans, but any awards granted under the Prior Plans will remain subject to the terms of the applicable
Prior Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<!-- Field: Split-Segment; Name: 01 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Proposal No.&nbsp;3 is not approved by
the Shareholders, or if the Board determines, in its sole discretion, not to proceed with the Domestication, the 2026 Plan will not become
effective, and the Prior Plans will remain in effect. However, we may need to consider alternative compensation structures to achieve
the objectives for which the Prior Plans were designed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="pros3_008"></A>2026 Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Background</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The purpose of the 2026 Plan is to enhance our
ability to attract, retain and motivate persons who make (or are expected to make) important contributions to our Company by providing
these individuals with equity-based compensatory opportunities. Equity awards are intended to motivate high levels of performance and
align the interests of our directors, employees and consultants with those of the Shareholders by giving directors, employees and consultants
the perspective of an owner with an equity stake in the Company and providing a means of recognizing their contributions to our success.
Our ability to grant equity awards is critical to our ability to be competitive and to attract, retain and motivate the talent we need
to best position our Company for success. The use of equity awards as compensation also allows us to conserve cash resources for other
important purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to approving the 2026 Plan, the Board and
compensation committee considered the Company&rsquo;s equity grant objectives and determined that approval of the 2026 Plan would be
the most effective tool in achieving our employee retention and incentive goals, and aligning employee interests with those of the Shareholders,
because it provides a direct and straightforward means of incentivizing employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Current Shares Under the Prior Plans</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The total number of Common Shares reserved for
issuance under the Prior Plans shall not exceed 14% of the total number of issued and outstanding Common Shares from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Set forth below is the number of our Common Shares
available for issuance pursuant to outstanding and future equity awards under the 2023 Plan and the Option Plan as of November 28,
2025. The closing price of our Common Shares on the Nasdaq Global Select Market on that date was $1.3935 (determined using the exchange
rate of $1 U.S. dollar to $1.3974 Canadian dollar as of November 28, 2025).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1pt solid; padding-bottom: 3pt; width: 50%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    subject to outstanding options<SUP>(1)</SUP></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-bottom: 3pt; width: 50%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,398,245</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-bottom: 3pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    subject to outstanding RSUs<SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; padding-bottom: 3pt; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">497,842</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-bottom: 3pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    available for future grants of awards </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; padding-bottom: 3pt; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">3,024,098</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1)&nbsp;As of November 28, 2025, options
outstanding under the Option Plan had a weighted average per share exercise price of $1.86 and a weighted average remaining term of
3.21 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2)&nbsp;As of November 28, 2025, the weighted
average remaining vesting term for RSUs was 1.00 year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Determination of Adoption of 2026 Plan</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In consideration of our belief that the ability
to continue granting equity compensation is vital to our attracting and retaining employees and facilitating long-term stockholder value
creation, including by retaining and incentivizing our executives and other employees, we believe that the adoption of the 2026 Plan
is reasonable, appropriate and in the best interests of the Company and its Shareholders at this time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accordingly, the Board recommends that Shareholders
vote for approval of this Proposal No.&nbsp;3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="pros3_009"></A><B>Summary of the 2026 Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This section summarizes certain principal features
of the 2026 Plan, subject to shareholder approval and effective upon the Domestication. The summary is qualified in its entirety by reference
to the complete text of the 2026 Plan, which is attached to this Circular/Prospectus as Annex <B>F</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Eligibility and Administration</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our employees, consultants and directors,
and employees, consultants and directors of our subsidiaries will be eligible to receive awards under the 2026 Plan. As of November
28, 2025, we had 28 employees, including five executive officers, and seven non-employee directors who would be eligible under the
2026 Plan. The 2026 Plan will be administered by the Board with respect to awards to non-employee directors and by our compensation
committee with respect to other participants, each of which may delegate its duties and responsibilities to committees of our
directors and/or officers (referred to collectively as the plan administrator below), subject to certain limitations that may be
imposed under Section&nbsp;16 of the Exchange Act, and/or stock exchange rules, as applicable. The plan administrator will have the
authority to make all determinations and interpretations under, prescribe all forms for use with, and adopt rules&nbsp;for the
administration of, the 2026 Plan, subject to its express terms and conditions. The plan administrator will also set the terms and
conditions of all awards under the 2026 Plan, including any vesting and vesting acceleration conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Limitation on Awards and Shares Available
for Awards</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the 2026 Plan is approved and the Continuance
and Domestication are completed, the number of shares reserved for issuance under the 2026 Plan will equal the sum of (i)&nbsp;6,500,000
shares; (ii)&nbsp;any shares that remain available for issuance under the Prior Plans as of the effective date of the 2026 Plan; (iii)&nbsp;any
shares that are subject to awards under the Prior Plans which are forfeited or lapse unexercised and which are not issued under the Prior
Plans; and (iv)&nbsp;an annual increase on the first day of each calendar year beginning January&nbsp;1, 2027 and ending on and including
January&nbsp;1, 2036, equal to the lesser of (A)&nbsp;6% of the aggregate number of shares outstanding on the final day of the immediately
preceding calendar year and (B)&nbsp;such smaller number of shares as is determined by the Board or the compensation committee. No more
than 83,423,715 shares may be issued under the 2026 Plan, if approved, upon the exercise of incentive stock options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of November 28, 2025, there were 11,896,087
shares subject to awards outstanding under the Prior Plans and 3,024,098 shares remaining available for issuance under the Prior
Plans. Shares issued under the 2026 Plan may be authorized but unissued shares, including shares authorized but unissued under the
Prior Plans, shares purchased on the open market, or treasury shares. Upon the effective date of the 2026 Plan, we will cease
granting awards under the Prior Plans, but any awards granted under the Prior Plans will remain subject to the terms of the
applicable Prior Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an award under the Prior Plans or the 2026
Plan expires, lapses or is terminated, exchanged for or settled for cash, surrendered, repurchased, cancelled without having been fully
exercised or forfeited, any shares subject to such award may, to the extent of such forfeiture, expiration or cash settlement, be used
again for new grants under the 2026 Plan. Further, shares delivered to us to satisfy the applicable exercise or purchase price of an
award under the Prior Plans or the 2026 Plan and/or to satisfy any applicable tax withholding obligations (including shares retained
by us from the award under the Prior Plans or the 2026 Plan being exercised or purchased and/or creating the tax obligation) will become
or again be available for grants of awards under the 2026 Plan. The payment of dividend equivalents in cash in conjunction with any awards
under the Prior Plans or the 2026 Plan will not reduce the shares available for grant under the 2026 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Awards granted under the 2026 Plan upon the assumption
of, or in substitution for, awards authorized or outstanding under a qualifying equity plan maintained by an entity with which we enter
into a merger or similar corporate transaction will not reduce the shares available for grant under the 2026 Plan. The 2026 Plan provides
that the sum of any cash compensation and the aggregate grant date fair value (determined as of the date of the grant under ASC Topic
718, or any successor thereto) of all awards granted to a non-employee director as compensation for services as a non-employee director
during any fiscal year may not exceed the amount equal to 750,000 U.S. dollars, increased to $1,000,000 U.S. dollars in the fiscal year
in which the effective date of the 2026 Plan occurs or in the fiscal year of a non-employee director&rsquo;s initial year of service
as a non-employee director (in each case, excluding any compensation awarded prior to the effective date of the 2026 Plan).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Awards</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2026 Plan provides for the grant of options,
including incentive stock options, or ISOs, and nonqualified stock options, or NSOs, restricted stock, dividend equivalents, restricted
stock units, or RSUs, performance shares, other incentive awards, stock appreciation rights, or SARs, and cash awards. No determination
has been made as to the types or amounts of awards that will be granted to specific individuals pursuant to the 2026 Plan. Certain awards
under the 2026 Plan may constitute or provide for a deferral of compensation, subject to Section&nbsp;409A of the Code, which may impose
additional requirements on the terms and conditions of such awards. All awards under the 2026 Plan will be set forth in award agreements,
which will detail all terms and conditions of the awards, including any applicable vesting and payment terms and post-termination exercise
limitations. Awards other than cash awards generally will be settled in shares of our common stock, but the plan administrator may provide
for cash settlement of any award. A brief description of each award type follows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I><U>Options</U></I>.
                                            Options provide for the purchase of shares of our common stock in the future at an exercise
                                            price set on the grant date. ISOs, by contrast to NSOs, may provide tax deferral beyond exercise
                                            and favorable capital gains tax treatment to their holders if certain holding period and
                                            other requirements of the Code are satisfied. The exercise price of an option may not be
                                            less than 100% of the fair market value of the underlying share on the date of grant (or
                                            110% in the case of ISOs granted to certain significant Shareholders), except with respect
                                            to certain substitute options granted in connection with a corporate transaction. The term
                                            of an option may not be longer than ten years (or five years in the case of ISOs granted
                                            to certain significant Shareholders). Vesting conditions determined by the plan administrator
                                            may apply to options and may include continued service, performance and/or other conditions.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I><U>SARs</U></I>.
                                            SARs entitle their holder, upon exercise, to receive from us an amount equal to the appreciation
                                            of the shares subject to the award between the grant date and the exercise date. The exercise
                                            price of a SAR may not be less than 100% of the fair market value of the underlying share
                                            on the date of grant (except with respect to certain substitute SARs granted in connection
                                            with a corporate transaction) and the term of a SAR may not be longer than ten years. Vesting
                                            conditions determined by the plan administrator may apply to SARs and may include continued
                                            service, performance and/or other conditions.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I><U>Restricted
                                            Stock and RSUs</U></I>. Restricted stock is an award of nontransferable shares of our common
                                            stock that remain forfeitable unless and until specified conditions are met, and which may
                                            be subject to a purchase price. RSUs are contractual promises to deliver shares of our common
                                            stock in the future, which may also remain forfeitable unless and until specified conditions
                                            are met, and may be accompanied by the right to receive the equivalent value of dividends
                                            paid on shares of our common stock prior to the delivery of the underlying shares. Delivery
                                            of the shares underlying RSUs may be deferred under the terms of the award or at the election
                                            of the participant, if the plan administrator permits such a deferral. Conditions applicable
                                            to restricted stock and RSUs may be based on continuing service, the attainment of performance
                                            goals and/or such other conditions as the plan administrator may determine.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I><U>Other
                                            Stock or Cash Based Awards</U></I>. Other stock or cash based awards may be awards of cash,
                                            fully vested shares and other awards valued wholly or partially by referring to, or otherwise
                                            based on, shares. Other stock or cash based awards may be granted to participants and may
                                            also be available as a payment form in the settlement of other awards, as standalone payments
                                            and as payment in lieu of base salary, bonus, fees or other cash compensation otherwise payable
                                            to any individual who is eligible to receive awards.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I><U>Dividend
                                            Equivalents</U></I>. Dividend equivalents represent the right to receive the equivalent value
                                            of dividends paid on shares and may be granted alone or in tandem with awards other than
                                            options or SARs. Dividend equivalents are credited as of dividend record dates during the
                                            period between the date an award is granted and the date such award vests, is exercised,
                                            is distributed or expires, as determined by the plan administrator.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I><U>Performance
                                            Awards</U></I>. Performance awards include any of the foregoing awards that are granted subject
                                            to vesting and/or payment based on the attainment of specified performance goals or other
                                            criteria the plan administrator may determine, which may or may not be objectively determinable.
                                            Performance criteria upon which performance goals are established by the plan administrator
                                            may include but are not limited to: (1)&nbsp;net earnings (either before or after one or
                                            more of the following: (a)&nbsp;interest, (b)&nbsp;taxes, (c)&nbsp;depreciation, (d)&nbsp;amortization
                                            and (e)&nbsp;non-cash equity-based compensation expense); (2)&nbsp;gross or net sales or
                                            revenue; (3)&nbsp;net income (either before or after taxes); (4)&nbsp;adjusted net income;
                                            (5)&nbsp;operating earnings or profit; (6)&nbsp;cash flow (including, but not limited to,
                                            operating cash flow and free cash flow); (7)&nbsp;return on assets; (8)&nbsp;return on capital;
                                            (9)&nbsp;return on shareholders&rsquo; equity; (10)&nbsp;total stockholder return; (11) return
                                            on sales; (12) gross or net profit or operating margin; (13) costs; (14) funds from operations;
                                            (15) expenses; (16) working capital; (17) earnings per share; (18) adjusted earnings per
                                            share; (19) price per share of common stock; (20) regulatory achievements or compliance;
                                            (21) implementation or completion of critical projects; (22) market share; (23) economic
                                            value; (24) debt levels or reduction; (25) sales-related goals; (26) comparisons with other
                                            stock market indices; (27) operating efficiency; (28) employee satisfaction; (29) financing
                                            and other capital raising transactions; (30) recruiting and maintaining personnel; and (31)
                                            year-end cash, any of which may be measured either in absolute terms for us or any operating
                                            unit of our company or as compared to any incremental increase or decrease or as compared
                                            to results of a peer group or to market performance indicators or indices.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Certain Transactions</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The plan administrator has broad discretion to
take action under the 2026 Plan, as well as make adjustments to the terms and conditions of existing and future awards, to prevent the
dilution or enlargement of intended benefits and facilitate necessary or desirable changes in the event of certain transactions and events
affecting our common stock, such as stock dividends, stock splits, mergers, acquisitions, consolidations and other corporate transactions.
In addition, in the event of certain non-reciprocal transactions with the Shareholders known as &ldquo;equity restructurings,&rdquo;
the plan administrator will make equitable adjustments to the 2026 Plan and outstanding awards. If a change in control occurs and the
awards are not continued, converted, assumed, or replaced with a substantially similar award by (a)&nbsp;the Company, or (b)&nbsp;a successor
entity or its parent or subsidiary, and provided that the service of the participants has not been terminated, then immediately prior
to the change in control, such awards (other than any portion that is subject to performance-based vesting) shall become fully vested,
exercisable and/or payable, as applicable, and all forfeiture, repurchase and other restrictions thereon shall lapse, in which case,
such awards shall be canceled upon the consummation of the change in control in exchange for the right to receive the change in control
consideration payable to other holders of Common Stock (i)&nbsp;which may be on such terms and conditions as apply generally to holders
of Common Stock under the change in control documents (including, without limitation, any earn-out or other deferred consideration provisions)
or such other terms and conditions as the plan administrator may provide, and (ii)&nbsp;determined by reference to the number of shares
subject to such awards and net of any applicable exercise price; provided that (A)&nbsp;to the extent that any such awards constitute
 &ldquo;nonqualified deferred compensation&rdquo; that may not be paid upon the change in control under Section&nbsp;409A without the
imposition of taxes thereon under Section&nbsp;409A, the timing of such payments shall be governed by the applicable award agreement
(subject to any deferred consideration provisions applicable under the change in control documents), (B)&nbsp;the portion of any award
subject to performance-based vesting shall be governed by the terms and conditions of the applicable award agreement and, in the absence
of applicable terms and conditions, the plan administrator&rsquo;s discretion, and (C)&nbsp;if the amount to which a participant would
be entitled upon the settlement or exercise of an award at the time of the change in control is equal to or less than zero, then such
award may be terminated without payment. Individual award agreements may provide for additional accelerated vesting and payment provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Foreign Participants, Claw-Back Provisions,
Transferability and Participant Payments</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The plan administrator may modify award terms,
establish subplans and/or adjust other terms and conditions of awards, subject to the share limits described above, in order to facilitate
grants of awards subject to the laws and/or stock exchange rules&nbsp;of countries outside of the United States. All awards will be subject
to the provisions of any claw-back policy implemented by our company to the extent set forth in such claw-back policy and/or in the applicable
award agreement. With limited exceptions for estate planning, domestic relations orders, certain beneficiary designations and the laws
of descent and distribution, awards under the 2026 Plan are generally non-transferable prior to vesting, and are exercisable only by
the participant. With regard to tax withholding, exercise price and purchase price obligations arising in connection with awards under
the 2026 Plan, the plan administrator may, in its discretion, accept cash or check, shares of our common stock that meet specified conditions,
a &ldquo;market sell order&rdquo; or such other consideration as it deems suitable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>No Repricing of Awards without Stockholder
Approval</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The plan administrator may not reduce the exercise
price of an option or SAR or cancel an option or SAR in exchange for cash, another award under the 2026 Plan or an option or SAR with
an exercise price that is less than the exercise price of the original option or SAR, unless such action is approved by the Stockholders
or taken in connection with certain corporate transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Plan Amendment and Termination</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board may amend or terminate the 2026 Plan
at any time; however, except in connection with certain changes in our capital structure, shareholder approval will be required for any
amendment that increases the number of shares available under the 2026 Plan. No award may be granted pursuant to the 2026 Plan after
the tenth anniversary of the earlier of the date on which the Shareholders approved the 2026 Plan or the date on which the Board adopted
the 2026 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Effective Date and Term of Plan</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2026 Plan was approved by the Board to be
effective upon the effectiveness of the Domestication, subject to approval of the 2026 Plan by the Shareholders. Unless earlier terminated
by the Board, the 2026 Plan will remain effective until the tenth anniversary of the earlier of (i)&nbsp;the date the Board adopted the
2026 Plan or (ii)&nbsp;the date the Shareholders approved the 2026 Plan. If the 2026 Plan is not approved by the Shareholders or the
Board determines, in its sole discretion, not to proceed with the Domestication, the 2026 Plan will not become effective, no awards will
be granted under the 2026 Plan and the Prior Plans will continue in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Federal Income Tax Consequences</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a general summary of the current
federal income tax consequences to us and to U.S. participants for awards granted under the 2026 Plan. The federal tax laws may change
and the tax consequences for any participant will depend upon his or her individual circumstances. Tax consequences for any particular
individual may be different. This summary does not purport to be complete, and does not discuss state, local or non-U.S. tax consequences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Non-Qualified Options</U>. The grant of a
non-qualified option under the 2026 Plan is not expected to result in any federal income tax consequences to the participant or to the
Company. Generally, upon exercise of a non-qualified option, the participant will realize ordinary income, and the Company will be entitled
to a tax deduction, in an amount equal to the difference between the option exercise price and the fair market value of the shares at
the time of exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Incentive Stock Options</U>. The grant or
exercise of an ISO under the 2026 Plan is not expected to result in any federal income tax consequences to the participant or to the
Company. However, the amount by which the fair market value of the shares at the time of exercise exceeds the option price will be an
 &ldquo;item of adjustment&rdquo; for participants for purposes of the alternative minimum tax, unless the shares are sold or otherwise
disposed of in the same year the ISO is exercised. Gain realized by participants on the sale of shares underlying an ISO is taxable at
capital gains rates, and no tax deduction is available to the Company, unless the participant disposes of the shares within (i)&nbsp;two
years after the date of grant of the option or (ii)&nbsp;within one year of the date the shares were transferred to the participant.
If the shares are sold or otherwise disposed of before the end of the one-year and two-year periods specified above, the difference between
the option exercise price and the fair market value of the shares on the date of the option&rsquo;s exercise (or the date of sale, if
less) will be taxed at ordinary income rates, and the Company will be entitled to a deduction to the extent that the participant recognizes
ordinary income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Stock Appreciation Rights</U>. The grant of
a SAR under the 2026 Plan is not expected to result in any federal income tax consequences to either the participant or the Company.
Generally, upon exercise of the SAR, the fair market value of the shares received, determined on the date of exercise of the SAR, or
the amount of cash received in lieu of shares, will be treated as compensation taxable as ordinary income to the participant in the year
of such exercise. The Company will be entitled to a deduction for compensation paid in the same amount which the participant realized
as ordinary income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Restricted Stock</U>. A participant generally
will not have taxable income on the grant of restricted stock under the 2026 Plan, nor will the Company then be entitled to a deduction,
unless the participant makes a valid election under Section&nbsp;83(b)&nbsp;of the Code. However, when restrictions on shares of restricted
stock lapse, such that the shares are no longer subject to a substantial risk of forfeiture, the participant generally will recognize
ordinary income, and the Company will be entitled to a corresponding deduction, for an amount equal to the difference between the fair
market value of the shares on the date such restrictions lapse over the purchase price for the restricted stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Restricted Stock Units</U>. A participant
generally will not realize taxable income at the time of the grant of RSUs under the 2026 Plan, and the Company will not be entitled
to a deduction at that time. When RSUs are settled, whether in cash or shares, the participant will have ordinary income, and the Company
will be entitled to a corresponding deduction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Stock Awards</U>. If a participant receives
a stock award under the 2026 Plan in lieu of a cash payment that would otherwise have been made, the participant generally will be taxed
as if the cash payment has been received, and the Company will have a deduction in the same amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Dividend Equivalents</U>. A participant generally
will not realize taxable income at the time of the grant of dividend equivalents under the 2026 Plan, and the Company will not be entitled
to a deduction at that time. When a dividend equivalent is paid, the participant will recognize ordinary income, and the Company will
be entitled to a corresponding deduction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Application of Section&nbsp;409A of the Code</U>.
Section&nbsp;409A of the Code imposes an additional 20% tax and interest on an individual receiving non-qualified deferred compensation
under a plan that fails to satisfy certain requirements. For purposes of Section&nbsp;409A, &ldquo;non-qualified deferred compensation&rdquo;
includes equity-based incentive programs, including some options, SARs and RSU programs. Generally speaking, Section&nbsp;409A does not
apply to ISOs, non-discounted non-qualified options and SARs if no deferral is provided beyond exercise, or restricted stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The awards made pursuant to the 2026 Plan are
designed in a manner intended to comply with the requirements of Section&nbsp;409A to the extent the awards granted under the 2026 Plan
are not exempt from Section&nbsp;409A. However, if the 2026 Plan fails to comply with Section&nbsp;409A in operation, a participant could
be subject to the additional taxes and interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Limitations on the Company&rsquo;s Compensation
Deduction</U>. Section&nbsp;162(m)&nbsp;of the Code limits the deduction certain employers may take for otherwise deductible compensation
payable to certain current and former executive officers of the Company to the extent the compensation paid to such an officer for the
year exceeds $1 million U.S. dollars. Additionally, under Section&nbsp;280G of the Code, in connection with a change in control, certain
compensatory payments in excess of prescribed limits made to &ldquo;disqualified individuals&rdquo; in connection with the change in
control may not be deductible by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>New Plan Benefits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The future awards, if any, that will be made
to eligible persons under the 2026 Plan are subject to the discretion of the plan administrator, and therefore, the benefits or number
of shares subject to awards that may be granted in the future to our executive officers, employees and directors is not currently determinable. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Equity Compensation Plan Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth information concerning
the Company&rsquo;s equity compensation plans as of December 31, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; vertical-align: middle; font-size: 10pt; text-align: center; white-space: nowrap">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; padding-bottom: 1pt; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; white-space: nowrap">Number of Securities to be<BR> Issued upon Exercise of <BR> Outstanding Options, <BR> Warrants and Rights (#)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; padding-bottom: 1pt; white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; padding-bottom: 1pt; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; white-space: nowrap">Weighted Average Exercise<BR> Price of Outstanding<BR> Options ($)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; padding-bottom: 1pt; white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; padding-bottom: 1pt; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; white-space: nowrap">Number of Securities<BR> Remaining Available<BR> for Future Issuance<BR> Under Equity <BR> Compensation Plans (#)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; padding-bottom: 1pt; white-space: nowrap; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Equity Compensation Plans Approved by Stockholders</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right">7,994,855</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><SUP>(1)</SUP></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right">2.14</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><SUP>(2)</SUP></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right">3,207,963</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><SUP>(3)</SUP></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Equity&#8239;Compensation&#8239;Plans&#8239;Not Approved by Stockholders</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">--</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><SUP></SUP></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">--</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><SUP></SUP></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">--</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Total</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7,994,855</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.14</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,207,963</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">Represents 6,876,345 Common Shares that were subject to outstanding options granted under the Option Plan and 1,118,510 RSUs granted under the 2023 Plan.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">This value is calculated based on the exercise price of options
                                            outstanding under the Option Plan and does not take into account outstanding RSUs, which have no exercise price.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(3)</TD><TD>Represents 3,207,963 Common Shares available for future issuance
                                            under the Prior Plans.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Consequences of Failing to Approve the Proposal</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2026 Plan will not be implemented unless
approved by the Shareholders. If the 2026 Plan is not approved by the Shareholders, the Prior Plans will remain in effect, and the Company
will continue to grant awards under the Prior Plans until the share reserve under the Prior Plans is exhausted or the term of the Prior
Plans expire. Once the remaining share reserve is exhausted, the Company may elect to provide compensation through other means, such
as cash-settled awards or other cash compensation, to assure that the Company and its affiliates can attract and retain qualified personnel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Vote Required and Recommendation of Board</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Approval of the 2026 Plan, which is subject to
and conditional upon the Domestication being approved, requires the affirmative vote of a majority of the votes cast at the meeting by
proxy or in person. If the Shareholders approve the 2026 Plan, it will become effective upon effectiveness of the Domestication. In connection
with any determination to implement the Domestication, the Board will set the timing for such Domestication. Although it is the current
intention of the Board to proceed with the Domestication, it has no obligation to do so and will have no liability associated with any
decision as to whether or not to proceed with the Domestication. If the Board determines, in its sole discretion, not to proceed with
the Domestication, the 2026 Plan will not become effective. The Board has reserved the right to terminate or abandon the 2026 Plan at
any time prior to the effectiveness of the Domestication. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board recommends that the Shareholders vote
FOR the approval of the 2026 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="pros3_010"></A>VOTING
COMMON SHARES AND THE PRINCIPAL HOLDERS OF COMMON SHARES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="pros3_011"></A>Voting of Common Shares &mdash; General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Record Date for the purpose of determining
holders of Common Shares is December 9, 2025.
Shareholders of record on the Record Date are entitled to receive notice of and attend the Meeting and vote at the Meeting on the basis
of one vote for each Common Share held, except to the extent that: (i)&nbsp;a registered Shareholder has transferred the ownership of
any Common Shares subsequent to the Record Date; and (ii)&nbsp;the transferee of those Common Shares produces properly endorsed share
certificates, or otherwise establishes that he or she owns the Common Shares and demands, not later than the day that is ten calendar
days before the Meeting or any adjournment thereof, that his or her name be included on the Shareholder list before the Meeting, in which
case the transferee shall be entitled to vote his or her Common Shares at the Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is authorized to issue an unlimited
number of Common Shares. As at the Record Date, there are 107,606,376 Common Shares issued and outstanding. At the Meeting,
every Shareholder present in person or represented by proxy and entitled to vote shall have one vote. On a poll or ballot, every Shareholder
present in person or by proxy has one vote for each Common Share of which such Shareholder is the registered holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When any Common Share is held jointly by several
persons, any one of them may vote at the Meeting in person or by proxy in respect of such Common Share, but if more than one of them
are present at the Meeting in person or by proxy and such joint owners of the proxy so present disagree as to any vote to be cast, the
joint owner present or represented whose name appears first in the register of Shareholders maintained by TSX Trust is entitled to cast
such vote.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="pros3_012"></A>Principal Holders of Common Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the knowledge of the directors and executive
officers of the Company, as at the date hereof, no persons or companies beneficially own, directly or indirectly, or exercise control
or direction over, Common Shares that carry more than 10% of the voting rights attached to the issued Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="pros3_013"></A><B>Indemnification of Directors and Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our corporate by-laws require that, except to
the extent expressly prohibited by law, we will indemnify our officers and directors against all costs, charges, and expenses, including
an amount paid to settle an action or satisfy a judgment reasonably incurred in respect of any civil, criminal, or administrative action
or proceeding as it relates to their services to the Company. The by-laws provide no limit to the amount of the indemnification. We have
purchased directors&rsquo; and officers&rsquo; insurance coverage to cover claims made against the directors and officers during the
applicable policy periods. The amounts and types of coverage have varied from period to period as dictated by market conditions. We believe
that we have adequate insurance coverage; however, there is no guarantee that all indemnification payments will be covered under our
existing insurance policies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no pending litigation or proceeding
involving any of our officers or directors as to which indemnification is being sought, nor are we aware of any threatened litigation
that may result in claims for indemnification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the provisions of the <I>Business
Corporations Act</I> (Alberta), our by-laws also provide that  we will indemnify a director or officer, a former director or officer,
or an individual who acts or acted at our request as a director or officer or an individual acting in a similar capacity of another entity,
and such person&rsquo;s heirs and legal representatives, against all costs, charges and expenses, including an amount paid to settle
an action or satisfy a judgment, reasonably incurred by such individual in respect of any civil, criminal, administrative investigative
or other proceeding in which the individual is involved because of that association with us or such other entity, provided however that
we shall not so indemnify an individual unless the individual (i)&nbsp;acted honestly and in good faith with a view to the best interests
of the Company or, as the case may be, to the best interests of the other entity for which the individual acted as a director or officer
or in a similar capacity at our request, and (ii)&nbsp;if the matter is a criminal or administrative action or proceeding that is enforced
by a monetary penalty, had reasonable grounds for believing that the individual&rsquo;s conduct was lawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we may advance money to a director,
officer or other individual for the costs, charges and expenses of a proceeding referred to above, but the individual shall repay the
Company if the individual does not fulfil the conditions set out in (i)&nbsp;and (ii)&nbsp;above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we become liable under the terms of our by-laws,
the insurance coverage discussed above, subject to its terms and conditions, will extend to our liability; however, each claim will be
subject to a per claim retention of varying amounts, depending on the nature of the claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The proposed Oncolytics Nevada Charter contains
provisions that limit the liability of our directors and officers for monetary damages to the fullest extent permitted by the NRS. In
addition, if the NRS is amended to provide for further limitations on the personal liability of directors of corporations, then the personal
liability of our directors and officers will be further limited to the greatest extent permitted by the NRS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The proposed Oncolytics Nevada Bylaws provide
that we will indemnify our directors and officers, and may indemnify our employees, agents and any other persons, to the fullest extent
permitted by the NRS, subject to limited exceptions. The proposed Oncolytics Nevada Bylaws also provide that it must advance expenses
incurred by or on behalf of a current or former director or officer in advance of the final disposition of any action or proceeding,
subject to limited exceptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, if the Domestication is implemented,
we intend into enter into indemnification agreements with each of our directors and executive officers that may be broader than the specific
indemnification provisions contained in the NRS. These indemnification agreements require us, among other things, to indemnify our directors
and executive officers against liabilities that may arise by reason of their status or service. These indemnification agreements also
require us to advance all expenses reasonably and actually incurred by the directors and executive officers in investigating or defending
any such action, suit or proceeding. We believe that these agreements are necessary to attract and retain qualified individuals to serve
as directors and executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also expect to maintain insurance policies
under which our directors and officers are insured, within the limits and subject to the limitations of those policies, against certain
expenses in connection with the defense of, and certain liabilities which might be imposed as a result of, actions, suits, or proceedings
to which they are parties by reason of being or having been directors or officers of Oncolytics. The coverage provided by these policies
may apply whether or not we would have the power to indemnify such person against such liability under the provisions of the NRS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="pros3_014"></A><FONT STYLE="text-transform: uppercase"><B>MATERIAL
DIFFERENCES BETWEEN ALBERTA CORPORATE LAW AND BRITISH COLUMBIA CORPORATE LAW</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our corporate affairs are governed by our articles
of incorporation, general by-laws and the provisions of the ABCA. A summary comparison of the significant differences between the rights
of shareholders under the ABCA and the rights of shareholders under the BCBCA is attached hereto as Annex <B>J</B> and does not represent
a complete statement of the rights of the Shareholders or a complete description of the specific provisions referred to below. This summary
is qualified in its entirety by reference to the full text of the ABCA and the BCBCA, the regulations made or laws developed thereunder
and our current constating documents and the constating documents of Oncolytics to be adopted in British Columbia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="pros3_015"></A>MATERIAL
DIFFERENCES BETWEEN BRITISH COLUMBIA CORPORATE LAW AND NEVADA CORPORATE LAW</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to and conditional upon the approval
of the Continuance Resolution and prior implementation of the Continuance, our corporate affairs will be governed by our Notice of Articles,
Articles and the provisions of the BCBCA. A summary comparison of the significant differences between the rights of shareholders under
the BCBCA and the rights of stockholders under the NRS is attached hereto as Annex <B>K</B> and does not represent a complete statement
of the rights of the Stockholders or a complete description of the specific provisions referred to below. This summary is qualified in
its entirety by reference to the full text of the BCBCA and the NRS, the regulations made or laws developed thereunder and the constating
documents of Oncolytics to be adopted in British Columbia and Nevada, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="pros3_016"></A><FONT STYLE="text-transform: uppercase"><B>MATERIAL
DIFFERENCES BETWEEN ALBERTA CORPORATE LAW AND NEVADA CORPORATE LAW</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon completion of the Domestication, subject
to and conditional upon the approval of the Continuance Resolution and prior implementation of the Continuance, our corporate affairs
will be governed by the Oncolytics Nevada Charter and the Oncolytics Nevada Bylaws and the provisions of the NRS. The ABCA differs from
the various state laws applicable to U.S. corporations and their stockholders, including Nevada law. The following is a general summary
of the material differences between the rights of shareholders under the ABCA and the rights of stockholders under the NRS. This summary
does not represent a complete statement of the rights of the Stockholders or a complete description of the specific provisions referred
to below, and is qualified in its entirety by reference to the full text of the NRS, the ABCA and the then-applicable governing documents
of Oncolytics. References to &ldquo;<B>Oncolytics Nevada</B>&rdquo; refer solely to Oncolytics Biotech Inc., a Nevada corporation, as
of the effective time of the Domestication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 25%; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 38%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Alberta</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 35%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Number and Election of Directors</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    ABCA provides that a reporting issuer must have no fewer than three directors, at least two of whom are not officers or employees
    of the issuer or its affiliates.</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the NRS, a corporation must have at
    least one director, and may provide in its articles of incorporation or in its bylaws for a fixed number of directors or a variable
    number of directors, and may otherwise provide for the manner in which the number of directors may be increased or decreased.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The NRS permits corporations to classify
    boards of directors provided that at least one-fourth of the total number of directors is elected annually.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The NRS provides that unless the articles
    of incorporation or the bylaws require more than a plurality of the votes cast, directors of every corporation must be elected at
    the annual meeting of the stockholders by a plurality of the votes cast at the election.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Oncolytics Nevada&rsquo;s board is not classified
    and, therefore, directors will be elected on an annual basis.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The proposed Oncolytics Nevada Bylaws provide
    that directors will be elected by a plurality of votes cast.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Removal
    of Directors</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    ABCA provides that, subject to certain limitations, the shareholders of a corporation may remove directors from office by ordinary
    resolution at a special meeting of shareholders.</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    NRS requires the vote of the holders of at least two-thirds of the voting power of the shares or class or series of shares of the
    issued and outstanding stock entitled to vote at an election of directors in order to remove a director or all of the directors.
    The articles of incorporation may provide for a voting threshold higher than two-thirds of the voting power, but not lower.
    Furthermore, the NRS does not make a distinction between removals for cause and removals without cause. </FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; text-align: justify; width: 25%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 38%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Alberta</B></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Vacancies on the Board of Directors</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the ABCA, a vacancy among the directors
    created by the removal of a director may be filled by the shareholders at the meeting at which the director is removed or, if not
    filled by the shareholders at such meeting, by the remaining directors. In the case of a vacancy caused by the death, resignation
    or disqualification to act as a director under the ABCA, the remaining directors may fill the vacancy.</P>
                           <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the ABCA, if as a result of one or
    more vacancies, the number of directors in office falls below the number required for a quorum, the remaining directors shall call
    a special meeting of shareholders to fill the vacancy, and if the remaining directors fail to call a meeting or if there are no directors
    then in office, the meeting may be called by any shareholder.</P></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the NRS, a vacancy or a newly created
    directorship may be filled by a majority of the directors then in office, although less than a quorum, or by the sole remaining director,
    unless otherwise provided in the  articles of incorporation or bylaws. Any director so appointed will hold office for the remainder
    of the term of the director no longer on the board.</P>
                           <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The proposed Oncolytics Nevada Charter and
    Oncolytics Nevada Bylaws provide that only the Board and not the Stockholders may fill vacancies on the Board of Directors.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Board of Director Quorum and Vote Requirements</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the ABCA, subject to the articles or
    bylaws, a majority of the number of directors appointed constitutes a quorum at any meeting of directors, and, notwithstanding any
    vacancy among the directors, a quorum of directors may exercise all the powers of the directors.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the ABCA, the board of directors may
    take action by the majority vote of the directors present at a meeting at which a quorum is present unless the articles or by-laws
    require a greater vote.</P></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the NRS, unless otherwise provided
    in the articles of incorporation or bylaws, a quorum for the transaction of business at a meeting of stockholders is a majority of
    the voting power entitled to vote at the meeting whether present in person or by proxy. Shares represented at a meeting of stockholders
    by proxy count towards a quorum, even if the proxy does not have the authority to vote on any matter.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Oncolytics Nevada Bylaws state that quorum
    for the transaction of business at a meeting of Stockholders is one-third of the voting power entitled to vote at the meeting whether
    present in person or by proxy.</P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; text-align: justify; width: 25%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 38%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Alberta</B></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Transactions with Directors and Officers</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the ABCA, directors and officers of
    a corporation who are a party to, or have a material interest in, a material contract or transaction with the corporation, are required
    to disclose in writing to the corporation, or request to have entered in the minutes of a meeting of directors, the nature and extent
    of any material interest they may have in a material contract, whether entered into or proposed, involving the corporation.</P>
                           <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Such disclosure must generally be made at
    the meeting at which the matter is first considered or at the first meeting after a director learns of their disclosable interest.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Directors who hold a disclosable interest
    are generally not entitled to vote on any resolutions approving the contract or transaction, subject to limited exceptions.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A contract or transaction in which a director
    or officer has a material interest in is neither void nor voidable solely for this reason, provided that this interest was sufficiently
    disclosed, the contract was approved by the directors or shareholders, and the terms were reasonable and fair to the corporation
    at the time of approval.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Failure to comply with these requirements
    may result in a court setting aside the contract or transaction, or requiring the director or officer to account to the corporation
    for any profits realized.</P></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    NRS Section&nbsp;78.140, a transaction between a corporation and one or more of its directors or officers who has a financial interest
    in the transaction or holds common director or officer positions, is not void or voidable solely for that reason, if: (a)&nbsp;the
    fact of the common directorship, office or financial interest is known to the board of directors or a committee thereof, and the
    disinterested directors or committee members approve the transaction in good faith&#894; (b)&nbsp;the fact of the common directorship,
    office or financial interest is known to the stockholders of the corporation, and the stockholders holding a majority of the voting
    power approve or ratify the transaction in good faith&#894; (c)&nbsp;the fact of the common directorship, office or financial interest
    is not known to the interested director or officer at the time the transaction is brought before the board of directors for action&#894;
    or (d)&nbsp;the transaction is fair as to the corporation at the time it is authorized or approved.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; text-align: justify; width: 25%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 38%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Alberta</B></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Limitation on Liability of Directors and Officers</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain actions to enforce a liability imposed
    by the ABCA must be brought within two years from the date of the resolution authorizing the act complained of. A director will be
    deemed to have complied with their fiduciary obligations to the corporation under certain sections of the ABCA if the director exercised
    care, diligence, and skill that a reasonably prudent person would exercise in a comparable circumstance, including relying in good
    faith on:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;financial
    statements represented to the director by an officer or in a written report of the auditor of the corporation to fairly reflect the
    financial condition of the corporation; or</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;an
    opinion report of a person whose profession lends credibility to a statement made by the professional person.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the ABCA, the directors of a corporation
    who vote for or consent to a resolution that authorizes the corporation to, inter alia: (a)&nbsp;pay a commission on the sale of
    shares not provided for under the ABCA; (b)&nbsp;pay a dividend, purchase, redeem or otherwise acquire shares in circumstances that
    would be in violation of the ABCA, including where the corporation is insolvent, or the payment of the dividend would render the
    corporation insolvent; (c)&nbsp;make a payment of an indemnity to an indemnifiable person in violation of the ABCA; (d)&nbsp;provide
    financial assistance in violation of the ABCA; or (e)&nbsp;make a payment to a shareholder in violation of the ABCA, are, in each
    case, jointly and severally liable to restore to the corporation any amount paid or distributed as a result and not otherwise recovered
    by the corporation.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the directors of a corporation
    who vote for or consent to a resolution that authorizes the issue of a share that is not fully paid are jointly and severally liable
    to the corporation to make good any amount by which the consideration received is less than the fair equivalent of the money that
    the corporation would have received if the shares had been issued for money on the date of that resolution. Notwithstanding the foregoing,
    under the ABCA, a director is not subject to statutory liability for the foregoing if the director did not know and could not reasonably
    have known that the shares were issued for a consideration less than the fair equivalent of the money that the corporation would
    have received if the shares had been issued for money.</P></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The NRS provides that directors and officers
    are not individually liable to the corporation, its stockholders or creditors for any damages as a result of any act or failure to
    act as such unless the presumption of the business judgment rule&nbsp;has been rebutted and it is proven that such director&rsquo;s
    or officer&rsquo;s act or failure to act constituted a breach of his or her fiduciary duties as a director or officer and such breach
    involved intentional misconduct, fraud or a knowing violation of law. The NRS also provides that directors and officers are presumed
    to act in good faith, on an informed basis and with a view to the interests of the corporation in making business decisions. In performing
    such duties, directors and officers may exercise their business judgment through reliance on information, opinions, reports, financial
    statements and other financial data prepared or presented by corporate directors, officers or employees who are reasonably believed
    to be reliable and competent. Reliance may also be extended to legal counsel, public accountants, advisers, bankers or other persons
    reasonably believed to be competent, and to the work of a committee (on which the particular director or officer does not serve)
    if the committee was established and empowered by the corporation&rsquo;s board of directors, and if the committee&rsquo;s work was
    within its designated authority and was about matters on which the committee was reasonably believed to merit confidence. However,
    directors and officers may not rely on such information, opinions, reports, books of account or similar statements if they have knowledge
    concerning the matter in question that would make such reliance unwarranted.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Note that Nevada law, which covers both directors
    and officers, does not exempt breaches of duty of loyalty from exculpation. Liability for improper payment of distributions is subject
    to the same exculpatory standard applicable to other liabilities.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The proposed Oncolytics Nevada Charter provides
    for the elimination of liability of directors and officers to the fullest extent permitted by law.</P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; text-align: justify; width: 25%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 38%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Alberta</B></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Indemnification of Directors and Officers</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the ABCA, a corporation may indemnify:
    (a)&nbsp;a current or former director or officer of that corporation; (b)&nbsp;a current or former director or officer of another
    corporation if, at the time such individual held such office, the corporation was a shareholder or creditor of the corporation, and
    if such individual acted at the corporation&rsquo;s request; or (c)&nbsp;the foregoing individual&rsquo;s heirs and legal representatives
    (each, an &ldquo;indemnifiable person&rdquo;) against all costs, charges and expenses, including an amount paid to settle an action
    or satisfy a judgment, reasonably incurred by the director or officer in respect of any civil, criminal, administrative, investigative
    or other action or proceeding in which he or she is involved by reason of being or having been a director or officer of the corporation
    or another corporation (as set out above), if: (i)&nbsp;the individual acted honestly and in good faith with a view to the best interests
    of the corporation; and (ii)&nbsp;in the case of a criminal or administrative action or proceeding that is enforced by a monetary
    penalty, the individual had reasonable grounds for believing that the individual&rsquo;s conduct was lawful.</P>
                           <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A corporation may advance funds to an indemnifiable
    person to defray the costs, charges and expenses incurred by an indemnifiable person in respect of that proceeding, provided that
    if it is ultimately determined that the payment of expenses was prohibited, the indemnifiable person will repay any amount advanced.
    Subject to the aforementioned prohibitions on indemnification, a corporation must pay all costs, charges and expenses reasonably
    incurred by an indemnifiable person in connection with the defence of any civil, criminal, administrative, investigative or other
    action or proceeding in which the person is involved by reason of being or having been a director or officer of the corporation or
    body corporate, if the person seeking indemnity: (a)&nbsp;was not judged by a court or competent authority to have committed any
    fault or omitted to do anything that the person ought to have done; and (b)&nbsp;(i)&nbsp;the individual acted honestly and in good
    faith with a view to the best interests of the corporation; and (ii)&nbsp;in the case of a criminal or administrative action or proceeding
    that is enforced by a monetary penalty, the individual had reasonable grounds for believing that the individual&rsquo;s conduct was
    lawful.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s bylaws provide that the
    Company will indemnify directors and officers to the extent permitted by law.</P></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The NRS includes a statutory mechanism that
    permits a corporation to indemnify any director or officer who is not liable pursuant to NRS 78.138 or acted in good faith and in
    a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation (and, in the case of a criminal
    action or proceeding, had no reasonable cause to believe the conduct was unlawful). Under the statutory indemnification regime of
    the NRS, the corporation, through its stockholders, directors or independent legal counsel, must determine that the indemnification
    is proper.</P>
                           <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The indemnification available pursuant to
    the statutory mechanisms provided under the NRS, as described above, does not exclude any other rights to which a person seeking
    indemnification or advancement of expenses may be entitled under the articles of incorporation or any bylaw, agreement, vote of stockholders
    or disinterested directors or otherwise, but, unless ordered by a court, indemnification may not be made to or on behalf of any director
    or officer finally adjudged by a court of competent jurisdiction, after exhaustion of any appeals taken therefrom, to be liable for
    intentional misconduct, fraud or a knowing violation of law, and such misconduct, fraud or violation was material to the cause of
    action.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the NRS, unless otherwise restricted
    by the articles of incorporation, the bylaws or an agreement made by the corporation, the corporation may pay the expenses of officer
    and directors in advance of the final disposition of an action, suit or proceeding upon receipt of an undertaking by or on behalf
    of the director or officer to repay the amount if it is ultimately determined that the director or officer is not entitled to be
    indemnified by the corporation.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The proposed Oncolytics Nevada Bylaws provide
    for indemnification and advancement of expenses to directors and officers to the fullest extent permitted by applicable law, subject
    to certain exceptions.</P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; text-align: justify; width: 25%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 38%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Alberta</B></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Call and Notice of Shareholder Meetings</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the ABCA, the board of directors may
    at any time call a special meeting of shareholders, and that holders of not less than five percent of the issued voting shares may
    give notice to the directors requiring them to call and hold a special meeting of shareholders for the purpose stated in the notice.</P>
                           <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the directors do not call such a meeting
    within 21 days after receiving the requisition, the requisitioning shareholders or any of them may call the meeting.</P></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The NRS provides that unless otherwise provided
    in the bylaws, the board of directors has the authority to set the date, time and place for the annual meeting of the stockholders.
    Under the NRS, a stockholders meeting may be held within or outside of Nevada.</P>
                           <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If for any reason directors are not elected
    by written consent pursuant to NRS 78.320 or at the annual meeting of the stockholders, they may be elected at any special meeting
    of the stockholders which is called and held for that purpose.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Shareholder Action by Written Consent</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    the ABCA, shareholders can take action by written resolution and without a meeting only if all shareholders entitled to vote on that
    resolution sign the written resolution. A written resolution is as valid and effective as if it were a resolution passed at a meeting
    of shareholders.</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The NRS provides that, unless the articles
        of incorporation or bylaws provide otherwise, any action required or permitted to be taken at a meeting of the stockholders may be
        taken without a meeting if, before or after the action, a written consent is signed by stockholders holding at least a majority of
        the voting power, or if a different proportion of voting power is otherwise required for action at a meeting, then by that proportion of written
        consents.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Oncolytics Nevada Bylaws prohibit
    action by written consent of stockholders.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Shareholder Nominations and Proposals</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    ABCA provides that a shareholder holding at least one percent of the total number of issued voting shares, or with a fair market
    value of at least C$2,000, in either case for a period of at least six months, and has the support of other shareholders holding
    not less than 5% of the issued voting shares, may submit proposals to the annual meeting of shareholders. A proposal that includes
    nominations for the election of directors must be signed by one or more holders holding, in aggregate, not less than 5% of the voting
    shares. A shareholder may also nominate directors at a meeting of shareholders.</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    NRS does not contain specific provisions regarding stockholder proposals. However, the Oncolytics Nevada Bylaws contain provisions
    which generally require stockholders to provide written notice of any proposal or nomination at least 90 days and not more than 120
    days prior to the anniversary date of the prior years meeting. The notice must contain specific information relating to (i)&nbsp;the
    nominating or proposing stockholder, the beneficial owner on whose behalf the nomination or proposal is being made and certain other
    related persons; (ii)&nbsp;the nominee, and (iii)&nbsp;the proposed business.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; text-align: justify; width: 25%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 38%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Alberta</B></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Shareholder Quorum and Vote Requirements</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    ABCA provides that, unless the by-laws provide otherwise, a quorum of shareholders is present at a meeting of shareholders (irrespective
    of the number of persons actually present at the meeting) if holders of a majority of the shares entitled to vote at the meeting
    are present in person or represented by proxy. The Company&rsquo;s bylaws provide that a quorum for the transaction of business at
    any meeting of shareholders shall be two persons present in person, each being a shareholder entitled to vote thereat or a duly appointed
    proxyholder for an absent shareholder so entitled, and together holding or representing by proxy not less than 5% of the votes entitled
    to be cast at the meeting.</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the NRS, unless otherwise provided
    in the articles of incorporation or bylaws, a quorum for the transaction of business at a meeting of stockholders is a majority of
    the voting power entitled to vote at the meeting whether present in person or by proxy. Shares represented at a meeting of stockholders
    by proxy count towards a quorum, even if the proxy does not have the authority to vote on any matter.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Oncolytics Nevada Bylaws state that quorum
    for the transaction of business at a meeting of Stockholders is one-third of the voting power entitled to vote at the meeting.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the NRS, a corporation must have at
    least one director, and may provide in its articles of incorporation or in its bylaws for a fixed number of directors or a variable
    number of directors, and may otherwise provide for the manner in which the number of directors may be increased or decreased.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The NRS permits corporations to classify
    boards of directors provided that at least one-fourth of the total number of directors is elected annually.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The NRS provides that unless the articles
    of incorporation or the bylaws require more than a plurality of the votes cast, directors of every corporation must be elected at
    the annual meeting of the stockholders by a plurality of the votes cast at the election.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Oncolytics Nevada&rsquo;s board is not classified
    and, therefore, directors will be elected on an annual basis.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The proposed Oncolytics Nevada Bylaws provide
    that directors will be elected by a plurality of votes cast.</P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; text-align: justify; width: 25%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 38%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Alberta</B></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Amendment of Articles of Incorporation</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the ABCA, the articles of the Company
    may be generally amended by special resolution, which requires the approval of not less than two-thirds of the votes cast by shareholders
    who vote on the resolution.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the NRS, except as noted below, every
        amendment to the articles of incorporation must be made in the following manner:</P>
                           <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-family: Times New Roman, Times, Serif">The
proposed amendment must be approved by the board of directors and submitted to the stockholders for approval.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT>&#8239; &#8239;&#8239;<FONT STYLE="font-family: Times New Roman, Times, Serif">The
    proposed amendment requires the approval of stockholders representing at least a majority of the voting power of the corporation, or
    such greater proportion of the voting power as may be required in the case of a vote by classes or series (as described below), or
    as otherwise required by the articles of incorporation. If any proposed amendment would adversely alter or change any preference or
    other right given to any class or series of outstanding shares, then the amendment must also be approved by the holders of shares
    representing a majority of the voting power of each class or series adversely affected by such amendment regardless of limitations
    or restrictions on the voting power thereof. The amendment does not have to be approved by the vote of the holders of shares
    representing a majority of the voting power of each class or series whose preference or rights are adversely affected by the
    amendment if the articles of incorporation specifically deny the right to vote on such an amendment.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Different series of the same class of shares
    do not constitute different classes of shares for the purpose of voting by classes except when the series is adversely affected by
    an amendment in a different manner than other series of the same class.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An amendment to increase or decrease the number of authorized shares of any class or series of stock of a publicly traded corporation
may be approved by the default voting standard set forth in a corporation&rsquo;s articles of incorporation or bylaws. In the Oncolytics
Nevada Bylaws that voting standard is more votes cast in favor of the matter than against the matter.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No action by the stockholders is required
    if the proposed amendment to the articles of incorporation consists only of a change in the name of the corporation.</P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; text-align: justify; width: 25%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 38%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Alberta</B></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Amendment of Bylaws</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    the ABCA, the directors may make, amend or repeal any bylaw that regulates the business or affairs of the corporation, unless the
    articles of the corporation, unanimous shareholders&rsquo; agreement or bylaws provide otherwise. When directors make, amend or repeal
    a bylaw, they are required under the ABCA to submit the change to shareholders at the next meeting of shareholders. Shareholders
    may confirm, reject or amend the bylaw, amendment or repeal by ordinary resolution, which requires a majority of the votes cast by
    shareholders who voted on the resolution.</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The NRS provides that, unless otherwise prohibited
    by any bylaw adopted by the stockholders, the board of directors may adopt, amend or repeal any bylaw, including any bylaw adopted
    by the stockholders. The NRS also provides that the articles of incorporation may grant the authority to adopt, amend or repeal bylaws
    exclusively to the board of directors.</P>
                           <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
                           <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The proposed Oncolytics
Nevada Charter and Oncolytics Nevada Bylaws provide that the Board of Directors may amend the Oncolytics Nevada Bylaws. They also provide
that the Oncolytics Nevada Bylaws may be amended by the vote of stockholders holding at least two-thirds of the voting power of the corporation,
voting together as a single class.</P>

</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Votes on Amalgamations, Mergers, Consolidations and Sales of
    Assets</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Many matters requiring shareholder approval
    under the ABCA must be approved by a special resolution. These extraordinary corporate actions include certain amalgamations, changes
    to authorized share structure, continuances, liquidations and dissolutions, and sales, leases or exchanges of all or substantially
    all the assets of a corporation other than in the ordinary course of business.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A special resolution is a resolution (a)&nbsp;passed
    by a majority of not less than two-thirds of the votes cast by the shareholders who voted in respect of the resolution at a meeting
    duly called and held for that purpose; or (b)&nbsp;signed by all shareholders entitled to vote on the resolution.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the ABCA, separate approval by holders
    of shares of a specific class or series may be required to effect extraordinary corporate actions.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the ABCA, arrangements are permitted
    and a corporation may make any proposal it considers appropriate if &ldquo;it is impracticable to effect the arrangement&rdquo; under
    the other provisions of the ABCA. In general, a plan of arrangement is approved by a corporation&rsquo;s board of directors and then
    is submitted to a court for approval. It is typical for a corporation in such circumstances to apply to a court initially for an
    interim order governing various procedural matters prior to calling any security holder meeting to consider the proposed arrangement.
    Under the ABCA, the court has the discretion to determine whether a plan of arrangement must be approved by shareholders, and the
    requisite minimum voting threshold. The court also determines, among other things, to whom notice shall be given and whether, and
    in what manner, approval of any person is to be obtained and also determines whether any shareholders may dissent from the proposed
    arrangement and receive payment of the fair value of their shares. Following compliance with the procedural steps contemplated in
    an interim order issued by the court, as applicable, (including as to obtaining security holder approval), the court would conduct
    a final hearing and approve or reject the proposed arrangement in the final order.</P></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the NRS, a merger or sale of all assets
    requires authorization by stockholders of the corporation being acquired or selling its assets holding at least a majority of the voting
    power of the outstanding shares entitled to vote, as well as approval of such corporation&rsquo;s board of directors.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With respect to approval by stockholders
    of a surviving corporation in a merger, the NRS does not require a stockholder vote of a constituent corporation in a merger (unless
    the corporation provides otherwise in its articles of incorporation) if (i)&nbsp;the plan of merger does not amend the existing articles
    of incorporation, (ii)&nbsp;each stockholder of the surviving Nevada corporation whose shares were outstanding immediately before
    the effective date of the merger will hold the same number of shares, with identical designations, preferences, limitations and relative
    rights immediately after the effective date of merger and (iii)&nbsp;the number of voting shares issued and issuable as a result
    of the merger will not exceed 20% of the total number of voting shares (i.e., shares that entitle their holders to vote unconditionally
    in elections of directors) of the surviving Nevada corporation outstanding immediately before the merger; and (iv)&nbsp;the number
    of participating shares (i.e. shares that entitled their holders to participate without limitation in distributions) issued and issuable
    as a result of the merger will not exceed 20% of the number of participating shares outstanding immediately before the merger.</P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; text-align: justify; width: 25%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 38%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Alberta</B></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dissenter&rsquo;s
    Rights of Appraisal</B></FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The ABCA provides that shareholders of a
    corporation entitled to vote on certain matters are entitled to exercise dissent rights. Dissenting shareholders who comply with
    the process set out in the ABCA may demand payment for the fair value of their shares. Dissent rights exist when there is a vote
    upon matters such as:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-family: Times New Roman, Times, Serif">an
    amalgamation with another corporation (other than with certain affiliated corporations);</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT>&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-family: Times New Roman, Times, Serif">an
    amendment to a corporation&rsquo;s articles to: (a)&nbsp;add, change or remove any provisions restricting or constraining the issue
    or transfer of shares; (b)&nbsp;add or remove an express statement establishing the unlimited liability of shareholders; or (c)&nbsp;add,
    change or remove any restriction upon the business or businesses that the corporation may carry on;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT>&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-family: Times New Roman, Times, Serif">a
continuance (reincorporation) under the laws of another jurisdiction;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT> &#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-family: Times New Roman, Times, Serif">a
    sale, lease or exchange of all or substantially all the property of the corporation other than in the ordinary course of business;
    and</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-family: Times New Roman, Times, Serif">an
    arrangement proposed by the corporation where there is a court order permitting a shareholder to dissent in connection with an application
    to the court for an order approving the arrangement.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">However, a shareholder is not entitled to
    dissent if an amendment to the articles of incorporation is effected by a court order approving a reorganization or by a court order
    made in connection with an action for an oppression remedy.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A court may make an order permitting a shareholder
    to dissent in certain circumstances.</P></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    the NRS, a stockholder is entitled to dissent from, and obtain payment for, the fair value of the stockholder&rsquo;s shares in the
    event of (i)&nbsp;accordance of full voting rights under certain circumstances in connection with acquisitions of a controlling interest
    in the corporation, (ii)&nbsp;consummation of a plan of merger, if approval by the stockholders is required for the merger, regardless
    of whether the stockholder is entitled to vote on the merger or if the domestic corporation is a subsidiary and is merged with its
    parent, or if the domestic corporation is a constituent entity in a merger pursuant to NRS 92A.133, (iii)&nbsp;consummation of a
    plan of conversion to which the corporation is a party, (iv)&nbsp;consummation of a plan of exchange in which the corporation is
    a party, (v)&nbsp;any corporate action taken pursuant to a vote of the stockholders, if the articles of incorporation, bylaws or
    a resolution of the board of directors provides that voting or nonvoting stockholders are entitled to dissent and obtain payment
    for their shares or (vi)&nbsp;any corporate action to which the stockholder would be obligated, as a result of the corporate action,
    to accept money or scrip rather than receive a fraction of a share in exchange for the cancellation of all the stockholder&rsquo;s
    outstanding shares, except where the stockholder would not be entitled to receive such payment pursuant to NRS 78.205, 78.2055 or
    78.207. Holders of covered securities (generally those that are listed on a national securities exchange), any shares traded in an
    organized market and held by at least 2,000 stockholders of record with a market value of at least $20 million (exclusive of the
    value of such shares held by the corporation&rsquo;s subsidiaries, senior executives, directors and beneficial stockholders owning
    more than 10% of such shares), and any shares issued by an open-end management investment company registered under the Investment
    Company Act of 1940 and which may be redeemed at the option of the holder at net asset value are generally not entitled to dissenter&rsquo;s
    rights. However, this exception is not available if (i)&nbsp;the articles of incorporation of the corporation issuing the shares
    provide that such exception is not available, (ii)&nbsp;the resolution of the board of directors approving the plan of merger, conversion
    or exchange expressly provides otherwise or (iii)&nbsp;the holders of the class or series of stock are required by the terms of the
    corporate action to accept for the shares anything except cash, shares of stock or other securities as described in NRS 92A.390(3)(b)&nbsp;or
    any combination thereof. The NRS prohibits a dissenting stockholder from voting his or her shares or receiving certain dividends
    or distributions after his or her dissent.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; text-align: justify; width: 25%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 38%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Alberta</B></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Oppression Remedy</B></FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the ABCA, a complainant has the right
    to apply to a court for an order where an act or omission of the corporation or an affiliate effects a result, or the business or
    affairs of which are or have been carried on or conducted in a manner, or the directors&rsquo; powers are or have been exercised
    in a manner, that would be oppressive or unfairly prejudicial to or would unfairly disregard the interest of any security holder,
    creditor, director or officer of the corporation. On such application, the court may make any interim or final order it thinks fit
    to rectify the matters complained of, including an order restraining the conduct complained of.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The oppression remedy provides the court
    with broad and flexible jurisdiction to intervene in corporate affairs to protect shareholders. While conduct that is in breach of
    fiduciary duties of directors or that is contrary to the legal right of a complainant will normally trigger the court&rsquo;s jurisdiction
    under the oppression remedy, the exercise of that jurisdiction does not depend on a finding of a breach of such legal and equitable
    rights.</P></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
    the NRS imposes fiduciary duties upon directors and officers, the NRS does not contain an &ldquo;oppression remedy.&rdquo; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Shareholder Derivative Actions</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the ABCA, a shareholder, former shareholder,
    director, former director, officer or former officer of a corporation or its affiliates, certain creditors or any other person who,
    in the discretion of a court, is a proper person to seek a derivative action may apply to the court for leave to bring an action
    in the name and on behalf of a corporation or any of its subsidiaries, or intervene in the action to which a corporation or any of
    its subsidiaries is a party, for the purpose of prosecuting, defending or discontinuing the action on behalf of the corporation or
    the subsidiary.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to bring the action, the complainant
    must give reasonable notice to the directors of the corporation (if not all directors have been named as defendants) and the complainant
    must satisfy to the court that:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT>&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-family: Times New Roman, Times, Serif">the
    complainant is acting in good faith;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT>&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-family: Times New Roman, Times, Serif">the
    directors of the corporation will not bring, diligently prosecute or defend or discontinue the action; and</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-family: Times New Roman, Times, Serif">it
appears to be in the interests of the corporation that the action be brought, prosecuted, defended or discontinued.</FONT></P></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NRS
    41.520 grants stockholders a derivative cause of action where the corporation refuses to enforce rights which may properly be asserted
    by it, where the plaintiff was a shareholder at the time of the transaction of which the plaintiff complains or that the plaintiff&rsquo;s
    share thereafter devolved on the plaintiff by operation of law. The complaint must also set forth with particularity the efforts
    of the plaintiff to secure from the board of directors and, if necessary, from the stockholders such action as the plaintiff desires,
    and the reasons for the plaintiff&rsquo;s failure to obtain such action or the reasons for not making such effort. In any such action,
    at any time within 30 days after service of summons upon the corporation or any defendant who is an officer or director of the corporation
    or held such office at the time of the acts complained of, the corporation or such defendant may move the court for an order, upon
    notice and hearing, requiring the plaintiff to furnish security as hereinafter provided. Such motion must be based upon one or more
    of the following grounds: (a)&nbsp;that there is no reasonable possibility that the prosecution of the cause of action alleged in
    the complaint against the moving party will benefit the corporation or its security holder or (b)&nbsp;that the moving party, if
    other than the corporation, did not participate in the transaction complained of in any capacity.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; text-align: justify; width: 25%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 38%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Alberta</B></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Anti-Takeover and Ownership Provisions</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The ABCA does not contain specific anti-takeover
    provisions, however, policies of Canadian securities regulatory authorities provide a corporation with certain powers which may be
    used to make itself less vulnerable to hostile takeover attempts. These powers include the ability to:</P>
                           <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-family: Times New Roman, Times, Serif">implement
    a staggered board of directors, which deters an immediate change in control of the board;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-family: Times New Roman, Times, Serif">provide
for the exclusive right of one or more class of shareholders to elect one or more directors;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-family: Times New Roman, Times, Serif">provide
    for supermajority voting in some circumstances, including on an amalgamation or for amendments to articles;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-family: Times New Roman, Times, Serif">provide
    for the creation of a shareholder rights plan to authorize the issue of new shares to existing shareholders at a below-market price
    in the event of a hostile take-over bid without any requirement to issue such shares to hostile bidders; and</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-family: Times New Roman, Times, Serif">issue
    &ldquo;blank check&rdquo; preferred shares, which may be used to make a corporation less attractive to a hostile bidder.</FONT></P></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless an issuer opts out of the provisions
    of NRS 78.411 through 78.444, such statutes generally prohibit a public Nevada corporation from engaging in a &ldquo;combination&rdquo;
    with a holder of 10% or more of the voting power of the outstanding voting shares of the Company, referred to as an interested stockholder,
    for a period of two years after the time the interested stockholder became an interested stockholder, except as otherwise provided
    therein. For these purposes, the term &ldquo;combination&rdquo; includes mergers, certain assets sales and other similar transactions
    with an interested stockholder.</P>
                           <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Oncolytics Nevada has opted out of NRS 78.411
    through 78.444 in the Oncolytics Nevada Charter.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the restrictions on business
    combinations with interested stockholders, Nevada law also protects a corporation and its stockholders from persons acquiring a &ldquo;controlling
    interest&rdquo; in a corporation. The provisions can be found in NRS 78.378 to 78.3793, inclusive.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to NRS 78.378, any person who acquires
    a controlling interest in a corporation may not exercise voting rights on any control shares unless the articles of incorporation
    or bylaws in effect on the 10<SUP>th</SUP> day following such acquisition provide that the provisions of these statutes do not apply
    to the corporation or to an acquisition of a controlling interest specifically by types of existing or future stockholders, or unless
    such voting rights are conferred by a majority vote of the disinterested stockholders of the issuing corporation at a special meeting
    of such stockholders held upon the request and at the expense of the acquiring person. NRS 78.3785 provides that a &ldquo;controlling
    interest&rdquo; means the ownership of outstanding voting shares of an issuing corporation sufficient to enable the acquiring person,
    individually or in association with others, directly or indirectly, to exercise (i)&nbsp;one-fifth or more but less than one-third,
    (ii)&nbsp;one-third or more but less than a majority or (iii)&nbsp;a majority or more of the voting power of the issuing corporation
    in the election of directors, and once an acquirer crosses one of these thresholds, shares that it acquired in the transaction taking
    it over the threshold and within the 90 days immediately preceding the date when the acquiring person acquired or offered to acquire
    a controlling interest become &ldquo;control shares&rdquo; to which the voting restrictions described above apply. In the event that
    the control shares are accorded full voting rights and the acquiring person acquires control shares with a majority or more of all
    the voting power, any stockholder, other than the acquiring person, who does not vote in favor of authorizing voting rights for the
    control shares is entitled to demand payment for the fair value of such person&rsquo;s shares, and the corporation must comply with
    the demand.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Corporations are entitled to opt out of the
    above controlling interest provisions of the NRS. In the Oncolytics Nevada Bylaws, Oncolytics Nevada opts out of these provisions.</P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; text-align: justify; width: 25%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 38%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Alberta</B></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forum Selection</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A company may include a forum selection clause
    in its bylaws, which provides a mechanism to designate the courts of a specified jurisdiction as the exclusive forum for hearing
    corporate disputes, subject to limitations under applicable corporate laws and judicial interpretation.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s bylaws do not include
    a forum selection clause.</P></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The proposed Oncolytics Nevada Bylaws
        provide that the Eighth Judicial District Court of the State of Nevada, in Clark County, Nevada shall be the sole and exclusive
        forum for (1)&nbsp;any derivative action or proceeding brought on behalf of the Company, (2)&nbsp;any action or proceeding asserting
        a claim of breach of a fiduciary duty owed by any current or former director, officer, stockholder, employee or agent of the Company
        to the Company or the  Stockholders, (3)&nbsp;any action or proceeding asserting a claim arising pursuant to the NRS,
        the Oncolytics Nevada Charter or Oncolytics Nevada Bylaws, (4)&nbsp;any proceeding to interpret, apply, enforce or determine
        the validity of the Nevada Charter or Nevada Bylaws, (5)&nbsp;any internal action (as defined in NRS 78.046) and any action or
        proceeding as to which NRS Title 7 confers jurisdiction to the District Courts of the State of Nevada, or (6)&nbsp;any action
        asserting a claim governed by the internal affairs doctrine.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Oncolytics Nevada Bylaws further provide
    that the federal district courts of the United States of America are the sole and exclusive forum for the resolution of any claim
    asserting a cause of action under the Securities Act.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="pros4_001"></A>INTEREST
OF CERTAIN PERSONS OR COMPANIES IN MATTERS TO BE ACTED UPON</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management of the Company is not aware of any
material interest, direct or indirect, of any director or executive officer of the Company, or anyone who has held office as such since
the beginning of the Company&rsquo;s last financial year, or any associate or affiliate of any of the foregoing in any matter to be acted
on at the Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="pros4_002"></A>INTEREST
OF INFORMED PERSONS IN MATERIAL TRANSACTIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are no material interests, direct or indirect,
of directors, officers, any shareholder who beneficially owns, directly or indirectly, more than 10% of the outstanding Common Shares,
or any known associate or affiliates of such persons in any transaction within the last financial year or in any proposed transaction
which has materially affected or would materially affect the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="pros4_003"></A>HOUSEHOLDING
 &mdash; SHAREHOLDERS SHARING THE SAME ADDRESS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Some banks, brokers and other nominee record
holders may be participating in the practice of &ldquo;householding&rdquo; proxy statements and annual reports. This means that only
one copy of our proxy materials or annual report to Shareholders may have been sent to multiple Shareholders in each household unless
otherwise instructed by such Shareholders. We will deliver promptly a separate copy of these documents to any Shareholder upon written
or oral request to our Chief Executive Officer at Oncolytics Biotech Inc., 322 11th Avenue SW, Suite&nbsp;804, Calgary, Alberta T2R 0C5,
telephone: (403) 670-7377. Any Shareholder who wants to receive separate copies of our proxy materials or annual report to Shareholders
in the future, or any Shareholder who is receiving multiple copies and would like to receive only one copy per household, should contact
the Shareholder&rsquo;s bank, broker, or other nominee record holder, or the Shareholder may contact us at the above address and telephone
number.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="pros4_004"></A>MANAGEMENT
CONTRACTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None of the management functions of Oncolytics
are to any substantial degree performed other than by the directors or executive officers of Oncolytics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="pros4_005"></A>RESTRICTED
SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No action to be taken as set out herein involves
a transaction that would have the effect of converting or subdividing, in whole or in part, existing securities into restricted securities
or creating new restricted securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="pros4_006"></A>ADDITIONAL
INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additional information relating to the Company
is available through the internet on the Canadian System for Electronic Document Analysis and Retrieval Plus (SEDAR+) which can be accessed
at www.sedarplus.ca. Financial information of the Company is provided in the comparative annual financial statements and management&rsquo;s
discussion and analysis of the Company for the most recently completed financial year. Copies of the financial statements and management
discussion and analysis of the Company may be obtained from the Chief Financial Officer of the Company at Suite&nbsp;804, 322 &mdash;
11th Avenue S.W., Calgary, Alberta T2R 0C5 or by email at info@oncolyticsbiotech.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="pros4_007"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain legal matters relating to the Domestication
under the laws of the State of Nevada will be passed upon by Brownstein Hyatt Farber Schreck, LLP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="pros4_008"></A>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements of Oncolytics
Biotech Inc. as of December&nbsp;31, 2024 and 2023 and for each of the three years in the period ended December&nbsp;31, 2024 incorporated
in this prospectus by reference to the Annual Report on Form&nbsp;20-F have been so incorporated in reliance on the report (which contains
an explanatory paragraph describing conditions that raise substantial doubt about the Company&rsquo;s ability to continue as a going
concern as described in Note 1 to the consolidated financial statements) of Ernst&nbsp;&amp; Young LLP, an independent registered public
accounting firm, given on the authority of said firm as experts in auditing and accounting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="pros4_009"></A>WHERE
YOU CAN FIND MORE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="pros4_011"></A>Availability of Reports and Other Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We file annual, quarterly and current reports,
proxy statements and other information with the SEC. Our SEC filings are available to the public at the SEC&rsquo;s website at http://www.sec.gov.
We maintain a website at www.oncolyticsbiotech.com. Information contained in or accessible through our website does not constitute a
part of this Circular/Prospectus. As we are also a Canadian issuer, we also file continuous disclosure documents with the Canadian securities
regulatory authorities, which documents are available on the SEDAR+ website maintained by the Canadian Securities Administrators at www.sedarplus.ca.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have filed with the SEC the Registration Statement
on Form&nbsp;F-4 (the &ldquo;<B>Registration Statement</B>&rdquo;) under the Securities Act with respect to the Continuance and the Domestication
as well as with the applicable provincial securities regulatory authorities in Canada. This Circular/Prospectus, which constitutes part
of the Registration Statement, does not contain all of the information set forth in the Registration Statement and the exhibits and schedules
thereto. For further information about us and the Continuance and the Domestication, please refer to the Registration Statement and the
exhibits and schedules filed as a part of the Registration Statement. Statements contained in this Circular/Prospectus as to the contents
of any contract or other document referred to are not necessarily complete. If a contract or document has been filed as an exhibit to
the Registration Statement, please refer to the copy of the contract or document that has been filed as an exhibit to the Registration
Statement, each statement about such contract or document being qualified in all respects by such reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="pros4_012"></A>Incorporation by Reference</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The SEC allows us to incorporate by reference
the information we file with it, which means that we can disclose important information to you by referring you to another document that
we have filed separately with the SEC. You should read the information incorporated by reference because it is an important part of this
Circular/Prospectus. Information in this Circular/Prospectus supersedes information incorporated by reference that we filed with the
SEC prior to the date of this Circular/Prospectus, while information that we file later with the SEC will automatically update and supersede
the information in this Circular/Prospectus. We incorporate by reference into this Circular/Prospectus and the Registration Statement
of which this Circular/Prospectus is a part the information and documents listed below that Oncolytics has filed with the SEC (Commission
File No.&nbsp;001-38512):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1129928/000112992825000019/oncyf-20241231.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                            Annual Report on Form&nbsp;20-F for the year ended December&nbsp;31, 2024, filed on March&nbsp;7,
                                            2025; and</FONT></A></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
Current Reports on Form&nbsp;6-K furnished to the SEC on <A HREF="https://www.sec.gov/Archives/edgar/data/1129928/000110465925033825/tm2512020d2_6k.htm" STYLE="-sec-extract: exhibit">April&nbsp;10,
2025</A> (Other Material Events), <A HREF="https://www.sec.gov/Archives/edgar/data/1129928/000112992825000034/q12025form6-k.htm" STYLE="-sec-extract: exhibit">May
14, 2025</A> (Financial Results), <A HREF="https://www.sec.gov/Archives/edgar/data/1129928/000112992825000062/q22025form6-k.htm" STYLE="-sec-extract: exhibit">August&nbsp;8,
2025</A> (Financial Results), <A HREF="https://www.sec.gov/Archives/edgar/data/1129928/000110465925075499/tm2522910d1_6k.htm" STYLE="-sec-extract: exhibit">August&nbsp;8,
2025</A> (Other Material Events), <A HREF="https://www.sec.gov/Archives/edgar/data/1129928/000110465925098796/tm2528273d1_6k.htm" STYLE="-sec-extract: exhibit">October&nbsp;10,
2025</A> (Other Material Events), <A HREF="http://www.sec.gov/Archives/edgar/data/1129928/000110465925100535/tm2528875d1_6k.htm" STYLE="-sec-extract: exhibit">October
20, 2025</A> (Other Material Events) and <A HREF="http://www.sec.gov/Archives/edgar/data/1129928/000112992825000089/q32025form6-k.htm" STYLE="-sec-extract: exhibit">November
12, 2025</A> (Financial Results)</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We also incorporate by reference into this
Circular/Prospectus all documents (other than any document or portion of a document that is furnished and deemed by the rules&nbsp;of
the SEC not to have been filed) that are filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d)&nbsp;of the Exchange
Act, including those filed by us with the SEC after the date of the initial filing of the Registration Statement of which this Circular/Prospectus
is a part and prior to effectiveness of such Registration Statement and those filed by us with the SEC after the date of this Circular/Prospectus
but prior to the date on which the Meeting is held. Information in such future filings updates and supplements the information provided
in this Circular/Prospectus. Any statements in any such future filings will automatically be deemed to modify and supersede any information
this Circular/Prospectus as well as any document we previously filed with the SEC, that is incorporated or deemed to be incorporated
herein by reference herein to the extent that statements in the later filed document modify or replace such earlier statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will furnish without charge to each person,
including any beneficial owner, to whom a Circular/Prospectus is delivered, upon written or oral request, a copy of any or all of the
documents incorporated by reference into this Circular/Prospectus but not delivered with the Circular/Prospectus, including exhibits
that are specifically incorporated by reference into such documents. You should direct any requests for documents to Oncolytics Biotech
Inc., Attention: Kirk Look, Chief Financial Officer, 322 11th Avenue SW, Suite&nbsp;804, Calgary, Alberta T2R 0C5. Our phone number is:
(403) 670-7377. You may also view the documents that we file with the SEC and incorporate by reference in this Circular/Prospectus on
our corporate website at https://oncolyticsbiotech.com/investor-overview/filings/. The information on our website is not incorporated
by reference and is not a part of this Circular/Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, the following documents of Oncolytics are specifically incorporated by reference into and form an integral part of this Circular/Prospectus:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our audited, consolidated financial statements for the year
ended December 31, 2024, together with the notes thereto, and the independent auditor&rsquo;s report thereon;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our management discussion and analysis for the year ended December
31, 2024;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our unaudited, condensed interim consolidated financial statements
for the three and nine-month periods ended September 30, 2025, together with the notes thereto;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our management&rsquo;s discussion and analysis, as at September
30, 2025, and for the three and nine-month periods ended September 30, 2025; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our management information circular dated June 18, 2025, prepared
in connection with our annual meeting of Shareholders held on August 8, 2025.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any documents of the
type referred to above, any audited annual consolidated financial statements, unaudited interim consolidated financial statements and
related management&rsquo;s discussion and analysis of financial condition and results of operations, any material change reports (except
confidential material change reports) and business acquisition reports filed by Oncolytics with the various securities commissions or
similar authorities in Canada or the U.S., which will subsequently be filed by Oncolytics on SEDAR and EDGAR, after the date of the Circular/Prospectus
and prior to the effective time of the Domestication, shall be deemed to be incorporated by reference into this Circular/Prospectus. The
foregoing documents may be viewed on SEDAR at www.sedarplus.ca and are also available on request without charge from Oncolytics&rsquo;
Chief Financial Officer by sending a written request to 4000, 421 &mdash; 7th Avenue S.W., Calgary, Alberta, T2P 4K9.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="pros4_010"></A>APPROVAL</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board has approved the contents of this Circular/Prospectus
and the sending thereof to our Shareholders, directors and independent registered public accounting firm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>DATED</B> this day of December 9,
2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ON
    BEHALF OF THE BOARD OF DIRECTORS</B> </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">/s/ Jared Kelly<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Jared Kelly</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer and Director</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">San Diego, California</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B><A NAME="pros4_013"></A>ANNEX A &mdash;
<FONT STYLE="text-transform: uppercase">SPECIAL SHAREHOLDERS RESOLUTION APPROVING THE CONTINUANCE</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>RESOLVED
AS A SPECIAL RESOLUTION THAT:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">1.</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Oncolytics
                                            Biotech Inc. (the &ldquo;<B>Corporation</B>&rdquo;) is hereby authorized to:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">make
                                            application to the Alberta Registrar of Corporations for authorization to continue the Corporation
                                            to British Columbia under the <I>Business Corporations Act</I> (British Columbia) (the &ldquo;<B>BCBCA</B>&rdquo;),
                                            pursuant to the laws of British Columbia;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">subject
                                            to obtaining the approval specified above, to file with the regulatory authorities of British
                                            Columbia, a Continuation Application and Notice of Articles and all other requisite documentation
                                            in order to continue the Corporation as if it had been incorporated under the laws of British
                                            Columbia, including any alteration of the Corporation&rsquo;s share structure;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(c)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">upon
                                            continuation under the laws of British Columbia, to adopt Articles that comply with the BCBCA,
                                            which Articles shall be endorsed by a director of the Corporation; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(d)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">upon
                                            continuance under the laws of British Columbia, to make application to the Alberta Registrar
                                            of Corporations for a Certificate of Discontinuance pursuant to Section&nbsp;189(6)&nbsp;of
                                            the <I>Business Corporations Act</I> (Alberta).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">2.</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">subject
                                            to the continuance of the Corporation under the BCBCA and the issuance of a certificate of
                                            discontinuance by the Alberta Registrar of Corporations and without affecting the validity
                                            or existence of the Corporation, by and under its existing articles of incorporation or by-laws
                                            or of any act done thereunder, effective upon issuance of the certificate of continuation,
                                            the continuation application containing the notice of articles and the articles, in the forms
                                            attached as Annexes <B>B and E</B> to the Circular/Prospectus are hereby adopted in substitution
                                            for the existing articles of incorporation and by-laws of the Corporation, together with
                                            such changes or amendments thereto as any director or officer of the Corporation determines
                                            appropriate;</FONT></TD></TR><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
                                                                         <TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt">3.</TD><TD STYLE="font-size: 10pt; text-align: justify">for United States federal income tax purposes, the continuance of the Corporation under the BCBCA is intended to constitute a &ldquo;reorganization&rdquo;
within the meaning of Section 368(a)(1)(F) of the Internal Revenue Code of 1986, as amended, and this special resolution is intended to
constitute a &ldquo;plan of reorganization&rdquo; within the meaning of Sections 1.368-2(g) and 1.368-3 of the United States Treasury
Regulations;</TD></TR>
                                                                         </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">4.</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">notwithstanding
                                            that this special resolution has been duly passed (and the continuance approved) by the shareholders
                                            of the Corporation, the directors of the Corporation are hereby authorized and empowered
                                            without further notice to or approval of the shareholders of the Corporation (i)&nbsp;not
                                            to act upon this special resolution, and (ii)&nbsp;to revoke or abandon this special resolution,
                                            in their sole discretion at any time prior to the endorsement of a certificate of continuation
                                            in respect thereof; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">5.</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">any
                                            director or officer of the Corporation is authorized and directed, for and on behalf of the
                                            Corporation, to execute and deliver, or cause to be executed and delivered, the continuation
                                            application and the articles and all such other documents and instruments, and to do or cause
                                            to be done all such other acts and things as in the opinion of such director or officer may
                                            be necessary or desirable for the purpose of giving effect to these resolutions.&rdquo;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 90; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B><A NAME="pros4_014"></A>ANNEX
B &mdash; </B></FONT><B><FONT STYLE="font-size: 10pt">FORM&nbsp;OF CONTINUATION APPLICATION</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><IMG SRC="tm2533062d1_424b3img07.jpg" ALT=""><p align="center" style="margin:0in 0in .0001pt;text-align:center;"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">A NAME OF COMPANY &#x2013; Choose one of the following:
The name is the name reserved
for the foreign corporation to be continued in. The name reservation number is: , OR
The foreign corporation is to be continued in with a name created by adding &#x201C;B.C. Ltd.&#x201D; after the incorporation
number of the company.
B FOREIGN CORPORATION&#x2019;S CURRENT JURISDICTION
1. Corporate number assigned by the foreign corporation&#x2019;s jurisdiction
2. Corporation&#x2019;s name in the foreign corporation&#x2019;s jurisdiction
YYYY / MM / DD
4. Foreign corporation&#x2019;s jurisdiction of incorporation, amalgamation or continuation
3. Foreign corporation&#x2019;s date of incorporation or the
 most recent date of amalgamation or continuation
If you are continuing a company into BC and want the BC incorporation number as its name, you will need to file this form on
paper. Complete this form and mail to the Corporate Registry, along with a letter from the corporation&#x2019;s home jurisdiction
authorizing the continuation in. For information on the content of the authorization letter, see the Corporate Online Help
Centre at www.corporateonline.gov.bc.ca for &#x201C;Continuation Application&#x201D; and &#x201C;Authorization for Continuation In.&#x201D;
DO NOT MAIL THIS FORM to BC Registry Services
unless you are instructed to do so by registry staff.
The Regulation under the Business Corporations Act
requires the electronic version of this form to be filed
on the Internet at www.corporateonline.gov.bc.ca
Freedom of Information and Protection of Privacy Act (FOIPPA): Personal
information provided on this form is collected, used and disclosed under the
authority of the FOIPPA and the Business Corporations Act for the purposes of
assessment. Questions regarding the collection, use and disclosure of personal
information can be directed to the Executive Coordinator of the BC Registry
Services at 1 877 526-1526, PO Box 9431 Stn Prov Govt, Victoria BC V8W 9V3.
Telephone: 1 877 526-1526 Mailing Address: PO Box 9431 Stn Prov Govt Courier Address: 200 &#x2013; 940 Blanshard Street
Email: bcregistries@gov.bc.ca Victoria BC V8W 9V3 Victoria BC V8W 3E6
Foreign Corporation
CONTINUATION APPLICATION
BUSINESS CORPORATIONS ACT, section 302
C ALTERATION EFFECTIVE DATE &#x2013; Choose one of the following:
The alteration is to take effect at the time that this notice is filed with the registrar.
The alteration is to take effect at 12:01a.m. Pacific Time on
being a date that is not more than ten days after the date of the filing of this notice.
The alteration is to take effect at Pacific Time on
being a date and time that is not more than ten days after the date of the filing of this notice.
YYYY / MM / DD
YYYY / MM / DD
a.m. or p.m.
D
Authorization for the continuation from the foreign corporation&#x2019;s jurisdiction is:
AUTHORIZATION FOR CONTINUATION
ATTACHED ALREADY FILED
Page 1/2 FORM 16 FOR (JAN 2020)
 &#x2714;
NR 3380276
207797382
Oncolytics Biotech Inc.
 &#x2714;
 &#x2714;
1998 / 04 / 02
Alberta
Oncolytics Biotech Inc.</font></p></td></tr></table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 91 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><IMG SRC="tm2533062d1_424b3img06.jpg" ALT=""><p align="center" style="margin:0in 0in .0001pt;text-align:center;"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">FORM 16 FOR (JAN 2020)
E
Is the foreign corporation currently registered in BC as an extraprovincial company?
REGISTRATION AS AN EXTRAPROVINCIAL COMPANY
YES NO
If YES, enter the BC registration number and name of the extraprovincial company below:
Extraprovincial Registration Number in BC
Extraprovincial Company Name in BC
(Including assumed name, if any, approved for use in BC)
CERTIFIED CORRECT &#x2013; I have read this form and found it to be correct.
YYYY / MM / DD
DATE SIGNED
F
X
NAME OF AUTHORIZED SIGNING AUTHORITY FOR
THE FOREIGN CORPORATION
SIGNATURE OF AUTHORIZED SIGNING AUTHORITY FOR THE
FOREIGN CORPORATION
Page 2/2
Telephone: 1 877 526-1526 Mailing Address: PO Box 9431 Stn Prov Govt Courier Address: 200 &#x2013; 940 Blanshard Street
Email: bcregistries@gov.bc.ca Victoria BC V8W 9V3 Victoria BC V8W 3E6
Foreign Corporation
CONTINUATION APPLICATION
BUSINESS CORPORATIONS ACT, section 302
 &#x2714;</font></p></td></tr></table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><IMG SRC="tm2533062d1_424b3img05.jpg" ALT=""><p align="center" style="margin:0in 0in .0001pt;text-align:center;"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">NOTICE OF ARTICLES
LAST NAME
B TRANSLATION OF COMPANY NAME
C
Set out the full name, delivery address and mailing address (if different) of every director of the company. The director
may select to provide either (a) the delivery address and, if different, the mailing address for the office at which the
individual can usually be served with records between 9 a.m. and 4 p.m. on business days or (b) the delivery address
and, if different, the mailing address of the individual&#x2019;s residence. The delivery address must not be a post office box.
Attach an additional sheet if more space is required.
Set out the name of the company as set out in Item A of the Continuation Application.
A
DELIVERY ADDRESS
NAME OF COMPANY
Set out every translation of the company name that the company intends to use outside of Canada.
DIRECTOR NAME(S) AND ADDRESS(ES)
MAILING ADDRESS
LAST NAME
DELIVERY ADDRESS
MAILING ADDRESS
LAST NAME
DELIVERY ADDRESS
MAILING ADDRESS
LAST NAME
DELIVERY ADDRESS
MAILING ADDRESS
NOA Page 1
POSTAL CODE/ZIP CODE
FIRST NAME MIDDLE NAME
POSTAL CODE/ZIP CODE
FIRST NAME MIDDLE NAME
PROVINCE/STATE COUNTRY
PROVINCE/STATE COUNTRY
POSTAL CODE/ZIP CODE
POSTAL CODE/ZIP CODE
PROVINCE/STATE COUNTRY
PROVINCE/STATE COUNTRY
FIRST NAME MIDDLE NAME
FIRST NAME MIDDLE NAME
POSTAL CODE/ZIP CODE
POSTAL CODE/ZIP CODE
PROVINCE/STATE COUNTRY
PROVINCE/STATE COUNTRY
POSTAL CODE/ZIP CODE
POSTAL CODE/ZIP CODE
PROVINCE/STATE COUNTRY
PROVINCE/STATE COUNTRY
FORM 16 FOR (JAN 2020)
Oncolytics Biotech Inc.
See attached Schedule.</font></p></td></tr></table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 93 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><IMG SRC="tm2533062d1_424b3img04.jpg" ALT=""><p align="center" style="margin:0in 0in .0001pt;text-align:center;"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">Maximum number of shares of this
class or series of shares that the com-pany is authorized to issue, or indicate
there is
Identifying name of class
or series of shares
Kind of shares of this class
or series of shares.
Are there special rights
or restrictions attached
to the shares of this class
or series of shares?
Type of
currency
THERE IS NO
MAXIMUM
()
MAXIMUM NUMBER
OF SHARES
AUTHORIZED
WITH A PAR
VALUE OF
($)
YES WITHOUT
PAR VALUE
()
NO
DELIVERY ADDRESS OF THE COMPANY&#x2019;S REGISTERED OFFICE POSTAL CODE
MAILING ADDRESS OF THE COMPANY&#x2019;S REGISTERED OFFICE POSTAL CODE
D REGISTERED OFFICE ADDRESSES
DELIVERY ADDRESS OF THE COMPANY&#x2019;S RECORDS OFFICE POSTAL CODE
MAILING ADDRESS OF THE COMPANY&#x2019;S RECORDS OFFICE POSTAL CODE
E RECORDS OFFICE ADDRESSES
F AUTHORIZED SHARE STRUCTURE
NOA Page 2
PROVINCE
BC
PROVINCE
BC
PROVINCE
BC
PROVINCE
BC
FORM 16 FOR (JAN 2020)
 Suite 1700, Park Place, 666 Burrard Street, Vancouver V6C 2X8
 Suite 1700, Park Place, 666 Burrard Street, Vancouver V6C 2X8
 Suite 1700, Park Place, 666 Burrard Street, Vancouver V6C 2X8
 Suite 1700, Park Place, 666 Burrard Street, Vancouver V6C 2X8
Common X X &#x2714;</font></p></td></tr></table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 94 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><IMG SRC="tm2533062d1_424b3img03.jpg" ALT=""><p align="center" style="margin:0in 0in .0001pt;text-align:center;"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">Schedule
Director(s)
Patricia S. Andrews [Redacted - Personal Information]
Deborah M. Brown [Redacted - Personal Information]
Angela Frances Holtham [Redacted - Personal Information]
Jared Kelly [Redacted - Personal Information]
James T. Parsons [Redacted - Personal Information]
Wayne Pisano [Redacted - Personal Information]
Jonathan Rigby [Redacted - Personal Information]
Bernd Seizinger [Redacted - Personal Information]</font></p></td></tr></table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 95 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><IMG SRC="tm2533062d1_424b3img02.jpg" ALT=""><p align="center" style="margin:0in 0in .0001pt;text-align:center;"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">FIRST NAME
DIRECTOR NAME
If you do not have a Business Number please enter the name of a director of your corporation (as per CRA
requirements) so that we can request one for you. The director&#x2019;s name is confidential information and is collected under
the authority of the Business Number Act.
'03.  #/"  	"6(

INSTRUCTIONS:
Please type or print clearly in block letters.
The Province of British Columbia has entered into a
partnership with the Canada Revenue Agency (CRA)
to use the national Business Number (BN) as a
convenient way for corporations to identify themselves
when communicating with federal and provincial
governments.
The Corporate Registry, under the authority of the
Business Number Act, is therefore collecting the BN
from both corporations applying for registration in
British Columbia and corporations currently registered
in British Columbia. This will allow corporations to use
their BN as an identifier the next time they communicate
with the Corporate Registry.
You will already have a BN if you have been incorporated
federally or if you are incorporated in another Canadian
jurisdiction.
You may have also received a BN from CRA if you:
s COLLECT&#x200B;'34(34
s HAVE&#x200B;EMPLOYEES
s IMPORT&#x200B;OR&#x200B;EXPORT&#x200B;GOODS&#x200B;TO&#x200B;OR&#x200B;FROM&#x200B;#ANADA
s OPERATE&#x200B;A&#x200B;TAXI&#x200B;OR&#x200B;LIMO&#x200B;SERVICE
s ARE&#x200B;REGISTERED&#x200B;WITH&#x200B;7ORK3AFE"#&#x200B;ANDOR
s ARE&#x200B;REGISTERED&#x200B;TO&#x200B;DO&#x200B;BUSINESS&#x200B;IN&#x200B;ANOTHER&#x200B;#ANADIAN
jurisdiction
A BUSINESS NUMBER
Your Business Number&#x200B;EG&#x200B;'34(34&#x200B;ACCOUNT	&#x200B;WOULD&#x200B;BE&#x200B;DISPLAYED&#x200B;AS&#x200B;A&#x200B;&#x200B;CHARACTER&#x200B;IDENTIlER&#x200B;FOR&#x200B;EXAMPLE&#x200B;
82123 5679 RT 0001. The first nine numbers uniquely identify your business &#x2013; it&#x2019;s those numbers we need.
Please enter the first 9 digits here:
COMPLETE ITEM A OR B
LAST NAME
B
Freedom of Information and Protection of Privacy Act (FOIPPA):
Personal information provided on this form is collected, used and
disclosed under the authority of the FOIPPA and the Business Number
Act for the purposes of assessment. Questions regarding the collection,
use and disclosure of personal information can be directed to the
.BOBHFSPG3FHJTUSJFT0QFSBUJPOT at 1 877 526-1526, 0/&#x200B;"OX&#x200B;&#x200B;3TN&#x200B;
0ROV&#x200B;'OVT&#x200B;6ICTORIA&#x200B;"#&#x200B;&#x200B;67&#x200B;6
Telephone: 1 877 526-1526 Mailing Address: PO Box 9431 Stn Prov Govt $ourier Address: 200 &#x2013; 940 Blanshard Street
www.bcreg.ca Victoria BC V8W 9V3 Victoria BC V8W 3E6
$75+0'55-07/$'4-4'37'56
%86,1(66&#x200B;180%(56&#x200B;$&amp;7, section
896115029</font></p></td></tr></table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 96 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B><A NAME="pros4_015"></A>ANNEX
C &mdash; SPECIAL SHAREHOLDERS RESOLUTION APPROVING THE DOMESTICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>RESOLVED
AS A SPECIAL RESOLUTION THAT:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">1.</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">subject
                                            to and conditional upon Oncolytics Biotech Inc. (&ldquo;<B>Oncolytics</B>&rdquo;) having
                                            been previously continued from the laws of the Province of Alberta under the <I>Business
                                            Corporations Act</I> (Alberta) to the laws of the Province of British Columbia under the
                                            <I>Business Corporations Act</I> (British Columbia) (the &ldquo;<B>BCBCA</B>&rdquo;) (such
                                            continuance, the &ldquo;<B>BCBCA Continuance</B>&rdquo;), the continuation of Oncolytics
                                            out of the Province of British Columbia under the BCBCA to the laws of the State of Nevada
                                            under the <I>Nevada Revised Statutes</I> (the &ldquo;<B>NRS</B>&rdquo;) is hereby authorized,
                                            approved and passed, and Oncolytics is hereby authorized to apply to the Registrar of Companies
                                            (British Columbia) for authorization to permit Oncolytics to continue as a Nevada corporation
                                            under the NRS;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">2.</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">subject
                                            to and conditional upon the BCBCA Continuance, the domestication of Oncolytics from the Province
                                            of British Columbia under the BCBCA to the laws of the State of Nevada under the NRS and
                                            the Oncolytics Nevada Charter are hereby authorized, approved and passed, and Oncolytics
                                            is hereby authorized to file with the Nevada Secretary of State the articles
                                            of domestication (the &ldquo;<B>Articles of Domestication</B>&rdquo;) and the articles of
                                            incorporation (the &ldquo;<B>Oncolytics Nevada Charter</B>&rdquo;) pursuant to, and in accordance
                                            with the NRS as if it had been incorporated thereunder (the &ldquo;<B>Domestication</B>&rdquo;)
                                            and the form, terms and provisions each of the Articles of Domestication and Oncolytics Nevada
                                            Charter are hereby authorized, approved and passed;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">3.</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">prior
                                            to or on the effective date of the Domestication, Oncolytics shall file the Articles of Domestication
                                            and Oncolytics Nevada Charter, the full text of which is attached as Annexes <B>D </B>and
                                            <B>E</B> to the Circular/Prospectus, respectively, with the Nevada Secretary of State and
                                            the bylaws, the full text of which is attached as Annex <B>H</B>, will become effective upon
                                            the effective time of the Domestication and each of the Articles of Domestication, the Oncolytics
                                            Nevada Charter and the bylaws is hereby approved in all respects and shall be in substitution
                                            for, and replace the notice of articles and the articles of Oncolytics as the organizational
                                            documents of Oncolytics Nevada;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">4.</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">following
                                            the Domestication, Oncolytics Nevada is authorized to file with the Registrar of Companies
                                            (British Columbia) a copy of any record issued by the Nevada Secretary of State to effect
                                            or confirm the Domestication;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">5.</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify">for United States federal income tax purposes, the BCBCA Continuance and the Domestication, together, are intended to constitute a &ldquo;reorganization&rdquo;
within the meaning of Section 368(a)(1)(F) of the Internal Revenue Code of 1986, as amended, and this special resolution is intended to
constitute a &ldquo;plan of reorganization&rdquo; within the meaning of Sections 1.368-2(g) and 1.368-3 of the United States Treasury
Regulations;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">6.</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">notwithstanding
                                            that this special resolution has been duly passed (and the Domestication and the Oncolytics
                                            Nevada Charter approved) by the shareholders of Oncolytics, the directors of Oncolytics are
                                            hereby authorized and empowered without further notice to or approval of the shareholders
                                            of Oncolytics (i)&nbsp;not to act upon this special resolution and (ii)&nbsp;to revoke or
                                            abandon this special resolution, in their sole discretion at any time prior to the filing
                                            of the Articles of Domestication and Oncolytics Nevada Charter with the Nevada Secretary of State; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">7.</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">any
                                            director or officer of Oncolytics is authorized and directed, for and on behalf of Oncolytics,
                                            to execute and deliver, or cause to be executed and delivered, all such documents and instruments,
                                            and to do or cause to be done all such other acts and things as in the opinion of such director
                                            or officer may be necessary or desirable for the purpose of giving effect to these resolutions.&rdquo;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 97; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B><A NAME="pros4_016"></A>ANNEX
D &mdash; FORM&nbsp;OF ARTICLES OF DOMESTICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">ARTICLES OF DOMESTICATION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">(PURSUANT TO NRS
92A.270)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B></FONT></TD>
    <TD STYLE="font-size: 10pt; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Domestic
    Entity Information:</B></FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Name
                                            of Domestic Entity as set forth in its Charter Documents:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Oncolytics Biotech Inc.</B></FONT></P></TD></TR>
  <TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Type
    of Domestic Entity as set forth in its Charter Documents: <B>Corporation</B></FONT></TD></TR>
  <TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="font-size: 10pt; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Prior
    Name:</B></FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Entity
                                            Name Before Filing Articles of Domestication:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Oncolytics Biotech Inc.</B></FONT></P></TD></TR>
  <TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD>
    <TD STYLE="font-size: 10pt; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Original
    Filing Date and jurisdiction:</B></FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Original
                                            Jurisdiction of Formation: <B>Alberta, Canada</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Original File Date: April&nbsp;2,
    1998</FONT></P></TD></TR>
  <TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.</B></FONT></TD>
    <TD STYLE="font-size: 10pt; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jurisdiction:</B></FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="text-align: justify; font-size: 10pt; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jurisdiction
    that constituted the principal place of business or central administration of the undomesticated organization, or any other equivalent
    thereto pursuant to applicable law, immediately before filing the articles of domestication. </FONT></TD></TR>
  <TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>British
    Columbia</B></FONT></TD></TR>
  <TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.</B></FONT></TD>
    <TD STYLE="font-size: 10pt; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; width: 18%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Signature:</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">(Required)</FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-top: 6pt; padding-bottom: 6pt; width: 2%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; width: 70%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>X</B><U>&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;</U></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&emsp;<B>Signature</B></FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-top: 6pt; padding-bottom: 6pt; width: 2%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; width: 6%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&emsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Date</FONT></P></TD></TR>
  <TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 6pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 6pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 98; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B><A NAME="pros4_017"></A>ANNEX
E &mdash; FORM&nbsp;OF NEVADA ARTICLES OF INCORPORATION<SUP></SUP></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLES OF INCORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ONCOLYTICS
BIOTECH INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B><U>ARTICLE&nbsp;I</U></B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
name</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The name of the Corporation
is Oncolytics Biotech Inc. (the &ldquo;<U>Corporation</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B><U>ARTICLE&nbsp;II</U></B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
registered office and registered agent</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The registered office of the
Corporation shall be the street address of its registered agent in the State of Nevada. The Corporation may, from time to time, in the
manner provided by law, change the registered agent and registered office within the State of Nevada. The Corporation may also maintain
an office or offices for the conduct of its business, either within or without the State of Nevada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B><U>ARTICLE&nbsp;III</U></B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
PURPOSE</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The purpose of the Corporation
is to engage in any lawful act or activity for which corporations may now or hereafter be organized under Nevada Revised Statutes (as
amended from time to time and including any successor provisions, the &ldquo;<U>NRS</U>&rdquo;) Chapter 78.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B><U>ARTICLE&nbsp;IV</U></B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
CAPITAL STOCK</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;4.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Capitalization</U>.
The total number of shares of all classes of stock that the Corporation is authorized to issue is 1,100,000,000 shares, divided
into two classes as follows: (i) 1,000,000,000 shares of common stock, $0.001 par value per share (&ldquo;<U>Common
Stock</U>&rdquo;) and (ii) 100,000,000 shares of preferred stock, $0.001 par value per share (&ldquo;<U>Preferred
Stock</U>&rdquo;). The number of authorized shares of any of the Common Stock or Preferred Stock may be increased or decreased (but
not below the number of shares thereof then outstanding) by the affirmative vote of the stockholders of the Corporation entitled to
vote thereon, and no vote of the holders of any class or series of Common Stock or Preferred Stock, voting separately as a class,
shall be required therefor (and any such right otherwise provided under NRS 78.2055(3), NRS 78.207(3)&nbsp;or NRS 78.390 is hereby
specifically denied), unless a vote of any such holders is expressly required pursuant to these Articles of Incorporation (as the
same may be amended and/or restated from time to time, and including any Certificate(s)&nbsp;of Designation (as defined below)
relating to any series of Preferred Stock, these &ldquo;<U>Articles</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;4.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Preferred
Stock</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(A)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Designation
of Series&nbsp;of Preferred Stock</U>. The Board of Directors of the Corporation (the &ldquo;<U>Board</U>&rdquo;) is hereby expressly
authorized, by resolution or resolutions, at any time and from time to time, to provide, out of the authorized but undesignated and unissued
shares of Preferred Stock, for one or more series of Preferred Stock and, with respect to each such series, to fix the number of shares
constituting such series and the designation of such series, the voting powers (if any) of the shares of such series, and the powers,
preferences and relative, participating, optional or other rights, if any, and any qualifications, limitations or restrictions thereof,
of the shares of such series and to cause to be filed with the Nevada Secretary of State a certificate of designation with respect thereto
(each, a &ldquo;<U>Certificate of Designation</U>&rdquo;). The powers, preferences and relative, participating, optional and other rights
of each series of Preferred Stock, and the qualifications, limitations or restrictions thereof, if any, may differ from those of any
and all other series at any time outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 99; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(B)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;</FONT><U>Voting Rights of Preferred Stock</U>. Except as otherwise required by law, holders of a series
of Preferred Stock, as such, shall be entitled only to such voting rights, if any, as shall expressly be granted thereto by these
Articles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;4.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Voting
Rights of Common Stock</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(A)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Common
Stock</U>. Each holder of record of Common Stock, as such, shall be entitled to one vote for each share of Common Stock held of record
by such holder on all matters on which stockholders generally or holders of Common Stock as a separate class or series are entitled to
vote (whether voting separately as a class or series, or together with any other class(es) or series of the Corporation&rsquo;s capital
stock); <U>provided</U> that to the fullest extent permitted by law, holders of Common Stock, as such, shall have no voting power with
respect to, and shall not be entitled to vote on, any amendment to these Articles that relates solely to the terms, number of shares,
powers, designations, preferences or relative, participating, optional or other special rights (including, without limitation, voting
rights), or to qualifications, limitations or restrictions thereof, of one or more outstanding series of Preferred Stock if the holders
of such affected series are entitled, either separately or together with the holders of one or more other such series, to vote thereon
pursuant to these Articles or pursuant to the NRS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(B)&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No Cumulative Voting</U>. No holder of shares of Common Stock shall have the right to
cumulate votes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;4.4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Dividends
and Other Distributions</U>. Subject to the rights, if any, of the holders of any outstanding series of Preferred Stock or any class or
series of stock having a preference over or the right to participate with the Common Stock with respect to the payment of dividends and
other distributions in cash, property or shares of capital stock of the Corporation and except as otherwise provided by these Articles
or the NRS, dividends and other distributions may be declared and paid ratably on the Common Stock out of the funds of the Corporation
that are legally available for this purpose at such times and in such amounts as the Board in its discretion shall determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;4.5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Special
Provision re Distributions</U>. Notwithstanding anything to the contrary in these Articles or the Bylaws (as defined below), the Corporation
is hereby specifically allowed to make any distribution that otherwise would be prohibited by NRS 78.288(2)(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;4.6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Liquidation,
Dissolution or Winding Up</U>. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the
Corporation, after payment or provision for payment of the debts and other liabilities of the Corporation and subject to the right, if
any, of the holders of any outstanding series of Preferred Stock or any class or series of stock having a preference over or the right
to participate with the Common Stock as to distributions upon dissolution or liquidation or winding up of the Corporation, the holders
of all outstanding shares of Common Stock shall be entitled to receive the remaining assets of the Corporation available for distribution
to its stockholders ratably in proportion to the number of shares held by each such stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B><U>ARTICLE&nbsp;V</U></B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
AMENDMENTS TO bylaws</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In furtherance and not
in limitation of the powers conferred by the NRS, the Board is expressly authorized to make, alter, amend, change, add to, rescind
or repeal, in whole or in part, the bylaws of the Corporation (as the same may be amended and/or restated from time to time, the
 &ldquo;<U>Bylaws</U>&rdquo;) without the assent or vote of the stockholders in any manner not inconsistent with the laws of the
State of Nevada or these Articles. In addition, the Bylaws may be amended or repealed in any respect, and new bylaws may be adopted,
in each case by the affirmative vote of the holders of at least two-thirds (66-2/3%) of the outstanding voting power of the
Corporation, voting together as a single class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B><U>ARTICLE&nbsp;VI</U></B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
board of directors</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;6.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Number
of Directors</U>. Except as otherwise provided in these Articles or the NRS, the business and affairs of the Corporation shall be
managed by or under the direction of the Board. The total number of directors constituting the Board shall be determined from time
to time exclusively by resolution adopted by the Board in the manner set forth in the Bylaws, except as otherwise provided for or fixed pursuant to the provisions of any
Certificate of Designation and this <U>Article&nbsp;VI</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;6.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Vacancies</U>.
Subject to any rights granted to the holders of any one or more series of Preferred Stock then outstanding, any newly created
directorship on the Board that results from an increase in the authorized number of directors and any vacancy occurring on the Board
(whether resulting from death, resignation, retirement, disqualification, removal, change in the total authorized number of
directors constituting the Board, or other cause) shall be filled only by the affirmative vote of a majority of the directors then
in office (other than directors elected by the holders of any series of Preferred Stock voting separately as a series or together
with one or more series, as the case may be) or by a sole remaining director, in either case even if less than a quorum. Any
director so elected to fill a vacancy or newly created directorship shall hold office for a term expiring at the next annual meeting
of stockholders and when his or her successor shall be elected or appointed and qualified, or until his or her earlier death,
resignation, retirement, disqualification or removal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;6.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Removal</U>.
Any or all of the directors (other than the directors elected by the holders of any series of Preferred Stock voting separately as a
series or together with one or more other such series, as the case may be) may be removed at any time either with or without cause
by the affirmative vote of at least the minimum percentage of the voting power of all outstanding shares of stock of the Corporation
entitled to vote thereon, voting together as a single class, then permitted under the NRS for such vote (which at the effective time
of these Articles is two-thirds (66-2/3%) of the voting power and in any event shall not be less than a simple majority
thereof).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;6.4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Rights
of Holders of Preferred Stock</U>. Whenever the holders of any one or more series of Preferred Stock issued by the Corporation shall have
the right, voting separately as a series or separately as a class with one or more such other series, to elect directors at an annual
or special meeting of stockholders, the election, term of office, removal and other features of such directorships shall be governed by
the terms of these Articles applicable thereto. Notwithstanding <U>Section&nbsp;6.1</U>, the number of directors that may be elected by
the holders of any such series of Preferred Stock shall be in addition to the number fixed pursuant to <U>Section&nbsp;6.1</U>, and the
total number of directors constituting the Board shall be automatically adjusted accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;6.5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Election
and Term</U>. Except as otherwise provided in these Articles or the Bylaws, directors of the Corporation shall be elected at each annual
meeting of the stockholders and shall serve until the next annual meeting of the stockholders and when their successors are duly elected
or appointed and qualified, or until their earlier death, resignation, retirement, disqualification or removal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B><U>ARTICLE&nbsp;VII</U></B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
CALL of SPECIAL MEETINGS OF STOCKHOLDERS</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the rights of the
holders of any series of Preferred Stock, special meetings of the stockholders of the Corporation may be called only by or at the direction
of the Board, the Chair of the Board or the Chief Executive Officer of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B><U>ARTICLE&nbsp;VIII</U></B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
LIMITATION OF LIABILITY of Directors and officers</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The liability of directors
and officers of the Corporation is hereby eliminated or limited to the fullest extent permitted by the NRS. Without limiting the effect
of the preceding sentence, if the NRS is amended to further eliminate or limit or authorize corporate action to further eliminate or limit
the liability of directors or officers, the liability of directors and officers of the Corporation shall be eliminated or limited to the
fullest extent permitted by the NRS, as so amended. Neither any amendment nor repeal of this <U>Article&nbsp;VIII</U>, nor the adoption
of any provision of these Articles inconsistent with this <U>Article&nbsp;VIII</U>, shall eliminate, reduce or otherwise adversely affect
any limitation on the personal liability of a director or officer of the Corporation existing at the time of such amendment, repeal or
adoption of such an inconsistent provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B><U>ARTICLE&nbsp;IX</U></B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
iNAPPLICABILITY OF COMBINATIONS WITH INTERESTED STOCKHOLDERS STATUTES</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Corporation hereby expressly elects not to be governed by the provisions of NRS 78.411 to 78.444, inclusive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B><U>ARTICLE&nbsp;X</U></B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
LIMITED WAIVER OF JURY TRIALS</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the fullest extent not
inconsistent with any applicable U.S. federal laws, any and all &ldquo;internal actions&rdquo; (as defined in NRS 78.046) must be tried
in a court of competent jurisdiction in the State of Nevada before the presiding judge as the trier of fact and not before a jury. This
<U>Article&nbsp;X</U> shall conclusively operate as a waiver of the right to trial by jury by each party to any such internal action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B><U>ARTICLE&nbsp;XI</U></B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
DEEMED NOTICE AND CONSENT; SEVERABILITY</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;11.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Severability</U>.
If any provision or provisions of these Articles shall be held to be invalid, illegal or unenforceable as applied to any circumstance
for any reason whatsoever: (i)&nbsp;the validity, legality and enforceability of such provisions in any other circumstance and of the
remaining provisions of these Articles (including, without limitation, each portion of any paragraph of these Articles containing any
such provision held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) shall not,
to the fullest extent permitted by applicable law, in any way be affected or impaired thereby and (ii)&nbsp;to the fullest extent permitted
by applicable law, the provisions of these Articles (including, without limitation, each such portion of any paragraph of these Articles
containing any such provision held to be invalid, illegal or unenforceable) shall be construed so as to permit the Corporation to protect
its directors, officers, employees and agents from individual liability to the fullest extent permitted under Nevada law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;11.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Deemed
Notice and Consent</U>. To the fullest extent permitted by law, each and every natural person, corporation, general or limited partnership,
limited liability company, joint venture, trust, association or any other entity purchasing or otherwise acquiring any interest (of any
nature whatsoever) in any shares of the capital stock of the Corporation shall be deemed, by reason of and from and after the time of
such purchase or other acquisition, to have notice of and to have consented to all of the provisions of (a)&nbsp;these Articles, (b)&nbsp;the
Bylaws and (c)&nbsp;any amendment to these Articles or the Bylaws enacted or adopted in accordance with these Articles, the Bylaws and
applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">*&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>*<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>*<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>*</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B><A NAME="pros4_018"></A>ANNEX
F &mdash; ONCOLYTICS BIOTECH INC. 2026 PLAN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">See attached.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 104; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin: 0">&nbsp;</P>


<DIV STYLE="padding: 6pt; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ONCOLYTICS BIOTECH INC.<FONT><BR>
2026 Incentive Award Plan</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ARTICLE&nbsp;I.<BR>
Purpose</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Plan&rsquo;s purpose is
to enhance the Company&rsquo;s ability to attract, retain and motivate persons who make (or are expected to make) important contributions
to the Company by providing these individuals with equity ownership opportunities and/or equity-linked compensatory opportunities. Capitalized
terms used in the Plan are defined in Article&nbsp;XI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ARTICLE&nbsp;II.<BR>
Eligibility</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Service Providers are eligible
to be granted Awards under the Plan, subject to the limitations described herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ARTICLE&nbsp;III.<BR>
Administration and Delegation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Administration</U>.
The Plan is administered by the Administrator. The Administrator has authority to determine which Service Providers receive Awards, grant
Awards and set Award terms and conditions, subject to the conditions and limitations in the Plan. The Administrator also has the authority
to take all actions and make all determinations under the Plan, to interpret the Plan and Award Agreements and to adopt, amend and repeal
Plan administrative rules, guidelines and practices as it deems advisable. The Administrator may correct defects and ambiguities, supply
omissions and reconcile inconsistencies in the Plan or any Award Agreement as it deems necessary or appropriate to administer the Plan
and any Awards. The Administrator&rsquo;s determinations under the Plan are in its sole discretion and will be final and binding on all
persons having or claiming any interest in the Plan or any Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Appointment
of Committees</U>. To the extent Applicable Laws permit, the Board may delegate any or all of its powers under the Plan to one or more
Committees or officers of the Company or any of its Subsidiaries; provided, however, that in no event shall an officer of the Company
or any of its Subsidiaries be delegated the authority to grant Awards to, or amend Awards held by, the following individuals: (i)&nbsp;individuals
who are subject to Section&nbsp;16 of the Exchange Act, or (ii)&nbsp;officers of the Company or any of its Subsidiaries or Directors to
whom authority to grant or amend Awards has been delegated hereunder. The Board may abolish any Committee or re-vest in itself any previously
delegated authority at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ARTICLE&nbsp;IV.<BR>
Stock Available for Awards</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Number
of Shares</U>. Subject to adjustment under Article&nbsp;VIII and the terms of this Article&nbsp;IV, Awards may be made under the Plan
covering up to the Overall Share Limit. As of the Plan&rsquo;s effective date under Section&nbsp;10.3, the Company ceased granting awards
under the Prior Plans; however, Prior Plan Awards remain subject to the terms of the applicable Prior Plan. Shares issued under the Plan
may consist of authorized but unissued Shares, Shares purchased on the open market or treasury Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Share
Recycling</U>. If all or any part of an Award or Prior Plan Award expires, lapses or is terminated, exchanged for or settled in cash,
surrendered, repurchased, canceled without having been fully exercised/settled or forfeited, in any case, in a manner that results in
the Company acquiring Shares covered by the Award or Prior Plan Award at a price not greater than the price (as adjusted to reflect any
Equity Restructuring) paid by the Participant for such Shares or not issuing any Shares covered by the Award or Prior Plan Award, the
unused Shares covered by the Award or Prior Plan Award will, as applicable, become or again be available for Award grants under the Plan.
Further, Shares delivered (either by actual delivery or attestation) to the Company by a Participant to satisfy the applicable exercise
or purchase price of an Award or Prior Plan Award and/or to satisfy any applicable tax withholding obligation (including Shares retained
by the Company from the Award or Prior Plan Award being exercised or purchased and/or creating the tax obligation) will, as applicable,
become or again be available for Award grants under the Plan. The payment of Dividend Equivalents in cash in conjunction with any outstanding
Awards or Prior Plan Awards shall not count against the Overall Share Limit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Incentive
Stock Option Limitations</U>. Notwithstanding anything to the contrary herein, no more than 83,423,715 Shares may be issued pursuant to
the exercise of Incentive Stock Options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Substitute
Awards</U>. In connection with an entity&rsquo;s merger or consolidation with the Company or the Company&rsquo;s acquisition of an entity&rsquo;s
property or stock, the Administrator may grant Awards in substitution for any options or other stock or stock-based awards granted before
such merger or consolidation by such entity or its affiliate. Substitute Awards may be granted on such terms as the Administrator deems
appropriate, notwithstanding limitations on Awards in the Plan. Substitute Awards will not count against the Overall Share Limit (nor
shall Shares subject to a Substitute Award be added to the Shares available for Awards under the Plan as provided above), except that
Shares acquired by exercise of substitute Incentive Stock Options will count against the maximum number of Shares that may be issued
pursuant to the exercise of Incentive Stock Options under the Plan. Additionally, in the event that a company acquired by the Company
or any Subsidiary or with which the Company or any Subsidiary combines has shares available under a pre-existing plan approved by stockholders
and not adopted in contemplation of such acquisition or combination, the shares available for grant pursuant to the terms of such pre-existing
plan (as adjusted, to the extent appropriate, using the exchange ratio or other adjustment or valuation ratio or formula used in such
acquisition or combination to determine the consideration payable to the holders of common stock of the entities party to such acquisition
or combination) may be used for Awards under the Plan and shall not reduce the Shares authorized for grant under the Plan (and Shares
subject to such Awards shall not be added to the Shares available for Awards under the Plan as provided above); provided that Awards
using such available shares shall not be made after the date awards or grants could have been made under the terms of the pre-existing
plan, absent the acquisition or combination, and shall only be made to individuals who were not Service Providers prior to such acquisition
or combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Non-Employee
Director Compensation</U>. Notwithstanding any provision to the contrary in the Plan, the Administrator may establish compensation for
non-employee Directors from time to time, subject to the limitations in the Plan. The Administrator will from time to time determine the
terms, conditions and amounts of all such non-employee Director compensation in its discretion and pursuant to the exercise of its business
judgment, taking into account such factors, circumstances and considerations as it shall deem relevant from time to time; provided that,
the sum of any cash compensation, or other compensation, and the value (determined as of the grant date in accordance with Financial Accounting
Standards Board Accounting Standards Codification Topic 718, or any successor thereto) of Awards granted to a non-employee Director as
compensation for services as a non-employee Director during any fiscal year of the Company may not exceed $750,000, increased to $1,000,000
in the fiscal year in which the Plan&rsquo;s effective date occurs or in the fiscal year of a non-employee Director&rsquo;s initial year
of service as a non-employee Director (in each case, excluding any compensation awarded prior to the Plan&rsquo;s effective date). Consulting
fees or other compensation the Company or any of its Subsidiaries may pay or provide to any non-employee director for services in addition
to the services normally performed by a non-employee director shall not be included in calculating compliance with such limits. The Administrator
may make exceptions to these limits for individual non-employee Directors in extraordinary circumstances, as the Administrator may determine
in its discretion, provided that the non-employee Director receiving such additional compensation may not participate in the decision
to award such compensation or in other contemporaneous compensation decisions involving non-employee Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ARTICLE&nbsp;V.<BR>
Stock Options and Stock Appreciation Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>General</U>.
The Administrator may grant Options or Stock Appreciation Rights to Service Providers subject to the limitations in the Plan, including
any limitations in the Plan that apply to Incentive Stock Options. The Administrator will determine the number of Shares covered by each
Option and Stock Appreciation Right, the exercise price of each Option and Stock Appreciation Right and the conditions and limitations
applicable to the exercise of each Option and Stock Appreciation Right. A Stock Appreciation Right will entitle the Participant (or other
person entitled to exercise the Stock Appreciation Right) to receive from the Company upon exercise of the exercisable portion of the
Stock Appreciation Right an amount determined by multiplying the excess, if any, of the Fair Market Value of one Share on the date of
exercise over the exercise price per Share of the Stock Appreciation Right by the number of Shares with respect to which the Stock Appreciation
Right is exercised, subject to any limitations of the Plan or that the Administrator may impose and payable in cash, Shares valued at
Fair Market Value or a combination of the two as the Administrator may determine or provide in the Award Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Exercise
Price</U>. The Administrator will establish each Option&rsquo;s and Stock Appreciation Right&rsquo;s exercise price and specify the exercise
price in the Award Agreement. Unless otherwise determined by the Administrator, the exercise price will not be less than 100% of the Fair
Market Value on the grant date of the Option or Stock Appreciation Right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Duration</U>.
Each Option or Stock Appreciation Right will be exercisable at such times and as specified in the Award Agreement, provided that, unless
otherwise determined by the Administrator, the term of an Option or Stock Appreciation Right will not exceed ten years. Notwithstanding
the foregoing and unless determined otherwise by the Company, in the event that on the last business day of the term of an Option or Stock
Appreciation Right (other than an Incentive Stock Option) (i)&nbsp;the exercise of the Option or Stock Appreciation Right is prohibited
by Applicable Laws, as determined by the Company, or (ii)&nbsp;Shares may not be purchased or sold by the applicable Participant due to
any Company insider trading policy (including blackout periods) or a &ldquo;lock-up&rdquo; agreement undertaken in connection with an
issuance of securities by the Company, the term of the Option or Stock Appreciation Right shall be automatically extended until the date
that is thirty (30) days after the end of the legal prohibition, black-out period or lock-up agreement, as determined by the Company;
provided, however, in no event shall the extension last beyond the ten year term of the applicable Option or Stock Appreciation Right.
Notwithstanding the foregoing, if the Participant, prior to the end of the term of an Option or Stock Appreciation Right, violates the
non-competition, non-solicitation, confidentiality or other similar restrictive covenant provisions of any employment contract, confidentiality
and nondisclosure agreement or other agreement between the Participant and the Company or any of its Subsidiaries, the right of the Participant
and the Participant&rsquo;s transferees to exercise any Option or Stock Appreciation Right issued to the Participant shall terminate immediately
upon such violation, unless the Company otherwise determines. In addition, if, prior to the end of the term of an Option or Stock Appreciation
Right, the Participant is given notice by the Company or any of its Subsidiaries of the Participant&rsquo;s Termination of Service by
the Company or any of its Subsidiaries for Cause, and the effective date of such Termination of Service is subsequent to the date of the
delivery of such notice, the right of the Participant and the Participant&rsquo;s transferees to exercise any Option or Stock Appreciation
Right issued to the Participant shall be suspended from the time of the delivery of such notice until the earlier of (i)&nbsp;such time
as it is determined or otherwise agreed that the Participant&rsquo;s service as a Service Provider will not be terminated for Cause as
provided in such notice or (ii)&nbsp;the effective date of the Participant&rsquo;s Termination of Service by the Company or any of its
Subsidiaries for Cause (in which case the right of the Participant and the Participant&rsquo;s transferees to exercise any Option or Stock
Appreciation Right issued to the Participant will terminate immediately upon the effective date of such Termination of Service).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 107; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Exercise</U>.
Options and Stock Appreciation Rights may be exercised by delivering to the Company a written notice of exercise, in a form the Administrator
approves (which may be electronic), signed by the person authorized to exercise the Option or Stock Appreciation Right, together with,
as applicable, payment in full (i)&nbsp;as specified in Section&nbsp;5.5 for the number of Shares for which the Award is exercised and
(ii)&nbsp;as specified in Section&nbsp;9.5 for any applicable taxes. Unless the Administrator otherwise determines, an Option or Stock
Appreciation Right may not be exercised for a fraction of a Share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Payment
Upon Exercise</U>. Subject to Section&nbsp;10.8, any Company insider trading policy (including blackout periods) and Applicable Laws,
the exercise price of an Option must be paid by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;cash,
wire transfer of immediately available funds or by check payable to the order of the Company, provided that the Company may limit the
use of the foregoing payment forms if one or more of the payment forms below is permitted;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;if
there is a public market for Shares at the time of exercise, unless the Company otherwise determines, (i)&nbsp;delivery (including electronically
or telephonically to the extent permitted by the Company) of an irrevocable and unconditional undertaking by a broker acceptable to the
Company to deliver promptly to the Company sufficient funds to pay the exercise price, or (ii)&nbsp;the Participant&rsquo;s delivery to
the Company of a copy of irrevocable and unconditional instructions to a broker acceptable to the Company to deliver promptly to the Company
cash or a check sufficient to pay the exercise price; provided that such amount is paid to the Company at such time as may be required
by the Administrator;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
the extent permitted by the Administrator, delivery (either by actual delivery or attestation) of Shares owned by the Participant valued
at their fair market value;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
the extent permitted by the Administrator, surrendering Shares then issuable upon the Option&rsquo;s exercise valued at their fair market
value on the exercise date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
the extent permitted by the Administrator, delivery of a promissory note or any other property that the Administrator determines is good
and valuable consideration; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
the extent permitted by the Company, any combination of the above payment forms approved by the Administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ARTICLE&nbsp;VI.<BR>
Restricted Stock; Restricted Stock Units</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>General</U>.
The Administrator may grant Restricted Stock, or the right to purchase Restricted Stock, to any Service Provider, subject to the Company&rsquo;s
right to repurchase all or part of such Shares at their issue price or other stated or formula price from the Participant (or to require
forfeiture of such Shares) if conditions the Administrator specifies in the Award Agreement are not satisfied before the end of the applicable
restriction period or periods that the Administrator establishes for such Award. In addition, the Administrator may grant to Service Providers
Restricted Stock Units, which may be subject to vesting and forfeiture conditions during the applicable restriction period or periods,
as set forth in an Award Agreement. The Administrator will determine and set forth in the Award Agreement the terms and conditions for
each Restricted Stock and Restricted Stock Unit Award, subject to the conditions and limitations contained in the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 108; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Restricted
Stock</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Dividends</U>.
Participants holding shares of Restricted Stock will be entitled to all ordinary cash dividends paid with respect to such Shares, unless
the Administrator provides otherwise in the Award Agreement. In addition, unless the Administrator provides otherwise, if any dividends
or distributions are paid in Shares, or consist of a dividend or distribution to holders of Common Stock of property other than an ordinary
cash dividend, the Shares or other property will be subject to the same restrictions on transferability and forfeitability as the shares
of Restricted Stock with respect to which they were paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Stock
Certificates</U>. The Company may require that the Participant deposit in escrow with the Company (or its designee) any stock certificates
issued in respect of shares of Restricted Stock, together with a stock power endorsed in blank.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Restricted
Stock Units.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Settlement</U>.
The Administrator may provide that settlement of Restricted Stock Units will occur upon or as soon as reasonably practicable after the
Restricted Stock Units vest or will instead be deferred, on a mandatory basis or at the Participant&rsquo;s election, in a manner intended
to comply with Section&nbsp;409A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Stockholder
Rights</U>. A Participant will have no rights of a stockholder with respect to Shares subject to any Restricted Stock Unit unless and
until the Shares are delivered in settlement of the Restricted Stock Unit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Dividend
Equivalents</U>. If the Administrator provides, a grant of Restricted Stock Units may provide a Participant with the right to receive
Dividend Equivalents. Dividend Equivalents may be paid currently or credited to an account for the Participant, settled in cash or Shares
and subject to the same restrictions on transferability and forfeitability as the Restricted Stock Units with respect to which the Dividend
Equivalents are granted and subject to other terms and conditions as set forth in the Award Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ARTICLE&nbsp;VII.<BR>
Other Stock or Cash Based Awards</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other Stock or Cash Based
Awards may be granted to Participants, including Awards entitling Participants to receive Shares to be delivered in the future and including
annual or other periodic or long-term cash bonus awards (whether based on specified Performance Criteria or otherwise), in each case subject
to any conditions and limitations in the Plan. Such Other Stock or Cash Based Awards will also be available as a payment form in the settlement
of other Awards, as standalone payments and as payment in lieu of compensation to which a Participant is otherwise entitled. Other Stock
or Cash Based Awards may be paid in Shares, cash or other property, or any combination of the foregoing, as the Administrator determines.
Subject to the provisions of the Plan, the Administrator will determine the terms and conditions of each Other Stock or Cash Based Award,
including any purchase price, performance goal(s)&nbsp;(which may be based on the Performance Criteria), transfer restrictions, and vesting
conditions, which will be set forth in the applicable Award Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 109; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ARTICLE&nbsp;VIII.<BR>
Adjustments for Changes in Common Stock<BR>
and Certain Other Events</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Equity
Restructuring</U>. In connection with any Equity Restructuring, notwithstanding anything to the contrary
in this Article&nbsp;VIII, the Administrator will equitably adjust each outstanding Award as it deems appropriate to reflect the Equity
Restructuring, which may include adjusting the number and type of securities subject to each outstanding Award and/or the Award&rsquo;s
exercise price or grant price (if applicable), granting new Awards to Participants, and making a cash payment to Participants. The adjustments
provided under this Section&nbsp;8.1 will be nondiscretionary and final and binding on the affected Participant and the Company; provided
that the Administrator will determine whether an adjustment is equitable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Corporate
Transactions</U>. In the event of any dividend or other distribution (whether in the form of cash, Common Stock, other securities, or
other property), reorganization, merger, consolidation, combination, amalgamation, repurchase, recapitalization, liquidation, dissolution,
or sale, transfer, exchange or other disposition of all or substantially all of the assets of the Company, or sale or exchange of Common
Stock or other securities of the Company, Change in Control, issuance of warrants or other rights to purchase Common Stock or other securities
of the Company, other similar corporate transaction or event, other unusual or nonrecurring transaction or event affecting the Company
or its financial statements or any change in any Applicable Laws or accounting principles, the Administrator, on such terms and conditions
as it deems appropriate, either by the terms of the Award or by action taken prior to the occurrence of such transaction or event (except
that action to give effect to a change in Applicable Laws or accounting principles may be made within a reasonable period of time after
such change), is hereby authorized to take any one or more of the following actions whenever the Administrator determines that such action
is appropriate in order to (x)&nbsp;prevent dilution or enlargement of the benefits or potential benefits intended by the Company to be
made available under the Plan or with respect to any Award granted or issued under the Plan, (y)&nbsp;facilitate such transaction or event
or (z)&nbsp;give effect to such changes in Applicable Laws or accounting principles:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To
provide for the cancellation of any such Award in exchange for either an amount of cash or other property with a value equal to the amount
that could have been obtained upon the exercise or settlement of the vested portion of such Award or realization of the Participant&rsquo;s
rights under the vested portion of such Award, as applicable; provided that, if the amount that could have been obtained upon the exercise
or settlement of the vested portion of such Award or realization of the Participant&rsquo;s rights, in any case, is equal to or less than
zero, then the Award may be terminated without payment;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To
provide that such Award shall vest and, to the extent applicable, be exercisable as to all Shares covered thereby, notwithstanding anything
to the contrary in the Plan or the provisions of such Award;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To
provide that such Award be assumed by the successor or survivor corporation, or a parent or subsidiary thereof, or shall be substituted
for by awards covering the stock of the successor or survivor corporation, or a parent or subsidiary thereof, with appropriate adjustments
as to the number and kind of shares and/or applicable exercise or purchase price, in all cases, as determined by the Administrator;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 110; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To
make adjustments in the number and type of Shares (or other securities or property) subject to outstanding Awards and/or with respect
to which Awards may be granted under the Plan (including, but not limited to, adjustments of the limitations in Article&nbsp;IV hereof
on the maximum number and kind of shares which may be issued) and/or in the terms and conditions of (including the grant or exercise price
or applicable performance goals), and the criteria included in, outstanding Awards;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To
replace such Award with other rights or property selected by the Administrator; and/or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To
provide that the Award will terminate and cannot vest, be exercised or become payable after the applicable event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Non-Assumption
of Awards</U>. Notwithstanding Section&nbsp;8.2 above, if a Change in Control occurs and a Participant&rsquo;s Award(s)&nbsp;are not continued,
converted, assumed, or replaced with a substantially similar award by (a)&nbsp;the Company, or (b)&nbsp;a successor entity or its parent
or subsidiary (an &ldquo;<B><I>Assumption</I></B>&rdquo;), and provided that the Participant has not had a Termination of Service, then
immediately prior to the Change in Control, such Awards (other than any portion that is subject to performance-based vesting) shall become
fully vested, exercisable and/or payable, as applicable, and all forfeiture, repurchase and other restrictions thereon shall lapse, in
which case, such Awards shall be canceled upon the consummation of the Change in Control in exchange for the right to receive the Change
in Control consideration payable to other holders of Common Stock (i)&nbsp;which may be on such terms and conditions as apply generally
to holders of Common Stock under the Change in Control documents (including, without limitation, any earn-out or other deferred consideration
provisions) or such other terms and conditions as the Administrator may provide, and (ii)&nbsp;determined by reference to the number of
Shares subject to such Awards and net of any applicable exercise price; provided that (A)&nbsp;to the extent that any such Awards constitute
 &ldquo;nonqualified deferred compensation&rdquo; that may not be paid upon the Change in Control under Section&nbsp;409A without the imposition
of taxes thereon under Section&nbsp;409A, the timing of such payments shall be governed by the applicable Award Agreement (subject to
any deferred consideration provisions applicable under the Change in Control documents), (B)&nbsp;the portion of any Award subject to
performance-based vesting shall be governed by the terms and conditions of the applicable Award Agreement and, in the absence of applicable
terms and conditions, the Administrator&rsquo;s discretion, and (C)&nbsp;if the amount to which a Participant would be entitled upon the
settlement or exercise of an Award at the time of the Change in Control is equal to or less than zero, then such Award may be terminated
without payment. The Administrator shall determine whether an Assumption of an Award has occurred in connection with a Change in Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Administrative
Stand Still</U>. In the event of any pending stock dividend, stock split, combination or exchange of shares, merger, consolidation or
other distribution (other than normal cash dividends) of Company assets to stockholders, or any other extraordinary transaction or change
affecting the Shares or the share price of Common Stock, including any Equity Restructuring or any securities offering or other similar
transaction, for administrative convenience, the Administrator may refuse to permit the exercise of any Award for up to sixty days before
or after such transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>General</U>.
Except as expressly provided in the Plan or the Administrator&rsquo;s action under the Plan, no Participant will have any rights due to
any subdivision or consolidation of Shares of any class, dividend payment, increase or decrease in the number of Shares of any class or
dissolution, liquidation, merger, or consolidation of the Company or other corporation. Except as expressly provided with respect to an
Equity Restructuring under Section&nbsp;8.1 above or the Administrator&rsquo;s action under the Plan, no issuance by the Company of Shares
of any class, or securities convertible into Shares of any class, will affect, and no adjustment will be made regarding, the number of
Shares subject to an Award or the Award&rsquo;s grant or exercise price. The existence of the Plan, any Award Agreements and the Awards
granted hereunder will not affect or restrict in any way the Company&rsquo;s right or power to make or authorize (i)&nbsp;any adjustment,
recapitalization, reorganization or other change in the Company&rsquo;s capital structure or its business, (ii)&nbsp;any merger, consolidation
dissolution or liquidation of the Company or sale of Company assets or (iii)&nbsp;any sale or issuance of securities, including securities
with rights superior to those of the Shares or securities convertible into or exchangeable for Shares. The Administrator may treat Participants
and Awards (or portions thereof) differently under this Article&nbsp;VIII.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 111; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ARTICLE&nbsp;IX.<BR>
General Provisions Applicable to Awards</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Transferability</U>.
Except as the Administrator may determine or provide in an Award Agreement or otherwise for Awards other than Incentive Stock Options,
Awards may not be sold, assigned, transferred, pledged or otherwise encumbered, either voluntarily or by operation of law, except by will
or the laws of descent and distribution, or, subject to the Administrator&rsquo;s consent, pursuant to a domestic relations order, and,
during the life of the Participant, will be exercisable only by the Participant. References to a Participant, to the extent relevant in
the context, will include references to a Participant&rsquo;s authorized transferee that the Administrator specifically approves.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Documentation</U>.
Each Award will be evidenced in an Award Agreement, which may be written or electronic, as the Administrator determines. Each Award may
contain terms and conditions in addition to those set forth in the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Discretion</U>.
Except as the Plan otherwise provides, each Award may be made alone or in addition or in relation to any other Award. The terms of each
Award to a Participant need not be identical, and the Administrator need not treat Participants or Awards (or portions thereof) uniformly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Termination
of Status</U>. The Administrator will determine how a Participant&rsquo;s disability, death, retirement, authorized leave of absence or
any other change or purported change in a Participant&rsquo;s Service Provider status affects an Award (including whether and when a Termination
of Service has occurred and the effect of such change on any vesting restrictions) and the extent to which, and the period during which,
the Participant, the Participant&rsquo;s legal representative, conservator, guardian or Designated Beneficiary may exercise rights under
the Award, if applicable. The Administrator shall, in its sole discretion, determine whether a Service Provider&rsquo;s transfer of employment
from the Company to an Subsidiary or vice versa shall result in a termination of the Service Provider&rsquo;s status as a Service Provider.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Withholding</U>.
Each Participant must pay the Company or a Subsidiary, if applicable, or make provision satisfactory to the Administrator for payment
of, any taxes required by Applicable Laws to be withheld in connection with such Participant&rsquo;s Awards by the date of the event creating
the tax liability. The Company may deduct an amount sufficient to satisfy such tax obligations based on the applicable statutory withholding
rates (or such other rate as may be determined by the Company after considering any accounting consequences or costs) from any payment
of any kind otherwise due to a Participant. Subject to Section&nbsp;10.8 and any Company insider trading policy (including blackout periods),
Participants may satisfy such tax obligations (i)&nbsp;in cash, by wire transfer of immediately available funds, by check made payable
to the order of the Company, provided that the Company may limit the use of the foregoing payment forms if one or more of the payment
forms below is permitted, (ii)&nbsp;to the extent permitted by the Administrator, in whole or in part by delivery of Shares, including
Shares retained from the Award creating the tax obligation, in an amount necessary to cover such tax obligations, (iii)&nbsp;if there
is a public market for Shares at the time the tax obligations are due, unless the Company otherwise determines, (A)&nbsp;delivery (including
electronically or telephonically to the extent permitted by the Company) of an irrevocable and unconditional undertaking by a broker acceptable
to the Company to deliver promptly to the Company sufficient funds to satisfy the tax obligations, or (B)&nbsp;delivery by the Participant
to the Company of a copy of irrevocable and unconditional instructions to a broker acceptable to the Company to deliver promptly to the
Company cash or a check sufficient to satisfy the tax withholding; provided that such amount is paid to the Company at such time as may
be required by the Administrator, or (iv)&nbsp;to the extent permitted by the Administrator, any combination of the foregoing payment
forms approved by the Company. If any tax withholding obligation will be satisfied under clause (ii)&nbsp;of the immediately preceding
sentence by the Company&rsquo;s retention of Shares from the Award creating the tax obligation and there is a public market for Shares
at the time the tax obligation is satisfied, the Company may elect to instruct any brokerage firm determined acceptable to the Company
for such purpose to sell on the applicable Participant&rsquo;s behalf some or all of the Shares retained and to remit the proceeds of
the sale to the Company or its designee, and each Participant&rsquo;s acceptance of an Award under the Plan will constitute the Participant&rsquo;s
authorization to the Company and instruction and authorization to such brokerage firm to complete the transactions described in this sentence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 112; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Amendment
of Award; Repricing</U>. The Administrator may amend, modify or terminate any outstanding Award, including by substituting another Award
of the same or a different type, changing the exercise or settlement date, and converting an Incentive Stock Option to a Non-Qualified
Stock Option. The Participant&rsquo;s consent to such action will be required unless (i)&nbsp;the action, taking into account any related
action, does not materially and adversely affect the Participant&rsquo;s rights under the Award, or (ii)&nbsp;the change is permitted
under Article&nbsp;VIII or pursuant to Section&nbsp;10.6. Notwithstanding the foregoing, the Administrator may not, except pursuant to
Article&nbsp;VIII, without the approval of the stockholders of the Company, reduce the exercise price per share of outstanding Options
or Stock Appreciation Rights or cancel outstanding Options or Stock Appreciation Rights in exchange for cash, other Awards or Options
or Stock Appreciation Rights with an exercise price per share that is less than the exercise price per share of the original Options or
Stock Appreciation Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Conditions
on Delivery of Stock</U>. The Company will not be obligated to deliver any Shares under the Plan or remove restrictions from Shares previously
delivered under the Plan until (i)&nbsp;all Award conditions have been met or removed to the Company&rsquo;s satisfaction, (ii)&nbsp;as
determined by the Company, all other legal matters regarding the issuance and delivery of such Shares have been satisfied, including any
applicable securities laws and stock exchange or stock market rules&nbsp;and regulations, and (iii)&nbsp;the Participant has executed
and delivered to the Company such representations or agreements as the Administrator deems necessary or appropriate to satisfy any Applicable
Laws. The Company&rsquo;s inability to obtain authority from any regulatory body having jurisdiction, which the Administrator determines
is necessary to the lawful issuance and sale of any securities, will relieve the Company of any liability for failing to issue or sell
such Shares as to which such requisite authority has not been obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Acceleration</U>.
The Administrator may at any time provide that any Award will become immediately vested and fully or partially exercisable, free of some
or all restrictions or conditions, or otherwise fully or partially realizable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Additional
Terms of Incentive Stock Options</U>. The Administrator may grant Incentive Stock Options only to employees of the Company, any of its
present or future parent or subsidiary corporations, as defined in Sections&nbsp;424(e)&nbsp;or (f)&nbsp;of the Code, respectively, and
any other entities the employees of which are eligible to receive Incentive Stock Options under the Code. If an Incentive Stock Option
is granted to a Greater Than 10% Stockholder, the exercise price will not be less than 110% of the Fair Market Value on the Option&rsquo;s
grant date, and the term of the Option will not exceed five years. All Incentive Stock Options will be subject to and construed consistently
with Section&nbsp;422 of the Code. By accepting an Incentive Stock Option, the Participant agrees to give prompt notice to the Company
of dispositions or other transfers (other than in connection with a Change in Control) of Shares acquired under the Option made within
(i)&nbsp;two years from the grant date of the Option or (ii)&nbsp;one year after the transfer of such Shares to the Participant, specifying
the date of the disposition or other transfer and the amount the Participant realized, in cash, other property, assumption of indebtedness
or other consideration, in such disposition or other transfer. Neither the Company nor the Administrator will be liable to a Participant,
or any other party, if an Incentive Stock Option fails or ceases to qualify as an &ldquo;incentive stock option&rdquo; under Section&nbsp;422
of the Code. Any Incentive Stock Option or portion thereof that fails to qualify as an &ldquo;incentive stock option&rdquo; under Section&nbsp;422
of the Code for any reason, including becoming exercisable with respect to Shares having a fair market value exceeding the $100,000 limitation
under Treasury Regulation Section&nbsp;1.422-4, will be a Non-Qualified Stock Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 113; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ARTICLE&nbsp;X.<BR>
Miscellaneous</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Right to Employment or Other Status</U>. No person will have any claim or right to be granted an Award, and the grant of an Award will
not be construed as giving a Participant the right to continued employment or any other relationship with the Company. The Company expressly
reserves the right at any time to dismiss or otherwise terminate its relationship with a Participant free from any liability or claim
under the Plan or any Award, except as expressly provided in an Award Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Rights as Stockholder; Certificates</U>. Subject to the Award Agreement, no Participant or Designated Beneficiary will have any rights
as a stockholder with respect to any Shares to be distributed under an Award until becoming the record holder of such Shares. Notwithstanding
any other provision of the Plan, unless the Administrator otherwise determines or Applicable Laws require, the Company will not be required
to deliver to any Participant certificates evidencing Shares issued in connection with any Award and instead such Shares may be recorded
in the books of the Company (or, as applicable, its transfer agent or stock plan administrator). The Company may place legends on stock
certificates issued under the Plan that the Administrator deems necessary or appropriate to comply with Applicable Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Effective
Date and Term of Plan</U>. The Plan was adopted by the Board to be effective upon the effectiveness of the domestication of the Company
from the Province of British Columbia under the Business Corporations Act (British Columbia) to the laws of the State of Nevada under
the Nevada Revised Statutes (the &ldquo;<B><I>Domestication</I></B>&rdquo;), subject to approval of the Plan by the Company&rsquo;s stockholders.
Unless earlier terminated by the Board, the Plan will remain effective until the tenth anniversary of the earlier of (i)&nbsp;the date
the Board adopted the Plan or (ii)&nbsp;the date the Company&rsquo;s stockholders approved the Plan, but Awards previously granted may
extend beyond that date in accordance with the Plan. If the Plan is not approved by the Company&rsquo;s stockholders or the Board determines
in its sole discretion not to proceed with the Domestication, then the Plan will not become effective, no Awards will be granted under
the Plan, and the Prior Plans will continue in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Amendment
of Plan</U>. The Administrator may amend, suspend or terminate the Plan at any time; provided that no amendment, other than an increase
to the Overall Share Limit, may materially and adversely affect any Award outstanding at the time of such amendment without the affected
Participant&rsquo;s consent. No Awards may be granted under the Plan during any suspension period or after Plan termination. Awards outstanding
at the time of any Plan suspension or termination will continue to be governed by the Plan and the Award Agreement, as in effect before
such suspension or termination. The Board will obtain stockholder approval of any Plan amendment to the extent necessary to comply with
Applicable Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Provisions
for Foreign Participants</U>. The Administrator may modify Awards granted to Participants who are foreign nationals or employed outside
the United States or establish subplans or procedures under the Plan to address differences in laws, rules, regulations or customs of
such foreign jurisdictions with respect to tax, securities, currency, employee benefit or other matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 114; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Section&nbsp;409A</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>General</U>.
The Company intends that all Awards be structured to comply with, or be exempt from, Section&nbsp;409A, such that no adverse tax consequences,
interest, or penalties under Section&nbsp;409A apply. Notwithstanding anything in the Plan or any Award Agreement to the contrary, the
Administrator may, without a Participant&rsquo;s consent, amend this Plan or Awards, adopt policies and procedures, or take any other
actions (including amendments, policies, procedures and retroactive actions) as are necessary or appropriate to preserve the intended
tax treatment of Awards, including any such actions intended to (A)&nbsp;exempt this Plan or any Award from Section&nbsp;409A, or (B)&nbsp;comply
with Section&nbsp;409A, including regulations, guidance, compliance programs and other interpretative authority that may be issued after
an Award&rsquo;s grant date. The Company makes no representations or warranties as to an Award&rsquo;s tax treatment under Section&nbsp;409A
or otherwise. The Company will have no obligation under this Section&nbsp;10.6 or otherwise to avoid the taxes, penalties or interest
under Section&nbsp;409A with respect to any Award and will have no liability to any Participant or any other person if any Award, compensation
or other benefits under the Plan are determined to constitute noncompliant &ldquo;nonqualified deferred compensation&rdquo; subject to
taxes, penalties or interest under Section&nbsp;409A. Notwithstanding any contrary provision of the Plan or any Award Agreement, any payment
of &ldquo;nonqualified deferred compensation&rdquo; under the Plan that may be made in installments shall be treated as a right to receive
a series of separate and distinct payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Separation
from Service</U>. If an Award constitutes &ldquo;nonqualified deferred compensation&rdquo; under Section&nbsp;409A, any payment or settlement
of such Award upon a termination of a Participant&rsquo;s Service Provider relationship will, to the extent necessary to avoid taxes under
Section&nbsp;409A, be made only upon the Participant&rsquo;s &ldquo;separation from service&rdquo; (within the meaning of Section&nbsp;409A),
whether such &ldquo;separation from service&rdquo; occurs upon or after the termination of the Participant&rsquo;s Service Provider relationship.
For purposes of this Plan or any Award Agreement relating to any such payments or benefits, references to a &ldquo;termination,&rdquo;
 &ldquo;termination of employment&rdquo; or like terms means a &ldquo;separation from service.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Payments
to Specified Employees</U>. Notwithstanding any contrary provision in the Plan or any Award Agreement, any payment(s)&nbsp;of &ldquo;nonqualified
deferred compensation&rdquo; required to be made under an Award to a &ldquo;specified employee&rdquo; (as defined under Section&nbsp;409A
and as the Administrator determines) due to his or her &ldquo;separation from service&rdquo; will, to the extent necessary to avoid taxes
under Section&nbsp;409A(a)(2)(B)(i)&nbsp;of the Code, be delayed for the six-month period immediately following such &ldquo;separation
from service&rdquo; (or, if earlier, until the specified employee&rsquo;s death) and will instead be paid (as set forth in the Award Agreement)
on the day immediately following such six-month period or as soon as administratively practicable thereafter (without interest). Any payments
of &ldquo;nonqualified deferred compensation&rdquo; under such Award payable more than six months following the Participant&rsquo;s &ldquo;separation
from service&rdquo; will be paid at the time or times the payments are otherwise scheduled to be made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Limitations
on Liability</U>. Notwithstanding any other provisions of the Plan, no individual acting as a director, officer, other employee or agent
of the Company or any Subsidiary will be liable to any Participant, former Participant, spouse, beneficiary, or any other person for any
claim, loss, liability, or expense incurred in connection with the Plan or any Award, and such individual will not be personally liable
with respect to the Plan because of any contract or other instrument executed in his or her capacity as an Administrator, director, officer,
other employee or agent of the Company or any Subsidiary. To the extent allowable pursuant to Applicable Laws and the Company&rsquo;s
governing documents, the Company will indemnify and hold harmless each director, officer, other employee and agent of the Company or any
Subsidiary that has been or will be granted or delegated any duty or power relating to the Plan&rsquo;s administration or interpretation,
against any cost or expense (including attorneys&rsquo; fees) or liability (including any sum paid in settlement of a claim with the Administrator&rsquo;s
approval) arising from any act or omission concerning this Plan unless arising from such person&rsquo;s own fraud or bad faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 115; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Lock-Up
Period</U>. The Company may, at the request of any underwriter representative or otherwise, in connection with registering the offering
of any Company securities under the Securities Act, prohibit Participants from, directly or indirectly, selling or otherwise transferring
any Shares or other Company securities during a period of up to one hundred eighty days following the effective date of a Company registration
statement filed under the Securities Act, or such longer period as determined by the underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Data
Privacy</U>. By accepting an Award, the Participant acknowledges and agrees that the Company (acting as data controller) may hold certain
personal information about the Participant, including the Participant&rsquo;s name, address and telephone number; birthdate; social security
number, insurance number or other identification number; salary; nationality; job title(s); any Shares held in the Company or its Subsidiaries
and affiliates; and Award details (the &ldquo;<B><I>Data</I></B>&rdquo;) to implement, manage and administer the Plan and Awards in accordance
with this Plan and the Award Agreements and in the Company&rsquo;s legitimate interests to operate a successful business. The Company
may receive the Data from its Subsidiaries and affiliates or the Participant, and may share the Data with its Subsidiaries and to third
parties assisting the Company with the Plan implementation, administration and management including to a broker or other third party with
whom the Company or the Participant may elect to deposit any Shares. These recipients may be located outside of the Participant&rsquo;s
country (and outside of the United States, European Economic Area or United Kingdom), and in such cases the Data will be transferred in
accordance with applicable law, including where required using approved international data transfer mechanisms such as standard contractual
clauses. The Data related to a Participant will be held only as long as necessary to implement, administer, and manage the Participant&rsquo;s
participation in the Plan. To the extent permitted under applicable law, a Participant may, at any time, exercise their right to request
access to their Data, to delete or correct their Data, to object to the Company&rsquo;s use of the Data, to request that the Company restricts
the use of Data or shares the Data with another controller, or to raise any issues around the Company&rsquo;s use of Data with the Company
or any data privacy regulator. To contact the Company, request a copy of any international data transfer mechanism, exercise any data
privacy right, or find out more information about how the Company uses the Data, a Participant may contact their local human resources
representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Severability</U>.
If any portion of the Plan or any action taken under it is held illegal or invalid for any reason, the illegality or invalidity will not
affect the remaining parts of the Plan, and the Plan will be construed and enforced as if the illegal or invalid provisions had been excluded,
and the illegal or invalid action will be null and void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Governing
Documents</U>. If any contradiction occurs between the Plan and any Award Agreement or other written agreement between a Participant and
the Company (or any Subsidiary) that the Administrator has approved, the Plan will govern, unless it is expressly specified in such Award
Agreement or other written document that a specific provision of the Plan will not apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Governing
Law</U>. The Plan and all Awards will be governed by and interpreted in accordance with the laws of the State of Nevada, disregarding
any state&rsquo;s choice-of-law principles requiring the application of a jurisdiction&rsquo;s laws other than the State of Nevada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.13&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Claw-back
Provisions</U>. All Awards (including any proceeds, gains or other economic benefit the Participant actually or constructively receives
upon receipt or exercise of any Award or the receipt or resale of any Shares underlying the Award) will be subject to any Company claw-back
policy, including any claw-back policy adopted to comply with Applicable Laws (including the Dodd-Frank Wall Street Reform and Consumer
Protection Act and any rules&nbsp;or regulations promulgated thereunder) as set forth in such claw-back policy or the Award Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 116; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.14&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Titles
and Headings</U>. The titles and headings in the Plan are for convenience of reference only and, if any conflict, the Plan&rsquo;s text,
rather than such titles or headings, will control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.15&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Conformity
to Applicable Laws</U>. Participant acknowledges that the Plan is intended to conform to the extent necessary with Applicable Laws. Notwithstanding
anything herein to the contrary, the Plan and all Awards will be administered only in conformance with Applicable Laws. To the extent
Applicable Laws permit, the Plan and all Award Agreements will be deemed amended as necessary to conform to Applicable Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.16&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Relationship
to Other Benefits</U>. No payment under the Plan will be taken into account in determining any benefits under any pension, retirement,
savings, profit sharing, group insurance, welfare or other benefit plan of the Company or any Subsidiary except as expressly provided
in writing in such other plan or an agreement thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.17&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Broker-Assisted
Sales</U>. In the event of a broker-assisted sale of Shares in connection with the payment of amounts owed by a Participant under or with
respect to the Plan or Awards, including amounts to be paid under the final sentence of Section&nbsp;9.5: (a)&nbsp;any Shares to be sold
through the broker-assisted sale will be sold on the day the payment first becomes due, or as soon thereafter as practicable; (b)&nbsp;such
Shares may be sold as part of a block trade with other Participants in the Plan in which all participants receive an average price; (c)&nbsp;the
applicable Participant will be responsible for all broker&rsquo;s fees and other costs of sale, and by accepting an Award, each Participant
agrees to indemnify and hold the Company harmless from any losses, costs, damages, or expenses relating to any such sale; (d)&nbsp;to
the extent the Company or its designee receives proceeds of such sale that exceed the amount owed, the Company will pay such excess in
cash to the applicable Participant as soon as reasonably practicable; (e)&nbsp;the Company and its designees are under no obligation to
arrange for such sale at any particular price; and (f)&nbsp;in the event the proceeds of such sale are insufficient to satisfy the Participant&rsquo;s
applicable obligation, the Participant may be required to pay immediately upon demand to the Company or its designee an amount in cash
sufficient to satisfy any remaining portion of the Participant&rsquo;s obligation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ARTICLE&nbsp;XI.<BR>
Definitions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As used in the Plan, the following
words and phrases will have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Administrator</I></B>&rdquo;
means the Board or a Committee to the extent that the Board&rsquo;s powers or authority under the Plan have been delegated to such Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Applicable
Laws</I></B>&rdquo; means the requirements relating to the administration of equity incentive plans under U.S. federal and state securities,
tax and other applicable laws, rules&nbsp;and regulations, the applicable rules&nbsp;of any stock exchange or quotation system on which
the Common Stock is listed or quoted and the applicable laws and rules&nbsp;of any foreign country or other jurisdiction where Awards
are granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Award</I></B>&rdquo;
means, individually or collectively, a grant under the Plan of Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock
Units, Dividend Equivalents or Other Stock or Cash Based Awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Award
Agreement</I></B>&rdquo; means a written agreement evidencing an Award, which may be electronic, that contains such terms and conditions
as the Administrator determines, consistent with and subject to the terms and conditions of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 117; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Board</I></B>&rdquo;
means the Board of Directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Cause</I></B>&rdquo;
means (i)&nbsp;if a Participant is a party to a written employment or consulting agreement with the Company or any of its Subsidiaries
or an Award Agreement in which the term &ldquo;cause&rdquo; is defined (a &ldquo;<B><I>Relevant Agreement</I></B>&rdquo;), &ldquo;Cause&rdquo;
as defined in the Relevant Agreement, and (ii)&nbsp;if no Relevant Agreement exists, (A)&nbsp;the Administrator&rsquo;s determination
that the Participant failed to substantially perform the Participant&rsquo;s duties (other than a failure resulting from the Participant&rsquo;s
Disability); (B)&nbsp;the Administrator&rsquo;s determination that the Participant failed to carry out, or comply with any lawful and
reasonable directive of the Board or the Participant&rsquo;s immediate supervisor; (C)&nbsp;the occurrence of any act or omission by the
Participant that could reasonably be expected to result in (or has resulted in) the Participant&rsquo;s conviction, plea of no contest,
plea of nolo contendere, or imposition of unadjudicated probation for any felony or indictable offense or crime involving moral turpitude;
(D)&nbsp;the Participant&rsquo;s unlawful use (including being under the influence) or possession of illegal drugs on the premises of
the Company or any of its Subsidiaries or while performing the Participant&rsquo;s duties and responsibilities for the Company or any
of its Subsidiaries; or (E)&nbsp;the Participant&rsquo;s commission of an act of fraud, embezzlement, misappropriation, misconduct, or
breach of fiduciary duty against the Company or any of its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Change
in Control</I></B>&rdquo; means and includes each of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;A
transaction or series of transactions (other than an offering of Common Stock to the general public through a registration statement filed
with the Securities and Exchange Commission or a transaction or series of transactions that meets the requirements of clauses (i)&nbsp;and
(ii)&nbsp;of subsection&nbsp;(c)&nbsp;below) whereby any &ldquo;person&rdquo; or related &ldquo;group&rdquo; of &ldquo;persons&rdquo;
(as such terms are used in Sections&nbsp;13(d)&nbsp;and 14(d)(2)&nbsp;of the Exchange Act) (other than the Company, any of its Subsidiaries,
an employee benefit plan maintained by the Company or any of its Subsidiaries or a &ldquo;person&rdquo; that, prior to such transaction,
directly or indirectly controls, is controlled by, or is under common control with, the Company) directly or indirectly acquires beneficial
ownership (within the meaning of Rule&nbsp;13d-3 under the Exchange Act) of securities of the Company possessing more than 50% of the
total combined voting power of the Company&rsquo;s securities outstanding immediately after such acquisition; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;During
any period of two consecutive years, individuals who, at the beginning of such period, constitute the Board together with any new Director(s)&nbsp;(other
than a Director designated by a person who shall have entered into an agreement with the Company to effect a transaction described in
subsections (a)&nbsp;or (c)) whose election by the Board or nomination for election by the Company&rsquo;s stockholders was approved by
a vote of at least two-thirds of the Directors then still in office who either were Directors at the beginning of the two-year period
or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
consummation by the Company (whether directly involving the Company or indirectly involving the Company through one or more intermediaries)
of (x)&nbsp;a merger, consolidation, reorganization, or business combination or (y)&nbsp;a sale or other disposition of all or substantially
all of the Company&rsquo;s assets in any single transaction or series of related transactions or (z)&nbsp;the acquisition of assets or
stock of another entity, in each case other than a transaction:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;which
results in the Company&rsquo;s voting securities outstanding immediately before the transaction continuing to represent (either by remaining
outstanding or by being converted into voting securities of the Company or the person that, as a result of the transaction, controls,
directly or indirectly, the Company or owns, directly or indirectly, all or substantially all of the Company&rsquo;s assets or otherwise
succeeds to the business of the Company (the Company or such person, the &ldquo;<B><I>Successor Entity</I></B>&rdquo;)) directly or indirectly,
at least a majority of the combined voting power of the Successor Entity&rsquo;s outstanding voting securities immediately after the transaction,
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 118; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;after
which no person or group beneficially owns voting securities representing 50% or more of the combined voting power of the Successor Entity;
<U>provided</U>, <U>however</U>, that no person or group shall be treated for purposes of this clause (ii)&nbsp;as beneficially owning
50% or more of the combined voting power of the Successor Entity solely as a result of the voting power held in the Company prior to the
consummation of the transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the foregoing,
if a Change in Control constitutes a payment event with respect to any Award (or portion of any Award) that provides for the deferral
of compensation that is subject to Section&nbsp;409A, to the extent required to avoid the imposition of additional taxes under Section&nbsp;409A,
the transaction or event described in subsection&nbsp;(a), (b)&nbsp;or (c)&nbsp;with respect to such Award (or portion thereof) shall
only constitute a Change in Control for purposes of the payment timing of such Award if such transaction also constitutes a &ldquo;change
in control event,&rdquo; as defined in Treasury Regulation Section&nbsp;1.409A-3(i)(5).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Administrator shall have
full and final authority, which shall be exercised in its discretion, to determine conclusively whether a Change in Control has occurred
pursuant to the above definition, the date of the occurrence of such Change in Control and any incidental matters relating thereto; provided
that any exercise of authority in conjunction with a determination of whether a Change in Control is a &ldquo;change in control event&rdquo;
as defined in Treasury Regulation Section&nbsp;1.409A-3(i)(5)&nbsp;shall be consistent with such regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Code</I></B>&rdquo;
means the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Committee</I></B>&rdquo;
means one or more committees or subcommittees of the Board, which may include one or more Company directors or executive officers, to
the extent Applicable Laws permit. To the extent required to comply with the provisions of Rule&nbsp;16b-3, it is intended that each member
of the Committee will be, at the time the Committee takes any action with respect to an Award that is subject to Rule&nbsp;16b-3, a &ldquo;non-employee
director&rdquo; within the meaning of Rule&nbsp;16b-3; however, a Committee member&rsquo;s failure to qualify as a &ldquo;non-employee
director&rdquo; within the meaning of Rule&nbsp;16b-3 will not invalidate any Award granted by the Committee that is otherwise validly
granted under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Common
Stock</I></B>&rdquo; means the common stock of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Company</I></B>&rdquo;
means Oncolytics Biotech Inc., or any successor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Consultant</I></B>&rdquo;
means any person, including any adviser, engaged by the Company or its parent or Subsidiary to render services to such entity if the consultant
or adviser: (i)&nbsp;renders bona fide services to the Company; (ii)&nbsp;renders services not in connection with the offer or sale of
securities in a capital-raising transaction and does not directly or indirectly promote or maintain a market for the Company&rsquo;s securities;
and (iii)&nbsp;is a natural person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.13&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Designated
Beneficiary</I></B>&rdquo; means the beneficiary or beneficiaries the Participant designates, in a manner the Administrator determines,
to receive amounts due or exercise the Participant&rsquo;s rights if the Participant dies or becomes incapacitated. Without a Participant&rsquo;s
effective designation, &ldquo;Designated Beneficiary&rdquo; will mean the Participant&rsquo;s estate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.14&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Director</I></B>&rdquo;
means a Board member.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.15&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Disability</I></B>&rdquo;
means a permanent and total disability under Section&nbsp;22(e)(3)&nbsp;of the Code, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 119; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.16&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Dividend
Equivalents</I></B>&rdquo; means a right granted to a Participant under the Plan to receive the equivalent value (in cash or Shares) of
dividends paid on Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.17&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Employee</I></B>&rdquo;
means any employee of the Company or its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.18&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Equity
Restructuring</I></B>&rdquo; means a nonreciprocal transaction between the Company and its stockholders, such as a stock dividend, stock
split, spin-off or recapitalization through a large, nonrecurring cash dividend, that affects the number or kind of Shares (or other Company
securities) or the share price of Common Stock (or other Company securities) and causes a change in the per share value of the Common
Stock underlying outstanding Awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.19&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Exchange
Act</I></B>&rdquo; means the Securities Exchange Act of 1934, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.20&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Fair
Market Value</I></B>&rdquo; means, as of any date, the value of a Share determined as follows: (i)&nbsp;if the Common Stock is listed
on any established stock exchange, its Fair Market Value will be the closing sales price for such Common Stock as quoted on such exchange
for such date, or if no sale occurred on such date, the last day preceding such date during which a sale occurred, as reported in The
Wall Street Journal or another source the Administrator deems reliable; (ii)&nbsp;if the Common Stock is not traded on a stock exchange
but is quoted on a national market or other quotation system, the closing sales price on such date, or if no sales occurred on such date,
then on the last date preceding such date during which a sale occurred, as reported in The Wall Street Journal or another source the Administrator
deems reliable; or (iii)&nbsp;without an established market for the Common Stock, the Administrator will determine the Fair Market Value
in its discretion. Notwithstanding the foregoing, with respect to any Award granted on the pricing date of the Company&rsquo;s initial
public offering, the Fair Market Value shall mean the initial public offering price of a Share as set forth in the Company&rsquo;s final
prospectus relating to its initial public offering filed with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.21&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Greater
Than 10% Stockholder</I></B>&rdquo; means an individual then owning (within the meaning of Section&nbsp;424(d)&nbsp;of the Code) more
than 10% of the total combined voting power of all classes of stock of the Company or its parent or subsidiary corporation, as defined
in Section&nbsp;424(e)&nbsp;and (f)&nbsp;of the Code, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.22&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Incentive
Stock Option</I></B>&rdquo; means an Option intended to qualify as an &ldquo;incentive stock option&rdquo; as defined in Section&nbsp;422
of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.23&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Non-Qualified
Stock Option</I></B>&rdquo; means an Option (or portion thereof) not intended or not qualifying as an Incentive Stock Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.24&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Option</I></B>&rdquo;
means an option to purchase Shares, which will either be an Incentive Stock Option or a Non-Qualified Stock Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.25&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Other
Stock or Cash Based Awards</I></B>&rdquo; means cash awards, awards of Shares, and other awards valued wholly or partially by referring
to, or are otherwise based on, Shares or other property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.26&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Overall
Share Limit</I></B>&rdquo; means the sum of (i)&nbsp;6,500,000 Shares; (ii)&nbsp;any shares that remain available for issuance under the
Prior Plans as of the Plan&rsquo;s original effective date in Section&nbsp;10.3; (iii)&nbsp;any Shares which are subject to Prior Plan
Awards which become available for issuance under the Plan pursuant to Article&nbsp;IV; and (iv)&nbsp;an increase commencing on January&nbsp;1,
2027 and continuing annually on each anniversary thereof through (and including) January&nbsp;1, 2036, equal to the lesser of (A)&nbsp;6%
of the number of Shares outstanding on the last day of the immediately preceding calendar year and (B)&nbsp;such smaller number of Shares
as determined by the Board or the Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 120; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.27&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Participant</I></B>&rdquo;
means a Service Provider who has been granted an Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.28&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Performance
Criteria</I></B>&rdquo; means the criteria (and adjustments) that the Administrator may select for an Award to establish performance goals
for a performance period, which may include (but is not limited to) the following: net earnings or losses (either before or after one
or more of interest, taxes, depreciation, amortization, and non-cash equity-based compensation expense); gross or net sales or revenue
or sales or revenue growth; net income (either before or after taxes) or adjusted net income; profits (including but not limited to gross
profits, net profits, profit growth, net operation profit or economic profit), profit return ratios or operating margin; budget or operating
earnings (either before or after taxes or before or after allocation of corporate overhead and bonus); cash flow (including operating
cash flow and free cash flow or cash flow return on capital); return on assets; return on capital or invested capital; cost of capital;
return on stockholders&rsquo; equity; total stockholder return; return on sales; costs, reductions in costs and cost control measures;
expenses; working capital; earnings or loss per share; adjusted earnings or loss per share; price per share or dividends per share (or
appreciation in or maintenance of such price or dividends); regulatory achievements or compliance; implementation, completion or attainment
of objectives relating to research, development, regulatory, commercial, or strategic milestones or developments; market share; economic
value or economic value added models; division, group or corporate financial goals; customer satisfaction/growth; customer service; employee
satisfaction; recruitment and maintenance of personnel; human resources management; supervision of litigation and other legal matters;
strategic partnerships and transactions; financial ratios (including those measuring liquidity, activity, profitability or leverage);
debt levels or reductions; sales-related goals; financing and other capital raising transactions; cash on hand; acquisition activity;
investment sourcing activity; and marketing initiatives, any of which may be measured in absolute terms or as compared to any incremental
increase or decrease. Such performance goals also may be based solely by reference to the Company&rsquo;s performance or the performance
of a Subsidiary, division, business segment or business unit of the Company or a Subsidiary, or based upon performance relative to performance
of other companies or upon comparisons of any of the indicators of performance relative to performance of other companies. The Administrator
may provide for exclusion of the impact of an event or occurrence which the Administrator determines should appropriately be excluded,
including (a)&nbsp;restructurings, discontinued operations, extraordinary items, and other unusual, infrequently occurring or non-recurring
charges or events, (b)&nbsp;asset write-downs, (c)&nbsp;litigation or claim judgments or settlements, (d)&nbsp;acquisitions or divestitures,
(e)&nbsp;reorganization or change in the corporate structure or capital structure of the Company, (f)&nbsp;an event either not directly
related to the operations of the Company, Subsidiary, division, business segment or business unit or not within the reasonable control
of management, (g)&nbsp;foreign exchange gains and losses, (h)&nbsp;a change in the fiscal year of the Company, (i)&nbsp;the refinancing
or repurchase of bank loans or debt securities, (j)&nbsp;unbudgeted capital expenditures, (k)&nbsp;the issuance or repurchase of equity
securities and other changes in the number of outstanding shares, (l)&nbsp;conversion of some or all of convertible securities to Common
Stock, (m)&nbsp;any business interruption event (n)&nbsp;the cumulative effects of tax or accounting changes in accordance with U.S. generally
accepted accounting principles, or (o)&nbsp;the effect of changes in other laws or regulatory rules&nbsp;affecting reported results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.29&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Plan</I></B>&rdquo;
means this 2026 Incentive Award Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.30&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Prior
Plans</I></B>&rdquo; means, collectively, the Oncolytics Biotech Inc. Amended and Restated Incentive Share Award Plan and the Oncolytics
Biotech Inc. Amended and Restated Stock Option Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.31&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Prior
Plan Award</I></B>&rdquo; means an award outstanding under the Prior Plans as of the Plan&rsquo;s original effective date in Section&nbsp;10.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.32&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Restricted
Stock</I></B>&rdquo; means Shares awarded to a Participant under Article&nbsp;VI subject to certain vesting conditions and other restrictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 121; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.33&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Restricted
Stock Unit</I></B>&rdquo; means an unfunded, unsecured right to receive, on the applicable settlement date, one Share or an amount in
cash or other consideration determined by the Administrator to be of equal value as of such settlement date awarded to a Participant under
Article&nbsp;VI, subject to certain vesting conditions and other restrictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.34&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Rule&nbsp;16b-3</I></B>&rdquo;
means Rule&nbsp;16b-3 promulgated under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.35&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Section&nbsp;409A</I></B>&rdquo;
means Section&nbsp;409A of the Code and all regulations, guidance, compliance programs and other interpretative authority thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.36&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Securities
Act</I></B>&rdquo; means the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.37&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Service
Provider</I></B>&rdquo; means an Employee, Consultant or Director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.38&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Shares</I></B>&rdquo;
means shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.39&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Stock
Appreciation Right</I></B>&rdquo; means a stock appreciation right granted under Article&nbsp;V.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.40&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Subsidiary</I></B>&rdquo;
means any entity (other than the Company), whether domestic or foreign, in an unbroken chain of entities beginning with the Company if
each of the entities other than the last entity in the unbroken chain beneficially owns, at the time of the determination, securities
or interests representing at least 50% of the total combined voting power of all classes of securities or interests in one of the other
entities in such chain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.41&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Substitute
Awards</I></B>&rdquo; means Awards granted or Shares issued by the Company in assumption of, or in substitution or exchange for, awards
previously granted, or the right or obligation to make future awards, in each case by a company acquired by the Company or any Subsidiary
or with which the Company or any Subsidiary combines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.42&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Termination
of Service</I></B>&rdquo; means Participant ceasing to be a Service Provider.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>*&nbsp;*&nbsp;*&nbsp;*&nbsp;*</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 122; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B><A NAME="pros4_019"></A>ANNEX
G &mdash; SECTION&nbsp;189 AND SECTION&nbsp;191 OF THE ABCA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 15%; vertical-align: bottom">Section 189</TD><TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; width: 70%; text-align: center">BUSINESS CORPORATIONS ACT</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 15%"><P STYLE="text-align: right; margin-top: 0; margin-bottom: 0">RSA 2000</P>
                                                                                <P STYLE="text-align: right; margin-top: 0; margin-bottom: 0">Chapter B-9</P></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">privileges, restrictions or conditions set out on or referred
to in the certificate representing the share, and continuance under this section does not deprive a holder of any right or privilege that
the holder claims under, or relieve the holder of any liability in respect of, an issued share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"> <B>(9)</B> &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Repealed 2021 c18 s46.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>(10)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;For
the purposes of subsection (8), &ldquo;share&rdquo; includes an instrument referred to in section 31(1), a share warrant or a like instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"><B>(11)</B> &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If the Registrar
determines on the application of an extra-provincial corporation that it is not practicable to change a reference to the nominal or
par value of shares of a class or series that it was authorized to issue before it was continued under this Act, the Registrar may,
notwithstanding section 26(1), permit the extra-provincial corporation to continue to refer in its articles to those shares, whether
issued or unissued, as shares having a nominal or par value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>(12)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;</B>A corporation shall set out in its articles the maximum number of shares of a class or series referred to in
subsection (11) and may not amend its articles to increase that maximum number of shares or to change the nominal or par value of
those shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">RSA 2000 cB-9 s188;2006 cS-4.5 s106;2021 c18 s46</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Continuance of an Alberta corporation into another jurisdiction</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>189(1)&#8239;&#8239;</B>Subject to subsection (9), a corporation
may, if</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 5%">&nbsp;</TD>
<TD STYLE="width: 5%; text-align: left">(a)</TD><TD STYLE="text-align: justify; width: 90%">it is authorized by the shareholders in accordance with this
section, and</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 5%">&nbsp;</TD>
<TD STYLE="width: 5%; text-align: left">(b)</TD><TD STYLE="text-align: left; width: 90%">the Registrar approves the proposed continuance in another jurisdiction on being satisfied that the continuance will not adversely affect creditors or shareholders of the corporation,</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">apply to the appropriate official or public body of another
jurisdiction requesting that the corporation be continued as if it had been incorporated under the laws of that other jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>(2)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;&#8239;</B>A notice of a meeting of shareholders that complies with section 134 and states that a dissenting shareholder is
entitled to be paid the fair value of the shareholder&rsquo;s shares in accordance with section 191 shall be sent in accordance with
section 134 to each shareholder, but failure to include that statement does not invalidate a discontinuance under this Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 123; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">G-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 15%; vertical-align: bottom">Section 189</TD><TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; width: 70%; text-align: center">BUSINESS CORPORATIONS ACT</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 15%"><P STYLE="text-align: right; margin-top: 0; margin-bottom: 0">RSA 2000</P>
                                                                                <P STYLE="text-align: right; margin-top: 0; margin-bottom: 0">Chapter B-9</P></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"> <B>(3)</B> &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Each share of the corporation carries the right to vote in respect of a continuance whether or not it otherwise carries the right to vote.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>(4)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>An
application for continuance becomes authorized when the shareholders voting on it have approved of the continuance by a special resolution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>(5)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>The
directors of a corporation may, if authorized by the shareholders at the time of approving an application for continuance under this section,
abandon the application without further approval of the shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>(6)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>&#8239;&#8239;&#8239;&#8239;On
receipt of notice satisfactory to the Registrar that the corporation has met the requirements of subsection (1)&nbsp;and that the corporation
has been continued under the laws of another jurisdiction, the Registrar shall file the notice and issue a certificate of discontinuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>(7)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Section&nbsp;267
applies with the necessary changes to the notice filed under subsection (6)&nbsp;as though the notice were articles that conform to law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"> <B>(8)</B> &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;On the date shown in the certificate of discontinuance, the corporation becomes an extra-provincial corporation as if it had been incorporated under the laws of the other jurisdiction.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>(9)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>A
corporation shall not be continued as a body corporate under the laws of another jurisdiction unless those laws provide in effect that</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%; text-align: left">(a)</TD><TD STYLE="text-align: justify; width: 90%">the property of the corporation continues to be the property
of the body corporate,</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%; text-align: left">(b)</TD><TD STYLE="text-align: justify; width: 90%">the body corporate continues to be liable for the obligations
of the corporation,</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%; text-align: left">(c)</TD><TD STYLE="text-align: justify; width: 90%">an existing cause of action, claim or liability to prosecution
is unaffected,</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%; text-align: left">(d)</TD><TD STYLE="text-align: left; width: 90%">a civil, criminal or administrative action or proceeding pending
by or against the corporation may be continued to be prosecuted by or against the body corporate, and</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%; text-align: left">(e)</TD><TD STYLE="text-align: left; width: 90%">a conviction against, or ruling, order or judgment in favour
of or against the corporation may be enforced by or against the body corporate.</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0 0pt 267.15pt">RSA 2000 cB-9 s189;2021 c18 s47</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 124; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">G-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 15%; vertical-align: bottom">Section 190</TD><TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; width: 70%; text-align: center">BUSINESS CORPORATIONS ACT</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 15%"><P STYLE="text-align: right; margin-top: 0; margin-bottom: 0">RSA 2000</P>
                                                                                <P STYLE="text-align: right; margin-top: 0; margin-bottom: 0">Chapter B-9</P></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Extraordinary sale, lease or exchange</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>190(1)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;A
sale, lease or exchange of all or substantially all the property of a corporation other than in the ordinary course of business of the
corporation requires the approval of the shareholders in accordance with subsections (2)&nbsp;to (6).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>(2)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>A
notice of meeting of shareholders complying with section 134 shall be sent in accordance with that section to each shareholder and shall</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%; text-align: left">(a)</TD><TD STYLE="text-align: justify; width: 90%">include or be accompanied with a copy or summary of the agreement
of sale, lease or exchange, and</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%; text-align: left">(b)</TD><TD STYLE="text-align: left; width: 90%">state that a dissenting shareholder is entitled to be paid the
fair value of the shareholder&rsquo;s shares in accordance with section 191, but failure to make that statement does not invalidate a
sale, lease or exchange referred to in subsection (1).</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>(3)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>At
the meeting referred to in subsection (2), the shareholders may authorize the sale, lease or exchange and may fix or authorize the directors
to fix any of its terms and conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"> <B>(4)</B> &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; Each
share of the corporation carries the right to vote in respect of a sale, lease or exchange referred to in subsection
(1)&nbsp;whether or not it otherwise carries the right to vote.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>(5)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>The
holders of shares of a class or series of shares of the corporation are entitled to vote separately as a class or series in respect of
a sale, lease or exchange referred to in subsection (1)&nbsp;only if that class or series is affected by the sale, lease or exchange in
a manner different from the shares of another class or series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>(6)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>A
sale, lease or exchange referred to in subsection (1)&nbsp;is adopted when the holders of each class or series entitled to vote on it
have approved of the sale, lease or exchange by a special resolution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>(7)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>The
directors of a corporation may, if authorized by the shareholders approving a proposed sale, lease or exchange, and subject to the rights
of third parties, abandon the sale, lease or exchange without further approval of the shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">1981 cB-15 s183</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 125; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">G-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 15%; vertical-align: bottom">Section 191</TD><TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; width: 70%; text-align: center">BUSINESS CORPORATIONS ACT</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 15%"><P STYLE="text-align: right; margin-top: 0; margin-bottom: 0">RSA 2000</P>
                                                                                <P STYLE="text-align: right; margin-top: 0; margin-bottom: 0">Chapter B-9</P></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Shareholder&rsquo;s right to dissent</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>191(1)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </B>Subject
to sections 192 and 242, a holder of shares of any class of a corporation may dissent if the corporation resolves to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">(a)</TD><TD STYLE="text-align: left; width: 90%">amend its articles under section 173 or 174 to add, change or remove any provisions restricting or constraining the issue or transfer
of shares of that class,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">(b)</TD><TD STYLE="width: 90%">amend its articles under section 173 to add, change or remove any restrictions on the business or businesses that the corporation
may carry on,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%; text-align: left">(b.1)</TD><TD STYLE="text-align: left; width: 90%">amend its articles under section 173 to add or remove an express
statement establishing the unlimited liability of shareholders as set out in section 15.2(1),</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">(c)</TD><TD STYLE="width: 90%">amalgamate with another corporation, otherwise than under section 184 or 187,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">(d)</TD><TD STYLE="width: 90%">be continued under the laws of another jurisdiction under section 189, or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">(e)</TD><TD STYLE="width: 90%">sell, lease or exchange all or substantially all its property under section 190.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"> <B>(2)</B> &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; A holder of
shares of any class or series of shares entitled to vote under section 176, other than section 176(1)(a), may dissent if the
corporation resolves to amend its articles in a manner described in that section.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>(3)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>In
addition to any other right the shareholder may have, but subject to subsection (20), a shareholder entitled to dissent under this section
and who complies with this section is entitled to be paid by the corporation the fair value of the shares held by the shareholder in respect
of which the shareholder dissents, determined as of the close of business on the last business day before the day on which the resolution
from which the shareholder dissents was adopted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>(4)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>A
dissenting shareholder may only claim under this section with respect to all the shares of a class held by the shareholder or on behalf
of any one beneficial owner and registered in the name of the dissenting shareholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>(5)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>A
dissenting shareholder shall send to the corporation a written objection to a resolution referred to in subsection (1)&nbsp;or (2)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">(a)</TD><TD STYLE="width: 90%">at or before any meeting of shareholders at which the resolution is to be voted on, or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">(b)</TD><TD STYLE="width: 90%">if the corporation did not send notice to the shareholder of the purpose of the meeting or of the shareholder&rsquo;s right to dissent,
within a reasonable time after the shareholder learns that the resolution was adopted and of the shareholder&rsquo;s
right to dissent.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 126; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">G-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 15%; vertical-align: bottom">Section 191</TD><TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; width: 70%; text-align: center">BUSINESS CORPORATIONS ACT</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 15%"><P STYLE="text-align: right; margin-top: 0; margin-bottom: 0">RSA 2000</P>
                                                                                <P STYLE="text-align: right; margin-top: 0; margin-bottom: 0">Chapter B-9</P></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>(6)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;</B>An application may be made to the Court after the adoption of a resolution referred to in subsection (1)&nbsp;or (2),</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">(a)</TD><TD STYLE="width: 90%">by the corporation, or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">(b)</TD><TD STYLE="width: 90%">by a shareholder if the shareholder has sent an objection to the corporation under subsection (5),</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">to fix the fair value in accordance with subsection (3)&nbsp;of
the shares of a shareholder who dissents under this section, or to fix the time at which a shareholder of an unlimited liability corporation
who dissents under this section ceases to become liable for any new liability, act or default of the unlimited liability corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>(7)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>If
an application is made under subsection (6), the corporation shall, unless the Court otherwise orders, send to each dissenting shareholder
a written offer to pay the shareholder an amount considered by the directors to be the fair value of the shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>(8)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Unless
the Court otherwise orders, an offer referred to in subsection (7)&nbsp;shall be sent to each dissenting shareholder</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">(a)</TD><TD STYLE="width: 90%">at least 10 days before the date on which the application is returnable, if the corporation is the applicant, or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">(b)</TD><TD STYLE="width: 90%">within 10 days after the corporation is served with a copy of the application, if a shareholder is the applicant.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"> <B>(9)</B> &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Every offer made under subsection (7)&nbsp;shall</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">(a)</TD><TD STYLE="width: 90%">be made on the same terms, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">(b)</TD><TD STYLE="width: 90%">contain or be accompanied with a statement showing how the fair value was determined.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>(10)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>A
dissenting shareholder may make an agreement with the corporation for the purchase of the shareholder&rsquo;s shares by the corporation,
in the amount of the corporation&rsquo;s offer under subsection (7)&nbsp;or otherwise, at any time before the Court pronounces an order
fixing the fair value of the shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"> <B>(11)</B> &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;A dissenting shareholder</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">(a)</TD><TD STYLE="width: 90%">is not required to give security for costs in respect of an application under subsection (6), and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 127; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">G-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 15%; vertical-align: bottom">Section 191</TD><TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; width: 70%; text-align: center">BUSINESS CORPORATIONS ACT</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 15%"><P STYLE="text-align: right; margin-top: 0; margin-bottom: 0">RSA 2000</P>
                                                                                <P STYLE="text-align: right; margin-top: 0; margin-bottom: 0">Chapter B-9</P></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">(b)</TD><TD STYLE="width: 90%">except in special circumstances must not be required to pay the costs of the application or appraisal.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>(12)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;&#8239;</B>In connection with an application under subsection (6), the Court may give directions for</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">(a)</TD><TD STYLE="width: 90%">joining as parties all dissenting shareholders whose shares have not been purchased by the corporation and for the representation
of dissenting shareholders who, in the opinion of the Court, are in need of representation,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">(b)</TD><TD STYLE="width: 90%">the trial of issues and interlocutory matters, including pleadings and questioning under Part&nbsp;5 of the <I>Alberta Rules&nbsp;of
Court</I>,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">(c)</TD><TD STYLE="width: 90%">the payment to the shareholder of all or part of the sum offered by the corporation for the shares,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">(d)</TD><TD STYLE="width: 90%">the deposit of the share certificates with the Court or with the corporation or its transfer agent,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">(e)</TD><TD STYLE="width: 90%">the appointment and payment of independent appraisers, and the procedures to be followed by them,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">(f)</TD><TD STYLE="width: 90%">the service of documents, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">(g)</TD><TD STYLE="width: 90%">the burden of proof on the parties.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>(13)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>On
an application under subsection (6), the Court shall make an order</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">(a)</TD><TD STYLE="width: 90%">fixing the fair value of the shares in accordance with subsection (3)&nbsp;of all dissenting shareholders who are parties to the application,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">(b)</TD><TD STYLE="width: 90%">giving judgment in that amount against the corporation and in favour of each of those dissenting shareholders,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">(c)</TD><TD STYLE="width: 90%">fixing the time within which the corporation must pay that amount to a shareholder, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">(d)</TD><TD STYLE="width: 90%">fixing the time at which a dissenting shareholder of an unlimited liability corporation ceases to become liable for any new liability,
act or default of the unlimited liability corporation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"> <B>(14)</B> &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;On</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">(a)</TD><TD STYLE="width: 90%">the action approved by the resolution from which the shareholder dissents becoming effective,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 128; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">G-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 15%; vertical-align: bottom">Section 191</TD><TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; width: 70%; text-align: center">BUSINESS CORPORATIONS ACT</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 15%"><P STYLE="text-align: right; margin-top: 0; margin-bottom: 0">RSA 2000</P>
                                                                                <P STYLE="text-align: right; margin-top: 0; margin-bottom: 0">Chapter B-9</P></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">(b)</TD><TD STYLE="width: 90%">the making of an agreement under subsection (10)&nbsp;between the corporation and the dissenting shareholder as to the payment to
be made by the corporation for the shareholder&rsquo;s shares, whether by the acceptance of the corporation&rsquo;s offer under subsection
(7)&nbsp;or otherwise, or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">(c)</TD><TD STYLE="width: 90%">the pronouncement of an order under subsection (13),</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">whichever first occurs, the shareholder ceases to have any
rights as a shareholder other than the right to be paid the fair value of the shareholder&rsquo;s shares in the amount agreed to between
the corporation and the shareholder or in the amount of the judgment, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"> <B>(15)</B> &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Subsection (14)(a)&nbsp;does not apply to a shareholder referred to in subsection (5)(b).</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"> <B>(16)</B> &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Until one of the events mentioned in subsection (14) occurs,</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">(a)</TD><TD STYLE="width: 90%">the shareholder may withdraw the shareholder&rsquo;s dissent, or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">(b)</TD><TD STYLE="width: 90%">the corporation may rescind the resolution,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">and in either event proceedings under this section shall
be discontinued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>(17)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>The
Court may in its discretion allow a reasonable rate of interest on the amount payable to each dissenting shareholder, from the date on
which the shareholder ceases to have any rights as a shareholder by reason of subsection (14) until the date of payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>(18)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>If
subsection (20) applies, the corporation shall, within 10 days after</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">(a)</TD><TD STYLE="width: 90%">the pronouncement of an order under subsection (13), or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">(b)</TD><TD STYLE="width: 90%">the making of an agreement between the shareholder and the corporation as to the payment to be made for the shareholder&rsquo;s shares,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">notify each dissenting shareholder that it is unable lawfully
to pay dissenting shareholders for their shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>(19)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Notwithstanding
that a judgment has been given in favour of a dissenting shareholder under subsection (13)(b), if subsection (20)&#8239;applies, the
dissenting shareholder, by written notice delivered to the corporation within 30 days after receiving the notice under subsection
(18), may withdraw the shareholder&rsquo;s notice of objection, in which case the corporation is deemed to consent to the withdrawal
and the shareholder is reinstated to the shareholder&rsquo;s full rights as a shareholder, failing which the shareholder retains a
status as a claimant against the corporation, to be paid as soon as the corporation is lawfully able to do so or, in a liquidation,
to be ranked subordinate to the rights of creditors of the corporation but in priority to its shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 129; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">G-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 15%; vertical-align: bottom">Section 192</TD><TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; width: 70%; text-align: center">BUSINESS CORPORATIONS ACT</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 15%"><P STYLE="text-align: right; margin-top: 0; margin-bottom: 0">RSA 2000</P>
                                                                                <P STYLE="text-align: right; margin-top: 0; margin-bottom: 0">Chapter B-9</P></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>(20)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;</B>A corporation shall not make a payment to a dissenting shareholder under this section if there are
reasonable grounds for believing that</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">(a)</TD><TD STYLE="width: 90%">the corporation is or would after the payment be unable to pay its liabilities as they become due, or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">(b)</TD><TD STYLE="width: 90%">the realizable value of the corporation&rsquo;s assets would by reason of the payment be less than the aggregate of its liabilities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0 0pt 226.25pt">RSA 2000 cB-9 s191;2005 c40 s7;2009 c53 s30</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Part</B></FONT><B>&nbsp;15</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Corporate Reorganization</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>and Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Articles of reorganization resulting from court
order</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>192(1)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>In this section,
 &ldquo;order for reorganization&rdquo; means an order of the Court made under</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">(a)</TD><TD STYLE="width: 90%">section 242,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">(b)</TD><TD STYLE="width: 90%">the <I>Bankruptcy and Insolvency Act </I>(Canada) approving a proposal, or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">(c)</TD><TD STYLE="width: 90%">any other Act of the Parliament of Canada or an Act of the Legislature that affects the rights among the corporation, its shareholders
and creditors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>(2)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>If
a corporation is subject to an order for reorganization, its articles may be amended by the order to effect any change that might lawfully
be made by an amendment under section 173.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>(3)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>If
the Court makes an order for reorganization, the Court may also</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">(a)</TD><TD STYLE="width: 90%">authorize the issue of debt obligations of the corporation, whether or not convertible into shares of any class or having attached
any rights or options to acquire shares of any class, and fix the terms of those debt obligations, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">(b)</TD><TD STYLE="width: 90%">appoint directors in place of or in addition to all or any of the directors then in office.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 130; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">G-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B><A NAME="pros4_020"></A>ANNEX
H &mdash; FORM&nbsp;OF NEVADA BYLAWS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">BYLAWS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ONCOLYTICS BIOTECH INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">a Nevada corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">Article&nbsp;I<U><BR>
OFFICES</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;1.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Principal
Office</U>. The principal office and place of business of Oncolytics Biotech Inc. (the &ldquo;<U>Corporation</U>&rdquo;) shall be at such
location as is established from time to time by resolution of the board of directors of the Corporation (the &ldquo;<U>Board of Directors</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;1.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Other
Offices</U>. Other offices and places of business either within or without the State of Nevada may be established from time to time by
resolution of the Board of Directors or as the business of the Corporation may require as determined by the Board of Directors or any
officer of the Corporation. The street address of the Corporation&rsquo;s registered agent is the registered office of the Corporation
in Nevada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">Article&nbsp;II<U><BR>
STOCKHOLDERS</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;2.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Annual
Meeting</U>. The annual meeting of the stockholders of the Corporation shall be held on such date and at such time as may be
designated from time to time exclusively by the Board of Directors. At the annual meeting, directors shall be elected and any other
business may be transacted as may be properly brought before the meeting pursuant to these Bylaws (as amended and/or restated from
time to time, these &ldquo;<U>Bylaws</U>&rdquo;). Except as otherwise restricted by the articles of incorporation of the Corporation
(as amended and/or restated from time to time, the &ldquo;<U>Articles of Incorporation</U>&rdquo;) or applicable law, the Board of
Directors may postpone, reschedule or cancel any annual meeting of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;2.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;&#8239;<U>Special Meetings</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Special
meetings of the stockholders may be called only in accordance with the provisions of the Articles of Incorporation. Stockholders (in
such capacity) shall have no right to request or call a special meeting. Except as otherwise restricted by the Articles of
Incorporation or applicable law, the Board of Directors may postpone, reschedule or cancel any special meeting of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No
business shall be acted upon at a special meeting of stockholders except as set forth in the notice of the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;2.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;<U>Place of Meetings</U>. Any meeting of the stockholders of the Corporation to be held at a physical location may be held
at the Corporation&rsquo;s registered office in the State of Nevada or at such other physical location in or out of the State of Nevada
and the United States as may be designated in the notice of meeting. A waiver of notice signed by all stockholders entitled to vote thereat
may designate the physical location, if any, for the holding of such meeting. The Board of Directors may, in its sole discretion, determine
that any meeting of the stockholders shall be held exclusively, or simultaneously with the conduct of the meeting at a physical location,
by means of remote communication (as described in Nevada Revised Statutes (as amended from time to time, the &ldquo;<U>NRS</U>&rdquo;)
78.320(4)) or other available technology permitted under the NRS, in accordance with <U>Section&nbsp;2.14</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 131; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">H-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;2.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;<U>Notice of Meetings; Waiver of Notice</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Chief Executive Officer, the President, any Vice President, the Secretary, an Assistant Secretary or any other individual designated by
the Board of Directors shall sign and deliver or cause to be delivered to the stockholders written notice of any meeting of stockholders
not less than ten days, but not more than 60 days, before the date of such meeting. The notice shall state the physical location, if any,
the date and time of the meeting, the means of remote communication, if any, by which the stockholders or the proxies thereof shall be
deemed to be present and vote and, in the case of a special meeting, the purpose or purposes for which the meeting is called. The notice
shall be delivered in accordance with, and shall contain or be accompanied by such additional information as may be required by, the NRS,
including, without limitation, NRS 78.379, 92A.120 or 92A.410. Any notice of a meeting of stockholders delivered pursuant to and in accordance
with NRS 78.370(9)&nbsp;shall be deemed to have satisfied any and all requirements applicable to such notice under these Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
the case of an annual meeting, subject to <U>Section&nbsp;2.13</U>, any proper business may be presented for action, except that (i)&nbsp;if
a proposed plan of merger, conversion or exchange is submitted to a vote, the notice of the meeting must state that the purpose, or one
of the purposes, of the meeting is to consider the plan of merger, conversion or exchange and must contain or be accompanied by a copy
or summary of the plan; and (ii)&nbsp;if a proposed action creating dissenter&rsquo;s rights is to be submitted to a vote, the notice
of the meeting must state that the stockholders are or may be entitled to assert dissenter&rsquo;s rights under NRS 92A.300 to 92A.500,
inclusive, and be accompanied by a copy of those statutes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;A
copy of the notice shall be personally delivered or mailed postage prepaid to each stockholder of record at the address appearing on the
records of the Corporation. Upon mailing, service of the notice is complete, and the time of the notice begins to run from the date upon
which the notice is deposited in the mail. If the address of any stockholder does not appear upon the records of the Corporation or is
incomplete, it will be sufficient to address any notice to such stockholder at the registered office of the Corporation. Notwithstanding
the foregoing and in addition thereto, any notice to stockholders given by the Corporation pursuant to NRS Title 7 (including, without
limitation, NRS Chapters 75, 78 and 92A), the Articles of Incorporation or these Bylaws may be given pursuant to any form of electronic
transmission permitted under the NRS. Notice shall be deemed given (i)&nbsp;by facsimile when directed to a number consented to by the
stockholder to receive notice, (ii)&nbsp;by e-mail when directed to an e-mail address designated or used by the stockholder to receive
notice, (iii)&nbsp;by posting on an electronic network together with a separate notice to the stockholder of the specific posting on the
later of the specific posting or the giving of the separate notice or (iv)&nbsp;by any other electronic transmission as consented to by
and when directed to the stockholder. The stockholder consent necessary to permit electronic transmission to such stockholder shall be
deemed revoked and of no force and effect if (A)&nbsp;the Corporation is unable to deliver by electronic transmission two consecutive
notices given by the Corporation in accordance with the stockholder&rsquo;s consent and (B)&nbsp;the inability to deliver by electronic
transmission becomes known to the Secretary, Assistant Secretary, transfer agent or other agent of the Corporation responsible for the
giving of notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
written certificate of an individual signing a notice of meeting, setting forth the substance of the notice or having a copy thereof attached
thereto, the date the notice was mailed or personally delivered to the stockholders and the addresses to which the notice was mailed,
shall be prima facie evidence of the manner and fact of giving such notice and, in the absence of fraud, an affidavit of the individual
signing a notice of a meeting that the notice thereof has been given by a form of electronic transmission shall be prima facie evidence
of the facts stated in the affidavit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 132; Options: NewSection; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">H-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Any
stockholder may waive notice of any meeting by a signed writing or by transmission of an electronic record, either before or after the
meeting. Such waiver of notice shall be deemed the equivalent of the giving of such notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;2.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Determination of Stockholders of Record</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;For
the purpose of determining the stockholders entitled to (i)&nbsp;notice of and to vote at any meeting of stockholders or any adjournment
thereof, (ii)&nbsp;receive payment of any distribution or the allotment of any rights, or (iii)&nbsp;exercise any rights in respect of
any change, conversion or exchange of stock, or for the purpose of any other lawful action, the Board of Directors may fix, in advance,
a record date, which shall not be more than 60 days nor less than ten days before the date of such meeting, if applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
no record date is fixed, the record date for determining stockholders: (i)&nbsp;entitled to notice of and to vote at a meeting of stockholders
shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of
business on the day next preceding the day on which the meeting is held; and (ii)&nbsp;for any other purpose shall be at the close of
business on the day on which the Board of Directors adopts the resolution relating thereto. A determination of stockholders of record
entitled to notice of or to vote at any meeting of stockholders shall apply to any postponement of any meeting of stockholders to a date
not more than 60 days after the record date or to any adjournment of the meeting; provided that the Board of Directors may fix a new record
date for the adjourned meeting and must fix a new record date if the meeting is adjourned to a date more than 60 days later than the date
set for the original meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;2.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Quorum; Adjourned Meetings</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Unless
the Articles of Incorporation provide for a different proportion, stockholders holding at least one-third of the voting power of the Corporation&rsquo;s
capital stock, represented in person or by proxy (regardless of whether the proxy has authority to vote on any matter), are necessary
to constitute a quorum for the transaction of business at any meeting. If, on any issue, voting by classes or series is required by the
laws of the State of Nevada, the Articles of Incorporation or these Bylaws, at least one-third of the voting power, represented in person
or by proxy (regardless of whether the proxy has authority to vote on any matter), within each such class or series is necessary to constitute
a quorum of each such class or series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
a quorum is not represented, a majority of the voting power represented or the person presiding at the meeting may adjourn the meeting
from time to time until a quorum shall be represented. At any such adjourned meeting at which a quorum shall be represented, any business
may be transacted which might otherwise have been transacted at the adjourned meeting as originally called. When a meeting of stockholders
is adjourned to another time or physical location hereunder, notice need not be given of the adjourned meeting if the time and physical
location, if any, thereof, and the means of remote communication, if any, by which stockholders and proxyholders may be deemed present
in person and may vote at such meeting are (i)&nbsp;announced at the meeting at which the adjournment is taken, (ii)&nbsp;displayed, during
the time scheduled for the meeting, on the same electronic network used to enable stockholders and proxyholders to participate in the
meeting by means of remote communication or (iii)&nbsp;set forth in the notice of meeting given in accordance with these Bylaws. However,
if a new record date is fixed for the adjourned meeting, notice of the adjourned meeting must be given to each stockholder of record as
of the new record date. The stockholders present at a duly convened meeting at which a quorum is present may continue to transact business
until adjournment, notwithstanding the departure of enough stockholders to leave less than a quorum of the voting power.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 133; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">H-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;2.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;<U>Voting</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Unless
otherwise provided in the NRS, the Articles of Incorporation, or any resolution providing for the issuance of preferred stock adopted
by the Board of Directors pursuant to authority expressly vested in it by the provisions of the Articles of Incorporation, each stockholder
of record, or such stockholder&rsquo;s duly authorized proxy, shall be entitled to one vote for each share of voting stock standing registered
in such stockholder&rsquo;s name at the close of business on the record date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as otherwise provided in these Bylaws, all votes with respect to shares (including pledged shares) standing in the name of an individual
at the close of business on the record date shall be cast only by that individual or such individual&rsquo;s duly authorized proxy. With
respect to shares held by a representative of the estate of a deceased stockholder, or a guardian, conservator, custodian or trustee,
even though the shares do not stand in the name of such holder, votes may be cast by such holder upon proof of such representative capacity.
In the case of shares under the control of a receiver, the receiver may vote such shares even though the shares do not stand of record
in the name of the receiver but only if and to the extent that the order of a court of competent jurisdiction which appoints the receiver
contains the authority to vote such shares. If shares stand of record in the name of a minor, votes may be cast by the duly appointed
guardian of the estate of such minor only if such guardian has provided the Corporation with written proof of such appointment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;With
respect to shares standing of record in the name of another corporation, partnership, limited liability company or other legal entity
on the record date, votes may be cast: (i)&nbsp;in the case of a corporation, by such individual as the bylaws of such other corporation
prescribe, by such individual as may be appointed by resolution of the board of directors of such other corporation or by such individual
(including, without limitation, the officer making the authorization) authorized in writing to do so by the chair of the board, the chief
executive officer, the president or any vice president of such corporation; and (ii)&nbsp;in the case of a partnership, limited liability
company or other legal entity, by an individual representing such stockholder upon presentation to the Corporation of satisfactory evidence
of his or her authority to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Notwithstanding
anything to the contrary contained in these Bylaws and except for the Corporation&rsquo;s shares held in a fiduciary capacity, the Corporation
shall not vote or cause to be voted, directly or indirectly, shares of its own stock owned or held as treasury shares (as defined in NRS
78.283(1)), and such treasury shares shall not be counted in determining the total number of outstanding shares entitled to vote.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Any
holder of shares entitled to vote on any matter may cast a portion of the votes in favor of such matter and refrain from casting the remaining
votes or cast the same against the proposal, except in the case of elections of directors. If such holder entitled to vote does vote any
of such stockholder&rsquo;s shares affirmatively and fails to specify the number of affirmative votes, it will be conclusively presumed
that the holder is casting affirmative votes with respect to all shares held.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;With
respect to shares standing of record in the name of two or more persons, whether fiduciaries, members of a partnership, joint tenants,
tenants in common, spouses as community property, tenants by the entirety, voting trustees or otherwise and shares held by two or more
persons (including proxy holders) having the same fiduciary relationship in respect to the same shares, votes may be cast in the following
manner:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
only one person votes, the vote of such person binds all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 134; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">H-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
more than one person casts votes, the act of the majority so voting binds all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
more than one person casts votes, but the vote is evenly split on a particular matter, the votes shall be deemed cast proportionately,
as split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
a quorum is present, unless the Articles of Incorporation, these Bylaws or the NRS, or other applicable law provide for a different proportion,
action by the stockholders entitled to vote on a matter, other than the election of directors, is approved by and is the act of the stockholders
if the number of votes cast in favor of the action exceeds the number of votes cast in opposition to the action, unless voting by classes
or series is required for any action of the stockholders by the laws of the State of Nevada, the Articles of Incorporation or these Bylaws,
in which case the number of votes cast in favor of the action by the voting power of each such class or series must exceed the number
of votes cast in opposition to the action by the voting power of each such class or series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
a quorum is present, directors shall be elected by a plurality of the votes cast by the holders of the shares present in person or by
proxy at the meeting and entitled to vote in the election of directors; provided, that, if the rules&nbsp;and requirements of the exchange
on which the Corporation&rsquo;s shares are then listed require a different voting standard for the election of directors, directors shall
be elected in accordance with the rules&nbsp;and requirements of such exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;2.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;&#8239;<U>Proxies</U>. At any meeting of stockholders, any holder of shares entitled to vote may
designate, in a manner permitted by the laws of the State of Nevada, another person or persons to act as a proxy or proxies. If a
stockholder designates two or more persons to act as proxies, then a majority of those persons present at a meeting has and may
exercise all of the powers conferred by the stockholder or, if only one is present, then that one has and may exercise all of the
powers conferred by the stockholder, unless the stockholder&rsquo;s designation of proxy provides otherwise. Every proxy shall
continue in full force and effect until its expiration or revocation in a manner permitted by the laws of the State of Nevada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;2.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;<U>No Action Without A Meeting</U>. No action shall be taken by the stockholders except at an annual or special
meeting of stockholders called and noticed in the manner required by these Bylaws. The stockholders may not in any circumstance take
action by written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;2.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Organization</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Meetings
of stockholders shall be presided over by the Chair of the Board of Directors, or, in the absence of the Chair, by the Vice Chair of the
Board of Directors, or if there be no Vice Chair or in the absence of the Vice Chair, by the Chief Executive Officer, or if there be no
Chief Executive Officer or in the absence of the Chief Executive Officer, by the President, or, in the absence of the President, or, in
the absence of any of the foregoing persons, by a chair designated by the Board of Directors. The individual acting as chair of the meeting
may delegate any or all of his or her authority and responsibilities as such to any director or officer of the Corporation present in
person at the meeting. The Secretary, or in the absence of the Secretary an Assistant Secretary, shall act as secretary of the meeting,
but in the absence of the Secretary and any Assistant Secretary the chair of the meeting may appoint any person to act as secretary of
the meeting. The order of business at each such meeting shall be as determined by the chair of the meeting. The chair of the meeting shall
have the right and authority to prescribe such rules, regulations and procedures and to do all such acts and things as are necessary or
desirable for the proper conduct of the meeting, including, without limitation, (i)&nbsp;the establishment of procedures for the maintenance
of order and safety, (ii)&nbsp;limitation on participation in the meeting to stockholders of record of the Corporation, their duly authorized
and constituted proxies and such other persons as the chair of the meeting shall permit, (iii)&nbsp;limitation on the time allotted for
consideration of each agenda item and for questions or comments by meeting participants, (iv)&nbsp;restrictions on entry to such meeting
after the time prescribed for the commencement thereof and (v)&nbsp;the opening and closing of the voting polls. The Board of Directors,
in its discretion, or the chair of the meeting, in his or her discretion, may require that any votes cast at such meeting shall be cast
by written ballot.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 135; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">H-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
chair of the meeting may appoint one or more inspectors of elections to act at the meeting or any adjournment thereof and to make a written
report thereof. The inspector or inspectors may (i)&nbsp;ascertain the number of shares outstanding and the voting power of each; (ii)&nbsp;determine
the number of shares represented at a meeting and the validity of proxies or ballots; (iii)&nbsp;count all votes and ballots; (iv)&nbsp;determine
any challenges made to any determination made by the inspector(s); and (v)&nbsp;certify the determination of the number of shares represented
at the meeting and the count of all votes and ballots. Such certification and report shall specify, and in determining the validity and
counting of proxies and ballots cast the inspectors may consider, such information as may be required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Only
such persons who are nominated in accordance with the procedures set forth in <U>Section&nbsp;2.12</U> shall be eligible to be elected
at any meeting of stockholders of the Corporation to serve as directors and only such business shall be conducted at a meeting of stockholders
as shall have been brought before the meeting in accordance with the procedures set forth in <U>Section&nbsp;2.12</U>. If any proposed
nomination or business was not made or proposed in compliance with <U>Section&nbsp;2.12</U> (including proper notice under <U>Section&nbsp;2.13</U>
and including whether the stockholder or beneficial owner, if any, on whose behalf the nomination or proposal is made solicited (or is
part of a group which solicited) or did not so solicit, as the case may be, proxies in compliance with such stockholder&rsquo;s representation
pursuant to <U>clause (a)(iv)(D)</U>&nbsp;of <U>Section&nbsp;2.13</U>), then the chair of the meeting shall have the power to declare
that such nomination shall be disregarded or that such proposed business shall not be transacted. If the stockholder (or a qualified representative
of the stockholder) does not appear at the annual or special meeting of stockholders of the Corporation to present a nomination or proposed
business, such nomination shall be disregarded and such proposed business shall not be transacted, notwithstanding that such proposal
or nomination is set forth in the notice of meeting or other proxy materials and notwithstanding that proxies in respect of such vote
may have been received by the Corporation. For purposes of this <U>Section&nbsp;2.10</U>, to be considered a qualified representative
of the stockholder, a person must be a duly authorized officer, manager or partner of such stockholder or authorized by a writing executed
by such stockholder (or a reliable reproduction or electronic transmission of the writing) delivered to the Corporation prior to the making
of such nomination or proposal at such meeting by such stockholder stating that such person is authorized to act for such stockholder
as proxy at the meeting of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;2.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Consent
to Meetings</U>. Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person objects
at the beginning of the meeting to the transaction of any business because the meeting is not lawfully called, noticed or convened and
except that attendance at a meeting is not a waiver of any right to object to the consideration of matters not included in the notice,
to the extent such notice is required, if such objection is expressly made at the time any such matters are presented at the meeting.
Neither the business to be transacted at nor the purpose of any regular or special meeting of stockholders need be specified in any written
waiver of notice or consent, except as otherwise provided in these Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;2.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Director
Nominations and Business Conducted at Meetings of Stockholders</U>. Nominations of persons for election to the Board of Directors of the
Corporation and the proposal of business to be considered by the stockholders may be made at an annual meeting of stockholders (i)&nbsp;by
or at the direction of the Board of Directors or the Chair of the Board of Directors or any authorized committee of the Board of Directors,
or (ii)&nbsp;by any stockholder of the Corporation who is entitled to vote on such matter at the meeting, who complied with the notice
procedures set forth in <U>Section&nbsp;2.13</U> and who was a stockholder of record at the time such notice is delivered to the Secretary
of the Corporation. Nominations of persons for election to the Board of Directors may be made at a special meeting of stockholders at
which directors are to be elected pursuant to the Corporation's notice of meeting (i)&nbsp;by or at the direction of the Board of Directors
or the Chair of the Board of Directors or (ii)&nbsp;by any stockholder of the Corporation who is entitled to vote on such matter at the
meeting, who complied with the notice procedures set forth in <U>Section&nbsp;2.13</U> and who was a stockholder of record at the time
such notice is delivered to the Secretary of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 136; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">H-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;2.13&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Advance
Notice of Director Nominations and Stockholder Proposals by Stockholders</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;For
director nominations or other business to be properly brought before an annual meeting by a stockholder and for director nominations
to be properly brought before a special meeting by a stockholder in each case pursuant to <U>Section&nbsp;2.12</U>, the stockholder of
record must have given timely notice thereof in writing to the Secretary of the Corporation, and, in the case of business other than
director nominations, such other business must be a proper matter for stockholder action. To be timely, a stockholder&rsquo;s notice
for director nominations or other business to be properly brought before an annual meeting shall be delivered to the Secretary at the
principal executive offices of the Corporation not later than the close of business on the 90<SUP>th</SUP> day nor earlier than the close
of business on the 120<SUP>th</SUP> day prior to the first anniversary of the immediately preceding year&rsquo;s annual meeting; provided
that in the event that the date of the annual meeting is more than 30 days before or more than 70 days after such anniversary date, or
if no annual meeting was held in the preceding year, notice by the stockholder to be timely must be so delivered not earlier than the
close of business on the 120<SUP>th</SUP> day prior to such annual meeting and not later than the close of business on the later of the
90<SUP>th</SUP> day prior to such annual meeting or the 10th day following the day on which public announcement (as defined below) of
the date of such meeting is first made by the Corporation. In no event shall the public announcement of an adjournment or postponement
of an annual meeting or special meeting commence a new time period (or extend any time period) for the giving of a stockholder&rsquo;s
notice as described above. The notice must be provided by a stockholder of record and must set forth:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;as
to each person whom the stockholder proposes to nominate for election or re-election as a director all information relating to such person
that is required to be disclosed in solicitations of proxies for election of directors, or is otherwise required, in each case pursuant
to Regulation 14A under the Securities Exchange Act of 1934, as amended (the &quot;<U>Exchange Act</U>&quot;), including such person's
written consent to being named in the proxy statement as a nominee and accompanying proxy card and to serving as a director if elected,
a questionnaire completed and signed by such person (in the form to be provided by the Secretary upon written request of any stockholder
of record within ten days of such request) with respect to the background and qualification of such proposed nominee and a written representation
and agreement (in the form to be provided by the Secretary upon written request of any stockholder of record within ten days of such request)
that such proposed nominee (A)&nbsp;is not and will not become a party to any agreement, arrangement or understanding with, and has not
given any commitment or assurance to, any person or entity as to how such proposed nominee, if elected as a director of the Corporation,
will act or vote on any issue or question that has not been disclosed to the Corporation or that could limit or interfere with such proposed
nominee&rsquo;s fiduciary duties under applicable law, (B)&nbsp;is not and will not become a party to any agreement, arrangement or understanding
with any person or entity other than the Corporation with respect to any direct or indirect compensation, reimbursement or indemnification
in connection with service or action as a director of the Corporation that has not been disclosed to the Corporation, and (C)&nbsp;would
be in compliance, if elected as a director of the Corporation, and will comply with, all applicable publicly disclosed corporate governance,
code of conduct and ethics, conflict of interest, confidentiality, corporate opportunities, trading and any other policies and guidelines
of the Corporation applicable to directors;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 137; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">H-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;as
to any other business that the stockholder proposes to bring before the meeting, a brief description of the business desired to be brought
before the meeting, the text of the proposal or business (including the text of any resolutions proposed for consideration and in the
event that such business includes a proposal to amend the Bylaws, the language of the proposed amendment), the reasons for conducting
such business at the meeting and any substantial interest (within the meaning of Item 5 of Schedule 14A under the Exchange Act) in such
business of such stockholder and the beneficial owner, if any, on whose behalf the proposal is made;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;as
to the stockholder giving the notice and the beneficial owner, if any, on whose behalf the director nomination is made or the business
is proposed: (A)&nbsp;the name and address of such stockholder, as they appear on the Corporation's books, and the name and address of
such beneficial owner, (B)&nbsp;the class and number of shares of stock of the Corporation which are owned of record by such stockholder
and such beneficial owner as of the date of the notice, and a representation that the stockholder will notify the Corporation in writing
within five business days after the record date for such meeting of the class and number of shares of stock of the Corporation owned of
record by the stockholder and such beneficial owner as of the record date for the meeting, and (C)&nbsp;a representation that the stockholder
intends to appear in person or by proxy at the meeting to propose such director nomination or business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;as
to the stockholder giving the notice or, if the notice is given on behalf of a beneficial owner on whose behalf the director nomination
is made or the business is proposed, as to such beneficial owner, and if such stockholder or beneficial owner is an entity, as to each
director, executive, managing member or control person of such entity (any such person, a &ldquo;<U>control person</U>&rdquo;): (A)&nbsp;the
class and number of shares of stock of the Corporation which are beneficially owned (as defined below) by such stockholder or beneficial
owner and by any control person as of the date of the notice, and a representation that the stockholder will notify the Corporation in
writing within five business days after the record date for such meeting of the class and number of shares of stock of the Corporation
beneficially owned by such stockholder or beneficial owner and by any control person as of the record date for the meeting, (B)&nbsp;a
description of any agreement, arrangement or understanding with respect to the director nomination or other business and/or the voting
of shares of any class or series of stock of the Corporation between or among such stockholder or beneficial owner or control person or
any of their respective affiliates or associates and/or any other person (collectively, &ldquo;<U>proponent persons</U>&rdquo;), including,
in the case of a director nomination, the nominee, including without limitation any agreements, arrangements or understandings relating
to any compensation or payments to be paid to any such proposed nominee(s), pertaining to the director nomination(s)&nbsp;or other business
proposed to be brought before the meeting of stockholders and any agreements that would be required to be disclosed pursuant to Item 5
or Item 6 of Exchange Act Schedule 13D (regardless of whether the requirement to file a Schedule 13D is applicable to the stockholder,
beneficial owner or control person) (which description shall identify the name of each other person who is party to such an agreement,
arrangement or understanding) and a representation that the stockholder will notify the Corporation in writing within five business days
after the record date for such meeting of any such agreement, arrangement or understanding in effect as of the record date for the meeting,
(C)&nbsp;a description of any agreement, arrangement or understanding (including any derivative or short positions, profit interests,
options, hedging transactions, and borrowed or loaned shares) that has been entered into as of the date of the stockholder's notice by,
or on behalf of, such proponent person, the effect or intent of which may be to provide any proponent person, directly or indirectly,
with the opportunity to mitigate loss, manage risk or benefit from changes in the share price of any class of the Corporation's stock,
transfer to or from the proponent person, in whole or in part, any of the economic consequences of ownership of any security of the Corporation,
or maintain, increase or decrease the voting power of the proponent person with respect to shares of any class of stock of the Corporation,
and a representation that the stockholder will notify the Corporation in writing within five business days after the record date for such
meeting of any such agreement, arrangement or understanding in effect as of the record date for the meeting, (D)&nbsp;a description of
any proxy (other than a revocable proxy given in response to a public proxy solicitation made pursuant to, and in accordance with, the
Exchange Act), agreement, arrangement, or understanding pursuant to which such stockholder or beneficial owner has or shares a right,
directly or indirectly, to vote any shares of any class or series of capital stock of the Corporation; (E)&nbsp;a description of any agreement,
arrangement or understanding with respect to any rights to distributions on the shares of any class or series of capital stock of the
Corporation, directly or indirectly, owned beneficially by such stockholder or beneficial owner that are separated or separable pursuant
to such agreement, arrangement or understanding from the underlying shares of the Corporation; (F)&nbsp;a description of any performance-related
fees (other than an asset-based fee) that such stockholder or beneficial owner, directly or indirectly, is entitled to receive based on
any increase or decrease in the value of shares of any class of capital stock of the Corporation or any interests described in <U>clause
(A)</U>&nbsp;of this <U>Section&nbsp;2.13(a)(iv)</U>; (G)&nbsp;a representation whether the stockholder or the beneficial owner, if any,
and any control person will engage in a solicitation with respect to the director nomination or business and, if so, the name of each
participant (as defined in Item 4 of Schedule 14A under the Exchange Act) in such solicitation and whether such person intends or is part
of a group which intends to (x)&nbsp;deliver a proxy statement and/or form of proxy to holders of at least the percentage of the Corporation's
outstanding stock required to approve or adopt the business to be proposed or director nomination to be made (in person or by proxy) by
the stockholder, (y)&nbsp;otherwise solicit proxies or votes from stockholders in support of such proposal or director nomination and/or
(z)&nbsp;solicit proxies or votes in support of any proposed nominee in accordance with Rule&nbsp;14a-19 promulgated under the Exchange
Act; and (H)&nbsp;the names and addresses of other stockholders and beneficial owners actually known (without any obligation of inquiry)
by any stockholder giving the notice (and/or beneficial owner, if any, on whose behalf the director nomination or proposal is made) to
support such director nomination or proposal, and to the extent known, the class and number of all shares of the Corporation&rsquo;s capital
stock owned beneficially and/or of record by such other stockholder(s)&nbsp;and beneficial owner(s); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 138; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">H-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;a
certification that the stockholder giving the notice and the beneficial owner(s), if any, on whose behalf the director nomination is made
or the business is proposed, has or have complied with all applicable federal, state and other legal requirements in connection with such
stockholder&rsquo;s and/or each such beneficial owner&rsquo;s acquisition of shares of capital stock or other securities of the Corporation
and/or such stockholder&rsquo;s and/or each such beneficial owner&rsquo;s acts or omissions as a stockholder of the Corporation, including,
without limitation, in connection with such director nomination or proposal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;A
stockholder providing notice of a proposed nomination for election to the Board of Directors or other business proposed to be brought
before a meeting shall update and supplement such notice from time to time to the extent necessary so that the information provided or
required to be provided in such notice shall be true and correct (x)&nbsp;as of the record date for determining the stockholders entitled
to notice of the meeting and (y)&nbsp;as of the date that is 15 days prior to the meeting or any adjournment or postponement thereof.
For the avoidance of doubt, the obligation to update and supplement as set forth in this <U>&lrm;Section&nbsp;2.13(b)</U>&nbsp;or any
other section of these Bylaws shall not limit the Corporation&rsquo;s rights with respect to any deficiencies in any stockholder&rsquo;s
notice, including, without limitation, any representation required herein, extend any applicable deadlines under these Bylaws or enable
or be deemed to permit a stockholder who has previously submitted a stockholder's notice under these Bylaws to amend or update any proposal
or to submit any new proposal, including by changing or adding nominees, matters, business and/or resolutions proposed to be brought before
a meeting of stockholders. Any such update and supplement shall be delivered in writing to the Secretary at the principal offices of the
Corporation (i)&nbsp;in the case of any update and supplement required to be made as of the record date for notice of the meeting, not
later than five days after the later of such record date and the public announcement of such record date and (ii)&nbsp;in the case of
any update or supplement required to be made as of 15 days prior to the meeting or adjournment or postponement thereof, not later than
ten days prior to the date of the meeting or any adjournment or postponement thereof. The Corporation may require any proposed nominee
to furnish within ten days of a request therefor such other information as may reasonably be required by the Corporation to determine
the eligibility of such proposed nominee to serve as a director of the Corporation, including information relevant to a determination
whether such proposed nominee is qualified under the Articles of Incorporation, these Bylaws, the rules&nbsp;or regulations of any stock
exchange applicable to the Corporation, or any law or regulation applicable to the Corporation to serve as a director of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 139; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">H-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;For
purposes of <U>Section&nbsp;2.13(a)</U>, a &ldquo;<U>public announcement</U>&rdquo; shall mean disclosure (x)&nbsp;in a press release
released by the Corporation following its customary procedures and reported by the Dow Jones News Service, Associated Press, Business
Wire or PR Newswire or a comparable national news service or is generally available on internet news sites, or (y)&nbsp;in a document
publicly filed by the Corporation with the Securities and Exchange Commission pursuant to Sections 13, 14 or 15(d)&nbsp;of the Exchange
Act and the rules&nbsp;and regulations promulgated thereunder. For purposes of <U>clause (a)(iv)(A)</U>&nbsp;of this <U>Section&nbsp;2.13</U>,
shares shall be treated as &ldquo;<U>beneficially owned</U>&rdquo; by a person if the person beneficially owns such shares, directly or
indirectly, for purposes of Section&nbsp;13(d)&nbsp;of the Exchange Act and Regulations 13D and 13G thereunder or has or shares pursuant
to any agreement, arrangement or understanding (whether or not in writing): (i)&nbsp;the right to acquire such shares (whether such right
is exercisable immediately or only after the passage of time or the fulfillment of a condition or both), (ii)&nbsp;the right to vote such
shares, alone or in concert with others and/or (iii)&nbsp;investment power with respect to such shares, including the power to dispose
of, or to direct the disposition of, such shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;This
<U>Section&nbsp;2.13</U> shall not apply to notice of a proposal to be made by a stockholder if the stockholder has notified the Corporation
of his, her or its intention to present the proposal at an annual or special meeting only pursuant to and in compliance with Rule&nbsp;14a-8
under the Exchange Act and such proposal has been included in a proxy statement that has been prepared by the Corporation to solicit proxies
for such meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
the stockholder does not provide the information required under <U>clause&nbsp;(a)(iii)(B)</U>&nbsp;and <U>clauses (a)(iv)(A)-(C)</U>&nbsp;of
this <U>Section&nbsp;2.13</U> to the Corporation within the time frames specified herein, or if the stockholder (or a qualified representative
of the stockholder) does not appear at the annual or special meeting of stockholders of the Corporation to present a director nomination
or proposed business, such director nomination shall be disregarded and such proposed business shall not be transacted, notwithstanding
that proxies in respect of such vote may have been received by the Corporation. The chair of the meeting shall have the power to determine
whether notice of a director nomination or of any business proposed to be brought before the meeting was properly made in accordance with
the procedures set forth in this <U>Section&nbsp;2.13</U>. Notwithstanding the foregoing provisions hereof, a stockholder shall also comply
with all applicable requirements of the Exchange Act, and the rules&nbsp;and regulations thereunder with respect to the matters set forth
herein. Notwithstanding anything to the contrary in these Bylaws, unless otherwise required by law, if any stockholder or proponent person
(i)&nbsp;provides notice pursuant to Rule&nbsp;14a-19(b)&nbsp;promulgated under the Exchange Act with respect to any proposed director
nominee and (ii)&nbsp;subsequently fails to comply with the requirements of Rule&nbsp;14a-19 promulgated under the Exchange Act (or fails
to timely provide reasonable evidence sufficient to satisfy the Corporation that such stockholder has met the requirements of Rule&nbsp;14a-19(a)(3)&nbsp;promulgated
under the Exchange Act in accordance with the following sentence), then the director nomination of each such proposed nominee shall be
disregarded, notwithstanding that the nominee is included as a nominee in the Corporation&rsquo;s proxy statement, notice of meeting or
other proxy materials for any annual meeting (or any supplement thereto) and notwithstanding that proxies or votes in respect of the election
of such proposed nominees may have been received by the Corporation (which proxies and votes shall be disregarded). If any stockholder
or proponent person provides notice pursuant to Rule&nbsp;14a-19(b)&nbsp;promulgated under the Exchange Act, such stockholder shall deliver
to the Corporation, no later than five business days prior to the date of the meeting and any adjournment or postponement thereof, reasonable
evidence that it or such stockholder associated person has met the requirements of Rule&nbsp;14a-19(a)(3)&nbsp;promulgated under the Exchange
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 140; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">H-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;2.14&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Meetings
Through Remote Communications</U>. Stockholders may participate in a meeting of the stockholders by any means of remote communication
or other available technology utilized by the Corporation, including without limitation, videoconferencing, teleconferencing, webcast
or other similar method of communication by which all individuals participating in the meeting can hear each other. If any such means
are utilized, the Corporation shall, to the extent required under the NRS, implement reasonable measures to (a)&nbsp;verify the identity
of each person participating through such means as a stockholder and (b)&nbsp;provide the stockholders a reasonable opportunity to participate
in the meeting and to vote on matters submitted to the stockholders, including an opportunity to communicate, and to read or hear the
proceedings of the meeting in a substantially concurrent manner with such proceedings. Participation in a meeting pursuant to this <U>Section&nbsp;2.14</U>
constitutes presence in person at the meeting. Notwithstanding anything to the contrary in these Bylaws, a meeting of stockholders may
be held solely by remote communication pursuant to and in accordance with NRS 78.320(4)-(6).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">Article&nbsp;III<U><BR>
DIRECTORS</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;3.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>General
Powers; Performance of Duties</U>. The business and affairs of the Corporation shall be managed by or under the direction of the Board
of Directors, except as otherwise provided in the NRS or the Articles of Incorporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;3.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Number,
Tenure, and Qualifications</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Board of Directors shall consist of at least three and not more than 20 individuals, with the number of directors within the
foregoing minimum and maximum fixed and thereafter changed from time to time solely by resolution adopted by the Board of Directors
without the need for an amendment to these Bylaws or the Articles of Incorporation. Each director shall hold office until his or her
successor shall be elected or appointed and qualified or until his or her earlier death, retirement, disqualification, resignation
or removal. No reduction of the number of directors shall have the effect of removing any director prior to the expiration of his or
her term of office. No provision of this <U>Section&nbsp;3.2</U> shall restrict the right of the Board of Directors to fill
vacancies or the right of the stockholders to remove directors, each as provided in these Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;3.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Chair
of the Board</U>. The Board of Directors shall elect a Chair of the Board of Directors from the members of the Board of Directors, who
shall preside at all meetings of the Board of Directors and stockholders at which he or she shall be present and shall have and may exercise
such powers as may, from time to time, be assigned to him or her by the Board of Directors, these Bylaws or as provided by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;3.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Vice
Chair of the Board</U>. The Board of Directors may elect a Vice Chair of the Board of Directors from the members of the Board of Directors
who shall preside at all meetings of the Board of Directors and stockholders at which he or she shall be present and the Chair is not
present and shall have and may exercise such powers as may, from time to time, be assigned to him or her by the Board of Directors, these
Bylaws or as provided by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 141; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">H-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;3.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Removal
and Resignation of Directors</U>. Subject to any rights of the holders of preferred stock, if any, and except as otherwise provided in
the NRS or the Articles of Incorporation, any director may be removed from office with or without cause by the affirmative vote of the
holders of not less than two-thirds of the voting power of the issued and outstanding stock of the Corporation entitled to vote generally
in the election of directors (voting as a single class) excluding stock entitled to vote only upon the happening of a fact or event unless
such fact or event shall have occurred. In addition, a director may be removed pursuant to and in accordance with NRS 78.335(8)&nbsp;by
majority vote of the other directors (even if less than a quorum), acting at a meeting and not by written consent, and without a vote
of the stockholders. Any director may resign effective upon giving written notice, unless the notice specifies a later time for effectiveness
of such resignation, to the Chair of the Board of Directors, the President or the Secretary, or in the absence of all of them, to any
other officer of the Corporation. The acceptance of a resignation shall not be necessary to make it effective unless otherwise expressly
provided in the resignation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;3.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;&#8239;<U>Vacancies; Newly Created Directorships</U>. Subject to any rights granted to the holders of
any one or more series of preferred stock then outstanding, if any, any vacancies on the Board of Directors resulting from death,
resignation, retirement, disqualification, removal from office, or other cause, and newly created directorships resulting from any
increase in the authorized number of directors, shall be filled only by a majority vote of the directors then in office or by a sole
remaining director, in either case though less than a quorum, and the director(s)&nbsp;so chosen shall hold office for a term
expiring at the next annual meeting of stockholders and when their successors are elected or appointed and qualified, or until his
or her earlier death, resignation, retirement, disqualification or removal. No decrease in the number of directors constituting the
Board of Directors shall shorten the term of any incumbent directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;3.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Annual
and Regular Meetings</U>. The Board of Directors may hold an annual meeting without call or notice other than this <U>Section&nbsp;3.7</U>,
to transact such business as the Board of Directors deems necessary or appropriate. The Board of Directors may provide by resolution the
place, date, and hour for holding regular meetings between annual meetings, and if the Board of Directors so provides with respect to
a regular meeting, notice of such regular meeting shall not be required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;3.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;<U>Special Meetings</U>. Subject to any rights of the holders of preferred stock, if any, and except as
otherwise required by law, special meetings of the Board of Directors may be called only by the Chair of the Board of Directors, or
if there be no Chair of the Board of Director, by the Chief Executive Officer, or by the President or the Secretary, and shall be
called by the Chair of the Board of Directors, the Chief Executive Officer, the President, or the Secretary upon the request of at
least a majority of the Board of Directors. If the Chair of the Board of Directors, or if there be no Chair of the Board of
Directors, each of the Chief Executive Officer, the President, and the Secretary, fails for any reason to call such special meeting,
a special meeting may be called by a notice signed by at least a majority of the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;3.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Place of Meetings</U>. Any regular or special meeting of the Board of Directors may be
held at such place as the Board of Directors, or in the absence of such designation, as the notice calling such meeting, may
designate. A waiver of notice signed by the directors may designate any place for the holding of such meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;3.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Notice
of Meetings</U>. Except as otherwise provided in <U>Section&nbsp;3.7</U>, there shall be delivered to each director at the address appearing
for him or her on the records of the Corporation, at least 24 hours before the time of such meeting, a copy of a written notice of any
meeting (i)&nbsp;by delivery of such notice personally, (ii)&nbsp;by mailing such notice postage prepaid, (iii)&nbsp;by facsimile, (iv)&nbsp;by
overnight courier, or (v)&nbsp;by electronic transmission or electronic writing, including, without limitation, e-mail. If mailed to an
address inside the United States, the notice shall be deemed delivered two business days following the date the same is deposited in the
United States mail, postage prepaid. If mailed to an address outside the United States, the notice shall be deemed delivered four business
days following the date the same is deposited in the United States mail, postage prepaid. If sent via overnight courier, the notice shall
be deemed delivered the business day following the delivery of such notice to the courier. If sent via facsimile, the notice shall be
deemed delivered upon sender&rsquo;s receipt of confirmation of the successful transmission. If sent by electronic transmission (including,
without limitation, e-mail), the notice shall be deemed delivered when directed to the e-mail address of the director appearing on the
records of the Corporation and otherwise pursuant to the applicable provisions of NRS Chapter 75. If the address of any director is incomplete
or does not appear upon the records of the Corporation it will be sufficient to address any notice to such director at the registered
office of the Corporation. Any director may waive notice of any meeting, and the attendance of a director at a meeting and oral consent
entered on the minutes of such meeting shall constitute waiver of notice of the meeting unless such director objects, prior to the transaction
of any business, that the meeting was not lawfully called, noticed or convened. Attendance for the express purpose of objecting to the
transaction of business thereat because the meeting was not properly called or convened shall not constitute presence or a waiver of notice
for purposes hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 142; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">H-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;3.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Quorum;
Adjourned Meetings</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;A
majority of the directors in office, at a meeting duly assembled, is necessary to constitute a quorum for the transaction of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;At
any meeting of the Board of Directors where a quorum is not present, a majority of those present may adjourn, from time to time, until
a quorum is present, and no notice of such adjournment shall be required. At any adjourned meeting where a quorum is present, any business
may be transacted which could have been transacted at the meeting originally called.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;3.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Manner
of Acting</U>. Except as provided in <U>Section&nbsp;3.14</U>, the affirmative vote of a majority of the directors present at a meeting
at which a quorum is present is the act of the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;3.13&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Meetings
Through Electronic Communications</U>. Members of the Board of Directors or of any committee designated by the Board of Directors may
participate in a meeting of the Board of Directors or such committee by any means of remote communication or other available technology
utilized by the Corporation, including, without limitation, videoconferencing, teleconferencing, webcast or other similar method of communication
by which all individuals participating in the meeting can hear each other. If any such means are utilized, the Corporation shall, to the
extent required under the NRS, implement reasonable measures to (a)&nbsp;verify the identity of each person participating through such
means as a director or member of the committee, as the case may be, and (b)&nbsp;provide the directors or members of the committee a reasonable
opportunity to participate in the meeting and to vote on matters submitted to the directors or members of the committee, including an
opportunity to communicate, and to read or hear the proceedings of the meeting in a substantially concurrent manner with such proceedings.
Participation in a meeting pursuant to this <U>Section&nbsp;3.13</U> constitutes presence in person at the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;3.14&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Action
Without Meeting</U>. Any action required or permitted to be taken at a meeting of the Board of Directors or of a committee thereof may
be taken without a meeting if, before or after the action, a written consent thereto is signed by all of the members of the Board of Directors
or the committee, excluding any director(s)&nbsp;not required to sign such consent pursuant to and in accordance with NRS 78.315(2). The
written consent may be signed manually or electronically (or by any other means then permitted under the NRS) and in counterparts, including,
without limitation, counterparts delivered by facsimile or electronic transmission, and shall be filed with the minutes of the proceedings
of the Board of Directors or committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 143; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">H-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;3.15&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Powers
and Duties</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as otherwise restricted by NRS Chapter 78 or the Articles of Incorporation, the Board of Directors has full control over the business
and affairs of the Corporation. The Board of Directors may delegate any of its authority to manage, control or conduct the business of
the Corporation to any standing or special committee, or to any officer or agent, and to appoint any persons to be agents of the Corporation
with such powers, including the power to subdelegate, and upon such terms as it deems fit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Board of Directors, in its discretion, or the chair presiding at a meeting of stockholders, in his or her discretion, may submit any contract
or act for approval or ratification at any annual meeting of the stockholders or any special meeting properly called and noticed for the
purpose of considering any such contract or act, provided a quorum is present.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Board of Directors may, by resolution passed by at least a majority of the Board of Directors, designate one or more committees, provided
that each such committee must have at least one director of the Corporation as a member. Unless the Articles of Incorporation, the charter
of the committee, or the resolutions designating the committee expressly require that all members of such committee be directors of the
Corporation, the Board of Directors may appoint natural persons who are not directors of the Corporation to serve on such committee. The
Board of Directors may designate one or more individuals as alternate members of any committee, who may replace any absent or disqualified
member at any meeting of the committee. In the absence or disqualification of a member of a committee, the member or members thereof present
at any meeting and not disqualified from voting, whether or not he, she or they constitute a quorum, may unanimously appoint another individual
to act at the meeting in the place of any such absent or disqualified member. Subject to applicable law and to the extent provided in
the resolution of the Board of Directors, any such committee shall have and may exercise all the powers of the Board of Directors in the
management of the business and affairs of the Corporation. Such committee or committees shall have such name or names as may be determined
from time to time by resolution adopted by the Board of Directors. The committees shall keep regular minutes of their proceedings and
report the same to the Board of Directors when required. Each committee of the Board of Directors may fix its own rules&nbsp;of procedure
and shall hold its meetings as provided by such rules, except as may otherwise be provided in the resolution of the Board of Directors
designating such committee. Unless otherwise provided in such a resolution, the presence of at least a majority of the members then serving
on the committee shall be necessary to constitute a quorum unless there are only one or two members then serving, in which event one member
shall constitute a quorum; and all matters shall be determined by a majority vote of the members present at a meeting of the committee
at which a quorum is present.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;3.16&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Compensation</U>.
The Board of Directors, without regard to personal interest, may establish the compensation of directors for services in any capacity.
If the Board of Directors establishes the compensation of directors pursuant to this <U>Section&nbsp;3.16</U>, such compensation is presumed
to be fair to the Corporation unless proven unfair by a preponderance of the evidence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;3.17&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Organization</U>.
Meetings of the Board of Directors shall be presided over by the Chair of the Board of Directors, or in the absence of the Chair of the
Board of Directors, by the Vice Chair, or in his or her absence by a chair chosen at the meeting. The Secretary, or in the absence, of
the Secretary an Assistant Secretary, shall act as secretary of the meeting, but in the absence of the Secretary and any Assistant Secretary,
the chair of the meeting may appoint any person to act as secretary of the meeting. The order of business at each such meeting shall be
as determined by the chair of the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 144; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">H-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">Article&nbsp;IV<U><BR>
OFFICERS</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;4.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;&#8239;<U>Election</U>. The Board of Directors shall elect or appoint at least a president, a secretary
and a treasurer or the equivalents thereof in accordance with NRS 78.130(1). The Board of Directors may from time to time, by
resolution, elect or appoint such other officers and agents as it may deem advisable, who shall hold office at the pleasure of the
Board of Directors, and shall have such powers and duties and be paid such compensation as may be directed by the Board of
Directors, including any committee thereof. Each officer of the Corporation shall serve until their respective successors are
elected and appointed and shall qualify or until their earlier resignation or removal. Any individual may simultaneously hold two or
more offices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;4.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;<U>Removal; Resignation</U>. Any officer or agent elected or appointed by the Board of Directors may be removed by the
Board of Directors with or without cause. Any officer may resign at any time upon written notice to the Corporation. Any such
removal or resignation shall be subject to the rights, if any, of the respective parties under any contract between the Corporation
and such officer or agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;4.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Vacancies</U>. Any vacancy in any office because of death, resignation, removal or
otherwise may be filled by the Board of Directors for the unexpired portion of the term of such office.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;4.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;<U>Chief Executive Officer</U>. The Board of Directors may elect a Chief Executive Officer who, subject
to the supervision and control of the Board of Directors, shall have the ultimate responsibility for the management and control of
the business and affairs of the Corporation, and perform such other duties and have such other powers as may be reasonably incident
to such responsibility or which are delegated to him or her by the Board of Directors, these Bylaws or as provided by law. If a
President of the Corporation is not elected or appointed, the Chief Executive Officer shall also be deemed the President of the
Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;4.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>President</U>.
The President, subject to the supervision and control of the Board of Directors, shall in general actively supervise and control the business
and affairs of the Corporation. The President shall keep the Board of Directors fully informed as the Board of Directors may request and
shall consult the Board of Directors concerning the business of the Corporation. The President shall perform such other duties and have
such other powers which are delegated and assigned to him or her by the Board of Directors, the Chief Executive Officer, if any, these
Bylaws or as provided by law. If a Chief Executive Officer of the Corporation is not elected or appointed, the President shall also be
deemed the Chief Executive Officer of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;4.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Vice
Presidents</U>. The Board of Directors may elect one or more vice presidents. In the absence or disability of the President, or at the
President&rsquo;s request, the Vice President or Vice Presidents (or such other officers), in order of their rank as fixed by the Board
of Directors, and if not ranked, the Vice Presidents (or such other officers) in the order designated by the Board of Directors, or in
the absence of such designation, in the order designated by the President, shall perform all of the duties of the President, and when
so acting, shall have all the powers of, and be subject to all the restrictions on the President. Each Vice President shall perform such
other duties and have such other powers which are delegated and assigned to him or her by the Board of Directors, the Chief Executive
Officer, the President, these Bylaws or as provided by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;4.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Secretary</U>.
The Secretary shall attend all meetings of the stockholders, the Board of Directors and any committees thereof, and shall keep, or cause
to be kept, the minutes of proceedings thereof in books provided for that purpose. He or she shall keep, or cause to be kept, a register
of the stockholders of the Corporation and shall be responsible for the giving of notice of meetings of the stockholders, the Board of
Directors and any committees, and shall see that all notices are duly given in accordance with the provisions of these Bylaws or as required
by law. The Secretary shall be custodian of the corporate seal, if any, the records of the Corporation, the stock certificate books, transfer
books and stock ledgers, and such other books and papers as the Board of Directors or any appropriate committee may direct. The Secretary
shall perform all other duties commonly incident to his or her office and shall perform such other duties which are assigned to him or
her by the Board of Directors, the Chief Executive Officer, the President, these Bylaws or as provided by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 145; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">H-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;4.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Assistant
Secretaries</U>. An Assistant Secretary shall, at the request of the Secretary, or in the absence or disability of the Secretary, perform
all the duties of the Secretary. He or she shall perform such other duties as are assigned to him or her by the Board of Directors, the
Chief Executive Officer, the President, these Bylaws or as provided by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;4.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Treasurer</U>.
The Treasurer shall have the care and custody of, and be responsible for, all of the money, funds, securities, receipts and valuable papers,
documents and instruments of the Corporation, and all books and records relating thereto. The Treasurer shall keep, or cause to be kept,
full and accurate books of accounts of the Corporation&rsquo;s transactions, which shall be the property of the Corporation, and shall
render financial reports and statements of condition of the Corporation when so requested by the Board of Directors, the Chair of the
Board of Directors, the Chief Executive Officer, or the President. The Treasurer shall perform all other duties commonly incident to his
or her office and such other duties as may, from time to time, be assigned to him or her by the Board of Directors, the Chief Executive
Officer, the President, these Bylaws or as provided by law. The Treasurer shall, if required by the Board of Directors, give a bond to
the Corporation in such sum and with such security as shall be approved by the Board of Directors for the faithful performance of all
the duties of the Treasurer and for restoration to the Corporation, in the event of the Treasurer&rsquo;s death, resignation, retirement
or removal from office, of all books, records, papers, vouchers, money and other property in the Treasurer&rsquo;s custody or control
and belonging to the Corporation. The expense of such bond shall be borne by the Corporation. If a Chief Financial Officer of the Corporation
has not been elected or appointed, the Treasurer shall also be deemed the Chief Financial Officer of the Corporation and if a Chief Financial
Officer of the Corporation has been elected, the Chief Financial Officer shall also be deemed the Treasurer of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;4.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Assistant
Treasurers</U>. An assistant treasurer shall, at the request of the Treasurer, or in the absence or disability of the Treasurer, perform
all the duties of the Treasurer. He or she shall perform such other duties which are assigned to him or her by the Board of Directors,
the Chief Executive Officer, the President, the Treasurer, the Chief Financial Officer, these Bylaws or as provided by law. The Board
of Directors may require an assistant treasurer to give a bond to the Corporation in such sum and with such security as it may approve,
for the faithful performance of the duties of the Assistant Treasurer, and for restoration to the Corporation, in the event of the Assistant
Treasurer&rsquo;s death, resignation, retirement or removal from office, of all books, records, papers, vouchers, money and other property
in the Assistant Treasurer&rsquo;s custody or control and belonging to the Corporation. The expense of such bond shall be borne by the
Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;4.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Execution
of Negotiable Instruments, Deeds and Contracts</U>. All (a)&nbsp;checks, drafts, notes, bonds, bills of exchange, and orders for the payment
of money of the Corporation, (b)&nbsp;deeds, mortgages, proxies, powers of attorney and other written contracts, documents, instruments
and agreements to which the Corporation shall be a party and (c)&nbsp;assignments or endorsements of stock certificates, registered bonds
or other securities owned by the Corporation shall be signed in the name of the Corporation by such officers or other persons as the Board
of Directors may from time to time designate. The Board of Directors may authorize the use of the facsimile signatures of any such persons.
Any officer of the Corporation shall be authorized to attend, act and vote, or designate another officer or an agent of the Corporation
to attend, act and vote, at any meeting of the owners of any entity in which the Corporation may own an interest or to take action by
written consent in lieu thereof. Such officer or agent, at any such meeting or by such written action, shall possess and may exercise
on behalf of the Corporation any and all rights and powers incident to the ownership of such interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 146; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">H-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">Article&nbsp;V<U><BR>
CAPITAL STOCK</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;5.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;<U>Issuance</U>. Shares of the Corporation&rsquo;s authorized capital stock shall, subject to any provisions or
limitations of the laws of the State of Nevada, the Articles of Incorporation or any contracts or agreements to which the
Corporation may be a party, be issued in such manner, at such times, upon such conditions and for such consideration as shall be
prescribed by the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;5.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;&#8239;<U>Stock Certificates and Uncertificated Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;All classes and series of shares of the capital stock of the Corporation shall be uncertificated and in book-entry form unless the Board
of Directors authorizes the issuance of certificates to evidence one or more classes or series of capital stock, in which case, each holder
of such shares in the Corporation shall be entitled to have a certificate signed by or in the name of the Corporation by (i)&nbsp;the
Chief Executive Officer, the President, or a Vice President and (ii)&nbsp;the Secretary, an Assistant Secretary, the Treasurer or the
Chief Financial Officer of the Corporation (or any other two officers or agents so authorized by the Board of Directors), certifying the
number of shares of stock owned by him, her or it in the Corporation. Any issuance of uncertificated shares shall have no effect on existing certificates for shares until such certificates are
surrendered to the Corporation, or on the respective rights and obligations of the stockholders. Whenever any such certificate is countersigned
or otherwise authenticated by a transfer agent or a transfer clerk and by a registrar (other than the Corporation), then a facsimile of
the signatures of any corporate officers or agents, the transfer agent, transfer clerk or the registrar of the Corporation may be printed
or lithographed upon the certificate in lieu of the actual signatures. In the event that any officer or officers who have signed, or whose
facsimile signatures have been used on any certificate or certificates for stock cease to be an officer or officers because of death,
resignation or other reason, before the certificate or certificates for stock have been delivered by the Corporation, the certificate
or certificates may nevertheless be adopted by the Corporation and be issued and delivered as though the person or persons who signed
the certificate or certificates, or whose facsimile signature or signatures have been used thereon, had not ceased to be an officer or
officers of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Within
a reasonable time after the issuance or transfer of any uncertificated shares on the books of the Corporation in book entry form, the
Corporation shall send to the registered holder thereof a written statement certifying the number and class (and the designation of the
series, if any) of the shares owned by such stockholder in the Corporation and any restrictions on the transfer or registration of such
shares imposed by the Articles of Incorporation, these Bylaws, any agreement among stockholders, any agreement between the stockholders
and the Corporation or by applicable securities laws, and, within ten days after receipt of a written request therefor from the stockholder
of record, the Corporation shall provide to such stockholder of record holding uncertificated shares, a written statement confirming the
information contained in such written statement previously sent to the stockholder of record. The Corporation may adopt a system of issuance,
recordation and transfer of its shares of stock by electronic or other means not involving the issuance of certificates. Except as otherwise
expressly provided by the NRS, the rights and obligations of the stockholders of the Corporation shall be identical whether or not their
shares of stock are represented by certificates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Each
certificate representing shares shall state the following upon the face thereof: the name of the state of the Corporation&rsquo;s organization;
the name of the person to whom issued; the number and class of shares and the designation of the series, if any, which such certificate
represents; the par value of each share, if any, represented by such certificate or a statement that the shares are without par value.
Certificates of stock shall be in such form consistent with law as shall be prescribed by the Board of Directors. No certificate shall
be issued until the shares represented thereby are fully paid. In addition to the foregoing, all certificates evidencing shares of the
Corporation&rsquo;s stock or other securities issued by the Corporation shall contain such legend or legends as may from time to time
be required by the NRS or such other federal, state or local laws or regulations then in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 147; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">H-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;5.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;&#8239;<U>Surrendered; Lost or Destroyed Certificates</U>. All certificates surrendered to the
Corporation, except those representing treasury shares, shall be canceled and no new certificate shall be issued until the former
certificate for a like number of shares shall have been canceled, except that in case of a lost, stolen, destroyed or mutilated
certificate, a new one may be issued therefor. However, any stockholder applying for the issuance of a stock certificate in lieu of
one alleged to have been lost, stolen, destroyed or mutilated shall, prior to the issuance of a replacement, provide the Corporation
with his, her or its affidavit of the facts surrounding the loss, theft, destruction or mutilation and, if required by the Board of
Directors, an indemnity bond in an amount not less than twice the then-current market value of the stock, and upon such terms as the
treasurer or the Board of Directors shall require which shall indemnify the Corporation against any loss, damage, cost or
inconvenience arising as a consequence of the issuance of a replacement certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;5.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;&#8239;<U>Replacement Certificate</U>. When the Articles of Incorporation are amended in any way
affecting the statements contained in the certificates for outstanding shares of capital stock of the Corporation or it becomes
desirable for any reason, in the discretion of the Board of Directors, including, without limitation, the merger of the Corporation
with another Corporation or the conversion or reorganization of the Corporation, to cancel any outstanding certificate for shares
and issue a new certificate therefor conforming to the rights of the holder, the Board of Directors may order any holders of
outstanding certificates for shares to surrender and exchange the same for new certificates within a reasonable time to be fixed by
the Board of Directors. The order may provide that a holder of any certificate(s)&nbsp;ordered to be surrendered shall not be
entitled to vote, receive distributions or exercise any other rights of stockholders of record until the holder has complied with
the order, but the order operates to suspend such rights only after notice and until compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;5.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Transfer of Shares</U>. No transfer of stock shall be valid as against the Corporation
except on surrender and cancellation of any certificate(s)&nbsp;therefor accompanied by an assignment or transfer by the registered
owner made either in person or under assignment(to the extent such shares are evidenced by a physical stock certificate) or by due
delivery of transfer instructions (in the case of uncertificated shares) and any documents required therefor to the person in charge
of the stock and transfer books and ledgers and in compliance with any procedures adopted by the Corporation or its agents and
applicable law, and a record shall be made of each such transfer. Certificates representing such shares, if any, shall be cancelled
and new certificates (if the shares are to be certificated) or uncertificated shares (if the shares are to be uncertificated) shall
thereupon be issued. Whenever any transfer shall be expressly made for collateral security and not absolutely, the collateral nature
of the transfer shall be reflected in the entry of transfer in the records of the Corporation. The Corporation shall, subject to
applicable law, have power and authority to make such rules&nbsp;and regulations as it may deem necessary or proper concerning the
issue, transfer and registration of certificates for shares of stock of the Corporation or uncertificated shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;5.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Transfer
Agent; Registrars</U>. The Board of Directors may appoint one or more transfer agents, transfer clerks and registrars of transfer and
may require all certificates for shares of stock to bear the signature of such transfer agents, transfer clerks and/or registrars of transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;5.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Miscellaneous</U>.
The Board of Directors shall have the power and authority to make such rules&nbsp;and regulations not inconsistent herewith as it may
deem expedient concerning the issue, transfer, and registration of certificates for shares of the Corporation&rsquo;s stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 148; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">H-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;5.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Inapplicability
of Controlling Interest Statutes</U>. Notwithstanding any other provision in these Bylaws to the contrary, and in accordance with the
provisions of NRS 78.378, the provisions of NRS 78.378 to 78.3793, inclusive, or any successor statutes, relating to acquisitions of controlling
interests in the Corporation shall not apply to the Corporation or to any acquisition of any shares of the Corporation&rsquo;s capital
stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">Article&nbsp;VI<U><BR>
DISTRIBUTIONS</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Distributions (as defined
in NRS 78.191) may be declared, subject to the provisions of the laws of the State of Nevada and the Articles of Incorporation, by the
Board of Directors and may be paid in money, shares of corporate stock, property or any other medium not prohibited under applicable law.
The Board of Directors may fix in advance a record date, in accordance with and as provided in <U>Section&nbsp;2.5</U>, prior to the distribution
for the purpose of determining stockholders entitled to receive any distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">Article&nbsp;VII<U><BR>
RECORDS AND REPORTS; CORPORATE SEAL; FISCAL YEAR</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;7.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Records</U>.
All original records of the Corporation, shall be kept at the principal office of the Corporation by or under the direction of the Secretary
or at such other place or by such other person as may be prescribed by these Bylaws or the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;7.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Corporate
Seal</U>. The Board of Directors may, by resolution, authorize a seal, and the seal may be used by causing it, or a facsimile, to be impressed
or affixed or reproduced or otherwise. Except as otherwise specifically provided in these Bylaws, any officer of the Corporation shall
have the authority to affix the seal to any document requiring it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;7.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Fiscal
Year-End</U>. The fiscal year-end of the Corporation shall be such date as may be fixed from time to time by resolution of the Board of
Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">Article&nbsp;VIII<U><BR>
INDEMNIFICATION</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;8.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;&#8239;<U>Indemnification and Insurance</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Indemnification
of Directors and Officers</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;For
purposes of this <U>Article&nbsp;VIII</U>, (A)&nbsp;&ldquo;<U>Indemnitee</U>&rdquo; shall mean each director or officer who was or is
a party to, or is threatened to be made a party to, or is otherwise involved in, any Proceeding (as defined below), by reason of the fact
that he or she is or was a director, officer, employee or agent (including, without limitation, as a trustee, fiduciary, administrator
or manager) of the Corporation or any predecessor entity thereof, or is or was serving in any capacity at the request of the Corporation
as a director, manager, officer, employee or agent (including, without limitation, as a trustee, fiduciary, administrator, partner, member
or manager) of, or in any other capacity for, another corporation or any partnership, joint venture, limited liability company, trust,
or other enterprise; and (B)&nbsp;&ldquo;<U>Proceeding</U>&rdquo; shall mean any threatened, pending, or completed action, suit or proceeding
(including, without limitation, an action, suit or proceeding by or in the right of the Corporation), whether civil, criminal, administrative,
or investigative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 149; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">H-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Each
Indemnitee shall be indemnified and held harmless by the Corporation to the fullest extent permitted by the laws of the State of Nevada,
against all expense, liability and loss (including, without limitation, attorneys&rsquo; fees, judgments, fines, taxes, penalties, and
amounts paid or to be paid in settlement) reasonably incurred or suffered by the Indemnitee in connection with any Proceeding; provided
that such Indemnitee either is not liable pursuant to NRS 78.138 or acted in good faith and in a manner such Indemnitee reasonably believed
to be in or not opposed to the best interests of the Corporation and, with respect to any Proceeding that is criminal in nature, had no
reasonable cause to believe that his or her conduct was unlawful. The termination of any Proceeding by judgment, order, settlement, conviction
or upon a plea of <I>nolo contendere</I> or its equivalent, does not, of itself, create a presumption that the Indemnitee is liable pursuant
to NRS 78.138 or did not act in good faith and in a manner in which he or she reasonably believed to be in or not opposed to the best
interests of the Corporation, or that, with respect to any criminal proceeding he or she had reasonable cause to believe that his or her
conduct was unlawful. The Corporation shall not indemnify an Indemnitee for any claim, issue or matter as to which the Indemnitee has
been adjudged by a court of competent jurisdiction, after exhaustion of all appeals therefrom, to be liable to the Corporation or for
any amounts paid in settlement to the Corporation, unless and only to the extent that the court in which the Proceeding was brought or
other court of competent jurisdiction determines upon application that in view of all the circumstances of the case, the Indemnitee is
fairly and reasonably entitled to indemnity for such amounts as the court deems proper. Except as so ordered by a court and for advancement
of expenses pursuant to this <U>Section&nbsp;8.1</U>, indemnification may not be made to or on behalf of an Indemnitee if a final adjudication
establishes that his or her acts or omissions involved intentional misconduct, fraud or a knowing violation of law and was material to
the cause of action. Notwithstanding anything to the contrary contained in these Bylaws, no director or officer may be indemnified for
expenses incurred in defending any threatened, pending, or completed action, suit or proceeding (including without limitation, an action,
suit or proceeding by or in the right of the Corporation), whether civil, criminal, administrative or investigative, that such director
or officer incurred in his or her capacity as a stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Indemnification
pursuant to this <U>Section&nbsp;8.1</U> shall continue as to an Indemnitee who has ceased to be a director, officer, employee or agent
of the Corporation or any predecessor entity thereof or a director, officer, employee, agent, partner, member, manager or fiduciary of,
or to serve in any other capacity for, another corporation or any partnership, joint venture, limited liability company, trust, or other
enterprise and shall inure to the benefit of his or her heirs, executors and administrators.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
expenses of Indemnitees must be paid by the Corporation or through insurance purchased and maintained by the Corporation or through other
financial arrangements made by the Corporation, as such expenses are incurred and in advance of the final disposition of the Proceeding,
upon receipt of an undertaking by or on behalf of such Indemnitee to repay the amount if it is ultimately determined by a court of competent
jurisdiction that he or she is not entitled to be indemnified by the Corporation. To the extent that an Indemnitee is successful on the
merits or otherwise in defense of any Proceeding, or in the defense of any claim, issue or matter therein, the Corporation shall indemnify
him or her against expenses, including attorneys&rsquo; fees, actually and reasonably incurred in by him or her in connection with the
defense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Indemnification
of Employees and Other Persons</U>. The Corporation may, by action of the Board of Directors and to the extent provided in such action,
indemnify employees and other persons as though they were Indemnitees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Non-Exclusivity
of Rights</U>. The rights to indemnification provided in this <U>Article&nbsp;VIII</U> shall not be exclusive of any other rights that
any person may have or hereafter acquire under any statute, provision of the Articles of Incorporation or these Bylaws, agreement, vote
of stockholders or directors, or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 150; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">H-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Insurance</U>.
The Corporation may purchase and maintain insurance or make other financial arrangements on behalf of any Indemnitee for any liability
asserted against him or her and liability and expenses incurred by him or her in his or her capacity as a director, officer, employee,
member, managing member or agent, or arising out of his or her status as such, whether or not the Corporation has the authority to indemnify
him or her against such liability and expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Other
Financial Arrangements</U>. The other financial arrangements which may be made by the Corporation may include the following (i)&nbsp;the
creation of a trust fund; (ii)&nbsp;the establishment of a program of self-insurance; (iii)&nbsp;the securing of its obligation of indemnification
by granting a security interest or other lien on any assets of the Corporation; and (iv)&nbsp;the establishment of a letter of credit,
guarantee or surety. No financial arrangement made pursuant to this subsection may provide protection for a person adjudged by a court
of competent jurisdiction, after exhaustion of all appeals therefrom, to be liable for intentional misconduct, fraud, or a knowing violation
of law, except with respect to advancement of expenses or indemnification ordered by a court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Other
Matters Relating to Insurance or Financial Arrangements</U>. Any insurance or other financial arrangement made on behalf of a person pursuant
to this <U>Section&nbsp;8.1</U> may be provided by the Corporation or any other person approved by the Board of Directors, even if all
or part of the other person&rsquo;s stock or other securities is owned by the Corporation. In the absence of fraud, (i)&nbsp;the decision
of the Board of Directors as to the propriety of the terms and conditions of any insurance or other financial arrangement made pursuant
to this <U>Section&nbsp;8.1</U> and the choice of the person to provide the insurance or other financial arrangement is conclusive; and
(ii)&nbsp;the insurance or other financial arrangement is not void or voidable and does not subject any director approving it to personal
liability for his action; even if a director approving the insurance or other financial arrangement is a beneficiary of the insurance
or other financial arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;8.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Amendment</U>.
The provisions of this <U>Article&nbsp;VIII</U> relating to indemnification shall constitute a contract between the Corporation and each
of its directors and officers which may be modified as to any director or officer only with that person&rsquo;s consent or as specifically
provided in this <U>Section&nbsp;8.2</U>. Notwithstanding any other provision of these Bylaws relating to their amendment generally, any
repeal or amendment of this <U>Article&nbsp;VIII</U> which is adverse to any director or officer shall apply to such director or officer
only on a prospective basis, and shall not limit the rights of an Indemnitee to indemnification with respect to any action or failure
to act occurring prior to the time of such repeal or amendment. Notwithstanding any other provision of these Bylaws (including, without
limitation, <U>Article&nbsp;X</U>), no repeal or amendment of these Bylaws shall affect any or all of this <U>Article&nbsp;VIII</U> so
as to limit or reduce the indemnification in any manner unless adopted by (i)&nbsp;the unanimous vote of the directors of the Corporation
then serving, or (ii)&nbsp;by the stockholders as set forth in <U>Article&nbsp;X</U>; provided that no such amendment shall have a retroactive
effect inconsistent with the preceding sentence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">Article&nbsp;IX<U><BR>
CHANGES IN NEVADA LAW</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">References in these Bylaws
to the laws of the State of Nevada or the NRS or to any provision thereof shall be to such law as it existed on the date these Bylaws
were adopted or as such law thereafter may be changed; provided that (a)&nbsp;in the case of any change which expands the liability of
directors or officers or limits the indemnification rights or the rights to advancement of expenses which the Corporation may provide
in <U>Article&nbsp;VIII</U>, the rights to limited liability, to indemnification and to the advancement of expenses provided in the Articles
of Incorporation and/or these Bylaws shall continue as theretofore to the extent permitted by law; and (b)&nbsp;if such change permits
the Corporation, without the requirement of any further action by stockholders or directors, to limit further the liability of directors
or limit the liability of officers or to provide broader indemnification rights or rights to the advancement of expenses than the Corporation
was permitted to provide prior to such change, then liability thereupon shall be so limited and the rights to indemnification and the
advancement of expenses shall be so broadened to the extent permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 151; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">H-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">Article&nbsp;X<U><BR>
AMENDMENT OR REPEAL</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In furtherance and not in
limitation of the powers conferred by statute, the Board of Directors is expressly authorized to make, alter, amend, rescind or repeal
these Bylaws, in whole or in part, or to adopt new bylaws; provided that these Bylaws may be amended or repealed in any respect, and new
bylaws may be adopted, in each case by the affirmative vote of the holders of at least two-thirds of the outstanding voting power of the
Corporation, voting together as a single class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">Article&nbsp;XI<U><BR>
forum for adjudication of disputes</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;11.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Forum
for Adjudication of Disputes</U>. To the fullest extent permitted by law, and unless the Corporation consents in writing to the
selection of an alternative forum, the Eighth Judicial District Court of Clark County, Nevada, shall be the sole and exclusive forum
for any actions, suits or proceedings, whether civil, administrative or investigative (a)&nbsp;brought in the name or right of the
Corporation or on its behalf, (b)&nbsp;asserting a claim for breach of any fiduciary duty owed by any current or former director,
officer, stockholder, or employee or agent of the Corporation to the Corporation or the Corporation&rsquo;s stockholders,
(c)&nbsp;any internal action (as defined in NRS 78.046) including any action asserting a claim against the Corporation arising
pursuant to any provision of NRS Chapters 78 or 92A, the Articles of Incorporation or these Bylaws, any agreement entered into
pursuant to NRS 78.365 or as to which the NRS confers jurisdiction on the district court of the State of Nevada, (d)&nbsp;to
interpret, apply, enforce or determine the validity of the Articles of Incorporation or these Bylaws or (e)&nbsp;asserting a claim
governed by the internal affairs doctrine; provided that such exclusive forum provisions will not apply to suits brought to enforce
any liability or duty created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. In
the event that the Eighth Judicial District Court of Clark County, Nevada does not have jurisdiction over any such action, suit or
proceeding, then any other state district court located in the State of Nevada shall be the sole and exclusive forum therefor and in
the event that no state district court in the State of Nevada has jurisdiction over any such action, suit or proceeding, then a
federal court located within the State of Nevada shall be the sole and exclusive forum therefor. Unless the Corporation consents in
writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest
extent permitted by applicable law, be the exclusive forum for the resolution of any complaint asserting a cause of action arising
under the federal securities laws of the United States of America, including, in each case, the applicable rules&nbsp;and
regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;11.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;<U>Deemed Notice and Consent</U>. To the fullest extent permitted by law, each and every natural person, corporation,
general or limited partnership, limited liability company, joint venture, trust, association or any other entity purchasing or
otherwise acquiring any interest (of any nature whatsoever) in any shares of the capital stock of the Corporation shall be deemed,
by reason of and from and after the time of such purchase or other acquisition, to have notice of and to have consented to all of
the provisions of (a)&nbsp;these Bylaws (including this <U>Article&nbsp;XI</U>), (b)&nbsp;the Articles of Incorporation and
(c)&nbsp;any amendment to these Bylaws or the Articles of Incorporation enacted or adopted in accordance with these Bylaws, the
Articles of Incorporation and applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;11.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Severability</U>.
If any provision or provisions of these Bylaws shall be held to be invalid, illegal or unenforceable as applied to any person or entity
or circumstance for any reason whatsoever, then, to the fullest extent permitted by law, the validity, legality and enforceability of
such provision or provisions in any other circumstance and of the remaining provisions of these Bylaws (including, without limitation,
each portion of any paragraph of these Bylaws containing any such provision held to be invalid, illegal or unenforceable that is not itself
held to be invalid, illegal or unenforceable) and the application of such provision or provisions to other persons, entities and circumstances
shall not in any way be affected or impaired thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">*&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;*&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;*&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;*</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 152; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">H-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B><A NAME="pros4_021"></A>ANNEX
I &mdash; DIVISION 2 OF PART&nbsp;8 OF THE BCBCA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="font: 13pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Division 2 &mdash; Dissent Proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><B>Definitions and application</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>237</B></TD><TD STYLE="text-align: justify; width: 0.25in">(1)</TD>
                                                                                       <TD STYLE="text-align: justify">In this Division:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.5in"><B>&quot;dissenter&quot; </B>means
a shareholder who, being entitled to do so, sends written notice of dissent when and as required by section 242;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.5in"><B>&quot;notice shares&quot; </B>means,
in relation to a notice of dissent, the shares in respect of which dissent is being exercised under the notice of dissent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><B>&quot;payout value&quot; </B>means,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD>in the case of a dissent in respect of a resolution, the fair value that the notice shares had immediately before the passing of the
resolution,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD>in the case of a dissent in respect of an arrangement approved by a court order made under section 291 (2)&nbsp;(c)&nbsp;that permits
dissent, the fair value that the notice shares had immediately before the passing of the resolution adopting the arrangement,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD>in the case of a dissent in respect of a matter approved or authorized by any other court order that permits dissent, the fair value
that the notice shares had at the time specified by the court order, or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD>in the case of a dissent in respect of a community contribution company, the value of the notice shares set out in the regulations,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">excluding any appreciation or depreciation in anticipation
of the corporate action approved or authorized by the resolution or court order unless exclusion would be inequitable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>This Division applies to any right of dissent exercisable by a shareholder except to the extent that</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD>the court orders otherwise, or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD>in the case of a right of dissent authorized by a resolution referred to in section 238 (1)&nbsp;(g), the court orders otherwise or
the resolution provides otherwise.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><B>Right to dissent</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>238</B></TD><TD STYLE="text-align: justify; width: 0.25in">(1)</TD>
                                                                                       <TD STYLE="text-align: justify">A shareholder of a company, whether or not the shareholder's shares carry the right to vote, is entitled to dissent as follows:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD>under section 260, in respect of a resolution to alter the articles</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD>to alter restrictions on the powers of the company or on the business the company is permitted to carry on,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD>without limiting subparagraph (i), in the case of a community contribution company, to alter any of the company's community purposes
within the meaning of section 51.91, or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.25in">(iii)</TD><TD>without limiting subparagraph (i), in the case of a benefit company, to alter the company's benefit provision;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD>under section 272, in respect of a resolution to adopt an amalgamation agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD>under section 287, in respect of a resolution to approve an amalgamation under Division 4 of Part&nbsp;9;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 153; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">I-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD>in respect of a resolution to approve an arrangement, the terms of which arrangement permit dissent;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(e)</TD><TD STYLE="text-align: left">under section 301 (5), in respect of a resolution to authorize or ratify the sale, lease or other disposition of all or substantially
all of the company's undertaking;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(f)</TD><TD STYLE="text-align: left">under section 309, in respect of a resolution to authorize the continuation of the company into a jurisdiction other than British
Columbia;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(g)</TD><TD>in respect of any other resolution, if dissent is authorized by the resolution;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(h)</TD><TD>in respect of any court order that permits dissent.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.3in; text-align: center">(1.1)</TD><TD STYLE="text-align: justify">A shareholder of a company, whether or not the shareholder's
shares carry the right to vote, is entitled to dissent under section 51.995 (5)&nbsp;in respect of a resolution to alter its notice of
articles to include or to delete the benefit statement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="text-align: center; width: 0.3in">(2)</TD><TD>A shareholder wishing to dissent must</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD>prepare a separate notice of dissent under section 242 for</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD>the shareholder, if the shareholder is dissenting on the shareholder's own behalf, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD>each other person who beneficially owns shares registered in the shareholder's name and on whose behalf the shareholder is dissenting,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD>identify in each notice of dissent, in accordance with section 242 (4), the person on whose behalf dissent is being exercised in that
notice of dissent, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD>dissent with respect to all of the shares, registered in the shareholder's name, of which the person identified under paragraph (b)&nbsp;of
this subsection is the beneficial owner.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(3)</TD><TD>Without limiting subsection (2), a person who wishes to have dissent exercised with respect to shares of which the person is the beneficial
owner must</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD>dissent with respect to all of the shares, if any, of which the person is both the registered owner and the beneficial owner, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD>cause each shareholder who is a registered owner of any other shares of which the person is the beneficial owner to dissent with respect
to all of those shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><B>Waiver of right to dissent</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 0.25in">239</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top; width: 0.25in">(1)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0in; text-align: left; vertical-align: top">A shareholder may not waive generally
    a right to dissent but may, in writing, waive the right to dissent with respect to a particular corporate action.</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="text-align: center; width: 0.25in">(2)</TD><TD>A shareholder wishing to waive a right of dissent with respect to a particular corporate action must</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD>provide to the company a separate waiver for</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD>the shareholder, if the shareholder is providing a waiver on the shareholder's own behalf, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD>each other person who beneficially owns shares registered in the shareholder's name and on whose behalf the shareholder is providing
a waiver, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD>identify in each waiver the person on whose behalf the waiver is made.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 154; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">I-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(3)</TD><TD>If a shareholder waives a right of dissent with respect to a particular corporate action and indicates in the waiver that the right
to dissent is being waived on the shareholder's own behalf, the shareholder's right to dissent with respect to the particular corporate
action terminates in respect of the shares of which the shareholder is both the registered owner and the beneficial owner, and this Division
ceases to apply to</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD>the shareholder in respect of the shares of which the shareholder is both the registered owner and the beneficial owner, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD>any other shareholders, who are registered owners of shares beneficially owned by the first mentioned shareholder, in respect of the
shares that are beneficially owned by the first mentioned shareholder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(4)</TD><TD>If a shareholder waives a right of dissent with respect to a particular corporate action and indicates in the waiver that the right
to dissent is being waived on behalf of a specified person who beneficially owns shares registered in the name of the shareholder, the
right of shareholders who are registered owners of shares beneficially owned by that specified person to dissent on behalf of that specified
person with respect to the particular corporate action terminates and this Division ceases to apply to those shareholders in respect of
the shares that are beneficially owned by that specified person.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><B>Notice of resolution</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>240</B></TD><TD STYLE="text-align: center; width: 0.25in">(1)</TD>
                                                                                       <TD STYLE="text-align: justify">If a resolution
                                            in respect of which a shareholder is entitled to dissent is to be considered at a meeting
                                            of shareholders, the company must, at least the prescribed number of days before the date
                                            of the proposed meeting, send to each of its shareholders, whether or not their shares carry
                                            the right to vote,</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD>a copy of the proposed resolution, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD>a notice of the meeting that specifies the date of the meeting, and contains a statement advising of the right to send a notice of
dissent.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="text-align: center; width: 0.25in">(2)</TD><TD>If a resolution in respect of which a shareholder is entitled to dissent is to be passed as a consent resolution of shareholders or
as a resolution of directors and the earliest date on which that resolution can be passed is specified in the resolution or in the statement
referred to in paragraph (b), the company may, at least 21 days before that specified date, send to each of its shareholders, whether
or not their shares carry the right to vote,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD>a copy of the proposed resolution, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD>a statement advising of the right to send a notice of dissent.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="text-align: center; width: 0.25in">(3)</TD><TD>If a resolution in respect of which a shareholder is entitled to dissent was or is to be passed as a resolution of shareholders without
the company complying with subsection (1)&nbsp;or (2), or was or is to be passed as a directors' resolution without the company complying
with subsection (2), the company must, before or within 14 days after the passing of the resolution, send to each of its shareholders
who has not, on behalf of every person who beneficially owns shares registered in the name of the shareholder, consented to the resolution
or voted in favour of the resolution, whether or not their shares carry the right to vote,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD>a copy of the resolution,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD>a statement advising of the right to send a notice of dissent, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD>if the resolution has passed, notification of that fact and the date on which it was passed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(4)</TD><TD>Nothing in subsection (1), (2)&nbsp;or (3)&nbsp;gives a shareholder a right to vote in a meeting at which, or on a resolution on which,
the shareholder would not otherwise be entitled to vote.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 155; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">I-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><B>Notice of court orders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>241</B></TD><TD STYLE="text-align: justify">If a court order provides for a right of dissent, the company
must, not later than 14 days after the date on which the company receives a copy of the entered order, send to each shareholder who is
entitled to exercise that right of dissent</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD>a copy of the entered order, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD>a statement advising of the right to send a notice of dissent.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><B>Notice of dissent</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>242</B></TD><TD STYLE="text-align: center; width: 0.25in">(1) </TD>
                                                                                       <TD STYLE="text-align: justify">A shareholder
                                            intending to dissent in respect of a resolution referred to in section 238 (1)&nbsp;(a),
                                            (b), (c), (d), (e)&nbsp;or (f)&nbsp;or (1.1) must,</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD>if the company has complied with section 240 (1)&nbsp;or (2), send written notice of dissent to the company at least 2 days before
the date on which the resolution is to be passed or can be passed, as the case may be,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD>if the company has complied with section 240 (3), send written notice of dissent to the company not more than 14 days after receiving
the records referred to in that section, or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD>if the company has not complied with section 240 (1), (2)&nbsp;or (3), send written notice of dissent to the company not more than
14 days after the later of</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD>the date on which the shareholder learns that the resolution was passed, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD>the date on which the shareholder learns that the shareholder is entitled to dissent.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="text-align: center; width: 0.25in">(2)</TD><TD>A shareholder intending to dissent in respect of a resolution referred to in section 238 (1)&nbsp;(g)&nbsp;must send written notice
of dissent to the company</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD>on or before the date specified by the resolution or in the statement referred to in section 240 (2) (b) or (3)&nbsp;(b)&nbsp;as
                                                                the last date by which notice of dissent must be sent, or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">if the resolution or statement does not specify a date, in accordance
with subsection (1)&nbsp;of this section.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="text-align: center; width: 0.25in">(3)</TD><TD>A shareholder intending to dissent under section 238 (1)&nbsp;(h)&nbsp;in respect of a court order that permits dissent must send
written notice of dissent to the company</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD>within the number of days, specified by the court order, after the shareholder receives the records referred to in section 241, or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD>if the court order does not specify the number of days referred to in paragraph (a)&nbsp;of this subsection, within 14 days after
the shareholder receives the records referred to in section 241.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="text-align: center; width: 0.25in">(4)</TD><TD>A notice of dissent sent under this section must set out the number, and the class and series, if applicable, of the notice shares,
and must set out whichever of the following is applicable:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD>if the notice shares constitute all of the shares of which the shareholder is both the registered owner and beneficial owner and the
shareholder owns no other shares of the company as beneficial owner, a statement to that effect;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD>if the notice shares constitute all of the shares of which the shareholder is both the registered owner and beneficial owner but the
shareholder owns other shares of the company as beneficial owner, a statement to that effect and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD>the names of the registered owners of those other shares,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 156; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">I-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD>the number, and the class and series, if applicable, of those other shares that are held by each of those registered owners, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.25in">(iii)</TD><TD>a statement that notices of dissent are being, or have been, sent in respect of all of those other shares;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD>if dissent is being exercised by the shareholder on behalf of a beneficial owner who is not the dissenting shareholder, a statement
to that effect and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD>the name and address of the beneficial owner, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD>a statement that the shareholder is dissenting in relation to all of the shares beneficially owned by the beneficial owner that are
registered in the shareholder's name.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="text-align: center; width: 0.25in">(5)</TD><TD>The right of a shareholder to dissent on behalf of a beneficial owner of shares, including the shareholder, terminates and this Division
ceases to apply to the shareholder in respect of that beneficial owner if subsections (1)&nbsp;to (4)&nbsp;of this section, as those subsections
pertain to that beneficial owner, are not complied with.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><B>Notice of intention to proceed</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>243</B></TD><TD STYLE="text-align: center; width: 0.25in">(1)&nbsp;</TD>
                                                                                       <TD STYLE="text-align: justify">A company that receives a notice of dissent under section 242 from a dissenter must,</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD>if the company intends to act on the authority of the resolution or court order in respect of which the notice of dissent was sent,
send a notice to the dissenter promptly after the later of</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD>the date on which the company forms the intention to proceed, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD>the date on which the notice of dissent was received, or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD>if the company has acted on the authority of that resolution or court order, promptly send a notice to the dissenter.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="text-align: center; width: 0.25in">(2)</TD><TD>A notice sent under subsection (1)&nbsp;(a)&nbsp;or (b)&nbsp;of this section must</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD>be dated not earlier than the date on which the notice is sent,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD>state that the company intends to act, or has acted, as the case may be, on the authority of the resolution or court order, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD>advise the dissenter of the manner in which dissent is to be completed under section 244.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><B>Completion of dissent</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>244</B></TD><TD STYLE="text-align: center; width: 0.25in">(1)&nbsp;</TD>
                                                                                       <TD STYLE="text-align: justify">A dissenter who receives a notice under section 243 must, if the dissenter wishes to proceed with the dissent, send to the company or
its transfer agent for the notice shares, within one month after the date of the notice,</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD>a written statement that the dissenter requires the company to purchase all of the notice shares,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD>the certificates, if any, representing the notice shares, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD>if section 242 (4)&nbsp;(c)&nbsp;applies, a written statement that complies with subsection (2)&nbsp;of this section.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="text-align: center; width: 0.25in">(2)</TD><TD>The written statement referred to in subsection (1)&nbsp;(c)&nbsp;must</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD>be signed by the beneficial owner on whose behalf dissent is being exercised, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD>set out whether or not the beneficial owner is the beneficial owner of other shares of the company and, if so, set out</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 157; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">I-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD>the names of the registered owners of those other shares,</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD>the number, and the class and series, if applicable, of those other shares that are held by each of those registered owners, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.25in">(iii)</TD><TD>that dissent is being exercised in respect of all of those other shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="text-align: center; width: 0.25in">(3)</TD><TD>After the dissenter has complied with subsection (1),</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD>the dissenter is deemed to have sold to the company the notice shares, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD>the company is deemed to have purchased those shares, and must comply with section 245, whether or not it is authorized to do so by,
and despite any restriction in, its memorandum or articles.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="text-align: center; width: 0.25in">(4)</TD><TD>Unless the court orders otherwise, if the dissenter fails to comply with subsection (1)&nbsp;of this section in relation to notice
shares, the right of the dissenter to dissent with respect to those notice shares terminates and this Division, other than section 247,
ceases to apply to the dissenter with respect to those notice shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="text-align: center; width: 0.25in">(5)</TD><TD>Unless the court orders otherwise, if a person on whose behalf dissent is being exercised in relation to a particular corporate action
fails to ensure that every shareholder who is a registered owner of any of the shares beneficially owned by that person complies with
subsection (1)&nbsp;of this section, the right of shareholders who are registered owners of shares beneficially owned by that person to
dissent on behalf of that person with respect to that corporate action terminates and this Division, other than section 247, ceases to
apply to those shareholders in respect of the shares that are beneficially owned by that person.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="text-align: center; width: 0.25in">(6)</TD><TD>A dissenter who has complied with subsection (1)&nbsp;of this section may not vote, or exercise or assert any rights of a shareholder,
in respect of the notice shares, other than under this Division.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><B>Payment for notice shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>245</B></TD><TD STYLE="text-align: center; width: 0.25in">(1)&nbsp;</TD>
                                                                                       <TD STYLE="text-align: justify">A company and a dissenter who has complied with section 244 (1)&nbsp;may agree on the amount of the payout value of the notice shares
and, in that event, the company must</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD>promptly pay that amount to the dissenter, or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD>if subsection (5)&nbsp;of this section applies, promptly send a notice to the dissenter that the company is unable lawfully to pay
dissenters for their shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="text-align: center; width: 0.25in">(2)</TD><TD>A dissenter who has not entered into an agreement with the company under subsection (1)&nbsp;or the company may apply to the court
and the court may</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD>determine the payout value of the notice shares of those dissenters who have not entered into an agreement with the company under
subsection (1), or order that the payout value of those notice shares be established by arbitration or by reference to the registrar,
or a referee, of the court,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD>join in the application each dissenter, other than a dissenter who has entered into an agreement with the company under subsection
(1), who has complied with section 244 (1), and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD>make consequential orders and give directions it considers appropriate.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="text-align: center; width: 0.25in">(3)</TD><TD>Promptly after a determination of the payout value for notice shares has been made under subsection (2)&nbsp;(a)&nbsp;of this section,
the company must</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD>pay to each dissenter who has complied with section 244 (1)&nbsp;in relation to those notice shares, other than a dissenter who has
entered into an agreement with the company under subsection (1) of this section, the payout value applicable to that dissenter's
notice shares, or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 158; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">I-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD>if subsection (5)&nbsp;applies, promptly send a notice to the dissenter that the company is unable lawfully to pay dissenters for
their shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="text-align: center; width: 0.25in">(4)</TD><TD>If a dissenter receives a notice under subsection (1)&nbsp;(b)&nbsp;or (3)&nbsp;(b),</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD>the dissenter may, within 30 days after receipt, withdraw the dissenter's notice of dissent, in which case the company is deemed to
consent to the withdrawal and this Division, other than section 247, ceases to apply to the dissenter with respect to the notice shares,
or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD>if the dissenter does not withdraw the notice of dissent in accordance with paragraph (a)&nbsp;of this subsection, the dissenter retains
a status as a claimant against the company, to be paid as soon as the company is lawfully able to do so or, in a liquidation, to be ranked
subordinate to the rights of creditors of the company but in priority to its shareholders.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="text-align: center; width: 0.25in">(5)</TD><TD>A company must not make a payment to a dissenter under this section if there are reasonable grounds for believing that</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD>the company is insolvent, or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD>the payment would render the company insolvent.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><B>Loss of right to dissent</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>246</B></TD><TD STYLE="text-align: left">The right of a dissenter to dissent with respect to notice shares
terminates and this Division, other than section 247, ceases to apply to the dissenter with respect to those notice shares, if, before
payment is made to the dissenter of the full amount of money to which the dissenter is entitled under section 245 in relation to those
notice shares, any of the following events occur:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: left">the corporate action approved or authorized, or to be approved
or authorized, by the resolution or court order in respect of which the notice of dissent was sent is abandoned;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">the resolution in respect of which the notice of dissent was
sent does not pass;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: left">the resolution in respect of which the notice of dissent was
sent is revoked before the corporate action approved or authorized by that resolution is taken;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: left">the notice of dissent was sent in respect of a resolution adopting
an amalgamation agreement and the amalgamation is abandoned or, by the terms of the agreement, will not proceed;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(e)</TD><TD STYLE="text-align: justify">the arrangement in respect of which the notice of dissent was
sent is abandoned or by its terms will not proceed;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(f)</TD><TD STYLE="text-align: left">a court permanently enjoins or sets aside the corporate action
approved or authorized by the resolution or court order in respect of which the notice of dissent was sent;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(g)</TD><TD STYLE="text-align: justify">with respect to the notice shares, the dissenter consents to,
or votes in favour of, the resolution in respect of which the notice of dissent was sent;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(h)</TD><TD STYLE="text-align: justify">the notice of dissent is withdrawn with the written consent of the company;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(i)</TD><TD STYLE="text-align: left">the court determines that the dissenter is not entitled to dissent
under this Division or that the dissenter is not entitled to dissent with respect to the notice shares under this Division.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 159; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">I-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><B>Shareholders entitled to return of shares and rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>247</B></TD><TD STYLE="text-align: justify">If, under section 244 (4)&nbsp;or (5), 245 (4)&nbsp;(a)&nbsp;or
246, this Division, other than this section, ceases to apply to a dissenter with respect to notice shares,</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD>the company must return to the dissenter each of the applicable share certificates, if any, sent under section 244 (1)&nbsp;(b)&nbsp;or,
if those share certificates are unavailable, replacements for those share certificates,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD>the dissenter regains any ability lost under section 244 (6)&nbsp;to vote, or exercise or assert any rights of a shareholder, in respect
of the notice shares, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD>the dissenter must return any money that the company paid to the dissenter in respect of the notice shares under, or in purported
compliance with, this Division.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 160; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">I-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B><A NAME="pros4_022"></A>ANNEX
J &mdash; MATERIAL DIFFERENCES BETWEEN ALBERTA CORPORATE LAW AND BRITISH COLUMBIA CORPORATE LAW</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Our corporate affairs
are governed by our Articles and the provisions of the <I>Business Corporations Act</I> (Alberta) (the &ldquo;<B>ABCA</B>&rdquo;). The
ABCA differs from the various laws applicable to British Columbia companies and their shareholders. The following is a summary of the
material differences between the ABCA and the <I>Business Corporations Act </I>(British Columbia) (the &ldquo;<B>BCBCA</B>&rdquo;). This
summary is qualified in its entirety by reference to the full text of the ABCA, the BCBCA and our governing corporate instruments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; vertical-align: top; width: 21%; padding: 5pt 5pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 43%; border-bottom: Black 1pt solid; padding: 5pt 5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Alberta</B></FONT></TD>
    <TD STYLE="font-size: 10pt; vertical-align: top; width: 2%; padding: 5pt 5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font-size: 10pt; width: 34%; border-bottom: Black 1pt solid; padding: 5pt 5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>British
    Columbia</B></FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding: 5pt 5pt 10pt; font-size: 10pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Number
                                      and Election of Directors</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="padding: 5pt 5pt 10pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    ABCA provides that a reporting issuer must have no fewer than three directors, at least two of whom are not officers or employees
    of the issuer or its affiliates.</FONT></TD>
    <TD STYLE="padding: 5pt 5pt 10pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 5pt 5pt 10pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    the BCBCA, a public company must have at least three directors. Under the Articles, directors are elected by the shareholders at
    the annual general meeting.</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; padding-right: 5pt; padding-bottom: 10pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Removal
    of Directors</B></FONT></TD>
    <TD STYLE="font-size: 10pt; padding-right: 5pt; padding-bottom: 10pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    ABCA provides that, subject to certain limitations, the shareholders of a corporation may remove directors from office by ordinary
    resolution at a special meeting of shareholders.</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-right: 5pt; padding-bottom: 10pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-right: 5pt; padding-bottom: 10pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Under
                                      the BCBCA, a director can be removed by special resolution or if the articles provide, by less
                                      than a special majority. Under the Articles, directors can be removed by a special resolution.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">The BCBCA does
    not contain specified term limits for directors. The Articles provide for directors to be elected at the annual general meeting.</FONT></P></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Vacancies
                                      on the Board of Directors</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Under
                                      the ABCA, a vacancy among the directors created by the removal of a director may be filled by the
                                      shareholders at the meeting at which the director is removed or, if not filled by the shareholders
                                      at such meeting, by the remaining directors. In the case of a vacancy caused by the death, resignation
                                      or disqualification to act as a director under the ABCA, the remaining directors may fill the vacancy.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Under the ABCA,
    if as a result of one or more vacancies, the number of directors in office falls below the number required for a quorum, the remaining
    directors shall call a special meeting of shareholders to fill the vacancy, and if the remaining directors fail to call a meeting
    or if there are no directors then in office, the meeting may be called by any shareholder.</FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Under
                                      the BCBCA and the Articles, the process for filling vacancies that occur outside of the process
                                      of election at each annual general meeting will be dependent on the circumstances of the vacancy:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
    the director has been removed before the expiration of his or her term of office by a vote of shareholders, the shareholders may
    elect, or appoint by ordinary resolution, a director to fill the resulting vacancy. If the shareholders do not elect or appoint a
    director to fill the resulting vacancy, the directors may appoint a director to fill that vacancy.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
    the director has been removed by the remaining directors, either due to being convicted of an indictable offence, or by ceasing to
    be qualified to act as a director in accordance with the BCBCA and failing to promptly resign, the directors may appoint a director
    to fill the resulting vacancy.</FONT></P></TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<!-- Field: Page; Sequence: 161; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">J-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 5pt 5pt; vertical-align: top; text-align: justify; width: 21%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5pt 5pt; text-align: center; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Alberta</B></FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 5pt 5pt; vertical-align: top; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5pt 5pt; text-align: center; width: 34%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>British
    Columbia</B></FONT></TD></TR>

<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; width: 21%"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; width: 43%"></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; text-align: justify; width: 2%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; width: 34%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
    the vacancy is a casual vacancy, i.e. the director is not removed and the vacancy otherwise occurs during the term of a director,
    such vacancy may be filled by the remaining directors.</FONT></P></TD></TR>

<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding: 10pt 5pt; font-size: 10pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Board
                                      of Director Quorum and Vote Requirements</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="padding: 10pt 5pt; font-size: 10pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Under
                                      the ABCA, subject to the articles or bylaws, a majority of the number of directors appointed constitutes
                                      a quorum at any meeting of directors, and, notwithstanding any vacancy among the directors, a quorum
                                      of directors may exercise all the powers of the directors.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Under the ABCA,
    the board of directors may take action by the majority vote of the directors present at a meeting at which a quorum is present unless
    the articles or by-laws require a greater vote.</FONT></P></TD>
    <TD STYLE="padding: 10pt 5pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 10pt 5pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    the BCBCA, the quorum necessary for the transaction of the business of the directors may be set out in the Company&rsquo;s articles.
    The Articles provide that the quorum necessary for the transaction of the business at a meeting of the board may be set by the board
    and, if not so set, is deemed to be set at a majority of the number of directors then in office.</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Transactions
                                      with Directors and Officers</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Under
                                      the ABCA, directors and officers of the corporation who are a party to, or have a material interest
                                      in, a material contract or transaction with the corporation, are required to disclose in writing
                                      to the corporation, or request to have entered in the minutes of a meeting of directors, the nature
                                      and extent of any material interest they may have in a material contract, whether entered into
                                      or proposed, involving the corporation.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Such
    disclosure must generally be made at the meeting at which the matter is first considered or at the first meeting after a director
    learns of their disclosable interest.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Directors
    who hold a disclosable interest are generally not entitled to vote on any resolutions approving the contract or transaction, subject
    to limited exceptions.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">A contract
    or transaction in which a director or officer has a material interest in, is neither void nor voidable solely for this reason, provided
    that this interest was sufficiently disclosed, the contract was approved by the directors or shareholders, and the terms were reasonable
    and fair to the corporation at the time of approval.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Failure to
    comply with these requirements may result in a court setting aside the contract or transaction, or requiring the director or officer
    to account to the company for any profits realized.</FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to certain exceptions, the BCBCA provides that a director or senior officer of a company holds a disclosable interest in a contract
    or transaction if the contract or transaction is material to the company, the company has entered, or proposes to enter, into the
    contract or transaction, and either of the following applies to the director or senior officer: (i)&nbsp;the director or senior officer
    has a material interest in the contract or transaction; or (ii)&nbsp;the director or senior officer is a director or senior officer
    of, or has a material interest in, a person who has a material interest in the contract or transaction. Under the BCBCA, a director
    who holds a disclosable interest in a contract or transaction may not vote on any directors&rsquo; resolution to approve such contract
    or transaction unless all directors have a disclosable interest, in which case any or all of the directors may vote. Excluded directors
    will, however, count for the purposes of quorum. A director or senior officer is liable to account to the company for any profit
    that accrues to the director or senior officer under or as a result of the interested contract or transaction unless appropriate
    disclosure was made and the contract or transaction was approved by directors who did not have a disclosable interest or by a special
    resolution of shareholders.</FONT></TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<!-- Field: Page; Sequence: 162; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">J-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 5pt 5pt; vertical-align: top; text-align: justify; width: 21%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5pt 5pt; text-align: center; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Alberta</B></FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 5pt 5pt; vertical-align: top; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5pt 5pt; text-align: center; width: 34%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>British
    Columbia</B></FONT></TD></TR>

<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; font-size: 10pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Limitation
                                      on Liability of Directors and Officers</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; font-size: 10pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Certain
                                      actions to enforce a liability imposed by the ABCA must be brought within two years from the date
                                      of the resolution authorizing the act complained of. A director will be deemed to have complied
                                      with their fiduciary obligations to the corporation under certain sections of the ABCA if the director
                                      exercised care, diligence, and skill that a reasonably prudent person would exercise in a comparable
                                      circumstance, including relying in good faith on:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;financial
    statements represented to the director by an officer or in a written report of the auditor of the corporation to fairly reflect the
    financial condition of the corporation; or</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;an
    opinion report of a person whose profession lends credibility to a statement made by the professional person.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Under
    the ABCA, the directors of a corporation who vote for or consent to a resolution that authorizes the corporation to, inter alia:
    (a)&nbsp;pay a commission on the sale of shares not provided for under the ABCA; (b)&nbsp;pay a dividend, purchase, redeem or otherwise
    acquire shares in circumstances that would be in violation of the ABCA, including where the corporation is insolvent, or the payment
    of the dividend would render the corporation insolvent; (c)&nbsp;make a payment of an indemnity to an indemnifiable person in violation
    of the ABCA; (d)&nbsp;provide financial assistance in violation of the ABCA; or (e)&nbsp;make a payment to a shareholder in violation
    of the ABCA, are, in each case, jointly and severally liable to restore to the corporation any amount paid or distributed as a result
    and not otherwise recovered by the corporation.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">In addition,
    the directors of a corporation who vote for or consent to a resolution that authorizes the issue of a share that is not fully paid
    are jointly and severally liable to the corporation to make good any amount by which the consideration received is less than the
    fair equivalent of the money that the corporation would have received if the shares had been issued for money on the date of that
    resolution. Notwithstanding the foregoing, under the ABCA, a director is not subject to statutory liability for the foregoing if
    the director did not know and could not reasonably have known that the share was issued for a consideration less than the fair equivalent
    of the money that the corporation would have received if the share had been issued for money.</FONT></P></TD>
    <TD STYLE="padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    the BCBCA, a director of a company who votes for a resolution that authorizes the payment of dividends, commissions and compensation,
    among other things, contrary to the requirements of the BCBCA is jointly and severally liable to restore to the company any amount
    paid by the company. A director will not be found liable if the director relied, in good faith, on (i)&nbsp;financial statements
    of the company represented to the director by an officer of the company or in a written report of the auditor of the company to fairly
    reflect the financial position of the company, (ii)&nbsp;a written report of a lawyer, accountant, engineer, appraiser or other person
    whose profession lends credibility, (iii)&nbsp;a statement of fact represented to the director by an officer of the company to be
    correct, or (iv)&nbsp;any record, information, or representation that the court considers provides reasonable grounds for the actions
    of the director. Further, any director is not liable if the director did not know and could not reasonably have known that the act
    done by the director or authorized by resolution voted for or consented to by the director was contrary to the BCBCA.</FONT></TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<!-- Field: Page; Sequence: 163; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">J-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 5pt 5pt; vertical-align: top; text-align: justify; width: 21%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5pt 5pt; text-align: center; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Alberta</B></FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 5pt 5pt; vertical-align: top; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5pt 5pt; text-align: center; width: 34%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>British
    Columbia</B></FONT></TD></TR>

<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Indemnification
                                      of Directors and Officers</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Under
                                      the ABCA, a corporation may indemnify: (a)&nbsp;a current or former director or officer of that
                                      corporation; (b)&nbsp;a current or former director or officer of another corporation if, at the
                                      time such individual held such office, the corporation was a shareholder or creditor of the corporation,
                                      and if such individual acted at the corporation&rsquo;s request; or (c)&nbsp;the foregoing individual&rsquo;s
                                      heirs and legal representatives (each, an &ldquo;indemnifiable person&rdquo;) against all costs,
                                      charges and expenses, including an amount paid to settle an action or satisfy a judgment, reasonably
                                      incurred by the director or officer in respect of any civil, criminal, administrative, investigative
                                      or other action or proceeding in which he or she is involved by reason of being or having been
                                      a director or officer of the corporation or another corporation (as set out above), if: (i)&nbsp;the
                                      individual acted honestly and in good faith with a view to the best interests of the Company; and
                                      (ii)&nbsp;in the case of a criminal or administrative action or proceeding that is enforced by
                                      a monetary penalty, the individual had reasonable grounds for believing that the individual&rsquo;s
                                      conduct was lawful.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">A corporation
    may advance funds to an indemnifiable person to defray the costs, charges and expenses incurred by an indemnifiable person in respect
    of that proceeding, provided that if it is ultimately determined that the payment of expenses was prohibited, the indemnifiable person
    will repay any amount advanced. Subject to the aforementioned prohibitions on indemnification, a corporation must pay all costs,
    charges and expenses reasonably incurred by an indemnifiable person in connection with the defence of any civil, criminal, administrative,
    investigative or other action or proceeding in which the person is involved by reason of being or having been a director or officer
    of the corporation or body corporate, if the person seeking indemnity: (a)&nbsp;was not judged by a court or competent authority
    to have committed any fault or omitted to do anything that the person ought to have done; and (b)&nbsp;(i)&nbsp;the individual acted
    honestly and in good faith with a view to the best interests of the corporation; and (ii)&nbsp;in the case of a criminal or administrative
    action or proceeding that is enforced by a monetary penalty, the individual had reasonable grounds for believing that the individual&rsquo;s
    conduct was lawful.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">The Company&rsquo;s
    bylaws provide that the Company will indemnify directors and officers to the extent permitted by law.</FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Under
                                      the BCBCA and the Articles, and subject to certain specified prohibitions, the company must (i)&nbsp;indemnify
                                      an eligible party against all eligible penalties to which the eligible party is or may be liable;
                                      and (ii)&nbsp;after the final disposition of an eligible proceeding, pay the expenses actually
                                      and reasonably incurred by an eligible party in respect of that proceeding.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Under
    the BCBCA, an &ldquo;eligible party&rdquo; includes an individual who is or was a director or officer of the company or any of the
    heirs and legal representatives of that individual.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">An &ldquo;eligible
    penalty&rdquo; means a judgment, penalty or fine awarded or imposed in, or an amount paid in settlement of, an eligible proceeding,
    and an &ldquo;eligible proceeding&rdquo; means a legal proceeding in which an eligible party, by reason of the eligible party being
    or having been a director or officer of the company, is or may be joined as a party, or is or may be liable for or in respect of
    a judgment, penalty or fine in, or expenses related to, the proceeding.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Under the BCBCA,
    a company must not indemnify a director or officer if the director or officer did not act honestly and in good faith with a view
    to the best interests of the company, or in the case of an eligible proceeding other than a civil proceeding, if the eligible party
    did not have reasonable grounds for believing their conduct was lawful.</FONT></P></TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<!-- Field: Page; Sequence: 164; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">J-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 5pt 5pt; vertical-align: top; text-align: justify; width: 21%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5pt 5pt; text-align: center; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Alberta</B></FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 5pt 5pt; vertical-align: top; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5pt 5pt; text-align: center; width: 34%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>British
    Columbia</B></FONT></TD></TR>

<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding: 5pt; font-size: 10pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Call
                                      and Notice of Shareholder Meetings</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="padding: 5pt; font-size: 10pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The
                                      ABCA provides that the board of directors may at any time call a special meeting of shareholders,
                                      and that holders of not less than five percent of the issued voting shares may give notice to the
                                      directors requiring them to call and hold a special meeting of shareholders for the purpose stated
                                      in the notice.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">If the directors
    do not call such a meeting within 21 days after receiving the requisition, the requisitioning shareholders or any of them may call
    the meeting.</FONT></P></TD>
    <TD STYLE="padding: 5pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 5pt; font-size: 10pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Under
                                      the BCBCA, a general meeting of shareholders must be held no later than 15 months after the annual
                                      reference date of the preceding calendar year. A company must send notice of the general meeting
                                      at least 21 days but not more than 2 months before the meeting.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">The holders
    of not less than 5% of the issued shares of a company that carry the right to vote at a general meeting may, subject to compliance
    with the requirements of, and to certain exceptions under, the BCBCA, requisition the directors to call a meeting of shareholders
    for the purpose of transacting any business that may be transacted at a general meeting.</FONT></P></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Shareholder
                                      Action by Written Consent</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    the ABCA, shareholders can take action by written resolution and without a meeting only if all shareholders entitled to vote on that
    resolution sign the written resolution. A written resolution is as valid and effective as if it were a resolution passed at a meeting
    of shareholders.</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    the BCBCA, shareholders may act by resolution consented to in writing by all the shareholders entitled to vote on that resolution
    at a meeting of shareholders, or in the case of an ordinary resolution, consented to in writing by shareholders holding at least
    a special majority (two-thirds) of the votes to be cast on the resolution after being submitted to all voting shareholders.</FONT></TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<!-- Field: Page; Sequence: 165; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">J-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 5pt 5pt; vertical-align: top; text-align: justify; width: 21%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5pt 5pt; text-align: center; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Alberta</B></FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 5pt 5pt; vertical-align: top; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5pt 5pt; text-align: center; width: 34%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>British
    Columbia</B></FONT></TD></TR>

<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Shareholder
                                      Nominations and Proposals</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    ABCA provides that a shareholder holding at least one percent of the total number of issued voting shares, or with a fair market
    value of at least C$2,000, in either case for a period of at least six months, and has the support of other shareholders holding
    not less than 5% of the issued voting shares, may submit proposals to the annual meeting of shareholders. A proposal that includes
    nominations for the election of directors must be signed by one or more holders holding, in aggregate, not less than 5% of the voting
    shares. A shareholder may also nominate directors at a meeting of shareholders.</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Under
                                      the BCBCA, a qualified shareholder may submit a shareholder proposal setting out a matter that
                                      he wishes to have considered at the next annual general meeting of the company and, subject to
                                      such shareholder&rsquo;s compliance with the prescribed time periods and other requirements of
                                      the BCBCA pertaining to shareholder proposals, the company must send the text of the proposal to
                                      shareholders and must allow a submitter to present the proposal, personally or by proxy, at the
                                      annual general meeting in relation to which the proposal was made if the submitter is a qualified
                                      shareholder at the time of that meeting.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">In addition,
    the BCBCA requires that the proposal be signed by qualified shareholders who, together with the submitter, are, at the time of signing,
    registered owners or beneficial owners of shares that, in the aggregate, constitute at least 1/100 of the issued shares of the company
    that carry the right to vote at general meetings, or have a fair market value in excess of the prescribed amount, $2,000.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">The Articles
    require shareholders wishing to nominate directors or propose business for a meeting of shareholders to give timely advance notice
    in writing, as described in section 10.12 of the Articles.</FONT></P></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; padding-top: 10pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Shareholder
                                      Quorum and Vote Requirements</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-top: 10pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    ABCA provides that, unless the by-laws provide otherwise, a quorum of shareholders is present at a meeting of shareholders (irrespective
    of the number of persons actually present at the meeting) if holders of a majority of the shares entitled to vote at the meeting
    are present in person or represented by proxy. The Company&rsquo;s bylaws provide that a quorum for the transaction of business at
    any meeting of shareholders shall be two persons present in person, each being a shareholder entitled to vote thereat or a duly appointed
    proxyholder for an absent shareholder so entitled, and together holding or representing by proxy not less than 5% of the votes entitled
    to be cast at the meeting.</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 10pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 10pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    the BCBCA, unless the articles otherwise provide, the quorum for transaction of business at a meeting of shareholders is 2 shareholders
    entitled to vote at the meeting whether present personally or by proxy. The Articles provide that a quorum for the transaction of
    business at a meeting of shareholders is present if shareholders who, in the aggregate, hold at least 5% of the issued shares entitled
    to be voted at the meeting are present in person or represented by proxy, irrespective of the number of persons actually present
    at the meeting.</FONT></TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<!-- Field: Page; Sequence: 166; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">J-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 5pt 5pt; vertical-align: top; text-align: justify; width: 21%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5pt 5pt; text-align: center; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Alberta</B></FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 5pt 5pt; vertical-align: top; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5pt 5pt; text-align: center; width: 34%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>British
    Columbia</B></FONT></TD></TR>

<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding: 5pt 5pt 10pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amendment of Governing
    Documents</B></FONT></TD>
    <TD STYLE="padding: 5pt 5pt 10pt; font-size: 10pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Under
                                      the ABCA, articles of the corporation may be generally amended by special resolution, which requires
                                      the approval of not less than two-thirds of the votes cast by shareholders who vote on the resolution.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Under the ABCA,
    the directors may make, amend or repeal any bylaw that regulates the business or affairs of the corporation, unless the articles
    of the corporation, unanimous shareholders&rsquo; agreement or bylaws provide otherwise. When directors make, amend or repeal a bylaw,
    they are required under the ABCA to submit the change to shareholders at the next meeting of shareholders. Shareholders may confirm,
    reject or amend the bylaw, amendment or repeal by a majority of the votes cast by shareholders who voted on the resolution.</FONT></P></TD>
    <TD STYLE="padding: 5pt 5pt 10pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 5pt 5pt 10pt; font-size: 10pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Under
                                      the BCBCA, unless the articles otherwise provide, any amendment to the Notice of Articles or Articles
                                      generally requires approval by a special resolution of the shareholders. A special resolution is
                                      a resolution passed by a special majority of the votes cast by shareholders, which as set out in
                                      the Articles is two thirds of the votes cast on the relevant resolution. Article&nbsp;9 of the
                                      Articles allows certain amendments to be approved by an ordinary resolution, meaning a resolution
                                      of shareholders passed by a simple majority of the votes cast. It also allows the directors to
                                      approve the subdivision or consolidation of shares or a name change.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Under the BCBCA,
    if an amendment to the Articles would prejudice or interfere with a right or special right attached to issued shares of a class or
    series of shares, then such amendment must be approved separately by the holders of the class or series of shares being affected
    by a special separate resolution.</FONT></P></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; padding-right: 5pt; padding-left: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Votes
    on Amalgamations, Mergers, Consolidations and Sales of Assets</B></FONT></TD>
    <TD STYLE="font-size: 10pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Many
                                            matters requiring shareholder approval under the ABCA must be approved by a special resolution.
                                            These extraordinary corporate actions include certain amalgamations, changes to authorized
                                            share structure, continuances, liquidations and dissolutions, and sales, leases or exchanges
                                            of all or substantially all the assets of a corporation other than in the ordinary course
                                            of business.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt">A special
    resolution is a resolution (a)&nbsp;passed by a majority of not less than two-thirds of the votes cast by the shareholders who voted
    in respect of the resolution at a meeting duly called and held for that purpose; or (b)&nbsp;signed by all shareholders entitled
    to vote on the resolution.</FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    the BCBCA, certain extraordinary corporate actions, such as continuations, certain amalgamations, sales, leases or other dispositions
    of all or substantially all of the undertaking of a company (other than in the ordinary course of business), liquidations, dissolutions
    and certain arrangements, are required to be approved by a special majority of the company&rsquo;s shareholders. A company&rsquo;s
    articles may set the requirement for a special majority between two-thirds and three-quarters of the votes cast on a resolution.
    The Articles set it at two-thirds.</FONT></TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<!-- Field: Page; Sequence: 167; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">J-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 5pt 5pt; vertical-align: top; text-align: justify; width: 21%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5pt 5pt; text-align: center; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Alberta</B></FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 5pt 5pt; vertical-align: top; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5pt 5pt; text-align: center; width: 34%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>British
    Columbia</B></FONT></TD></TR>

<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; font-size: 10pt"></TD>
    <TD STYLE="padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; font-size: 10pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Under
                                      the ABCA, separate approval by holders of shares of a specific class or series may be required
                                      to effect extraordinary corporate actions.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Under the ABCA,
    arrangements are permitted and a corporation may make any proposal it considers appropriate if &ldquo;it is impracticable to effect
    the arrangement&rdquo; under the other provisions of the ABCA. In general, a plan of arrangement is approved by a corporation&rsquo;s
    board of directors and then is submitted to a court for approval. It is typical for a corporation in such circumstances to apply
    to a court initially for an interim order governing various procedural matters prior to calling any security holder meeting to consider
    the proposed arrangement. Under the ABCA, the court has the discretion to determine whether a plan of arrangement must be approved
    by shareholders, and the requisite minimum voting threshold. The court also determines, among other things, to whom notice shall
    be given and whether, and in what manner, approval of any person is to be obtained and also determines whether any shareholders may
    dissent from the proposed arrangement and receive payment of the fair value of their shares. Following compliance with the procedural
    steps contemplated in an interim order issued by the court, as applicable, (including as to obtaining security holder approval),
    the court would conduct a final hearing and approve or reject the proposed arrangement in the final order.</FONT></P></TD>
    <TD STYLE="padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; font-size: 10pt; text-align: justify"></TD></TR>

<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; padding-top: 10pt; padding-right: 5pt; padding-left: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dissenter&rsquo;s
    Rights of Appraisal</B></FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 10pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The
                                      ABCA provides that shareholders of a corporation entitled to vote on certain matters are entitled
                                      to exercise dissent rights. Dissenting shareholders who comply with the process set out in the
                                      ABCA may demand payment for the fair value of their shares. Dissent rights exist when there is
                                      a vote upon matters such as:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT>
    <FONT STYLE="font-size: 10pt">an amalgamation with another corporation (other than with certain affiliated corporations);</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT>
    <FONT STYLE="font-size: 10pt">an amendment to a corporation&rsquo;s articles to: (a)&nbsp;add, change or remove any provisions restricting
    or constraining the issue or transfer of shares; (b)&nbsp;add or remove an express statement establishing the unlimited liability
    of shareholders; or (c)&nbsp;add, change or remove any restriction upon the business or businesses that the corporation may carry
    on;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT>
    <FONT STYLE="font-size: 10pt">a continuance (reincorporation) under the laws of another jurisdiction;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT>
    <FONT STYLE="font-size: 10pt">a sale, lease or exchange of all or substantially all the property of the corporation other than in
    the ordinary course of business; and</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT>
    <FONT STYLE="font-size: 10pt">an arrangement proposed by the corporation where there is a court order permitting a shareholder to
    dissent in connection with an application to the court for an order approving the arrangement.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">However,
    a shareholder is not entitled to dissent if an amendment to the articles of incorporation is effected by a court order approving
    a reorganization or by a court order made in connection with an action for an oppression remedy.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">A court may
    make an order permitting a shareholder to dissent in certain circumstances.</FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-top: 10pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 10pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    the BCBCA, a shareholder, whether or not the shareholder&rsquo;s shares carry the right to vote, is entitled to dissent in respect
    of a resolution to: (i)&nbsp;alter the company&rsquo;s articles to alter restrictions on the powers of the company or on the business
    the company is permitted to carry on; (ii)&nbsp;adopt an amalgamation agreement; (iii)&nbsp;approve an amalgamation into a foreign
    jurisdiction; (iv)&nbsp;approve an arrangement if the terms of the arrangement permit dissent; (v)&nbsp;authorize or ratify the sale,
    lease or other disposition of all or substantially all of the company&rsquo;s undertaking; and (vi)&nbsp;authorize the continuation
    of the company into a jurisdiction other than British Columbia. A shareholder is also entitled to dissent in respect of any court
    order that permits dissent and in respect of any other resolution if dissent is authorized by the resolution. A shareholder asserting
    dissent rights is entitled, subject to specified procedural requirements, including giving notice of dissent and making a proper
    demand for payment, to be paid by the company the fair value of the shares in respect of which the shareholder dissents. Under the
    BCBCA, if the shareholder and the company do not agree on the fair value for the shareholder&rsquo;s shares, the company or the dissenting
    shareholder may apply to a court to fix a fair value for the shares.</FONT></TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<!-- Field: Page; Sequence: 168; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">J-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 5pt 5pt; vertical-align: top; text-align: justify; width: 21%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5pt 5pt; text-align: center; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Alberta</B></FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 5pt 5pt; vertical-align: top; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5pt 5pt; text-align: center; width: 34%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>British
    Columbia</B></FONT></TD></TR>

<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Oppression Remedy</B></FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Under
                                      the ABCA, a complainant has the right to apply to a court for an order where an act or omission
                                      of the corporation or an affiliate effects a result, or the business or affairs of which are or
                                      have been carried on or conducted in a manner, or the directors&rsquo; powers are or have been
                                      exercised in a manner, that would be oppressive or unfairly prejudicial to or would unfairly disregard
                                      the interest of any security holder, creditor, director or officer of the corporation. On such
                                      application, the court may make any interim or final order it thinks fit to rectify the matters
                                      complained of, including an order restraining the conduct complained of.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">The oppression
    remedy provides the court with broad and flexible jurisdiction to intervene in corporate affairs to protect shareholders. While conduct
    that is in breach of fiduciary duties of directors or that is contrary to the legal right of a complainant will normally trigger
    the court&rsquo;s jurisdiction under the oppression remedy, the exercise of that jurisdiction does not depend on a finding of a breach
    of such legal and equitable rights.</FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    BCBCA provides an oppression remedy that enables a court to make any order, whether interim or final, to rectify matters that are
    oppressive or unfairly prejudicial to any shareholder, which includes a beneficial shareholder or any other person who the court
    considers to be an appropriate person to make such an application. The oppression remedy provides the court with very broad and flexible
    powers to intervene in corporate affairs to protect shareholders and other applicants.</FONT></TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<!-- Field: Page; Sequence: 169; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">J-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 5pt 5pt; vertical-align: top; text-align: justify; width: 21%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5pt 5pt; text-align: center; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Alberta</B></FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 5pt 5pt; vertical-align: top; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5pt 5pt; text-align: center; width: 34%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>British
    Columbia</B></FONT></TD></TR>

<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Shareholder
                                      Derivative Actions</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="text-align: justify; font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Under
                                      the ABCA, a shareholder, former shareholder, director, former director, officer or former officer
                                      of a corporation or its affiliates, certain creditors or any other person who, in the discretion
                                      of a court, is a proper person to seek a derivative action may apply to the court for leave to
                                      bring an action in the name and on behalf of a corporation or any of its subsidiaries, or intervene
                                      in the action to which a corporation or any of its subsidiaries is a party, for the purpose of
                                      prosecuting, defending or discontinuing the action on behalf of the corporation or the subsidiary.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">In order
    to bring the action, the complainant must give reasonable notice to the directors of the corporation (if not all directors have been
    named as defendants) and the complainant must satisfy to the court that:</FONT></P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 5.75pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
    complainant is acting in good faith;</FONT></P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 5.75pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
    directors of the corporation will not bring, diligently prosecute or defend or discontinue the action; and</FONT></P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;it
    appears to be in the interests of the corporation that the action be brought, prosecuted, defended or discontinued.</FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    the BCBCA, a shareholder, defined for derivative actions to include a beneficial shareholder and any other person whom a court considers
    to be an appropriate person to make an application under the BCBCA, or a director of a company may, with leave of the court, bring
    a legal proceeding in the name and on behalf of the company to enforce an obligation owed to the company that could be enforced by
    the company itself, or to obtain damages for any breach of such an obligation. An applicant may also, with leave of the court, defend
    a legal proceeding brought against a company.</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; padding-top: 10pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Anti-Takeover
                                      and Ownership Provisions</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-top: 10pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The
                                      ABCA does not contain specific anti-takeover provisions, however, policies of Canadian securities
                                      regulatory authorities provide a corporation with certain powers which may be used to make itself
                                      less vulnerable to hostile takeover attempts. These powers include the ability to:</FONT></P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 5.75pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;implement
    a staggered board of directors, which deters an immediate change in control of the board;</FONT></P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 5.75pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;provide
    for the exclusive right of one or more class of shareholders to elect one or more directors;</FONT></P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 5.75pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;provide
    for supermajority voting in some circumstances, including on an amalgamation or for amendments to articles;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0; margin-left: 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;provide
for the creation of a shareholder rights plan to authorize the issue of new shares to existing shareholders at a below-market price in
the event of a hostile take-over bid without any requirement to issue such shares to hostile bidders; and</FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-top: 10pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 10pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">While
the BCBCA does not contain specific anti-takeover provisions with respect to &ldquo;business combinations,&rdquo; rules&nbsp;and policies
of certain Canadian securities regulatory authorities, including Multilateral Instrument 61-101 &mdash; Protection of Minority Security
Holders in Special Transactions, or Multilateral Instrument 61-101, contain requirements in connection with, among other things, &ldquo;related
party transactions&rdquo; and &ldquo;business combinations,&rdquo; including, among other things, any transaction by which an issuer
directly or indirectly engages in the following with a related party: acquires, sells, leases or transfers an asset, acquires the related
party, acquires or issues treasury securities, amends the terms of a security if the security is owned by the related party or assumes
or becomes subject to a liability or takes certain other actions with respect to debt.</FONT></P></TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<!-- Field: Page; Sequence: 170; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">J-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 5pt 5pt; vertical-align: top; text-align: justify; width: 21%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5pt 5pt; text-align: center; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Alberta</B></FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 5pt 5pt; vertical-align: top; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5pt 5pt; text-align: center; width: 34%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>British
    Columbia</B></FONT></TD></TR>

<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; width: 21%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; width: 43%"><P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;issue
                                            &ldquo;blank check&rdquo; preferred shares, which may be used to make a corporation less
                                            attractive to a hostile bidder.</FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; text-align: justify; width: 2%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; width: 34%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The
                                            term &ldquo;related party&rdquo; includes directors, senior officers and holders of more
                                            than 10% of the voting rights attached to all outstanding voting securities of the issuer
                                            any holder hat beneficially owns, in the aggregate, more than 50 per cent of the securities
                                            of any outstanding class of equity securities.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Multilateral
    Instrument 61-101 requires, subject to certain exceptions, the preparation of a formal valuation relating to certain aspects of the
    transaction and more detailed disclosure in the proxy material sent to security holders in connection with a related party transaction
    including related to the valuation. Multilateral Instrument 61-101 also requires, subject to certain exceptions, that an issuer not
    engage in a related party transaction unless the shareholders of the issuer, other than the related parties, approve the transaction
    by a simple majority of the votes cast.</FONT></P></TD></TR>

<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; padding-top: 10pt; padding-right: 5pt; padding-left: 5pt; width: 21%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
    Records</B></FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 10pt; padding-right: 5pt; padding-left: 5pt; width: 43%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Under
                                            the ABCA, directors and shareholders may examine, without charge:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;a
    corporation&rsquo;s articles of incorporation, by-laws, and any unanimous shareholder agreement;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
    minutes of meetings and resolutions of shareholders;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;all
    notices pertaining to the election of, or change of directors; and</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;a
    corporation&rsquo;s securities register.</FONT></P></TD>
    <TD STYLE="padding-top: 10pt; padding-right: 5pt; padding-left: 5pt; font-size: 10pt; text-align: justify; width: 2%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt; padding-top: 10pt; padding-right: 5pt; padding-left: 5pt; width: 34%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Under
                                            the BCBCA, specified books and records must be available for inspection by any shareholder
                                            at a registered and records office, with some exceptions. The records available for inspection
                                            include:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 5.75pt 15.35pt; text-align: justify; text-indent: -15.35pt"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;the
    Notice of Articles and Articles;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 5.75pt 15.35pt; text-align: justify; text-indent: -15.35pt"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;minutes
    of meetings and resolutions of shareholders;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 5.75pt 15.35pt; text-align: justify; text-indent: -15.35pt"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;the
    central securities register; and</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15.35pt; text-align: justify; text-indent: -15.35pt"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;the
    register of directors.</FONT></P></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt; padding-top: 10pt; padding-right: 5pt; padding-left: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registered Office</B></FONT></TD>
    <TD STYLE="padding-top: 10pt; padding-right: 5pt; padding-left: 5pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    the ABCA, a company must maintain a registered office in Alberta. Unless the directors of the company expressly designate a separate
    records office, the registered office of a company is also its records office.</FONT></TD>
    <TD STYLE="padding-top: 10pt; padding-right: 5pt; padding-left: 5pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 10pt; padding-right: 5pt; padding-left: 5pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    the BCBCA, a company must maintain a registered office and a records office in British Columbia.</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt; padding-top: 10pt; padding-right: 5pt; padding-left: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forum Selection</B></FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt; padding-top: 10pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">A
                                      corporation may include a forum selection clause in its bylaws, which provides a mechanism to designate
                                      the courts of a specified jurisdiction as the exclusive forum for hearing corporate disputes, subject
                                      to limitations under applicable corporate laws and judicial interpretation.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">The Company&rsquo;s
    bylaws do not include a forum selection clause.</FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-top: 10pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 10pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    BC company may include a forum selection clause in its articles which provides a mechanism, subject to certain limitations, to require
    an action against the company to be brought in the company&rsquo;s home jurisdiction. The Articles do not include a forum selection
    clause.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 171; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">J-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B><A NAME="pros4_023"></A>ANNEX
K &mdash; MATERIAL DIFFERENCES BETWEEN BRITISH COLUMBIA CORPORATE LAW AND NEVADA CORPORATE LAW</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Upon consummation
of the Continuance, our corporate affairs will be governed by our Articles and the provisions of the <I>Business Corporations Act</I>
(British Columbia) (the &ldquo;<B>BCBCA</B>&rdquo;). The BCBCA differs from the various laws applicable to Nevada corporations and their
stakeholders. The following is a summary of the material differences between the BCBCA and the <I>Nevada Revised Statutes </I>(the &ldquo;<B>NRS</B>&rdquo;).
This summary is qualified in its entirety by reference to the full text of the NRS, the BCBCA and our governing corporate instruments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; vertical-align: top; width: 26%; padding: 5pt 5pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 40%; border-bottom: Black 1pt solid; padding: 5pt 5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>British
    Columbia</B></FONT></TD>
    <TD STYLE="font-size: 10pt; vertical-align: top; width: 2%; padding: 5pt 5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font-size: 10pt; width: 32%; border-bottom: Black 1pt solid; padding: 5pt 5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; padding: 10pt 5pt"><P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Stockholder/Shareholder
                                      Approval of Business Combinations; Fundamental Changes</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding: 10pt 5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    the BCBCA, certain extraordinary corporate actions, such as continuations, certain amalgamations, sales, leases or other dispositions
    of all or substantially all of the undertaking of a company (other than in the ordinary course of business), liquidations, dissolutions
    and certain arrangements, are required to be approved by a special majority of the company&rsquo;s shareholders. A company&rsquo;s
    articles may set the requirement for a special majority between two-thirds and three-quarters of the votes cast on a resolution.
    The Articles set it at two-thirds.</FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 10pt 5pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 10pt 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Under
                                      the NRS, a merger or sale of all assets requires authorization by stockholders of the corporation
                                      being acquired or selling its assets holding at least a majority of the voting power of the outstanding
                                      shares entitled to vote, as well as approval of such corporation&rsquo;s board of directors.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">With respect
    to approval by stockholders of a surviving corporation in a merger, the NRS does not require a stockholder vote of a constituent
    corporation in a merger (unless the corporation provides otherwise in its articles of incorporation) if (i)&nbsp;the plan of merger
    does not amend the existing articles of incorporation, (ii)&nbsp;each stockholder of the surviving Nevada corporation whose shares
    were outstanding immediately before the effective date of the merger will hold the same number of shares, with identical designations,
    preferences, limitations and relative rights immediately after the effective date of merger and (iii)&nbsp;the number of voting shares
    issued and issuable as a result of the merger will not exceed 20% of the total number of voting shares (i.e., shares that entitle
    their holders to vote unconditionally in elections of directors) of the surviving Nevada corporation outstanding immediately before
    the merger; and (iv)&nbsp;the number of participating shares (i.e. shares that entitled their holders to participate without limitation
    in distributions) issued and issuable as a result of the merger will not exceed 20% of the number of participating shares outstanding
    immediately before the merger.</FONT></P></TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<!-- Field: Page; Sequence: 172 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 5.75pt 5.4pt; vertical-align: top; text-align: justify; width: 26%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5.75pt 5.4pt; text-align: center; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>British
    Columbia</B></FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 5pt 5pt; vertical-align: top; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5.75pt 5.4pt; text-align: center; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD></TR>

<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Special
    Vote Required for Combinations with Interested Stockholders/Shareholders</B></FONT></TD>
    <TD STYLE="padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    BCBCA contains no restriction on adoption of a shareholder rights plan. The BCBCA does not restrict related party transactions; however,
    in Canada, takeover bids and related party transactions are addressed in provincial securities legislation and policies.</FONT></TD>
    <TD STYLE="padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; font-size: 10pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Unless
                                      an issuer opts out of the provisions of NRS 78.411 through 78.444, such statutes generally prohibit
                                      a public Nevada corporation from engaging in a &ldquo;combination&rdquo; with a holder of 10% or
                                      more of the voting power of the outstanding voting shares of the Company, referred to as an interested
                                      stockholder, for a period of two years after the time the interested stockholder became an interested
                                      stockholder, except as otherwise provided therein. For these purposes, the term &ldquo;combination&rdquo;
                                      includes mergers, certain assets sales and other similar transactions with an interested stockholder.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Oncolytics
    Nevada has opted out of NRS 78.411 through 78.444 in the Oncolytics Nevada Charter.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt">In addition
    to the restrictions on business combinations with interested stockholders, Nevada law also protects a corporation and its stockholders
    from persons acquiring a &ldquo;controlling interest&rdquo; in a corporation. The provisions can be found in NRS 78.378 to 78.3793,
    inclusive.</FONT></P></TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<!-- Field: Page; Sequence: 173; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">K-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 5.75pt 5.4pt; vertical-align: top; text-align: justify; width: 26%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5.75pt 5.4pt; text-align: center; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>British
    Columbia</B></FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 5pt 5pt; vertical-align: top; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5.75pt 5.4pt; text-align: center; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD></TR>

<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; padding: 5.75pt 5.4pt; text-align: justify; width: 26%"></TD>
    <TD STYLE="font-size: 10pt; padding: 5.75pt 5.4pt; text-align: justify; width: 40%"></TD>
    <TD STYLE="font-size: 10pt; padding: 5.75pt 5.4pt; text-align: justify; width: 2%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 5.75pt 5.4pt; width: 32%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Pursuant
    to NRS 78.378, any person who acquires a controlling interest in a corporation may not exercise voting rights on any control shares
    unless the articles of incorporation or bylaws in effect on the 10<SUP>th</SUP> day following such acquisition provide that the provisions
    of these statutes do not apply to the corporation or to an acquisition of a controlling interest specifically by types of existing
    or future stockholders, or unless such voting rights are conferred by a majority vote of the disinterested stockholders of the issuing
    corporation at a special meeting of such stockholders held upon the request and at the expense of the acquiring person. NRS 78.3785
    provides that a &ldquo;controlling interest&rdquo; means the ownership of outstanding voting shares of an issuing corporation sufficient
    to enable the acquiring person, individually or in association with others, directly or indirectly, to exercise (i)&nbsp;one-fifth
    or more but less than one-third, (ii)&nbsp;one-third or more but less than a majority or (iii)&nbsp;a majority or more of the voting
    power of the issuing corporation in the election of directors, and once an acquirer crosses one of these thresholds, shares that
    it acquired in the transaction taking it over the threshold and within the 90 days immediately preceding the date when the acquiring
    person acquired or offered to acquire a controlling interest become &ldquo;control shares&rdquo; to which the voting restrictions
    described above apply. In the event that the control shares are accorded full voting rights and the acquiring person acquires control
    shares with a majority or more of all the voting power, any stockholder, other than the acquiring person, who does not vote in favor
    of authorizing voting rights for the control shares is entitled to demand payment for the fair value of such person&rsquo;s shares,
    and the corporation must comply with the demand.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Corporations
    are entitled to opt out of the above controlling interest provisions of the NRS. In the Oncolytics Nevada Bylaws, Oncolytics Nevada
    opts out of these provisions.</FONT></P></TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<!-- Field: Page; Sequence: 174; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">K-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 5.75pt 5.4pt; vertical-align: top; text-align: justify; width: 26%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5.75pt 5.4pt; text-align: center; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>British
    Columbia</B></FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 5pt 5pt; vertical-align: top; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5.75pt 5.4pt; text-align: center; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD></TR>

<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Appraisal
                                      or Dissenter&rsquo;s Rights; Rights to Dissent Compulsory Acquisition</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    the BCBCA, a shareholder, whether or not the shareholder&rsquo;s shares carry the right to vote, is entitled to dissent in respect
    of a resolution to: (i)&nbsp;alter the company&rsquo;s articles to alter restrictions on the powers of the company or on the business
    the company is permitted to carry on; (ii)&nbsp;adopt an amalgamation agreement; (iii)&nbsp;approve an amalgamation into a foreign
    jurisdiction; (iv)&nbsp;approve an arrangement if the terms of the arrangement permit dissent; (v)&nbsp;authorize or ratify the sale,
    lease or other disposition of all or substantially all of the company&rsquo;s undertaking; and (vi)&nbsp;authorize the continuation
    of the company into a jurisdiction other than British Columbia. A shareholder is also entitled to dissent in respect of any court
    order that permits dissent and in respect of any other resolution if dissent is authorized by the resolution. A shareholder asserting
    dissent rights is entitled, subject to specified procedural requirements, including giving notice of dissent and making a proper
    demand for payment, to be paid by the company the fair value of the shares in respect of which the shareholder dissents. Under the
    BCBCA, if the shareholder and the company do not agree on the fair value for the shareholder&rsquo;s shares, the company or the dissenting
    shareholder may apply to a court to fix a fair value for the shares.</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    the NRS, a stockholder is entitled to dissent from, and obtain payment for, the fair value of the stockholder&rsquo;s shares in the
    event of (i)&nbsp;accordance of full voting rights under certain circumstances in connection with acquisitions of a controlling interest
    in the corporation, (ii)&nbsp;consummation of a plan of merger, if approval by the stockholders is required for the merger, regardless
    of whether the stockholder is entitled to vote on the merger or if the domestic corporation is a subsidiary and is merged with its
    parent, or if the domestic corporation is a constituent entity in a merger pursuant to NRS 92A.133, (iii)&nbsp;consummation of a
    plan of conversion to which the corporation is a party, (iv)&nbsp;consummation of a plan of exchange in which the corporation is
    a party, (v)&nbsp;any corporate action taken pursuant to a vote of the stockholders, if the articles of incorporation, bylaws or
    a resolution of the board of directors provides that voting or nonvoting stockholders are entitled to dissent and obtain payment
    for their shares or (vi)&nbsp;any corporate action to which the stockholder would be obligated, as a result of the corporate action,
    to accept money or scrip rather than receive a fraction of a share in exchange for the cancellation of all the stockholder&rsquo;s
    outstanding shares, except where the stockholder would not be entitled to receive such payment pursuant to NRS 78.205, 78.2055 or
    78.207. Holders of covered securities (generally those that are listed on a national securities exchange), any shares traded in an
    organized market and held by at least 2,000 stockholders of record with a market value of at least $20 million (exclusive of the
    value of such shares held by the corporation&rsquo;s subsidiaries, senior executives, directors and beneficial stockholders owning
    more than 10% of such shares), and any shares issued by an open-end management investment company registered under the Investment
    Company Act of 1940 and which may be redeemed at the option of the holder at net asset value are generally not entitled to dissenter&rsquo;s
    rights. However, this exception is not available if (i)&nbsp;the articles of incorporation of the corporation issuing the shares
    provide that such exception is not available, (ii)&nbsp;the resolution of the board of directors approving the plan of merger, conversion
    or exchange expressly provides otherwise or (iii)&nbsp;the holders of the class or series of stock are required by the terms of the
    corporate action to accept for the shares anything except cash, shares of stock or other securities as described in NRS 92A.390(3)(b)&nbsp;or
    any combination thereof. The NRS prohibits a dissenting stockholder from voting his or her shares or receiving certain dividends
    or distributions after his or her dissent.</FONT></TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<!-- Field: Page; Sequence: 175; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">K-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 5.75pt 5.4pt; vertical-align: top; text-align: justify; width: 26%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5.75pt 5.4pt; text-align: center; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>British
    Columbia</B></FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 5pt 5pt; vertical-align: top; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5.75pt 5.4pt; text-align: center; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD></TR>

<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Stockholder/Shareholder
                                      Consent to Action Without Meeting</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    the BCBCA, shareholders may act by resolution consented to in writing by all the shareholders entitled to vote on that resolution
    at a meeting of shareholders, or in the case of an ordinary resolution, consented to in writing by shareholders holding at least
    a special majority (two-thirds) of the votes to be cast on the resolution after being submitted to all voting shareholders.</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The
NRS provides that, unless the articles of incorporation or bylaws provide otherwise, any action required or permitted to be taken at
a meeting of the stockholders may be taken without a meeting if, before or after the action, a written consent is signed by stockholders holding at least a majority of the voting power, or if a different
proportion of voting power is otherwise required for action at a meeting, then by that proportion of written consents</FONT>.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">The Oncolytics
    Nevada Bylaws prohibit action by written consent of Stockholders.</FONT></P></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; padding-top: 10pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Special
                                      Meetings of Stockholders/Shareholders</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-top: 10pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The
                                      provisions of the BCBCA, its regulations and the articles of a company apply to the calling, holding
                                      and conduct of shareholder meetings, including special meetings.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Under the BCBCA,
    the holders of not less than 5% of the issued shares of a company that carry the right to vote at a general meeting may, subject
    to compliance with the requirements of, and to certain exceptions under, the BCBCA, requisition the directors to call a meeting of
    shareholders for the purpose of transacting any business that may be transacted at a general meeting.</FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-top: 10pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 10pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    the NRS, unless otherwise provided in the articles of incorporation or the bylaws, the entire board of directors, any two directors,
    or the president may call special meetings of the stockholders. The proposed Oncolytics Nevada Charter provides that subject to the
    rights of the holders of any series of Preferred Stock, special meetings of stockholders for any purpose or purposes may only be
    called at any time by or at the direction of the Board of Directors, the Chairperson of the Board or the Chief Executive Officer.</FONT></TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<!-- Field: Page; Sequence: 176; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">K-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 5.75pt 5.4pt; vertical-align: top; text-align: justify; width: 26%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5.75pt 5.4pt; text-align: center; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>British
    Columbia</B></FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 5pt 5pt; vertical-align: top; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5.75pt 5.4pt; text-align: center; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD></TR>

<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Distributions
                                      and Dividends; Repurchases and Redemptions</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Under
                                      the BCBCA, a company may declare and pay dividends out of profits, capital or otherwise by issuing
                                      shares or warrants and, unless the company is insolvent or the payment of the dividend would render
                                      the company insolvent, by payment in property including money.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Under
    the BCBCA, the purchase or other acquisition by a company of its shares is generally subject to solvency tests similar to those applicable
    to the payment of dividends as set out above.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Under
    the BCBCA, subject to solvency tests similar to those applicable to the payment of dividends (as set out above), a company may redeem,
    on the terms and in the manner provided in its articles, any of its shares that has a right of redemption attached to it.</FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The
                                      NRS provides that no distribution (including dividends on, or redemption or purchases of, shares
                                      of capital stock or distributions of indebtedness) may be made if, after giving effect to such
                                      distribution, (i)&nbsp;the corporation would not be able to pay its debts as they become due in
                                      the usual course of business or (ii)&nbsp;except as otherwise specifically permitted by the articles
                                      of incorporation, the corporation&rsquo;s total assets would be less than the sum of its total
                                      liabilities plus the amount that would be needed at the time of a dissolution to satisfy the preferential
                                      rights of preferred stockholders. Directors may consider financial statements prepared on the basis
                                      of accounting practices that are reasonable in the circumstances, a fair valuation, including but
                                      not limited to unrealized appreciation and depreciation, and any other method that is reasonable
                                      in the circumstances.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">The proposed
    Oncolytics Nevada Charter will opt out of the balance sheet test of NRS 78.288(2)(b).</FONT></P></TD></TR>

<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; padding-top: 10pt; padding-right: 5pt; padding-left: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Vacancies on Board
    of Directors</B></FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 10pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Under
                                      the BCBCA and the Articles, the process for filling vacancies that occur outside of the process
                                      of election at each annual general meeting will be dependent on the circumstances of the vacancy:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 5.75pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
the director has been removed before the expiration of his or her term of office by a vote of shareholders, the shareholders may elect,
or appoint by ordinary resolution, a director to fill the resulting vacancy. If the shareholders do not elect or appoint a director to
fill the resulting vacancy, the directors may appoint a director to fill that vacancy.</FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-top: 10pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 10pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Under
                                      the NRS, a vacancy or a newly created directorship may be filled by a majority of the directors
                                      then in office, although less than a quorum, or by the sole remaining director, unless otherwise
                                      provided in the articles of incorporation or bylaws. Any director so appointed will hold office
                                      for the remainder of the term of the director no longer on the board.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">The proposed
    Oncolytics Nevada Charter and Oncolytics Nevada Bylaws provide that only the Board and not the Stockholders may fill vacancies on
    the Board of Directors.</FONT></P></TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<!-- Field: Page; Sequence: 177; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">K-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 5.75pt 5.4pt; vertical-align: top; text-align: justify; width: 26%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5.75pt 5.4pt; text-align: center; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>British
    Columbia</B></FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 5pt 5pt; vertical-align: top; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5.75pt 5.4pt; text-align: center; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD></TR>

<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; padding: 5.75pt 5.4pt; width: 26%"></TD>
    <TD STYLE="font-size: 10pt; padding: 5.75pt 5.4pt; width: 40%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 5.75pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
    the director has been removed by the remaining directors, either due to being convicted of an indictable offence, or by ceasing to
    be qualified to act as a director in accordance with the BCBCA and failing to promptly resign, the directors may appoint a director
    to fill the resulting vacancy.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
    the vacancy is a casual vacancy, i.e. the director is not removed and the vacancy otherwise occurs during the term of a director,
    such vacancy may be filled by the remaining directors.</FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding: 5.75pt 5.4pt; text-align: justify; width: 2%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 5.75pt 5.4pt; width: 32%"></TD></TR>
</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; padding-top: 5.75pt; padding-right: 5.4pt; padding-left: 5.4pt; width: 26%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Constitution
                                            of Directors</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5.75pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    the BCBCA, a public company must have at least three directors.</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5.75pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; width: 2%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5.75pt; padding-right: 5.4pt; padding-left: 5.4pt; width: 32%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Under
                                            the NRS, a corporation must have at least one director, and may provide in its articles of
                                            incorporation or in its bylaws for a fixed number of directors or a variable number of directors,
                                            and may otherwise provide for the manner in which the number of directors may be increased
                                            or decreased.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">The proposed
    Oncolytics Nevada Charter provides that subject to rights of the holders of any series of Preferred Stock to elect additional directors,
    the Board of Directors shall consist of one or more directors and the total number of directors shall be determined from time to
    time exclusively by resolution adopted by the Board of Directors.</FONT></P></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; padding-top: 10pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Removal
                                      of Directors Terms of Directors</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-top: 10pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Under
                                      the BCBCA, a director can be removed by special resolution or if the articles provide, by less
                                      than a special majority.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Under the Articles,
    directors can be removed by a special resolution.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">The BCBCA does
    not contain specified term limits for directors. The Articles provide for directors to be elected at the annual general meeting.</FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-top: 10pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 10pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The
                                      NRS requires the vote of the holders of at least two-thirds of the voting power of the shares or
                                      class or series of shares of the issued and outstanding stock entitled to vote at an election of
                                      directors in order to remove a director or all of the directors. The articles of incorporation
                                      may provide for a voting threshold higher than two-thirds of the voting power, but not lower.
                                      Furthermore, the NRS does not make a distinction between removals for cause and removals without
                                      cause.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The
    NRS permits any Nevada corporation to classify its board of directors into any number of classes with staggered terms of office,
    so long as at least one-fourth of the total number of directors is elected annually.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">The Oncolytics
    Nevada Charter and Oncolytics Nevada Bylaws do not provide for a classified board.</FONT></P></TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<!-- Field: Page; Sequence: 178; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">K-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 5.75pt 5.4pt; vertical-align: top; text-align: justify; width: 26%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5.75pt 5.4pt; text-align: center; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>British
    Columbia</B></FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 5pt 5pt; vertical-align: top; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5.75pt 5.4pt; text-align: center; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD></TR>

<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Inspection
                                      of Books and Records</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Under
                                      the BCBCA, specified books and records must be available for inspection by any shareholder at a
                                      registered and records office, with some exceptions. The records available for inspection include:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 5.75pt 15.35pt; text-align: justify; text-indent: -15.35pt"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
    Notice of Articles and Articles;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 5.75pt 15.35pt; text-align: justify; text-indent: -15.35pt"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;minutes
    of meetings and resolutions of shareholders;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 5.75pt 15.35pt; text-align: justify; text-indent: -15.35pt"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
    central securities register; and</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15.35pt; text-align: justify; text-indent: -15.35pt"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
    register of directors.</FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The
                                      NRS grants any person who has been a stockholder of record of a corporation for at least six months
                                      immediately preceding the demand, or any person holding, or thereunto authorized in writing by
                                      the holders of, at least 5% of all of its outstanding shares, upon at least five days&rsquo; written
                                      demand, the right to inspect in person or by agent or attorney, during usual business hours (i)&nbsp;a
                                      certified copy of the articles of incorporation and all amendments thereto, (ii)&nbsp;a certified
                                      copy of the bylaws and all amendments thereto and (iii)&nbsp;a stock ledger or a duplicate stock
                                      ledger, revised annually not later than 60 days after the date by which an annual list is required
                                      to be filed with the Nevada Secretary of State, containing only the names, alphabetically arranged,
                                      of all persons who are stockholders of record of the corporation, showing their places of residence,
                                      if known, and the number of shares held by them, respectively. A Nevada corporation is not required
                                      to keep a list of any person who is a beneficial owner of any shares who is not simultaneously
                                      the stockholder of record thereof or any other information concerning any person having an interest
                                      in the corporation. A Nevada corporation may require a stockholder to furnish the corporation with
                                      an affidavit that such inspection is not desired for a purpose unrelated to the business of the
                                      corporation and that the stockholder has not at any time sold or offered for sale any list of stockholders
                                      of any corporation or aided or abetted the same.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt">In addition,
    the right to inspect the books of account and financial statements of a corporation, to make copies thereof and to conduct an audit
    thereof is granted only to a stockholder of record who owns at least 15% of the issued and outstanding shares of a Nevada corporation,
    or who has been authorized in writing by the holders of at least 15% of such shares. Such person must furnish an affidavit stating
    that the inspection, copies or audit is not desired for any purpose not related to his or her interest as a stockholder and as a
    condition to these inspection rights, the board of directors may require the stockholder and each other person exercising rights
    to enter into and comply with a confidentiality agreement. However, the inspection rights discussed in this paragraph do not apply
    to any corporation, such as Oncolytics Nevada, that furnishes to its stockholders a detailed annual financial statement or any corporation
    that has filed during the preceding 12 months all reports required to be filed pursuant to Section&nbsp;13 or Section&nbsp;15(d)&nbsp;of
    the U.S. Exchange Act.</FONT></P></TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<!-- Field: Page; Sequence: 179; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">K-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 5.75pt 5.4pt; vertical-align: top; text-align: justify; width: 26%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5.75pt 5.4pt; text-align: center; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>British
    Columbia</B></FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 5pt 5pt; vertical-align: top; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5.75pt 5.4pt; text-align: center; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD></TR>

<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Amendment
                                      of Governing Documents</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Under
                                      the BCBCA, unless the articles otherwise provide, any amendment to the Notice of Articles or Articles
                                      generally requires approval by a special resolution of the shareholders. A special resolution is
                                      a resolution passed by a special majority of the votes cast by shareholders, which as set out in
                                      the Articles is two thirds of the votes cast on the relevant resolution. Article&nbsp;9 of the
                                      Articles allows certain amendments to be approved by an ordinary resolution, meaning a resolution
                                      of shareholders passed by a simple majority of the votes cast. It also allows the directors to
                                      approve the subdivision or consolidation of shares or a name change.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Under the BCBCA,
    if an amendment to the Articles would prejudice or interfere with a right or special right attached to issued shares of a class or
    series of shares, then such amendment must be approved separately by the holders of the class or series of shares being affected
    by a special separate resolution.</FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Under
                                      the NRS, except as noted below, every amendment to the articles of incorporation must be made in the following manner:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 5.75pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
    proposed amendment must be approved by the board of directors and submitted to the stockholders for approval.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 5.75pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
    proposed amendment requires the approval of stockholders representing at least a majority of the voting power of the corporation,
    or such greater proportion of the voting power as may be required in the case of a vote by classes or series (as described below),
    or as otherwise required by the articles of incorporation. If any proposed amendment would adversely alter or change any preference
    or other right given to any class or series of outstanding shares, then the amendment must also be approved by the holders of shares
    representing a majority of the voting power of each class or series adversely affected by such amendment regardless of limitations
    or restrictions on the voting power thereof. The amendment does not have to be approved by the vote of the holders of shares representing
    a majority of the voting power of each class or series whose preference or rights are adversely affected by the amendment if the
    articles of incorporation specifically deny the right to vote on such an amendment.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Different
    series of the same class of shares do not constitute different classes of shares for the purpose of voting by classes except when
    the series is adversely affected by an amendment in a different manner than other series of the same class.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify">An amendment to increase or decrease the number of authorized shares of any class or series of stock of a publicly traded corporation
may be approved by the default voting standard set forth in a corporation&rsquo;s articles of incorporation or bylaws. In the Oncolytics
Nevada Bylaws that voting standard is more votes cast in favor of the matter than against the matter.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">No action
    by the stockholders is required if the proposed amendment to the articles of incorporation consists only of a change in the name
    of the corporation.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The
    NRS provides that, unless otherwise prohibited by any bylaw adopted by the stockholders, the board of directors may adopt, amend
    or repeal any bylaw, including any bylaw adopted by the stockholders. The NRS also provides that the articles of incorporation may
    grant the authority to adopt, amend or repeal bylaws exclusively to the board of directors.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Oncolytics Nevada Charter and Oncolytics Nevada Bylaws authorize the Board of Directors to amend the Oncolytics Nevada Bylaws. They
also provide that the Oncolytics Nevada Bylaws may be amended by the vote of stockholders holding at least two-thirds of the voting power
of the corporation, voting together as a single class.</P></TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<!-- Field: Page; Sequence: 180; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">K-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 5.75pt 5.4pt; vertical-align: top; text-align: justify; width: 26%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5.75pt 5.4pt; text-align: center; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>British
    Columbia</B></FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 5pt 5pt; vertical-align: top; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5.75pt 5.4pt; text-align: center; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD></TR>

<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Indemnification
                                      of Directors and Officers</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Under
                                      the BCBCA and the Articles, and subject to certain specified prohibitions, the Company must (i)&nbsp;indemnify
                                      an eligible party against all eligible penalties to which the eligible party is or may be liable;
                                      and (ii)&nbsp;after the final disposition of an eligible proceeding, pay the expenses actually
                                      and reasonably incurred by an eligible party in respect of that proceeding Under the BCBCA, an
                                      &ldquo;eligible party&rdquo; includes an individual who is or was a director or officer of the
                                      company or any of the heirs and legal representatives of that individual.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">An &ldquo;eligible
    penalty&rdquo; means a judgment, penalty or fine awarded or imposed in, or an amount paid in settlement of, an eligible proceeding,
    and an &ldquo;eligible proceeding&rdquo; means a legal proceeding in which an eligible party, by reason of the eligible party being
    or having been a director or officer of the company, is or may be joined as a party, or is or may be liable for or in respect of
    a judgment, penalty or fine in, or expenses related to, the proceeding.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Under the BCBCA,
    a company must not indemnify a director or officer if the director or officer did not act honestly and in good faith with a view
    to the best interests of the company, or in the case of an eligible proceeding other than a civil proceeding, if the eligible party
    did not have reasonable grounds for believing their conduct was lawful.</FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The
                                      NRS includes a statutory mechanism that permits a corporation to indemnify any director or officer
                                      who is not liable pursuant to NRS 78.138 or acted in good faith and in a manner he or she reasonably
                                      believed to be in or not opposed to the best interests of the corporation (and, in the case of
                                      a criminal action or proceeding, had no reasonable cause to believe the conduct was unlawful).
                                      Under the statutory indemnification regime of the NRS, the corporation, through its stockholders,
                                      directors or independent legal counsel, must determine that the indemnification is proper.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The
    indemnification available pursuant to the statutory mechanisms provided under the NRS, as described above, does not exclude any other
    rights to which a person seeking indemnification or advancement of expenses may be entitled under the articles of incorporation or
    any bylaw, agreement, vote of stockholders or disinterested directors or otherwise, but, unless ordered by a court, indemnification
    may not be made to or on behalf of any director or officer finally adjudged by a court of competent jurisdiction, after exhaustion
    of any appeals taken therefrom, to be liable for intentional misconduct, fraud or a knowing violation of law, and such misconduct,
    fraud or violation was material to the cause of action.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Under
    the NRS, unless otherwise restricted by the articles of incorporation, the bylaws or an agreement made by the corporation, the corporation
    may officer and directors in advance of the final disposition of an action, suit or proceeding upon receipt of an undertaking by
    or on behalf of the director or officer to repay the amount if it is ultimately determined that the director or officer is not entitled
    to be indemnified by the corporation.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">The proposed
    Oncolytics Nevada Bylaws provide that Oncolytics Nevada shall indemnify and advance expenses to its directors and officers to the
    fullest extent permitted by law, subject to certain exceptions.</FONT></P></TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<!-- Field: Page; Sequence: 181; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">K-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 5.75pt 5.4pt; vertical-align: top; text-align: justify; width: 26%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5.75pt 5.4pt; text-align: center; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>British
    Columbia</B></FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 5pt 5pt; vertical-align: top; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5.75pt 5.4pt; text-align: center; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD></TR>

<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Transactions
                                      with Directors and Officers</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to certain exceptions, the BCBCA provides that a director or senior officer of a company holds a disclosable interest in a contract
    or transaction if the contract or transaction is material to the company, the company has entered, or proposes to enter, into the
    contract or transaction, and either of the following applies to the director or senior officer: (i)&nbsp;the director or senior officer
    has a material interest in the contract or transaction; or (ii)&nbsp;the director or senior officer is a director or senior officer
    of, or has a material interest in, a person who has a material interest in the contract or transaction. Under the BCBCA, a director
    who holds a disclosable interest in a contract or transaction may not vote on any directors&rsquo; resolution to approve such contract
    or transaction unless all directors have a disclosable interest, in which case any or all of the directors may vote. Excluded directors
    will, however, count for the purposes of quorum. A director or senior officer is liable to account to the company for any profit
    that accrues to the director or senior officer under or as a result of the interested contract or transaction unless appropriate
    disclosure was made and the contract or transaction was approved by directors who did not have a disclosable interest or by a special
    resolution of shareholders.</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    NRS Section&nbsp;78.140, a transaction between a corporation and one or more of its directors or officers who has a financial interest
    in the transaction or holds common director or officer positions, is not void or voidable solely for that reason, if: (a)&nbsp;the
    fact of the common directorship, office or financial interest is known to the board of directors or a committee thereof, and the
    disinterested directors or committee members approve the transaction in good faith&#894; (b)&nbsp;the fact of the common directorship,
    office or financial interest is known to the stockholders of the corporation, and the stockholders holding a majority of the voting
    power approve or ratify the transaction in good faith&#894; (c)&nbsp;the fact of the common directorship, office or financial interest
    is not known to the interested director or officer at the time the transaction is brought before the board of directors for action&#894;
    or (d)&nbsp;the transaction is fair as to the corporation at the time it is authorized or approved.</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; padding-top: 10pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Limited
                                      Liability of Directors</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-top: 10pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    the BCBCA, a director of a company who votes for a resolution that authorizes the payment of dividends, commissions and compensation,
    among other things, contrary to the requirements of the BCBCA is jointly and severally liable to restore to the company any amount
    paid by the company. A director will not be found liable if the director relied, in good faith, on (i)&nbsp;financial statements
    of the company represented to the director by an officer of the company or in a written report of the auditor of the company to fairly
    reflect the financial position of the company, (ii)&nbsp;a written report of a lawyer, accountant, engineer, appraiser or other person
    whose profession lends credibility, (iii)&nbsp;a statement of fact represented to the director by an officer of the company to be
    correct; or (iv)&nbsp;any record, information, or representation that the court considers provides reasonable grounds for the actions
    of the director. Further, any director is not liable if the director did not know and could not reasonably have known that the act
    done by the director or authorized by resolution voted for or consented to by the director was contrary to the BCBCA.</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 10pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 10pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The
NRS provides that directors and officers are not individually liable to the corporation, its stockholders or creditors for any damages
as a result of any act or failure to act as such unless the presumption of the business judgment rule&nbsp;has been rebutted and it is
proven that such director&rsquo;s or officer&rsquo;s act or failure to act constituted a breach of his or her fiduciary duties as a director
or officer and such breach involved intentional misconduct, fraud or a knowing violation of law. The NRS also provides that directors
and officers are presumed to act in good faith, on an informed basis and with a view to the interests of the corporation in making business
decisions. In performing such duties, directors and officers may exercise their business judgment through reliance on information, opinions,
reports, financial statements and other financial data prepared or presented by corporate directors, officers or employees who are reasonably
believed to be reliable and competent. Reliance may also be extended to legal counsel, public accountants, advisers, bankers or other
persons reasonably believed to be competent, and to the work of a committee (on which the particular director or officer does not serve)
if the committee was established and empowered by the corporation&rsquo;s board of directors, and if the committee&rsquo;s work was within
its designated authority and was about matters on which the committee was reasonably believed to merit confidence. However, directors
and officers may not rely on such information, opinions, reports, books of account or similar statements if they have knowledge concerning
the matter in question that would make such reliance unwarranted.</FONT></P></TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<!-- Field: Page; Sequence: 182; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">K-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 5.75pt 5.4pt; vertical-align: top; text-align: justify; width: 26%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5.75pt 5.4pt; text-align: center; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>British
    Columbia</B></FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 5pt 5pt; vertical-align: top; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5.75pt 5.4pt; text-align: center; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD></TR>


<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5.4pt; padding-left: 5.4pt; width: 26%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; width: 2%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5.4pt; padding-left: 5.4pt; width: 32%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Note
that Nevada law, which covers both directors and officers, does not exempt breaches of duty of loyalty from exculpation. Liability for
improper payment of distributions is subject to the same exculpatory standard applicable to other liabilities.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Under the NRS,
    unless the articles of incorporation provide otherwise, neither a director nor an officer of a Nevada corporation is personally liable
    to the corporation, its stockholders or its creditors as a result of any act or failure to act, unless the presumption of the business
    judgment rule&nbsp;is rebutted and it is proven that the director or officer breached his or her fiduciary duty and such breach involved
    intentional misconduct, fraud or knowing violation of law.</FONT></P></TD></TR>
</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; padding-top: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; width: 26%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Limited
                                      Liability of Officers</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-top: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    the BCBCA, directors and officers have a duty to act honestly and in good faith with a view to the best interests of the company,
    to exercise the care, diligence and skill that a reasonably prudent individual would exercise in comparable circumstances and to
    act in accordance with the BCBCA, its regulations and the Articles of the company. No provision in a contract of the Articles may
    relieve a director or officer from those duties. However, under the BCBCA, if, in a legal proceeding against a director or officer
    of the company, the court finds that the officer or director is or may be liable in respect of negligence, default, breach of duty
    or breach of trust, the court may relieve the officer or director from liability on terms the court considers necessary if it appears
    to the court that, despite the finding of liability, the officer or director acted honestly and reasonably and ought fairly to be
    excused.</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; width: 2%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
    &ldquo;Limited Liability of Directors&rdquo; above. The proposed Oncolytics Nevada Bylaws provide for indemnification and advancement
    of expenses to directors and officers to the fullest extent permitted by applicable law, subject to certain exceptions.</FONT></TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="margin: 0; font-size: 10pt"></P>

<!-- Field: Page; Sequence: 183; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">K-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font-size: 10pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font-size: 10pt">
    <TD STYLE="padding: 5.75pt 5.4pt; font-size: 10pt; vertical-align: top; text-align: justify; width: 26%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 5.75pt 5.4pt; font-size: 10pt; text-align: center; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>British
    Columbia</B></FONT></TD>
    <TD STYLE="padding: 5.75pt 5.4pt; font-size: 10pt; vertical-align: top; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 5.75pt 5.4pt; font-size: 10pt; text-align: center; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD></TR>

<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; padding: 5.75pt 5.4pt; width: 26%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Stockholder/Shareholder
                                      Lawsuits</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding: 5.75pt 5.4pt; text-align: justify; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    the BCBCA, a shareholder, defined for derivative actions to include a beneficial shareholder and any other person whom a court considers
    to be an appropriate person to make an application under the BCBCA, or a director of a company may, with leave of the court, bring
    a legal proceeding in the name and on behalf of the company to enforce an obligation owed to the company that could be enforced by
    the company itself, or to obtain damages for any breach of such an obligation. An applicant may also, with leave of the court, defend
    a legal proceeding brought against a company.</FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 5.75pt 5.4pt; text-align: justify; width: 2%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 5.75pt 5.4pt; text-align: justify; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NRS
    41.520 grants stockholders a derivative cause of action where the corporation refuses to enforce rights which may properly be asserted
    by it, where the plaintiff was a stockholder at the time of the transaction of which the plaintiff complains or that the plaintiff&rsquo;s
    share thereafter devolved on the plaintiff by operation of law. The complaint must also set forth with particularity the efforts
    of the plaintiff to secure from the board of directors and, if necessary, from the stockholders such action as the plaintiff desires,
    and the reasons for the plaintiff&rsquo;s failure to obtain such action or the reasons for not making such effort. In any such action,
    at any time within 30 days after service of summons upon the corporation or any defendant who is an officer or director of the corporation
    or held such office at the time of the acts complained of, the corporation or such defendant may move the court for an order, upon
    notice and hearing, requiring the plaintiff to furnish security as hereinafter provided. Such motion must be based upon one or more
    of the following grounds: (a)&nbsp;that there is no reasonable possibility that the prosecution of the cause of action alleged in
    the complaint against the moving party will benefit the corporation or its security holder or (b)&nbsp;that the moving party, if
    other than the corporation, did not participate in the transaction complained of in any capacity.</FONT></TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<!-- Field: Page; Sequence: 184; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">K-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 5.75pt 5.4pt; vertical-align: top; text-align: justify; width: 26%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5.75pt 5.4pt; text-align: center; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>British
    Columbia</B></FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 5pt 5pt; vertical-align: top; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5.75pt 5.4pt; text-align: center; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD></TR>

<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Oppression
                                      Remedy</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    BCBCA provides an oppression remedy that enables a court to make any order, whether interim or final, to rectify matters that are
    oppressive or unfairly prejudicial to any shareholder, which includes a beneficial shareholder or any other person who the court
    considers to be an appropriate person to make such an application. The oppression remedy provides the court with very broad and flexible
    powers to intervene in corporate affairs to protect shareholders and other applicants.</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
    the NRS imposes fiduciary duties upon directors and officers, the NRS does not contain an &ldquo;oppression remedy.&rdquo;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; padding-top: 10pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Advance
                                      Notification Requirements for Proposals of Stockholders/Shareholders</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-top: 10pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Under
                                      the BCBCA, a qualified shareholder may submit a shareholder proposal setting out a matter that
                                      he wishes to have considered at the next annual general meeting of the company and, subject to
                                      such shareholder&rsquo;s compliance with the prescribed time periods and other requirements of
                                      the BCBCA pertaining to shareholder proposals, the company must send the text of the proposal to
                                      shareholders and must allow a submitter to present the proposal, personally or by proxy, at the
                                      annual general meeting in relation to which the proposal was made if the submitter is a qualified
                                      shareholder at the time of that meeting.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">In addition,
    the BCBCA requires that the proposal be signed by qualified shareholders who, together with the submitter, are, at the time of signing,
    registered owners or beneficial owners of shares that, in the aggregate, constitute at least 1/100 of the issued shares of the company
    that carry the right to vote at general meetings, or have a fair market value in excess of the prescribed amount, $2,000.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">The Articles
    require shareholders wishing to nominate directors or propose business for a meeting of shareholders to give timely advance notice
    in writing, as described in section 10.12 of the Articles.</FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-top: 10pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 10pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    NRS does not contain specific provisions regarding stockholder proposals.</FONT></TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<!-- Field: Page; Sequence: 185; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">K-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 5.75pt 5.4pt; vertical-align: top; text-align: justify; width: 26%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5.75pt 5.4pt; text-align: center; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>British
    Columbia</B></FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 5pt 5pt; vertical-align: top; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5.75pt 5.4pt; text-align: center; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD></TR>

<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Anti-Takeover
                                      and Ownership Provisions</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">While
                                      the BCBCA does not contain specific anti-takeover provisions with respect to &ldquo;business combinations,&rdquo;
                                      rules&nbsp;and policies of certain Canadian securities regulatory authorities, including Multilateral
                                      Instrument 61-101 &mdash; Protection of Minority Security Holders in Special Transactions, or Multilateral
                                      Instrument 61-101, contain requirements in connection with, among other things, &ldquo;related
                                      party transactions&rdquo; and &ldquo;business combinations,&rdquo; including, among other things,
                                      any transaction by which an issuer directly or indirectly engages in the following with a related
                                      party: acquires, sells, leases or transfers an asset, acquires the related party, acquires or issues
                                      treasury securities, amends the terms of a security if the security is owned by the related party
                                      or assumes or becomes subject to a liability or takes certain other actions with respect to debt.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The
    term &ldquo;related party&rdquo; includes directors, senior officers and holders of more than 10% of the voting rights attached to
    all outstanding voting securities of the issuer any holder hat beneficially owns, in the aggregate, more than 50 per cent of the
    securities of any outstanding class of equity securities.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Multilateral
    Instrument 61-101 requires, subject to certain exceptions, the preparation of a formal valuation relating to certain aspects of the
    transaction and more detailed disclosure in the proxy material sent to security holders in connection with a related party transaction
    including related to the valuation. Multilateral Instrument 61-101 also requires, subject to certain exceptions, that an issuer not
    engage in a related party transaction unless the shareholders of the issuer, other than the related parties, approve the transaction
    by a simple majority of the votes cast.</FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Unless
                                      an issuer opts out of the provisions of NRS 78.411 through 78.444, such statutes generally prohibit
                                      a public Nevada corporation from engaging in a &ldquo;combination&rdquo; with a holder of 10% or
                                      more of the voting power of the outstanding voting shares of the Company, referred to as an interested
                                      stockholder, for a period of two years after the time the interested stockholder became an interested
                                      stockholder, except as otherwise provided therein. For these purposes, the term &ldquo;combination&rdquo;
                                      includes mergers, certain assets sales and other similar transactions with an interested stockholder.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Oncolytics
    Nevada has opted out of NRS 78.411 through 78.444 in the Oncolytics Nevada Charter.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">In addition
    to the restrictions on business combinations with interested stockholders, Nevada law also protects a corporation and its stockholders
    from persons acquiring a &ldquo;controlling interest&rdquo; in a corporation. The provisions can be found in NRS 78.378 to 78.3793,
    inclusive.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt">Pursuant
to NRS 78.378, any person who acquires a controlling interest in a corporation may not exercise voting rights on any control shares unless
the articles of incorporation or bylaws in effect on the 10<SUP>th</SUP> day following such acquisition provide that the provisions of
these statutes do not apply to the corporation or to an acquisition of a controlling interest specifically by types of existing or future
stockholders, or unless such voting rights are conferred by a majority vote of the disinterested stockholders of the issuing corporation
at a special meeting of such stockholders held upon the request and at the expense of the acquiring person. NRS 78.3785 provides that
a &ldquo;controlling interest&rdquo; means the ownership of outstanding voting shares of an issuing corporation sufficient to enable
the acquiring person, individually or in association with others, directly or indirectly, to exercise (i)&nbsp;one-fifth or more but
less than one-third, (ii)&nbsp;one-third or more but less than a majority or (iii)&nbsp;a majority or more of the voting power of the
issuing corporation in the election of directors, and once an acquirer crosses one of these thresholds, shares that it acquired in the
transaction taking it over the threshold and within the 90 days immediately preceding the date when the acquiring person acquired or
offered to acquire a controlling interest become &ldquo;control shares&rdquo; to which the voting restrictions described above apply.
In the event that the control shares are accorded full voting rights and the acquiring person acquires control shares with a majority
or more of all the voting power, any stockholder, other than the acquiring person, who does not vote in favor of authorizing voting rights
for the control shares is entitled to demand payment for the fair value of such person&rsquo;s shares, and the corporation must comply
with the demand.</FONT></P></TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<!-- Field: Page; Sequence: 186; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">K-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 5.75pt 5.4pt; vertical-align: top; text-align: justify; width: 26%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5.75pt 5.4pt; text-align: center; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>British
    Columbia</B></FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 5pt 5pt; vertical-align: top; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding: 5.75pt 5.4pt; text-align: center; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD></TR>

<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding: 5pt 5pt 10pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 5pt 5pt 10pt; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 5pt 5pt 10pt; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 5pt 5pt 10pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Corporations
    are entitled to opt out of the above controlling interest provisions of the NRS. In the Oncolytics Nevada Bylaws, Oncolytics Nevada
    opts out of these provisions.</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; width: 26%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forum
    Selection&nbsp;&nbsp;</B></FONT></TD>
    <TD STYLE="font-size: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    BC company may include a forum selection clause in its articles which provides a mechanism, subject to certain limitations, to require
    an action against the company to be brought in the company&rsquo;s home jurisdiction.</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; width: 2%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    proposed Oncolytics Nevada Bylaws provide that the Eighth Judicial District Court of the State of Nevada, in Clark County, Nevada
    shall be the sole and exclusive forum for (1)&nbsp;any derivative action or proceeding brought on behalf of the Company,
    (2)&nbsp;any action or proceeding asserting a claim of breach of a fiduciary duty owed by any current or former director, officer,
    stockholder, employee or agent of the Company to the Company or the Stockholders, (3)&nbsp;any
    action or proceeding asserting a claim arising pursuant to the NRS, the Oncolytics Nevada Charter or Oncolytics Nevada Bylaws,
    (4)&nbsp;any proceeding to interpret, apply, enforce or determine the validity of the Nevada Charter or Nevada Bylaws, (5)&nbsp;any
    internal action (as defined in NRS 78.046) and any action or proceeding as to which NRS Title 7 confers jurisdiction to the District
    Courts of the State of Nevada, or (6)&nbsp;any action asserting a claim governed by the internal affairs doctrine. The Oncolytics
    Nevada Bylaws further provide that the federal district courts of the United States of America are the sole and exclusive forum for
    the resolution of any claim asserting a cause of action under the Securities Act.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 187; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">K-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="annexl"></A>ANNEX
L</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>HISTORICAL STATEMENT OF EXECUTIVE COMPENSATION FOR THE YEAR ENDED
DECEMBER 31, 2024</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information in this Annex L is provided as
at December&nbsp;31, 2024, unless otherwise stated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has formed a compensation committee
(the &ldquo;<B>Compensation Committee</B>&rdquo;) which consists of three outside, independent directors: Ms.&nbsp;Brown (Chair); Ms.&nbsp;Holtham;
and Dr.&nbsp;Seizinger. Mr.&nbsp;Pisano, the Chair of the Board, served as an ex officio member of the Compensation Committee prior to
his appointment as Interim Chief Executive Officer of the Company. No member of the Compensation Committee has been an employee officer
of the Company or any of its affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Philosophy&nbsp;&amp; Governance of Compensation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Compensation Committee exercises general responsibility
for the Company&rsquo;s human resources and compensation policies and processes. Among other responsibilities, the Compensation Committee
reviews and makes recommendations to the Board regarding the amount of regular and incentive compensation to be paid to the Chief Executive
Officer and the amounts of regular and incentive compensation to be paid to certain designated executives after considering the Chief
Executive Officer&rsquo;s assessment of the performance of such executives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each member of the Compensation Committee is an
independent director and is ineligible to participate in any of the Company&rsquo;s executive officer compensation programs other than
the Option Plan and the 2023 Plan. Each member has extensive director and officer experience with various public and private companies
in the design and implementation of executive compensation plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has adopted a Compensation Framework
(the &ldquo;<B>Framework</B>&rdquo;) which guides the philosophy for compensation at the Company. The Framework is structured to enable
the Company to attract and retain the qualified personnel required to be successful in what is an enormously competitive international
environment, encourage commitment to the Company and its goals, align executive interests with those of its Shareholders, and reward executives
for performance in relation to overall corporate progress goals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In arriving at its recommendations for compensation,
the Compensation Committee, using the Framework, considers the long-term interests of the Company as well as its current stage of development
and the economic environment within which it operates. The market for biotechnology companies in the development phase is challenging.
Based on these factors, the Compensation Committee recognizes the need to strike a balance between compensation to retain employees and
resources expended to maintain operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Peer Group</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Framework uses a board-approved peer group
to help guide and assess compensation at the Company. Generally, the desire is to approach the 50th percentile for each of the components
of compensation, balancing base salary along with short- and long-term incentives. In arriving at a peer group, the Company engages from
time to time the assistance of a compensation consultant who assists the Compensation Committee with a peer list of companies selected
on the basis of being of similar size (in terms of the number of employees), value (in terms of market cap), and operating in a similar
environment. The list of comparator companies is reviewed and approved by the Compensation Committee and discussed with the Board (the
 &ldquo;<B>Peer Group</B>&rdquo;). The Peer Group is updated at least every three years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 188; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">L-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Peer Group Selection Criteria</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2022, the Company engaged Aon Consulting Inc.&rsquo;s
Human Capital Solutions division with the mandate to assist in a review and update to the Peer Group. These companies were selected based
on a rigorous, multi-step process that considered the following criteria:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><B>Sector</B>: Companies operating in the biotechnology or biopharmaceutical sector, with a focus on pre-commercial
entities. Preference was given to those with therapeutic programs in immuno-oncology or related areas.</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><B>Stage of Development</B>: Companies in the clinical development stage, generally in Phase II or Phase
III trials. This ensures alignment with Oncolytics&rsquo; own development stage and risk profile.</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><B>Market Capitalization</B>: Companies with a 30-day average market capitalization between $50 million
and $300 million.</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><B>Headcount</B>: Companies with fewer than 100 employees, consistent with Oncolytics&rsquo; headcount.
This ensures comparability in organizational scale and complexity.</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><B>Geographic Scope</B>: Companies headquartered in North America (United States and Canada), to reflect
similar regulatory, capital market, and talent environments.</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><B>Business Model and Therapeutic Focus</B>: Consideration was given to companies with similar business
models (e.g., platform-based or single-asset development) and therapeutic areas (e.g., oncology, immunotherapy, metabolic diseases).</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><B>Historical Consistency</B>: Where appropriate, companies from the prior Peer Group were retained to
maintain year-over-year consistency, unless significant changes in size, business model, or ownership occurred.</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><B>Exclusions</B>: Companies were excluded if they were acquired, merged, or had market capitalizations
significantly outside the target range.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The updated Peer Group was approved on January&nbsp;31,
2023 by the Compensation Committee following a comprehensive review of each company&rsquo;s financial profile, therapeutic focus, and
alignment with Oncolytics&rsquo; business model and strategic direction. There were no updates to the Peer Group for 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Approved Peer Group</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following companies comprised the Company&rsquo;s
approved Peer Group for its compensation analysis:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT> </FONT><FONT STYLE="font-family: Symbol; font-size: 10pt"></FONT><FONT STYLE="font-size: 10pt">Actinium
    Pharmaceuticals,&nbsp;Inc.</FONT></TD>
    <TD STYLE="width: 37%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Symbol; font-size: 10pt"> </FONT><FONT STYLE="font-size: 10pt">Alaunos
    Therapeutics,&nbsp;Inc.</FONT></TD>
    <TD STYLE="width: 31%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT> </FONT><FONT STYLE="font-size: 10pt">Alpine
    Immune Sciences,&nbsp;Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT> </FONT><FONT STYLE="font-size: 10pt">Aptose
    Biosciences Inc.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT> </FONT><FONT STYLE="font-size: 10pt">Arbutus
    Biopharma Corporation</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Symbol; font-size: 10pt"> </FONT><FONT STYLE="font-size: 10pt">Atossa
    Therapeutics,&nbsp;Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Symbol; font-size: 10pt"> </FONT><FONT STYLE="font-size: 10pt">aTyr
    Pharma,&nbsp;Inc.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Symbol; font-size: 10pt"> </FONT><FONT STYLE="font-size: 10pt">BriaCell
    Therapeutics Corp.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Symbol; font-size: 10pt"> </FONT><FONT STYLE="font-size: 10pt">Cardiff
    Oncology,&nbsp;Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Symbol; font-size: 10pt"> </FONT><FONT STYLE="font-size: 10pt">Corvus
    Pharmaceuticals,&nbsp;Inc.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Symbol; font-size: 10pt"> </FONT><FONT STYLE="font-size: 10pt">ESSA
    Pharma Inc.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Symbol; font-size: 10pt"> </FONT><FONT STYLE="font-size: 10pt">Evelo
    Biosciences,&nbsp;Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Symbol; font-size: 10pt"> </FONT><FONT STYLE="font-size: 10pt">Fusion
    Pharmaceuticals Inc.<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>1</SUP></FONT></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Symbol; font-size: 10pt"> </FONT><FONT STYLE="font-size: 10pt">Genprex,&nbsp;Inc.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Symbol; font-size: 10pt"> </FONT><FONT STYLE="font-size: 10pt">Lantern
    Pharma Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Symbol; font-size: 10pt"> </FONT><FONT STYLE="font-size: 10pt">Leap
    Therapeutics,&nbsp;Inc.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Symbol; font-size: 10pt"> </FONT><FONT STYLE="font-size: 10pt">Oncternal
    Therapeutics,&nbsp;Inc.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Symbol; font-size: 10pt"> </FONT><FONT STYLE="font-size: 10pt">PDS
    Biotechnology Corporation</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Symbol; font-size: 10pt"> </FONT><FONT STYLE="font-size: 10pt">Surface
    Oncology,&nbsp;Inc.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Symbol; font-size: 10pt"> </FONT><FONT STYLE="font-size: 10pt">Theseus
    Pharmaceuticals,&nbsp;Inc.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT><FONT STYLE="font-family: Symbol; font-size: 10pt"> </FONT><FONT STYLE="font-size: 10pt">Verastem,&nbsp;Inc.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Corporate Objectives</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A core tenet of the Framework is that compensation
should be based on performance. To measure performance, it is necessary to have previously agreed-to objectives against which to measure
success. The Company is divided into specific functional groups, currently Clinical Development, Manufacturing, Business Development and
Finance. Management, in conjunction with the Compensation Committee, recommends to the Board a set of annual objectives for each functional
group and is focused on the approved strategic direction of the Company. The Compensation Committee is tasked with establishing the associated
performance weighting. The objectives are intended to be measurable, achievable and meaningful for the Company and each functional group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Compensation Risks</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following a review of the risks in the Company&rsquo;s
compensation policies and practices, the Compensation Committee found no risks that are reasonably likely to have a material adverse
effect on the Company. The Compensation Committee&rsquo;s role of approving the compensation policies and practices includes considering
whether the compensation policies and practices could encourage a Named Executive Officer (as defined below) to take inappropriate or
excessive risks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>1</SUP> Subsequently acquired by AstraZeneca plc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 189; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">L-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Company&rsquo;s corporate trading policy,
insiders (including Named Executive Officers and directors) are not permitted to hedge their position in Common Shares, options, share
awards, debentures or other debt instruments by use of any financial instrument, which would include but is not limited to options, puts,
calls, warrants or short sells, designed to benefit the holder from a change in the market value of the Common Shares of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Clawback Policy</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November&nbsp;2, 2023, the Board adopted a
Policy for the Recovery of Erroneously Awarded Incentive-Based Compensation (the &ldquo;<B>Clawback Policy</B>&rdquo;) providing for the
recovery of certain incentive-based compensation from current and former executive officers of the Company in the event the Company is
required to restate any of its financial statements filed with the SEC under the Exchange Act in order to correct an error that is material
to the previously-issued financial statements, or that would result in a material misstatement if the error were corrected in the current
period or left uncorrected in the current period. Adoption of the Clawback Policy was mandated by new Nasdaq listing standards introduced
pursuant to Exchange Act Rule&nbsp;10D-1. The Clawback Policy is in addition to Section&nbsp;304 of the <I>Sarbanes-Oxley Act of 2002</I>
which permits the SEC to order the disgorgement of bonuses and incentive-based compensation earned by a registrant issuer&rsquo;s chief
executive officer and chief financial officer in the year following the filing of any financial statement that the issuer is required
to restate because of misconduct, and the reimbursement of those funds to the issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Executive Compensation Elements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Framework establishes the key elements of
the compensation program to include base salary, health benefits, and payments allocated to employees to be directed by them to their
personal retirement accounts. As well, short- and long-term incentives are also part of the Company&rsquo;s compensation program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Base Salary</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Base salaries for each executive officer are determined
by the individual&rsquo;s skill set, abilities, experience and past performance. The Peer Group is used as a guide in setting an appropriate
range for each base salary. For 2024, the Compensation Committee, using their knowledge of the industry, concluded the base salary levels
were in line with the updated Peer Group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Short- and Long-Term Incentives</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December&nbsp;31, 2024, the Chief Executive
Officer was eligible for a short-term incentive bonus of up to 50% of his base salary; the Chief Financial Officer and Chief Medical Officer
were eligible for a short-term incentive bonus of up to 40% of their respective base salaries; Vice President, Product Development was
eligible for a short-term incentive bonus of up to 35% of her base salary; and Vice President, Clinical Operations was eligible for a
short-term incentive bonus of up to 25% of her base salary. For each of the foregoing executives, 100% of the short-term incentive bonus
was based on corporate objectives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For 2024, the Company&rsquo;s performance was
guided by clearly defined corporate objectives, with a strategic focus on advancing the clinical development of pelareorep and securing
the financial resources necessary to support its long-term growth. These objectives were aligned with the Company&rsquo;s overarching
goal of developing pelareorep as a novel immunotherapeutic agent for the treatment of metastatic breast and pancreatic cancers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From a clinical development perspective, the Company
prioritized the advancement of pelareorep in pancreatic cancer by progressing the design of a registration-enabled Phase 3 clinical protocol
in collaboration with the Global Coalition for Adaptive Research (GCAR). This included the development of a regulatory strategy and preparations
for engagement with the U.S. Food and Drug Administration (FDA). The Company also expanded the GOBLET study to include a new treatment
cohort and continued enrollment in the anal carcinoma cohort, further broadening the clinical potential of pelareorep.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 190; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">L-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In metastatic breast cancer, the Company was focused
on achieving the key milestone of completing the BRACELET-1 study, including final overall survival analyses and designing a registration-enabling
clinical protocol.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s financing objectives were
centered on strengthening its capital position and enhancing shareholder value. Key initiatives included securing short-term funding to
support operations, initiating outreach to potential biopharmaceutical collaborators, and executing a comprehensive investor relations
strategy. These efforts were aimed at increasing institutional ownership and expanding the investor base through targeted engagement with
both strategic and non-traditional investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Quantitative measures were generally not established
for the corporate objectives for 2024. Instead, these performance objectives and areas of emphasis were used as a guide by the Compensation
Committee and the Board in determining overall corporate performance as they represented those areas in which the executive team and the
employees were expected to focus their efforts during the year. In evaluating management&rsquo;s performance relative to corporate performance
for 2024, the Compensation Committee determined to award a corporate achievement level of 54.5%. This corporate achievement level was
then used to determine the short-term incentive bonuses for each executive and are set forth in the &ldquo;<I>Summary Compensation Table</I>&rdquo;
below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company utilizes options and share awards
to ensure that the long-term interests of its executives align with the interests of the Company&rsquo;s Shareholders. The Board determines
and approves the amount of each option and share award grant based on the overall performance of the Company and having regard to previous
grants made to its executives and the overall equity ownership levels of executives. Typically, when options are awarded, a third of the
executive&rsquo;s option grant vests immediately, a third vests on the first anniversary and the final third vests on the second anniversary.
When share awards are granted, vesting occurs annually over a three-year period. The value of the long-term incentive option and share
award grants are listed in the &ldquo;<I>Summary Compensation Table</I>&rdquo; below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June&nbsp;18, 2025, the Company had only
issued options under its Option Plan and RSUs under its 2023 Plan. As a material inducement to Mr.&nbsp;Kelly commencing employment as
Chief Executive Officer of the Company in June&nbsp;2025, the Company made standalone grants to Mr.&nbsp;Kelly of certain options to purchase
Common Shares and performance-based restricted share units entitling Mr.&nbsp;Kelly to receive Common Shares upon vesting of the RSUs.
These grants to Mr.&nbsp;Kelly were not made under, and are not governed by the terms of, the Option Plan or 2023 Plan. The Company has
relied on Nasdaq Listing Rule&nbsp;5635(c)(4)&nbsp;and the &ldquo;Eligible Interlisted Issuer&rdquo; exemption from TSX rules&nbsp;under
section 602.1 of the TSX Company Manual with respect to these grants made to Mr.&nbsp;Kelly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Performance Graph</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following graph and table compare the change
in the cumulative total shareholder return on the Common Shares over the period from December&nbsp;31, 2019 to December&nbsp;31, 2024
(assuming a $100 investment was made on December&nbsp;31, 2019) with the cumulative total return of the S&amp;P/TSX Capped Health Care
Index over the same period, assuming reinvestment of dividends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2533062d1_424b3img09.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 191; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">L-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The performance trend shown by the above graph
does not necessarily reflect the trend in our executive compensation reported over the same period. The market price of the Company&rsquo;s
shares, similar to the share prices of many publicly-traded biotechnology companies, has historically been highly volatile. As outlined
in this Appendix L, the Compensation Committee balances the various short-term and long-term objectives and provides bonuses, options
and share awards based on performance against these objectives. The movement in share price based upon one index is not considered wholly
representative of the actions to be taken regarding compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
<TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD>
<TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><B>Dec 31,</B> <B><BR>
2019</B></TD>
<TD STYLE="text-align: center; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><B>Dec 31,</B> <B><BR>
2020</B></TD>
<TD STYLE="text-align: center; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><B>Dec 31,</B> <B><BR>
2021</B></TD>
<TD STYLE="text-align: center; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><B>Dec 31,</B> <B><BR>
2022</B></TD>
<TD STYLE="text-align: center; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><B>Dec 31,</B> <B><BR>
2023</B></TD>
<TD STYLE="text-align: center; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><B>Dec 31,</B> <B><BR>
2024</B></TD>
<TD STYLE="text-align: center; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="width: 34%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">S&amp;P/TSX Capped Health Care Index</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">100.00</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">78.71</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">60.14</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">25.41</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">31.04</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">33.67</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Oncolytics Biotech Inc.</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">100.00</TD>
<TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">49.11</TD>
<TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">28.46</TD>
<TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">36.10</TD>
<TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">29.11</TD>
<TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">21.63</TD>
<TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Compensation Advisors and Executive Compensation-Related
Fees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Compensation Committee, from time to time,
engages external compensation advisors to provide recommendations to the committee with respect to compensation for directors and officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The table below summarizes the fees billed by
Radford related to determining compensation for the Company&rsquo;s directors and executives (&ldquo;<B>Executive Compensation Related
Fees</B>&rdquo;) and the fees billed by the specialist related to other services (&ldquo;<B>All Other Fees</B>&rdquo;) for the financial
years ended December&nbsp;31, 2024 and 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 68%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
<TD STYLE="white-space: nowrap; text-align: center; font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Year ended</TD>
<TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><B>Executive Compensation- Related <BR>
Fees</B> <B><BR>
$</B></TD>
<TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><B>All Other Fees<BR>
</B> <B>$</B></TD>
<TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">December&nbsp;31, 2024</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="width: 74%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">December&nbsp;31, 2023</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">61,101</TD>
<TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September&nbsp;14, 2025, the Company retained
Anderson Pay Advisors, LLC to review the Company&rsquo;s peer group, director and executive compensation levels, and equity compensation
strategy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Summary Compensation Table</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth all compensation
paid, payable, awarded, granted, given, or otherwise provided, directly or indirectly, by the Company, or a subsidiary of the Company,
in Canadian dollars, to the Chief Executive Officer, the Interim Chief Executive Officer, the Chief Financial Officer and the individuals
who were, as at December&nbsp;31, 2024, the next three most highly compensated executive officers of the Company whose total compensation
was, individually, more than $150,000 (collectively, the &ldquo;<B>Named Executive Officers</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
<TD COLSPAN="35" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD COLSPAN="6" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt"><B>Non-equity
incentive plan<BR>
compensation <BR>($)</B></FONT></TD>
<TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">Name
and principal<BR>
position</FONT></TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">Year</FONT></TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-size: 7pt"><B>Salary
<BR>
($)</B></FONT></TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-size: 7pt"><B>Share-<BR>
based<BR>
awards<SUP>(1)<BR>
</SUP> ($)</B></FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-size: 7pt"><B>Option-<BR>

based<BR>
 Awards<SUP>(1)</SUP> <BR>
($)</B></FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt"><B>Annual<BR>

incentive<BR>
 plans</B></FONT><B><FONT STYLE="font-size: 7pt">(2)(3) <BR>
($)</FONT></B></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-size: 7pt"><B>Long-term<BR>

incentive plans<BR>
 ($)</B></FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-size: 7pt"><B>Pension<BR>

value<BR>
 ($)</B></FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-size: 7pt"><B>All
other<BR>
 compensation<SUP>(4)<BR>
</SUP> ($)</B></FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-size: 7pt"><B>Total<BR>

compensation<BR>
 ($)</B></FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Wayne
Pisano<SUP>(5)</SUP></FONT></TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">2024</FONT></TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">217,312</FONT></TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">157,498&nbsp;</FONT></TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">19,472&nbsp;</FONT></TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">394,282</FONT></TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">Interim Chief Executive</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">2023</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">Officer</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">2022</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Dr.&nbsp;Matthew
C. Coffey<SUP>(7)</SUP></FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">2024</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">709,950</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">156,887&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">106,500&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">90,881&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">1,064,218</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">President and Chief</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">2023</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">735,223</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">401,890&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">760,146&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">257,328&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">91,436&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">2,246,023</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">Executive Officer</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">2022</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">654,404</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">136,616&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">310,842&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">83,198&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">1,185,060</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">Kirk J. Look</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">2024</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">597,479</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">210,496&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">126,491&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">77,636&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">1,012,102</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">Chief Financial Officer</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">2023</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">533,404</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">196,443&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">366,180&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">149,353&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">74,786&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">1,320,166</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">2022</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">486,593</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">109,293&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">184,905&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">69,354&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">850,145</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Dr.&nbsp;Thomas
C. Heineman<SUP>(6)</SUP></FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">2024</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">749,706</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">240,701&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">126,491&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">54,675&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">1,171,573</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">Chief Medical
    Officer</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">2023</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">615,207</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">184,575</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">342,774</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">172,258</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">46,999</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">1,361,813</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">2022</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">599,999</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">109,293</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">228,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">44,679</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">981,971</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
</TABLE>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 192; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">L-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD COLSPAN="6" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt"><B>Non-equity
incentive plan<BR>
compensation <BR>($)</B></FONT></TD>
<TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD>
<TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 12%"><FONT STYLE="font-size: 7pt">Name
and principal<BR>
position</FONT></TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt; width: 1%"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 7%"><FONT STYLE="font-size: 7pt">Year</FONT></TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt; width: 1%"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 1%"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 7%"><FONT STYLE="font-size: 7pt"><B>Salary
<BR>
($)</B></FONT></TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt; width: 1%"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 1%"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 7%"><FONT STYLE="font-size: 7pt"><B>Share-<BR>
based<BR>
awards<SUP>(1)<BR>
</SUP> ($)</B></FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt; width: 1%"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 1%"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 7%"><FONT STYLE="font-size: 7pt"><B>Option-<BR>

based<BR>
 Awards<SUP>(1)</SUP> <BR>
($)</B></FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt; width: 1%"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 1%"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt"><B>Annual<BR>

incentive<BR>
 plans</B></FONT><B><FONT STYLE="font-size: 7pt">(2)(3) <BR>
($)</FONT></B></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt; width: 1%"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 1%"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 7%"><FONT STYLE="font-size: 7pt"><B>Long-term<BR>

incentive plans<BR>
 ($)</B></FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt; width: 1%"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 1%"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 7%"><FONT STYLE="font-size: 7pt"><B>Pension<BR>

value<BR>
 ($)</B></FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt; width: 1%"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 1%"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 7%"><FONT STYLE="font-size: 7pt"><B>All
other<BR>
 compensation<SUP>(4)<BR>
</SUP> ($)</B></FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt; width: 1%"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 1%"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 7%"><FONT STYLE="font-size: 7pt"><B>Total<BR>

compensation<BR>
 ($)</B></FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>

  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">Allison Hagerman</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">2024</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">422,622</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">107,531</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">39,256</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">66,426</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">635,835</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">Vice President,</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">2023</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">410,313</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">53,529</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">98,639</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">100,527</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">64,631</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">727,639</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">Product Development</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">2022</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">390,774</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">109,293</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">129,932</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">61,449</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">691,448</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Amy
    G. Levin<SUP>(6)(8)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">2024</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">474,261</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">83,823</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">30,532</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">66,090</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">654,706</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">Vice President, Clinical</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">2023</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">423,232</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">45,316</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">83,801</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">74,066</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">57,132</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">683,547</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt">Operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt">2022</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Notes:</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 7pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">The methodology,
                                            assumptions and estimates related to the value of share and option-based awards are disclosed
                                            in note 3 &ldquo;Summary of Material Accounting Policies&rdquo; and note 11 &ldquo;Share-Based
                                            Compensation&rdquo; in the Company&rsquo;s 2024 audited consolidated financial statements,
                                            and &ldquo;Critical Accounting Estimates&rdquo; in the Company&rsquo;s 2024 Management&rsquo;s
                                            Discussion&nbsp;&amp; Analysis.</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 7pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">The
                                            amounts shown relate to the annual cash short-term incentive awards and are paid in the year
                                            earned.</FONT></TD>
</TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 7pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">In 2024, RSUs
                                            were issued to our Named Executive Officers in lieu of cash under our short-term incentive
                                            program.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 7pt">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">The dollar amounts
                                            set forth under this column are related to contributions to the officers&rsquo; respective
                                            retirement savings plan and amounts provided for health care benefits by the Company.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 7pt">(5)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">Mr.&nbsp;Pisano
                                            was appointed Interim Chief Executive Officer in the second quarter of 2024. Reflects compensation
                                            paid to Mr.&nbsp;Pisano during 2024 in his capacity as Interim Chief Executive Officer and
                                            as a director. Includes fees of $115,112 and 19,472 options received by Mr.&nbsp;Pisano in
                                            his role as a director. Mr.&nbsp;Pisano ceased to be the Interim Chief Executive Officer
                                            of the Company on June&nbsp;11, 2025 upon the appointment of Mr.&nbsp;Kelly as Chief Executive
                                            Officer of the Company.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 7pt">(6)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">U.S. Employees
                                            are paid salaries, bonuses and other compensation in U.S. Dollars. These amounts are presented
                                            in Canadian dollars and have been converted at a U.S./CDN exchange rate of U.S.$1.00 = $1.4389,
                                            $1.3226 and $1.3544 for the years 2024, 2023 and 2022, respectively.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 7pt">(7)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">During the second
                                            quarter of 2024, the Company announced that Dr.&nbsp;Coffey was taking a medical leave of
                                            absence. None of the compensation paid to Dr.&nbsp;Coffey related to his role as a director
                                            of the Company. On February&nbsp;7, 2025, it was announced that Dr.&nbsp;Coffey had resigned
                                            as President and Chief Executive Officer.</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 7pt">(8)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">Ms.&nbsp;Levin
                                            was appointed as the Vice President, Clinical Operations effective January&nbsp;1, 2023.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 193; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">L-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Outstanding Option-Based Awards and Share-Based
Awards</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth for each Named
Executive Officer all option-based awards (comprised of options granted under the Option Plan) and share-based awards (comprised of RSUs
granted under the 2023 Plan) outstanding as of December&nbsp;31, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font-size: 7pt; vertical-align: bottom">
<TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD COLSPAN="13" STYLE="border-bottom: Black 1pt solid; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">Option-based
Awards</FONT></TD>
<TD STYLE="padding-bottom: 1pt; font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD COLSPAN="10" STYLE="border-bottom: Black 1pt solid; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">Share-based
Awards</FONT></TD>
<TD STYLE="padding-bottom: 1pt; font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: bottom">
<TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font: bold 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">Name</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt"><B>Number
of<BR>
securities<BR>
underlying<BR>
unexercised<BR>
options</B></FONT><FONT STYLE="font-size: 7pt"><SUP>(1)</SUP> <B><BR>
(#)</B></FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: bold 7pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">Option
exercise <BR>
price ($)</FONT></TD>
<TD STYLE="font: bold 7pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: bold 7pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">Option
<BR>
expiration<BR>
date</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt"><B>Value
of<BR>
unexercised in-<BR>
the-money<BR>
options</B></FONT><FONT STYLE="font-size: 7pt"><SUP>(2)</SUP> <BR>
<B>($)</B></FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt"><B>Number
of shares<BR>
or units of shares <BR>
that have not<BR>
vested <BR>
(#)</B></FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt"><B>Market
or payout<BR>
value of share-<BR>
based awards that <BR>
have not vested</B> <FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
<B>($)</B></FONT><SUP>(3)</SUP></FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt"><B>Market
or<BR>
payout value of<BR>
vested share-<BR>
based awards<BR>
not paid out or<BR>
distributed <BR>
($)</B></FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 13%"><FONT STYLE="font-size: 7pt">Wayne</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Pisano<SUP>(4)</SUP></FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 12%; text-align: center"><FONT STYLE="font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-size: 7pt">64,004</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-size: 7pt">85,125</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: White">
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">Dr.&nbsp;Matthew <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">C. Coffey<SUP>(5)</SUP></FONT></FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">77,263</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">3.99</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">1-Dec-25</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">255,171</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">339,377</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: White">
<TD STYLE="font: 7pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">65,000</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">2.08</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">10-Dec-25</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: White">
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">420,000</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">3.40</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">8-Mar-26</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: White">
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">100,000</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">2.31</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">9-Dec-26</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: White">
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">42,105</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">2.66</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">16-Jan-27</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: White">
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">301,000</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">2.76</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">4-Feb-28</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: White">
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">350,000</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">1.91</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">4-Feb-28</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: White">
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">205,100</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">1.13</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">4-Feb-28</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">41,020</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">Kirk J. Look</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">48,842</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">3.99</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">1-Dec-25</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">246,480</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">327,818</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">55,000</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">2.08</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">10-Dec-25</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">155,000</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">3.40</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">8-Mar-26</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">80,000</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">2.31</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">9-Dec-26</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">31,578</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">2.66</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">16-Jan-27</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">105,000</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">2.76</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">15-Aug-28</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">231,700</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">1.91</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">8-Dec-28</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">243,600</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">1.13</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">18-Dec-29</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">48,720</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: White">
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">Dr.&nbsp;Thomas C. <FONT STYLE="font-size: 7pt">Heineman</FONT></FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">70,000</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">2.84</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">1-Aug-25</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">270,344</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">359,558</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: White">
<TD STYLE="font: 7pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">55,000</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">2.08</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">10-Dec-25</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: White">
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">120,000</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">3.40</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">8-Mar-26</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: White">
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">80,000</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">2.31</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">9-Dec-26</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: White">
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">88,900</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">2.76</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">15-Aug-28</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: White">
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">231,700</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">1.91</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">8-Dec-28</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: White">
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">243,600</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">1.13</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">18-Dec-29</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">48,720</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">Allison <FONT STYLE="font-size: 7pt">Hagerman</FONT></FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">5,263</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">3.90</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">9-Dec-25</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">112,094</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">149,085</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font: 7pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">55,000</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">2.08</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">10-Dec-25</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">45,000</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">3.40</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">8-Mar-26</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">80,000</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">2.31</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">9-Dec-26</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">7,894</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">2.66</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">28-Dec-26</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">21,700</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">2.76</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">15-Aug-28</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">72,800</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">1.91</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">8-Dec-28</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">75,600</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">1.13</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">18-Dec-29</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">15,120</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: White">
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">Amy G. Levin</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">50,000</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">2.27</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">1-Sep-25</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">88,247</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">117,369</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: White">
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">25,000</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">2.08</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">10-Dec-25</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: White">
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">25,000</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">2.31</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">9-Dec-26</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: White">
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">21,700</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">2.76</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">15-Aug-28</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: White">
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">56,700</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">1.91</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">8-Dec-28</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Nil</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: White">
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">58,800</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">1.13</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 7pt">18-Dec-29</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 7pt">11,760</FONT></TD>
<TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 7pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Notes:</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 7pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">As at December&nbsp;31,
                                            2024, all options granted to our Named Executive Officers had fully vested except for the
                                            options granted on August&nbsp;15, 2023 (expiring August&nbsp;15, 2028), December&nbsp;8,
                                            2023 (expiring December&nbsp;8, 2028) and December&nbsp;18, 2024 (expiring December&nbsp;18,
                                            2029).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 7pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">These amounts
                                            are calculated based on the difference between the closing price of the Common Shares underlying
                                            the options on the TSX on December&nbsp;31, 2024 ($1.33), and the exercise price of the options.
                                            These amounts include all options, vested and unvested, as at December&nbsp;31, 2024.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 7pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">These amounts
                                            are calculated based on the closing price of the Common Shares on the TSX on December&nbsp;31,
                                            2024 ($1.33).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 7pt">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">Mr.&nbsp;Pisano
                                            was appointed Interim Chief Executive Officer in the second quarter of 2024. Reflects compensation
                                            paid to Mr.&nbsp;Pisano in his capacity as Interim Chief Executive Officer. Mr.&nbsp;Pisano
                                            ceased to be the Interim Chief Executive Officer of the Company on June&nbsp;11, 2025 upon
                                            the appointment of Mr.&nbsp;Kelly as Chief Executive Officer of the Company.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 7pt">(5)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">During the second
                                            quarter of 2024, the Company announced that Dr.&nbsp;Coffey was taking a medical leave of
                                            absence. None of the compensation paid to Dr.&nbsp;Coffey related to his role as a director
                                            of the Company. On February&nbsp;7, 2025, it was announced that Dr.&nbsp;Coffey had resigned
                                            as President and Chief Executive Officer.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 194; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">L-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Value Vested or Earned During the Year</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth for each Named
Executive Officer the value vested or earned on all option-based awards, share-based awards, and non-equity incentive plan compensation
during the financial year ending December&nbsp;31, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
<TD STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Name</TD>
<TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><B>Option-based awards &ndash;<BR>
</B> <B>Value vested during the <BR>
year<BR>
</B> <B>($)</B></TD>
<TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><B>Share-based awards &ndash; <BR>
Value vested during the <BR>
year<BR>
</B> <B>($)</B></TD>
<TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><B>Non-equity incentive plan <BR>
compensation &ndash;<BR>
</B> <B>Value earned during the year ($)</B></TD>
<TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wayne Pisano<SUP>(1)</SUP></FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="width: 43%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.&nbsp;Matthew C. Coffey<SUP>(2)</SUP></FONT></TD>
<TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right">75,399</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Kirk J. Look</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">38,565</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Dr.&nbsp;Thomas C. Heineman</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">36,629</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Allison Hagerman</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10,779</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Amy G. Levin</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8,988</TD>
<TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Notes:</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(1)</TD><TD>Mr.&nbsp;Pisano was appointed Interim Chief Executive Officer in the second quarter of 2024. Mr.&nbsp;Pisano ceased to be the Interim
Chief Executive Officer of the Company on June&nbsp;11, 2025 upon the appointment of Mr.&nbsp;Kelly as Chief Executive Officer of the
Company.</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(2)</TD><TD>During the second quarter of 2024, the Company announced that Dr.&nbsp;Coffey was taking a medical leave of absence. None of the compensation
paid to Dr.&nbsp;Coffey related to his role as a director of the Company. On February&nbsp;7, 2025, it was announced that Dr.&nbsp;Coffey
had resigned as President and Chief Executive Officer.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>DIRECTOR COMPENSATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Director Compensation Table</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table details the compensation received
by each director of the Company in 2024 who was not at any point during the year ended December&nbsp;31, 2024 a salaried employee of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
<TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Name</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><B>Fees<BR>
Earned<BR>
 <FONT STYLE="font-family: Times New Roman, Times, Serif">($)</FONT><SUP>(1)</SUP></B></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><B>Share- <BR>
based<BR>
 awards<SUP>(2)</SUP></B> <B><BR>
($)</B></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><B>Option-
<BR>
Based<BR>
Awards<BR>
 <FONT STYLE="font-family: Times New Roman, Times, Serif">($)</FONT><SUP>(2)</SUP></B></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><B>Non-Equity<BR>
 Incentive Plan<BR>
 Compensation</B> <BR>
<B>($)</B></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><B>Pension</B> <B><BR>
Value<BR>
 ($)</B></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><B>All Other</B> <BR>
<B>Compensation ($)</B></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Total<BR>
 ($)</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="width: 22%; font: 10pt Times New Roman, Times, Serif; text-align: left">Patricia Andrews</TD>
<TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">71,945</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">36,417</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">108,362</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Deborah M. Brown</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">89,212</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">15,578</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">104,790</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Angela Holtham</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">94,967</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">15,578</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">110,545</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">James T. Parsons</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">79,140</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">15,578</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">94,718</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Jonathan Rigby</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">71,945</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">15,578</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">87,523</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Bernd R. Seizinger</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">87,773</TD>
<TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">15,578</TD>
<TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">103,351</TD>
<TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Notes:</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(1)</TD><TD STYLE="text-align: justify">Directors are paid fees in U.S. Dollars. These amounts are presented in Canadian dollars and have been
converted at a U.S./CDN exchange rate of U.S.$1.00 = $1.4389.</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">The methodology, assumptions and estimates related to the value of share and option-based awards are disclosed
in note 3 &ldquo;Summary of Material Accounting Policies&rdquo; and note 11 &ldquo;Share-Based Compensation&rdquo; in the Company&rsquo;s
2024 audited consolidated financial statements, and &ldquo;Critical Accounting Estimates&rdquo; in the Company&rsquo;s 2024 Management&rsquo;s
Discussion&nbsp;&amp; Analysis.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 195; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">L-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board has approved the following compensation
structure for the independent directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Annual Retainer</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each director receives a base retainer of U.S.$40,000.
In addition to the base retainer directors are eligible to receive the following additional fees depending on committee involvement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>Additional
Retainers (U.S.$)</U></B></FONT>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 86%; font: 10pt Times New Roman, Times, Serif; text-align: left">Board chair</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">40,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Audit Committee chair</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">20,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Governance Committee chair</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Compensation Committee Chair</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Science&nbsp;&amp; Development Committee Chair</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">15,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Non-chair member of the Audit Committee</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Non-chair member of the Governance or Science&nbsp;&amp; Development Committee</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Non-chair member of the Compensation Committee</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the above retainers, the Company
will grant 30,000 options annually for directors other than the Chair. The Chair will receive 37,500 options annually. All such options
vest in their entirety one year following the grant date. New directors will be entitled to receive an initial grant of 45,000 options,
which vest immediately.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Commencing effective January&nbsp;1, 2025 until
June&nbsp;11, 2025, when he ceased to be Interim Chief Executive of the Company, Mr.&nbsp;Pisano received no compensation for serving
as Chair, rather, all compensation received by Mr.&nbsp;Pisano was in connection with his role as Interim Chief Executive Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company also reimburses the directors for
any reasonable expenses incurred by them while acting in their directors&rsquo; capacity. During the year ended December&nbsp;31, 2024,
total compensation of $609,289 was paid to the directors, other than Dr.&nbsp;Coffey and Mr.&nbsp;Pisano, which consisted of fee payments
of $494,982 and option-based awards of $114,307.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Outstanding Option-Based Awards and Share-Based
Awards</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth for each director,
other than Named Executive Officers who are directors, all option-based awards (comprised of options granted under the Option Plan) outstanding
as of December&nbsp;31, 2024. The Company had no share-based awards (comprised of share awards granted under the 2023 Plan) issued to
directors of the Company, other than Named Executive Officers who are directors, outstanding as of December&nbsp;31, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
<TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font: bold 10pt Times New Roman, Times, Serif">Name</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Number of securities<BR>
 underlying unexercised<BR>
 options</B></FONT><SUP>(1)</SUP> <B><BR>
(#)</B></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font: bold 10pt Times New Roman, Times, Serif">Option Exercise Price ($)</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Option expiration date</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Value of unexercised in-<BR>
the-money options</B></FONT><SUP>(2)</SUP> <B><BR>
($)</B></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="width: 29%; font: 10pt Times New Roman, Times, Serif; text-align: left">Patricia Andrews</TD>
<TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right">45,000</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right">1.76</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: center">5-Jan-29</TD>
<TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Deborah M. Brown</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,263</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5.42</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">7-Nov-27</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">30,000</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.40</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">8-Mar-26</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">30,000</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.14</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">16-Jun-26</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,700</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">30,000</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.76</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">15-Aug-28</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">30,000</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.13</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">18-Dec-29</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,000</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Angela Holtham</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">30,000</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.40</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">8-Mar-26</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">30,000</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.14</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">16-Jun-26</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,700</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">30,000</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.76</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">15-Aug-28</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">30,000</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.13</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">18-Dec-29</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,000</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">James T. Parsons</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">45,000</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.14</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">16-Jun-26</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8,550</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">30,000</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.76</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">15-Aug-28</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">30,000</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.13</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">18-Dec-29</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,000</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 196; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">L-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
<TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font: bold 10pt Times New Roman, Times, Serif">Name</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Number of securities<BR>
 underlying unexercised<BR>
 options</B></FONT><SUP>(1)</SUP> <B><BR>
(#)</B></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font: bold 10pt Times New Roman, Times, Serif">Option Exercise Price ($)</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Option expiration date</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Value of unexercised in-<BR>
the-money options</B></FONT><SUP>(2)</SUP> <B><BR>
($)</B></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 29%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wayne Pisano<SUP>(3)</SUP></FONT></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right">37,500</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right">3.40</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: center">8-Mar-26</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">37,500</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.14</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">16-Jun-26</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7,125</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">37,500</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.76</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">15-Aug-28</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">37,500</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.13</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">18-Dec-29</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7,500</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Jonathan Rigby</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">45,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.84</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">30-Aug-26</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">30,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.76</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">15-Aug-28</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">30,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.13</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">18-Dec-29</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Bernd R. Seizinger</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,263</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7.60</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">8-Jun-25</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">30,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.40</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">8-Mar-26</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">30,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.14</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">16-Jun-26</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,700</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">30,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.76</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">15-Aug-28</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">30,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.13</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">18-Dec-29</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Notes:</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(1)</TD><TD STYLE="text-align: justify">As at December&nbsp;31, 2024, all options granted to our directors had fully vested except for the options
granted on December&nbsp;18, 2024 (expiring December&nbsp;18, 2029).</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">These amounts are calculated based on the difference between the closing price of the Common Shares on
the TSX on December&nbsp;31, 2024 ($1.33), and the Exercise Price of the options. These amounts include all options, vested and unvested,
as at December&nbsp;31, 2024.</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">(3)</TD><TD STYLE="text-align: justify">These options were granted to Mr.&nbsp;Pisano in his capacity
as a director (Chair) of the Company.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Value Vested or Earned During the Year</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth for each director,
other than Named Executive Officers who are directors, the value vested on all option-based awards (comprised of options granted under
the Option Plan), share-based awards (comprised of RSUs granted under the 2023 Plan), value earned on non-equity incentive plan compensation
during the financial year and ending December&nbsp;31, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 78%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; width: 62%">Name</TD>
<TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center">&nbsp;</TD>
<TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: center"><B>Option-based awards - Value<BR>
 vested during the <BR>
year</B> <B>($)</B></TD>
<TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
<TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center">&nbsp;</TD>
<TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: center"><B>Non-equity incentive plan <BR>
compensation - Value earned<BR>
 during the year</B> <B><BR>
($)</B></TD>
<TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Patricia Andrews</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Deborah M. Brown</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Angela Holtham</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">James T. Parsons</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Wayne Pisano</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Jonathan Rigby</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Bernd R. Seizinger</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
<TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>EQUITY COMPENSATION PLAN INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Option Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a summary of the Option Plan
dated effective as of May&nbsp;9, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company, with the approval of its Shareholders,
has established the Option Plan. The number of Common Shares reserved for issuance under the Option Plan and all other security based
compensation arrangements of the Company (including the 2023 Plan) in aggregate shall not exceed 14% of the total number of issued and
outstanding Common Shares from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 197; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">L-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Option Plan, the Board or the Compensation
Committee may from time to time designate directors, officers, employees of, or consultants to, the Company or any subsidiary of the Company
(such persons being &ldquo;<B>Eligible Persons</B>&rdquo;) to whom options may be granted and the number of options to be granted to each.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Options may be exercised at a price (the &ldquo;<B>Exercise
Price</B>&rdquo;) which shall be fixed by the Board at the time the option is granted. No option can be granted with an Exercise Price
at a discount to the market, which shall be the closing price of the Common Shares on the stock exchange upon which the Common Shares
are listed on the last trading date prior to the date the option is granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any option shall be exercised or shall expire
or terminate for any reason without having been exercised in full, any Common Shares to which such option relates shall be available for
the purposes of the granting of options under the Option Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number of Common Shares that may be acquired
under an option granted to a participant under the Option Plan shall be determined by the Board as at the time the option is granted,
provided that the aggregate number of Common Shares reserved for issuance to any one Eligible Participant under the Option Plan or any
other security based compensation arrangement of the Company, shall not exceed five percent (5%) of the total number of issued and outstanding
Common Shares (calculated on a non-diluted basis).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Without obtaining the approval of Shareholders
in accordance with the rules&nbsp;of the TSX or the requirements of any other stock exchange on which the Common Shares are then listed,
no options shall be granted pursuant to the Option Plan, if such grant together with grants pursuant to all other share compensation arrangements
of the Company, could result, at any time, in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">a number of Common Shares issuable pursuant to options granted to insiders exceeding ten percent (10%)
of the number of outstanding Common Shares at any time;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">the issuance within a one year period to insiders, of a number of Common Shares exceeding ten percent
(10%) of the number of outstanding Common Shares; or</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">the issuance to any one insider and such insider&rsquo;s associates, within a one year period, of a number
of Common Shares exceeding five percent (5%) of the number of outstanding Common Shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The value of option grants to each non-employee
director shall not exceed $150,000 annually for any individual non-employee director (other than initial option grants to new directors).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The expiration of options is to be no greater
than ten years from the date of grant and typically either vest immediately or as to one-third on each of the first, second and third
anniversary following the date of grant, as determined by the Board at the time the option is granted. Options are not transferable or
assignable except to the person or persons to whom the participant&rsquo;s rights pass by the participant&rsquo;s will or applicable law
following the death or permanent disability of a participant. The Option Plan provides that if the expiration date of an option occurs
during a &ldquo;blackout period&rdquo; or within five (5)&nbsp;business days after a blackout period, such expiration date shall be deemed
to be extended to the date which is the tenth (10th) business day after the last day of the applicable blackout period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to any written agreement between the Company
and a participant providing otherwise, if any participant shall cease to be an Eligible Person for any reason other than the termination
for cause or the death or permanent disability of the participant, such participant&rsquo;s option will terminate immediately as to the
then unvested portion thereof and at 5:00 p.m.&nbsp;(Calgary time) on the earlier of the date of the expiration of the applicable option
period and the ninetieth (90th) day after the date such participant ceases to be an Eligible Person as to the then vested portion of the
option. If a participant ceases to be an Eligible Person as a result of the termination of such participant for cause, effective as of
the date notice is given to the participant of such termination, all outstanding options shall be terminated and all rights to receive
Common Shares thereunder shall be forfeited by such participant, and the participant shall not be entitled to receive any Common Shares
or other compensation in lieu thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to any written agreement between the Company
and a participant providing otherwise, if in the event of the death or permanent disability of a participant, any option previously granted
to such participant shall be exercisable until the end of the applicable option period or until the expiration of 12 months after the
date of death or permanent disability of such participant, whichever is earlier, and then only: (i)&nbsp;by the person or persons to whom
the participant&rsquo;s rights under the option shall pass by the participant&rsquo;s will or applicable law; (ii)&nbsp;to the extent
that he or she was entitled to exercise the option as at the date of the participant&rsquo;s death or permanent disability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 198; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">L-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding the foregoing, the Board may,
at its sole discretion, extend the period during which any options may be exercised, in the case of options held by non-employee directors,
by not more than one year, and in the case of options held by other persons, by not more than three years, but in no case longer than
the original expiry date of the options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of a change of control of the Company
(as such term is defined in the Option Plan), all options which have not otherwise vested in accordance with their terms shall immediately
vest and be exercisable, notwithstanding the other terms of the options or the Option Plan for a period of time ending on the earlier
of the expiry time of the option and the ninetieth (90th) day following the change of control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to any required approval of the TSX and
any other stock exchange on which the Common Shares are then listed, the Option Plan and any options granted thereunder may be amended
by the Board without approval of any participant or Shareholder (provided that no such amendment may be made that will materially prejudice
the rights of any participant under any option previously granted to the participant without consent by such participant). Such amendments
may include, without limitation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">amending, modifying or terminating the Option Plan with respect to all Common Shares in respect of options
which have not yet been granted thereunder;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">making any amendment of a &ldquo;housekeeping nature&rdquo;, including to make any amendment typographical,
grammatical, clerical or administrative nature or clarification correcting or rectifying any ambiguity, immaterial inconsistency, defective
provision, mistake, or error or omission in the Option Plan or any option;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">changing the provisions relating to the manner of exercise of options, including changing or adding any
form of financial assistance provided by the Company or adding or amending provisions relating to a cashless exercise of options;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">accelerating vesting or extending the expiration date of any option (provided that such option is not
held by an insider), provided that the period during which an option is exercisable does not exceed 10 years from the date the option
is granted;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">adding a cashless exercise feature, payable in cash or securities, whether or not providing for a full
deduction of the number of underlying Common Shares from the Option Plan reserve; and</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">making any addition to, deletion from or alteration of the provisions of the Option Plan or any option
that are necessary to comply with applicable law, the rules&nbsp;of the TSX, or the requirements of any other exchange on which the Common
Shares are then listed and to avoid unanticipated consequences deemed by the Board to be inconsistent with the purpose of the Option Plan.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding the foregoing, Shareholder approval
is required for any change to the Option Plan or options granted under it which:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">increases the number of Common Shares reserved for issuance under the Option Plan;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">extends eligibility to participate in the Option Plan to persons other than Eligible Persons;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">permits options to be transferred, other than for normal estate settlement purposes or to an RRSP or similar
plan;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">permits awards other than options to be made under the Option Plan;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">extends the term of an option beyond the maximum expiry date set out in the Option Plan (except where
an expiry date would have fallen within a blackout period);</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">reduces the Exercise Price of an option, except for the purpose of maintaining option value in connection
with a conversion, change, reclassification, redivision, redesignation, subdivision or consolidation of shares or a reorganization, amalgamation,
consolidation, merger, takeover bid or similar transaction involving the Company (for this purpose, cancellation or termination of an
option prior to its expiry date for the purpose of reissuing options to the same option-holder with a lower Exercise Price will be considered
an amendment to reduce the Exercise Price of an option);</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">changes the insider participation limitation at any time under the Option Plan; or</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">amends the amending provision of the Option Plan.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 199; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">L-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s annual burn rate under the
Option Plan was 2.64% for the year ending December&nbsp;31, 2024, 3.17% for the year ending December&nbsp;31, 2023 and 1.73% for the year
ending December&nbsp;31, 2022. For this purpose, the burn rate is calculated by dividing the total number of options granted during the
applicable fiscal year divided by the weighted average number of Common Shares outstanding for the applicable fiscal year. The burn rate
is subject to change, from time to time, based on the number of options granted and the total number of Common Shares issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2023 Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a summary of the 2023 Plan dated
effective as of May&nbsp;9, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company, with the approval of its Shareholders,
has established the 2023 Plan. Under the 2023 Plan, the Board may, at such times and in such amounts as the Board may deem advisable in
its sole and absolute discretion, issue performance share units (&ldquo;<B>PSUs</B>&rdquo;) to eligible employees, including officers,
and RSUs to eligible persons. The number of Common Shares reserved for issuance under the 2023 Plan and all other security based compensation
arrangements of the Company (including the Option Plan) in aggregate shall not exceed 14% of the total number of issued and outstanding
Common Shares from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to earlier vesting in accordance with
the terms of the 2023 Plan and unless otherwise determined by the Board, share awards granted under the 2023 Plan vest on the third anniversary
date of the date of grant. Upon vesting, each RSU is deemed to be redeemed for no further consideration for one Common Share (subject
to adjustment for dividend equivalents) and each PSU is deemed to be redeemed for no further consideration for one Common Share (subject
to adjustment for dividend equivalents) multiplied by the percentage (&ldquo;<B>Vesting Percentage</B>&rdquo;) of outstanding PSUs that
will vest based upon the relative achievement of any performance-related measures or criteria as determined by the Board in its sole discretion,
which may include the Company&rsquo;s performance compared to identified operational or financial targets and the Company&rsquo;s Shareholder
return.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate number of Common Shares issuable
at any time to insiders, under all security based compensation arrangements of the Company shall not exceed 10% of the issued and outstanding
Common Shares (calculated on a non-diluted basis). The aggregate number of Common Shares issued pursuant to all security based compensation
arrangements of the Company, within a one year period, shall not exceed 10% of the issued and outstanding Common Shares (calculated on
a non-diluted basis). The 2023 Plan further provides that the aggregate number of Common Shares reserved for issuance to any one participant
under all security based compensation arrangements of the Company, shall not exceed 5% of the total number of issued and outstanding Common
Shares (calculated on a non-diluted basis).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The maximum number of Common Shares that may be
reserved for issuance to non-employee directors pursuant to RSUs under the 2023 Plan is 1% of the Common Shares outstanding at the time
of the grant (on a non-diluted basis), less the aggregate number of Common Shares reserved for issuance to such non-employee director
under any other security based compensation arrangement, and the total annual grant of RSUs to any one non-employee director cannot exceed
a grant value of $150,000 (less the amount awarded to such non-employee director).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2023 Plan provides that if the issue date
of any share award occurs during a blackout period, then the issue date for such share award shall not occur until the date which is the
tenth (10th) business day after the last day of such blackout period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise determined by the Board in its
sole discretion, upon a Change of Control (as such term is defined in the 2023 Plan), all unvested share awards shall become automatically
vested (in the case of PSUs, with a deemed Vesting Percentage of 100). Common Shares issuable in respect of share awards shall be, and
shall be deemed to be, issued to participants effective immediately prior to the completion of the transaction which would result in the
Change of Control unless issued prior thereto in accordance with the 2023 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 200; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">L-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise determined by the Board or unless
otherwise expressly set forth in a share award agreement pertaining to a particular share award or any written employment or other agreement
governing a participant&rsquo;s role as an eligible person if a participant ceases to be an eligible person as a result of the termination
of such participant for cause or if a participant voluntarily ceases to be an eligible person for any reason other than as a result of
the death, permanent disability or retirement of the participant, all outstanding share awards Agreements under which share awards have
been granted to such participant shall be forfeited for no compensation. Upon the death, permanent disability or retirement of a participant
(other than the early retirement of an eligible employee), all outstanding share awards shall immediately vest. If a participant ceases
to be an eligible person other than in the circumstances provided above, all share awards awarded to such participant under any outstanding
share awards shall fully vest effective as of the date of cessation of employment (the &ldquo;<B>Cessation Date</B>&rdquo;), unless otherwise
determined by the Board, and the participant shall be entitled to receive the number of Common Shares equal to the number of share awards
granted multiplied by a fraction: (A)&nbsp;the numerator of which is the number of days from the date of grant thereof to the Cessation
Date; and (B)&nbsp;the denominator of which is the total number of days during which such share award were scheduled to vest upon grant.
In such circumstances, the Vesting Percentage in respect of PSUs shall be determined as of the Cessation Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2023 Plan and any share awards granted thereunder
may be amended, modified or terminated by the Board without approval of Shareholders, subject to any required approval of the TSX. Such
changes may include, without limitation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">amending, modifying or terminating the 2023 Plan with respect to all Common Shares in respect of share
awards which have not yet been granted thereunder;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">making any amendment of a &ldquo;housekeeping nature&rdquo;, including to make any amendment typographical,
grammatical, clerical or administrative nature or clarification correcting or rectifying any ambiguity, immaterial inconsistency, defective
provision, mistake, or error or omission in the 2023 Plan or any share award; and</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">making any addition to, deletion from or alteration of the provisions of the 2023 Plan or any share award
that are necessary to comply with applicable law, the rules&nbsp;of the TSX, or the requirements of any other stock exchange on which
the Common Shares are then listed and to avoid unanticipated consequences deemed by the Board to be inconsistent with the purpose of the
2023 Plan.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">Notwithstanding
the foregoing, the 2023 Plan or a share award may not be amended without shareholder approval to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">increase the number of Common Shares issuable pursuant to outstanding share awards at any time;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">change the insider participation limit under the 2023 Plan;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">expand the categories of individuals who are &ldquo;eligible employees&rdquo; who are eligible to participate
in the 2023 Plan;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">extend the term of any share award beyond the term of such awards provided for under the terms and conditions
of the 2023 Plan;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">permit the transfer or assignment of share awards, except to permit a transfer to a family member, an
entity controlled by the holder of the share awards or a family member, a charity or for estate planning or estate settlement purposes;
or</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">change the amendment provisions of the 2023 Plan.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, no amendment to the 2023 Plan or
any share awards granted pursuant thereto may be made without the consent of a 2023 Plan participant if it adversely alters or impairs
the rights of such participant in respect of any share award previously granted to such participant under the 2023 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s annual burn rate under the
2023 Plan was 1.12% for the year ending December&nbsp;31, 2024, 0.60% for the year ending December&nbsp;31, 2023 and nil% for the year
ending December&nbsp;31, 2022. For this purpose, the burn rate is calculated by dividing the total number of share awards granted during
the applicable fiscal year divided by the weighted average number of Common Shares outstanding for the applicable fiscal year. The burn
rate is subject to change, from time to time, based on the number of share awards granted and the total number of Common Shares issued
and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Other Equity Incentive Grants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a material inducement to Mr.&nbsp;Kelly&rsquo;s
appointment as Chief Executive Officer on June&nbsp;11, 2025, and in accordance with NASDAQ Listing Rule&nbsp;5635(c)(4), the Company
granted to Mr.&nbsp;Kelly (i)&nbsp;options exercisable for 4,750,000 shares with an exercise price of $0.57 and a term of five years from
June&nbsp;11, 2025, becoming exercisable (A)&nbsp;as to 2,850,000 Common Shares in three annual installments based on Mr.&nbsp;Kelly&rsquo;s
continued service and (B)&nbsp;as to 1,900,000 Common Shares based on the achievement of performance-based vesting conditions and (ii)&nbsp;RSUs
which will entitle Mr.&nbsp;Kelly to receive that number of Common Shares equal to 2% of the Company&rsquo;s then outstanding Common Shares
upon the Company entering into a definitive agreement for (x)&nbsp;certain transactions providing for the acquisition of the Company or
(y)&nbsp;the exclusive license of pelareorep. These equity incentive grants are intended to align Mr.&nbsp;Kelly&rsquo;s long-term incentives
with the creation of shareholder value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 201; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">L-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY
COMPENSATION PLANS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company currently has two share-based compensation
plans: the Option Plan and the 2023 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As at December&nbsp;31, 2024, the only outstanding
options granted under an equity compensation plan were options granted under the Option Plan. The Common Shares available for issuance
under such plans as at December&nbsp;31, 2024 are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
<TD STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Plan category</TD>
<TD STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Number of Common Shares to<BR>
 be issued upon exercise of <BR>
outstanding options and share <BR>
awards</TD>
<TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><B>Weighted-average exercise price<BR>
 of outstanding<BR>
</B> <B>options<SUP>(1)</SUP></B></TD>
<TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><B>Number of Common Shares <BR>
remaining available for future<BR>
 issuance under<BR>
</B> <B>equity compensation plans</B></TD>
<TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="width: 43%; font: 10pt Times New Roman, Times, Serif; text-align: left">Equity compensation plans approved by security holders</TD>
<TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right">7,994,855</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right">2.14</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right">3,207,963</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Equity compensation plans not approved by security holders</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">N/A</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">N/A</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">N/A</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Total</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">7,994,855</TD>
<TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">2.14</TD>
<TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">3,207,963</TD>
<TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note:</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">(1)</TD><TD STYLE="text-align: justify">Relates to outstanding options only.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>TERMINATION AND CHANGE OF CONTROL BENEFITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has entered into an employment agreement
(each, an &ldquo;<B>Employment Agreement</B>&rdquo;) with Mr.&nbsp;Kelly and with each Named Executive Officer, other than Mr.&nbsp;Pisano.
Each Employment Agreement shall continue until terminated by either party in accordance with the notice provisions thereof. If an Employment
Agreement is terminated by the Company other than for cause or, for Messrs.&nbsp;Kelly and Look and Ms.&nbsp;Hagerman, by the executive
officer for good reason, the other party shall be entitled to 6 months&rsquo; base salary in the case of Mr.&nbsp;Kelly and 12 months&rsquo;
base salary in the case of Mr.&nbsp;Look, Ms.&nbsp;Hagerman, Ms.&nbsp;Levin and Dr.&nbsp;Heineman. If an Employment Agreement, other than
Mr.&nbsp;Kelly&rsquo;s, is terminated by the Company other than for cause or by the executive officer for any reason, then all unexercised
and unvested options then held by the other party are governed by the terms of the Option Plan and all unvested share awards held by the
other party are governed by the terms of the 2023 Plan. If Mr.&nbsp;Kelly&rsquo;s Employment Agreement is terminated by the Company other
than for cause or by Mr.&nbsp;Kelly for good reason, then Mr.&nbsp;Kelly&rsquo;s time-based equity awards and any performance-based equity
awards for which performance has been obtained shall accelerate and vest in full as of the date of the termination of employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, if there is a change of control of
the Company and the other party is terminated without cause within three months prior to (for Mr.&nbsp;Kelly) or one year following such
change of control, then the other party shall be entitled to 24 months&rsquo; base salary in the case of Mr.&nbsp;Look, 18 months&rsquo;
base salary in the case of Mr.&nbsp;Kelly, and 12 months&rsquo; base salary in the case of Ms.&nbsp;Hagerman, Ms.&nbsp;Levin and Dr.&nbsp;Heineman.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Termination pay as discussed herein for Mr.&nbsp;Look
and Ms.&nbsp;Hagerman includes payment in lieu of benefits that otherwise would have been provided to such executive officer during the
applicable severance term (including, but not limited to, for Mr.&nbsp;Look, payment of the health care premiums for Mr.&nbsp;Look and
his or her spouse and dependents, and for Mr.&nbsp;Look and Ms.&nbsp;Hagerman, annual contributions to the executive officer&rsquo;s Registered
Retirement Savings Plan in an amount equal to 10% of the executive officer&rsquo;s base salary and a $750 annual physical fitness benefit).
Termination pay as discussed herein for Mr.&nbsp;Kelly includes any earned but unpaid incentive bonus to the date of such termination
if terminated other than for cause and includes the full target bonus for the year in which change of control occurs if terminated during
the three months prior to or one year following a change of control of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Employment Agreement provides that the other
party is subject to certain confidentiality and non-competition restrictions during and following the course of his or her employment
with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 202; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">L-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table reflects amounts payable to
Mr.&nbsp;Kelly and each Named Executive Officer, other than Mr.&nbsp;Pisano and Mr.&nbsp;Coffey, with termination without cause or change
of control benefits, assuming that their employment was terminated as of June&nbsp;18, 2025, without cause (and, for Messrs.&nbsp;Kelly
and Look and Ms.&nbsp;Hagerman, for good reason) or due to a change of control of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
<TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Name</TD>
<TD STYLE="text-align: center; white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center"><B>Termination without Cause Severance<SUP>(1)(2)</SUP></B> <B><BR>
($)</B></TD>
<TD STYLE="text-align: center; white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="text-align: center; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="text-align: center; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Change
of Control Severance<SUP>(3)</SUP> ($)</B></FONT></TD>
<TD STYLE="text-align: center; white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="width: 56%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jared Kelly<SUP>(4)(5)</SUP></FONT></TD>
<TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 18%; font: 10pt Times New Roman, Times, Serif; text-align: right">413,684</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 18%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,654,735</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kirk J. Look<SUP>(5)</SUP></FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">716,432</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,432,864</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.&nbsp;Thomas C. Heineman<SUP>(4)</SUP></FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">792,792</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">792,792</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allison Hagerman<SUP>(5)</SUP></FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">489,978</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">489,978</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amy G. Levin<SUP>(4)</SUP></FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">474,261</TD>
<TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">474,261</TD>
<TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Notes:</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(1)</TD><TD STYLE="text-align: justify">Named Executive Officers shall be entitled to exercise all or any part of their vested options, within
the period ending on the earlier of the date of expiration of the option and the 90th day after the date such Named Executive Officer
is terminated unless otherwise approved by the Board.</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">Upon termination without cause, unless otherwise approved by the Board, Named Executive Officers are entitled
to receive the number of Common Shares equal to the number of RSUs granted multiplied by a fraction (A)&nbsp;the numerator of which is
the number of days from the grant date in respect of the applicable share award to the termination date; and (B)&nbsp;the denominator
of which is the total number of days comprising the vesting period in respect of such share award. The Common Shares will be issued at
the earlier of the 31st day following the completion of the vesting period and the 90th day after the date such Named Executive Officer
is terminated. Pursuant to Mr.&nbsp;Kelly&rsquo;s employment agreement, if Mr.&nbsp;Kelly is terminated without cause or resigns for good
reason, then all of Mr.&nbsp;Kelly&rsquo;s time-based equity awards and any of his performance-based equity awards for which performance
has been obtained shall accelerate and vest in full as of the date of the termination of employment.</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(3)</TD><TD STYLE="text-align: justify">Upon a change of control of the Company, the Named Executive Officers shall be entitled to exercise all
or a part of their options, whether vested or not, within the period ending on the earlier of the date of expiration of the option and
the 90th day after the date such officer is terminated. On a change of control of the Company, Named Executive Officers shall be entitled
to all Common Shares equal to the number of RSUs granted, whether vested or not. All applicable Common Shares shall be issued effective
immediately prior to the completion of the change of control transaction.</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">(4)</TD><TD STYLE="text-align: justify">U.S. Employees are paid in U.S. dollars. These amounts are presented in Canadian dollars and have been converted at a U.S./CDN exchange
rate of U.S.$1.00 = $1.4389.</TD>
</TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(5)</TD><TD STYLE="text-align: justify">The amounts reported under &ldquo;Termination without Cause Severance&rdquo; for Messrs.&nbsp;Kelly and
Look and Ms.&nbsp;Hagerman also include amounts payable to such executive officer upon his or her resignation for good reason.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>PENSION PLAN BENEFITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company does not provide pension plan benefits
to its Named Executive Officers and employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 203; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">L-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>QUESTIONS MAY&nbsp;BE
DIRECTED TO ONCOLYTICS <BR>
BIOTECH INC.&rsquo;S PROXY SOLICITATION AGENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2533062d1_424b3img01.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>North America
Toll Free: 1-877-452-7184</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Collect Calls
Outside North America: 416-304-0211</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Email: <U>assistance@laurelhill.com</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 204; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tm2533062d1_424b3img08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2533062d1_424b3img08.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !* 5T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ I"
M<5%<W$5K;23SR+'%&I9W8X  KPWQ+\5=<\5ZR/#_ (#AESO*2787[PZ9!_A'
MO0!Z]JOBS0M$)&I:K:VY'\+/S^76N/N_CEX,MG*I=RS$'&4C.*YS0/@/'/,;
M[Q=J,M]=/UCC<X'U/>NYM?A3X*M5 30K=O>0;C0!EV?QP\%W3A'O9(">\D9Q
M79:5XET?7%W:9J5M=>T;\_EUK N_A/X*NUPVA6Z>\>5K@]>^!]WI=ZNI>"-3
MDLYD'$+R'KWPW^- 'N-%>(^"?B[?6>JCPYXVB>"]\WRH[EEVCT^;\>]>UQNL
MB!U8,I&00<@B@!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445G:]JL6AZ%?:I
M-_J[6%I"/7 Z4 >+_%7Q1?>*_%%MX!\/2[ED<)=LO=\\J3Z #)KU#P1X*T[P
M7HD=E9HK3E09YR/FD;O^'M7F/[/^D#4+C6O%5Z@DN9;@QQ2-R03\SD?7(KW8
M#&: %'2BBB@ HHHH X;XC_#RR\:Z-(1&(]3@0M;3#@[O[I]1Q7'_  9\8WRW
M=SX(UW]W>Z>"L&\_,0I.Y#ZX[>U>T'H:^?/C%IQ\)?$/0_%]B?*^TS S;>,L
MA&<_530!]!CI2U'!*D\$<R'*2*&4^Q&:))DBQO95SZG% $E%-219!E6##U!S
M2/*D?+LJCU)Q0 ^BF(X< J00>013B: %HJ)YXH^9)$4?[3 4U;VV?[D\3>P<
M&@">BD!SSVH+ <D@"@!:*@:]MD.&N(@?=Q3TFCD^XZ-_NMF@"2B@4QY%C!+$
M #N3Q0 ^BFHZN,JP8>H.:=0 45&\\4;8>1%)[%@*>K;NG2@!:*:\BQC+L%'J
M3BD25)%W(RL/4'- #Z*B-S &*F6,$=06%)]J@_Y[1_\ ?8H FHJ);B)VVK*A
M/H&!J0G R: %HIB2I)]QU;'7:<T[- "T4QI409=E4>YQ48O;5FVBXA)] XH
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M4X(_>+5SX9>#I/!7A"+3IY%DN97,\^WHK$#Y1], ?A5/XT(TGPKU=44LQ\K
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M5,*  .P%/(S6!J>EWMSXPT#4('Q:6:7(N%WXSO50O'?D&N@% $3HC<.B,/\
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M+"#Z^6*F"!<!0 !V I5Z53U"ZO;<1?8[$71:0+(#,(]B]VY'/TH NT4@-+0
M4444 %8?B7PGH_BW3_L>KVBSHI)1LX9#TR#V-;E% '@M_P#!3Q'X<U#[=X(U
MUX\#B.:3:P_$#!_$5/%>?'*S B:VM;C;P&81'/X\&O<Z* /"YKGXYWX,0@MK
M8'^-1$N/QYI-)^!VJ:W>G4?'.L2W$IX,4,I8D=LL1Q^ KW0]J6@#+T+P_IGA
MS3H[#2K1+:W0?=7J3ZD]S[UJ444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2533062d1_424b3img07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2533062d1_424b3img07.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 1, U$# 2(  A$! Q$!_\0
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M=4VI#:4)]L[+:>5H=R'$()/J=>M!G7SFS$L;X_CYM<Y-QAXR\"OVQRS3>II
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M40AU/4C:3V^(:)[UG1>9K].P=O)VL!DQ8<I;:H:+G=XD4KCK1U!YTJ7IH'L
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MJ^KT/_=5(8AR*YQW_P EY=8;2E-3\IR*1:HH'[RVU]!=(^L=+:T_[ZZXS/\
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MASK9(#MMB"T9'*N\R-[:JT1;.\Y,BL=91YC[8'[,%0(&SM6CT@ZJ0YKR+9,
M@PY%W?>#TUSR(<&)&<D2Y;FM]#3+8*U$#N=#0'<D"J#O\_(I=QPN[PK;D4#F
MAEBWPKLB)9Y M$V.M2%R42'RV8Y0@+=(4ESK2O83O>C..0Y;^%\]8_F%UM-T
MN6,)L,FV(E6JW/3U0)2WFUE2VF4K<"7$)">L)(!3HD;H)#(YYL4*'!]IM.11
M[O/<=;B6%5H=-P>#825N!D Z;'4/VA(3LZWOM7\7X@<4^:T:]-"YR2_<OD86
MMJWN^WHF@$EA3! 4E0"23OMK1!((-0H9>C&N:[CFMSL622K!?<?B1;3+BX_-
MD/,+:=>4ZPZPAHNLJ65MJ'6A(.O78J#1N+LSS+.[9<7!>L)=O-WNF5F3%C,N
M.6[IBM0X;3I=;<:#JT*4M2""H?$ 04[ 74[XB,3-FM,^(W=[F[<YDB S;8=L
M>7-2^P"7VUL$!2"@).]CZM;V*]'?$'B#EKLDJV.7&_2+RRY(A6VU6YY^8IMM
M10XI;72"T$K!02YT@*'3Z]JI3C;C/*<DN?'VE7S Y%MQZ9.NES3 "GG[E+D)
M0_M4I"P'5!I:SV) 6G7PD5),0M$'PX<FY(U(L613[).M<%FS7"W6N3=5N%OS
ME/LN*90LH<6\ZITE82E1<)WV.@L=[Q XH,:M-XBBYW'Y3G.6R/;HEO=5-$IM
M*U.LK8("D*0&U]04!K7\1O(G<\8;;^+G^0'K@\G'6"I#A,5P2$NI<\M3)9("
MPX%@I*=;V#5!PN*<[R'*(4LNWC";A*5?<M]I@QF7O8I,@-1XL5:G&W&RYY*5
M%24_$"5:4/6O2Q\<9?R5B^+66#:F\.M=ALPG3V<DM$I],^[S&5^<0E3S2U*;
M\QQ16I2M+>T02GL%U91XA+!BMUM,!ZT9).7=DH,!VW6=Y]J45-%WI;4D:40@
M$D#TT:R#X@,219WY[B[@VXU<1:4V_P!@=5,>F>6EPL-L)!6M24J'5H:3I6R-
M&J[XOM.0WF[\)F\V:XP6\<Q-]^8N7$<;")I0S&2V>H=E] >5T^NCNHM@UKNV
M!9%A.>9+CU[7;9GR[(F-Q;7(E2;;+F2TN-+=CMH4Z 64>7U!)Z?0Z!H+FD>(
MS#K?B.27^Y+N-H;QPMBZ6^X0'&ID?S" V?*(VH+V.E2=@]^_8ZW&1<SXCBJ8
MSEQN@:C2+4Y>D2$-J<1[*@M@KVD$DDNH"4@$J)T :HV]8C>^3^0OG#(QRYPK
M#D5\M4),6;#6VZ+? 2_(5(DMD;9#CQ2A*7-*UT[ *M5IL/P!6/S<WL7(UAOT
M[#[-;VL4M,J#;)<I<F&Y(=DH=;]G0I9\M'LZ"M(^%30WJ@Z@PK-6LW@ORFK1
M>;0EISH\N]0%Q'%@@$*2E7J-'_<>QT:P+'RUC&197E./0KAU7#&DMJN2G$%#
M306%'LX?A5T]*@K7[I!!JNL)RO.L>X0ODQZWWO(;NU.>AXV+I!4W<)4=2THB
MNRVPD%&BHE2EI2>A/4H DU45^X(Y#Q2%D6/LKCY.]=\-=97-M=L=B)DR&YJ7
MW6WW%O.)4\^'Y&CM .SH:'8.AH//UDO*%R+18\IO-LZ%.,W.#8I"XTD#_P"I
M+*1U@_0H#I5]!-9O&G-5HY5=>%GM-_CQVBZDS+C:W(S!6VYY:T!:NQ4% C7_
M %3]5?S%N5+7D6/S?D:R9##D6V 73 N&/S8104I[,H+K24N+V-=+95_#L14?
M\/5P;QC$,5P29%EHR5JQHO-S2MGI3&<?<4I2723M+BG%.:3K?P*WK5$7#2N3
M^0K!D<7EK-'<)MLN^9!>;=,0W<Y]EE1WK&\F'TM"-/6 RXRXH !M)V%J*MG1
MU$[5@V0IP/(I>+.W9B4NW0H]WQVUXE<;$_(0F2A4E8>D/K#\LLAY!4TKJ4%#
MN?A-%=E7;([98Y=LC3YC<61<Y'LD-M>]ON]"E]"?X]*%'_=2RWUF^B:66)C'
MLDIR(OVR*XQUJ1K:D=8'6@[[+3M)^@UR_F^!\=W6'QS=L>X]GHQNUY/NYQU8
MO-:>;0Y%<05F.MD.K3YGDA2TI(V-D]C6//QF[MWM;N66"^7/C_Y\7J1<[>S
MD2?.;6VCV-Y<=M)6]'"@O]U*D[*21H; ==5A7F[Q[#:I5QEAXQHS9<<$:.X^
MX0/]5MM*EK/\$@D_57(^"<23LLS;%X>1XW>7, ZL@<@6Z[-OI1'A+<BF(U(2
M?W.X=4VTYW2 .P*>UQ<)RKEA_AVMWSECWUJ3;VY,=30AOR+@AE,AQ#12T$J<
M60WT$:220 >]$22W\[87/QR]WI=RD6^+9'4L7%FY6^1$E1G%!);0J.XVETJ7
MU)Z0$GJZ@$[-?+/.^)2K ]=HSEWEH9F& ] CV*<Y/9D!/66UQ4LEY!Z?BVI
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M5L0FVI*Y2U/@);2' VI74>RDA9"2I.P"='1HJN^0>)\BOG)B',=>FV^VS;G
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M0K8_F9^%Z9CW&4>XPA?;EF,&]Q[Q%;MHASU,*;D/.@>6X(C;J>J0ZI0)21U
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M(]I]G#*9+J%LJ=4VV2KI'0%DC9T-]ZLCQ"Y=A&&\TLYGBMSQS,[]<(=LARL
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M]2EO;; UKN2>KL*M'FWG;*>/>+^-YC\^VXM<<B;0;M?ID0OQK>I,0O*0ELJ
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MWW'>L%+32G0XKX>I03ZI[FM-8.?,_P VS#CZQNYW AVR=D=Q:C9%%M@9;O\
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M.(MT6^QXCL=MY8/QR$I+;>QV))6!_&L2\\M87CB0FXY# B:=>9"%+[];) >
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M2PZW(;U_H=GJ"DJV I!">\:'/5Q5?95BC7FSMSHERN;;R[D0A$6'$C]"5RE
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M^)%@6]UALH=<0W'0AQQP$D J6%:2/0 =SNB,MWD;%V8#<YR^0D1'8!N2'E.
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M;=+G;22E:"D@G9.M;W14(L?+F;9+$E3R_!M;%OQ%%]=CB$I2I+ZE24I(*E_
MTH,H7K15W WZ[P&^4.0[:7Y4R^VN9'AQ;'<'(Z+5Y9>$Y[RG&NKS#TI0 2DZ
MZMGN2!JK2G<U8^W=[;#BS&G6Y"V"])6E8:0V]&>D(*5 $=70SU$'0"2#ON-^
M+W/6-Q[%#NSL:[M1[@[Y=O;<MZTNSD^67/,:0=$HZ 5;5KZ/I(!"F[]X@<@R
M).>Q;!> U'9L-PGQ'O(8$F"['?0WHI0ZLIVE2CIT)7V"M#TJ0/\ *URMDJ\*
MAY#;G(#L^TQ'LJ= <C1V'8REJD$!?E#:DI0#L)!6"=_3:6/\PXYE5_BVJR&7
M<UR8C,\R8\57DM-/(*FE.*.B.H)/T=CV.CVK.R#D>T8MD=KL<]B:TY<EI8C2
M$Q5&.IU044M]8_O'I/T:] 2-B@HX\V9U=;3=)L&YVMF/9[%-NXE)MY<1=?(E
MNM-.(VY\#3K;85V)]=I.JLWE7D&;C;.(H1>(&*P+P^M$R_7%"5LQ &%.(1\:
MDH"EJ'2"HZ[$:)(K?\?<C(Y$PQ600K-<(J2IY+424E*''BA2DCI)5T]R-;)
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M((ASW(2)=LE&3$EA*4DN-+4A!(VHI/;U2=$CO4[HA5:<F_\ 2;Q!_P!N3?\
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M.Z4 >6YLCX-G_:*E\/PRXO!X@RSCAN?=S8\EDS)4N0IYKVEM4E?6X&U>7T@
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M@B7' E-Y??ISD2WV-J[M.(6E" M3JY'0$I 'T=)-;W*^%+7FULR.VWB[WF5
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M1/31#SXH$6&UYC\Y\6E6:\XVU&>-N;EMR3+1((#)2M( !*B 1WU]9JS\"O\
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MF^\!V"_XW:+*]-N;4:V69RQL.-.-]:F5^3M2]ME*E?L$?1TG:@4D'5/?-/\
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MT2" =#TL'C0R2X\IP[.ABQ7[%+PS=5VNZVZV7&*GJB-J6G]M( ;D ]/2KR@
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M\TY_S'R;P#EEU8M%GQ.\Y#<D6V':I+_M1:;:<1TRPH]"R>C8*= ?5WJVN?\
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M4$*9DD.I(!VE?H=@Z^BO?*_%AS9ASO)+,W'\%>7@;$.Y7!QE<SID1I 24M-
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M*@-?17.3OB3Y1>A-XW;<OMUPN,?D5C$D9<W;&5-3XKK*E%9:'P=:%:WT$ D
M?7O#C\[<TX\W/NEQSV'=X..<A,8>_#58H[2KFPXX IUQ:?\ 1J 4  V$^G<F
M@ZSQGP[<=X=*QB39L;:@/XT)(M:VY#VV3(&GU*VO]JI>AM3G4?XUHU^&GB3*
M\)A8Y'L[<FQ6RZ/7"-[!=I(<C3%J475)?0[YB22I6T]6AO6AH5S4UXHN1XV4
MRIYSFV3F8?)"L3&&"W,"1(A+=Z0YY@_:;0/0@ ?#\154:Q7F7,.,N+K+9L16
MY"?R7D2_17[BRW%6ZTE#I4&V_:UH8"UD]BX?1)ULT*=H1_#9QS%?0\WCI#J+
MXC) HSY)/R@E/0E_NYW^'MT_N_\ 5I??#7QQDEHR6V7''$OQ,CN2;Q<A[9(2
MMR8D )>0L.=32AH?Z,I'\.YKE*)R!RWD/*O"T;+\Y;PA^2F\(>=CB"\Q)\DC
MH6Z&W%L%QQ!""@*/0H$IT36YXU\1G,F?<Q*7';:7C3.6/V.;9GU6QAF-$0HH
M"DJ4^):GQV5KH*5#>A0="VKPG\5V2"N)#Q<MLN7.+>7.JXRUJ7,C@AEY2E.D
ME0V=[.E$[4":RXG!/&-\L<N#$M3$ZVNY"<B?3'N+ZT_*B5A1=*DN;!"@-M[Z
M?^K53\PWG)V?&=QW:8W(#F*6%^Q2I7LRF6BR\M+J MI0<.E*6- ']Y/]WU-4
MSP7F6>\<1\=N5MR6.,4OO*LO'I..KMS:NM#TA?4\9!^,+!'8)T.PWOO066[X
M1;AE_,\'*F(F&V6Q0\H^79$RQ7*=(DRW&E*T@QG/^;LN*.O,4@[)'I]%7_RG
MPG@')<VW7S,;:EY^SM.):F^W/1 AE>O,0XIM: IM6NZ5[2>_;N:XTB\P\C8K
MQ*J\8M.@6*RQLKORKX;';[>+@EAMX!#K49[I0\ 2>LCXSV[CUJUO&;=9&;^"
M6-=K;?W'X=Q3:WGY2X26U3VG76OWFSV;VI044C?IT^E!?^.<:8$[Q,WA-HMT
M&=@3D9<1$%N0J2PME2B5)"RI1/<GOU;!]-:J)L>#WB=C%%8[\W'W;=[2B8TI
MZ[3%R([J$E*%-/ETN-:22 $* U]%<S9;S!G/"XSNPV+,[#C$#C2W6]R'8E6*
M(P,C6_\ &XKH3T^6"5%(#('?N>^ZLS%N4N4>0.6.24L9/'Q[%\1AQ+@+0;4T
M](>4_ \WR"ZK10E*P5;T5$]M@=J"[;%X=^/,93B:;7C;4(8L^_)M);D/;8=>
M3TNN*/7^U4H>I<ZC2W^';CVUQ++%BX_Y3%FO+F0P4>VR#Y,]9)4]LN;5LJ/P
MJVGOZ5R5@/+_ #KF<KB1ASDN%%]X-EG35J3CL91MRHPZ@IO_ %UK &^KX1U'
M2?35UX!X@[@KP5-<G9C=%Q[JU!E)DW&W0$.+\UN4[';<2P2E!)*4'I)2G9/<
M"@\."O!=CN"SI%_S"UP+QEB+[/ND.5&F27([2'G%*;)95TMEU*5$%702/H4=
M"IMC?A%XHQ*YQKA;,74Q*BF1[,I=REN)C)?0I#J&TJ=*4(4%J^$  $[ ! -<
MNQ/%9RE:,'YI1)OIFW3&;7;+G:YUQA6_VADR'$A2'$1%+9(*3L DJ3OOWK;9
MUXC^6N'O>/;+EDD'*)L3&K9>X$]=I:C)MSDJ0EEP="/WVT=14.LD]AL^M!TS
M&X=PO'&K!&Q"V6Y.2X-!D-8[%EW*040?:&RDAX!:E%"QVZEA1 V4]ZUGAGX'
MD\-6[*KE>EVQ[*\KNSMVN9L[:DQ&2HGH9:ZP%%"=J.R 25'M53>%AR>[XIN5
M3<\RAYY-^0;.7+U"CM,)=V%D)*&B4 C>OAUVUVWNH7GG/G,T*5G=[L^:P(=L
ML'(#>+1+0_9674NLO*2D*<<[*^#J&NG1/?:CVT'5U_\ #MQ[D\^_3+GC_M,F
M^S(<^XK]MD(\]^+_ /0Z])< 3TZ]$Z!_O UYY9P7QOD)RIF^VAAU>;+C(NB7
MIKJ%35QTGR.C]H.A2!LCR^D]MG=<VS?$9FV$Q^2,/R/-9EPR.V9/;[)8[W:[
M'"$A]4EHN^6IIU:(Z0 E0ZUJ[;WW]*CF%<[99R+-XM1DZ[?=[A!Y*EV,SY,"
M(MY33<8J2H%KJ;0X.H@K9(!UV/TT'2D[PL<.Y_9[,EZR(O,2V1U0(\MF\2EK
M<9\PJ4R\\A[J?3UDDI<4H ['\*G><<08AR-@8PN_V9$K&$AE*;<P\Y&2@-$%
ML)4TI*DA/2- $>E<]^%-ZXQO!/>7[1--NN;+E[=C2DM!PM+2^\00D]B>U5MQ
M[S%G=FX6X1M+'*4=#^:2BS,R6XQ(TA=D0ADK$<E1Z5N+4#I3VU>M!U;BWABX
MPPW'<@L=LQ*-\G7] ;NB)K[TMR6D#X4K<>6M9 ^CXNQ[C1KUXUX7X\X%?<;Q
MN.JSO77HC)1.NTB2IT(V4--!]U6@-GX4:JN>'>6<NY.\-><W65>(SF0V61=;
M9$R&#%2&YHC@^7*2T#T[5Z:3\.QV^JN;;6]E>5<7^&!Y'(HO%_GY&A3$Z5&:
M?<M)5%6"A8!VZH=U NG9.M]J#L>V^$_BRTY2WD47&"W=&;F;PPKY0E%J/+))
M4XVUYO0CJ))4$I /;8.AK:VWP[<>VBUXW;HF/>5#QVYN7FUM&9(5[/+65%3F
MRX2O96KX5[3W]*Y,NOBCY8M>+6S'OE<3KZO/+GB[^218,)EYUF,VVML);D+1
M&0ZLN$?$0-)[ FKJMF?\GR_!]F%^O3+36?0(%Q3&?@N1W5.AL*\M[4=QQM+G
M3W*4J.E)/:@FF-^$WBG$LLB9):<53#N\.:Y/BN)GR2W&>6%!9;:+G0@*ZCM(
M3T[T==AJ6YCQ'B.?Y-C.0W^S(N%XQI]4FU2E/.(,9PZV>E*@%_NI.E@C8WJN
M1,/>XTX6\-#O*_'J[;?.4DXR),F8]=%RI3SSGEB0Z^SYAWT+42=I^'IUV!-8
ME_\ $[R1@^/<D0&,\M>=RK5BUOR*%D,6W1VQ$?>DMMKC+0WMM0*5DC8ZM4'4
M"O"SQ><2R'&DXLVW9[_<?E:X,HER MR7U!0=2YYG6V01L!!2!] [FO.W^%3B
MZV17&&,95TN7*+>'5N7&6M;LR,"&7EK4Z2I0ZCO9THG:MFJ1S[D/E7",HXIQ
M>Z<LVNU/9BW<94Z]NV.,VQ#"66G&F6D+.CT$J2%+42KJ^('0%0?%?%7R5R-;
M\*M+^;6K G)%GNMQDY4];6'&[JY$D*:;2VATAM(4E(6KI[]^VJ#K7(_#?QWE
MD3*X]TQX2$93+8G78B9(2IZ0R &G$D. M*2 ->7T_P =UM;UPSB&1\9#C^Z6
MM=PQ4,H8]DD2WEN=*%!23YQ7YG4" >KJWOZ:Y;P#GKEGF[*^+[1;<D@X8W?\
M1<OET>3:6Y1ZV9BFBIE*S\/FI2GU) "B0"=&M;8?%1FF3<XXU#L&43)V&Y3<
M[E;(S=UM=N9#'DMKZ7&4-.*D'H6!W>"0L?0*#J2R^'? ; \MZ)9GC(795X\M
M^1<93SBX*EJ6II2EN$DE2U'K_>[ZZM 5J;KX3>+KM#L49>.OQ!9(*;9">M]U
MF17TQ0=AE;K;J5N(W]"RKU-<AX7SWR-@GABLUZBYRYD5[R#*/DIP268BWK,E
M4F1UKZG5)25.=("?/4$)]!H"NH."\MS[*>)<Q^?[;:I\)Z7'AS ["4](C>4%
M(+R8CCC2'!U$$)(^@Z[T%EYYQ+BG)F#?,[)+6;CCNF1[&)3S)_9$%O\ :-K2
MOL4C^]WUWW47L'A6XJQK&+_C\/#XR[7?TI3<T39#\IV4$_N=3KJU.?">XTH:
M/<:-<(^#!B7C.<<>W1NT#$2YC%SN"7F[DZ_\\E)6M(;+6@VVMHIWT]U: /T]
MIKA7BUYPDX1.SMUJ->;,]9+E.<BR/DUMN"^T%%GR&V7S*6E)&EAY&_I["A3L
M_C/A;">"X%R.-0WK7'DI2J4].N4B5I#8/2.I]Q?0E()[#0K&L'A\XYM$FQ7*
MU6)*'+5<)5YMSZ)TAQ+<F4/V[HVX0H+'T':1_= KDYSG#.I=NRZQ7G/K-R#;
MG>+I&2*#5IBI0U*7K]FZE(4E82"0$D#8/Q GO6:QSEG^'W_B],[(V<?XYN-L
MLL5H8_;($H(E/-(*V93*B'6$J)^!30"4@CL:#I:\>%?C"^8PJP2L:_\ F\W5
MZ^(+4Z2A]J:Z=N/-O!P.(*OJ2H)_A6'>_!_Q)D:+6FXXG[1\G1DPFR;A*2IY
MA*NM+;Y#H+Z0H[T[U5RO8>8N1\$X7YARMGD<7;(;=ESL&/:9\1A?D?\ /66U
M.Z.UI;4E11T?NIWM.CWJ;\P<V\L>&:4TSDN4-9FG)+!(197V;.S%2Q>_-3Y;
M24I!*D=#J=!:COH)/TT'4L#BG&K#?<@O]GM;<&^7J$S!E2$NN="VV4%#*0WU
M%" D'7PI'\=U3GAK\&>+\.XU8YV26FWW+.8+$EE^X,2Y#\0)=6OJ+;3O2A)4
MV0E2@V"='N?INWC^5.;Q2VP;]=V+OD\.&R+LZT&TJ$@H!42V@ (!.]#0[5QQ
M9?%7EF1\W8[&M>0S;O@63W*YVUN)=;=;XP0AEM>E,AEQ4GX5)UU/!(4/H!H.
MB,&\,'#UC3<+EC6.Q7&;I#?MZGVKB_(:1&=V'6F-NJ#*5;5L-=-;C(/#9QWD
MV+XMCTZQ.?)F+@)LXCW"2P]$3T]!2EY#@<(*>Q"E'?TUQ=PKRWEMEXRXKP>Q
MYE XYMKV/7:]NWV="9D^TNM2W0F,D/'H U\2M?%H]JFN/^(3EOEZ7@D2TY-$
MPMR[X)*R&:ZW:&I75(8D.-A;:7?W4N!"3H[ "NPWHT'1<WPF<5S<:L]A^:YB
MVRSS7KA 1#N$IA<9YX[=*'$.A82K?=.^GZ@-5FW;PR<:7NT7JVS,92]&O%T^
M6I:O;) =]MT!Y[;@<ZVE:&OV92/X=S7*EM\5O).<6W$E#,K/@C@P1_*)4J7;
MV76[M*;><:\D!PCH3^SZB&SO9/T:%7!=.6L]=\#]FY+MMR0K+6;3$O,UWV5H
MIDMI4E4A/1T]*=M]?[H!&NVJ"T+)X;N.,<@XW$MV--QFL>N*[M;BF4^5HEJ2
M4J>6LKZG5$'1\PJ_^05O,0X^Q"Q6C(H>/Q6A;[[<)4VYI9EN/!Z4Z A\E162
M@GI *4D :[ 5QG$\6W)N2Y3'M=LN33+.>7B.,/=$%E1B0$37691.TGS"6V@O
M:MZZ^U1NWYGEDN)QNW;<QCX# F\D7R')D6^W1F&0ILK*''4Z2ASML$+'<D$[
M(&A3M?&.&>.+3)Q=JRVV.7\&:?A6MIN>ZZJWI?04NH6DN'J*DD_Z3J(]1JM)
MC?A!XDQ+(HE\M6)^RW*'(<E1'/E"4I$9;@4%AMLNE"$JZU;2 $[T=; UR;>L
MRS[B[)O$+G.*9;&BP[+D]L,J Y;6GQ=?,;9;5U.'NVGI5L>7H[)[^E=5^*;E
M.3QSC%AA6F\7*SY%?[FB!;G+9"B27'%:*E)/M:T,MC0_?6>WU&@D=IX#X[P^
M+B;D.R(@1\-,EZT+<G/E,+S@?.42IP]8()_TG4!]&JCC_A+X=R>Q6IE..)DV
M^(Y*E0'XMVE@MKE*"WG&W$/;VH@'>^WHG0)%5[Q'RSD7,'@[Y&NF426IUV@L
MWJV*EMMM(+Z&FE!*U!HEOJT=$H/2=;%458.>N5+/C6 81@;OR<BW8#!NK'P6
MX"<\KMIU<UYL!E/3H^3M8))H.R[EX6>,+GBF/8Z<9$.W8_U_)2[?-D19,3K_
M 'RE]MQ+IZO56U'J/<[K?XIPIAN$Y#%OMGM*X]WC6M-F;ENS7WE>R!PN!L^8
MM04>LD]9!4?KKF#'LLY$OWB6RMJ?R",6D(PZWSF;"EF/(84\ZRXHM-;40HH<
M)5UH)*@ "2-57^'<]\BX3X9.-Y5OS=W(KOE=[$!Z0XS"7)LZ"IXEL+?6EM3C
MA3\)D*T-$#Z*#M/D;P^X'RQ?H%ZRBR*N%RAQUQ$/-S'X_6PH[4RX&EI#C9/?
MI6"/X=ZC.2^%OB(VBU"\VI<2QV2(S#:C/WR6S"##2NII+R"\$.!*CO;@)/T[
MJBV^9.=;@.,,8?O5NQR_9%?;I:G;J]%@SRY%:90XR^MN.ZMI+R0I6T)6$[ V
M-5*/'GC%WNW%7&UFD9 '1(RFUP+@Z[;VEIFN*/2'5MGX-!0*O+T4GJT>PH.B
MKI@>)YU=\5R:3$9N<JPJ<D6>8Q)7Y;)<1T*4D(4$+!3V^(*'U5!6?"#Q=#M\
M^%"LUQML:;,]N6B!?9\<-N_'LM]#P\L'S%[2G0/5W'8:H>'R7REAC?,KEJR"
MVJQCBE!C0K#&L+#7MY]C24A1;Z0TTA?[3I0-G93L) K22/$_R1BEBRN,G/+9
MG4@X G+(UVAVV.W\DRBM*?(4EO:%I(5VZQU=N]"G8+'"6%1N*W>.&;&AK#'8
MZXKEL;?=3UMJ)4K;@5YFR225=6R3ZUK[_P"';CS*52E77'$3#)L:,<=\R4_I
M4!*TN):T%Z!"T)4%CX]C]ZN4KIRMSM%O.1VP<FPD&)@C6<)>1CD;J;60=Q$
M['ED^JU=2NPUKO5@^)OD+*KGX)L<S"W7US';K=(UEESY,) 2=2/)+@2K?P)"
ME[_V#7H3061$\*_#<9N[8^+&AZ1=(T;Y08?O,IR5(:8=ZV5K4IXN$)7Z*WW
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MON "?K[U5%TO669)X5K]+N^?G(;JK/6&6K;-9:*H+J;D0'5=)\SH4=:02$I
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M"="N7HV:YGCWB;SM;W):KU$L>(1+A%M7LT=+5Z(:=5T-I!TE2ECJ*FNYV!Z
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M92G386L(/5\7P@#T#N.3QGA\R/=F'\4LCS-W0VBXMKMS)3-2V.EL/#I_:!(
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M&QO-;Y,QSYY6VW6;(Y#I<D.LNH4'T>8H#S4I5K74"*<NY'*X\SK*,;E<EY;
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M0KK)26U$:'H*LSG'EAQ_!;:Q;,E?MZ85\A6W++I: XTY 0I'4X4K*04@G7Q
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M8_73WOX']ML=_%F/UT$NI41][^!_;;'?Q9C]=/>_@?VVQW\68_702TI!4%$
MD>AUZ5_$MI1U=*0GJ.SH>IJ)^]_ _MMCOXLQ^NGO?P/[;8[^+,?KH):E(2
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M_%F/UT$M"0D    >@%?VHC[W\#^VV._BS'ZZ>]_ _MMCOXLQ^N@EJ4A"0E(
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M'ZZ"74J(^]_ _MMCOXLQ^NGO?P/[;8[^+,?KH)=2HC[W\#^VV._BS'ZZ>]_
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MAN,_N[Q/\$C?HI[AN,_N[Q/\$C?HJ=4H(+[AN,_N[Q/\$C?HI[AN,_N[Q/\
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MFK/@M_SF\8)AR<9=NK"[/=C:USY@>Z%!3Z2"0V@=70#KZ2*HY/(W(.=X?PS
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M,2X(R4E!'U@C6JFU*#F9_CR??O#_ ,&8_<;+<5&+<+1\J0@RZAQAI#*PX'@
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M\^L:^T-J_P ZU^JM9[GL"^Q&.?A,?]%/<]@7V(QS\)C_ **#9_/K&OM#:O\
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MC-RML1#C\FX>TLI2IQT=U+6E]#"U*/< +/INNC*4'&6?<3WZP3,=LMYE27K
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MB.A?1O8^*@F<;G+&X6(6*\WRXQ8[MW\WV:/:DR)Q>\M1"RVE+(<4E( *E>6
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M![4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@B')'(?N]AV=;=CN.13;M<46V)
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MGS5=B=?ND#O7UB_*.=<ERN-K=$OL:P_+,&ZO7&X0X+;ID>R2&VFW6 YU)0'
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M5D<BM.(G$PXXZ'5*^-/6!T(\LI/5O?5Z5OIG*G)^1<FY)%QFTS78./W>' 7
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M41HJ\WIZMD$C>]Z[4&UO4QB=BMR?C/MR&517NEQI84DZ2H'1'\:Y[N4VZ0/
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M4C92"?5943_L[#G-AC*+OQMA[TC,9EPN<GDA4=B5/CLN>Q>7*F()2$I3U'I
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M&M?2-UAH\.]KCV/V2/DE^:N8OQR1%[4Y'7*3-4V&UJZ5,EHI4GJ'04:'4=:
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M&$EF-T+DEV,ICK3\9\LIZNH?O>FOXT&S]^-KBW.ZP+K9+Y8I$&VR+NV+A';
MF1F" ZMKH<5W!*?A7TGX@=:J/L>*.RRWV8\?$<O?E2;<+Q#83;FPJ5!_O2$;
M= 2E.T[2LI6>I.DG=1K$/"0O'77WG[[9Q(7CDS'2_:[ (KLD/AO_ )U)67UJ
M>>VC9)(!ZCKI[[L6V\/_ "??;-<?E;S/D[%U8WY7LVO,VIL^=OK[?Z/]S1]?
MWNU%8UX\0V-6Z#;I<*'=K^U+M*;ZL6J*'%18"O1]T*4G0]=)3U+/2K23HUN\
M]Y CV+C-S*K?/:1$6B,\Q,,4R4*;=<;2E7EA;9.PL?WAK>^^M&K)_A(C=&+/
MQY&,W>X6>PL6!\Y9C*;I&?;:)*'FV_.0IE>U+WI:@00#Z U:>=\;(S3C-S$&
MY3%I;4B,A+T:( TV&G&UZ0T% )2?+T!U=@?IU0:#(?$5C^-WR^V]ZTWV0Q8)
M+$:[7.-#2J+!+J4*0M:BL*4G3B=]"5%/<D :)W/,')KO%>.0+HS8YE_<EW.)
M;DQX:FTJ27G4HZMK4D?3V&^YT#H;(TN1<&?+]GY+@?+?D?/.0U(\SV3J]CZ&
M66M:ZQYF_)WOX?WM?1LR/E/ 7^0L3;MD.XMVN?&FQ;A%E/1R^VEYAY+J ML+
M05))1H@*!T>QHBNGO$8[C.<9U&OMCO+MCLK-OE+<B0VU_);+S 6XJ0KS/BTK
M>PWUD!).M=ZEV3\^8YBUZEP7XUSEQ+>8Z;G=8D<+B6XOZ\H/**@KN%))Z$JZ
M0H%72#6%>.$9-_M7)#,R_-)F9K;V(;SS$$I;BK1&\E2TH+I*@22H)*@0.W4?
M6H_>O#!#E\A3,FBMXE/^4O9536\FQ=%S>;6RVEOKC/><@M=24)^%06 H=0^D
M$J2>(?D2^<=X;;WL=A/RKG<[K$MC;[#+;QCAUU*2H(<<0E2M$A()UU$;[5CO
M<^6C%UNP+I'O=P1:/9XU[O[<% B09#B4$)?Z5]C\:"KRTK2CJ&R!4NY%P,9]
M;K/$$WV 6^[P[KU>3YG7Y#H<\O74-=6M;[Z^HU!,LX N-^EY9!@Y0S;\4RR6
MW,O%N<MI>E%82VAQ+$CS4I;2XEI(/4VLCN01OL&\5S[CJ+QE$1<.ZH@XP74W
MB\*B@0XI0TEWIZ^KJ65)4-!"5'Z];&]3=_$' 5C=]=;BW+%[Q;68DLQKW;@X
MM4=]X-MO);0\ I*CU)UUI4D_O)[:.RD<%0+EBO(^/SYZWX&9RGI#GE,A"HJ5
ML-M!(V5!9'E!6R #O6OKBML\,ACX3?,?<<P^UN7!$5M-PQG$DVUU267DNDOZ
MD*\PJZ!V'2 23H^E!)LP\1>.X;<+VR_;;W/A61UJ/<KI;X8=BQ7W DH94HK"
MBHA:-E*2E/4.I0K^9#XBL?QR^7V ]:;[(CV&2Q&NUSC0TJBP2\E"D+6HK"E)
MTXG?0E13W) &B:CYMQ*_(N&:8SB;]VD)RRXQ)DBW'%);S8>_8I6M%S"A'::Z
M6@5A84H%*@.ZAJVLAX+^7K-R7 ^6_(^><AI_S/9.KV/H99:UKK'F;\G>_A_>
MU]&R$SSO/+9QY8DW2Y)D/)=?:B1HL-HNORGW%=+;3:/I4HGZ2 .Y) !-1NY<
MV1K6W9V'<5R1=_NB'WF<>:C,KFH::(#CJ]/>6E *DZ/F;/4  3VK:<G\>N<@
MV&WQXES^1[K:[A'NEOG*C^>AM]H[3UM]2>M!!4DI"DG1[$'O4>NO&.7W"[V/
M*&LJL\3-+?%DP'I(L;J[?(C/+0OI]G,KK2I);00KS3OOL:/8CZ3XB<;G2L<B
MV>!>;_,O\1R;#CV^&.M+;;J6G?-\Q2 V4*5I041W! V= _"O$9CK=\E0EVN^
M-P(EX^095[5#3["Q,*PA+:E=?5I2E( 6$E(Z@%%)K^\><$,\?7VP7)J\N3E6
MVU2X#P=CA*I+TF2F0Z_L*TCXPK2 #V4._;O <5X<RG+9680;K=Q:<1D9N_=E
MVQ^TK$N2EIYMQORI!="0RM3:23Y:B=*TKOV*L9SG_'6\A<@&%=C;&[F+*O(!
M%'R<F:5!(8*^KKWUD(Z^CH"CKJW61CG-=ORYZ_"SV"_SH]F=DQGY2(:$M.2&
M'"VMAHJ6"M>QL$#IUZJ!V*C<CP^SWI4BUIR=E&#R+^,B=M)MI,SS_/$@M"3Y
MO2&B\ K7E%6MIZJS+CP.]*XKO^'L9!Y+ESN\B[>U+B$M:<E^TEAUH. N-D?L
MU +3U))]-ZHC%R3Q)Q[1CTB9$Q*^/W:'?(=DF660EAJ1'7(4WT*)\TMJ!0X"
MGI6=D@'I[D;>X\TP,;N.3+O*I++%MBVMQ%K1!W+2]++B4,A27%!UQ2TI2$I"
M0D@_$H'8B%L\+CUIQO)(L.]VBVW*ZWB!?&!:["(MOAOQ?+*4",E[:FU>4-_&
M%?$3NI%D_!#^62[]<I60(CWBY)M#S+\:#IN++@+<<2Z$*<)6A:W.[94"$C76
M2=@K*E>(C';7CMZN=UMUZM,JS28L6=:),,*FM*D+2EA00VI25I65#10I7H1Z
M@BO-7,=POZ9$>QV&7:[G:;C&3?(F0,)2N' 6A3JI"0TZ0OJ0@A/2I1ZCW3V(
MK72^ +CD+-^F9!DT>5D-YG6N2]*@VPL1FF8+R76V6V5/+5\1"]K4X>Z]ZT *
MG%KP-RTYUEN2M7%*G;[&B,(87'V(Y82XD*)ZOC!\S>M)UKU.^Q'EQIRA&Y0M
MWRC LEWM]K=:1(B3K@VTEJ8TO?2ILH<6?0=PH)4-C8%:IKF"# RR[6FX2%R"
MG((UABML0O+++KL5+X"UEP]8UU'J"4ZV!TG6SC<4<.S./LGOU\EW&T]=U:;0
MY;L=M2[;"+B5*4J0II3[NWE]6BH%/8#>SWJ#VGCJZ<D7C-KW <E8R\C+XEYL
MLN]6EY*7E1X;3*BN,X6G"VH^8G>T[UL$CU*L'(^?<;QE-R]HCW.2[!O;6/J9
MAQ?-<=EN,I=;2VD':@0M(WV[GOV[UKKQSQ"Q>YW5Z]M38$:):8$TV=R"GVMM
MV3(<90A3H>+9*E)2GI[)3ZE9![85I\/]Q;DN3KOE35QN+^6L94\XQ;/(:ZFX
MZ6?9T(+RBE.D@A14HCT(/K4@RCBJ9=LIR2_0;C;//N]HBVDP;S:C-B=+3KJU
M%Q =1Y@6'2GIV-:WL^E!]7+FF+:+79W9>,9"S>;O*<B0<?\ 9V53GE(25K4-
M.EH("03UEP#T[[(%1/C#FV?EYLBK@]['\IY)>+8W&?MY2[Y,9+RD(4>L>4I(
M;[J*5]6B.V^H>=C\.5UQ:V8^_9LHA0[_ &2XRYL/JM3B[6PS);"'(C<7VCK0
MT  4@/=E;^@]-;7$. 7\>?QZ1<,D%UDVV]72]/K3 \D2536W4*; \Q70$EXD
M'XMA.NWK1'E?/$G%C\?9)EUFQ._W6SVN&[*BW!;+3$6X!"NC;2E.=?3OOU%
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MRUQ7DI1Y9&D!8TD$I5H['<WQF5VC<2\5K*ITAI<=#4*/)A06"\Y(=6EMOH9
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MAU#/7\(#:2>E!)[=RJ^P/G_(?/XVO%TSB!?'\UN#\&7B28\=H6A7ENJ2$*0
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M(H0"23VWZT5'>1<NR7C+@>#*]K1,S!Q%OMGMLEL% ER'6F5/*0- A*G"KI[
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MN-:\,Q^VQYC2X\EJ);&&TO-+UU-K"4CJ2=#:3V[#ZJ]+3Q7A=AM4RV6W$K'
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M=632@K;^S1Q!]U6$?EV'_+I_9HX@^ZK"/R[#_EU9-*"MO[-'$'W581^78?\
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MPJ[UD7K/\Y:M?-62-Y(U&@8>N;'M=M1 :*5*1#;=2MYQ0*E=*E]@G7T]75V
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M(^,)  '5O0]*^+OA6/7]NX(N=BMMP1<&41I@E1&W/:6D$E"'.H'J2DJ40#L
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M_9("B.R] $CZ:"ZD<V<=N2Y$5&>XPJ5'Z?.83>8Y6WU*2E/4GKV-J6D#?J5
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M;Y[326BX4I;;"VQT*Z4J)6Z0G8 ULU86/\UX1E'MYM^01UH@QC-><?0MA!C
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ME3"DAT.*ZDZ1T]1ZAH'8K XLY=C<HWO,V(*$_)UCFLQ67BVXTZOKCH<4'&W
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M-:;9+H)24!95KJ!!&M[V#0;VE?"7FULAU*TJ:*>H+!VDCUWOZJ@V6<VX?BV
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M;E+;/4^M;3[O4I]2E;*%$D[Z@!5OUB6NZP[W"1,M\IJ9%6I24O,+"D$I44J
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MJ _B#7E8,I@Y+B<#(H/G+MTZ&B<SMHEPMJ0%CX!L[T?0;-!#/[,G#WW48/\
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MZUUN@["'Y*VU A)20H>BB1W HKO^E*40I2E I2E I2E I2E I2E I2E I2E
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M/^X4$]I7)4?/,TSJWXG%>RFZ6.7#Y"D6!^2VS"$A]I$9Q: ^&PXP5I)Z2$?
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MF+_!<'_%YG]+0672JT]NYB_P7!_Q>9_2T]NYB_P7!_Q>9_2T%ETJM/;N8O\
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M'9'4%!*5=*N^_4V_RW?K[QOP3D=V@794^_VRW+=9N,UAO;C@/92T(2E'T^@
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MTBWJ;!04)"B5=9'^L/3^-7C7YX_\L3_Z$\;?]HS/_L3=%AL__NP.!?87(_\
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MDO[@LE_'K/\ U5/?/R7]P62_CUG_ *JO='BFPL\H99@*TW%F^8[;U7%Q3C*
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MO\F" M7G=<AEMII:72OIZOB*=Z'?OVZ,Q_CS%<2:2U8\9L]F:2RJ.E%O@-,
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II2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tm2533062d1_424b3img06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2533062d1_424b3img06.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 1, U$# 2(  A$! Q$!_\0
M'@ ! 0 " P$! 0$           <%!@$$" ,""0K_Q !;$   !@$# 0,'!PD%
M! 4*! <  0(#! 4&!Q$2(0@3,107(D%15Y05%AA25M'2(S)589*3E9;4"7&!
MT]4S0F*T)#=R=9$9-3A#4W-V@J&U-#9C=+,E1(.BLL/_Q  6 0$! 0
M             0+_Q  :$0$! 0$! 0$             $0$A$C%A_]H # ,!
M  (1 Q$ /P#^J8
M
M
M
M
M
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MSWV] S66_4R_\0&\ -,?U5J:RRBP;F-/H'92N#"[%CBTXKV$XDU)WZ^LQN8
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MK^J-U;'E<!XG$$XD]E),R\#+I_@9'X&0#80
M
M                                                      >4.T]V
ME\!TZRMZMRFX0CR!@DIKXZ2??<6LB4H^[(]_#B1&K9.Z>JB$ZQ[M%:,7,NB;
MJ<PB2'+F0EENIF(>CO,.GX?EE)(F5;[)(UGP4>W4R+I_/7M6V+UIVFM5'GU&
MM:<FL&",_JMR%MI+_!*2(2H6M><?Z*\8QTCB,2;#E+D)94PAR2SW;QLJV,VW
MD[\5&1EX^!^/K,SS-U?UF-03FV]C$JH9+2WY1-?2RWS49)2GDHR+<S,B(O69
MC^0O9W_M,\WT9PY_&\AKBSJ''8X5+TR4;3\51=$H6YQ4;C1%X$?I%X$K;8B@
M^O':6S[M&WJ;#,;<WHK*C5$JHI&U#B;_ %&]SZ^KFHU*/P,]MA#R_OZZRV^2
M>:25Q/DDS+JD]MMR/U'U/J)-J;11J2H23SL:+0PVR4GRUXHL",DMMW93RE;K
M/D?1)&6Y]3WZC^3FAO;_ -6M%'*J%\M*RC%X22:^0[<DK(VO4E#^W>(V+\WT
MC273T3(MAIG:$[5.?]I*[.3E%H;52TLUQ**$9MPXWL,D;^FO;_?5NKJ>VQ=
M/+^D.JNHVGFA%.S;Y/?,SY<HB7&CPN+KLDC];#23V))$9'S,R26Q=2W(CO\
MV;]7<?UDTV8M,>M6[6+$=5"4XGT5IXD1I):#ZI5P4GH9%[?6/X &HS(B,S,B
M+8M_4/Z<?V.-D\[0ZI5ZC/N&)-<^@O\ B<1(2K_Z-)%M/,?T:&MY]_YBB_\
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MVNRRW':0TTA+32$DE"$%LE)%T(B+U$ _8  (
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M0>S6ZR*BM*"3C5_1*8.3#>D-R$+;>0:FG$.-GL9&25$9&1&1D?\ > WP
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M$BLHCQF&TM-,MIXI0A);)21>HB(B(?8
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M'??KX#3M2NW/HMI1E3N.7V8(*W87W<EF#$>E%&5ZR<4V@TD9>M)&9EZR 9_
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MU!HM5<,K,KQF8J?1V2%.19*F5M&M*5J0?HK(E%Z23+J7J ;&
M                  -?ML\I*:U.K>EKD6B6TO+@P(SLN0VV9F25K;:2I2$F
M:3(E*(B,R,B/H-@$'[*TI9R-58=N9)S%G,Y[EHATR[TVE\3A+V\>Z.,31(/P
MV29>)& ^M+7VV7ZY6&I6+2J>PJ&J7YK/5TY4F)*9?;D&^I3A*9W0HN\X]V:=
M]MCY%OL.C&[-]G1U=!'@3JZ=(9S9_-;-3Y+CL./.D\2H[#9)7P07?%L9J/\
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M_#]0JE)G84$W<C5Q/BM;7(B5L1[$I*B)23,B/<NHQUGVN*O)LLR:IH=0M/\
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MF*<=9$I<V.1&>R&T;JY=33L1<C2HTE[P T  !
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MS(E;&1':3_<A!$1?^ Q^6Z:XCGZHZLGQ6DR-4??N3MZYF4;6_CQ[Q)[?X#9
M 8B?B%#:5\6!-I*Z9!B[>3QGXC:VF=BV+@DRV3TZ=/4/W1XK2XSW_P CT\"I
M[\R-WR&,AGO-M]N7$BWVW/;?VF,H #J3:J%9/0W9<-B4[">\HBK>:2M3#O!2
M.:#,O15Q6M.Y==E*+P,Q^+BBK<AB%%M:^+9Q242^XF,)=1R+P/BHC+<MSZCO
M  Q5)BE)C)OG3T\"J-_CWIP8J&>\X[\>7$BWVW/;?PW/VC$1M)<&AY(>11\,
MQYC(#5S.U;JV$RC5[>])'+?]>XVP &+R3%J7,:MRLOZB!>5KADI<.RC(D,J,
MO S0LC(__ ?&CPG'<8HETE/05=33+)1*KH,-MF.HE=%$;:4DGKZ^G49H &KX
MKI;A>"S7YF-XC0X]+D$9//U58S&<<(SW,E*0DC/K[1M             #J..
M3BM8[;<>.JM4RZI^0J0HGD.DIONT);X&2DJ2;IJ4:TFDT((DKYF:.V
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M\#_1UE_'9_\ G@*6 FGT<\#_ $=9?QV?_GA]'/ _T=9?QV?_ )X"E@)I]'/
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M<E$DM_R_K,R+_$?N_P!&-,,7Q^7=V;-A&JHC1OO2?ENQ624?6V2\9G_@0"O
M)!:Z,Z84LBI8FL6+#MK(\DAI.ZL3[UW@ISCT>/;T4*/<]BZ#*?1SP/\ 1UE_
M'9_^> I8":?1SP/]'67\=G_YX?1SP/\ 1UE_'9_^> I8":?1SP/]'67\=G_Y
MXQ63Z-Z7X;2OVURU80:]DT)6\J[L5;&I1)21$EXS,S4HB(B+Q,!8 'GU['="
MV*B+9*L9"HTIUQAE+=Y9+>4XW_M$=T3IN$:/]XC3Z/KV&5F:;:/PL0;REQ^2
MO'G$H6W8,7U@ZVX2U$E''@\9J,U&1$1;GN>P"V@(_C.CFEN8U96-,F;/AFM3
M1N-WM@1H6D]E(4DWB-*B/H:3(C+V#*_1SP/]'67\=G_YX"E@(K%TPT?G9._C
MD>6MZ]8(U.5Z,DFF\G8B-1<>_P!]R)23,O$B46_B0Z5EA>B%1!ES)ELEB+$E
MK@/O*R:;Q:D(+DMM1D_T4DNIEZB\=@%W 1IO2;21Z\B4S4I;MM+C'-CP49-,
M4\ZQT_*I24C<T=2]+PZCX2-,M(XN5-XVOY05=K)*CB-7-DX;9*(S3S4ETTHW
M(C,N1EOMT 6P!+(&@6G-K#:EPH\R9%=+=M]C(9RT++VDHG]C& S'3W1W3]R(
MWD#DZM5*2XXT2[FR5NA&W-9\73XI3R3NH]B+<MS 7(!+XO9\T]FQFI$>)/?C
MNH)QMUN_GJ2M)EN1D9/[&1EZQ]?HYX'^CK+^.S_\\!2P$/RW3K1[!GHK%V[,
MARI1*4Q%*[L77W4I_.4EM#QJ-);ENK;8MRW,;!%[/FGTV,S(9@V2V74$XA7R
MY8%NDRW(^K_L 5 !+)N@>G-8R3TR/,B-*6ELG'\AG(2:U*)*4[F_XFHR(B]9
MF1#L?1SP/]'67\=G_P"> I8":?1SP/\ 1UE_'9_^>'T<\#_1UE_'9_\ G@*6
M FGT<\#_ $=9?QV?_GA]'/ _T=9?QV?_ )X"E@)I]'/ _P!'67\=G_YXX5V=
M<!0DU*@6*4D6YF=[/(B+]^ I@"&XKI[H]F\V1&H7)]HIE)K4['N;(V5))7$S
M0[WO!?7IZ*C&S_1SP/\ 1UE_'9_^> I8"466A.F].TRY,BV$=#SR(Z%*O;#T
MG%JXI3T>]9F1#N?1SP/]'67\=G_YX"E@(YD^D.E6&0F)EX<JLC/R6XC3LB_G
MI2MYQ7%""_+^)F/KD.B^F.*5Q3[6/8Q(AO-1R<.ZL5?E'7$MMIV2\9]5*27L
MZ]>@"O )#.T6TQK;JLJ),>Q:L;,G3B,_+5B?>]VDE+ZD]L6Q&1]3+]0R?T<\
M#_1UE_'9_P#G@*6 FGT<\#_1UE_'9_\ GA]'/ _T=9?QV?\ YX"E@);.T!TZ
MJX3\R9&FQ8C"%.NOO9!.0AM!%N:E&;^Q$1>LQJI8KH6>/JO/EIOY)2_Y*J4>
M3S223VV_=G^7W)6WI;>.W7PZ@+X/@U"CL27Y#;#3<A_CWKJ4$2W.);)Y'XGL
M7AOX",*TXT:3>0*;Y0WM)[27HD0LGF&X^A1&:5)+RCJ2B2HR]I)/;?8QL?T<
M\#_1UE_'9_\ G@*6 BLS3#1^NR:-CTJ6MB\DD1M5[F232>7N1FDB3W^^YDE1
MD7B?$]M]C'YL--='*I=PB9..,NG)H[!+F2S2.+WG^S)PN_\ 1-7^Z1]3]0"V
M (?.T[T=KL48R5V1*<HI"D(9FQ[VP>0ZI:N"4I)#QFHS5Z.Q%OOT"AT[T=RB
M9"B5+TR>_,C.RV4LWEB>[;3B6W-S[[9)I6HDFD]E$?JZ& N ":?1SP/]'67\
M=G_YXQF1Z+:98E3OVMM'L8D!@TDX\=U8JX\E$E/1+QGU4HB\/6 KP":?1SP/
M]'67\=G_ .>'T<\#_1UE_'9_^> I8"'.Z>Z.L8],O'79K57$EN077W+JR3M(
M0Z;2FDI-WDI7,N)$DCY'X;C(TVCFEU^U%7!;G.*E,G(997>6#;RFR5Q-?=J>
M)9$2C(CW+H9D L ":?1SP/\ 1UE_'9_^>.O-T#TYK&2>F1YD1I2TMDX_D,Y"
M36I1)2G<W_$U&1$7K,R(!4P$T^CG@?Z.LOX[/_SP^CG@?Z.LOX[/_P \!2P$
MT^CG@?Z.LOX[/_SP^CG@?Z.LOX[/_P \!2P$T^CG@?Z.LOX[/_SQNF+8I6X9
M4(K*EIUF&A2EDAZ2[(5N9[GZ;BE*_P#J RX                "+:Q8+F-]
MDMS8XJ1QI#N*.UT:8E]+:O*#E-N&VGTB4DU-I61+Z$1F7I$+2(:[VG.>N=KI
MS$Q9;Y53\9J;;/7$2.E!/-DX2D,.+)QW8M]R02CZ?K :.O1_4$ZJ*[1%9UL]
M#=N<<K-R.S\G./1&VVR:)N2]LE2TJ/<EGLHU*V21D9XN7B%UCLC"H5K4Y//B
M6=Z\;V-)EL1E+2FO<Y$@TS5I4@U)):DK=3R4DSVZ]:^CM>:,.*-*=2<?Y$IM
M&QRR(]UGLG_ZEU/_ '?7L,SD.N^#5%S9TOR[72,GK8C\Q-6X\32U]VR;BDI6
MHN)'PZGL9[$>YEL"HC2Z$YVS$MK>5%L"R-IBJ^1UG<[N,I:FO+6TM1.\5J;C
MN(;4I>Y*+D1&K<]^[D6F.H\]-RW!K[5G(7#N?*KWY7;*/91WFGBA,-([[="D
MJ4QMR0@F^Z5LKTMSW+ NUC095D<ZLN&8F-,LQ:=V/,>L4/-RG[!HUML(-*2(
MS(TF1*(S)7CT'>R#M3XCA6M%G@&53(6.)C0(DN-9SIA)3*6^M:>Z)''T>/ M
MU&K;TB\ &D9+I!G-4FRA8\S/7CKS]7*D03L"D.2S2R\F622=D(W,U^3K4E3B
M$KXGU5U(ZOHWC<W&*OR2PCWYR$164G,N9B'$N%R=-+:&D2'2;4VE1),R_.+A
MNI1D>WTNNT+IOCMW:U%AF57&L:IDGY[)N\O)4&:2W<,B,D]5IZ&>_4A^:[M$
MZ:6]K3UL+-:B3-N"(X+3<@C[_=2DIV/P+D:%$DCVY;'MN [:\8GEK<SD"8I%
M5%C[D)<DEI+=\Y"%DDT[\C]%)]=MNFVXF-CIKECVNRKQNLF_)WR^Q8$:9,?Y
M)7'1$[E3RVS7WWE9;J21DGAT09^!F6S9-VK=.JJ!D:*C)Z>_O::-(?74M3T-
M&LV2_*$;BBXI(CZ&KJ1'O[!VLB[4&GF*T]W+GWT=R92UR;&PKH2N_>90:4&2
M-RV2:C[Q!$6Y?G%X$8#X1,;S*%AF674> 36?9/*XI;4^V95K'+N6"-7+BHF6
MC-TR29[K->V^XRF7:?UU5IC48Y#I+RXBU:X_DS5!,:C2VW&NJ7N\==:+?D6Y
M^D9F9[['U&$D=K33AW&$V-;D5?+M'ZE=M$II$E,=]YM+3CFQFK<D[$TLC5U(
MN)]?#?8J;7S![*RHZ:1D=9"R.UALRVZHY:7%I[QKO$HYEZ)F:=S+J1J(MR+8
M!H-A U'NZ;",7R;%K.Y@-=Q.O+>#*@&MUUI[FRP:5OM'Z/%M3KB$F1\3)!'R
MW+J:5:9:@8K:HKV95I1-$B>NUM)LEB;$GR7)).,O1F.\,T&:3<Y&I+9^D1'R
M,MQ28W:!P*RHY5K57[-W%CR?(]JU"GE.O;&K@@B+TO12I1J(^)$DS,R(C,=6
M!VD-/Y&,6-]-OH]-7UZVT25SW$$23<,R;XJ0I27"4:5$1MJ5U2HO$C(@_5GA
MUFK4I=N_!=M*X\4>KI#T9;33LF0;R%<$I-:>*E)2>QF9)+H7(AH]2UJ5A.%7
M<+',5O)L-^0Q#HZ^WGP7IE5')KB\\M2I!)<01D7=MFZ:M_$TI/INLCM/:41*
M.%<O9[2HK)KSD>/).27%U;>W>;>O9.Y;J\"W+<QF$ZV8(Y+5&1E%>Y(*P8J^
M[0YR,Y3R.;39;>)K3Z1&70RZ[@(F]I!EE!;0)>+U>007D4M;6U+J[**A-6;+
MRSD%-0EXTNI6E1*,F^](^I$23))CU&(O*[5&(4.M.0Z>9+-@XW(KDP2AS)LT
MB\O7)0:N"4&DN'$]BW-1D9J+P&]TVK.'Y%FEEB57D,*PR.M2:YD",OFM@B,B
M,EF70C(U%NG?<M_ !MH"<RNT5IM#F7L1>8UJWZ,R38H96;GDRC62"2HTD9<N
M1DGB6YD9^ V_$\MILZQ^)>8_91[>HEI-3$N*ODA9$9D?7VD9&1D?4C(R,$9<
M                !T;UN0[26"(B.]E*CN$TC<BY+XGQ+<^A==O$=X 'D&F[
M.N;U=355IP$.5=$NLM:V*4IKD4Y;L4YJ3]+8N[[B0HCWV5Y09)W&1BZ?ZJ3L
MEN)QTLNH:G.17'V&)S*(ZG&K1MPU-_\ 25K5O&[PS6HD&HO1XET2/5H M>4Z
M[1?/R2[!?AS(U8].B+<1&M$-?DOEB4^^9&ATC+>.ZV9[=3(^/4R,BZ.=4-KI
MU6.(R3RAW%8KEX556_.)J,ZR2EH7$D$IR0@UH;1S2224I:.1;(/IMZZ'PDP8
MTTVSD1VG^Z42T=Z@E<%>TM_ _P!8"#V>GV4ZDZ8:58\KNXL)%>Q,NI=HUY21
MN(BI2VRMHW4+6I2W#69[[$;77KL1SW*-)=2+S"Y-+>8W99'/;H&JBIDPK9AA
MB,^RZZE;[J%2$_[=HF5;[+/;="B+KO[! $>6[+2K,K#.(4M_'+.5:1+^9-7D
M*K5KR54%<5]N,TVT;_(C1WC:>/=EL9*41GR,SZM7HIG=;/Q)E]=XB*U65QKD
MPY;<IZ%8(6:I:W%.RT?G^B1J03I&E)IV(MB/U< #RQ;Z;YR57D;$.AN9G&X3
M8URIS\8W+!9D]R:FD4TB5'2:D$A:%(67H;MGW>Y^A<.C/1T6AR*Z=7/.2^:R
MF3O*6W3[M!&MC\HKNVMR,B1LCJE1\2WW/8@ !/\ 73$[7-M/'JFE)PK!<^ Z
ME;*FTK;2W+:<6M/>>ANE*5*V,CWVVV/P% &MYYFK. U$6SE1G)$-<Z-#?<;4
M1>3I>=2T3JM_%*5*3O\ J/?U )<SIE::3ZG-9;3U=KGC5A"DQ[)?E$1$],IQ
MUM9/D2U,-<%);2V9(X[=VCT3ZF.C;:69,WV>IU,BN=5>S+PKDZNLDM)7%0NR
M3)4TVXM26^2$;]=R(U$>V_0;]$UKJ7\PN:=]+<"!5JD(=M9<IMMI1L-LK>,D
MF>_%'?DDU>!&D]Q^H^O>%R\EJ:1BS6Z_9QGY3$CN%I8)#1H)?):B+;\\C(]M
MMB,]RZ;A%X>EN;1&G%66-WEU0/R+-]FK3;QVK-,A[N3CRI;J'T-K41I>21H6
MHT$;?0S(S+9=(=/]1,>U @3LI3+G4Z8ALJ2=FAQ+,\F&DO331R])#QI6E*2W
M-![J-*>]/C3$:YX"NL>L"RNM*&TZVRIU3NWIN$9M[$?4R625<3+HK;H9C]1=
M8L:\D9?L+"/6I?G/0&36YS0I3;W=;J6DMD;JV+91EL9D7B"I9::,9?.U!>3C
MEK-QJDA2[&TCV%DQ&D(3,EL+;4;"&UDZM)&\XO\ *J1L9$1$LMN./I=*,OPG
M3_.<9=K[*='MK)7D+N'>30G>[\E:0;CBI4M6R%J2:3+<U[DI1]%%M1M4M>8^
MF.2-U;M0=@A-?\I/N)F-M.]WWQ-<&6U?[5S<]R01D9^!;GT&7I-3)^69#)C4
M.-NS:*%-5 EW,B6AA/>H/9TFFMC4X2#]$S/CU(R+?8!A:+!KV'D6EDR771&?
MD6BDPK-4%24LL/*;C)0A"3/D:=VUD6Q&1$77;<AU,IQB\/5IB=C5-<0&I[[+
M5_-=E13J;"&39I49M&Z;R7TELE*D(09[%R,TD-WOM1(.,Y?%I+%I49F362;)
MN>I1=WLP:.];,O'<DK)?]Q'[!H,+M.09LNKBEC=BB5.:BJ[A3S).-KDMJ<83
MW9J):DFE/I+2DR09GX\5;$33'M ,C1AT"H51657\EXY:1D-M6Y-(=M#=;.,\
MCNW^NY),TJ5MQVZDDQ3LKTRR3-LCP%Z386-.S%HIL.XG5[D8WB=>1'(VS[U#
MF_(T.>DA.Y<?SBW+?\H[4V.J4QO!E);<Q8\G-SDG9)$6_DO_ +W8C_5T&P9E
MK6QAB&$O4%C/E(J57E@Q$4UO!B),B6I1K6GFHC,]DIW,^)^'3<J:.Z*7N/MV
MGD599SZ=O(8Z"J&+;BY*I6HK:$LM<GDH01.ES4A2D&LD&1[D9$?QK-*-16SJ
M&$KG1:>Z?=BVD5^S)QZIKT3#D1D\^\/FLVC<8,T&HR):.IDC<4RLUVKK>#6K
MB5LAZ?.OG*)$%*T\R4@E.*>W/8N'<I)TM]NBTEZQF-/-36\]L+^O54R:F=3/
M-M2&W7V7T'WB>22)QE:D\B(O23ONGIZC(S#4,VH,KH=1,AR&DJK*V9NZ>- 9
METKL(IM:\RMU71$Q26U-K[TM]N1D9'NGP,M'7@.IMO,BOW<&QE9.^=0Y'OF+
M)EJ)6(0EKRYIQE#J=S6HG]R;;6E?>)+<B3Z/IT 1Y7O-$<SN<:LXMY E7K-!
M.@Q:2&FP1WD^"S.*0X^9J<2DG5,\&_RBDGNR?AR(S]10T);B,(2TIA*4)(FE
MF1F@MO ]C/J7]YC[         ->U#QR1F&!9%11)7D4JRKWXC4CKLVI;:DDH
M]NNQ&8V$ $*NF\SR+3RHH$X)<4QU;L+Y2B1K"&AJPBMJ)+L>,ZW()6RB(E$2
MR;(TI-)FDSV&G.X1J920;5=?17$J%9UES75E2FV8-ZI[Y3:HG?+6^2=BXN&1
MH4LT$HDET(>I@ >;G=)LX4JUL6DS6[EVWICBN.69*;;B--1O*3)'><2+O&W.
M1;<E\>G(C+?7\;T8S^1CR(MJ=\W/>F5:+9'EK3+,I+<DE29"'42UN*-2.1&9
MDVI2327'<MB]8@"HIK;I'>ZJ3Z>@KW8U1C5?6RE'+EL^4DJ2XWW#2$H)U"B4
MAM3JB6>Y$:D^)^$YO-.=1<N7'>R+%+*??.2J23'FL6["8=>U'6R<MM3??EN9
MK0ZYZ*%DLEHW,C3L7K$ 1Y$LM'\^GR3>1CML62L5]\Q+R!RY9-J<_(;4453"
M>_-2"VXI+=".[Z%X%N-EKM(<NJ-2X3BE7A4D5<-Z#+A26WC90EHO*&'5O2DK
M+O'#<-1DVYR[PCWW27'TL *\K0=.,]@4U4TQCUI*>K+HWHB+*1'VG,J2T2GK
M D33V=29+XNM&K<TF9M>EL?HW#8QQ*%MM4&PKC)YX_)[29Y4^6[JCW-SO'-T
MGONDN7HI,BV+;8LX (Z-Y.E5M/-EPJYVWF,LJ<9@,.-MKD+(NB"4XI*$F9]-
MU&1$/.U+B.:(N:W.K+![1[(56$N3:U!RH!<N^B$PT<<RDJ0:&DMI;,UJ2I7-
M:N/7B5YSO*2P?#KC(%0G;!NLC*E.1V#(EJ0@MU[;^LDD9[>O8:Q)UKJF\W8H
M66DNQEMQENV:Y*&V6S>;>=0DB5U4?=LFLR+P2HC\ $?P/1;,L0C5>.RJ?RM#
MMK1V[MVW)9-B&B&AKO8YD:R<,R-DTHXH-)D[ON6QCT))J\E7D"9+-_#:IR6D
MU0%5AJ<-);<D][WI;&?7KQZ;^!C6I7: PAA^A0S:JG-W4XZ^)(B,K6T;A-J<
MWY;;&@R3T4G<CW+U;F61/6G!4_*9JRJL0FM2:Y2U/D26TDX3:E<CZ*22S))J
M3N1&>Q[&"IWJ#I/D5YJ8AS'7IM?6S;.!=V<R8B,Y#)Z)Q[LFRY=^I1]TV1HV
M2G;<^9=4GID+07/L2RB=:.KAY7'8FU-HX<.,F)(MWF79"GS/O92TDLN^Y[*X
MI,R02322=A;VM:\6*'9SY5BQ%JX;S;29G,W"62V4O$LTI(U((DJW/D1="W\#
M'5U1UD8TZ.A)F$Q:%;(D/-NN6#<5DFVFB<49.+W29FD_1+H1^T@$_N]-<H>T
M9.(BIG)M9.6IOU5=?*CHE1(ZK#OS0AQ2R:[Q*.O19ER,R(S&K5VE>HE%%>F1
ML:7-6J%9L-LV$QAR8I$BPCNEY0:'D)<?-M+RSXN$@S2E)KZ];!4ZT2LREML8
MGBLNU)J-&DSW9TE$),,WVR<0R>_)2G20HE&DBXEN7I;F-LRC-6<5O,9@2HSB
MF;R8N B6E1$AE[NEN()1?\?!22_7M[01YRJ=$L[M:1Z)<Q+=#4.JNT5;2[=#
M2VY"Y"5P-R9?-)*2G?CNHTHVVW+H.W?Z69Y?1<P@KIY\WY9KXAO3;&8PAY,E
M#D;FU'<1(/\ (\4.+])#:DJ(]E*Y;%O<WM24T,VE_(L]Z.XMYQ#J'64F[&1*
M\E)YI*UI-TU+ZDA!&?'8_%22/OQNT;3+N\9JY%?)BR;B;8P736M)I@KB+4@S
M</V+4G9.WM!4OU%TJU!CP\EH,:I)LFB>G295/(;LD.2(BSAL=T;9O24=V@W^
M_,U'R4DRW2DN6XRTO2S,E-6=K8UMK;KDY#&?G5<>V2EV96)BMDIMK=Y+:"\H
MW6I!J1S)!D>Y&1'3INLGDFE5?G2,?DO094?RQ4=4R.PIE@TFI*E*=6A)FI)%
MLDMSW41?K'1K=>&[C+W:J-4(CUT>+%F29MC8-QG6FWV>^+9A1&I1I3^<6_0]
MP&K8GIK+J]$95-=8G>KD'?2K*)7U=E'.PB$J6MZ.\E]3Y(YH(TF?Y0S\2V5U
M(]7N]+=0+SN+FTIY=CE+^)6M2U8,S([+\60IWE$-_@XAOO#:]%2FB-)+,_ M
MC%QTPU5K=6($RPJ&5(KV7$H:=<D,K<=(RW)2FVUJ4UN6QDEPDJV/JDANP#S-
M%T>S2LU%C*9>MV*R.<1VMGL/HD(CDEHN_:?4[*)>RW3<-9DTYR)9'ONDB3K<
M;0W,[#!9;=_67-K;,OU<B57.R(Z69[K$M+C[[+GE:N3BF^9;K)K<C21D1D1)
M]>@ ^,-"6XC"$M*82E"2)I9D9H+;P/8SZE_>8^P "
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MNOJ":J^#C;2WV7%'(4;QD\KBRE!&DFRZFHR,^A;IYB*_[79Q_-$S\8>8BO\
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MBO\ M=G'\T3/QC=,6QMK%*A%>S.L;%"5*7W]I,<E/'N?@;BS,S+V%Z@&7
M
M
M
M
M
M
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MT/\ 4TQ_;L?N#EVA_J:8_MV/W +0 B_+M#_4TQ_;L?N#EVA_J:8_MV/W +0
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M B_+M#_4TQ_;L?N#EVA_J:8_MV/W +0 B_+M#_4TQ_;L?N#EVA_J:8_MV/W
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MQ%.&#P;$8> 8;28U7NOO0*B&U!8<DJ2IU2&TDE)J-)$1GL778B+]0S@(
M
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M9C$=6,PF?,?)YE\Q+B93D3]*[BQ0VDE!;2I\B-MPORAN-]R1N<S,C(U;)3T
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M(1(NY+Y-NJ<?X;;H;_W>>ZC4I7YI%Z1%I
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M^A$7@0P-'I+A&,P[.)48=0U<6S3W<YB'6LM-RD]?1<2E)$M/4^A[EU/VC;
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M#E6#I/S'F&4H7)<))));AD6ZC)*2+<_41#O@
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MR07)LC5W9<7=C-PBZ;D ]0   @
M
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M'9  'Y2VA"E&E))-1[J,B\?[Q^@
M
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MNNW7P,=Z#G&.6:;)4/(*N6FL,RG&Q-;640RWW[W97H;;'^=MX"%T>F6655K
M0]2R"?L\!B8^Y;L/1U?)<]I#O)3N[A+,ORA;*:)?5)_WC3\;T'R0]/+VNDT>
M4M9.SADG'8Y3Y%*BM?4M*2)ME44D.K(U)Y)4^1<2,]SW,P'JJ%E=)9PYTN'<
M0)<2"M;<M]B4A:(ZDENM+BB/9)D74R/;8:&OM&X7)J<8MZNWAVE-=V!P#GM2
MD);AF3#CQJ>W/T/1:/H>Q^D1C<<5Q:)CN%P*6) CU[+4-#!QF6TI0DR023+8
MNA_W^L0?$])[Z7A.D5!;8<N*>(WJ7++RIV*MEYMN,^E,EOBXHUIYK;V)1$O?
M_=+;<$7WY[X[\W/G!\OU?R#MR^5?+&_)=M]M^]Y<=M^GB,C#M(EE7-SX4EF;
M"=;[UJ1&<)QMQ.VY&E1'L9?K(>9,MT4S BD2JR!,8APL[DWK5?3N0/*'XCD4
MFR=93*)3'-+BE*X.DD_SC+8]C%AT5PPL,T[57MQ+J$N1)E3%1K]<,Y2%NN*6
MK<HGY!*3,S,DHZ%R]0#$X7VC:O,)>-H<QC(Z&#DBEHJ+*S:C''EK2A2^)&R^
MXI!FE"S(G$IWV]HR>/:U-9A<$S0XCD=O1>5JA'DK+<5$#FE1I6I)./I>6A*B
M,C6AI2=R/8S$+T@T5RBAFZ;H^95YCMG2..IN;>ZO&)L)R.IMQ*VXC"93YMJ4
MI2-E);:V(C(SV,TG4=%2RW3*BIM/K3![*7&K7%Q&<E@2H:H#D;FHVWEI6^E]
M*^)D2D$TKTM]C,NH*JM[E=)B[9.7-Q J6S2:R5.E(9(TD9),]U&73=22W]JB
M]HX3EU$N_*C3=5RKLV^^*M*4V<GAMOS[O?EQV]>VPT?,].W<GUOP:_DU+%A3
MT]=8H<??[M1,2'38[HR0H]S,R2YU(CV]I;D)7CFB=]"U0D'>P\IF12RQ[(85
MG6.4Z:XDJ49H-Y2TE-(TI/NE(2:B,B(B/CT(CT.UG&./73U.W?U;ENRLFW("
M9K9OH69&9)4WRY$9D1[$9>H8]&IV/Q,>CW%Y9P,:BR)#L9L[6PCH2I:'%(V)
M:7#09GPWV)1F6^QD1D9%YEK<>G8E>Z/8W:8DEJTA9E+?/)DR(KC=@2VY:U.-
M\'#>-2B4DUDM"22:=MSZ#9++2O)*G3['/)L:O',TKG[DXDBI<K7V&429CCJ6
MY3<ITD+:=2;9GPW4G8^J3Z&5<VM7,->RV9C*<EK/EN)$1-=BJE()1,J2I1*+
M<^NR4*4>W@G8SV(R':D:E8A$@2IK^54C,*(\4>1)<L64MLNF6Y(6HU;)5MUV
M/KL([9X)ESF0YB[(Q9$J3D^%L5Y3:UV.F-%GM,22<:/O'$K)*E.H2A24J+ZQ
MD1;CLWF$Y3B.!:<46,8^\S70XZ47+-"S6JG,O)CDE!H\L/N=C6:R6LN2NI;>
M)F I]IJWAM+>T5/-R2MCS[QI3U<A<I!%(07$MTJWV/<U$2?K'X;[&/LUJ-2Q
MZ.3;W$V)CL!B:]"-^RG1TMFI#BD;\TN&DN7'<DF9*+P,B/<A#-.-+LLP1C2&
M59XN]9O4S%K7V+$5^(MR)Y1));+IF:VT*024]>[ZEN6R/47ZK=+LIQ>YH<@F
M8F[DL6MN\@?<I(\B*I[A,D&N/*;)UU+1F2",C(UI41.GTWW(!Z L\TQZDKF9
M]C>UD""\V;S4J5,;;:<06VZDJ49$9>DGJ73J7M'?@6<.UKV9\*6Q,@O()QJ3
M'<2MI:?K)41[&7ZR'GK!-$;N#::8OW-%&3"J9UY8/0C=:=;JDRE&J,R1;[*-
M)*-/H$9$9'L>VQBBZ,X99X=IS84T^$F"\=G:.QHR%H4E+#LMY;.W$S(B-"TG
MMZM]C(O $;;59YC-[8.P*W(JFPG,M$^Y&BSFG74-F6Y+-*5&9)/<NI].H[K6
M05;[<%;5E#<1.2:XBD/H,I"23R,VSW],B3UW+?IU$"P/1"WQJAT5CHH8];,H
MX<UBZ6TMGDRIZ(M)DI25?E.3II,^/+KL9^&XZ& 81G33ND=/889+JXF&PIL.
MPLI$Z(MIY:HBF6E,);>4M2%'L>ZDI,N1;EX[%7)>JV$MIE*7F% E,1M+L@SL
MV")E"MN*E^EZ)'N6QGX[C&Y%K-CF+Y+05UA80XU=<0)$]JY?F-MQ$H:4T1%S
M4>Q\N^+8R/U"4Z<: R:)>B"K#%8+2L<J9[5JH^X6;$AUMOCOL9\S-1.=4\BW
MW,SZC%4&EV4X9(TOL)>!.9''QV)=QI,"+(AF[&\HDI..;:774H5^3+;HHN*3
M,O'H8>C[;,J"AJH]G9WE;75L@TDS,ERVVF7#46Z>*U&1'N7AL?4+/,:"E6PB
MPO*V M_N^Y3)EMMFYS/BCCR,M^1D9%MXGX#RX>A>;4E9@4Q<&V7&KXMLQ*I<
M;<JWI->4N23K2$%.2IA:4-_DE<#(R_W3-.XH>F^B?S<U"Q>P>I)*J>FP]NJA
MOW;L9^7&?\H-9MJ[HS3S)&Q<D%QVZ$8"QY%E=)B$),R]N(%+$4HD)?L92([9
MJ]A*69%O^H=>XSS&L>BM2;7(JJLC/-DZV],FM-(6@S(B41J41&1F9=2Z=2&@
MZXPLRL;3'F:"NFS:,T2?+ET[=<N8V\:4DS_^.W;2T9&X2S2DU^&W3<:5I%HC
M=T]AIHYE%#'<*BPZ5525/N,ODQ*6^T9((B/KNVE7I)+;;ITWV!%UN\WQ['($
M699WE;7QI9D45V7,;:1(49;D39J,B49^K;<=+ <^AYUI]59:3?R9!G1?*S3)
M<+\BCKOR5X;$1;[B XII9E6$Q\'EV>#N96W$Q1_'W:MB3#4NO?4_S)1]ZZE!
MMK1LA1H4HR)!=#(4+!M/;VE[*,;#)-<F-D+>-O5YP$/(4E+RFEI2@ED?';<R
M+??8!2J?-<>R&3,CU5]66<B$1'*:AS&W5L;^',DJ,T_X[#YUF?XQ=PILRNR.
MHGPX1\94B+.:<;CG['%)49)/^_81?S5Y1B2\3FXEC\"-8U6"3*DTK4TEGRXR
MC&PTX1*+F7)#I[]4^.YEOUT9[1S/LFJ=1E2**UWN\1CU$9BY<JF'79*'G%+0
M2(9I;2V1+]$UF9[;[GX$"O2I:K82;?>?/&@[ORCR3G\IL;=__P"RWY?G_P##
MX_J&4M,MHZ.P@P+*YKZ^=.5QB1I4I#3L@_8VE1D:S_NW$-S+0=ZPO=2Y-?BT
M%3=IA#%-6*2EA/.2DI.[9$9EPVY,>D>Q="Z^CTU;--#LFM,KM%6L#*+6DOJ6
ML@K3C;U/SC+80:7&W534]X@N9]XE;"_$SZ;D1F'JBQLHE/!?FSY3,*&PDUNR
M)+A-MMI+Q-2C,B(OUF-!U$UXQ; L%C9.U95]S$G2FH4 XUBPEJ2\XLD%L\I7
M DIWW4K<^)$9CXZXX79Y3A](U60/EQ53;PK*14NNH2=@RRO=37)9D@U>"BYF
M234@MS+Q$T>TFR3(7KBX1BGR)&M,RI[9JBD/1N]CQX_=)D2'.[<4V2E\#4:4
M*49DDO6>P(M-[JA185B57?9980L?CSEL,I-V4E;9.NF1)2EPMB477?D738C/
MP(8YO6_%D9G84$VUKZU+$:%)C3I4YI#4XI).&A+)F9<CV;WZ;[\BV'4U]Q2Q
MR?!H3=/5'<2ZZWK[(J]M3:%O-L24..(0;BDHY<$JV)2B(_#<:5E.DEAEEOJO
M;KQ9LG,@Q&+6U3<M4<W2>)J1R8/99D@TK6T1GOQW(C)1D6X*M5IEM'1V$&!9
M7-?7SIRN,2-*E(:=D'[&TJ,C4?\ =N.W:VT&BKWY]E-CU\%A/-V5+=2TTV7M
M4I1D1%_>/*^8Z&Y/9Y19*MH&46M+>TE9 <3C;U.:XSC"#2XVZJ:GO$%S/O"6
MPOQ,^FY$9U/M$8!?YCBF,)H#FR7::XCV$B)#7%*5):0A:3[ORI*F%.)-25D3
MA<3-/B1[&"*;#RBFL6:]Z);P93-CN<)QF2A:96Q;GW9D?I[$1F?'?H0P3VK^
M%Q\KK<;7D]7\LV*'%Q8Q2D&;O!PFU)+K^=S5Q)/B9DK8O1/:*6&BEW<Z4-8W
M15]]2VEMD#ELN\R)^ F71K_.5);1"4E!*7L:4H;_ /:+->Q&9'F<.P:_QO+M
M,K)[!/)(U;22:":Q7R(SB(3IO,FB3NMTE*:432U[ER<+D6Z>1F LGS_QCG+1
M\XZCG#9.1)3Y<UNPT2C2:U^EZ*>1&6Y]-RV'+.>8S)HV[IK(JEVG<4:$6")S
M1QU*(C,R)PE<3,B(S\?4?L$3IM-LKP/0V9"HL>9:R>;>R)5@VPB(]*=B.3UK
M4MLWE=RMWN32:2=/8MB(RW+83J\PG),7H&'KW&YEFJTU,@6<.KLGH'E,MKR5
M);+)CC'2YR;5Z/1.Y%NK8^0*]9L9OCDJE9N&;^K>J'C-+4]N:VIAPR(S,DN$
MKB>Q)4?0_4?L'Q+43%#>JV2R:F-VU03E>WY>URF)/P-HN7Y0C]J=Q CT8O<J
M??G3,1365-GGD*]7C\MV,I4>(S&)MQUU*%J;-2UIY&A"E'U+?<]]OMJ7I1D,
MBPU/K8&%IR LQ9C-U5TAZ*VU5<&4M<72<6EQ"6UI-U/=)7N:CZ$8#T.YD52U
M%E2EV<-$:([W$AY4A!(9<W(N"SWV2K=1%L?7J7M&(C:BTJ:I^PM9L2@C-2I$
M7G83HZ4J[E:DJ42DN*21;)-6QF2B+\XDF1D)'=Z,Y*_JQ$B-,IDX#:R8-Y=R
ME/((_+H;9I)'=F?)1/*1%69D1E^15N9;EOUZ/1B]7<84NVHVGHE9F=Y<R">=
M9<2VR_Y2<=W;D>YF;B#(BW4G?J1;="+B_F^.1<=1D#U_5LT*R)2;1R:VF*HC
M/8C)TU<>I_K'5C9]52K"4VB3'^36*]JR^5BFQSC+:6I9$9;.&HB(D;\S22#(
M^BC,CVA2=*,DQJ=2VQXB=]5T^775E\WXKT4EKCR>1,2&DN.):Y(-1GP4I*B)
M:O7T&5S+%\[=O,GR+&<8.$JPQVJ@LP9!PENM\)3RI+*6U.&R;J&7-T\C-LU&
M1;F1& I]SJU0PZ2HMJJ9%R*!8V\2G1(K)3;S:7'W4M\C4DS(^)JW,O$;3<W=
M=CE<]86UA%JX#);NRIKR66D%X>DM1D1?XF/-&,:39LMVYERJFP0B;FM'<LE:
MOUZ91Q8_<D\XXF+Q92HN[/T4D9F1%^<8J&N6*VMW,PBXKZ-64Q*"W.=,HVW&
M4N24&PXVE;9/*0VI;:EI61*4GP/8]]@&YR]1,4@5U?82LGIHT"Q/:%*>GM(:
ME'_^FHU;+_\ EW'UNLYQO&GVV;?(*JJ><-!(;FS6V5*-9F2-B4HM^1I/;V['
MMX",Y3BUT[F2\I3II)OZZTQGY':HENP$O5;W>N+4EPEO$T3;A+3R4TM9EP+H
M8UVO[/&01Z*^AVM5%NYYZ;QL<BRW'&EDY,24CFT@UF1I+=37I*(B/IUZ'L5Z
M)A9QCED5D<3(*N459N4XV9K:_)-M]^]V5Z'@?YVW@/U49GC^0%..KO:RR* H
MTRSAS&W?)S+?<G.)GP/H?CMX#S?J9I?.Q/!<@G,4S%?5QM+)-1)4PIM)>5)X
MJ)LR2>ZMB[P^1$9=3Z]1V*O$\WF*<R/%<%9Q.9 PE5-%C3G(BD6<I2FUHXI:
M<4DVD)0OB;O#<W=C21;@/0=9GN,W=;(L:[(ZF?7QW":>EQ9S3C32S,B)*EI4
M9$>YD6QGZR'-9GF,W<?OZ[(JF>QY24/O(LYIQ/?GX-;I49<S^KX_J'F&1HOF
M^34VI:9-%:.,W]=318L>\<JVI#QL25J?2I$/BRA)(,MMS,S+8MS/T2W?4?2)
MQZUU+L6X\6@J'<?KGZ^R2IMMIF?"<D.I<-)'NGA^1W49$7'H1GL>P7MBQB29
M<F*S*9=E1N/?L(<(UM<BW3R275.Y=2W\1ING.L>/:C1R1&G1(EOWTELZ=R6V
MJ6267UM&X;9'RXF:-R/;P,8+LVP)\K 7,ONHWDM]F$E5Y+9/Q90M*4L-?W(9
M2V7]^XEV#Z4Y5$^:=(_@ATDJIS"5D,G)?*8BFEQEO/K)*>#AO&XXAQ"#2:"2
M1;[JZ$0(]'IS*C?M)]7&N*^5;P6S=D5S,IM4AI.WBILCY)+PZF7K&!QS5_';
M;3['<MM;&%C4*[8;>81:S&V>JBW)!*49$I7ZB$.TIT0R#'LEK&,BA93(F4TV
MRE1K1IVG*J>-_O?3-2$IFJ-:7"W0YOLHB,S,B(QV\7TQRC!H> 6%G@[F8%7X
M@JADTT>1#4["DFXE1K_+.H;4A:2X*4E1F7$NAEOL5Z+DY130FICLBV@L-PD(
M=DK=DH23"%_F*69GZ)*]1GMOZAQ+RFE@/FS*MX$9XE-(-MZ2A"B4Z9DT6QGX
MK,C)/UC+IN/+!=F+*WXV"XY.8:>QZQIV*_+EM24FEE,5U;\9I)&9*<+=SNMT
MD?HHZ[$-XT;P+*L4Q>?/S7%4Y#DDZV@Q3CD_&=[J+%0VPS+Y*5QZ<5O[$?,N
M?0N70!Z#  !
M                                         &M5.F>'T.0R+^LQ2DKK
MV3R-^SB5S+4EWD>ZN3J4DI6Y^.Y]1LH
M                    .I/J8-J<8YL*/,.*\F2P<AI*^Z=3OQ<1N7HJ+<]E
M%U+<QVP                 !UK&MB7$"1!GQ69T*2VIIZ-);)QMU!EL:5),
MC)1&70R,?9II##2&VT);;01)2A);$DB\"(O40_8  Q>0XO39= 3!O:B!=0DN
M)>*-8QD/MDM)[I5Q61EN7J/Q(90 '"4DA))21)21;$1>!#D
M
M
M
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M(^GK]0#8P  0
M
M
M        &"S#!J+/J]J#?US=E$:=)]#3BE))*R(R(_1,O4H__$:C]&W37[*1
MOWSOXQ2P 33Z-NFOV4C?OG?QA]&W37[*1OWSOXQ2P 33Z-NFOV4C?OG?QA]&
MW37[*1OWSOXQ2P 33Z-NFOV4C?OG?QA]&W37[*1OWSOXQ2P 33Z-NFOV4C?O
MG?QA]&W37[*1OWSOXQ2P 33Z-NFOV4C?OG?QA]&W37[*1OWSOXQ2P 33Z-NF
MOV4C?OG?QA]&W37[*1OWSOXQ2P 33Z-NFOV4C?OG?QA]&W37[*1OWSOXQ2P
M33Z-NFOV4C?OG?QA]&W37[*1OWSOXQ2P 33Z-NFOV4C?OG?QA]&W37[*1OWS
MOXQ2P 33Z-NFOV4C?OG?QA]&W37[*1OWSOXQ2P 33Z-NFOV4C?OG?QA]&W37
M[*1OWSOXQ2P 33Z-NFOV4C?OG?QA]&W37[*1OWSOXQ2P 33Z-NFOV4C?OG?Q
MA]&W37[*1OWSOXQ2P 33Z-NFOV4C?OG?QA]&W37[*1OWSOXQ2P 33Z-NFOV4
MC?OG?QA]&W37[*1OWSOXQ2P 33Z-NFOV4C?OG?QA]&W37[*1OWSOXQ2P 33Z
M-NFOV4C?OG?QA]&W37[*1OWSOXQ2P 33Z-NFOV4C?OG?QA]&W37[*1OWSOXQ
M2P 33Z-NFOV4C?OG?QA]&W37[*1OWSOXQ2P 33Z-NFOV4C?OG?QA]&W37[*1
MOWSOXQ2P 33Z-NFOV4C?OG?QA]&W37[*1OWSOXQ2P 33Z-NFOV4C?OG?QA]&
MW37[*1OWSOXQ2P 33Z-NFOV4C?OG?QA]&W37[*1OWSOXQ2P 33Z-NFOV4C?O
MG?QA]&W37[*1OWSOXQ2P 33Z-NFOV4C?OG?QA]&W37[*1OWSOXQ2P 33Z-NF
MOV4C?OG?QA]&W37[*1OWSOXQ2P 33Z-NFOV4C?OG?QA]&W37[*1OWSOXQ2P
M33Z-NFOV4C?OG?QA]&W37[*1OWSOXQ2P 33Z-NFOV4C?OG?QA]&W37[*1OWS
MOXQ2P :3C&B^%89<-6M+0,0+!I*DH?0XX9D2BV/H:C+P,;L
M          G<#6([G.;7'*S#<BL6JJ>BNG7+)PDPV'%-H<,S)<E+II2EQ)F:
M6S/QV(Q1!YWQS3^PI=<\LN++!LKFMV5\U,@7=;?,LUS;)1V&^;T7RYM2^*D+
MW(V%F9$6Q*Z$ N+F7T34-F6NZKD17E.):?.4V2'#;)1N$E6^QFDDJ,]O#B>_
M@8P6.ZSX-E.,-9#7Y74.5#A*/RER8VVE'$N2B5R,N)DGTC(]C(NHE.$:4Y-5
M:SV>83L<99I+QR:PS5>5(6JC-1)WE[=X:%'*[O=PFR-23-'CNX8QV$Z0W<NE
MT=J+S#%1FL.L'_E(YCD5QEW:*ZAJ0V2'%&M)K4C;DDE$?4TEMN"K\6>8R=O#
MJBR*I.TF-I>C0O+FN_?09;DI".7)1&74C(MMAR6=8VJ\;I2R&J.X<-245Q36
MO*%&DS)1$WRY'L9'OTZ;#S]J3@NH^7YZMM%-,.MAY+638+T/Y+:@' 8<94I2
MUKWEF^6SOHD:4[$1%OX'KE1B5OF<K-J6IPPS?=U'58_.SO8R6HJ&)#2UFK=9
M/]X24*0DDH,C)?YQ>EL'J96;8ZFP=@'?5A3FFW'7(IS&^]0AL]G%&GEN1)/H
M9^KUCBKSG&[R S.KL@J["$\^45N3%FMN-K>/P;2I*C(U_P#"740NST)MYFGN
MIT=BDB)O;O*';5M#KC9'90TR&G$LJ<(SXI<0VI'%6Q%RZD6YC\S]);[/GM0K
MEG&7,'7/KZ\J>OE.QN^58PUN/-R5E'<6VDN1MMD?,S-*3WV+8!<[3,H-=;P*
MUM3<R7(EIB.MLRF$KBFII;B5+0M:5'N2.A))2CWWVV(S+F%G>-6-R51$R*JE
M6QI4LH#,UI;YI29DH^[)7+8C(R,]O48B>.:69;(7A>1W%0F/D<S+G<AOV"DM
M+\A:.*^PRWR)6R^".Y1Z!JZF9^&YCYXMHE<4>-X$2<?8BV]?FTNXL'4+9[Q$
M9UR7^4-9*]+DAQHN)&:MC(C+H>Q%DN=2L>JOEF,U:U]A<U45<M^G8L(Z924)
M+?JE:TDCU>DLTI+<MS(=MS.L>BV5?63+NM@V\]"5QZV1-:3(=W+IQ1RW5_\
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MMJ0M:E$M&RM_7T($2"/VC,K<QZ[;;K*Z7?U^25M$V[)@3*QEY$LFC)Q4=_\
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MG.?B:K^L#S\YE[B<Y^)JOZP!: $7\_.9>XG.?B:K^L#S\YE[B<Y^)JOZP!:
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MR7)T)Q^^=U*<R:.[CMW'A2516*PEL\4E*27<M,I:)U+C2E$:C,_14:BW#UJ
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MN$IB/NEIQ"#2XKO4K,VB5RW(SX[%N+\TX3K:%D2DDHB/91;&7]Y'X C]@
M
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M[%NDNG0N@[=960Z6OC0*^(Q @QFTM,18S9-M-(26R4I2DB))$70B+H [(
M                           C>E]H_1Z)9C8Q324F'?9=(:-1;D2T7-@I
M.Y>OJ1"R"8:"QF9NG-S'D-(?CO95E#;C3J24A:3O)Y&DR/H9&738P&I8GFN:
M9/(Q:D7=3*:5;P'[-VPLZJ.EXR;2P1-,(29H-)F\:C4HC5LG;8O$M:LM>\R6
MY0JBO,I=<B;+-F"E<*4^5BJ(3CCBED;#*R22B,E'L:B_.Z;^AKW!\<RBMC5]
MS0UEK C&1L19L1MUMK8N)<$J(R3TZ=/5T'T7A]"[%.,NDKEQCBE!-E41LT''
M(]R9VVV[O_@\/U (C<:B9PFLU+M694V)$I),J/ ?\DA*B$;;B"(MS6;RE;&K
M?D@D^.Q^ SGG(M_G+-E3;=Z%2U^0-4!08=<AY3BE$T1.27#/=!.*=+CP(B(C
M(SWWZ;_)THPB;)L)$C#J!^18$93'7:MA2Y);D9DX9IW7U2D^N_@7L'8F:<8G
M8W4>WE8S3R;6/P[F<[!:4\WP_,XK-.Y<?5UZ>K8%2'#M;\BF9-04-V49J5:W
MLQ$1]MKBF77M^5)XEUZ.-N,H)6WB2D'_ +Q[;HG(L@R'4'*(<2U;K*W&CC$=
M>U%2Z]/YM$ZI2E*/T4'OP3Q(CW2HS,_ MX+%:4G("RIX!+@.N/PU%&1O&<7R
M[Q;9[>@I7-6YEL9\CW\3'7M,&QR[NX=S8T%9.MX>WD\^3$;<?9V/<N*S+D6Q
M]2V/H?4$1B-JIET#&<;R*1<0;-&3U4R:BN:AD@J];<1<A!H42C-:4FDFU\]]
MS41D:?S1K]9K5F\^F@H5-EDM^VBPN_13-G8?E(+LA:?)B49&CDEKBO9.Z35[
M.0] 0-.,3JIT^9"QBGB2[!"VY;[$!I"Y"5GNM*S).ZB4?4R/Q]8[R<3I$369
MB::O3,9)LFI!14$XV2$J2@DJVW+BE:R+;P):B+Q,!%SU U FU]\Y/L*W%;3&
M**-9S(+D1+J)3ZVW'%=X9K/@U^3X;(5N2N7I'L1#X4VM&36>J\:O6HXE2_+9
M:7$EPT(8:9.N1)<VD<B5WZ5+Z(V/=)'T+8S*S7^!8SE4Z+-NL>JK>9%Z,2)T
M)MYQKKOZ*E),RZD1]/66X[$[$:*S3(3,I:^6F0\F0\3\5M9..I22$K5N751)
M(DD9]=BV\ 'G@M>,HR?%,TG0YKU!*@)*WIS?IUME)KUK-M"?RZ")S8TI6:V]
MR_*I+<;/E>=9;B66R*!%^W*[UNHC-SID)HD1W)4AYM;RDH).YDEI))29[<E%
MON706*7BM+8-MMRJ>!);:8.*A#T5"R0R9I,VR(RZ(,T(]'P]%/L(=>PP;&[:
M3829V/U<R18,)BS'I$)M:Y+*3W2VX9IW6DCZDD]R(%1O(-3LZQJT?HH#T3);
M"MO&(ZGCC$TN=&5"<DKCF23XI?+N]B46Q>DC=);F*+H]J 6I>/65RT^B1"^4
MY#$1:$<3[E)EP)1?6+?8]^NXV&HPG'L?AQ8E915M=&BO')89BQ&VTM.F1I-Q
M)$1;*,E*(U%U,C/VCNU5+7T3+K-; C5[+KRY#C<5E+25NK/DM9DDBW4HS,S/
MQ,_$$=T                                    3[-[6;#U5TVAL2WV8
MDQZP*2PVX:4/$F*:D\TET5L?4M_ Q01--0/^N+2K_P!_9_\ )J%+       !
M@LUR1S$,;EW*8*K!F'Q=DM-KXK2P2B[UQ);'R-".2N/3?CMN-#@:X3[.PJH$
M?%'?++Q'E5,3LHTMR8A*7S>=5W9]R:4$VK@9*/\ +-EON9[5*?!8LX,B')1W
MD:0VIIU&YER2HMC+<NI=#]0Q\?$ZJ+*J)#47B]4Q5PX2N\6?=-*)!*3MOZ6Y
M-(ZJW/IX]3 3,NT02:1R]=QB:W11Y":Z4_S,WVIW ^3!-</2(GN#',E;&M?A
ML1F-\D9=)A3,6KWZU*;:XY&_&1(Y)B(0US=7RX^F25&A'@6YK+P'97@M&Y42
M*Q4'>#(FG8NM=ZOTI!OD_P ]^6Y?E")6Q'MZMMN@[ZJ."J\1<*8Y6*(YQ$/&
MM1\6C42C22=]BW-*3,]MSV+KT(!),J[2K.+(SAIR@6]88_+:CQ(I2^/RBA2>
M2G"5P/AP)+IJ+971!'OZ73YW':99J(N1$K'U+LJNY16,0_+"+RMDU*(Y)*X>
MB22;?W3L?5LBW](AO5OHWAU]/?FSZ5$B6^4E+CIOND9D^A*'O!1;<DH273PZ
M[;;GO^9NB^&6,YR;)I$.RG$O(4Z;[I&9.N)=<\%^M:2/]74BV(S(RLS:Y1\G
MY324;,;RF18)>><5WG$H[#:2W<,MCWW6MM)%T_.,]^FPGSVNLZOCR)T_&V&J
MQ<BSB0GH]D;CCKT,GE&3J#9239+3'69&E2]CV(R%/31P47CEP3'_ /,5QTQ#
M?-:CV:)1J))%OL751F9D6Y]-]]BVUAG1K$F9,Q_Y/D/*EE*YMR+&2ZVV<GEW
MYM-K<-+1KY*W-LDGL9D70$<8+J#.R2U=JKBG8J+$J^/:-%#FG+9<8=-22]-3
M39DLE(,C2:=NI&1GUVW<:[B>G]'A)OJJH[Z7GT-M./S)K\MXT((R0CO'EK42
M$[GLDCV+<^G4QL0
M                                              )IV>__ ,A6G_Q9
MD_\ ]]GBEB0:21K:9H]E#%%,9K[IS(\K1"ER6N];9>.[G\%*1_O$1[&9 *^
M\0L]O:ZPG [O%,SQ\UZ\U<Q%1%HHS"B:M7G#V9DM[?\ JS+8S(CZ]-MN1;>L
M-)F,OCZ=4:<]EQ)N7&P2[!R"T3;1.&9GP21=/1(R3N7B9;@K;@  0
M                                              334#_KBTJ_]_9_
M\FH4L334#_KBTJ_]_9_\FH4L
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M&.?&$!%G 2[%NU%I-F^00J.AS^CMK>:LVX\.-))3CJB(SV27KZ$9_P" J((
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M0<2]A#D ''$O80<2]A#D ''$O80<2]A#D ''$O80<2]A#D ''$O80<2]A#D
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M<S5Q*])\2]A!Q+V$.0!''$B]1#D
M
M
M            'Y-"342C21J+P/;J0T'4#2%&H[S[-EE5_'HI*4(E4,145,60
ME)D9I4M3"GTDK8B42'4[E_B*  #YDPV26R)"=F_S.GYOJZ#Z
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
*          #_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>tm2533062d1_424b3img05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2533062d1_424b3img05.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 1, U$# 2(  A$! Q$!_\0
M'@ ! 0$  P$! 0$!          <&! 4( @,!"0K_Q !A$   !0," @0(!@X%
M"@(*  <  0(#! 4&$0<2$R$4%S&5"!4B5E>6TM,8051FE-06(R<R455A9Y*3
MI-'BXS="<76T)#,V4G-V@;*SM35T"24F-#A#8G*1L5.C1*)C@Z'_Q  6 0$!
M 0                   0+_Q  8$0$! 0$!                $0$A8?_:
M  P# 0 "$0,1 #\ _P!4P
M
M
M
M
M
M
M
M
M
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MV0FH.Q9U)1*DJKM/:2:B)3B<\/*L%CD6<@L>M   0
M
M
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M)J+^MY1Y(A[H "@  (
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MGUDG?40\=^$'YHZ<^LD[ZB+0 "+^._"#\T=.?62=]1#QWX0?FCISZR3OJ(M
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M\(/S1TY]9)WU$5>WG*J]0X*ZXQ$BUA3*3ELP'E/,(=QY1-K4E*E)SV&:2/\
M(0[$ 0                'RM.Y"B_"6!X)T._\ 1Y7MH3%NV12+KMR9<5:@
M)IT6I3(*G6H31N$I[,=Q"TN[TI).%&1%^ Q[X %>!M;?_1W7GKA5K7K=2NNW
MJ?<%,IK5/GS8T-:6IYMJ,VW"90E"6L),D[2,R\DL8[!Z^U9TO+5*+;#)U+Q:
M5%KT2MF9Q^-Q^ :CX7WR=N[=]]SQCL,;L875O4MS3.DTAV/3F*C.JU2:I<5$
MV;T.*AUPE&2GG]B]B?),N2%&9FDB+F!4.5X"J:>YJ=&H5\.TBBWG';A-4_Q;
MQ/%<;CJ>?9:7QDY2LW'"+D6PEG]\.?-\!NCTYN\(=J7-.H5'N>W"H4R%/XU3
M43B%Y:D)<=?W%L3E'#+E@^1D+'*U-;LZWH,N_&HEO526ZMENGTM]ZJ&Z:<GE
MK8PAQPMI;C^UEM+M'"@Z^6E5;YI%L4^3*J,BJTY-3BS8<-UZ*MI2R0G+J4FE
M.>?,S(BQ@S(\$!U(4> Q$9N"JU-N[G"3)K$"J0XRZ?N1!0P_TA]E'VWF3SOE
M&KEMY<E8&OT[\'&K:>:P7)=[%T4B;2JY5I-5>I[MMI*:TIU!)X:)O'-1)+!'
M@D<^?(LBAWGJ_:&GU0:@UZL)A2EL])4VEAUXV6<XXSIMI433><EO7M3R/GR'
M/?U%MN.5;-=69VT6&W4)ZDDI268ZT*6AS)%A1&E"C+;GL 8[6?1:;J/6K4N6
MWKD.T[OMAYYR!4%PBF,J;=1L=:=9-2=R5$1<R41E@3]WP,V:S;3L6XKI17ZU
M4KLBW57)\JE(X$\V2VE%3'XF&VS1Y/,U_'DCS@5>V-:K<NV_:K:5/Z>Y4*>R
MP^I]4!Y,=Q+J#66UTT[2\G!\S+.>6<'C*WOX2]'H-.U&;ID64_5[-8XCZ9D-
MYJ*XK8A9_;MNTB(EEVF1GVEDN8"KTFWJ70*,U2*738E,I32#;:A0F4LLMI/)
MF24)(B(N9]A?&(?8W@R5NS:!4K&=OI%3TKE,S8[=ONT=*9C34C?EOI9.\TH-
M9F1\//81F*)1]<;)K--JTUNO-,,TF.B5..8R[&X32\['2)U*36A1D9)6G)*,
ML$9CNK-U H-_Q93]#G'*Z(Z3,AEUAR.\PLR)1$MIQ*5IRDR,LI+)'DLD"(O9
M/@L5^E5ZQ7+KU$5=5OV,:E4&F-T=$1Q*^&;3:Y#Q.*XIH0>"PE.3YF,I!\ *
M'$7!-5YN.-L4J;!>8*F[6Y$ATY1,2E%QCYLIF.I)/];D>4B[T37:Q;BK\>C4
MZOHDSI#[L1G$=Y+3C[>[B,I=-!-FXG8HS1NW8+.,#]V=:+.>JE2IQU93$NGQ
MWY;Z),-]DC99/#RVU+01.DCXS;-6,E^$%3F@^"#;;%]V[<5R>+;N;H=KP[>B
MPJE24+2AUA>XI:36M1)499+;CE_K&,U<O@+4VZ9%TUV7=U01?%6KB*U#K3!/
MHCP#;6@V&^AE(X;O#2@TDI6#\KECL%/+PGM,U;MER&ZHF2DH;:I\I:WF#R?&
M:231FZT6#RX@C07QF0[JNZWV/;::>N?<+"&YT5$YEUEMQY"8RL$E]Q2$J)IH
M\\G%FE/Y>0'4CU&\"Z-J+0;WCR+J5 K=>K95R#5X]/\ +IKAQD1W&R3Q?MB%
MH2HC+<GDO'Q9/;5?P>V:NK1U3E702]/'6W$J5!)1SML7@8+R_M7/"_Z_81?E
M%#NN]:)9-$\;UJH-PH!K0VAS:IQ3JUGA"&T((U+4H^Q*2,S^(A+]0_"4I=*H
M]MN6FXU5IM=JITIM<B'+4B&M"%+<XS3;9NI61)(N&9)5Y6>PC,!; &#N[5^C
MV#<-JT&M(FKJ5?XB6E0(#[[:#;1N49[$J,BS@OPEG)X(C,9_3WPB[?NJHR*1
M4Y35.K15N;1V&$LO&RM;+RT(0;QIX9.J0C=PS5N//(@17 &.I&KUH5ZZ5V[
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MDC(C[!]P]>+8CV_;4NKU*.W4*Y$3+8B4AN1/W(/!&XDD,DYPR,R+>M"2Y\\
M*2 Q\K5NU8-TE;LBHNL592E(0VY"?2VXLFS<-M#IHX:U["-6Q*C5@CY#.61X
M0%#U&*W'J*E;,:JRY,4TU5A^(]]J;=7EDE-;7<\+)^6DDI,^>XMH"I@,!2M>
M;#K;\QJ'<3+AQ8[TM2U,NH;=99_SKC*U()+Z4?&;1J(AS+-UBL_4"IJ@4&LI
MG2NCE,0DX[K1/L&9%Q6E+0DG49,BW(-1$9ES ;,
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MW%6:VDN8+<2%&1&:<YP9D1X^(<H
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M]C7#;].J,/QA3JG/0RMA]GR<$LVG%FRX9*2HD.8,RS\9&14@
M
M
M                9O46PZ;J;9=5MFK&ZB%/:V&['5M=961DI#B#^)25)2HC
M_"1#2  BKVBUZW@[1:??M]0*];-)ELS2A4VB'"D5%UE1*:.6Z;[B3)*B2HTM
MH02C(LX+D.2SX/A-6C3J&=>W%$NY5TF]T/[_ #+7(Z/MXG+[_;OS\6=OQ"P@
M AE,\&ZI1*0FTI-\R'=.6>EI9H4:#P)2VGTN%P'Y1.&3K2.*HTI)M)Y).XU8
M'$D^#/7;@I<:G7-?Q5B+2J/,I%%)FCICJ8Z1'..;\@R>5QW$MF9%M)I)Y,\9
M/(OP /-TO28J]X05BI8C50J;:-(:16)S\%;$*HO,D704H6HMKJD*<></8:B3
M@B,\X&D=\'&3(N*7)=N9IRC.W8BZVZ>=-/BH<-E3;K)O<;"DJRDR/81IP9>5
MGE;0 1&W- +GMZDPK?9U,FQ[6I,9^/28D"G)8E-$M"D-](>-Q29!-$KR4\-!
M&9$:MV!R]'_!]7IG>M5NB74Z3(J,^$W!<9M^AII$9TDK-7'?;2ZX3KYGRWY2
M6,D22R+& "*S=%KYI][7M6;6O^DT6#=4AJ1(B3;:5,>84B.ACR'>EH3S)&?*
M;/F?QCI3\#ZELTJ'3XEQRXS4"@PZ5"?Z.E3S,F-+.4W*,S/:K[9VM[2+&2S^
M#T( "#5_P:ZS>D6XIUR7NS.NNI1X42+48E'Z/$A-QI!2$$48WU*7N<+*S-TL
M]A;<#C57P6)<VX:Q48URTF*U7GVIE6XUL,R9)2"0A+JXCSCA\!+FPCVK2[M,
MSP8]!  CL?0JN4:NU)%!OIZB6E4ZN5:ETJ/ +IG&,TJ=;:EDX7#:<4@C4DVU
M'A2B)1$8^J3X/OBNUK)HWC_B_8W<3E?X_0\=)W./KX6WB>1CCXW9/[WLY\K
M #"7MI?]F-\VI<7C/H?B)B>ST;@;^/TEDF\[MQ;=N,]AY[.0R"?!IB2+2T[M
MZ?6CEP;5I\JG/[8NPY[;\1491EY9\(R)1J_K?@_*+4 "16EI+?%M1V&7M2NG
M-TNEKIM'9*C\)ILS))(?F()\RE.()!$6.$7-7+)Y%8C(=;C-)?<2\^E!$XXE
M&PE*QS,DY/&3^+)C]0
M
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M #YZ[M.O/ZU^^8WMAUW:=>?UK]\QO;'UU+:>^8=L]SQ_8#J6T]\P[9[GC^P
M^>N[3KS^M?OF-[8==VG7G]:_?,;VQ]=2VGOF';/<\?V ZEM/?,.V>YX_L /G
MKNTZ\_K7[YC>V'7=IUY_6OWS&]L?74MI[YAVSW/']@.I;3WS#MGN>/[ #YZ[
MM.O/ZU^^8WMAUW:=>?UK]\QO;'UU+:>^8=L]SQ_8#J6T]\P[9[GC^P ^>N[3
MKS^M?OF-[8UE.J,2KP6)L"4S-A2$$XS(CN$XVXD^Q25%DC(_PD,KU+:>^8=L
M]SQ_8&KI].BTF"Q"@QF84-A!-M1X[9-MMI+L2E)<B(OP$ Y
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M;]=MRYH=(J==JE0CS4W#%71U,NN;FE'"2Z;G%41??&GEDLX'JH !
M       ?FZ^VSG>M*<)-6#/G@NT_^ XE"KL"YZ-#JU*E(FTZ8T3T>0U]ZX@^
MQ1 .> ^5K2TA2UJ)"$EDU*/!$0+<2VV:U*)*"+)J,\$1?AR ^@'7,W#39%>D
M45N8VNJQX[<IV*1^6AI:E)0L_P AFA1?\!V(            #A5BM4^WJ<[/
MJDV/3H+1I)R3*<)MM.Y1)3E1\BR9D7]ID YH /E+B5FHDJ)1I/!X/.#_  &
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M54WE,0VE]KSB4*6:4_E)*5'_ ,!V(
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MA/:N"LU&VK'K\)^7'GS')3BJ;)B(Z0E2UF:EDVI?&3N,S+89$>!K'*S=%/\
M!2NJZ)]2F1KDGTF?6V5FX>^!Q$K<8:1_J\-!MEC\)&*;J'I['U)I+=)J%4J,
M.D*61S8,%32$3V\D?!>4IM2R0>.9-J09D9D9F1X&I0A+:$H0DDH26"218(B
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M,?L'8 (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                         ^7'
M$LMJ<6HDH21J4H^PB+M,>4E_^D\T%0M2?'U3/!XRFDO&1_\ _!ZBK7_@T_\
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M+]1ZE[H/A44+S'U+]1ZE[H6@ $7^%10O,?4OU'J7N@^%10O,?4OU'J7NA:
M1?X5%"\Q]2_4>I>Z#X5%"\Q]2_4>I>Z%H !%_A44+S'U+]1ZE[H/A44+S'U+
M]1ZE[H6@ $7^%10O,?4OU'J7N@^%10O,?4OU'J7NA:  1?X5%"\Q]2_4>I>Z
M#X5%"\Q]2_4>I>Z%H !%_A44+S'U+]1ZE[H/A44+S'U+]1ZE[H6@ $7^%10O
M,?4OU'J7N@^%10O,?4OU'J7NA:  1?X5%"\Q]2_4>I>Z#X5%"\Q]2_4>I>Z%
MH !%_A44+S'U+]1ZE[H/A44+S'U+]1ZE[H6@ $7^%10O,?4OU'J7N@^%10O,
M?4OU'J7NA:  1?X5%"\Q]2_4>I>Z#X5%"\Q]2_4>I>Z%H !%_A44+S'U+]1Z
ME[H/A44+S'U+]1ZE[H6@ $7^%10O,?4OU'J7N@^%10O,?4OU'J7NA:  1?X5
M%"\Q]2_4>I>Z#X5%"\Q]2_4>I>Z%H !%_A44+S'U+]1ZE[H5>WJTW<E#@U1F
M-,AM3&4O)CU",N-(;)19VN-+(E(47QI,B,AV(                  XE6;4
M]2IC:$FI:V5I2DNTS-)X(?Y$>#-X.FI5K_9_;MTV)<]NP+NM]RD-UQNE.R"A
M.&M"TFM#9&LT*VFE6TC/GV#_ &" %K_$"M> [JI:-_08]'M>M753&'F'%56-
M29$9HSW$:B)+R4KPG\)D61_J;X4MHW7<36G%3M*W';IE6[=4:L2:>Q,CQEJ9
M;;=(\+>6A.<J26,YY]@N0Z>Z;RH%C4SQC<=<IMOT_<2.EU26W&:W'V%O69%G
M\F0*\>WOH9J;6-)M3)B+-)RZ+[NB%54VW J<4RIS#"FS-3KSCC;:EJ)H\[#/
MFI/Q9,OY?'@Y:A7+JQ=U\IHLZ31WZ]0ZHFSW:G%;9J[++"4N[S2YY+K#A$:=
MRR0K:?WQ&1CV=1JU3KCI<:I4F?%JE.DIWL3(3R7F74_A2M)F2B_*1CE\1.\D
M;BWF6=N>>/P@5Y(M/2*^J;X1FHE4EV_=$2WKEJ*WHU3@7#$;IJ&U0TM;Y$,G
MN(XLE$>,)R6"/L+(V_@K4^_=-K0H>FUR6 Y3H5"CNL?9.Q4XSL29A9FA:&DK
MXI*62LGN26#SGM'H( 'D![P<[WJG@O7/:9T]B+<IW=)N"% E2FS:F-%/Z0VA
M2T*4E).(+X^PS+=@?G>&F.I>M-Q7Q=T^Q568ZJPY=L4ZCR*I%?D5"2\9KR:V
MUFVAM)^21K47;GD0]@FXDED@U$2U$9DG/,R+M_\ V0&XE*TH-1$I6=J3/F>.
MW %>9?!;T2NS1Z]ZFY<D696VZE;]-:9N*9.9<=@FRV27*:IM*B\A"S4I"T(,
MC+D:C,B,<777P=KGU)UBK=U4=DJ?-IUO0G;<K)O-EPZK'DNN$V:=VXDJ0O:H
MS+:9+/GR'I6AW#3KDBO2*9+;F,,R'8KBV^Q+K:S0X@_RI41D?]@[$!X8HO@\
M:P75I]I=:-1I<"T6J=4:I<%9?J!L5*,W)6\Z<9@V6GTFYY+RU9(\%RR>2P./
M6/!CU2NG3'3JTJI2DJG66NM18U53+8)*T):(Z;(2GBFI)*6AM.T_*3M\K!<Q
M[0NR_*!8S<)5<J;4 YKW1XS:B4I;SF,F2$)(U'@B,SP7(N9COB/)9 KPQ1_!
MPU0EKORX*S;Z"N6\;(J;$U#<Z.HDU-^09M125Q,82REI._[SE]\.50+,NNP[
M3TI>NR@W33(-O753SGIN&N,55"$JBN1TNL\%Q9,LH=4CR58QN(_B'KZEW_;U
M;E0(T&K,27YZ9*XS:#/+I1W.&^9<OZBSVG^4: "O*=IVG>MBZ\5:X*?;52L7
M3AY<^=<K-0K46939RMIFW)BLI4;K+BS+<O))+'(RSVT?P6X%2M[P;+;)RFO)
MFFQ+FQZ<YAMSANR'GF&_*,B2>Q;9<S+'QX%E !X>TQ\'362Q+QM"_*@5/J51
MJ<VHG<5&C-M-28C4[*UJ<DG(-$@FUH9PE"2,B+ED=!1?!*U+LVFZ6+HM&03,
MF;3'[QI)S6"Z(_#D[VYB#XFU9FT9H42#49X3R,Q_H  %>)+AT0U1N<M3;$19
M3<*A79>_CU%VRZI&-J-$)QE6Y#"%J>-P^$>"-*<;N9D/0WA*V_=UT:*5RVK)
MBG*KE80W3.,IYMLHS#BB0\^9K4G.ULUG@CW'GD0JHZZCW!3J^J<5/EMRS@RE
MPY/#S]J>21&I!_E+<7_Y!'B>K>#+JO:VGFK]C0H<&ZZ;<=-I\JF2:6EFFLE-
M96VTXQP79"C29M-(4:S/:9I[2,\#NKYT4U,U9B:G7/,L]%L5*I64FUJ5;ZJG
M&?DS7"<XANNN(5P4%_521K/X\F0]?5&X:;2)].A3)C<:545N-Q6EG@W5(;4X
MLB_L0E2O["'ZTBL0;@ID:I4R8Q4*?*03K$J,X3C;J#[%)47(R_*0+7D"KZ,:
MEZG%<M?J=G(M.5'T]D6E3:0Y4XTB54I#B<[W%MJ-IM!&1$DE+[3R>!T4+P8=
M1+?TYU-H#M)F775KELN%!IU8F5*-QHSK;1)52U$:TI)"5FI2'$EM,N2E&9$9
M^Z  KQ\YI==,_0J#0ZQIQ?M3K$&IM2(JI%Z0EU2GNH9(DRHC_&-"4)5E)-&K
M^L9X,AU-W:<:V5&U;&J?V-U5W6*G4XV$WE2J["8:9(WU&4:>RI1)?;V$A2C;
M2K*L[?R^UP KQ%?6FUW7C8FOMDPZ6Y4KXGW'3JRVTP^W&.5%448R6TZZI*2)
M/!=265<C3CM':7[IM?=8T^MI=+T_OU%\4IV8NEUV3><!VITQU>W:3SBG30]'
M<[%(RHR)&,%D>N*M<-.H;].9GRVXKM1DE$B)7G+SQI4HD%^7:A1_\ JUPTZA
MOTYF?+;BNU&242(E><O/&E2B07Y=J%'_ , *ANG4>O3_  CHTJLI;?J](L&-
M3[@FQ48874'9"'20D\$1F24.JP782R[,D/08 "        .NH]P4ZOJG%3Y;
M<LX,I<.3P\_:GDD1J0?Y2W%_^1V(  #JJI=5'HCS[,ZI1HK[,-RHN,N.%Q$Q
MFS(G'=O;L2:B(SQVF7X0':@.JIETT>LRDQH-2C2I2HC4XF&W"-SH[F>&Z:>T
MDJVG@S+G@QVH     .NKEPTZVXK,BIRVX;#TAJ*VMSL4ZXLD-H+\JE&1%_:%
M<N&G6W%9D5.6W#8>D-16UN=BG7%DAM!?E4HR(O[0'8@    ./4*C%I,%^;.D
MLPH<=!N/2)#A-MMH(LFI2CY$1?A,!R &>JFH5LT6%5I<VNP&(])2VN<LWTGT
M<G"(V]Y%S+>1EM+M5DL9':4:L1+@I46I0'3>AR4$XTX:%(-23^/:HB,O^) .
M: Z&7?=O0)E0BRJQ$BOT]<=N4E]TD$TM\\,I,SP65GR(OC,=?4=6K/I-3K,"
M97XC$FC,=)J)+,]D1&"/[8O&U)X4D]IGN\HN7,!K@'7T"OP;HI$:J4UXY$&0
MDU-.FVILU%DR^]41&7,C[2'8   /E:TM(4M:B0A)9-2CP1$ ^@'%3582ZDJG
M)F,'4$LE(.(3J>*31GM)>S.=IF1EG&,D.4  .@K5^4"WJ_2Z)/J;3%7J>>B0
MB)2W'"(R(U821X3DR+<>"R>,COP        '75*X:=1YU,A39;<>54GE,0VE
M]KSB4*6:4_E)*5'_ ,!^E&K5/N*FLU&ES6*C ?(S:DQ7"<;7@S(\*+D>#(R_
MX .: #^*42$FI1DE)%DS,\$1 /Z _B5$I)&1D9'S(R^,?T  !TEW7K0[#I::
MC7JBU38BW4L(6YDS<<5]ZA"4D:E*/!\B(SY'^ !W8#\69;+[+#J'"V/$2FS5
MR-62R7(^?9\0XE*N"G5Q^HLP);<IVG23B2TH[67B2E1H/\NU:3_X@.Q
M          ==7[BI-ITE^J5NIPZ-3&"(WIM0D(89;R9$6Y:S(BR9D7,_C =B
M PL+7?3>J1Y;U.ORW*HB(A+D@J=5&92FDJ6E"5*2VI1D1J4E.<=ID-T   ZZ
MN7#3K;BLR*G+;AL/2&HK:W.Q3KBR0V@ORJ49$7]H#L0'"IE:I]:*4=/FQYI1
M9"XKYL.$OA/(^_;5CL462R1\R'-   ?+;B74)6A1+0HLDI)Y(R ?0
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M;WK2DN1[2_#S',C56-4:A4*>3,CB0S;)TWHSB&E[T[BV+4DDN<NW:9X/D>#
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M3W#U/#C)A1&(Z5N.)90ELEO.&XM1$6,J4?-1_A,^9C]@
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M1L/O-DOM,LI)6%&1[3,O3];KU,MJFNU&L5&)2J>UCB2YSZ66D9/!96HR(O\
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MR4VHU<7CLO%CLLX""*,\<A4DC,C8*/LXO%+!Y1LW8(SQ@92U?"(AW)$=J!'
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MAHSZ+M6985Y1*2:L&;BL7H 'PT:S;1Q"23F"W$D\D1_'@Q]@
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M\R4?,;76'3J9J;0&J2PNWNBFI1O-W!1EU!)'CR'&MK[1MN)/)DK)]OQ=HWP
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MWM.GWQ3KIM>+<<VY9+33]0*0^M-46RZYTY/#,SCJ)))V;MG&RWL["P ]/@
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M\0YVA#%ULWC$1<K]R+-NF1$-E5D512%J**7$-2S/HV[?G=Q"->[LYX >C0
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M64JVJ(E%DOB,B,!V@
M
M                                              /.'A 5.W*)JG2J
MA5+NJ^E%8125-0;R:X*J=+0;N5PGTO(6V9I,DK(E;3/=Y)\C$CN*^;HK%F6J
MY49U)IMEOW'4FJA<Z6I5$IU92EM)QI4@XZB6TEU9N95N)"U-I,SP9#W6 *\"
MS[BN0K7LIBJWC">T[>J-5(JO49]3B4U6WA]%9<F$I+SC19?X:UKV+VIYJVD/
M2G@\5:IHT*.=4:M)N1+*YJX4QAM]3KL9*UFTEM4@N([@BVH6K.\B2>3SD68
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M$F5!M32F'U$M.">6THB4C<I*N1D6#(R^(;D !
M
M
M $U5UP;CV_81C/+/3!2@ 33[L7S'_; ^[%\Q_P!L%+$RUCNQ5MU.T8[MW?89
M3)\N0W+J.8J<DF.M:$[I#:T%E22["R?9D!]?=B^8_P"V!]V+YC_M@DU+UGNV
M;4*CXPN%JG/Q[=*=&@J<B1U2'.%)-+Y1W65/+W$VVO:E:23GF1EDAH+BUDFS
MIEOS+7N^)4VVZ [5IU.@KBOIE*8=C*>3DDFM*C:6\6$J+!XY<@5N?NQ?,?\
M; ^[%\Q_VP3JC:KW)5K^H/2KE13Z36H9U6#3G'H<8W&5R5I801.,J<=,VDMF
M:4*2K*SY]F.JM35G4%-E3J[(J3LV73XE.GG2ZNW%;7,;D)6E:T*8;(DL[E(-
M':LE-+2K!&1 *U]V+YC_ +8'W8OF/^V#L[QN"JV!I<[)<>56[D1';BL*0TA*
MI<YPR;;VH+"2(W%$>.1$1<_PB,KUFK?!B0ZW>+MHUJFTF<F1'DQX:7)]08=;
M)HE-J0LU&XVM"^&RHC/B8(^P!4_NQ?,?]L#[L7S'_;!-(NK]R.3Y2CN4E7$5
M4**[:'"C*Z)&.&AQQW"6^,GAJ4I6]:C2>-N.9#/Q-9+T9MZD>-+H>I+\F=!2
MZY57:;$D$T[ =>-?%Z.IA+2W$EL/::LH6DS(^1!:_NQ?,?\ ; ^[%\Q_VP3R
MN:FUN%6JW3F[_@%)-*)$1U%1II1&(Z5LDXTZI3!J9DJ)2B2IPEM*-62)/(DV
MO3NX&[ILBC55IZ9(1*CDLG9Y-$^OM(S5PB)L\X[4%M,L&7(P&7^[%\Q_VP/N
MQ?,?]L%+ $33[L7S'_; ^[%\Q_VP4L $T^[%\Q_VP/NQ?,?]L%+ !-/NQ?,?
M]L#[L7S'_;!2P 33[L7S'_; ^[%\Q_VP4L $T^[%\Q_VP/NQ?,?]L%+ !-/N
MQ?,?]L#[L7S'_;!2P 33[L7S'_; ^[%\Q_VP4L $T^[%\Q_VP/NQ?,?]L%+
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MJ!TBH0-3RJ\&J522W%@N'35OE&1"?6WQ2:82:5..-I7MP1DDTI/GD:BVKNU
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M
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M<8^,?0        ^20DBP22(LYQ@?0
M
M                            )IX17]%DC^]:1_W*,*6)IX17]%DC^]:1
M_P!RC *6                 R&L7]$=[_W'._PZQKQD-8OZ([W_ +CG?X=8
M#L[%_P!";>_NZ/\ ])([P='8O^A-O?W='_Z21W@                 )IX.
M/]#E#_VDO_%/"EB:>#C_ $.4/_:2_P#%/"E@
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M2*S*Z6RRJ.P3\]]YJ,VK;E+32UFALCV)^\27))$-*
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M\T5"03#NU&Q)J8W\(S)/(C-&>1'VC0   ,_J#_H%<O\ =DG_ *2AH!G]0?\
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M&A#CBDMY4I1X01%S&@
M
M              $T\(_^AJO_ /W1?\4T*6)IX1_]#5?_ /NB_P"*: 4L
M            !G]0?] KE_NR3_TE#0#/Z@_Z!7+_ '9)_P"DH!P])?Z*K,_N
M6%_T$#6#)Z2_T569_<L+_H(&L                 !-/!U_HM9_O>L?]SE"
MEB:>#K_1:S_>]8_[G*%+
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MFGC2ZAA9E]M-1DG'-&,F1\AZ':)1-()9841%DB5NY_V_&/L
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MS2E)XR:3;/XRS\8K@
M
M
M
M          )LO19Y:U*ZP[W3D\X34V\%_P#R@%) 33J4>](E\=Z-^Z#J4>](
ME\=Z-^Z 4L!-.I1[TB7QWHW[H.I1[TB7QWHW[H!2P$TZE'O2)?'>C?N@ZE'O
M2)?'>C?N@%+ 33J4>](E\=Z-^Z#J4>](E\=Z-^Z 4L!-.I1[TB7QWHW[H.I1
M[TB7QWHW[H!2P$TZE'O2)?'>C?N@ZE'O2)?'>C?N@%+ 33J4>](E\=Z-^Z#J
M4>](E\=Z-^Z 4L!-.I1[TB7QWHW[H.I1[TB7QWHW[H!2P$TZE'O2)?'>C?N@
MZE'O2)?'>C?N@%+ 33J4>](E\=Z-^Z#J4>](E\=Z-^Z 4L!-.I1[TB7QWHW[
MH.I1[TB7QWHW[H!2P$TZE'O2)?'>C?N@ZE'O2)?'>C?N@%+ 33J4>](E\=Z-
M^Z#J4>](E\=Z-^Z 4L!-.I1[TB7QWHW[H.I1[TB7QWHW[H!2P$TZE'O2)?'>
MC?N@ZE'O2)?'>C?N@%+ 33J4>](E\=Z-^Z#J4>](E\=Z-^Z 4L!-.I1[TB7Q
MWHW[H.I1[TB7QWHW[H!2P$TZE'O2)?'>C?N@ZE'O2)?'>C?N@%+ 33J4>](E
M\=Z-^Z#J4>](E\=Z-^Z 4L!-.I1[TB7QWHW[H.I1[TB7QWHW[H!2P$TZE'O2
M)?'>C?N@ZE'O2)?'>C?N@%+ 33J4>](E\=Z-^Z#J4>](E\=Z-^Z 4L!-.I1[
MTB7QWHW[H.I1[TB7QWHW[H!2P$TZE'O2)?'>C?N@ZE'O2)?'>C?N@%+ 33J4
M>](E\=Z-^Z#J4>](E\=Z-^Z 4L!-.I1[TB7QWHW[H.I1[TB7QWHW[H!2P$TZ
ME'O2)?'>C?N@ZE'O2)?'>C?N@%+ 33J4>](E\=Z-^Z#J4>](E\=Z-^Z 4L!-
M.I1[TB7QWHW[H.I1[TB7QWHW[H!2P$TZE'O2)?'>C?N@ZE'O2)?'>C?N@%+
M33J4>](E\=Z-^Z#J4>](E\=Z-^Z 4L!-.I1[TB7QWHW[H.I1[TB7QWHW[H!2
MP$TZE'O2)?'>C?N@ZE'O2)?'>C?N@%+ 33J4>](E\=Z-^Z#J4>](E\=Z-^Z
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M*J#<1M+\& DDL,+))90@B,R))=A$1F1?$9]H[P 0
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M/&#I^CEI5*U;2S7G'9-QS'EO3Y+ZT*<=,CV-Y-!FG!-(;+!?E^,S&Z
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M]N(C+."^,5X
M
M       33PD?Z%+F_P!FS_UVQ2Q-/"1_H4N;_9L_]=L!2P
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M.)K%\GL?Z1,]@.)K%\GL?Z1,]@!2P$TXFL7R>Q_I$SV XFL7R>Q_I$SV %+
M33B:Q?)['^D3/8#B:Q?)['^D3/8 4L!-.)K%\GL?Z1,]@.)K%\GL?Z1,]@!2
MP$TXFL7R>Q_I$SV XFL7R>Q_I$SV %+ 33B:Q?)['^D3/8#B:Q?)['^D3/8
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MD19/M,?T$
M                   !U5TW-3[,MRHURK/''IL!E4B0ZE!K-*$]I[2(S/\
MX#M1-/"6_H"OW^Z7_P#E ?CK76[GI\RU:=:\B>S+J4F2VI-.3$WKV1EK1N.2
MDT$@EDDU;?*P1XSV"8R=4]1:-7;A;D37)#L-J<TTRN-'5!>D,PV7";CDA!/F
MX2UK<PXK"D)422,RY>GP ><9FL%2M:8_5J?>"[]LVDL19=4FH:BK-/%-UM31
M+CMH3E)\%W;C<1$>3,E$.*N_M1&)SM+8N5F9<K<JD\2F/,1B;0IV.^\]'/:V
M2TDHVTHWF9FGM+X\^ER(B+!%C^P?T!YRMK6>7>-7C>-;O=L>AONSSCR7VHK#
MKKK4DFRAJ4^VI!*;3G*2+>HSSG"3'Z6'JG7[@I\J&FYVZA7I]:.FQFT2(3RH
M329#W$6;+;*5-[6&58XIKR9$/1"DDKM(C^/F/Z"O-CM^W'-IU;CL7]+<J\"I
MP4+ET4Z9+@&Q(FDR2$'T92T+)!GE#F5$9$9*47,_RGZK7=(8O/;5JK2Z;XME
MRK:K'1(9](7"0:7.9MJ2LG3^V\T)Y)/;@AZ7))%G!$6>?(?T!#["O"MN:QSK
M;J5WN5&/%C,+:ARY$!EYXUQB<4HV41TN+PHS\I"DD1%S(\'FX  (#X>>3'9<
M=6>$(2:E'^0NT?8XE6_\*F_[%?\ RF G]^:C)<TUH%S4*J^+*-67H+BZXME/
M^1PG\*XYI=2:4^2I)96DR3ORHN0PUV:DR*4[4T1=3#;CPZ*F;19!I@.^/I)K
M>)2,DSAW:I#3>Q@D*\OF>3(Q0_!Z+.@.FG^[%,_PK8WY(21$1$1$79R[ 'G]
M_62M^)GX;E58B74Q.JJI-,)#1R(T5N%)=8-39EDD$LH^%F7E921F>XR/IIFJ
M%[RJ#<\"379-%N"W+<9J#DF'$C&B8XI3FR01.M++8X@DY26-JD*(L8Y^FL%G
M..8_H*\]3;JO2+JNNVV[HJ:*9TEBGIJ4R- -@EN0E.$1DADE\<W,&G[UL]ID
M9&9D1T;1JOW#=EO2ZO<+C*'ERG(C4.,1<-KHZC9<62L$9\1Q#B\'V)-)=I'G
M?@"          ,#>.H").DEX7#;4M92*8S4H[3_"+<W*B..LN$27"P>UUE9%
MDC2>,\R,3L[MNRCSJ9"O*\9%ET>:W+E1JK.*G%+7L2P3<=Y?#5&)1FI]9)0G
M<:4I\K)*&W\'W_0>L?[VW+_WN:*49$?:60'GJQM1+DN>X*53JU=+T*;6*<ER
M/#HIP>)#6F/O4N3'>96\V:\&M*LFCRTI-*3QNZNV=8;NA%94F34*C<%(1$C2
M;EJ#T6(EME4O"&TF;:&S0EODX>U)GA?E'C ],[2SG!9_"/Z C]N:LRJYH14J
M]2ZE"K]UTZG.NR&8RD.K:?+?M)QIOL/R<[<$9[3'0R-0HZ)]%C(UB_\ 9^5%
MDOO7&2J89'*03.R*2^!PD92M;FQ236>WDK!&+\/DD)(L$DB+.>SXP'F2W=9+
MGJ$E#DRYB:N(GJ2W'M+H\=/36WTM\9SAFWQT^2I;FXE[48YE@C(=G9&JM>KM
M-FQ3N=N979U:53HZ$R(3IP&DR'C<6;+;*5-[6&58XIKR9%^7/HH 'F:A:M2J
MK4:;.IVJ)56EU"XFX$6"XJFK?.,EB09J<)MA*D\5QLC27)1)2GGE1D._L2\-
M1"T=KEUSU2:D\JB-3::BH,Q3>5(X2E.J2B*DB-GF@TI5]L/"LXR0O0 (#(U"
MCHGT6,C6+_V?E19+[UQDJF&1RD$SLBDO@<)&4K6YL4DUGMY*P1CH(VLES/8>
MEW,4&X4T^E/PK6Z/'+QFX\M9.?:U-F_Y24D?D+(D=I\B,>FR0DBP22(LY[/C
M'T D.@-[U*\TUYRJ7 W5I#$Q]HHJ)<19QDID.H21M,LH6WY*4E]L4LSQG/:*
M\
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M6.PL#N+6TKI-HG0#B/RG#HT>7'8XG#2E92'$N.&I*$)26%(+:2"2E)'@BQC
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MI'9./'::-:G30DD[U$1&K!=ID1$7_P""(OR C]
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MHT>9"6IMMI3)5*2N.9(:0T@S94X;9J)#:"W;<\LYSS!&L
M
M
M
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MP[5\YJ/]/:]H.L.U?.:C_3VO: : !G^L.U?.:C_3VO:#K#M7SFH_T]KV@&@
M9_K#M7SFH_T]KV@ZP[5\YJ/]/:]H!H &?ZP[5\YJ/]/:]H.L.U?.:C_3VO:
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MK#M7SFH_T]KV@ZP[5\YJ/]/:]H!H &?ZP[5\YJ/]/:]H.L.U?.:C_3VO: :
M!G^L.U?.:C_3VO:#K#M7SFH_T]KV@&@ 9_K#M7SFH_T]KV@ZP[5\YJ/]/:]H
M!H &?ZP[5\YJ/]/:]H.L.U?.:C_3VO: : !G^L.U?.:C_3VO:'=Q93$Z,W(C
M/-R([J26AUI1*2LC[#(RY&0#]0                &55I19"U&I5G4 U&>3
M,Z6QD_\ ^T:H &4ZIK'\S;?[K8]@9JZZ5I794N+&JMITE#\EIV0VB+;9RL--
M[>(M7"95L2G>G)JP7,5 8B^+%K%P7#3JO1:[$H\B-!E0%E+IRI9*0\;1FI.'
MF]JD\+EG<7/F7(!EU2='"<J))MRCNL4]M+LF8S;2G(J$J;0XG[>E@VS,T.(,
MB)1GY1<ASZE3=)Z/<S5 F6S1&*HXEE24*H!<,R=6I#7VTFN&1J4E22+=VE^4
MAG&/!F*FQ+@A4ZLP&8M3A-0V7I-+6[+CDW'993EPI"4K3]I)1IV)/RC+)#0U
MK2*M71)K,JKW)!.7.I+,!EV!25L]&?9?6\S(22I"\[5*3Y.2SM^^+. 5PV7]
M'I57D4R/;-*E28Y+-]4>V%NLM$A;C:C6ZE@T)+<RX6341'M/&1Q:;6]$:HV:
MVZ)0XY='5+Q.MQ44^$3?%WX=92>#1E1?ZQ)5MSM/'[0O![*EUJ!,BU."XVQ1
MVJ4X<RFK<D&I/&-;Z'$OI)*EJ>49DI"NSMYC\J7X--.IE!;HZJD4V&B93)Y*
MF1U/.\2*2$K3Q%.&KAN)09$@S,D;UD64GM(--5;/TTH=LOW!/M6@1:2Q'Z4Z
M^Y1FR4EO&<FCA[LX_JXW9Y8SR'1U![1RES&(\BWJ(7%BL3>D-VZ;D=MAXS)I
MQQY+)MMI4:3YK478-KJ#8Z=0:3$I4B>_"IZ9C4F4B,:D./I;/>ELEI41H^V$
MA1F6>2<?'DIW'\'FHP84^D1KM;*@3J>BD/,OTU3LI,-#SRTMH?-_!*)M[A[E
M(5R21XR YC,O1IZ1,9^QZC-'%Z3O<?MM33;AQ]W')IQ3))=-&U62;-1X(S''
MC5C1B:N,TQ:\%Z3)6;;<1%H/G(Y(0O*FNC;TIVN(42E$23(^1CD+T'G3(KU/
MFW)'<I+;]3E06(]-4VZT[,2\G+KAO*XA(2^LB)*49/!F?Q#K&_!E*GU"FO0:
MS"?CPGU2$LUFFNS%*4MEIM>7>DH6>#:(T[C/:2C3S(BP':N/:0-QY#_V*TYQ
MEF3T,G&K4=6E][>I'#8-,<R?,E(41\/=C:9GR&MA:96)/ALR6K+HB6WD$M*7
MZ,VTLB,L^4A;9*2?Y#(C+XR&5G:)3IDROO=/H)1JHI*SIQT=_HA.$X:^D*;*
M67^4<R^VMF@\EDR,\;:-:M&?MZVJ93)50>JTF)'0RY.D9XCZDE@UJR9GD_RF
M9_A,^T$=3U36/YFV_P!UL>P'5-8_F;;_ '6Q[ U8 ,IU36/YFV_W6Q[ =4UC
M^9MO]UL>P-6 #*=4UC^9MO\ =;'L!U36/YFV_P!UL>P-6 #*=4UC^9MO]UL>
MP'5-8_F;;_=;'L#5@ RG5-8_F;;_ '6Q[ =4UC^9MO\ =;'L#5@ RG5-8_F;
M;_=;'L!U36/YFV_W6Q[ U8 ,IU36/YFV_P!UL>P'5-8_F;;_ '6Q[ U8 ,IU
M36/YFV_W6Q[ =4UC^9MO]UL>P-6 #*=4UC^9MO\ =;'L!U36/YFV_P!UL>P-
M6 #*=4UC^9MO]UL>P'5-8_F;;_=;'L#5@ RG5-8_F;;_ '6Q[ =4UC^9MO\
M=;'L#5@ RG5-8_F;;_=;'L!U36/YFV_W6Q[ U8 ,IU36/YFV_P!UL>P'5-8_
MF;;_ '6Q[ U8 ,IU36/YFV_W6Q[ =4UC^9MO]UL>P-6 #*=4UC^9MO\ =;'L
M!U36/YFV_P!UL>P-6 #*=4UC^9MO]UL>P'5-8_F;;_=;'L#5@ RG5-8_F;;_
M '6Q[ =4UC^9MO\ =;'L#5@ RG5-8_F;;_=;'L!U36/YFV_W6Q[ U8 ,IU36
M/YFV_P!UL>P'5-8_F;;_ '6Q[ U8 ,IU36/YFV_W6Q[ =4UC^9MO]UL>P-6
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M4ER(OR$/W
M
M $T\(;^CV#_O1;G_ 'N"*6)IX0W]'L'_ 'HMS_O<$!2P
M& \(+^@74G_=JI?X5P;\8#P@OZ!=2?\ =JI?X5P!LJ+_ .#P/]@W_P I#FCA
M47_P>!_L&_\ E(<T                 $T\&O\ H)LS_P B7_,H4L33P:_Z
M";,_\B7_ #*%+
M
M                            33PAOZ/8/^]%N?\ >X(I8FGA#?T>P?\
M>BW/^]P0%+                 8#P@OZ!=2?]VJE_A7!OQ@/""_H%U)_P!V
MJE_A7 &RHO\ X/ _V#?_ "D.:.%1?_!X'^P;_P"4AS0
M33P:_P"@FS/_ ")?\RA2Q-/!K_H)LS_R)?\ ,H4L
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M3J4>](E\=Z-^Z#J4>](E\=Z-^Z%+ !-.I1[TB7QWHW[H.I1[TB7QWHW[H4L
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M81RY,XV&TM])F+);SN"^^6HB+)G\9X(<P 0
M
M                         $T\(K^BR1_>M(_[E&%+$T\(K^BR1_>M(_[E
M& 4L                !D-8OZ([W_N.=_AUC7C(:Q?T1WO_ ''._P .L!V=
MB_Z$V]_=T?\ Z21W@Z.Q?]";>_NZ/_TDCO                  33P<?Z'*
M'_M)?^*>%+$T\''^ARA_[27_ (IX4L
M
M                                            !-/"*_HLD?WK2/\
MN484L33PBOZ+)']ZTC_N48!2P                &0UB_HCO?\ N.=_AUC7
MC(:Q?T1WO_<<[_#K =G8O^A-O?W='_Z21W@Z.Q?]";>_NZ/_ -)([P
M           $T\''^ARA_P"TE_XIX4L33P<?Z'*'_M)?^*>%+
M                              !-ES-8-ZME'L@T9Y;JK,SCZ,*2 ":=
M-UB_$]C][3/JP=-UB_$]C][3/JPI8S-Q7-)I%V6G2V6VE,59^0T^I9&:DDVP
MMPMN#P1Y26<D?(!FNFZQ?B>Q^]IGU8.FZQ?B>Q^]IGU89E.NM<KMRWA1;>I;
M$N3#+-%4Y'<_RHF74M3#RI;:'32:C-*4+3G&#47:.VH=^717;IM*/$K-%DTB
MJQ)<B2I=!DQY"5QG6FW&R)<H^&>Y:D^4E6TT?UL@.PZ;K%^)['[VF?5@Z;K%
M^)['[VF?5AG9FNU4I%[SJ'484&/%<KS-.ILS"R2\R7#Z0A>5<G4$X2R,N1I/
ML\A0SB?"AJTNA2Y\2E1C=9K#*FX[T9]M3U(<2ZLG4DHT[G=K#GE%E&<<N8*H
MO3=8OQ/8_>TSZL'3=8OQ/8_>TSZL,$]X0=SUFLRV*!#@/0'JTU"IKZ(*Y;KT
M549]PW=G2&B4:EL&:3)22V*+D9CT%#4XN(PI['&-"37A&SRL<_)R>.?Q9/'X
M3!$ZZ;K%^)['[VF?5@Z;K%^)['[VF?5A2P 33INL7XGL?O:9]6#INL7XGL?O
M:9]6%+ !-.FZQ?B>Q^]IGU8.FZQ?B>Q^]IGU84L $TZ;K%^)['[VF?5@Z;K%
M^)['[VF?5A2P 33INL7XGL?O:9]6#INL7XGL?O:9]6%+ !-.FZQ?B>Q^]IGU
M8.FZQ?B>Q^]IGU84L $TZ;K%^)['[VF?5@Z;K%^)['[VF?5A2P 33INL7XGL
M?O:9]6#INL7XGL?O:9]6%+ !-.FZQ?B>Q^]IGU8.FZQ?B>Q^]IGU84L $TZ;
MK%^)['[VF?5@Z;K%^)['[VF?5A2P 33INL7XGL?O:9]6#INL7XGL?O:9]6%+
M !-.FZQ?B>Q^]IGU8.FZQ?B>Q^]IGU84L $TZ;K%^)['[VF?5@Z;K%^)['[V
MF?5A2P 33INL7XGL?O:9]6#INL7XGL?O:9]6%+ !-.FZQ?B>Q^]IGU8.FZQ?
MB>Q^]IGU84L $TZ;K%^)['[VF?5@Z;K%^)['[VF?5A2P 33INL7XGL?O:9]6
M#INL7XGL?O:9]6%+'\/L,!->FZQ?B>Q^]IGU8.FZQ?B>Q^]IGU828]4+SI]D
M6]6)US5"%+JBYJFTS$4TVY*6X<EU)-(0R2B22VVN2CW'R+/,Q_6=6+J@6TY,
MK5V/4TH,Q)R8,MVFL5EY@XK:RX)*9..X1K4:DH21*-)D6_<1I!58Z;K%^)['
M[VF?5@Z;K%^)['[VF?5A\:>RZW(N.^#FW/4ZM#ITAMF'%FQXC9-I7%9>R?"8
M0HU$IQ1<SQCM(SYB5T?7J\J92Z7!JZE5"OR+><G0^#&;254=?<C(B+26"(E)
M6ZM"TD9%Y.XR(C+ 5?INL7XGL?O:9]6#INL7XGL?O:9]6$M3KS=EORJ$]5BD
M/(ID25"K].<B-)>=EDXAN,]A!'M-9N,>2@]N)'Y"Q^NE>J%W5:_J11;ENQDW
MDL*)Z*3T*+TIU,V8TK:VI@W'"VLMEAM2#+&3R9F IO3=8OQ/8_>TSZL'3=8O
MQ/8_>TSZL*6 (FG3=8OQ/8_>TSZL'3=8OQ/8_>TSZL*6 ":=-UB_$]C][3/J
MP=-UB_$]C][3/JPI8 )ITW6+\3V/WM,^K#.:@VUJ]?ML.4=R!9,-*Y423Q4U
M.8H\L26WR+'1OC-K'Y,BW  FG3=8OQ/8_>TSZL'3=8OQ/8_>TSZL*6 ":=-U
MB_$]C][3/JP=-UB_$]C][3/JPI8 )ITW6+\3V/WM,^K!TW6+\3V/WM,^K"E@
M FG3=8OQ/8_>TSZL'3=8OQ/8_>TSZL*6 ":=-UB_$]C][3/JP=-UB_$]C][3
M/JPI8 )ITW6+\3V/WM,^K#J;NINL%UVI6J(NFV1'14H3T,WDU28HT$XVI&['
M1N>-V<"P@ D]$9U@HU&@4]-*LAU,2.VP2SJLPC5M22<XZ-^0<WINL7XGL?O:
M9]6'UKM=%P6G;E(EVX]LFJJC1.L\)+G264MN..,EN(\&LF]I&6#(SY&)-"UP
MN.MW<4A-Q^+Z-49YNTJ J/'2;D,X$EUHCWMFLS4IEMSD>2XFWLP0"K]-UB_$
M]C][3/JP=-UB_$]C][3/JPDL;62KJHU&4SJ,4ZF2V*4[5+@V0/\ U6^\\E+K
M/$)DF2W)-1[5I-2-N3/RB&JLG6=\[L;IU:NF$Y27X\Y%*GRS8CG5C;D-(:=0
M9$DEJPM:?M9$E6W<2>9 K8=-UB_$]C][3/JP=-UB_$]C][3/JPQ6G^I5>KG@
M^7'<B[G14J^Q2U2$2&I$*2<1[@&HLMLLH)!DKGL<)9\N9F.IJ&L][F[6K792
M[]FC3$" RU$B-*^WK5(6[,:2YA*D*8:)PDJ/:1^3VD>0I?3=8OQ/8_>TSZL'
M3=8OQ/8_>TSZL)<]KY=DFIO*BFIINK4J- A0UQD&=.K*N(3F\R+)DGAO&HE&
M:2X'+M//<Z"ZFUZ\[M7%K=SMRUH@Q'$T[I$)I:S7!CNK<Z.EDGCRMQ9[B<))
M9QMP0#<=-UB_$]C][3/JP=-UB_$]C][3/JPI8 B:=-UB_$]C][3/JP=-UB_$
M]C][3/JPI8 (CI[;6KU@6C"H3<"R9B(RG5$\JIS$FK>ZMSLZ,?9OQ_P&CZ;K
M%^)['[VF?5A2P 33INL7XGL?O:9]6#INL7XGL?O:9]6%+ !-.FZQ?B>Q^]IG
MU8.FZQ?B>Q^]IGU84L $TZ;K%^)['[VF?5@Z;K%^)['[VF?5A2P 33INL7XG
ML?O:9]6#INL7XGL?O:9]6%+ !-.FZQ?B>Q^]IGU8.FZQ?B>Q^]IGU84L $TZ
M;K%^)['[VF?5@Z;K%^)['[VF?5A2P 33INL7XGL?O:9]6&]HBJDNDQ55AN*S
M4S072&X+BG&4J_\ H4I*3,O[2(<X                      =1<5H4&[V6
M&:]1*=6VF%\1ENHQ&Y"6UXQN22R/!X,RR7X1VX .BG6';53ID:FR[>I4JGQB
M,F(CT)M331'V[$FG"<_D'+I]M4BD(A(@TJ%#3";6S%*/'0@H[:C(U(1@O)29
MI29D6"/!?@'9  ZBH6?0:LTIJ=1*=-:5(Z6:)$1MQ)O;=O%P9??[>6[MQR'V
M_:M%E/QGGJ/ >>C-DTPXY&0I32"[$I,R\DN9\B_".T !FY>FEH5""W"E6I1)
M,-KA[([U.96VCAI-#>$FG!;4J-)?@(S(N1C0L,-QF6V66TM--I)"&T$1)2DB
MP1$1=A$/L
M       !_#21XR1'CGS']
M
M
M
M
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MT:WQ] C_ %@.NB7Z-;X^@1_K I8 )IUT2_1K?'T"/]8#KHE^C6^/H$?ZP*6
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M1K?'T"/]8#KHE^C6^/H$?ZP*6 ":==$OT:WQ] C_ %@.NB7Z-;X^@1_K I8
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MI(?J\MUMV02]Y.NH4Z:7%DHB,E+(S+:G_5+&T
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M?X1WX
M
M FWA+_\ PXZJ_P"Z=5_P;HI(FWA+_P#PXZJ_[IU7_!N@*,U_FD?V$/L?#7^:
M1_80^P                 33P9__AXTV_W>@_\ 00*6)IX,_P#\/&FW^[T'
M_H(%+                 !--"/_  B[_P#>VL?XM8I8FFA'_A%W_P"]M8_Q
M:Q2P                                         <,ZQ (__?8WZU/[
MQS!@5^#]I<XM2E:;6@I2CR:CH44S,_U8#9>.('RZ-^N3^\/'$#Y=&_7)_>,7
M\'O2ST:V?W#%]V.FKVENBEL5"BP:I8-G1)-8D]#@H5;T=1//;35MR31DGDD^
M:C(C/!=ID0"F^.('RZ-^N3^\/'$#Y=&_7)_>(T=M^#ZF)*E'9]EE'BU8J$ZX
M=N,X3-,R+A%]IY_?%E1927,S/!'CFT^P=#:G<DB@Q[ M0ZJP^Y'6PY:S;9;V
MT(<61+4R2582ZV>2,R/<6# 5CQQ ^71OUR?WAXX@?+HWZY/[Q%Z?0/!]J4Z/
M":LJTD2I");C+,BUD,J<*,O8_@EL%DTJ(^7:>#,LD1F.3 LW0JK52/3X&GEN
M5!]Y#2]\.SR>9:)Q!+;XKJ8YH:,TFE6%J29$9&9%D@%?\<0/ET;]<G]X>.('
MRZ-^N3^\2JJ:>:&46LRZ3,L:S6:C$IRZL]'^QZ.I2(J3,E.<FC(\&1^27E?D
M'4(HW@_KIKDW[ ;=2E"X[9QEV6:92C?/#)ICG&XJDK,C(E$DR/!\^1@+9XX@
M?+HWZY/[P\<0/ET;]<G]XB#],\'F,44UV1:Y%(2XK*;0)7 )#B6U\?$?[1M6
MI*3XNW&>8_1%"T#<BG);T[H3C/2CA-J;L=:CD/$:R4EDBBY>QPUY-O<1$DS,
M\ +7XX@?+HWZY/[P\<0/ET;]<G]XE='TWT5KU:D4N#IO;KLN.1<8U6@E#+2C
M0E>Q3JHY-DO:M)F@U;BSS(:#X/>EGHUL_N&+[L!M/'$#Y=&_7)_>'CB!\NC?
MKD_O&+^#WI9Z-;/[AB^[#X/>EGHUL_N&+[L!M/'$#Y=&_7)_>'CB!\NC?KD_
MO&+^#WI9Z-;/[AB^[#X/>EGHUL_N&+[L!M/'$#Y=&_7)_>'CB!\NC?KD_O&+
M^#WI9Z-;/[AB^[#X/>EGHUL_N&+[L!M/'$#Y=&_7)_>'CB!\NC?KD_O&+^#W
MI9Z-;/[AB^[#X/>EGHUL_N&+[L!M/'$#Y=&_7)_>'CB!\NC?KD_O&+^#WI9Z
M-;/[AB^[#X/>EGHUL_N&+[L!M/'$#Y=&_7)_>'CB!\NC?KD_O&+^#WI9Z-;/
M[AB^[#X/>EGHUL_N&+[L!M/'$#Y=&_7)_>'CB!\NC?KD_O&+^#WI9Z-;/[AB
M^[#X/>EGHUL_N&+[L!M/'$#Y=&_7)_>'CB!\NC?KD_O&+^#WI9Z-;/[AB^[#
MX/>EGHUL_N&+[L!M/'$#Y=&_7)_>'CB!\NC?KD_O&+^#WI9Z-;/[AB^[#X/>
MEGHUL_N&+[L!M/'$#Y=&_7)_>'CB!\NC?KD_O&+^#WI9Z-;/[AB^[#X/>EGH
MUL_N&+[L!M/'$#Y=&_7)_>'CB!\NC?KD_O&+^#WI9Z-;/[AB^[#X/>EGHUL_
MN&+[L!M/'$#Y=&_7)_>'CB!\NC?KD_O&+^#WI9Z-;/[AB^[#X/>EGHUL_N&+
M[L!M/'$#Y=&_7)_>'CB!\NC?KD_O&+^#WI9Z-;/[AB^[#X/>EGHUL_N&+[L!
MM/'$#Y=&_7)_>'CB!\NC?KD_O&+^#WI9Z-;/[AB^[#X/>EGHUL_N&+[L!M/'
M$#Y=&_7)_>'CB!\NC?KD_O&+^#WI9Z-;/[AB^[#X/>EGHUL_N&+[L!M/'$#Y
M=&_7)_>'CB!\NC?KD_O&+^#WI9Z-;/[AB^[#X/>EGHUL_N&+[L!M/'$#Y=&_
M7)_>'CB!\NC?KD_O&+^#WI9Z-;/[AB^[#X/>EGHUL_N&+[L!M/'$#Y=&_7)_
M>'CB!\NC?KD_O&+^#WI9Z-;/[AB^[#X/>EGHUL_N&+[L!M/'$#Y=&_7)_>'C
MB!\NC?KD_O&+^#WI9Z-;/[AB^[#X/>EGHUL_N&+[L!M/'$#Y=&_7)_>'CB!\
MNC?KD_O&+^#WI9Z-;/[AB^[#X/>EGHUL_N&+[L!M/'$#Y=&_7)_>'CB!\NC?
MKD_O&+^#WI9Z-;/[AB^[#X/>EGHUL_N&+[L!M/'$#Y=&_7)_>)QX2E5A.>#G
MJHA$R.I2K4JI$DG4F9GT-WEVCL_@]Z6>C6S^X8ONP/P>M+#(R/32SS(_B.@Q
M?=@-DU6('"1_ET;L+_YJ?WCZ\<0/ET;]<G]XF-U:5Z,67"CRJKIS:Z&Y#Z8K
M*(MK-RG''5$9DE+;3*E'R29]GQ#/1J;X.TN6VPW9MH[5H0X4E=JH1&+<T;J4
MJ?-@FTJ-"5*VFHE<CY9 6_QQ ^71OUR?WAXX@?+HWZY/[Q%Z9;V@-5?89;L.
MV([TA;*&6YUH%%4Z3IFEI:2=CIRA2BP2R\G)D6<F6>+.A>#I3)4EB59]HL'&
M<2TZ\NU$DRE2I"HY?;>!L,N*A:<D>"VF9X(L@+EXX@?+HWZY/[P\<0/ET;]<
MG]XC]2L_0>F2CBKL"V),PI#D;HD"TDRWS6VE"G,-M,*4:4DXC*R+:6XBSDQ_
M8MFZ%3$5IQ&GMMHCT9+JITE^SR:8:X?^<23JXY(6I/QI29GV\N0"O^.('RZ-
M^N3^\/'$#Y=&_7)_>(A*I&@$2C3JNO3NBJI<)2DOS&K$<<:+::DJ,E)BF2B2
M:%$9IR1&6#QR'[2K?T"A'+0]8%NID1(2:C(B%9AJD-1U*-)+4R4;>6#(\EMR
MDC(S(B,C,+3XX@?+HWZY/[P\<0/ET;]<G]XC5%M;0FX:E#@0--Z([*EL(E-I
M78ZVR2TLU$A;BE12)LE&A6#6:<XSV&0V/P>]+/1K9_<,7W8#:>.('RZ-^N3^
M\/'$#Y=&_7)_>,7\'O2ST:V?W#%]V'P>]+/1K9_<,7W8#JO!JJL)OP>]-T+F
M1TJ3;\$C2IU)&1\%/Y12?'$#Y=&_7)_>)Y7M&=';8I$JJ533VS8D",G>Z\J@
M1CP6<$1$39F9F9D1$1&9F9$1&9C+RZ#H) 0A4G3FBL+4TM]3+EBN$ZTTD\&Z
MXWT7<VWG^NLB2>#P9X/!5K\<0/ET;]<G]X>.('RZ-^N3^\2CJ_T*-AY]-CV8
MMEF8Q 6XBW6%)XSR6U-)(R:YDHG6SW%DO*YGR,=2W2/!Z?M^)6XUDVK-ITJ,
M],:7"M),A9M-*2AU1MHCFM.Q2DD9&1&7X.1@BV^.('RZ-^N3^\/'$#Y=&_7)
M_>(9T'P>R5&2NP*"UTAEI]!O6.M!$AU2D-&HU12)&]2#))*P:CQC.2SI;>TN
MT3NM;B:18=FSN&PS(4IJWX^TD.IW-^4;6,FDL[<Y(C+)%DLA3O'$#Y=&_7)_
M>'CB!\NC?KD_O&+^#WI9Z-;/[AB^[#X/>EGHUL_N&+[L!M/'$#Y=&_7)_>'C
MB!\NC?KD_O&+^#WI9Z-;/[AB^[#X/>EGHUL_N&+[L!M/'$#Y=&_7)_>'CB!\
MNC?KD_O&+^#WI9Z-;/[AB^[#X/>EGHUL_N&+[L!U6A=5A(I-W;ID=.;LK!EE
MU)9+I:^?:*3XX@?+HWZY/[Q@JIH=I'1:9+J$S3FT&8<1E;[SGV/QE;4)(U*/
M!-F9X(CY$61C6:3X/LB.TXS8-O/.NN<)$)NRE*F&?#)S/1RC<7;L4E6_;MP9
M<^8"W^.('RZ-^N3^\/'$#Y=&_7)_>(RS;.@LQQE$+3ZW:H;L9,PCIMF=+)#:
MMVTUFU&42%'L61)5A64F6,CXI5 \'^L1*1)9L6V&6:M,Z!!5-M HIR'L&>U)
M.QTGCD9;OO<X+.3(@%I\<0/ET;]<G]X>.('RZ-^N3^\3>#I'HQ4:3*J;%@V9
MT"*X^V_(<H$9M+:F5J0[G<V7)*D*Y]G+/8,X5!T$5%C2$Z<45292ML9I-B.&
M[)+;N-;3?1=[B"3@S6DC262R?,LA:_'$#Y=&_7)_>'CB!\NC?KD_O$3<H_@]
M-N1R^PFU%M/1VI?26[32N.TTXM2$*=>*.:&LJ0HOMBDX-)YP.9&L[0F5$K$M
M&GUMIATE3J)<MVT";9)3:S0M*'%1R2Z9*298;-1Y[ %@\<0/ET;]<G]X>.('
MRZ-^N3^\1%5(T ;G28;NGE#CRHSL=EUI^Q7&S2I]PVV?OHI9)2R,B,N7QYP.
MPM6R]"+T.3XJL.U%]'9*0LY5K-Q2-HU*3Q$\5A.]&4*+<G)<NT!7O'$#Y=&_
M7)_>'CB!\NC?KD_O$310] G84>4WIW0W&92R;B[+'6I4LS2:B-A)1<O)VI-1
MJ;)22+!F9$9&/CQ7X//$925DVLI#C*'U/IM$C980MQ;:3><*/L9/>VM)DX:3
M(TF1D0"W^.('RZ-^N3^\/'$#Y=&_7)_>);0=--%KEJM1IU.TWMMY^GNK9D.+
MM)#;!.(425(2\I@FUF1GV)4?Q_@'??![TL]&MG]PQ?=@-IXX@?+HWZY/[QRF
MW$NH2M"B6A19)23R1D,#\'O2ST:V?W#%]V-M2Z5"H=.C4^FPV*? C-DTQ%BM
M):::07(DI2DB))%^ B <H                    875/3#K*C4Y**HJE2*>
MMQ^-(2QQ5-OF@R:<(MQ?>+VKQ\>W'+.1N@ 0XO!:ITF$Y3IU?FNTHU.OI8BD
MJ,YTAR,S'-Y;B5^4>&W#Q@B,WCSV<^RI6C-STBY&:ZU>%-?J29#C[BI-#<4E
MPG(T=A9&292<*/HY*SG'E&6#QD5\ $7D^#HNI4M]F;<2>GDB:J'-B0#:5$>?
ME'(0Z1&ZK.S<:#3DB6E1D>,F0_:FZ$52B.4]BGW64>FLS850?;3$=0^XZPTT
MTXE*T2$IX;J64D:%H7C<KF?+%B !(;H\'Y-R5RK5XKCE1JW/<>1Q=BEQT15Q
MSC\#@\0DGA)[M^2/<6<?$/X]HC6Y9,39-TP7*[$\7-Q9"*.M,5MF(X;B4J9Z
M0:E*6I1Y5Q"QRP18/-? !$YW@UIJLY54FW$IVLN*=DN.HBJ1&7)6^TZ1J8XN
M%M$3*4<)9JR7/=NYC]('@_RJ=;=4I*)]O2"F35S$R7Z&_P 9"E...$K<F81\
M1)N>2XC898/ESY6@ $XMG2RH4&\8=;>KC#Q,0DQ)'1X;C,BI*)M""=EK-Y2'
M5$:3,E<,E%G&[!&1T<
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MD8R>=J=J"/\  DN1=@U(           )C:;U0U$MO4BD5">KG6*C2([QMD?
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M<FTGV<^7.@
M
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M!%_@S?G6U.]8_P"6'P9OSK:G>L?\L!: $7^#-^=;4[UC_EA\&;\ZVIWK'_+
M6@!%_@S?G6U.]8_Y8?!F_.MJ=ZQ_RP%H 1?X,WYUM3O6/^6'P9OSK:G>L?\
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M_P L5JATOQ'18%.Z7*J'1&$,=+G.\1][:DD[W%X+<L\9,\<S,P'.
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M=_87,B"K
M
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MP([T6-(XBBV-.F@W$[2/:>3;1S,C,L<L9,=L"
M
M
M
M
M
F                                               /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tm2533062d1_424b3img04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2533062d1_424b3img04.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 1, U$# 2(  A$! Q$!_\0
M'@ ! 0 " P$! 0$           <&" ,$!0(!"0K_Q !=$   !0(# @<*"0D&
M!0($!04  0(#! 4&!Q$2$R$(%Q@Q5Y66%!4B0556T=+3U!8W45)VDI2TU2,R
M.%1A<W23LS,U0G*RM20T-G&!0Y$)1&*Q)6-U=X)3@X2AP?_$ !8! 0$!
M               ! O_$ !<1 0$! 0                 1 2'_V@ , P$
M A$#$0 _ /ZI@
M
M
M
M
M
M
M
M
M
M
M
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M\F1OI3Q.[3+]0.3(WTIXG=IE^H M "+\F1OI3Q.[3+]0.3(WTIXG=IE^H M
M"+\F1OI3Q.[3+]0.3(WTIXG=IE^H M "+\F1OI3Q.[3+]0.3(WTIXG=IE^H
MM "+\F1OI3Q.[3+]0.3(WTIXG=IE^H M "+\F1OI3Q.[3+]0.3(WTIXG=IE^
MH M "+\F1OI3Q.[3+]0.3(WTIXG=IE^H M "+\F1OI3Q.[3+]0.3(WTIXG=I
ME^H M "+\F1OI3Q.[3+]0.3(WTIXG=IE^H M "+\F1OI3Q.[3+]0.3(WTIXG
M=IE^H M "+\F1OI3Q.[3+]0.3(WTIXG=IE^H M "+\F1OI3Q.[3+]0.3(WTI
MXG=IE^H M "+\F1OI3Q.[3+]0.3(WTIXG=IE^H M "+\F1OI3Q.[3+]0.3(W
MTIXG=IE^H M "+\F1OI3Q.[3+]0.3(WTIXG=IE^H M "+\F1OI3Q.[3+]0.3
M(WTIXG=IE^H M "+\F1OI3Q.[3+]0.3(WTIXG=IE^H M "+\F1OI3Q.[3+]0
M.3(WTIXG=IE^H M "+\F1OI3Q.[3+]0.3(WTIXG=IE^H M "+\F1OI3Q.[3+
M]0.3(WTIXG=IE^H M "+\F1OI3Q.[3+]0.3(WTIXG=IE^H M "+\F1OI3Q.[
M3+]0.3(WTIXG=IE^H M "+\F1OI3Q.[3+]0.3(WTIXG=IE^H M "+\F1OI3Q
M.[3+]0.3(WTIXG=IE^H M "+\F1OI3Q.[3+]0.3(WTIXG=IE^H M "+\F1OI
M3Q.[3+]0.3(WTIXG=IE^H M "+\F1OI3Q.[3+]0.3(WTIXG=IE^H M "+\F1
MOI3Q.[3+]0.3(WTIXG=IE^H M "+\F1OI3Q.[3+]0.3(WTIXG=IE^H M "+\
MF1OI3Q.[3+]0.3(WTIXG=IE^H M "+\F1OI3Q.[3+]0.3(WTIXG=IE^H M "
M+\F1OI3Q.[3+]05RCTWO/2(, I,F:45A#'=,QS:/O:4DG6XO_$L\LS/QF9F
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M*A?4:\95,3(N*-!5369;KKBB;CJ62U)2V:M!&:B+-6G5NRSRW# JIP1,**Q
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M=6^;>U6ZMQQ9YK6MQQ2EK49\ZE&9C)00
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MF4F!6Z=.JD+/NF#&EMN/L9&1'K01FI.1F1;R+G >N
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M8_00
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M%P1JUF)M.L4Z2Q<-RTQI#,TJO*V+3R2B[!)-+:8,D;/,])FWFHE*U'F>8R#
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M:<_!SW9EA3A[7+$KEP=WNMR:;+E/2(SR*J\Z9DM9&6J,II*&U9$>:DK5F?\
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MNRG%*5O49N.J4H\SW\X#W0  0
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MUJ%9\-V%1F*?23AN+)QHFC<DK-YPEJ)LLLD)0G/PLN8B"S   @
M                                 #Y6A+B%(6DEH461I469&0^@ <7<
MS/<^PV2-AIT;+26G+Y,N;(=2?08%3<IZY,9+AT]XI$9.9DEMPDFDE:2/(\B4
M>6>>6>?./0               <;[*9+#C2\]#B32K2HTGD99'D9;R_[D."DT
MJ)0J7$IT!A,:%$:2PRRG/)"$EDDM_P"PAVP <;3#3&K9-H;U*-2M"2+,SYS/
M]H-,-,:MDVAO4HU*T)(LS/G,_P!HY  <;+#4=)I:;0TDS-1DA)$1F?.8Y
M                '1IM$A4A^>_$8V3T]_NF2LU&HW'-*49F9F?^%"2(BW$1
M;B'>
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MI7FM?'9.?[(./JE>:U\=DY_L@%+ 33CZI7FM?'9.?[(./JE>:U\=DY_L@%+
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MI7FM?'9.?[(./JE>:U\=DY_L@%+ 33CZI7FM?'9.?[(./JE>:U\=DY_L@%+
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M*Y\N8BRRP
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MF,OU!U;\AM=0D.,&XM1*4M+*UFV@S,N=*2\?R@/?
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M4EN(B(A+9M$E5S@Q57$2<RY*JMT5>#<U4-*36M%-:F-+;9(BWFAJ,@CTE_\
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MTV2].A1YDJ1/FO2G'7EM(-:S4ZI1EF>_).1?(0#/0  0
M                     33!O^_,4?I:[]RABEB:8-_WYBC]+7?N4,!2P
M!YEQ7-1[0I+U4KU6@T2F,F1.3:C)1'91F>1:EK,B+,S(MY^,=.U,0;6OQIYR
MV;EI%Q-LF1.KI,]J43>?-J-M1Y?^0'O@,4@8L615+F7;D*\K?EW"A1H726*H
MPN6E1<Y&T2M1&67-D,K    $/X+']CBS_P#N'6O];8N UNP9LR'B)8..ULU
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MQ?32*M:L.P':G:K+S5)H\SNN+476G4D]+>5DG0^6T0DRTJS)1GM%Y;BMK0
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MMF4AXU&9K)!&2"WGN(B,]Q9%F9GSF8[P
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M'F3#:GW%FVV1Y'I3D1Y%GGD0SH
M
M                                                          33
M!O\ OS%'Z6N_<H8I8FF#?]^8H_2UW[E# 4L            !-,#_ .QOKZ6U
M+_6D4L33 _\ L;Z^EM2_UI%+
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M;(CS& .8K<=MR8.R*O?U=L2C5&T*C*JSE+K2Z83=0CN--J-S>23-*R<\%9&
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MG&4RE!'FA7ADO,RRW;]P4D
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M:A(>9):UFM:D-..*0V9J49GH27. R
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M.MS.V]65J@U;$^&BM.0:)<$.&S!;G14LI<6^^XK9L(0A9K;)PB(EF1$E)GF
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M1&DR/,BW&=OHDV54:1$E3J<Y29CK9*=@O.(<6RKQI-2#-)Y?*1F0#O
M                                  ":8-_WYBC]+7?N4,4L33!O^_,4
M?I:[]RA@*6    )!PL,8:Q@1@?6[RH4:!+J<)V.VVU4TK4P9./)09J)"DGN)
M1GN,A),)^&1<%0KU\0[Q3:-PT:VK?.O.7'8$EV1"3EO[F6;AJ+:F6>XE>+_V
M+&W0#7C C$/''%0K=NZL4:R*-A]6VSE-P67):ZNQ'4DS:4I1GLE&KP<R(BR(
M_P#P-AP0   33@^_]#UCZ6W+_O<T4L33@^_]#UCZ6W+_ +W-%+
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M/2:<\RR2O\'?OY1L28'P@V'PQ;AM[3N+5W'W.RAO/+:%M-6C/_#EGEOYQ9
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M<J5QTPYJ*U3ZMIHUO-4^(E$59J)I#27%+S69GFM;BLMV22+<+J
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M:AN5.JDPA2([9J-#2&V&VT)+4I2C/3F9GO/F(@ST  $
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MVDJ-)]SM-D@\S/P%$:B^4Q3321F1F1&9<Q_(/T$
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MFO.52X&ZM(8F/M%%1+B+.,E,AU"2-IEE"V_!2DORBEF>6>?.*\
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MLLL\CY^88'4\=X:,+;3NZD4TZM(NAZ%&IM,-_9*6[(46:5+TJRV:=HI1Z?\
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MI.*CI);6;63)[$D(1FT24^$1&6HCS#8   $
M
M
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ML1.Q%3]B'*KMOS2Q$[$5/V("T (ORJ[;\TL1.Q%3]B'*KMOS2Q$[$5/V("T
M(ORJ[;\TL1.Q%3]B'*KMOS2Q$[$5/V("T (ORJ[;\TL1.Q%3]B'*KMOS2Q$[
M$5/V("T (ORJ[;\TL1.Q%3]B'*KMOS2Q$[$5/V("T (ORJ[;\TL1.Q%3]B'*
MKMOS2Q$[$5/V("T (ORJ[;\TL1.Q%3]B'*KMOS2Q$[$5/V("T (ORJ[;\TL1
M.Q%3]B'*KMOS2Q$[$5/V("T (ORJ[;\TL1.Q%3]B'*KMOS2Q$[$5/V("T (O
MRJ[;\TL1.Q%3]B'*KMOS2Q$[$5/V("T (ORJ[;\TL1.Q%3]B'*KMOS2Q$[$5
M/V("T (ORJ[;\TL1.Q%3]B'*KMOS2Q$[$5/V("T (ORJ[;\TL1.Q%3]B'*KM
MOS2Q$[$5/V("T (ORJ[;\TL1.Q%3]B'*KMOS2Q$[$5/V("T (ORJ[;\TL1.Q
M%3]B'*KMOS2Q$[$5/V("T (ORJ[;\TL1.Q%3]B'*KMOS2Q$[$5/V("T (ORJ
M[;\TL1.Q%3]B'*KMOS2Q$[$5/V("T (ORJ[;\TL1.Q%3]B'*KMOS2Q$[$5/V
M("T (ORJ[;\TL1.Q%3]B'*KMOS2Q$[$5/V("T (ORJ[;\TL1.Q%3]B'*KMOS
M2Q$[$5/V("T (ORJ[;\TL1.Q%3]B'*KMOS2Q$[$5/V("T (ORJ[;\TL1.Q%3
M]B'*KMOS2Q$[$5/V("T (ORJ[;\TL1.Q%3]B'*KMOS2Q$[$5/V("T (ORJ[;
M\TL1.Q%3]B'*KMOS2Q$[$5/V("T (ORJ[;\TL1.Q%3]B'*KMOS2Q$[$5/V("
MT (ORJ[;\TL1.Q%3]B'*KMOS2Q$[$5/V("T":8*_\WB-]+9?])@>%RJ[;\TL
M1.Q%3]B,*PTX0E+MJ1>*Y]G8A-IJ5P2*A&TV74E:F5MM)29Y,[CS0K<8*V=
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MQ$[$5/V(<JNV_-+$3L14_8@+0 B_*KMOS2Q$[$5/V(<JNV_-+$3L14_8@+0
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M.S>EB8CT&];HKUM8;NU>%>-EQ:"5/;JT1A=&DMH<1H>-;FE:")S\YLU?F_M
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MU"-4(]PQ2I"F7&R)"W81.FXIPS3D1Z,R\'/F&U0(
M
M
M
M
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M4U4V%%2Z:FJ-'6-:4R6IS"W"22G3263!/%X'@FDB3OW$ IW)HPHZ/+=ZO;]
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MFQ2Q-.#+^CEA?]&:=]V; 4L
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M)!$199%D6X!F FG!O^):V_\ *_\ >'!2Q-.#?\2UM_Y7_O#@"E@
M       )IP9?T<L+_HS3ONS8I8FG!E_1RPO^C-.^[-@*6
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M&KEJMB4Z@,4^X2K%&H]9:J)JAR6TJ<4TMMDFW3227E*49&G9J4>6_<.@='Q
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MA=P!:FFK&+YEC_7F>@-6,7S+'^O,] I8 B::L8OF6/\ 7F>@-6,7S+'^O,]
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M]1\!L1Z:] .F5"VZ3&AS8U03#B..DRM]EDVM9I4P>1K29:])EF:2,LCSSV6
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M3K$"JRZ;8$FHP-7<DAWNQ2F#462C1F6XS+,LRWY&9>,QZ>K&+YEC_7F>@4L
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MI8  (              FG!E_1RPO^C-.^[-BEB:<&7]'+"_Z,T[[LV I8
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MZ=T8FXO6U-OZ$JX;9?5:M 9N7;E0W4]TDM+IG$T]TGI26Q5^4S-7A%NW;Z[
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M'Y:-A4*Q"JB:#![W-5.8Y4)+*'G%-&^O+6M"%*-+>HRS,D$DC/,\LS,P5D
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MPM(_IOBE@           FEC?'7B?^[I7]!P4L32QOCKQ/_=TK^@X I8
M              )IP>O^@:G]++F_WV<*6)IP>O\ H&I_2RYO]]G"E@
M    )IPFOT=,3OHW4/NZQ2Q-.$U^CIB=]&ZA]W6*6           Z5:_N:?_
M  [G^DQAO!]^(7#;Z-4W[JV,RK7]S3_X=S_28PW@^_$+AM]&J;]U; 9^
M      )IP;_B6MO_ "O_ 'AP4L33@W_$M;?^5_[PX I8
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M0[Y[#UCW4.4#;OD.^>P]8]U%, $3/E V[Y#OGL/6/=0Y0-N^0[Y[#UCW44P
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MVM(;2ZA#C;ZB2\TIM9?\0YSI41&1_L,A41-.#?\ $M;?^5_[PX"J6  "
M          )IP9?T<L+_ *,T[[LV*6)IP9?T<L+_ *,T[[LV I8
M                              )I?WQQ86?O:G]T,4L32_OCBPL_>U/[
MH8I8                 )I8WQUXG_NZ5_0<%+$TL;XZ\3_W=*_H."E@
M             FEE?'CB9_"TC^F^*6)I97QXXF?PM(_IOBE@           F
MEC?'7B?^[I7]!P4L32QOCKQ/_=TK^@X I8                   )IP>O\
MH&I_2RYO]]G"EB:<'K_H&I_2RYO]]G"E@          )IPFOT=,3OHW4/NZQ
M2Q-.$U^CIB=]&ZA]W6*6           Z5:_N:?\ P[G^DQAO!]^(7#;Z-4W[
MJV,RK7]S3_X=S_28PW@^_$+AM]&J;]U; 9^          )IP;_B6MO\ RO\
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MR/0 QKCUPVZ0K5ZZC>N''KAMTA6KUU&]<9+\%Z-Y)@_9D>@/@O1O),'[,CT
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M@R_HY87_ $9IWW9L4L33@R_HY87_ $9IWW9L!2P
M                  32_OCBPL_>U/[H8I8FE_?'%A9^]J?W0Q2P
M         32QOCKQ/_=TK^@X*6)I8WQUXG_NZ5_0<%+
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M>U 4L!-.3CA_Y&D]:S/:AR<</_(TGK69[4!2P$TY..'_ )&D]:S/:AR<</\
MR-)ZUF>U 4L!-.3CA_Y&D]:S/:AR<</_ "-)ZUF>U 4L!-.3CA_Y&D]:S/:A
MR<</_(TGK69[4 O[XXL+/WM3^Z&*6-<[WP#L>+BMAM%:I,A+$IRH$ZDZG*,U
M:8QF6\W<RW_)D*#R<</_ "-)ZUF>U!5+ 33DXX?^1I/6LSVH<G'#_P C2>M9
MGM012P$TY..'_D:3UK,]J')QP_\ (TGK69[4!2P$TY..'_D:3UK,]J')QP_\
MC2>M9GM0%+ 33DXX?^1I/6LSVH<G'#_R-)ZUF>U 4L!-.3CA_P"1I/6LSVH<
MG'#_ ,C2>M9GM0"QOCKQ/_=TK^@X*6-<[-P#L>3B]B+$<I,A4>,BF&TDJG*(
MTZF7#5O)W,]Y%SYB@\G'#_R-)ZUF>U 4L!-.3CA_Y&D]:S/:AR<</_(TGK69
M[4!2P$TY..'_ )&D]:S/:AR<</\ R-)ZUF>U 4L!-.3CA_Y&D]:S/:AR<</_
M "-)ZUF>U 4L!-.3CA_Y&D]:S/:AR<</_(TGK69[4!2P$TY..'_D:3UK,]J'
M)QP_\C2>M9GM0"ROCQQ,_A:1_3?%+&N=H8!V/(QCQ#AN4F0J/&C4M322J<HC
M2:D/&K>3N9\Q<Y[O$*#R<</_ "-)ZUF>U 4L!-.3CA_Y&D]:S/:AR<</_(TG
MK69[4!2P$TY..'_D:3UK,]J')QP_\C2>M9GM0%+ 33DXX?\ D:3UK,]J')QP
M_P#(TGK69[4!2Q-+&^.O$_\ =TK^@X')QP_\C2>M9GM1/K-P#L>3B[B+$<I,
MA4>,BF&TDJG*(TZF7#5O)W,]Y>/,!L8 FG)QP_\ (TGK69[4.3CA_P"1I/6L
MSVH"E@)IR<</_(TGK69[4.3CA_Y&D]:S/:@*6 FG)QP_\C2>M9GM0Y..'_D:
M3UK,]J I8":<G'#_ ,C2>M9GM0Y..'_D:3UK,]J I8":<G'#_P C2>M9GM0Y
M..'_ )&D]:S/:@*6 FG)QP_\C2>M9GM0Y..'_D:3UK,]J <'K_H&I_2RYO\
M?9PI8URP+P#L>JV347Y5)D..)N:X6",JG*3X#=9FMH+(G2+<E"2SYSRS/,S,
MQ0N3CA_Y&D]:S/:@JE@)IR<</_(TGK69[4.3CA_Y&D]:S/:@BE@)IR<</_(T
MGK69[4.3CA_Y&D]:S/:@*6 FG)QP_P#(TGK69[4.3CA_Y&D]:S/:@'":_1TQ
M.^C=0^[K%+&N7"&P#L>CX#8B3XE)D-RHUOSGFEJJ<I9)4EA9D>E3ID>\N8RR
M%"Y..'_D:3UK,]J"J6 FG)QP_P#(TGK69[4.3CA_Y&D]:S/:@BE@)IR<</\
MR-)ZUF>U#DXX?^1I/6LSVH"E@)IR<</_ "-)ZUF>U#DXX?\ D:3UK,]J SZM
M?W-/_AW/])C#>#[\0N&WT:IOW5L>15^#I8#=)FK31Y)*2PLR/OK,Y])__FC%
M,#L +%JN"F'\V329#DF3;U/>=653EI)2U1FS,\B=(BWF>XBR!6P(":<G'#_R
M-)ZUF>U#DXX?^1I/6LSVH(I8":<G'#_R-)ZUF>U#DXX?^1I/6LSVH"E@)IR<
M</\ R-)ZUF>U#DXX?^1I/6LSVH"EB:<&_P"):V_\K_WAP.3CA_Y&D]:S/:CA
MX,<1J!@9:T=A)H9:;?2A)J-61=T.>,]Y@*B                 FG!E_1RP
MO^C-.^[-BEB:<&7]'+"_Z,T[[LV I8
M         )I?WQQ86?O:G]T,4L32_OCBPL_>U/[H8I8
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M#[\0N&WT:IOW5L!GX          FG!O^):V_\K_WAP4L33@W_$M;?^5_[PX
MI8                ":<&7]'+"_Z,T[[LV*6-<N#SA=7:A@+AS*9Q5O&G-/
M6] <1#BM4HVF"..@R0C7!4K27,6I2CR+>9GO ;&@)GQ17%TPWS_)H_X>'%%<
M73#?/\FC_AX"F )GQ17%TPWS_)H_X>'%%<73#?/\FC_AX"F )GQ17%TPWS_)
MH_X>'%%<73#?/\FC_AX"F )GQ17%TPWS_)H_X>'%%<73#?/\FC_AX"F )GQ1
M7%TPWS_)H_X>'%%<73#?/\FC_AX"F )GQ17%TPWS_)H_X>'%%<73#?/\FC_A
MX"F )GQ17%TPWS_)H_X>'%%<73#?/\FC_AX"F )GQ17%TPWS_)H_X>'%%<73
M#?/\FC_AX"F )GQ17%TPWS_)H_X>'%%<73#?/\FC_AX"F )GQ17%TPWS_)H_
MX>'%%<73#?/\FC_AX"F )GQ17%TPWS_)H_X>'%%<73#?/\FC_AX"F )GQ17%
MTPWS_)H_X>'%%<73#?/\FC_AX#]O[XXL+/WM3^Z&*6-<KWPNKK.*V&S"L5;Q
M?<><J!(D.-4K:,91C,]&4$D[^8]1*W<V1[Q0>**XNF&^?Y-'_#P53 $SXHKB
MZ8;Y_DT?\/#BBN+IAOG^31_P\$4P!,^**XNF&^?Y-'_#PXHKBZ8;Y_DT?\/
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MB*PG%6\67&44S7);:I6T>S9<,M><$T^#S%I(N??F"MC0$SXHKBZ8;Y_DT?\
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M;Y_DT?\ #QQ<&..N+@7:S+DAV4M#;Y&^]IUK_P"(<WGI(BS_ .Q$"JB  "
M            )IP9?T<L+_HS3ONS8I8FG!E_1RPO^C-.^[-@*6
M                             ":7]\<6%G[VI_=#%+$TO[XXL+/WM3^Z
M&*6                 ":6-\=>)_P"[I7]!P4L32QOCKQ/_ '=*_H."E@
M               FEE?'CB9_"TC^F^*6)I97QXXF?PM(_IOBE@
M FEC?'7B?^[I7]!P4L32QOCKQ/\ W=*_H. *6                   ":<'
MK_H&I_2RYO\ ?9PI8FG!Z_Z!J?TLN;_?9PI8          ":<)K]'3$[Z-U#
M[NL4L33A-?HZ8G?1NH?=UBE@          .E6O[FG_P[G^DQAO!]^(7#;Z-4
MW[JV,RK7]S3_ .'<_P!)C#>#[\0N&WT:IOW5L!GX          FG!O\ B6MO
M_*_]X<%+$TX-_P 2UM_Y7_O#@"E@                )IP9?T<L+_HS3ONS
M8I8USX/!XJ\0F'/>Y%G'3_@] [G[J5+VNS[G1IUZ2RU999Y;LP5L8 FFK&+Y
MEC_7F>@-6,7S+'^O,] (I8"::L8OF6/]>9Z U8Q?,L?Z\ST *6 FFK&+YEC_
M %YGH#5C%\RQ_KS/0 I8"::L8OF6/]>9Z U8Q?,L?Z\ST *6 FFK&+YEC_7F
M>@-6,7S+'^O,] "E@)IJQB^98_UYGH#5C%\RQ_KS/0 I8"::L8OF6/\ 7F>@
M-6,7S+'^O,] "E@)IJQB^98_UYGH#5C%\RQ_KS/0 I8"::L8OF6/]>9Z U8Q
M?,L?Z\ST *6 FFK&+YEC_7F>@-6,7S+'^O,] "E@)IJQB^98_P!>9Z U8Q?,
ML?Z\ST *6 FFK&+YEC_7F>@-6,7S+'^O,] !?WQQ86?O:G]T,4L:YWN>*O&M
MAMMT6=W7M*AW/LUR]GGW,>K7F6?-S9>,4'5C%\RQ_KS/0"J6 FFK&+YEC_7F
M>@-6,7S+'^O,] (I8"::L8OF6/\ 7F>@-6,7S+'^O,] "E@)IJQB^98_UYGH
M#5C%\RQ_KS/0 I8"::L8OF6/]>9Z U8Q?,L?Z\ST *6 FFK&+YEC_7F>@-6,
M7S+'^O,] !8WQUXG_NZ5_0<%+&N=FGBKQO8B[%%G=V:*9W1M%R]G_8N:-&19
M\V>>8H.K&+YEC_7F>@%4L!--6,7S+'^O,] :L8OF6/\ 7F>@$4L!--6,7S+'
M^O,] :L8OF6/]>9Z %+ 335C%\RQ_KS/0&K&+YEC_7F>@!2P$TU8Q?,L?Z\S
MT!JQB^98_P!>9Z %+ 335C%\RQ_KS/0&K&+YEC_7F>@ LKX\<3/X6D?TWQ2Q
MKG:!XJ\<>(>Q19W=G<U+V^M4O9Y:'M&C(L_ESS_9D*#JQB^98_UYGH!5+ 33
M5C%\RQ_KS/0&K&+YEC_7F>@$4L!--6,7S+'^O,] :L8OF6/]>9Z %+ 335C%
M\RQ_KS/0&K&+YEC_ %YGH 4L32QOCKQ/_=TK^@X&K&+YEC_7F>@3ZS3Q5XW<
M1=BBSN[-%,[HVBI>S_L5Z-&19\V>>8*V, 335C%\RQ_KS/0&K&+YEC_7F>@$
M4L!--6,7S+'^O,] :L8OF6/]>9Z %+ 335C%\RQ_KS/0&K&+YEC_ %YGH 4L
M!--6,7S+'^O,] :L8OF6/]>9Z %+ 335C%\RQ_KS/0&K&+YEC_7F>@!2P$TU
M8Q?,L?Z\ST!JQB^98_UYGH .#U_T#4_I9<W^^SA2QKE@6>*OP)J/<*+.V'PF
MN'5W0J7JVG?F;M<LBRTZ]>GQZ<L]^8H6K&+YEC_7F>@%4L!--6,7S+'^O,]
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MOBE@           FEC?'7B?^[I7]!P4L32QOCKQ/_=TK^@X I8
M         )IP>O\ H&I_2RYO]]G"EB:<'K_H&I_2RYO]]G"E@          )
MIPFOT=,3OHW4/NZQ2Q-.$U^CIB=]&ZA]W6*6           Z5:_N:?\ P[G^
MDQAO!]^(7#;Z-4W[JV,RK7]S3_X=S_28PW@^_$+AM]&J;]U; 9^
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M#B*9M8Y5J*1LY,N:?",\CS+?NYL@&Q@":<8&('15)Z]A^L'&!B!T52>O8?K
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MD?TWQ2P           32QOCKQ/\ W=*_H."EB:6-\=>)_P"[I7]!P!2P
M               33@]?] U/Z67-_OLX4L33@]?] U/Z67-_OLX4L
M   !-.$U^CIB=]&ZA]W6*6)IPFOT=,3OHW4/NZQ2P          '2K7]S3_X
M=S_28PW@^_$+AM]&J;]U;&95K^YI_P##N?Z3&&\'WXA<-OHU3?NK8#/P
M     !-.#?\ $M;?^5_[PX*6)IP;_B6MO_*_]X< 4L                !-
M.#+^CEA?]&:=]V;%+&O>!6,=$L_!6PZ%5Z1>4.JTRA0H<N.=DUE>R>;80E:=
M28AD>2B,LR,R/Q& V$ 33E#6G^HWEV&K?N8<H:T_U&\NPU;]S 4L!-.4-:?Z
MC>78:M^YARAK3_4;R[#5OW,!2P$TY0UI_J-Y=AJW[F'*&M/]1O+L-6_<P%+
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M3$1$)DN(,_SB,R01J+G4E7CS!%0
M
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M1;CMTG$4GO51[>IU1CN32@I=):I$AEM1J;U*T$ELR\!/YV2E&DMAP
M
M
M                                     'R3:"6:R21+,LC5EO,A]
M  /E:$N)-*DDI)\Y&69#P[PMB5=$!J/#N.JVRZVYK[II*8REK+(RTJ3(9=09
M;\_S<\R+>/> !C=A6%3L/;:31H+LF8VIYZ2_*GK)Q^2\ZLUNN.&1$1J4I1GN
M(B+F(B+<,C(B21$19$6XB(?H
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
?                                      #_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm2533062d1_424b3img03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2533062d1_424b3img03.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 1, U$# 2(  A$! Q$!_\0
M'0 ! 0 # 0$! 0$           4$!@@' P() ?_$ %80  $# P$#!@H&!0@(
M!04  P ! @,$!081!Q(5$Q06(571""(Q5&63E*.DX29!4I&2TB,R-E%A149U
M@H6RP<,7,S1Q=':!LR0E0G*Q&#<X4[1$8G/_Q  9 0$! 0$! 0
M     0(#! 7_Q  N$0$! 0$  0," P8' 0      $0$A,0(#00024='P%")A
M<8&1!1,C)%*AP>'_V@ , P$  A$#$0 _ /ZI@
M
M
M
M
M
M
M
M
M
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MN -/Z17S[%O^Y_>.D5\^Q;_N?WBD;@#3^D5\^Q;_ +G]XZ17S[%O^Y_>*1N
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MBD;@#3X\GNS*RCCGCHN2FG9$O)M?JFJ_Q4W N;4W(  J
M     #3\B_:IG_!)_?4^)]LB_:IG_!)_?4^)AL
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M/= \ON^UZO9]7V>OR  .0
M        #'J/]MM?_&Q?_)OQH-1_MMK_ .-B_P#DWXN)H #3(
M          T_(OVJ9_P2?WU/B?;(OVJ9_P $G]]3XF&P
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M\N2W[)[A51,@YQ>JM).2B9^JQC6M:U/XKIJO[S?P X^OU^KW-^[U;T  8
M                                             8]1_MMK_P"-B_\
MDWXT&H_VVU_\;%_\F_%Q-  :9                     &GY%^U3/\ @D_O
MJ?$^V1?M4S_@D_OJ?$PV
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MAC=OMMM%#2[_ -I6,1JK_P!50.'U.>SGI_TO%Y_;+Y[Y7  'S@
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MK)'<\B71KD5?*>A&M9!;:2C?:7T]+! ];A"BNCC1JJG7U=2&RC#0 &F0
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MXBZZ=:)H!(\(3;Q0>#_AM-?*JTU=_JJJJ2FI[70.1)Y=&/EE>FOU,BCD>O\
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M7;WP;.\4BX"'PF]=O?!L[QPF]=O?!L[Q2+@(?";UV]\&SO'";UV]\&SO%(N
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M/Z1A_P 2X:C>*ZX5,]I;5VSF4:5\2I)SALFJZKU:)_U^XVX8;X  5
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MJ=J-HOK[C87XU>K%=YK+<;<ZJ;5,9/&R.35DK41'L5DK%1=U%ZU33J ]
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M35-Z-Z/C5OE1-%5.L#K,$_'9Y*K'[9-*]9)9*6)[WKY7*K$55*
M                    !#RG^2/Z1A_Q+A#RG^2/Z1A_Q+A/E?@ !4
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ML3$B>C>2?4.5$D77RHFGD)N*[:J3/-I%XQS&[9-=;-8T=#=,F;*UM%#5I_\
MXD2Z*LTC4ZW[OBL\BKO=0A6]\"MO9])ZAO<.!6WL^D]0WN-*RW;GBMAV>YAE
M5INMNRJ/&*.:KK*2TU\4SVK&U7+&Y6JNXY=U4ZS'PS;K9<LRZ_6"=L=FJ+:^
MWPPOK*IC>>RU=-SAD<2+HJN1J*FB:JNBJ(5OO K;V?2>H;W#@5M[/I/4-[C]
M4UXH*RX5E!3UM-/74:,6IIHY6NE@WT56;[475N\B*J:^71=#,$*P>!6WL^D]
M0WN' K;V?2>H;W&<!"L'@5M[/I/4-[AP*V]GTGJ&]QG 0K!X%;>SZ3U#>X<"
MMO9])ZAO<9P$*P>!6WL^D]0WN' K;V?2>H;W&<!"L'@5M[/I/4-[AP*V]GTG
MJ&]QG 0K!X%;>SZ3U#>X<"MO9])ZAO<9P$*P>!6WL^D]0WN' K;V?2>H;W&<
M!"L'@5M[/I/4-[AP*V]GTGJ&]QG 0K!X%;>SZ3U#>X<"MO9])ZAO<9P$*P>!
M6WL^D]0WN' K;V?2>H;W&<!"L'@5M[/I/4-[AP*V]GTGJ&]QG 0K!X%;>SZ3
MU#>XC9?::&FQVKDAHZ>*1NYH]D36JGCM^M$-G(>;?LQ6_P!3^^T;X,\L[@5M
M[/I/4-[AP*V]GTGJ&]Q&VG9Q#LSV=9+EM12OKH+);I[@^FB<C72I$Q7JU%7J
M15TTU/)JWPE<KZ0XOCEKV5U%UR.]6)]_DH&WVFB;2TZ3)&B+(]$:]5WF+U>3
M7^ A7N7 K;V?2>H;W#@5M[/I/4-[CSG9CMYI\TJLNM>26*HP/(,4="MVH;K5
MP2Q112L62*9M1&Y6.8YJ+UKHJ*BZH;S:LXQR_6"2^6R_VNXV2)'*^Y4E;'+3
M,1OZRK(URM33Z^OJ$*S>!6WL^D]0WN' K;V?2>H;W&A8OM]QC+LXR.QVZNHJ
MJV66UTMUDOT%=%+1R1S/F:J(]JZ)N+"NJZZ=?\#;L>SS&LNME1<K%D5IO5NI
MU5)JNWUT4\,2HFJHY['*B:)U]:B%9_ K;V?2>H;W#@5M[/I/4-[CSO.O"8V=
M8'AL63SY3:KG:)+E3VI)[;<*>5J3RR-9HKN41J(U%5[NO5&M<NG4;E/M"Q6F
MO%OM,V36>*ZW!C9:.A?7Q)/4L=UM=&Q7;ST7ZE1%U$*I<"MO9])ZAO<.!6WL
M^D]0WN-$VR;><8V-8W=:ZOKZ*LN]#3MJ6V%E=%'6SL5[6[S8U7>T3>UUTTZC
MTD0K!X%;>SZ3U#>X<"MO9])ZAO<2MHV91;.L R/*9Z9]9#9;?/<'T\;D:Z5L
M4:O5J*O4BKIIJ>/6WPI+]0P8I=,QV6W+%L7R2II*.EO<5VI*YD4M3IS?EHV.
M1[6N5S6[R(NBJFJ"%>[<"MO9])ZAO<.!6WL^D]0WN,%V=8VW)DQQ<AM29"K.
M42T+6Q\[5NFN]R6]OZ:=>NABIM/PUT]= F6V)9J&-\U7&ERAWJ=C'JQ[I$WO
M$:UR*U571$5-%ZQ"K' K;V?2>H;W#@5M[/I/4-[B?1Y]C%QQN7(:3([356")
M%62ZPUT3Z5B)Y565';J:?[SYP[1<4J+'37J+)[-)9JF18H+BRX1+3RO1%56M
MDWMURZ-<NB+]2_N$*J<"MO9])ZAO<.!6WL^D]0WN,"WYYC-VQV6_T.16FML4
M6\LETIZZ*2E9N_K:RH[=33Z^OJ-6R/;KC5LL=@N]EKJ+*[?=K_16!M19ZZ*>
M.*6IE2-'*]JJB[N\BJWRB%;QP*V]GTGJ&]PX%;>SZ3U#>XU;:EM1I]ET6+/J
M*"6N2_7ZDL,:1/1O)/G5R)(NOE1-WR%-=I6(I>X;-TJLG%YI7P16_B,/.'R,
M71[&Q[V\KFKU*B)JGUB%5N!6WL^D]0WN' K;V?2>H;W'D6S_ ,**P[0<^SVT
MTCK338UB$G-ZO()K[3KORHC%<O()ULB17JWE7.1%<QR:=1Z5%M$Q2;'HK]'D
M]FDL4STBCN;:^):9[U71&I+O;JKKU:(HA5/@5M[/I/4-[AP*V]GTGJ&]QKT>
MV# YEI>3S;''\[D;%3[MVIUY9[DU:UGC^,JHJ*B)Y=2K9\VQW(77%MJO]KN;
MK:]8ZU*.LCE6E<FNK9=UR[B]2]3M/(HA69P*V]GTGJ&]PX%;>SZ3U#>XT7*_
M"(V?8KL^R7,4RFU7FT8_"LM;PFX05#VN_P#3&FC]$>Y>IK55-5,_&]K5IRBX
M2NI*BW.L26>"\,N[+K3R-='(YZ+O1M<KFM;N?ZQ?$5=41=6J(5M? K;V?2>H
M;W#@5M[/I/4-[B7;MHN*7>PRWN@R>S5MEBD2*2XT]PBDIV/54:C5D1RM1=7(
MFFOE5/WFJ;0-N5KQW9MDN78IP_/F8_&^:OH[5=H-8F,:KI-YZ*Y$<UK57=7K
M40K?^!6WL^D]0WN' K;V?2>H;W'RQB^,R;&K3>(XG01W"DAJVQ.756)(Q'(B
MK]>FNA3$*P>!6WL^D]0WN' K;V?2>H;W&<!"L'@5M[/I/4-[AP*V]GTGJ&]Q
MG 0K!X%;>SZ3U#>X<"MO9])ZAO<9P$*P>!6WL^D]0WN' K;V?2>H;W&<!"L'
M@5M[/I/4-[AP*V]GTGJ&]QG 0K!X%;>SZ3U#>X<"MO9])ZAO<9P$*P>!6WL^
MD]0WN' K;V?2>H;W&<!"L'@5M[/I/4-[AP*V]GTGJ&]QG 0K!X%;>SZ3U#>X
M<"MO9])ZAO<9P$*P>!6WL^D]0WN' K;V?2>H;W&<!"L'@5M[/I/4-[AP*V]G
MTGJ&]QG 0K6L@MM)1OM+Z>E@@>MPA171QHU53KZNI#92'E/\D?TC#_B7!A\
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M[^AJ/_L,-J,2TVNEL=KH[=11<A14<+*>"+>5VY&QJ-:FJJJKHB)UJNIE@
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MC[KB-LO5PLE;51SK46:9T]$L57-$UKU8L:[[6.1LB;KE\5Z.1%Z]-413XWS
M[%DF28]?[C0\XNV/R32VVHY:1O(.ECY.1=UKD:[5BZ>,BZ>5-% Y7H<=R38P
MNU#:BMBQS8I1W.VT%LH+)%_YA$M4V9S>=R04;$1\SDE;&R.-'*Y43>4U:]^$
MKM0Q>@VE6N&]72HK;;9K7=;3<<KQJ&VU4;Y[@E-(U:=NB.B5%ZM]C7IU]?D4
M[1SK [#M+QBLQ[);<RZ6BKW5EIW/?&NK7(YKFO8J.8YKFHJ.:J*BHBHIH$/@
MF[+HENCWX]55=1=*:*DKZNNO-=4U%5%%,V:-))I)W/>K7L:J*KM41-W7=54
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M8M'_  </]Q"H85EHWVZST-)(K72001Q.5GD56M1%T_AU&:
M                0\I_DC^D8?\ $N$/*?Y(_I&'_$N$^5^  %0
M            :Q<J_AV8-EYM456M!N[E-'ON3](O7I^[J,OI3Z(NOLWS'\]_
M[._S2X9:U#Z4^B+K[-\QTI]$77V;YEP%ZG$/I3Z(NOLWS'2GT1=?9OF7 .G$
M/I3Z(NOLWS'2GT1=?9OF7 .G$/I3Z(NOLWS'2GT1=?9OF7 .G$/I3Z(NOLWS
M'2GT1=?9OF7 .G$/I3Z(NOLWS'2GT1=?9OF7 .G$/I3Z(NOLWS'2GT1=?9OF
M7 .G$/I3Z(NOLWS'2GT1=?9OF7 .G$/I3Z(NOLWS'2GT1=?9OF7 .G$/I3Z(
MNOLWS'2GT1=?9OF7 .G$/I3Z(NOLWS'2GT1=?9OF7 .G$/I3Z(NOLWS'2GT1
M=?9OF7 .G$/I3Z(NOLWS'2GT1=?9OF7 .G$/I3Z(NOLWS'2GT1=?9OF7 .G$
M/I3Z(NOLWS'2GT1=?9OF7 .G$/I3Z(NOLWS'2GT1=?9OF7 .G$/I3Z(NOLWS
M)647_GMBJ8>'7"#>W?TD\&ZQ-'(O6NIN)#S;]F*W^I_?:3;%SR=*?1%U]F^8
MZ4^B+K[-\RX"]3B'TI]$77V;YCI3Z(NOLWS+@'3B'TI]$77V;YCI3Z(NOLWS
M+@'3B'TI]$77V;YCI3Z(NOLWS+@'3B'TI]$77V;YCI3Z(NOLWS+@'3B'TI]$
M77V;YCI3Z(NOLWS+@'3B'TI]$77V;YCI3Z(NOLWS+@'3B'TI]$77V;YCI3Z(
MNOLWS+@'3B'TI]$77V;YCI3Z(NOLWS+@'3B'TI]$77V;YCI3Z(NOLWS+@'3B
M'TI]$77V;YCI3Z(NOLWS+@'3B'TI]$77V;YCI3Z(NOLWS+@'3B'TI]$77V;Y
MCI3Z(NOLWS+@'3B'TI]$77V;YCI3Z(NOLWS+@'3B'TI]$77V;YCI3Z(NOLWS
M+@'3B'TI]$77V;YCI3Z(NOLWS+@'3B'TI]$77V;YCI3Z(NOLWS+@'3B'TI]$
M77V;YCI3Z(NOLWS+@'3B'TI]$77V;YCI3Z(NOLWS+@'3B'TI]$77V;YCI3Z(
MNOLWS+@'3B'TI]$77V;YCI3Z(NOLWS+@'3B'TI]$77V;YCI3Z(NOLWS+@'3B
M'TI]$77V;YCI3Z(NOLWS+@'3B'TI]$77V;YCI3Z(NOLWS+@'3B'TI]$77V;Y
MCI3Z(NOLWS+@'3B'TI]$77V;YCI3Z(NOLWS+@'3C4;Q>N(SVF/F%;2Z5\3M^
MIAW&KUKU:Z^7K-N(>4_R1_2,/^)<&&^  %0                     0_Y[
M_P!G?YIH^T_/KU@^U79=2QRQ)BV0UM5:+@Q\2*YM2M.Z6E<C_*FJQ2-5/KWD
M-X_GO_9W^::1X2FRZ];6]E=7:,8K:2V972U5-<K/75[GMA@JH96O:KU8USD1
M6[S5T1?UB8NO%<-\+3(DGVM77(N:]'Z6T5F0X>D<*,=+24U1/2N:Y?\ UJZ2
M.%Z+^Z9#?(O";39[B-'#F%DR3(;Y9[-25V57.PVA'4=N?)$DCU>JN;KHF\Y6
MQH]4:FJH0=HW@@U61XSL>L=CN%%1TF*-AME[6H5Z+76S6&2>-FZU=7OEIXUT
M=HFCG:J1]OG@LY_M:R+/42KL5ZM%]I&T]FFOEZN$3;#^@W'-9;X6+!-O/U?R
MCG(Y%=UHY&HA4>TU'A$X?219M+4354$.)VR"\5DDD2(E1230NEBE@\;5Z.W7
M-Z]U=Y-#4+KX9V(V>HOC*C',O6GL'-G7NLBM*/@M;)X8YF/F<DGD1LJ;R,WG
M-W7+IIHJ^5[4=FT.5;8MC^"T=YH);ZRSP4&<VJ@EY7_RND=#4Q.DZD5K73Q\
MFQ7M3>;,_1.I3TW*_!ZR*^8SX0-NIZRUQS;07HZUNDED1L*)0Q4_Z?2-=WQX
MW+XJ/ZE3Z^H#8<M\*?$L3O%WI%MV07BW61(W7N]VBVK44%J1[$>G+R:HJJC'
M->Y(VO5K517:#PIMIMVV<[!+KE6*W*FHJ]):%E-<)HFSQ1LFJ8HUDW7>*Y-R
M15ZSQ3*O DO$N4Y756ZP[/\ )*?)I(:E]SRE*E:JTS<C'%,D<3(U951KR>\U
MKWQ:*Y4550]QV][&*S:?L)EP&SNMT4BNM[&I7-6.F6*">)[VJUK7Z(K(U1&Z
M*G6B>3K \G?MLRO -I&-6"7:IC^U&AOM+<'U4=JM<$=;:6P4SIFU>D,SFNCW
MFHQ6O1NJN;H[RF\T/A76&VX]C[76_)\PKGXY07^YUEFLR.6EIZB+>9/-$V1=
MU7[KW<G%RBMT7RHB*OHLFR3&;-C-^H,5QJQX[67*AFI%EH*"*E1RN8K6[ZQL
M15354_><X9GX(F97K&</MU/0877W2S8I06.GR!]PKK7<[/5P0I&^:GJ*:/?J
M8MY$>V*18TU3K_65 /9<]\)_',#K+G&ZP91?*.T4D5==KE9[4LM-;H9&;[72
MN<YJJNYXRMC1[FIY40F93X8.'XQ=\@HF67*+W#8*6FK[I<+1:^7IJ2DGA29D
M[G[Z+N[BJJHB*_Q7+NJB:GE.U3P1]I6T!F3VZX7RS9E3W.TP4%NNV17FX0+:
MI&4J12N2WPL6"59)$=)RCGHY%?UH[=1%WFS>#CE%'B6UNW5%9:$J\PQR@M%$
ML4\KHXIH;:M*]9%6)%1G*+JBM155O6J(O4!M65^%;B&,W*OIJ:VY%DM):J6&
MNN]RL-L=54MKAE9RC'3NU1=5C5'JUB/<C>M40]<M-UH[[:Z.Y6^HCJZ"LA94
M4]1$NK)8W(CFN1?W*BHIS+2>#]M1P2WY5:,-K\3J+;E]NI8;A47F6I;-;*IE
M%'22R0-9$Y*ABMC1S6O6)47RKHNAT)L\PVGV=X%CN+4DSZFFLUO@M\<TB:.D
M;%&C$<O\5TU V$                          "'FW[,5O]3^^TN$/-OV8
MK?ZG]]I-\+GEK^WG+KE@.Q3.LEL\C(KK:;+5UM*^5B/:V6.)SFJK5ZE35$ZC
MG7-MLV78OG>!8K?=M>/X%2W'$GWNJO\ >[;1Q,JZE9V-;$ULLC&-T8]>IJZK
MN:Z>4]P\*Y=/!FVI_P#+5?\ ]AYIN ;/K?M0SG!]IE'66#)<,;A"V/1LB5*R
M5"S1N56INK&K42-[57>U1>K3RE1!V3>%++1VW/)\JR.CV@8]9+E1VZR95B]L
M5J7RHJ&?[)#%&][)96/T;O1NW?&Z]-%4]#;X5&'TN.Y#<;Q17W'KC8I::&KQ
M^YV]6W)7U"[M,V*)CG)+RKO%:K'*FJ*BJFBZ>49=X&V17''KYAULN%CJL$H[
MY2Y+BEJO#II&4<S5=SBW3,:WJI';SE8YCE<S>T1JHB'ZMO@@7Q<=OE53VK!L
M&R3B5LNEGH\>CGJ:5DE%(LK6U51(R.25LCG.31L;=Q%U3>4#8<>\+%9MH^T-
ME\M%^LMAQZU6J2*R5MH5+GSNIEF9N-8Q7<KOZ1;NZY6IJNJIH[3<Z/PJ,19:
M\MJK];[]B%7B\,%1<+9?*#<JECG56P.B;$Z1)>4>U6-1JJN]U*B'F&3; ]MF
M;WC.LAK+UC&.76^4MHI*>@L-UKHV/IZ6>5\]/+5MA9+&DS953E8V[R:JF[U:
MK&M?@691+-M J)'8UBRWVDM,MLIK;6UER2EK:&J=.Q:B6H8Q\['KNZO\5=%5
M$;XJ*H;EM/\ #%GQO$Y*BRX+DU-D<%UM=+/:;Y;6PRI35=0D:3,_3(QV\B/8
MW1ZJUZM1[434W*^>%=BF/W.XPU%HR22V6B:.FO5]I[;REOM$[T:JQ5$J.UWF
M;[=]8T>UFOC*AJVT'97MHVKXE=67RY8C;:^&KM=99[!0SSRT"2TM4V>22>K=
M3MF194:C$:V-6L1$_6554T"^^!3?:[)\JJ&8YLZN\&47/BT]WOO.IZRU22[J
MU,,<*1(RJ8CD?R:O?$OC>,BZ ;MX0GA>TV%XAFC<.M]YK[E8Y8J&3(8+6M1:
M:6L<^/6"237K=NO1%5&JUJN1%<BG31R7G7@U;3V8?M P/"ZW$78AE=T==DK+
MQ-4Q5M$Z1\;YH&QQQ/8]JNC7=>KD5J.TW7:(IT;M$V<6/:GCCK'D,=;+;G2M
MF5M!<:F@DWFZZ?I:>1C].OR;VB_6@&!MNRJX8-L=S?(K4]D=SM5FJZVE?(Q'
MM;+'"YS55J^5-43J.::#;KFV)4NS.[R;6L9VB3Y1<;=0U6(T]K@AK&LJ43E'
MPOAF5R+#JKEWF*FC5UT.ALWV3QUNP3(=G>,NYJVJLE3:J!USK)ZA&+)$YK5E
MF>LDCD17=;EWET_>?K97L3Q;9MC=CAI<7Q^WWVDMT-)57&V6^**25[8T;(J2
M(QKE1515U715UZP-?MWA4XA<K_24D=!?X['67);-297+;E;:*BLWUC2)DV]O
M=;VJQ'JQ&*Y-$<O42_\ ZQ<3='<YHL>RN>FH[O)C\=3';6K'6W%LZP\U@7E/
M'>JHKD5=&[J+JY%143RO!/ AN6%WZSV],?V?5ECMEZXBS*:F.HEO,M.DRS,A
M6F5B0ME151O+)*O4W7<U-[J/!RR/_0G?,0DIL2O]37Y577M]MOL<LM!5TLU7
M),V)TB1[\,J->W](QKE8YO5O)U@;C4>$_C5%C,-QJ['D]+=Y[HME@QB6U.2Z
M3UB,Y18XXT7<<FYX_*(_DT:BJKDT,&L\+K#+?C*76IMV105K+Y%CM3876Q>)
M4M=*Q7Q1OA1W6CVHBM<Q7(N\FBZ:JGFN*^"OM"Q"EL]\MMVLT%]L%_DNEEQ:
MLNM=7VFCI):7F\U(VLF8LZ;VJR(Y(]&.ZD9HJEN+P:\TO6119??KA88\EKLU
MMF1W&CH)9EI*:CHZ=\+((9'1HZ631V\KG-C155?)HFH;Q1^%-C%58+K6/LN3
M4MXMMTBLT^,RVQ5N?.Y6(^)C8VN<Q4>Q=Y'[^[HBZJFAK=]\)UU\J<4IL>HK
MCC]SZ;T..7ZT7^A;'501S0OETT1SF^,U&.:]CEZM21M)\''/[]E6<7>P7JWQ
M4-^OUMN,EI6[5EMXC24]'R$M-/4T\:R0ZOW7IR:/1R-1'>54-=P/P0,OQG)'
M7&1<7ME%)FEJR=*"VUE7,D$%/320RQ<I+'O2R*KFJCW*F_JY51FB(H>V;;]H
M=YP7(]E5':98HX,ARJ*TUZ21H]74[J>>14:J_JKO1MZT(%)X86'U=WYMP7*(
MK:V^OQN6^R6S2WQ5[9EA;$Z7?U\9Z(B.1JM3>:CE:NJ)M&V39E=-H>0;,ZZW
M5%'##C.317FL;5/>UTD+8)HU;'NM75^LK>I=U-$7K_?YY+X-V2OV1U6+)76E
M+A+GJY2DO+2\ES7BB5>XJ\GKRG)IIIIN[W5O:=8&L;,_"IO4E^SF\9E39$E$
MN2S8WC>)4=GIGSSRQJJJV-T<KGR2HUCG2*]6QM145''I%;X76'6_&6W2:UY&
MRX)?(L<GQ];;I<Z:OE8KXHGPJ[31[416N:YS5WD77354U)?!LS.RU;,DLEPL
M3\HMF;W3)K=2UTLR4=325D:QN@FD;&KXI-U==YK7HBHGZR*I_D/@UYI><DAR
M^_7"PLR2NS6V9'<:*@EF6DIJ.CIWP,@AD=&CI9-';RN<V-%55\FB:A:NWAK8
M?8)KVVZ8SF-##C\M-'?:E]H1\5IY>.-\:SN9([_]J(J,WW(J+JFFBKL%M\*?
M%*JCRF6X6O([!4X]2P5T]ONEJ>RJJ*>=RM@D@B8KE>CW-5J-ZG(O4Y&FJYSX
M..29-C>W6WTM;:HY\[N%)5VUTTLB-B9%!31N2;2-5:NL+]-U'=2IY.O3];7=
M@.=9;EN:WS%,CI+!/>,=MEIII6U4\$ROIZN6:>-\D3=Z)DD<FXDD:J]-55$Z
MDU##VH>&-T:V=YQ66C#<AMV9X]0T]<EER&@9$KH)I>394^+-NNC1R.141^\B
MZ(K38YO"2M.,7;)Y\BDN]/S.DLO(8WPICJQE56I.D<$2Q2/6>618]%;U-9N:
M[RHJJGCR^!?F-:FTB6.'%,:3*,7BL]-1TEVK[BL55%4\LU\]341))*UR=2NW
M45NB(C7>4W/)?!OSS*LHN6:/K<=M>5,DQZY6ZE9//4T?/*!M6V>*5RQ,=R3V
MU6C7M:KD\JM3310W2L\+K#;/B^07:\VS(K'66"IHZ:Y6*OMN[<(>=2-C@D2-
MKG)(QRNZG1N=^JY/*FAJFU;PDJZ[;)]HU9A[KO@>:870LNU1;LDL\:RS4[F/
M6-4:KG-W)%8Y-Y%WFJQ45$4PLG\&W/\ :14Y-DN25F-T&47>JL44-NMM142T
M5+14%:E2[6=\+7R2OUDT_1M1/%3]ZDKPOL;9@^-;<,YO=YM5OM&2X?36"W0S
MU*QSRUD:U+N3T<B-57)(FZC7*JZ.ZDTZPZML57)7V2WU,RHLLU/'(]431-5:
MBK_\F<2\6_9BT?\ !P_W$*@                             !#RG^2/Z
M1A_Q+A#RG^2/Z1A_Q+A/E?@ !4                     $/^>_]G?YI<-8
MN5KI;OF#8:N+E8VT&^C=Y6]?**GU*G[U,OH39?,O>O\ S&>M;%P$/H39?,O>
MO_,.A-E\R]Z_\Q>IQ92&-LKI$8U)'(B.>B=:HGD15/V0^A-E\R]Z_P#,.A-E
M\R]Z_P#,.G%P$/H39?,O>O\ S#H39?,O>O\ S#IQ<!#Z$V7S+WK_ ,PZ$V7S
M+WK_ ,PZ<7 0^A-E\R]Z_P#,.A-E\R]Z_P#,.G%P$/H39?,O>O\ S#H39?,O
M>O\ S#IQ<!#Z$V7S+WK_ ,PZ$V7S+WK_ ,PZ<7 0^A-E\R]Z_P#,.A-E\R]Z
M_P#,.G%P$/H39?,O>O\ S#H39?,O>O\ S#IQ<!#Z$V7S+WK_ ,PZ$V7S+WK_
M ,PZ<7 0^A-E\R]Z_P#,.A-E\R]Z_P#,.G%P$/H39?,O>O\ S#H39?,O>O\
MS#IQ<!#Z$V7S+WK_ ,PZ$V7S+WK_ ,PZ<7 0^A-E\R]Z_P#,.A-E\R]Z_P#,
M.G%P$/H39?,O>O\ S#H39?,O>O\ S#IQ<!#Z$V7S+WK_ ,PZ$V7S+WK_ ,PZ
M<7"'FW[,5O\ 4_OM'0FR^9>]?^8E91B]LMUBJ:BGIN3F9N[KN4<NFKD1>I5_
M<I-L7)6X@A]";+YE[U_YAT)LOF7O7_F+U.+@(?0FR^9>]?\ F'0FR^9>]?\
MF'3BX"'T)LOF7O7_ )AT)LOF7O7_ )ATXN A]";+YE[U_P"8=";+YE[U_P"8
M=.+@(?0FR^9>]?\ F'0FR^9>]?\ F'3BX"'T)LOF7O7_ )AT)LOF7O7_ )AT
MXN A]";+YE[U_P"8=";+YE[U_P"8=.+@(?0FR^9>]?\ F'0FR^9>]?\ F'3B
MX"'T)LOF7O7_ )AT)LOF7O7_ )ATXN A]";+YE[U_P"8=";+YE[U_P"8=.+@
M(?0FR^9>]?\ F'0FR^9>]?\ F'3BX"'T)LOF7O7_ )AT)LOF7O7_ )ATXN A
M]";+YE[U_P"8=";+YE[U_P"8=.+@(?0FR^9>]?\ F'0FR^9>]?\ F'3BX"'T
M)LOF7O7_ )AT)LOF7O7_ )ATXN A]";+YE[U_P"8=";+YE[U_P"8=.+@(?0F
MR^9>]?\ F'0FR^9>]?\ F'3BX"'T)LOF7O7_ )AT)LOF7O7_ )ATXN A]";+
MYE[U_P"8=";+YE[U_P"8=.+@(?0FR^9>]?\ F'0FR^9>]?\ F'3BX"'T)LOF
M7O7_ )AT)LOF7O7_ )ATXN A]";+YE[U_P"8=";+YE[U_P"8=.+@(?0FR^9>
M]?\ F'0FR^9>]?\ F'3BX"'T)LOF7O7_ )AT)LOF7O7_ )ATXN A]";+YE[U
M_P"8=";+YE[U_P"8=.+@(?0FR^9>]?\ F'0FR^9>]?\ F'3AE/\ )'](P_XE
MPU&\8[;[1/:9J2GY*1U?$Q7;[G=6JK]:K^Y#;AAO@ !4
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MX4-#!;*&GHZ6)L--3QMBBC8FB,8U-$1/X(B(?<
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M#>*;GEIN=-)1U=/ON9RD3VJU[=YJHY-454U147]RGWL]HI+!:*&UT$7(4-%
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M.*V7"'DZV*5SYH%:U&HJZ]>J_O-J&&^  %0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
L                                                      !__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tm2533062d1_424b3img02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2533062d1_424b3img02.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 1, U$# 2(  A$! Q$!_\0
M'@ !  ,! 0$! 0$!          8'" 4$ P(!"0K_Q !=$  ! P0! @,$!@8'
M P<(! \! @,$  4&$0<2(0@3,108(D$5,E%7EM,6(U)48947,T)Q@934"575
M)#4W8G61M"4T.')VH;*U&4-3<W2"@R8V5F.2HK-DD]'2\/_$ !<! 0$! 0
M               ! @/_Q  :$0$! 0$! 0$             $0$A03%A_]H
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MQ2%:&I43P/DBUY[#ZXQ,:8C^LB.GXA]I2?[0[CN/M&P-U+*RI2E*!2HW@/\
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M%I4JG>*/%SQ3S4S<CBN5-RY%MCKE2H;\=UA]#*1M3@;6D%:1\RC>NWVU#O\
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M)9,M=8?N,/JF1SMB8PXIE]H_+I<00H?W;U7D5@CRXYCJRK(#'(UTB0T%:_\
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M$HC=:&4]:B2- ;WZU<'*/@UR*;S#=.3>*N2Y/'.1WAH-71DP4RX\G0 ZM%0
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MB2"DZ3T#L0-]NXK)'@LG<MQ^))2,(X2Q?D&S?2L@F[7B;%:>#FD=3?2XM*M
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M0J1<97/._$O@R,W&87'CBPW53J[%:['$B.21&2HH;>EN2&G0I:^DKZ&@@!)
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M5QQIPMN%'F3$+*0I)&R@>GI7EO'B<B6M[)'6,!S&[63'I+T6X7R Q"5$;4R
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M/;5I4H*'?\-]XG,V^1,RZ&Y>++$@PK/(9LY;9:1&D(>27V_/)=4HMI2>E38
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M1Z5-KZM%LGT [GOO2=<C',NLN8-3G;)<XUU:A2W(,AR*X%I;?1KK;)';J3L
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MQ$V4W!C>T.!)??<.D-H'JI1/R'\3Z"NO0*5&LTY&QWCU5D3D%Q^CS>K@U:H
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MCW0ZEIM2%M)2VE/G$J6%**^D?"G9K@RO"[R*]B-MQM^ZVNZVQG&H]G:8<O\
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M;+I5!Y+RWEEC\'QSK45W+19V75R(JFGF XM24*?202V4@*+GKT_QU577C/\
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M"0P3H.-ZWU)]>X]-'?I7WR3FO L0@6N=>,NM,&)=&O/A/+E)*9#6@2XDC>T
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MY9<;ZWF8E1Q%;CJF)D^:I)<\_P!H0!Y02&R#H'JU6K*4*R*_QCG4?&\<P)O
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MSGEAM:OU@^)I1&TGMK1JTK9QC;X7'DW$)D^YWF'/8D,S9MQD^9*D>=U>8HK
M 23U'02 E/8  #51+#_#NSBF4XU?W<UR.]2\?A.6R$S.]D2P(BTI'E%#4='I
MY:#UC2R4C9([41R\LS_,;!XBU6QA,&3B<?$9%U7"<F!A;CJ'0.KJ6@(2K>D[
M4L)"222-:K@8!XG,@SJ]W2P6^WXM?+W]!.7FW_0=W<D12XA:4JBNO%H)*MK&
MG&RI/\ -;LGD7@NR\EWYRYW&XW.)[199-AEQ8;C26I45X[(5U-J4E25 *"D*
M3W&CL=JC2?#&ER<F?+Y%R^3<19WK")2%PF5(AN=/P(2B,$H4"@'K ZB?4G0
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MU9[B+=<5W-IZ)C;,.Z2W2%I;$R:AP^<EL.'0#:"2$DDZJ]U]10KH("]=BH;
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M90KH/F(/9)/UNW8;[DKQ(6MOFN;A2'K/&L]HM0NEVO,^XJ9+04%E*6D>64*
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M&'^([ <YN]MMEKNDYN9<T%<!-SLLZWHF )Z_U*Y#+:7#T_%I))UW]**S/AF
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MHF_DT%ETJOK7S]@%WN<6WMY&S&ERW S';N##L/SW#Z(07D)"E'Y)!)/V58-
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M"G22Z7$:THK))42#O9WNO!D:<1Q7"'XU^39;3B$>.([K-P#3,!MG72&U)7I
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MH:]*#*N1/3L1SKF"XP+[.]J=S#'6#&>6VML-/&)U$)*?V5% /R'\>]?N#?\
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MVX18\DSXHC2%!++WG)Z'2?0).]$G^%9.1X/\PM^$7^$BZ62[75Z8(%LCR_\
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MT'.HE76.^R3O=$9+Q7E[DV^9)"R)RYF)'?RU=E=MDVZP&X*6!)4U[,F-Y?M
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M\PZAYE8VEQM04E0^T$>M?2O':+/ Q^V1K;:X,:VVZ,@-L1(;26FFDCT2E"0
MD?P KV40I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
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MCOJ"F@L_$H=.^]!>^3\SX)A=Z8M%]RZT6JYOA"D1I4M"%@+.D%6S\(4>P*M
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MD9;O2C4XQROK1H!4A)*=C76*[MX\2^2VW*%LQH\&Y,NV@38=HCQ-3'7/8#(
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MPA*M=:2.L!0^VVN)L[=R_&V!=I<!60(=EMO,1?U9<0Q*<8\Y+14I24J*!\R
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M-A:E]75KL !7BQSPZWG%VX,F%F3)NENF>TP4R+<^_!808ZF%MAAR6IP A74
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M=J6M1[ #OV %2.E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
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M"JXX/X6A<'\2V_!X-P>N2(Z75.SGT!"GG75*4M?0#I(VHZ2#V&NY]:HS+?\
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MI5BRNZ7VZY?:WIC]CFV1IVR8XW;52/:6R@R)8;<Z7EI!WH!.R-[J7\=^$;]
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ME*F4K<40 T%'203V[PAGP=R[?"QQ;5XQ>\W.RP'K.VK(L6]MBN0U.EUHEHR
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M[(_"U?N394Z1GN;P[J7; Y86&K79/9D-@O-/(D*"WW.I?6R"I/U2- !.CO\
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M2>M)'7L]0&M?X4%P\3>-)GD;,;/;KIA4S%L?R.-,EXY?9,YMY-Q:C$^:5M)
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M$) !)4?\:Z]L\(W&_%N)9<>/,+BVW(+G9Y4%M\R77G5E;2@$)<?<5T JUO1
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MK61N"_"9D8YYP[)9_$T#BV#B[\F9<)<6]JG-7.0H%+2(K2G%EEH;ZM$_,_P
M#9'+G-^(<'VB%/RRXN11/D"+"BQH[DB1*=_9;:;!4K^/;0[?:*SC'\;MUR*Q
M<KWJSS,8M]GQJ]6Z!:;A>+?/Z'&7SI8D-MDN^9L%(TA(!^L*G_BAX\S"?R#Q
M7R-A]@&72,.G2%2K"F4W'=?:>;""MM3A">I.MZ)^=4'D7AQY=S+"^;WI.#-6
MN[YADMJN]OMC-UBN LMKZG=N>8$A2!];>MG?3U#O0QI_/?&#Q7QKEUQQN^Y
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M*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%5IB7_3]R-_V19/\
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M=*1L=SV].YJ5TH(3;N$>/+39;G9X>"XY'M-T6E<Z BUL>1**3M/F(Z>E6CW
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ME*!2E*!2E*!56WG"LZMW)=]R7%KACPB7>!"BNQKQ'?6XVJ.I\]25-K TH/\
MH1_9_C5I4H*T\GF+]\P?_*S/S*>3S%^^8/\ Y69^95ETH*T\GF+]\P?_ "LS
M\RGD\Q?OF#_Y69^95ETH*T\GF+]\P?\ RLS\RGD\Q?OF#_Y69^95ETH*T\GF
M+]\P?_*S/S*>3S%^^8/_ )69^95ETH*T\GF+]\P?_*S/S*>3S%^^8/\ Y69^
M95ETH*T\GF+]\P?_ "LS\RGD\Q?OF#_Y69^95ETH*T\GF+]\P?\ RLS\RGD\
MQ?OF#_Y69^95ETH*T\GF+]\P?_*S/S*>3S%^^8/_ )69^95ETH*T\GF+]\P?
M_*S/S*>3S%^^8/\ Y69^95ETH*T\GF+]\P?_ "LS\RGD\Q?OF#_Y69^95ETH
M*T\GF+]\P?\ RLS\RGD\Q?OF#_Y69^95ETH*T\GF+]\P?_*S/S*>3S%^^8/_
M )69^95ETH*T\GF+]\P?_*S/S*>3S%^^8/\ Y69^95ETH*MG0.89L*1',W!T
M!YM3?5[),.MC6_ZVIAQQB[N#\>8OCCTA$MZSVN+;UOMI*4NJ:92V5 'T!*=Z
M_C4BI0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4
MI0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4
MI0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*5^'74LM+<6H)0@%2E'Y >IK)K
M_P#M/^#V'W&_;[PYT**>MN""E6CZ@]?I0:UI61__ *43@_\ ?+U_D!__ +U.
M\8\9.,YK9(]YQ_"^0;Y:)/5Y,^W8R\^P[TJ*5=*T[!TI*@='L01\J+%^TJE_
M>@A_=KR=^$9-/>@A_=KR=^$9-$712J7]Z"']VO)WX1DT]Z"']VO)WX1DT%T4
MJE_>@A_=KR=^$9-/>@A_=KR=^$9-!=%*I?WH(?W:\G?A&33WH(?W:\G?A&30
M712J7]Z"']VO)WX1DT]Z"']VO)WX1DT%T4JE_>@A_=KR=^$9-/>@A_=KR=^$
M9-!=%*I?WH(?W:\G?A&33WH(?W:\G?A&30712J7]Z"']VO)WX1DT]Z"']VO)
MWX1DT%T4JE_>@A_=KR=^$9-/>@A_=KR=^$9-!=%*I?WH(?W:\G?A&33WH(?W
M:\G?A&30712J7]Z"']VO)WX1DT]Z"']VO)WX1DT%T4JE_>@A_=KR=^$9-/>@
MA_=KR=^$9-!=%*I?WH(?W:\G?A&33WH(?W:\G?A&30712J7]Z"']VO)WX1DT
M]Z"']VO)WX1DT%T4JE_>@A_=KR=^$9-/>@A_=KR=^$9-!=%*I?WH(?W:\G?A
M&33WH(?W:\G?A&30712J7]Z"']VO)WX1DT]Z"']VO)WX1DT%T4JE_>@A_=KR
M=^$9-/>@A_=KR=^$9-!=%*I?WH(?W:\G?A&33WH(?W:\G?A&30712J7]Z"']
MVO)WX1DT]Z"']VO)WX1DT%T4JE_>@A_=KR=^$9-/>@A_=KR=^$9-!=%*I?WH
M(?W:\G?A&33WH(?W:\G?A&30712J7]Z"']VO)WX1DT]Z"']VO)WX1DT%T4JE
M_>@A_=KR=^$9-/>@A_=KR=^$9-!=%*I?WH(?W:\G?A&33WH(?W:\G?A&3071
M2J7]Z"']VO)WX1DT]Z"']VO)WX1DT%T4JE_>@A_=KR=^$9-/>@A_=KR=^$9-
M!=%*I?WH(?W:\G?A&33WH(?W:\G?A&30712J7]Z"']VO)WX1DT]Z"']VO)WX
M1DT%T4JE_>@A_=KR=^$9-/>@A_=KR=^$9-!=%*I?WH(?W:\G?A&33WH(?W:\
MG?A&30712J7]Z"']VO)WX1DT]Z"']VO)WX1DT%T4JE_>@A_=KR=^$9-/>@A_
M=KR=^$9-!=%*I?WH(?W:\G?A&33WH(?W:\G?A&30712J7]Z"']VO)WX1DT]Z
M"']VO)WX1DT%T4JE_>@A_=KR=^$9-/>@A_=KR=^$9-!=%*I?WH(?W:\G?A&3
M3WH(?W:\G?A&30712J7]Z"']VO)WX1DT]Z"']VO)WX1DT%T4JE_>@A_=KR=^
M$9-/>@A_=KR=^$9-!=%*I?WH(?W:\G?A&33WH(?W:\G?A&30712J7]Z"']VO
M)WX1DT]Z"']VO)WX1DT%T4JE_>@A_=KR=^$9-/>@A_=KR=^$9-!=%*I?WH(?
MW:\G?A&33WH(?W:\G?A&30712J7]Z"']VO)WX1DT]Z"']VO)WX1DT%T4JE_>
M@A_=KR=^$9-/>@A_=KR=^$9-!=%*I?WH(?W:\G?A&33WH(?W:\G?A&30712J
M7]Z"']VO)WX1DU:N,WU.3V&#=409UM3*;#@B7..J/):_@XVKND_P-!TZ4I0*
M4I0*4I0*4I0*4I0>*]?\S3__ ,'<_P#A-?X$^';A5'/&>2<=<NTFS-Q[9)N2
MGX=N,]Y892%%M#(6@J4K>@ ?7Y5_OM>O^9I__P"#N?\ PFO\!_#WS*QP=F\R
M^R;,_?8\NURK6Y&BW P74I>2$E:'@VLI4!Z?#1K'N\07 K?"#F-+8O<NZ,7R
M(Y*1'NMH<M4^,$.%&GHRUK*0HC:5;^( _96]>#N8,FX8_P!GEQ/=,2CVF3>;
MG?W+.V+TTZY'2'[C+3U$-K0KL0/G]O8UA#G;G^/R[8,4L5NL$NS6K'Q(+3EU
MO"[M->4\H*5U2%H0>@=(T@)T-FMW\'\/Y-S/_L\^)[9B,BTQ[S;+^Y>&S>G7
M6XZ@Q<9:NDEM"U=R1\OM[BB[^K:5XC.3N.,NOV&\DVC%5WU6,S<AL5SQLR?8
MY!CH4I;+S;JNL'X=["AV_OV(5</&1R+/D\5P[?.XXQ=W*L3&03;AEWM+$-M[
MS"DM-J2^- C6@KJ/8]ZFSOATY.Y)RZ]YER1=<4:OB,8FX]8K;C?M)ALJDH4E
M;SSCR>LGXM:2D]O[N_+Q7P2R)%_XS_3B-C>18]CF%.8Y<(3G6\7)2EDAUD+:
M Z0"=+)2H'T%&>(M.\<V<L<)WK(6XF&*OEJS!C&57II;[UAE-. DR&U>8E?2
MG0)/61KO\ZG.*^*'(K+B&<9;EF8<69I9\=M9F>Q\=RGW)0>*@EL.EQQ82A1^
M'>M[_NJ*W[P>\FJX4<XS@7?%[M9[+E$:[XV[>7WPKV%M2U&-*2EA6R"0 4E6
MP3LC0J=6C@+-LTQ7,,1SS&^,<7Q^_P!K5$,O 69")8>Z@6U+#C2$J2D[5K?J
M!]IH/5Q_FWB+FW/$KO?\:Q"XXKD24K?BV9QUJ79&UHZVW'5/.=+P&P%! ZM[
MZ1438Y=\2*^>'.,E_P!%@G-6A-\7+$.Y>5[.7O+Z ?.WU_/TU_&I5@/%//;%
M]PJ!EF=8[%P_%2G9QIN0B;>TH1T-HEAP="4Z *@@G9W_  (F3/#MY;\5<GDQ
M4F ;"[BZ;((WF+]J\X/^9U%/1T]&OGU;W\J"J;;SWS;RS;,KS7C>TX>Q@]CF
M28L.%?1)5/NXC[#JDK;4$-[T0D$>OK7(R[QJY->E<2.X6_A6+P<UM$NX2)F>
M./)CPW6%="FO-;=0/K!:1L'9UZ5U;=P+S=Q-;,LPKC:ZX?(PB^S),J'-OID(
MG6@2-EU*4(24. ;)22?7U^RO5!\#T*'D/$,&:W9\EPG#K%/MEQBW=HK=EOR-
MJ\U#10I&O,4I6RH%/;6R*+Q,O"IS]?\ FHYM;\@9L$J7C5Q1"%[Q1YQVUW *
M1U;94LD[3KOW/J*KZQ>-VXJY<Y=P2^6VW07[ F>K&9B6G4MSEQ6BM;+Q*SU.
M:Z5?!T]M]AVJT?#3PQD_ K&28I(N,"YX"B:J3C92ZLSHC2SM;#P* DI2?JJ"
MR?78'H*KSWP07//L7Y68D7*VPL@O>3NY%C-RCNN[AE3:4=#Q\L%(6 I*@CJ&
MB#W(U1'8SCQ7978_#+QWEUELULNO(^:IC-P+/Y3ABK=4DK=(0' OI2E)_M]B
M1LUYN4/&%D%M\)^'\I83;+5.OU[F18#MON+;KC+3ZPM+S82AQ"@0X@@;5Z?;
M7*M'@GRS(+AQO&RS,7;'9<'QI%N@NX;<W6)QN"B \Z%K9 2V4#I!'Q'7<#O7
MEM_@GS/&L>E8;;+_ &VXX;'S:!E%K7=Y;JIJ&4;,IMWI8Z2M1T4Z.B=D].Z'
M'YR/QUW]W.N%K3C-KL\JVY;%MTB^/2FG5KB*E.% ;:*7$A)'EN_6"O05SX_C
M"Y&ON9YK;6,RX6P^-8[]*M$:'E[\MB:^VVO27-)D:4#O6P!W![5\L*\ >4X=
M=D2TWJS24Q\XA7F(%OO;9M$8O*0P/U79W;Q^'ZO;ZU=BR^&/EO"<KSB9:\<X
M=R:#?L@E7EB3E2);TQE#JMI;VF.0-  Z!/<GO1>-CVY;[EOBJE*97)4TDNJC
M[\HKT.HHWWZ=[UOY5Z:\EI$Q-JABX)CHGAE D)B$ED.=(Z@CJ[].]ZWWUJO7
M1DI2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2
ME I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2
ME I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E!_%
M)"TE*@%)(T0?0U6ONR</?=1@_P"'(?Y=672@K3W9.'ONHP?\.0_RZG&-XQ9L
M-LL>SV"TP;':8_5Y,"VQD1V&NI14KI;0 D;4I2CH=R2?G73J&<I\C?T:6FSS
M?H_Z2^D;S"M'E^=Y7E^T/!OS-]*M].]]/;?IL4$SI53<2\Z#EO.<VMEOBP$6
M3'97L*)29CBY<AT!)4LLEH)0WW4 ?,4HE)VD;J;1^1<9EVJVW)F]1'(-RE^P
M0WDKV'Y'4I/E)_ZP*%@CY=)^R@D=*A-FYMP'(KG<;=:\PLUPG6YMQZ3'C3$+
M6VAO^L5H'N$ZT2-Z/K7:B9O89[]E9CW6,\[>HRIEN0E?>4RE*5*6C[0 M)__
M !A0=RE0[D'ES$>,&6QD>0VRTRY#:W(L6;*2RM_I'?0/?6]#JUH$BHY9?$AA
M2L(Q&_9/?;5B4G([>U<&;?.GHZD)6D$_$0G:03KK( _NH+4I7)OV5V;%[$Y>
MKM<XUOM#805SGW EI(6H)22KTT2H#?\ &N)8>8L&R>S76[VK+;/-MEJ[SY;<
MQ'EQ1K?4XHG201W!/8CTH)C2JDRKQ1<?V# 9666^_0LAM\:;'@.)MTA*U(=>
M6E*>H>J= E?<=PDZW7<Y2Y@MO&.*67(I"6'[5<+E#A+E/R1':8:?4!YZE*21
MI(/5HZW]HH)_2H3&YLP&9B<G)F<OLZ[#&>]F>G^UH#;;O;3:MGLL[&D^IV-#
MO7HQWEO#,M%L-FR6W7/Z2=>8B>S/A?FN-)ZG6Q]BTI[E)T=?*@EU*A5[YIP3
M&H#LVZY7:X$9N:Y;BX_(2G<AO^L:2/52D_,#>OG4HMEZM][M,>Z6^='G6R0T
M'F9D=U*V7&R-A25@Z(U\Z#VTJ&XES'@V>WF1:<=RNTWJY,(+JXT.4EQ90#HK
M2 ?B2#V*D[&ZBN7<NY=$Y5F83B6%VS('H5H8NTB7<K^JW@)==<;"$I3%>V06
MB=DCUH+<I5?<8<T6?DC'<?G*3]#7.\>U)9M4AT+<*XSA;?Z%)[.)2H=E#L00
M?G7HO/.7'^.V^/.N>7VF!%D//1VG'Y*4]:V5E#P /?X% A1]!\S03FE0*=S+
MCMGO$]%SO%F@V.-!AS$W1=R2>H2'%H;*D]/2E!*1TKZR%;/8:V?3;.:<"O&,
M7'(H>7V=^QVU?ES)XF(#4=7;062?A)V-;]=C6]T$TI4(1S=@"\35DZ<PLYL*
M7_953O:T] >_^R]=]?\ U-;_ (5^;ASGQ[:\<MU_E9E96K/<5*1$F>V(*'RG
MZX1H]^G1ZOV?GJ@G-*CM]S2';L N666Y;-Y@1K:[<F%1GP6Y*$MEP=+@V-*
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MD;.C_ UWKASIQ[:[1:;K*S*S-6V[!9@2O:T%N5TD!00H'2B"H @=Q_@:"/\
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MLK4=RXQ'#<GWVFT(:9+;A"6$^65 NE!V1\([FM+YAE(Q5FU.%,57MUSC6_\
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M?6$Z*TE2M)  [@(O>>-,]O.57#D5K#50I1R2TW-O%3/B^V/,16'F7'%.!SR
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ML(/4G1%:+I1&4\:XUSW#[EC=X5A;UX.+7Z^.?1S=PB)7.CSG5N-RHQ6Z$A2
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MM_!_(%VR6]7"Z6.[2HL_(\=N2',@N,!^6IB*MSSU/!@AI*DCI/0@$:(Z2H[
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MBTI5W3\SVUW/?5=7KCCD-MBZ8I#PY<R!(SYG)DWX7&*B.89F-/J ;4X'?-2
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M5^97EA<D9M>KK8\<@72V"Z78RI!N=QQ&X6M$:/'2UU)$23(#CJU*>1I?6E(
M5V4149F^(/,HV4*QI]ZV0IMM-P9N$^%BUQO*)"V#'*%ML1G@ME*D2 5=96 I
M)'4?F5,/>:3]U?)WX:5^93WFD_=7R=^&E?F5#,7\5EZDS9"KY:[:S!7BT>[0
MO8RLK=GK0I7D$E9!"P 4I ZAI0))JP;!R]=O=Q:Y O,&(N]HMJY+T.'U-QR^
ME2DA*>HJ4$]0'<DG6Z#P^\TG[J^3OPTK\RGO-)^ZOD[\-*_,KRW7F/,L;MEY
MC2[79;G=K->K= F2HZW8\?V>46=.(:)6HK3YI3TE8'8*WWZ:E_..>73CW$84
M^S^0F9*NL.WE<BW/SPA#SH0I28[*T..* /9*3LF@C7O-)^ZOD[\-*_,I[S2?
MNKY._#2OS*AL?Q-93!EV@3;9!FPV;G<&+TM-NDP)2(3#;"A(1%=<4ME0#_64
M.%14A'4G74!7VSGQ9'#<;QBXN2+ AV?=+@J4)3_E)5;(LU<=2F-N#J>4GRU
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H4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tm2533062d1_424b3img09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2533062d1_424b3img09.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $8 ?8# 2(  A$! Q$!_\0
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M>JO<WAM9M-O+.3RS(IG\LJP! ."CMSR*T:Q_$^J2:+X;O-0A0--%& F1G!)
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MU^A=UGQ!#I&8E@ENKKRC*((B 0@(!8DG &35RTU**[MYI1%/&T#%98GC.]&
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M]E<_CMQ6QHN__A,?$FW_ %&Z#_OO9S^F*JUG;U_!D)W5_3\3I****104444
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M.WD!CW_AV"^U*WU)+N[M+V%/+\ZV909%]&!4@C\*KWG@^QN]5.I)=ZA:W$@
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M55OKN2:Z $L<GE["!]W "@C'U^N:UZ* ,C5] 35/->.\N+2>2,1.\1!#*"2
M58$'&3SP>>M6;#2H=.MIHX'E\V9B\L[D-([G^(\8S[8Q[5>HH RM(T-='DNG
M2^N[@7,AED6?R\;SU8;4'ITZ>U)<^'[:YGG?SKB.&Y(-S;QL!'.<8^;C(X !
MVD9[YK6HH HWNEPWJP$/);S6YS#-!@-'Q@@9!!&.Q!%26&GPZ?$Z1%V:1S)+
M)(<M(QZDG_(':K5% !1110 4444 %%%% !1110 4444 %%%% !1110 5%/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5)I\T-'^#&7FAZ-K48DN+.WG#C(E488CV9>?UKF+WX9VN_SM+OY[60<J'^8
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*//3^[)_W[;_  J6B@"+ST_NR?\ ?MO\*//3^[)_W[;_  J6B@"+ST_NR?\
M?MO\*//3^[)_W[;_  J6B@"+ST_NR?\ ?MO\*//3^[)_W[;_  J6B@"+ST_N
MR?\ ?MO\*//3^[)_W[;_  J6B@"+ST_NR?\ ?MO\*//3^[)_W[;_  J6B@!
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M,J$3R([[CRB%1C/ P2><=_Y4Q$E%%% PJ*?_ %8_WT_]"%2U%/\ ZL?[Z?\
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M7 Z3?/9VT=DUI;EDU@0RV\F76USROE>HQR#QC/2M!/$FIS0V5TJVJVVHM+'
M!&Q>%E#%2WS8;[IR !CWI-Z7#K8ZZBN"TWQ'XAELK.UL[5-0NELXKF5F4+O#
MDX4EI!@\'Y@&Y_A%;*WFHZS'>[4MX[!));:6,LZS#:N"P=3C.>V.G.>U.6B?
MD"U.DHKD/!VH7BV^F:=.(&@?3$GB**0RX(4AB3@YR#P!^/6NOIM68D[A1112
M&%%%<;Y7C[_GOIGY?_6J7*W0UIT^>_O)>IV5%>/6=KXM'BU_+\\:@&)D>0GR
M]O/4]-OI^E=?Y7C[_GOIGY?_ %JB-2_1G34P:@U[Z^__ (<[*BN6UK3[^Z32
MYY;>UU&>WB)N=/D8!96(4%TSQD'.,\<]JR]1NX]1\++8Z+!+)(@:[D@N.2%2
M0[HW'\>6RN.^.3ZZ7TN<35G8[VBN!5&O/ NJ &VN-'CM':T+0%9"^W<3R< *
MV0  ,8]N9](M+K3);G4H-.&G6CV4<:6V],37!. ^U"0.H'8GTI]6B;Z';T5Q
M=]X9TBTU70(/[/MI3+<2"9Y(E8RGRF/S$CGD9J'5=(@TN>ZN'L4OM*6$1$PN
M!/IZA>=@/;!S@8//<4#.ZHK@?$=K9:/?P:YIMM \MU"Z7"&'>/*8<SX [9Y]
M0<5O?9;?PWX-N3HL2'RK9I8V4 ^8VW.\^I-)NR;?3^OZ_P" "U:7<Z"BN9TO
M0])DT.RO6"FX=(IWO2V))'X;YGZD$]CQ6;<>+M5M_MBI_9ETT4*S*\0D6-<R
M;"NXY\S&1R,=ZIJSY>HD[JYW%%<C<^(=:M=4.FM%8/+]IAC\\!PNR0''RY/(
M*GN.U0/XJUEKIM*M[*&;4XY9E9XT'EL$"D$*TBXSO&?F.,'@TAG:T5P6NZCJ
M.JZ5<"6&&T6RGMEN(2S-)YC%2<,K;=HW8Y!SSTQ6KXNM$FO-"D6SMKBX%\%4
M3\ C8QP6VL0,@'H>0*/\P.HHK@'NWT77=;U%]*LTOS';1HL#[QND9ADL53KP
M3TS@<UH7>O:_9:8\MY!8V<Z&1D692[3JJY&V.-VV]P3N..#WX5]+AUL=?17G
MNH7=RDFMZC93&WGFTVUF)8L^W<6!"\C;QZ?E4\%W?:-K&JRJ\$R->VL=QO5\
ML9%4$IECM +9P<^G%5;6PKZ7.[HKFO$#?:O$.BZ5<$BPN?->5,X$K*HVH?4<
MDX[XJ2]M[;0=TNER65E)+LC:.4$H%!8C9$N"6))X!&>O:IOI<?6QT-%<9;^*
M-6NTL'$5G#'-92W4K&-W8F-@&4+E<9[9)Z^W.EX=U;6=499KW3EALIH1+#,I
M48)_AXD8MP?O87IT%,5SH:***!A1110 4444 %13_P"K'^^G_H0J6HI_]6/]
M]/\ T(4 2T444 %16W_'K#_N#^52U7@E5((U99 0H!'EMZ?2@"Q147GI_=D_
M[]M_A1YZ?W9/^_;?X4 2T5%YZ?W9/^_;?X4>>G]V3_OVW^% $M%1>>G]V3_O
MVW^%'GI_=D_[]M_A0!+4<D$,S(TL2.8SN0LH.T^H]#2>>G]V3_OVW^%'GI_=
MD_[]M_A0!+4-W:6]];/;74*RPN,,C#(-+YZ?W9/^_;?X4>>G]V3_ +]M_A0!
M0C\.Z9''.@BE8SQ^5)(]Q(\A3^Z'+%@/8&H5\)Z,N<VTC@PBW(DN97'ECHN"
MQ''4>AYK5\]/[LG_ '[;_"CST_NR?]^V_P * ,]_#FF2PQQO%.QC8NDINI3*
MI(QQ)NW8QQC.*?%H.FPWMM=Q0,DUM%Y46V5PJIW&W.T_B/2KOGI_=D_[]M_A
M1YZ?W9/^_;?X4 4$T*T.GRVEP@D66X:X<IF/+E]P(P<C''?M3%\,:0L<Z"WD
MQ/*)GS<2$AQT93NRI[97'%:7GI_=D_[]M_A1YZ?W9/\ OVW^% % ^'M,9T9H
M9'*[<[[B1M^TDC?EOGP23\V:??:'8ZC=Q75P+CSXE*QM%=2Q;0>N C#KZU<\
M]/[LG_?MO\*//3^[)_W[;_"@#-_X1C2!;Q0+;.J13?:%*SR*QD_O%@V6/N2:
MEM] TRUNGN8;;;(Q9L&1BJEOO%5)VJ3W( J[YZ?W9/\ OVW^%'GI_=D_[]M_
MA0!F+X7TB/R/+MI(S"GEHT=Q(K;/[I(;++['(J23P]IDDTLODR(9A^\6*XDC
M5CC&2JL!G'?&>.M7_/3^[)_W[;_"CST_NR?]^V_PH S['PYIFG7,-Q:Q3+)#
M%Y,9:YD<*G]W#,1BM6HO/3^[)_W[;_"CST_NR?\ ?MO\* ):*B\]/[LG_?MO
M\*//3^[)_P!^V_PH EHJ+ST_NR?]^V_PH\]/[LG_ '[;_"@!PAB$S3"-!*P"
MEPHW$#MFGU%YZ?W9/^_;?X4>>G]V3_OVW^% $%[I=I?NCSH_F("J21RO&Z@X
MR RD$9P*K-X<TIOL^+8QFW4I&T4KQG:3D@E2"P)Y(.<UH>>G]V3_ +]M_A1Y
MZ?W9/^_;?X4 99\*:*89H%M'2&;.Z*.>1$YZX4, N>^,9[UH1Z?;16L%LJNT
M4!!C#R,Y!'3)))./>I//3^[)_P!^V_PH\]/[LG_?MO\ "@"K>:/97]Y;W5PL
MQFMSF(I<2(%/KA6 ]OIQ3;O0M.O99))X'9I2#(%F=5DP  & (##CH<BKGGI_
M=D_[]M_A1YZ?W9/^_;?X4 4UT*P2>ZF5)O,ND\N4FXD.5]!\WR^VW&.U2:9I
M-GI%G]DLHW2W!X1Y7D ]AN)P/858\]/[LG_?MO\ "CST_NR?]^V_PH H6WA[
M2[23=!;LB[BPB\US$I/<1D[0?H*HWG@S3)M/DMK57MW>(0AS))(%3<&V[2V,
M<<>G:MWST_NR?]^V_P *//3^[)_W[;_"@#&N_"EE/;100EXE6Z2XE9I'=Y-H
MP!O+;A['/&.*LMX;TIH88OL[KY+M)'(D\BR!F^\?,#;B3WR>:T//3^[)_P!^
MV_PH\]/[LG_?MO\ "@#+N?"NBW;,9[+=O55=1*X5]O3< <,1ZG)JS=Z+8WTE
MJ\T<N;4YA$<[QA#TSA2!TX^E6_/3^[)_W[;_  H\]/[LG_?MO\* ,Z;PWI5Q
M<7<TUO)*]VNR8//(RL <CY2V!CM@<=L4C^&-)D">9!,Y563>]S*S%6&"I8MD
MKP.#D5I>>G]V3_OVW^%'GI_=D_[]M_A0!EKX6T=!,/L\K":%8) ]S*V47H.6
MXQV(Y_.F/X1T9S(6AN3YLBRO_ILWS,OW3]_M_A6OYZ?W9/\ OVW^%'GI_=D_
M[]M_A0!#?Z;9ZG;B"\@$J*P9<DAE8="&'(/N#FJ[>']->)$>*5BD@E61KB0R
M;@",[]VX\$C&<8-7O/3^[)_W[;_"CST_NR?]^V_PH SK7PUI5G<0SP02J\*,
MD8-Q(556.6&TMC!/;'IZ"IM/T6PTLDV<3QC!"J9794!.2%5B0HSV&*M^>G]V
M3_OVW^%'GI_=D_[]M_A0!+147GI_=D_[]M_A1YZ?W9/^_;?X4 2T5%YZ?W9/
M^_;?X4>>G]V3_OVW^% $M%1>>G]V3_OVW^%'GI_=D_[]M_A0!+44_P#JQ_OI
M_P"A"CST_NR?]^V_PIDL@D5559,[U/,;#^(>U %BBBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
=** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tm2533062d1_424b3img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2533062d1_424b3img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !" 7L# 2(  A$! Q$!_\0
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MT=&_Y\6_[X'^-9>UE_*S?V$?YT9'VNY_Y^9_^_K?XT?:[G_GYG_[^-_C6O\
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M;;?]?J?^@M7HM>=?&W_D3;;_ *_4_P#06I@9/P(_U6M_[T/\FK<^-'_(B?\
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M//X!O9+&2V/BS6WB:,Q^6S1[6&,8/R]*\8\#79TSQWI,CG9MN1$_MNRA_G3
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MH?Y-6Y\:/^1$_P"WN+^M '._ C_CYUO_ '8?_9Z[KXD_\D\UG_K@/_0A7"_
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MXGTH>%/BYINN2C9IMY<AVE_A1R-K@_GN_$^E 'LI( R3@"O/OA,#=0:_JO\
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MG H Y_X$?\?.M_[L/_L]=U\2?^2>:S_UP'_H0K@O@5-&M]K$32*)'2(JI/+
M;LX%=U\39HXOA[JPDD12\05 QQN.X<#U- 'F7P4_Y'6?_KR?_P!"6O<+W_CP
MN/\ KDW\C7AGP7FCC\;R"21%+VCJH9@-QW+P/4U[AJ4L<&F74DSK&BQ-EF.
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M#0]+L-.U4&QLK:V+J0QAB5-WUP*U_$5K;WGAZ]BNH(IX_*9MDB!AD#@X-%%
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7X4O_  C6B?\ 0&T[_P !4_PHHH __]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
